Illness and treatment beliefs, cognitive functioning and quality of life in end stage renal disease (ESRD). by Griva, K.
Illness and treatment beliefs, cognitive 
functioning and Quality of Life in End Stage 
Renal Disease (ESRD)
Submitted by Konstadina Griva 
for the degree of PhD at University College London
The copy write of this thesis rests with the author and no quotation from it or 
information derived from it may be published without prior written consent of 
the author
1
UMI Number: U602524
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602524
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Dedication:
For my parents, 
Panagiotis Grivas and Fotini Griva
2
Abstract
This thesis examines the neuropsychological functioning and health-related quality of life 
(HQoL) in patients with ESRD undergoing on different treatments (hemodialysis; 
peritoneal dialysis and transplantation). The aim was to investigate the effects of illness and 
treatment beliefs on HQoL in patients with End Stage Renal Disease. Comparisons were 
undertaken between dialysis and transplant patients, between patients on haemodialysis 
(HD) and on peritoneal dialysis (PD) and patients with a cadaver (CAD) or a living related 
renal transplant (LRD).
A sample of 117 transplant (mean age = 50.3 years) and 145 dialysis patients (mean age =
50.1 years) completed questionnaires assessing illness and treatment beliefs, mood and 
HQoL. A neuropsychological test battery was also administered and the patients’ 
biochemistry was assessed. Haemodialysis and Peritoneal Dialysis patients were 
administered the neuropsychological battery test battery on 2 consecutive days (pre- and 
24-hours post-dialysis) whereas transplant patients were only assessed once. 
Neuropsychogical results indicated almost equivalent cognitive functioning among 
treatment groups. Transplant patients outperformed dialysis patients only in memory tasks. 
Significant improvements in neuropsychological functioning (attention, concentration, 
memory, and psychomotor speed) were found in hemodialysis patients 24 hours post­
dialysis. No such fluctuations were found in peritoneal dialysis patients. Although 
biochemical changes were found in the hemodialysis patients at the same time points, these 
were not consistently related to the neurospychological changes.
Results also showed that illness and treatment beliefs did not differ between the dialysis 
groups. Transplant recipients however, were more likely to hold an acute timeline, perceive 
more control, less consequences, less symptoms and less illness and treatment related 
burden compared to dialysis. HQoL was impaired in dialysis patients, particularly in 
physical SF-36 dimensions compared to transplant patients and general population norms. 
Post-hoc analyses revealed that peritoneal dialysis patients had more compromised HQoL 
than both haemodialysis and transplant patients. Multiple regressions indicated that illness 
and treatment intrusiveness, consequences and medication concerns predicted QoL in both 
dialysis and transplant patients over and above the effect of sociodemographic, medical,
3
and mood variables. Explained variance ranged from 28.4% to 65.8%, with different 
variables emerging as significant predictors in emotional and physical SF-36 dimensions 
(mental and physical component scores) in dialysis and transplantation.
The findings suggest that although NP outcomes are roughly equivalent in ESRD 
treatments, dialysis and transplantation may induce distinct illness and treatment beliefs 
which appear to have a direct influence on HQoL.
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CHAPTER 1: MEDICAL BACKGROUND
Section 1: Renal System and Renal Kidney Failure
Kidneys act principally to control the volume and composition of body fluids. By matching 
urine output to dietary salt and water intake, the kidneys regulate blood and extravascular 
volume, and arterial pressure. Kidneys serve key endocrine functions as well, activating 
vitamin D so as to regulate calcium, phosphorus and parathyroid hormone levels and 
synthesising erythropoeitin, the key stimulus for marrow production of red blood cells. 
Finally, they excrete those metabolic and mineral wastes, which might otherwise be toxic to 
the organism.
Normally, kidneys perform all these tasks flawlessly. But sometimes the kidneys lose their 
ability to filter fluids and waste, causing dangerous levels of these substances to accumulate 
in the body. This condition is known as kidney (renal) failure. There are three types of 
kidney failure: acute, chronic and end-stage renal disease.
Acute or reversible renal failure develops suddenly in previously normal kidneys due to 
physical trauma (such as crush injuries or major surgery), drugs or other chemical agents, in 
the presence of overwhelming infection, or if the blood supply to the kidneys is 
compromised by failure of the heart’s pumping action, or losses of blood, salt or water so 
that the blood pressure drops and the kidneys are no longer supplied with blood. If the 
underlying problem can be successfully treated, complete recovery of the kidneys is 
possible. In this case, renal support is needed only for days or weeks before renal function 
returns.
More common is chronic irreversible renal failure, which involves the progressive 
deterioration of kidney function over time. It develops slowly and often imperceptibly, yet 
it can affect almost every system in the body. Over time, chronic kidney failure can lead to 
congestive heart failure, bone disease, and damage to the central nervous system. 
Unfortunately, signs and symptoms often do not appear until irreversible damage has
32
occurred. Renal failure of this kind may either be the result of primary renal disease or of 
renal damage in a systemic disorder.
When people with irreversible loss of kidney function reach that point in the course of their 
illness that their kidneys fail to support life, they are said to have End-stage renal disease 
(ESRD). In ESRD total or nearly total and irreversible kidney failure has occurred. 
Nephrons are lost to the extent that the retention of non-volatile, metabolic waste products, 
salt, and water is potentially fatal. ESRD can lead rapidly to death unless renal replacement 
treatment (RRT) is started (Mallick & Gokal, 1999).
Section 2: Treatments for ESRD
There are two forms of RRT: kidney transplantation and dialysis (Will & Johnson 1994). 
Dialysis involves the removal of waste products from the blood by allowing these products 
to diffuse across a thin membrane into dialysis fluid, which is then discarded along with the 
waste products. The fluid is composed to draw or "attract’ excess salts and water from the 
blood to cross the membrane, without the blood itself being in contact with the fluid 
(Pastan & Bailey, 1998). There are two principle models of dialysis: haemodialysis (HD) 
and peritoneal dialysis (PD).
2.1 Haemodialysis (HD)
HD may be performed in a hospital setting, in a free-standing outpatient dialysis unit, in a 
satellite unit run by nursing staff or at home.
2.1.a Hospital HD
The method first used to achieve dialysis was the artificial kidney, or haemodialysis. This 
involves the attachment of the patient’s circulation to a machine through which fluid is 
passed, and exchange can take place (see Figure 1.1).
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Figure 1.1: Diagram of Haemodialysis procedure
Haemodialysis requires an extracorporeal filter or dialyser, consisting of a synthetic 
semipermeable membrane to which blood is taken and returned through sterile tubing. 
Dialysis fluid, which has an electrolyte composition similar to that of the extracellular fluid, 
is passed in the opposite direction across the outside of the membrane channels of the 
dialyser through which the blood is circulating. Electrolytes and non-volatile waste 
products diffuse into this dialysis fluid from the blood across the membrane, which is then 
returned to the body (Gokal & Hutchinson, 2002). At the same time alkali can be restored 
to the body by diffusion from dialysis fluid to blood across the membrane (Mallick & 
Gokal, 1999).
This procedure requires permanent easy access to the patients’ blood circulation, which is 
usually achieved by creating an arteriovenous fistula in the forearm. When this fistulae 
cannot be formed, several other options are available, including the placement of synthetic 
grafts subcutaneously or of a long central line into a large vein or indwelling vascular 
catheter. The process entails some discomfort and may at times be technically difficult. 
Repeated surgical procedures or sepsis may occur (Feldman et al., 1996; Nolph, 1993). 
Several types of dialysers, dialysates and ‘dialysis machines’ which monitor the procedure 
are commercially available and the frequency, duration of dialysis sessions, and dialysis 
schedules vary from centre to centre. The most common frequency is three times a week for 
a three to four hour-long session.
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2.1.b Home HD
The same techniques as described above apply to home hemodialysis but sessions take 
place at home and hence can be scheduled at patients’ convenience (Mackenzie & Mactier, 
1998; Oberley & Schatell, 1995).
Although home HD appears attractive, the current lack of easy-to-use HD machines poses a 
significant disincentive for patients. Blood access is usually obtained through a fistula or a 
graft puncture (which requires a helper). A training period of at least 6 weeks is necessary 
to learn the technique and appropriate living arrangements are required. There is a risk, 
albeit low, of air embolism associated with the procedure, making the process stressful for 
the patient and the helper. The overall dialysis procedure is more time consuming simply 
because a significant percentage of the time is spent in setting up, priming, taking down and 
cleaning the HD machine. The effective treatment makes up only a small portion of the 
total time spent on dialysis-related tasks.
Only a small proportion of patients reaching ESRD receives home HD; partly because such 
patients need suitable space, vascular access, which they can cannulate reliably, and also 
the ability to learn and use the relatively complicated equipment and procedures necessary 
for safe and high quality hemodialysis.
2.2 Peritoneal Dialysis (PD)
In PD, there is an exchange of solutes and fluid between the peritoneal blood and the 
dialysis solution in the peritoneal cavity across the peritoneal membrane, which acts as a 
filter (Gokal, 1987; Gokal & Mallick, 1999). It requires placement of a catheter into the 
abdominal cavity and repeated instillation and drainage of sterile dialysate.
The crucial components of the peritoneal dialysis system are peritoneal blood flow, the 
highly vascular membrane and the flow rate and volume of peritoneal dialysis solutions. 
Since neither peritoneal blood flow nor the vascularity of the membrane can be 
manipulated, the only factor that can be adjusted to achieve maximum solute and fluid
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removal is the flow rate of dialysis solutions, i.e. how often exchanges are performed. To 
increase clearance for example the amount of fluid and the frequency of exchange can be 
increased, but both maybe limited by the patient’s comfort and convenience. Success of PD 
is dependent on the long-term viability of the peritoneal membrane and lies in preserving 
the peritoneum as a dialysing membrane for as long as possible.
PD is often regarded and has been advocated as the preferred initial modality of choice for 
patients with co-morbidities, particularly those with impaired cardiac function (Blake, 
2001; Burkart, 2001). In addition, more prolonged preservation of residual renal function, 
less strict control of diet and fluid intake and increased independence makes this treatment 
attractive in some patients starting dialysis. The two main types of PD are discussed in the 
following sections.
2.2.a Continuous Ambulatory Peritoneal Dialysis (CAPD)
CAPD has been used as an alternative to HD since 1976 (Popovich et a l ,  1976) and is the 
most common form of PD.
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Figure 1.2: Diagram of Peritoneal Dialysis
CAPD involves a closed system (see Figure 1.2) in which fluid is initially instilled by 
gravity into the peritoneal cavity and then drained out after several hours. The basic CAPD 
system consists of a plastic bag containing 0.5-3.0L PD fluid, a transfer set and a permanent
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catheter. The solutions contain glucose as an osmotic agent and lactate, sodium, potassium 
and calcium in differing concentrations (Hutchinson & Gokal, 1992). Various catheters are 
available designed to keep complications to a minimum. The connection between the bag 
and the transfer is broken several times a day and the procedure must be carried out by a 
strict, sterile, non-touch technique.
CAPD is carried out by the patient, who has to perform on a daily basis the required fluid 
exchanges, typically 4 or 5, requiring scrupulous attention to sterile technique. This 
typically requires no machine and does not involve visiting the hospital or dialysis unit. 
Various advantages have been claimed for CAPD and PD in comparison for HD (see Table 
1.1).
Table 1.1: Advantages and disadvantages of CAPD (PD) in comparison to HD
____________ Advantages____________
• Home based without a complex machine
• Easy to teach and learn
• Easier for travel
• More liberal diet and fluid allowance
• Continuous fluid and solute removal
• Longer preservation of residual renal 
function
• More suitable for specific patients groups 
(children, elderly, patients with diabetes 
and cardiovascular instability)
• Low cost (cheaper than HD)
___________Disadvantages___________
• Mechanical complications (abdominal wall 
hernia, back pain, fluid leaks, abdominal 
fullness occasional pain with drainage)
• Infections (peritonitis, exit site infection)
• Lower long term viability
• Metabolic complications, malnutrition
• Risk for inadequate dialysis, limited 
possibilities to increase adequacy
• Peritoneal membrane damage
• Fatigue and bum out from the continuous 
and rigorous schedule of bag exchanges 
especially in the elderly
• Psychological problems related to 
indwelling catheter
• Lower long term technique viability_____
2.2.b Automated Peritoneal Dialysis (APD)
APD is a modification of the technique described above in which exchanges are performed 
overnight by a machine. It is used to refer to all forms of PD that use a mechanical device 
to assist in the delivery infusion and drainage of dialysate from the peritoneum cavity 
(Diax-Buxo & Suki, 1994; Ronco & Diaz-Buxo, 2001).
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APD obviates the need for intensive manual involvement and limits the process of PD to 
two procedures-setting up of the dialysis regimen with an initial connection of the catheter 
to the machine and disconnection from the patient with dismantling of the machine at the 
end of dialysis. It is a home-based, self-care treatment and is predominantly done during the 
night. Thus, patients (and their helpers) are free during the day with short-dwell cycles run 
in and out of the peritoneum cavity by the cycler machine. APD treatment can offer several 
options, diurnal or nocturnal, tidal, with diurnal full or void abdomen, with different fluid 
volumes and dwell times and can be tailored to peritoneal transport characteristics and to 
the patient’s psychological needs.
However, because there is often a need to provide additional dialysis to achieve adequate 
dialysis, daytime exchanges may become necessary, thereby complicating the procedure 
and intruding in the patients’ daytime routine. Higher adequacy targets have been set by the 
National Kidney Foundation-DOQI and the UK renal registry and some APD patients have 
problems in reaching the selected targets (National Kidney Foundation Dialysis Outcome 
Quality Initiative: NKF-DOQI 1997a). Moreover, APD is much more expensive than 
CAPD.
The most important consideration in the selection of APD other than the patient’s 
preference, lifestyle needs and the availability of equipment, is the individual’s peritoneal 
transporter status. For patient with low peritoneal permeability, APD may be inappropriate 
especially when there is little residual renal function. These patients are unable to remove 
adequate amounts of solute and are best managed with haemodialysis (Gokal, 1996; Gokal 
& Mallick, 1999).
2.3 Biochemistry and dialysis
The uraemic syndrome is the prototype of a slowly progressive endogenous intoxication, 
when a detoxifying organ (in this case the kidney) fails. It is characterised by the gradual 
retention of a host of metabolites and solutes that interfere with various biochemical 
functions. Roughly, three groups of solutes can be distinguished: (i) small, water-soluble, 
non-protein-bound molecules such as urea and creatinine; (ii) large molecules with a
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molecular weight between 300 and 12000 D, classically referred to as middle molecules, 
and (iii) small protein-bound compounds.
The uraemic syndrome is biochemically indexed by this range of solutes, but relatively 
little is known about the exact mechanisms leading to uraemia, the unique contribution of 
each of these types of solutes to uraemia manifestation and their interrelations (Lesaffer et 
al., 2000). There is also no clear consensus on the role of these different solutes in the 
uraemic syndrome. In general, urea only becomes toxic at concentrations that are higher 
than those found in uraemic patients (Bergstrom, 1997; Vanholder et al., 1994).
HD (hospital and home) is performed intermittently, usually three times a week, for periods 
of three or more hours at a time. This results in periods of very high rates of artificial 
kidney function or ‘clearance’, alternating with longer inter-dialytic periods of poor kidney 
function. HD produces massive fluid shifts and metabolic alterations over a limited time 
span. Waste products and fluid are removed during dialysis and gradually accumulate again 
between treatments. As a result it is not uncommon for a patient’s weight to increase by 2-4 
kgs between treatments.
The intermittent HD results in a "sawtooth" effect (see Figure 1.3), producing a dramatic 
alkalinisation and reduction in urea during treatment, followed by a degree of rebound as 
the molecules equilibrate from the extravascular compartment (Nehemkis & Gerber, 1986). 
In fact, the fluctuation induced in the body (internal milieu) are so rapid and therefore so 
unphysiological that the phenomena were aptly termed ‘the unphysiology of dialysis’ in a 
paper published by Kjellstrand et al. in 1975. It was Kjellstrand and colleagues who first 
drew attention to the issues of possible negative effects of the unphysiology of intermittent 
dialysis treatment.
Studies that have analysed the brain density in HD patients showed that it decreases after 
HD with an influx of water in the tissue but similar changes were not observed for patients 
on CAPD. This effect leads to normalisation of the brain tissue that shows severe 
dehydration on the pre-dialysis phase (La Greca et al., 1980; 1982).
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Figure 1.3: HD and PD biochemical profile
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Removal of toxins by PD also differs in many aspects from that of HD, the most important 
being the continuous or nearly continuous nature of treatment. PD clearance is slow but 
continuous, with uraemic solutes and organic acids reaching a stable concentration in the 
blood (Ronco et al., 1998). As such PD is claimed to provide a more physiologic renal 
replacement as it provides effective control of uraemia and electrolyte disturbances and 
effectively corrects various forms of acidosis (Gokal & Mallick, 1999).
It is also the case that HD achieves more efficient clearance of small molecules, such as 
urea (Lessafer et al., 2000), whereas PD may achieve more efficient clearance of larger 
molecules (Berkoben & Schwab, 1999).
2.4 Renal Transplantation (TX)
Renal TX is considered the ‘ultimate renal replacement therapy (RRT)’. Successful renal 
TX represents the ‘closest’ return to normality and certainly the fullest resolution of 
uraemic state. In contrast with dialysis treatments, which only approximate the function of 
healthy kidneys, TX replaces all functions of the kidney. Renal TX usually restores
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erythropoeitin production, corrects anaemia (Besarab et al., 1987) and renal excretory, 
metabolic and endocrine function are recovered and nutritional status is improved (Miller et 
al., 1987).
A single kidney is placed usually in the pelvis close to the bladder to which the ureter is 
connected, without disturbance of the patient’s own kidneys. The kidney is attached to a 
nearby artery and vein. This surgery leads to a hospital stay of 2 to 3 weeks if 
uncomplicated.
Rejection continues to be the single largest impediment to success in TX (Matas, 1988; 
Pelletier et al., 1998) which has largely been overcome during the first few months using 
drugs such steroids and cyclosporin. Acute rejection still occurs in approximately 20-50% 
of kidney recipients during the first year post-transplantation (Sollinger, 1995) although 
year graft survival rates improved significantly over the last 20 years (Cecka, 2000).
Immunosuppressive drugs are taken on a permanent basis following TX to reduce the 
likelihood of rejection. Maintenance immunosuppression traditionally involves the use of a 
Calcineurin Inhibitor (CNI) either cyclosporin or tacrolimus. There is no consensus about 
whether the regimen with cyclosporin or tacrolimus is more effective; both are considered 
effective in preventing acute rejection (Keown, 2001). Major side-effects are associated 
with each of the traditional immunosuppressive drugs used in transplantation, particularly 
cyclosporin (and related tacrolimus) and corticosteroids. Complications include the 
acceleration of vascular disease so that myocardial infarction and strokes are commoner in 
transplant patients than in age-matched controls. TX recipients also suffer from multiple 
other complications including bone loss (Julian et al., 1992), increased incidence of 
fractures (Ramsey-Goldman et a l,  1999) and increased risk for the development of 
malignancy and infection as compared with age-matched population. During subsequent 
years there is also a steady loss of transplanted kidneys through rejection; and many 
patients require a second or even a third graft, and have to rely on dialysis between 
transplants.
There are two types of kidney transplantation:
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2.4.a Cadaver transplantation (CAD TX)
CAD TX is the type of transplantation where the graft comes from a cadaver donor. A 
cadaver donor is a person who is brain dead but who is maintained on artificial life support, 
such as an accident victim. The average time for ESRD patients to receive a cadaver 
transplant is long, typically greater than 2 years, and it continues to increase.
2.4.b Living related donor transplantation (LRD TX)
In LRD TX, the kidney is donated by a living donor often related but sometimes unrelated 
to the recipient. It can be scheduled electively and is more likely to be an early treatment, or 
even the initial modality of RRT.
Renal transplantation from living donors accounts for approximately 9% of all renal 
transplants performed in Europe (Mallick et al., 1995) although rates in the UK are 15% 
(International figures on organ donation and transplantation activities, 1998). Living donors 
are predominantly blood relatives, although there has been an increase in recent years in 
genetically unrelated kidney donations from emotionally related persons such as a 
recipient’s friend or partner.
Living related donor transplants have been considered to offer a number of advantages over 
cadaver kidney transplants, which affect their outcome.
(a) The elective nature of the surgery allows a more complete evaluation and preparation of 
the recipient and donor and can be performed when donor’s and recipient’s health is 
optimal.
(b) It may also permit a shorter delay between starting dialysis and transplantation and also 
offers a chance to avoid the potential negative consequences and medical risks of chronic 
dialysis (Asderakis et a l,  1998).
(c) The donor kidney incurs minimal ischaemic damage because the donor and recipient 
surgeries are scheduled together.
(d) The clinical outcomes of kidney transplantation such as graft and recipient survival 
rates have been found to be substantially better when organs are from living donors 
(Berkoven & Schwab, 1999; Cecka, 2000; 2001; Medin et al., 2000; Melchor & Gracida, 
1999; Ojo et al., 1995). Receiving a kidney from living related donor confers up to 7%
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increase in survival in Europe (EBPG European Expert Group on Renal Transplantation,
2000). Even a poorly matched kidney graft fares better than a well-matched cadaver graft 
(Terasaki et al.t 1995; 1997).
The physical disadvantages of LRD TX are borne by the donor. In general for a completely 
healthy kidney donor the risk of death is extremely low and major complications are 
uncommon but the physical impact of a successful surgical operation should not be 
underestimated.
Section 3: Incidence and Prevalence rates of ESRD and RRTs
3.1 ESRD
The number of patients with ESRD is increasing worldwide (Schena, 2000; van Dijk et a l ,
2001) and is expected to double over the next decade (Briggs et al., 2000; USRDS, 2001). 
Across Europe, approximately 50-80 people per million of the population (pmp) develop 
ESRD each year requiring some form of RRT (Brunner & Selwood, 1990). The current 
estimated rate of adult patients reaching ESRD and starting RRT in the UK is 90 pmp and 
approximately 5350 patients started RRT in 1999 (Feest et al., 1990; Internet UK renal 
registry report, 2000 see also http://www.renalreg.com/home.htm). The incidence of ESRD 
is three times greater for people with Afro-Caribbean or Indian origin (Roderick et al., 
1994) and it further increases six-fold to ten-fold from age 30-50 to age 70-90 (Stengel et 
a l , 2003).
The prevalence of ESRD (patients with transplants or treated with dialysis) was A ll  pmp in 
UK in 1994/1995 (Horl et a l , 1999).
This increase in ESRD population is inevitable because of population ageing and the age- 
related increase in the incidence of ESRD, improvements in the technology of dialysis, and 
better immunosuppression for TX that cut down mortality rates (Roderick et a l , 1998).
The criteria for RRT acceptance have broadened to include older patients and those with 
comorbidities. Contemporary patients receiving RRT in Europe bear little resemblance to
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those given treatment up to the mid-1980s. Recognition of these demographic shifts is key 
to interpreting the literature on the clinical, psychological and neuropsychological 
outcomes of ESRD in that the current ESRD patients now are quite different from their 
counterparts 10 or 20 years ago.
The following two sections review the breakdown of patients in the various treatment 
modalities.
3.2 Transplantation
The main bar to expanding transplantation is organ availability. The supply of donor organs 
(cadaver and living donor) which averages 28 pmp per year in the UK is greatly outstripped 
by demand which is 79 pmp (United Kingdom Transplant Support Service Authority, 
UKTSSA, 1993). At the end of 1999 in Great Britain and Ireland, 4740 patients were 
awaiting a kidney transplant, but only 1602 transplants were performed in that calendar 
year (UKTSSA, 1999). The majority of organ donation is carried out posthumously. In the 
UK in 2001, 2717 received an organ transplant; 378 of which were from a living related 
donor. Therefore, in the UK in 2001, 2339 patients received their kidney transplant from a 
cadaver donor.
3.3 Dialysis treatment distribution
Given the shortage of donor organs, most ESRD patients rely on some form of dialysis as 
treatment for their condition. There is considerable international and inter-regional 
variation in the distribution of the different dialysis modalities (HD vs. PD) (Dalziel & 
Garrett, 1987). In England & Wales 66% of dialysis patients are on HD compared with 
73% in Scotland. After an initial expansion and popularity in home HD during the 1970s 
and early 1980s, the number of patients receiving home HD has decreased progressively 
over the last decade (Blagg, 1996; MacKenzie & Mactier, 1998).
By world standards, the UK has relatively high PD utilisation (Internet address: 
http:/www/oanda.com/cgi_bin/ncc. 1998; Jassal et al., 2002). This contrasts with other
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European countries and the US where CAPD is used in less than 20% of patients (MacLeod 
et al., 1998). The rate on increase in CAPD is lower than in HD, producing proportional 
falls in these modalities in the UK (UK renal registry report, 2000).
APD has been the fastest growing method of renal replacement therapy, with the number of 
APD patients doubled since 1996 to 30,000 worldwide (Gokal & Mallick, 1999). The 
growth of APD has been paralleled by the development of new automatic machines which 
have made possible personalised treatment prescription and perhaps have improved 
treatment acceptability and adherence (Ronco & Diaz-Buxo, 2001). APD is utilised by 
31.9% of all PD patients, including the daytime dwell mode, daytime empty mode and 
schedules with one or more additional manual exchanges (Ronco & Diaz-Buxo, 2001; 
USRDS, 1999).
A wide range of factors both medical and non-medical would influence choice of treatment 
(Horl et al., 1999). In certain patients only one form of dialysis therapy (HD or PD) is 
possible and for some kidney transplantation may be difficult but in the majority of cases 
the choice of dialysis modality is based on non-medical factors (Jassal et al., 2002; Stack,
2002). These include financial reimbursement, facilities, physician bias and patients’ 
preferences (MacLeod et al., 1998; Wuerth et al., 2002).
Not all patients receiving dialysis are suitable for TX and there is evidence that selection 
criteria vary widely throughout the UK (McMillan & Briggs, 1995). This is reflected in the 
variation in the proportion of dialysis patients who are on the transplant waiting list in 
different regions. In some areas patients not yet on dialysis are accepted for TX and 
compete for organs with patients who may have been on dialysis for many years.
Practice guidelines regarding suitability for transplantation have been available in the 
United States for some years (Kasiske et a l, 1995) and European Best Practice Guidelines 
have recently been published (EBPG European Expert Group on Renal Transplantation,
2000)
In the UK definitive criteria for acceptance onto the cadaver transplant waiting list have yet 
to be agreed although major co-morbid factors reduce the likelihood of acceptance in many 
Transplant Units.
45
Section 4: Renal Replacement Treatments (RRTs) and Survival
The increase in numbers of patients on RRT has ‘inevitably’ been accompanied by a 
decline in overall survival as treatment becomes available for patients of all ages and with a 
range of comorbidities. On average the yearly mortality among patients being treated with 
dialysis is nearly 25% (USRDS, 1999) with deaths being mainly due to cardiovascular 
diseases (50%) and infections (15%). The rates of death among patients undergoing dialysis 
in the US are 25-50% higher than those in Japan and Europe (Friedman, 1996; Schena, 
2000).
4.1 Dialysis vs. Transplantation
Studies that compared clinical outcomes between dialysis and TX patients have focused 
mainly on survival and mortality rates. Studies from the pre-cyclosporin era (before 1984) 
were unable to show a substantial survival advantage of TX compared with dialysis. 
However immunosuppression treatment, Human Leukocyte Antigen (HLA) matching and 
organ preservation have fuelled an increase in graft survival with the result that survival in 
kidney TX is much superior to that experienced by dialysis patients. The comparison is 
biased by the fact that preferentially relatively young and healthy patients receive 
transplants, whereas the individuals who remain on dialysis comprise a precipitate of 
elderly with one or several co-morbidities severe enough to prevent acceptance for 
transplantation.
To minimise such selection biases several studies compared TX patients with dialysis 
patients on TX waiting lists. These results produced convincing evidence that TX improved 
long term survival relative to dialysis (Johnson et al., 2000; Mallick et al., 1995; Medin et 
a l, 2000; Ojo et al., 1994; 2001; Rabbat et al., 2000; Schaubel et a l, 1995; Schnuelle et 
al., 1998). The death rate for waiting-listed dialysis patients was found to be twofold to 
eightfold greater than it is for TX recipients (Becker et al., 2000). The estimated additional 
life-years gained from TX vary from 8 years in a diabetic recipient who is 60 years old or
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older to 31 years in a non-diabetic recipient who is 20 years old to 44 years old (Port et al., 
1993; Wolfe et al., 1999). Studies have also shown that failed TX terminates the patient 
survival benefit accruable from kidney transplantation and patients who lose graft function 
are at increased mortality risk unless repeat transplantation is performed (Ojo et al., 1998).
4.2 Different dialysis treatments (HD vs. PD)
Ever since the introduction of PD as a treatment modality for ESRD, there has been 
considerable debate about its success and the comparability of outcomes between PD and 
HD (Maiorca et al., 1989). Numerous studies have evaluated and compared the clinical 
outcomes associated with the different dialysis treatments. The major difficulty in 
objectively assessing treatment outcomes is that there are no randomly allocated 
prospective trials comparing the different treatments.
4.2.a Survival
The first serious attempt to look at outcome after correction for confounding variables was 
made by Burton and Walls (1987) who concluded that on an intention to treat basis there 
was no difference in mortality between PD and HD. Subsequently numerous studies have 
been published (examples of these are summarised in Table 1.2) which have found 
conflicting results.
Table 1.2: Survival comparisons: HD vs. PD
Study Year Outcome
Picolli
Bloembergen
1995
1995
1995
1995
1996b
1997
1999
1999
2000 
2000 
2002 
2003
No difference
CAPD worse except for younger patients
Locatelli
Disney
Maiorca
Fenton
Collins
Vonesh
Murphy
CAPD better 
CAPD better 
No difference 
CAPD better 
No difference 
No difference
No difference; CAPD better only in elderly
CAPD worse 
CAPD worse
Van Biesen
Keshaviah
Termorshuizen CAPD worse for elderly patients
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Recent reviews of the literature concluded that survival rates among patients treated with 
PD or PD are similar (Alloatti et al., 2000; Coles & Williams 1998; Gokal et ah, 1999).
4.2.b Dialysis technique failure
It is common for ESRD patients to change RRT modalities during the course of their 
treatment. Reasons for transfer include: complications of the therapy, inability to perform 
the therapy (lack of suitable access, medical contraindications), and patient request or 
lifestyle issues. In some cases it may be medically appropriate to transfer from PD to HD 
rather than a technique failure.
In terms of retention of patients on the original therapy (technique survival), there is 
consistent data to show that PD patients do not stay on their original therapy (Blake et al., 
2000; Churchill et al., 1998; Gentil et al., 1991; Gokal et al., 1987; Maiorca et al., 1996a; 
Serkes et al., 1990). Only 1-4% of patients who start PD continue for longer than 8 years 
(Gokal & Oreopoulos, 1996), largely due to technique-related complications such as 
peritonitis (Davies et al., 1998; Kim et al., 2002; Maiorca et al., 1996a; Schaubel et al.,
2001). Although APD is associated with lower peritonitis rate than CAPD (Huang et al., 
2001; Van Biesen et al., 2002) technique survival is still lower than figures reported for 
HD. It should however be acknowledged that at times peritonitis is the "precipitating" event 
for transfer, while the real underlying reason might be patient burnout, poor adherence, 
inadequate dialysis, a request based on lifestyle, or an underlying exit site infection. Two 
papers for example (Maiorca et al., 1995a; 1996c) commented on the increased incidence 
of CAPD drop out compared to drop out rates in HD. This was almost entirely due to 
patients’ or partners’ choice to discontinue PD treatments for several reasons 
(psychological, working, social).
Access problems are also frequent in HD and are responsible for 50% of the 
hospitalisations of HD patients (Ifudu et al., 1996). Without an adequate vascular access, 
HD efficiency is reduced, which results in increased morbidity and mortality (Santoro, 
2000).
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CHAPTER 2: HEALTH RELATED QUALITY OF LIFE IN  ESRD
In the early days of the RRT the challenge faced by the Nephrologists was to overcome the 
technical difficulties and provide a safe environment for more patients on RRT. To some 
extent this challenge has been met although it remains a difficult task to provide high 
quality care for the large heterogeneous group of patients on RRT.
Outcomes other than morbidity and mortality may provide a significant contribution to the 
discussion regarding the allocation of health care resources and medical decision processes. 
The following chapters review the literature on the health related quality of life (HQoL), 
illness and treatment beliefs, and neuropsychological functioning in ESRD and its 
treatments.
Section 1: The concept of Quality of Life (QoL) and its measurement
1.1 Definition/Conceptualisation of QoL/HQoL
Although QoL is increasingly assessed in research and clinical practice no consensus exists 
concerning the definition or the measurements of this multidimensional concept. Only a 
very small proportion of the studies that examined HQoL in ESRD have defined the term or 
have discussed how this term would be conceptualised and put in operation (Cagney et al., 
2000).
QoL or HQoL are often used interchangeably to describe the effects that diseases, 
treatments or other interventions may have on person’s functioning and well-being. But the 
concept of QoL may be considered distinct from health, although related to it. QoL is a 
multidimensional phenomenon including but not restricted to health (Welch, 1994). It can 
include a number of dimensions that refer to physical, psychological, mental, emotional, 
social, spiritual, and vocational function. Patients actually perceive and react to many 
health and non health-related aspects of their lives, such as family life, finances, housing
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work and others aspects of human experience, that are not related to the domain of health. 
Hence only the subset of the overall QoL that relates specifically to a person’s health status 
that is more sensitive to changes in health refers to the measure of the patients’ HQoL.
Based on the WHO definition of health, defined as ‘a state of complete physical, mental 
and social well-being and not merely absence of disease or infirmity’ (WHO 1948; 1958), 
HQoL is operationalised by assessing the domains of physical, mental/cognitive, and social 
functioning. It is the health-related quality of life that is traditionally measured in clinical 
trials and medical research to evaluate the benefit/burden ratio of available treatment 
modalities. The physical domain is typically considered to encompass ambulation, 
mobility, fatigue, pain, sleep, and ability to perform daily activities. Depression, anxiety, 
emotional well-being and cognitive status fall within the mental/cognitive domain. The 
social domain of HQoL includes, for example, work status, role functioning, personal 
relationships, and sexual functioning.
In this thesis the focus will be on HQoL since this construct has been applied in ESRD 
research to date. The terms subjective and objective HQoL, a distinction commonly used in 
clinical ESRD literature, will be avoided and where appropriate the terms physical and 
emotional HQoL will be employed.
1.2 Measurement of HQoL
Two main approaches have been used to measure HQoL: generic and disease-specific 
instruments:
• Disease-specific instruments are those which include the dimensions most relevant to
patients affected by particular condition (disease or treatment). They tend to be more
sensitive to clinical changes than generic instruments but do not allow comparisons 
between patients with different pathologies (Guyatt et al., 1989).
• Generic instruments include different dimensions of HQoL considered generally
imported and broadly applicable across types and severities of disease, across different 
treatments and medical interventions and across demographic and social subgroups 
(Patrick & Deyo, 1989). Generic instruments enable comparisons across studies and
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disease groups which help judge the severity of problems associated with disease 
(Guyatt & Jaeschke, 1990), but they may not focus adequately on specific areas of 
interest or particular problems/issues among different populations and illness groups 
(Tsevat et al., 1994). Commonly used generic tools in HQoL research include the 
Sickness Illness Profile (SIP; Bergner et al. 1981; 1993) and the 36-item short form of 
the Medical Outcomes Survey (SF-36; Ware & Sherboume, 1992).
There is no ideal instrument to measure HQoL in all circumstances. A combined approach 
using generic instruments augmented by disease-specific measurements or items as 
suggested by Kutner (1994) may be the preferred approach (Garratt et al., 1993; 
Valderrabano et al., 2001).
It should nevertheless be kept in mind that QoL and HQoL instruments will never capture 
all aspects of life that are important to the individual, although systems in which patients 
specify all or at least some of the qualities are likely to come closest. The individual nature 
and the shortcomings of many existing measures have been highlighted by many 
investigators (Carr et al., 2001). The increasing interest in developing individualised 
measures reflect the perception that QoL is unique to the individual and cannot be 
adequately assessed using standardised measures. Individual measures such as the Schedule 
for the Evaluation of Individualised Quality of Life (SEIQoL; O’Boyle et al., 1992) have 
been advocated but are limited by difficulties in making group comparisons. Although the 
debate is still ongoing, several disease-specific and generic (assessing health concepts 
relevant to everyone’s health status and well-being) measures have been demonstrated to be 
valid, reliable, and robust across languages, cultures and clinical settings and as such this 
will be the focus of this work.
Previous research in HQoL in ESRD has employed a range of generic and disease-specific 
HQoL measures. It is beyond the scope of this chapter to describe available HQoL 
instruments; detailed reviews have been published elsewhere (Cagney et al., 2000; Edgell 
et ah, 1996; Rettig et al., 1997; Salek, 1996) but irrespective of the type or the focus of the 
instruments (generic vs. disease-specific) used, the need for comprehensiveness, reliability, 
validity and responsiveness cannot be overstated. This unfortunately has not always been 
demonstrated or reported in ESRD studies (Cagney et al., 2000; Edgell et al., 1996). Of the
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101 studies reviewed by Edgell et a l (1996) only 35 reported satisfactory psychometric 
properties for the instrument used and 45 papers reported no psychometric evidence at all.
This review will focus on some of the most common HQoL measures used in ESRD 
research. It is not intended to be comprehensive and only a subset of the large literature will 
be directly cited. Emphasis will be given on those studies, which used well-established 
generic instruments (such as the SF-36, NHP or the SIP) or kidney-specific measures that 
have undergone adequate evaluation and development such as the Kidney Disease 
Questionnaire (KDQ; Laupacis et a l , 1992), or the Kidney Disease Quality of Life 
(KDQoL; Hays et a l , 1994). These so called new generation of generic and disease- 
specific measures have had extensive testing in the ESRD population and have been 
advocated as reasonable choices (Cagney et a l, 2000; Nissenson, 1994).
1.3 The place of HQoL in ESRD research
Recent work used/treated measures of HQoL as outcomes per se and as predictors of other 
outcomes.
1.3.a HQoL as a predictor of clinical outcomes
HQoL scores are strong predictors of clinical outcomes in ESRD including survival and 
hospitalisation (Kalantar-Zadeh et a l, 2001; Knight et a l2003; Lopes et a l, 2003; Merkus 
et a l, 2000; Parkerson & Gutman, 2000).
Lowrie et a l  (1997; 2003) for instance, have demonstrated that dialysis patients with scores 
lower than 51 on the Mental Component Scale (MCS) of the SF-36 have progressively 
increasing risks of death. Patients with scores of 0-37 have twice the relative risk of death 
than those patients with scores of 51 or higher. In a prospective study of 1000 HD patients, 
a 10% increase in death risk and a 5.8% in hospitalisation rate for every five-point decrease 
in PCS was found (De Oreo, 1997). MCS was not associated with survival, but a five point 
decrease in MCS correlated with a 2% increase in hospitalisation rate.
A large prospective study using the SF-36 and the short form KDQoL, was carried out in 
17,236 HD patients in the United States, Europe and Japan (Mapes et a l, 1999; 2003).
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Results indicated that a five-point increase in HQoL scores for PCS, MCS and kidney 
disease targeted issues was associated with a 4 % to 8% reduction in risk of hospitalisation, 
and a 9% to 29% reduction in mortality after adjusting for sociodemographic, clinical, and 
laboratory factors.
1.3.b HQoL as an outcome
The bulk of studies have treated HQoL as an outcome per se of ESRD and associated 
treatment. These will be selectively reviewed in the following two sections.
Section 2: Research in HQoL and Dialysis
There have been numerous HQoL studies in dialysis and kidney transplantation although 
relatively few studies have been conducted on PD and Home HD patients. Diabetic 
patients, elderly patients and those who return to dialysis after failure of a renal graft have 
also been the subject of several studies.
With a few exceptions, data on HQoL of dialysis and renal transplant patients are derived 
from cross-sectional studies. The few longitudinal studies have either assessed only 
hospital HD or CAPD patients (Kutner et al., 1986; Meers et al., 1996) or compared HQoL 
before and after kidney TX (Laupacis et a l , 1996; Parfrey et a l , 1988a; Russell et a l, 
1992). A selective overview of the most relevant studies will be presented.
2.1 Comparisons between dialysis and general population
Overall the observed mean scores of dialysis patients on HQoL instruments fall below 
those of general population indicating that HQoL is substantially compromised (Beusterien 
et a l, 1996a; Diax-Buxo et a l, 2000; Gudex, 1995; Khan et a l, 1995; Moreno et a l, 
1996a; Wight e ta l,  1998).
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The research was spurred on by Evans and colleagues in 1985, when they published a 
‘landmark’ paper that focused the attention of the medical community on HQoL in ESRD 
patients. In that paper, HQoL data from the classic National Kidney Dialysis and Kidney 
Transplantation study of 859 patients showed that physical functioning scores of dialysis 
patients were worse than those of the population, although emotional well-being was less 
affected (Evans et al., 1985). These early data on the lack of congruence between physical 
and mental indicators of HQoL was confirmed in later studies using generic HQoL 
instruments (e.g. SF-36; SIP).
HQoL impairments were found to be particularly pronounced with respect to physical 
dimensions of HQoL (DeOreo, 1997; DeWit et al., 2001; Fukuhara et al., 2003; Khan et 
al., 1995; Pemeger et al., 2003; Wight et al., 1998), whereas emotional HQoL remains 
generally intact. Mean scores in the emotional dimensions of HQoL are typically close or 
equivalent to those of general population (Diax- Buxo et al., 2000; Lamping et al., 2000; 
Merkus et al., 1999b; Mingardi., 1998; Mingardi et al., 1999; Mittal et al., 2001a), but not 
always within normal range (Beusterien et al., 1996a; Khan et al., 1995; Wight et al., 
1998).
Prospective studies indicate a progressive deterioration in HQoL both following initiation 
of dialysis and as a function of time on a specific dialysis modality. Again the effect 
appears to be greater for physical rather than emotional HQoL. For example in the 
combined Oxford and Manchester study of 159 patients (78 HD and 81 CAPD) a marked 
deterioration was observed in patients’ mobility following commencement of treatment but 
on various psychological scales (life-stress, happiness and satisfaction), their mean scores 
proved comparable to a normal population (Auer et al., 1990).
A prospective multicentre study of (incident) HD and PD patients over the first 18 months 
of treatment also showed that physical HQoL (PCS) decreased over time with the greatest 
decline being noted for the PD group. Mental HQoL on the other hand appeared to remain 
stable in both groups (Merkus et al., 1999b). Inspection of individual SF-36 subscales 
showed that deterioration was concentrated in physical functioning and somewhat less in 
the general health sub-scale. Another study recruited only PD patients and showed a steady 
decline in all HQoL dimensions (assessed by generic and renal specific sub-scales) over the 
two-year study period (Bakewell et al., 2002). Although the patients who completed all five
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HQoL assessments were on PD for different periods of time, their decline was uniform. The 
most significant changes were in PCS, MCS, and three kidney specific sub-scales: patient 
satisfaction; symptoms; and burden of kidney disease.
Opposite findings have also been reported. Mittal et al. (2001a) evaluated HQoL using the 
SF-36 in a cohort of 134 prevalent HD patients, with assessments taken every three months 
for 2 years. There was no significant mean change in self-assessed physical (PCS) and 
mental well being (MCS). Both PCS and MCS tended to decline in the initial months of 
HD but stabilised over time. Despite not finding statistically significant changes in the 
mean scores, analysis of individual rate of change indicated that more patients had 
deterioration in PCS whereas the reverse was true for the MCS with more patients reporting 
improvement in MCS. These findings of stable physical and emotional well-being over 
time were replicated in prevalent PD patients (CAPD and APD) (Mittal et al., 2001b). 
Sesso et al., (2003) found that HQoL in the first 7 months on HD were dependent on 
patients’ socio-economic status (SES). HQoL improved in the high SES group but not in 
the low and medium SES patients.
2.2. Dialysis treatment HQoL comparisons: HD vs. PD
Inconclusive data exist regarding differences in HQoL between HD and PD patients (see 
reviews by Gokal et al., 1999; Valderrabano et al., 2001). Evidence is conflicting with 
studies reporting equal or superior HQoL for either PD or HD treatment.
The vast majority of studies comparing HQoL in hospital HD and CAPD patients report no 
significant group differences in either physical or mental processes of HQoL after adjusting 
for case-mix differences such as sociodemographic, clinical, and dialysis characteristics 
(Bremer et al., 1989; Churchill et al., 1987; Diaz-Buxo et a l, 2000; Evans et al., 1985; 
Harris et al., 2002; De Wit et al., 2002; Hart & Evans, 1987; Julius et al., 1989a; Merkus et 
al., 1999b; Mingardi et al., 1999; Moreno et a l, 1996a; 1996b; Nissenson 1992a; Simmons 
& Abress, 1990; Tucker et al., 1991; Waiser et a l, 1998; Wight et a l, 1998) or when 
dialysis groups were closely matched (Bakewell et a l, 2001; Harris et al. 2002; 
Killingworth & Van de Akker, 1996).
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The issue of sufficient and appropriate adjustment for casemix differences is critical given 
the absence of patients’ random allocation to treatment. It is further highlighted by several 
studies comparing HQoL between HD and PD patients before and after case-mix 
adjustments. Significant group differences in mental HQoL indicators favouring PD 
patients were found only in case-mix unadjusted comparative analyses. These treatment 
effects however disappeared after case-mix adjustments (Bremer et al., 1989; Merkus et al., 
1999a; 1999b; Simmons & Abress, 1990). These findings include studies highly regarded 
for their methodological rigour that used large samples, psychometrically sound 
instruments, and directly compared the issue of case-mix (Bremer et al., 1989; Evans et al., 
1985; Merkus et a l, 1999a; 1999b).
In the studies where treatment related differences persisted after case-mix adjustments, 
results could be summarised as follows:
HD patients were found to score higher than PD in measures reflecting physical HQoL 
(Barrett et al., 1990; Julius et al., 1989b; Diax-Buxo et al., 2000). Prospective studies 
similarly showed a more favourable effect of HD on physical HQoL over time compared to 
with PD (Merkus et al., 1999b; Mittal et al., 2001b). The lower physical well-being scores 
have largely been explained by lower albumin levels in the PD groups (Mittal et al., 2001b) 
and the continuous physical burden of PD compared with the intermittent character of HD. 
In addition, peritonitis may explain the higher pain perception in PD patients.
Psychological indicators of HQoL tend to favour PD or CAPD patients (Merkus et al., 
1997; Simmons et al., 1990; Wolcott et al., 1988a; Wight et a l, 1998). Simmons & Abress 
(1990) however noted that the advantage of CAPD over HD was no longer significant for 
patients on treatment for 1 to 3 years, suggesting that it may only become evident only as 
time on therapy lengthens and/or as patients doing less well switch therapies or die. A 
meta-analysis by Cameron et a l  (2000) examined differences among RRTs in two 
fundamental QoL dimensions: psychological well-being and emotional distress. Their 
results indicated that CAPD patients reported higher psychological well-being than HD but 
as stated by the authors this finding is threatened by possible publication bias (i.e. studies 
not showing statistically significant differences may not have been published).
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2.3 Dialysis treatment comparisons: hospital HD vs. home HD
Home HD has been consistently associated with improved HQoL compared with hospital 
HD (Bremer et al., 1989; Evans et al., 1985; Kutner et al., 1986). A meta-analysis by 
Cameron et al. (2000) also found that patients on hospital HD report significantly more 
emotional distress than home HD patients. On the other hand, studies that HQoL was 
assessed using preference based instruments report no significant differences between the 
two HD groups (Churchill et al., 1987). How home HD compared with the other home 
based treatment modalities (CAPD; APD) remains to be evaluated.
2.4 Dialysis treatment comparisons: CAPD vs. APD
The HQoL on APD has rarely been studied with only five HQoL studies incorporating 
APD patients. Three of these studies reported data on the aggregate level (combined sample 
of CAPD and APD patients) making it impossible to draw conclusions on the relative 
performance of the APD patients (De Wit et a l, 2002; Morton et al., 1996a; 1996b). One 
study focused on the impact of different types of APD equipment on HQoL (McComb et 
al., 1997).
Only three studies compared APD and CAPD. Bro et al. (1999) in a small randomised trial 
(n = 25) comparing HQoL in APD and CAPD patients found no significant group 
differences in physical and emotional well-being. Significantly more time for work, family, 
and social activities was available to patients on APD compared to those on CAPD. Sleep 
problems on the other hand tended to be more marked in the APD group. In a most recent 
investigation (De Wit et al., 2001), APD patients had higher emotional well-being as 
indexed by the MCS SF-36 scores and were significantly less anxious and depressed than 
CAPD patients. Physical functioning indicators were however equivalent between the two 
groups. It is also worth noting the report of McComb et al. (1997), who found no 
significant change in HQoL when a small sample of 26 patients were switched from CAPD 
to APD.
Diaz-Buxo et al. (2000) compared SF-36 scores in hospital HD, CAPD and APD patients. 
They found that among PD patients, those on APD (n = 532) had worse scores on scales
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reflecting physical processes and better scores on scales reflecting mental/emotional 
processes than CAPD patients (n = 728).
2.5 Dialysis comparisons: Conclusions
The inconsistent results in the literature may in part be explained by cross-sectional 
designs, and improper or insufficient adjustment for casemix differences that are likely to 
impinge upon HQoL.
As patients are not randomly assigned to RRT, many key variables relevant to HQoL (such 
as age or comorbidity) may differ significantly between groups (Cameron et al., 2000). In 
reviewing the literature, it should be borne in mind that lacking random allocation, it is 
difficult to ascertain and estimate the effect of different dialysis modalities (HD vs. PD) due 
to the presence of many confounders (Nissenson, 1994). This presents additional challenges 
to the synthesis and interpretation of the literature. The observed superiority of one 
treatment may be attributable not to valid differences in the HQoL afforded by a particular 
treatment modality but to pre-existing non-renal and/or non-treatment related differences. 
Research findings are hence ambiguous, when investigators do not take such casemix 
differences into consideration (Greenfield et al., 1994).
The meta-analysis by Cameron et al. (2000) also concluded that although psychological 
dimensions of HQoL differ systematically across patients receiving alternative RRTs, it is 
not clear whether this occurs because of valid differences between treatment modalities, 
pre-existing differences among patients, or a combination of these two alternatives.
Inconsistencies may also relate to the characteristics of the various measurement tools used 
to assess HQoL. This is illustrated by Deniston et al. (1989). HQoL was assessed using 19 
different HQoL instruments in a cross sectional sample of 742 ESRD patients. Depending 
on the choice of instrument, different conclusions were reached about the relationship 
between demographic characteristics, treatment modality and HQoL. Depending on which 
of the 19 scales (or a greater number of sub-scales) was examined, either PD or HD was 
judged to provide better HQoL. To summarise, the impact of dialysis modality on HQoL is 
uncertain. Overall, the analysis suggests that PD and HD are equivalent therapies when
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appropriate correction is made for casemix differences. Comparisons of PD with HD must 
be treated with considerable caution. The studies that are available, however, suggest both 
treatments may result in similar HQoL levels.
Another issue particularly pertinent to PD vs. HD comparisons relates to the specific 
dialysis group being compared. Results are less clear-cut when comparisons also involve 
home HD or APD patients rather than solely comparisons between hospital HD and CAPD 
patients.
APD and Home HD appear to be associated with more favourable HQoL relative to 
hospital HD and CAPD albeit not consistently so. For example, Diaz-Buxo et al. (2000) 
performed a cross-sectional study of HQoL in 16,755 HD and 1,260 PD patients (CAPD 
and APD) using the SF-36. HD and PD patients scored similarly for scales reflecting 
physical processes. APD patients scored higher than HD for mental processes, although no 
differences were found between HD and CAPD. Two earlier studies have also shown that 
home HD offers patients a better quality of life, a greater independence, and a better 
rehabilitation opportunity than PD (Bremer et al., 1989; Evans et al., 1985). Evans et al. 
(1985) for instance, found that PD patients had better health status and physical well-being, 
and greater life satisfaction than hospital HD patients but not as good as home HD or 
transplant patients.
A reinvestigation of how home HD compares with the other treatment modalities is 
warranted given that dialysis techniques and practices have changed substantially since 
1980’s when this question was last addressed. Finally although the question of which 
dialysis modality imparts the best HQoL is not a new agenda and has indeed been 
repeatedly investigated none of the previous studies have evaluated and compared HQoL 
between the four dialysis treatments: Home HD, hospital HD, APD and CAPD.
It is thus important not just to document HQoL in the modem dialysis population but also 
to evaluate HQoL outcomes of hospital vs. home-based dialysis care.
It is possible and relevant to speculate that home-based dialysis may impair the HQoL to 
greater extent than hospital based treatment for several reasons: increased demands or 
responsibility placed upon the patient and his/her family; time requirements performing for 
instance the CAPD bag exchanges may be greater (Devins et al. 1990a) or the presence of 
dialysis-related equipment (e.g. machines) in patients’ homes or personal space may act as
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a constant reminder of their condition. Home-based delivered dialysis may also pose more 
HQoL risks as it allows for less compartmentalisation in different life aspects, requires 
tremendous motivation and might entail more emotional strain on their partner.
Conversely, one might argue that PD regimens might afford better HQoL as they allow 
more flexibility in everyday life and impose fewer dietary and social restrictions. It is 
generally held that the greater patients’ involvement in PD regimen and Home HD should 
discourage learned helplessness and allow the patient to take control of the treatment, hence 
maximising HQoL (Ronco & LaGreca, 1997). On the other hand PD may be more 
distressing on a more sustained basis due to the responsibility patients must take for their 
health and well-being. Investigators (Maiorca & Cancarini, 1996; Maiorca et a l, 1995a; 
1996b) have also commented that after a number of years there may be burnout of either 
the CAPD patients or the caregiver. These comparisons are now evaluated.
Section 3: HQoL Research and Transplantation
Because of the high cost, interest in transplantation outcomes is particularly intense (Beidel, 
1987; Dew, 1998; Levy 1994). In general, the relative success of transplantation has led to 
a shift in research agendas beyond the success of the procedure and graft and patient 
survival, to include an examination of recipients’ psychological response to transplantation, 
and their functioning and HQoL (Hanaeur, 1994). Given that potential recipients of an 
organ have generally poor functioning it is not surprising that transplantation has been 
found to lead to HQoL improvements (Bravata et a l, 1999; Caine et a l, 1996; Dew et a l, 
1997; Wright-Pinson etal., 2000).
There are many reasons for the improvement in HQoL of dialysis patients after 
transplantation. On a physical level the correction of anaemia has a definite effect on HQoL 
leading to improvements in symptoms such as fatigue, sleep, and appetite disorders. There 
is an improvement in sexual dysfunction -  women resume menstruation and recover their 
fertility while men recover their sexual potency and libido. Fluid intake and diet restrictions 
are lifted. On a psychological and social level, the physical dependence on the HD
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machine, or the rigorous CAPD and APD routine disappear and patients have more 
freedom to pursue work social and family activities.
3.1 Prospective studies pre- to post-transplantation
Prospective studies that assessed patients prior and post-transplantation uniformly showed 
substantial improvements in all HQoL dimensions (Christensen et al., 2002; Dew, 1998; 
Dew et al., 2000a; 2000b; Hathaway et a l , 1998; Russell, et al., 1992). In most previous 
studies the period of assessment ranged from a few months to nine years, but serial 
sampling has not been performed. Data on the HQoL of TX patients over time are 
contradictory.
(a) Most studies show an improvement, typically at 12 months post-transplantation. Gains 
were most consistently noted for physical functioning HQoL and global QoL perceptions. 
These effects are maintained at longer follow-ups but no further improvements occur (Jofre 
et al., 1998; Laupacis et al., 1996; Pafrey et al., 1988a; Park et al., 1996; Simmons et a l , 
1977; 1981).
(b) Some show continuous improvements over time (Hilbrands et a l , 1995a) whereas in 
some cases poorer results were achieved (Jofre et a l, 1998; Rebollo et a l, 2000)
(c) Factors such as gender, race, previous dialysis experience, diabetes, and creatinine have 
had an effect on the magnitude of HQoL improvements (Jofre et a l, 1998; Johnson et a l, 
1998b; Wright-Pinson et a l, 2000).
Patients pre-transplantation functioning is another important consideration. A study 
comparing HQoL pre- and after different types of solid organ transplantation (Wright- 
Pinson et a l  2000) showed that the trajectory of HQoL improvement among lung, liver, 
heart, and kidney TX patients, is different, as patients start at different levels of HQoL prior 
to TX operation. Renal TX patients who start out the best, mainly because of dialysis, 
improved the least and retained their functional classification (Kamofsky), and HQoL 
levels (PCS and MCS) during the first 2 postoperative years.
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3.2 HQoL in Transplantation compared to general population
HQoL levels afforded by transplant patients have typically been reported as equivalent or 
nearly equivalent to that of the general population (Bremer et al., 1989; Dew, 1998; Evans 
et al., 1985; Gouge et al., 1990; Insense et al., 1999; Littlefield et al., 1996; Painter et al., 
1997; Shield et al., 1997).
3.3 HQoL in transplantation compared to dialysis
Findings consistently show that among RRTs, transplantation imparts the best HQoL for 
ESRD patients (Cameron et al., 2000; Valderabanno et a l, 2001). Dew et al., (1997) 
reviewed 66 studies with more than 6,500 renal transplant recipients and concluded that 
data were sufficient to confirm that TX produces a significant improvement in both 
physical (78% of the patients) and psychosocial aspects (70%) of HQoL as well as in global 
health perceptions (100%). When data were averaged across patients a between treatment 
HQoL advantage was identified for renal transplantation compared to dialysis. There is 
indeed ample evidence (from empirical investigations) in support of this conclusion (e.g. 
Bakewell et a l,  2001; Evans et al., 1985, Googe et a l,  1990, Hathaway et al., 1998; Jofre 
et a l,  1998; Johnson et a l, 1982, Wight et a l, 1998).
Cameron and associates (2000) questioned the validity of some of the findings in the 
previous literature. They warned that publication bias and casemix differences might have 
biased the results to favour TX over dialysis. The need for consistent documentation and 
sufficient control of casemix variables in such comparisons becomes clear if the impact of 
treatments has to be clearly understood.
3.4 HQoL in CAD and LRD transplantation
The majority of previous HQoL studies has been limited to samples of CAD patients or 
have not specified the transplant donor source (Devins et al., 1990a; Morris & Jones, 
1988). Freeman (1985) attributed the findings of enhanced HQoL (Evans et al., 1985) to
the large proportion (50%) of living related transplant recipients recruited in studies. These 
conclusions have not however been substantiated by empirical evidence. Studies evaluating 
the effect of transplant source on global QoL and health status (e.g. life satisfaction and 
functional ability) reported no differences between the two transplant groups. Evans et a l 
(1984) found that the source of transplant did not significantly affect physical and 
emotional measures of HQoL. Similarly Julius et a l (1989b) found no differences between 
CAD and LRD transplant patients in measures of physical functioning. In the most recent 
investigation, Christensen et a l, (2002) found that the main effect of donor source was 
unrelated to depression and HQoL.
Section 4: Transplantation specific outcomes
Health care providers and transplant recipients themselves have become increasingly aware 
that TX may give rise to new set of stressors, psychosocial challenges and adaptive 
demands (Grady et a l, 1996; Hanson, 1987; Hathaway & Strong, 1988; McQuellon et a l, 
1998; Robertson, 1999; Wainwright et a l, 1999).
It may be expected that although the recipients of different transplanted organs will have 
many similar types of concerns, these may vary in the degree of importance. Commonly 
reported stressors identified across a range of transplant populations, include the cost and 
side-effects of immunosuppressive medication, worries about the viability of the 
transplanted organ, fear of rejection and the need to adhere to a rigorous post-transplant 
care regime (Fallon et a l, 1997; Frey, 1990; Gubby, 1998; Hathaway et a l,  1990; Hauser 
et a l,  1991; Hayward et a l, 1989; Kong & Molassiotis, 1999; Sutton & Murphy, 1989; 
White et a l,  1990). It has been argued that a viable organ transplantation, albeit a life 
saving procedure for several end-stage medical conditions, does not cure disease but rather 
extends life by trading one chronic disease for another (Johnson, 1990). 
Immunosuppressive therapy continues indefinitely after transplantation and is often 
accompanied by some dietary restrictions. Transplant recipients are also required to 
regularly attend outpatient transplant clinic and laboratory appointments and check ups, 
although their frequency decreases with time. They are also expected to engage in several
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preventative or health protective behaviours (e.g. use sun block agents) or monitoring 
behaviours (e.g. monitor themselves for early signs of rejection). Accumulating evidence 
suggests that a considerable number of transplant recipients fail to adhere completely to 
their treatment recommendations (Bunzel & Laederach-Hofmann, 2000; Colon et al., 1991; 
Hilbrands et al., 1995b; Kiley et al., 1993; Rovelli et al., 1989a; 1989b; Schweizer et al., 
1990; Siegal & Greenstein, 1997). This is of particular concern in the light of evidence 
indicating that poor adherence is a major determinant of graft failure (Burke et al., 1996; 
Didlake et al., 1988; Dunn et al., 1990; Hilbrands et al., 1995b; Hong et al., 1992; Kalil et 
al., 1992; Schweizer et a l, 1990) and mortality (Rodriguez et al., 1991).
Other areas of concern and potential stress for organ recipients include: impact on family 
relationships, post-transplant adjustment (e.g. resuming an independent role, change in 
physical and social activity), integration of the transplanted organ to body image, and 
emotional responses most notably feelings of gratitude and guilt towards the donor or 
donor’s family as well as feelings of personal inadequacy and/or responsibility for ultimate 
graft survival (Bosnak, 1996; Bunzel et al., 1992a; 1992b; Bunzel & Wollenek, 1992; 
Castelnuouvo-Tedesco, 1981; Hathaway et al., 1990; Kimball & Famularo, 1980; Kuhn et 
al., 1988; Lewino et al., 1996; Mai, 1986; Muslin, 1971; Rauch & Kneen, 1989; Robertson, 
1999; Schlebusch, 1986; Schlebusch et al., 1989; Schlebusch & Pillay, 1992; Simmons, 
1983; Simmons et al., 1977; Witzke et al., 1997). It is possible that these specific emotional 
and behavioural responses to transplantation may differ between transplant types (living vs. 
cadaver), and may in turn impinge upon HQoL.
These issues, though highly relevant remain largely unexplored by HQoL instruments. 
Although these have provided useful data and offer ready comparisons across studies and 
patient groups, they fail to capture these specific and often subtle emotional and 
behavioural concerns of transplant recipients. Measurement specificity is the alternative 
approach and the value of condition-specific instruments has been widely recognised 
(Bradley, 1994; Welch, 1994). Specific instruments can be expected to provide more 
sensitive measurement of processes and responses unique to transplantation but existing 
transplantation-specific measures have been proven to be relatively unproductive as they 
are limited both in terms of their content and coverage as well as their psychometric
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properties. Transplantation-specific QoL instruments (Quality o f Life Inventory; Carrington 
et al., 1996; Bone Marrow Transplantation Symptoms Checklist; Fife et al., 2000; End 
Stage Renal Disease Symptom Checklist-Transplantation Module; Franke et al., 1999; 
Heart Transplant Symptom checklist; Grady & Jalowiec 1995; General Health/QoL rating 
scale; Lanuza et al., 2000; Kidney Transplant Questionnaire; Laupacis et a l, 1993) assess 
mainly physical functioning usually incorporating some psychosocial functioning items. 
They thus take little consideration of transplant-specific emotional responses or treatment 
related issues.
There appear to be no widely used psychometrically sound instruments to assess the 
specific responses of receiving an organ transplant. A few studies use transplant-specific 
measures but those that do, tend to employ idiosyncratic instruments and the psychometric 
properties and development of which are not always described in sufficient detail for 
research or clinical use (Fife et al., 2000; Kerr et a l, 1991’, Lanuza et a l, 2000; Siegal et 
a l, 1989; Teichman et a l, 2000; Witzke et al., 1997; Wolcott et al., 1986). For example 
Wolcott et al. (1986) developed a recipient questionnaire for bone marrow transplant 
patients but did not report on its psychometric properties nor item content. Other 
investigators (Bortman et a l, 1999; Greenstein et al., 1997; Ostrowski et a l, 2000; Schlitt 
et al., 1999) employed transplantation-specific questionnaires but analysed each item 
separately reporting the percentages of patients endorsing or not a particular item rather 
than identifying subscales and establishing or examining the psychometric properties of 
their measure.
One central problem in the existing questionnaires is their limited scope. Typically the 
measures are tailored to study particular samples, such as kidney, bone marrow or heart 
transplant patients (Franke et al., 1999; Grant et a l, 1992; Jacobs et al., 1998; Ketefian & 
Starr, 1990; Laupacis et al. 1993; McQuellon et al., 1997; Molassiotis, 1999; Parfrey et al., 
1989; Park et al., 1992; Sutton & Murphy, 1989; Wirth & Barton, 1985) or were designed 
to assess newly transplanted patients (Hayward et al., 1989). This restricts their use with 
other transplant populations. The transplant-specific questionnaires appear to cover some 
but not all of the important aspects of post transplant experience identified in the literature. 
Other transplantation specific measures have specifically been designed to measure a very 
specific single concept such as body image (Bone Marrow Transplantation Symptoms
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Checklist; Fife et al. 2000; Body Image Questionnaire; Schlebusch et al., 1992), symptom 
experience {Heart Transplant Symptom Checklist; Grady & Jalowiec, 1995; Transplant 
Symptom Frequency and Distress Scale; Lough et al., 1987), treatment (Heart Transplant 
Regimen; Grady & Jalowiec, 1995), knowledge about transplant regimen (De Geest et al., 
1995; Soine et al., 1992) or understanding of self care principles (Wirth & Barton 1985) 
and thus, albeit of value, they are limited by a narrow focus.
Transplant stressor instruments, on the other hand, are somewhat more comprehensive in 
their content but have been designed to measure and document the stressors of organ 
transplantation rather than measuring the effects of these stressors {Heart Transplant 
Stressor Scale', Grady & Jalowiec, 1995; Recipient Stressor Scale', Gubby, 1998; Kidney 
Transplant Recipient Scale', Hayward et al., 1989; Kidney Transplant Questionnaire; 
Ketefian & Starr, 1990). Overall, none of the existing measures adequately assessed the 
emotional and behavioural issues associated with transplantation and this limits our 
understanding of the psychological processes of organ transplantation.
Section 5: Factors associated with HQoL in ESRD
Table 2.1 lists the different factors reported in the literature to influence HQoL in dialysis 
and transplant patients.
Table 2.1: Factors associated with HQoL in ESRD
Poorer HQoL Better HQoL
Comorbidity 
Diabetes 
Poor nutritional status (albumin) 
Poor dialysis adequacy 
Rejection episodes 
Low GFR 
Unemployment 
 Depression (high)______
Haemoglobin (high) 
Socio-economic level (high) 
Educational level (high) 
Race (black)
Social support (high)
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5.1 Clinical factors
Clinical factors other than treatment modality have been associated with HQoL in ESRD. 
These include: comorbidity (Khan, 1998; Khan et al, 1995; Merkus et a l, 1997; Mingardi, 
1998a; 1998b), especially diabetes (Moreno et a l, 1996a; 1996b), haemoglobin/anaemia, 
(Moreno et al., 2000; Valderrabano, 2000) and albumin levels indicative of patients’ 
nutritional status (Mingardi et al., 1999). Several studies have, however, shown that the 
traditional clinical parameters (such as comorbidity, diabetic status, albumin) that 
determine outcomes such as mortality, may have a lesser effect in HQoL outcomes (Martin 
& Thompson, 2000; Merkus et a l, 1997; Mozes et a l, 1997; Steele et a l, 1997).
Time of diagnosis of CRF and pre-dialysis care influence HQoL after dialysis onset, with 
patients with delayed diagnosis and referral reporting worse physical and emotional well­
being in the first two months of dialysis (Sesso & Yoshihiro, 1997).
5.2 Sociodemographic variables
Many factors that affect HQoL in general (such as SES, finances, social deprivation index, 
living conditions) are expected to exert powerful influences on patients’ HQoL but a 
discussion of each one of these is beyond the scope of this thesis.
The influence of age however, deserves some further mention, as it is likely to differ 
between dialysis and transplantation, and is also very closely linked to clinical parameters 
such as comorbidity.
Many authors have indicated that increased age has a negative effect on HQoL of ESRD 
patients undergoing dialysis (Evans et a l, 1985; Merkus et a l, 1997). This effect is mainly 
observed in the physical rather than the psychological dimensions of HQoL (Kutner & 
Brogan 1992; Lamping et a l, 2000; Mingardi et a l, 1999; Moreno et a l, 1996a; Wight et 
a l, 1998). Age is also important because the impact of ESRD on HQoL appears to be less 
in elderly patients. In studies comparing different groups of dialysis patients with the 
healthy population, the groups of elderly patients with ESRD showed fewer differences 
than the group of younger ESRD patients (Horina et a l, 1992; Muthny & Koch, 1991). 
Elderly patients reported greater satisfaction and accepted the limitations associated with
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ESRD better than the younger patients with ESRD. Similar results have also been reported 
for elderly transplant recipients (Benedetti et al., 1994; Hestin et al., 1994; Rebollo et al.,
2001). In the last study the elderly transplant patients had a HQoL even better than that of 
the general population of the same age and gender.
This selective review illustrates that research so far has placed emphasis on modelling 
demographic and clinical factors that promote or limit optimal HQoL (Feurer et al., 2002). 
These sociodemographic and clinical characteristics however explain only a relatively 
small percentage of HQoL, suggesting that HQoL may be determined by multitude of other 
factors. Recent work has suggested that psychological factors (such as patients’ mood, 
cognitions, perceptions, beliefs, and attitudes) may also be associated with outcomes such 
HQoL in ESRD patients. These factors may be either directly related with HQoL or may 
mediate or moderate the relationship between these sociodemographic and clinical 
parameters and HQoL. These factors are discussed in the next sections.
Section 6: Depression in ESRD
Another psychosocial outcome that has received considerable attention, much earlier than 
the explosion of research interest in HQoL, is depression.
Perceptions of HQoL and depressive mood are linked in several ways: Firstly, depression 
has become an important domain for HQoL researchers (Cagney et a l , 2000). Measures of 
depressive mood are included in many HQoL indices (Edgell et al., 1996).
Depression may also be conceptualised as a predictor of HQoL. For example, it may have a 
significant impact on perceptions of HQoL in that depressive affect and magnitude of 
negative outlook may result in a more negative view of patients’ functional status, well­
being and HQoL. Several studies found that depression and anxiety are strongly associated 
with HQoL in ESRD (Martin & Thompson, 2000; Steele et a l , 1997).
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6.1 Depression prevalence
Depression is the most commonly encountered psychological problem in ESRD 
(Christensen & Moran 1998; Finkelstein & Finkelstein, 1999; 2000; Kimmel, 2000a; 2001;
2002), affecting both HD and PD patients (Wuerth et al., 2001). The prevalence of 
depression has however varied greatly in different studies (Furr, 1998; Kimmel et al., 1993; 
Smith et al., 1985; Watnick et al., 2003).
The differences have been attributed principally to the differing criteria and methodology 
used to diagnose and measure depression. It is important to be clear what is meant by 
depression, and how it is measured. Depressive affect should not be confused with the 
clinical diagnosis of depression. Rates of depressive affect based on self-report ratings of 
symptoms range from 25% (Martin & Thompson, 2000; Rodin & Voshart, 1987) to 50% 
(Kutner et al., 1985). Estimates of the prevalence of clinical depression (based on 
psychiatric assessment and diagnostic criteria) range from 12% to 45%, depending on the 
method and criteria used to define a depressive disorder (Aghanwa & Morakinyo, 1997; 
Craven e al., 1987; 1988; Hinrichsen et al., 1989; Hong et al., 1987; Lowry & Artcherson, 
1980). As is the case with other chronic medical conditions, there is evidence that 
depression among ESRD patients frequently goes unrecognised and untreated (Smith et al., 
1985).
Another reason for the variability of the findings may be due to the difficulty of diagnosing 
depression in ESRD patients (Kimmel et al., 1993). Symptoms of depression can be 
divided into somatic and cognitive categories. Typically the somatic aspects of depression 
are included in diagnostic evaluations but there is an overlap between the somatic 
symptoms of depression and those of uraemia (Kimmel et al. 1993; Smith et al., 1985). 
Depressive symptoms such as sleep disturbance, appetite disturbances or weight change, 
and fatigue) are common manifestations of ESRD and associated treatments. Using the 
cognitive symptoms of depression, such as hopelessness and helplessness, feelings of guilt, 
worthlessness and self-loathing, loss of interest in life or pleasure, may be critical in 
separating uraemic symptomatology from depression (Sacks et al. 1990)
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6.2 Depression comparison between RRTs
Only a few studies have compared depressive affect in patients established on either 
different dialysis treatments or different RRTs.
Some studies report no differences in depression rates between HD and PD patients 
(Iacovides et a l , 2002; Iordanidis et a l, 1995; Killingworth & Van den Akker, 1996; 
Majkowicz et a l, 2000; Mittal et a l, 2001b; Zimmermann et a l, 2001). Others (Griffin et 
a l, 1994; Oldenburg et a l, 1988) found that HD patients showed better psychological 
adjustment than PD patients (lower anxiety and higher positive mood scores), despite being 
more severely ill and suffering from physical symptomatology to a greater degree than PD 
patients. In contrast, Kimmel et a l (1998a) found that the adjusted risk of hospitalisation 
for any mental disorder, depression, and alcohol and drug use was lower in PD compared 
with HD.
More clear-cut are the findings regarding depression rates between dialysis and transplant 
patients. Dialysis patients appear to be more depressed (and anxious) than transplant 
patients (Cameron et a l, 2000; Christensen et a l, 2000; Gokal, 1993; Waiser et a l, 1998; 
Zimmermann et a l, 2001).
6.3. Depression consequences
Whereas clear understanding of the causes of depression remains inconclusive, evidence 
has accumulated on the consequences of depression in ESRD patients. Depression may 
detract substantially from the HQoL of ESRD patients and is particularly problematic given 
that dialysis patients are at increased risk for suicide (Kimmel, 2001). Several studies have 
noted a strong relationship between depressive symptoms and overall HQoL (Martin & 
Thomspon, 2000; Steele et a l, 1997).
Although the precise relationship between depression and medical outcomes remains 
unclear (Finkelstein & Finkelstein, 1999), several studies have found that depression has an 
impact on ESRD patients’ morbidity and mortality (Christensen & Moran, 1998;
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Finkelstein & Finkelstein, 2000). Higher levels of depression have been found to lead to 
more hospital admissions (Numan et al., 1981) for renal or psychiatric care. Studies on PD 
suggested that patients with higher depression scores have greater rates of peritonitis than 
patients with less severe depressive symptoms (Juergensen et al., 1996; 1997; Troidle et a l, 
2003; Wuerth et al., 1997). The directionality of these associations remains in question as 
peritonitis episodes are likely to trigger depressive symptoms.
Findings of the relationship between depression and survival have however been mixed 
(reviewed by Kimmel, 2001; 2002), with some showing that depression leads to poorer 
survival rates (Kimmel 1992; 2000a; Kimmel et al., 2000; Lopes et al., 2003; Peterson et 
al., 1991) and others that depression does not predict survival (Christensen et a l, 1994; 
Devins et a l,  1990b). Early studies of the association of depression and mortality in ESRD 
patients were, however, often poorly controlled for the medical factors that might have 
affected mortality and also been confounded with depression, such as the symptoms of 
comorbid renal and systemic diseases. Variable follow-up times also contribute to the 
conflicting findings. Studies with long follow-up times, i.e. more than 3 years (Devins et 
a l, 1990b; Christensen et al., 1994) failed to find a relationship between depression and 
mortality. Significant associations between depression and survival have mainly been 
reported in studies with shorter follow up times (typically 1-2 years) (Peterson et a l, 1991; 
Shulman et al., 1989).
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Section 7: Study aims and hypotheses regarding HQoL
(a) To assess and describe levels of HQoL in ESRD patients
(b) To compare HQoL outcomes between patients on different RRTs and to compare these 
outcomes with norms
(c) To evaluate the effect of transplant type and immunosuppressive regimens on HQoL 
among transplant recipients
(d) To identify variables that predict HQoL in dialysis and transplantation
(e) To develop a transplant specific instrument to provide a thorough coverage of an 
individual’s emotional and behavioural response to receiving a transplanted organ, and 
the pressures and stresses that this may cause.
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CHAPTER 3: PATIEN TS’ ILLNESS A N D  TREATM ENT BELIEFS
In part the present study was conducted within a framework of a biopsychosocial model 
that considers that individuals’ cognitive interpretations of illness and treatment, rather than 
their objective illness severity or treatment burden, are critical in psychosocial adjustment 
and HQoL. In particular, this research investigated the role of illness and treatment self­
schemas: illness representations, and perceived illness and treatment effects (perceptions of 
illness-related or treatment-related disruption). The basic theoretical framework underlying 
this research was the self-regulatory framework by Leventhal and colleagues, which is 
briefly reviewed below.
Section 1: The theoretical framework - the Self-Regulatory Model
During the last decade, in the field of psychological research in chronic illness, 
considerable attention has been directed to Leventhal’s self-regulatory model (SRM; 
Leventhal et al., 1980; 1984; 1998; Leventhal & Diefenbach 1991). The SRM identifies the 
factors involved in the processing of information by the patient regarding their illness, how 
this information is integrated to provide a ‘lay’ view of the illness and how this ‘lay’ view 
guides coping behaviours and outcomes.
Patients’ representation of illness, or the manner in which an individual conceptualises and 
gives meaning to an illness and its consequences, is a key component of the SRM and has 
been a significant focus of inquiry in the field of Health Psychology (Petrie & Weinman, 
1997). Illness representations can be further defined as individual’s representations of their 
disease, including disease-related beliefs, emotions, knowledge, and experiences (Skelton 
& Croyle, 1991). Understanding such illness representations is important because the 
responses of patients to their conditions (e.g. seeking medical care, developing self-care 
behaviours, becoming depressed) are believed to be determined at least partially by these 
beliefs (Leventhal et a l, 1996; Schiaffino, & Cea, 1995).
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Although there are differences in methodology and terminology, research into the structure 
of lay theories about illness has established that the content of an illness representation can 
be ordered into logical themes or dimensions (Baumann et al., 1989; Lau & Hartman 1983; 
Lau et al., 1989; Leventhal et al., 1980):
(1) Identity - the label the patient uses to describe the illness, and the signs and the 
symptoms the patient views as being part of the illness
(2) Cause - personal ideas about the cause of the illness for example as a consequence of 
genetic factors or of external agents such as viruses or germs.
(3) Timeline - expectations about the duration of the disease and its characteristic course, 
perceptions about whether the illness is expected to be acute, episodic or chronic,
(4) Consequences -  personal ideas about short and long term effects and outcomes of the 
disease; the perceived physical social and economic consequences of the illness
(5) Control or cure - beliefs about the extent to which the illness is amenable to control or 
cure.
Leventhal et al. (1980) proposed that the SRM is a parallel-processing model in that people 
typically make simultaneous cognitive and emotional representation of their illness. Thus 
an illness representation may not only comprise the dimensions outlined previously, but 
also emotional representations (see Figure 3.1.).
SOCIO-CUITURAL CONTEXT 
SELF-SYSTEM
Biological Characteristics and Psychological traits and defenses
situational stimuli 
(inner / outer)
Coping ProceduresIllness Representation
Coping ProceduresEmotional Representation
Appraisals
Appraisals
Figure 3.1: The Self Regulatory Model
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Illness representations are guided by three basic sources of information: (a) personal 
experience with an illness (including symptomatic information), (b) information from the 
external social environment, from perceived significant others or authoritative sources such 
as doctors or parents and (c) the general pool of ‘lay’ information assimilated by the 
individual for previous social communication and cultural knowledge of the illness.
A major tenet of the SRM is that a causal relationship exists between illness representations 
and illness outcomes such as psychological and physical adjustment, which is mediated by 
coping responses. SRM postulates dynamic interactions between illness representations, 
coping and outcomes through stages of appraisal and feedback processes.
Numerous studies have examined illness representation in various patient groups and 
provided empirical support for the theoretical premises (Hagger & Orbell, 2003). 
Components of illness have been found to be associated with functional status (Scharloo et 
al., 1998), psychosocial adjustment (Moss-Morris et al., 1996; Schiaffino et al., 1998), 
depression (Edwards et al., 2001; Rutter & Rutter, 2002), and treatment adherence (Griva 
et al., 2000; Hampson et al., 1995; Meyer et al., 1985; Skinner et a l, 2002). In addition 
preliminary evidence suggest that interventions designed to alter patients’ illness 
representation can improve their adaptive outcome (Petrie et al., 2002). It is beyond the 
scope of this thesis to document the numerous studies of illness representations in patients 
other than ESRD. The interested reader is directed to the work of Petrie & Weinman (1997) 
and Cameron & Leventhal (2003) for more detailed reviews of previous research.
Despite a cogently argued rationale and the ample empirical evidence on illness 
representations determining a range of physical and psychological outcomes, the 
application of this framework in ESRD has been limited. No studies have been published 
which assessed the five components of illness representations in ESRD explicitly using the 
SRM. This does not mean that patients’ perspective has been completely overlooked. 
ESRD research has examined patients’ beliefs and cognitions but not strictly from a self- 
regulatory perspective and without explicitly adopting the SRM model. The constructs 
assessed bear a strong conceptual resemblance to SRM components and can be mapped 
onto one of the five illness representation components.
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A selective overview of this line of research and its conceptual background will be 
presented and the conceptual links of these concepts to the self-regulatory framework will 
be discussed.
Section 2: Illness Intrusiveness
The bulk of ESRD research has focused on perceptions of illness intrusiveness or 
disruption.
2.1 The conceptual background of illness intrusiveness
The concept of ‘illness intrusiveness’ refers to illness induced lifestyle disruptions to valued 
activities and interests that limit the personally rewarding experience and compromise 
HQoL (Devins et al., 1983).
The notion of intrusiveness is relevant in all chronic illnesses and in ESRD in particular 
since it introduces significant psychosocial challenges and adaptive demands and involves 
considerable illness and treatment-related constraints. Despite safe and effective long-term 
treatments, individuals with ESRD experience threat of death, loss of physical strength and 
stamina, economic hardships, dietary and fluid restrictions, and dependency on medical 
technology and personnel, which may interfere substantially with important facets of a 
person’s life (Devins et al., 1990a; 1990c; 1991).
Direct intrusiveness may be introduced through the physiological effect of irreversible renal 
failure such as reduced physical strength and stamina or increased uraemic symptoms. 
Treatment-related symptoms are also thought to contribute to the overall perceptions of 
illness-related disruption. These physical aspects may limit patients’ ability to perform 
social, family, or self-care behaviours or to maintain active participation in vocational and 
leisure activities and other life domains.
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Such effects are usually augmented by the presence of non-renal comorbid conditions and 
renal complications such as diabetes, renal bone disease or cardiovascular problems. Direct 
interference may also be caused by the treatment when it often comes into conflict with 
patients’ lifestyle. Hospital-based dialysis for example may require that a person dialyses 
during working hours, thus making difficult or preventing maintenance of full-time 
employment.
Devins et al. (1990b) argued that indirect interference might also be introduced to the 
extent that family relationships and friendship patterns change. Following the onset of 
ESRD and the need for RRT, family members’ perception of their relative may change 
dramatically. The person may be seen as chronically sick, dependent and ‘helpless’, 
whereas she/he may have previously been considered very independent and capable. 
Family roles and responsibilities may therefore begin to shift with the result that ESRD 
patient’s autonomy and independence are eroded significantly.
Perceived illness intrusiveness cannot be fully explained by the objective features of an 
illness or a treatment. Patients with the same medical diagnoses and treatments may have 
quite different perceptions of the burdensome aspects of their illness. Faced with the 
objective constraints of their illness, patients make their own evaluation and subjective 
appraisal of the effect of their disease on their lives (Devins et al., 1990b; Kimmel et al., 
1998b; Greenberg & Peterson, 1997a). Perceptions of illness intrusiveness are conceptually 
linked or similar to the ‘consequences’ beliefs from the SRM. Both constructs measure 
patients’ appraisal of the short or long term physical psychosocial and financial 
impact/burden associated with their disease.
2.2 Factors associated with illness intrusiveness in ESRD
A wide range of factors may influence perceptions of illness intrusiveness such as age, 
disability, social support (family environment), personality and cultural factors (Devins et 
a l, 1997a; 1997b). The effect of cultural factors was demonstrated by Kutner & Devins 
(1998) who showed that elderly white dialysis patients experienced more symptoms, had
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higher levels of illness intrusiveness, greater dissatisfaction with their health and more 
global life dissatisfaction than did elderly African-American patients.
2.3 Illness intrusiveness and outcomes in ESRD
This subjective appraisal of illness burden is thought to be central in determining patients’ 
response to illness. Illness intrusiveness is thought to mediate the relationship between 
outcomes such as HQoL/psychosocial adjustment and the objective circumstances of 
disease (e.g., pain, fatigue, and disability) or associated-treatments (e.g., side-effects, 
complications, and disruptive treatment schedules). Models such as the SRM also postulate 
that perception of illness may be as or more important to adjustment and coping with 
illness, than medical severity and the objective features of an illness (Greenberg & 
Peterson, 1997a; Weinman & Petrie, 1997).
Illness intrusiveness is hypothesised to influence psychosocial outcomes among people 
affected by chronic disease such as ESRD through at least two complementary 
mechanisms:
• directly, as a result of reduced positive experience when the condition interferes with 
continued participation in valued activities and interests
• indirectly, due to reduced expectations of personal control.
A growing body of evidence supports the claim that illness intrusiveness mediates the 
psychosocial impact of ESRD (Devins et al., 1983). Illness intrusiveness has been found to 
be negatively associated with HQoL (Devins, 1991; 1994; Devins et a l, 1990a; 1990c; 
1990d; Patel et al., 2002) and depression (Devins et al., 1993a; 1997a; 1997b; Eitel et al., 
1995; Kimmel et al., 1995a; 1996; Sacks et a l, 1990). Factors such as age and self-concept 
have been demonstrated to moderate the association between illness intrusiveness and 
emotional distress (Devins etal. 1997a).
Higher illness intrusiveness was associated with poorer survival despite being dissociated 
with clinical indicators of illness severity (Kimmel et a l, 1998b; Shulman et al., 1989). 
Although the mechanisms underlying such associations are unclear, neurohumoral and
78
behavioural pathways, as well as the effects of adherence and social support may be 
involved (Kimmel, 2001; 2000a; 2000b Kimmel et al., 1998a; 1998b; 1998c).
2.4 Illness perceptions as an outcome in ESRD
Perceived illness intrusiveness/burden may also be considered as an important outcome in 
and of itself rather than as a determinant of other outcomes. One way of assessing the 
impact of RRT is to assess the illness and treatment intrusiveness, which measures the 
degree to which the illness interferes with lifestyle, activities and interests (Devins, 1994).
It has been suggested that illness intrusiveness may be greatest for CAPD or home HD 
patients who must administer their treatment daily while continuing with their everyday 
activities and work. These patients may be less able to separate their treatment from their 
non-treatment activities (cf. Lewin, 1951). In contrast, because HD patients typically 
receive treatment within distinctive blocks each week, they may be better able to separate 
their treatment from other daily activities. In contrast to the rigorous schedule of HD and 
the regular dialysate exchanges of PD, renal transplantation would appear to be relatively 
the most non-intrusive ESRD treatment insofar as the treatment regimen after 
transplantation typically entails little more that the daily immunosuppressive medication. 
Research has indeed indicated that relative to chronic dialysis, successful renal 
transplantation is associated with lower perceived illness and treatment intrusiveness. 
Systematic differences however have failed to emerge in comparisons involving the various 
dialysis modalities (Devins et al., 1983; 1990a; Devins, 1994; Sacks et a l , 1990).
Importantly, research to date has focused predominantly on illness-related beliefs or 
implicitly collapsed illness and treatment perceptions. Illness burden was seen as directly 
related to the exigencies of treatment. It is instructive to consider in more detail what 
aspects of treatment may be considered as stressful or the extent to which treatment disrupts 
life and personal and social behaviours. Treatment-related beliefs may be distinct from 
views and beliefs regarding illness and these are considered below as a separate category 
called treatment perceptions.
79
Section 3: Treatment Perceptions in ESRD
3.1 Conceptual background
In contrast to patients’ beliefs about their illness the investigation of treatment beliefs has 
been less far reaching (Home, 1997; 2003a; 2003b; Home & Weinman, 1999).
The SRM does consider the importance of treatments for the illness through the 
cure/control component of illness representations and some researchers (e.g. Hampson et 
al., 2000) have explicitly labelled this component as treatment effectiveness. However, it 
does not examine in detail the perceptions of the treatment, and how these may vary in the 
same underlying condition.
Treatment representations are clearly qualitatively different from illness representations 
albeit possibly related to patients’ implicit model of illness. It is feasible that the self- 
regulatory patient will not just have their own ideas about their illness but also about 
treatment being offered. Treatment constitutes a major part of the experience of any chronic 
illness (in this case, ESRD) so it should be anticipated that patients develop their views and 
beliefs regarding treatment issues or engage in treatment appraisals and evaluations that 
complement illness representations.
Home and colleagues have produced valuable work in the area of medication beliefs that 
emphasised the importance of patients’ beliefs about treatment in general. In a series of 
studies Home, Weinman et al. (1999; 2002; Cooper et al., 2002) have demonstrated that the 
concrete experience of different illnesses and their treatments lead to different illness and 
treatment representations, which in turn are associated with particular patterns of coping 
and medication adherence.
Although this line of research has focused on beliefs regarding medication, it highlighted 
the value of treatment beliefs and their relationship to health related behaviours and 
outcomes.
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3.2 ESRD and treatment perceptions
Patients’ subjective appraisal of treatments (re: side-effects and intrusiveness) is a key to 
understanding the balance between benefit and burden of different ESRD treatments. Some 
aspects of the treatment or side-effects of treatment (e.g. impotence, muscular weakness) 
have little or no direct effect on morbidity and mortality, yet can be perceived by renal 
patients as extremely disturbing and may influence broader outcomes such as HQoL. This 
issue is clearly highlighted in the early literature on treatment stressors.
All individuals with ESRD face a variety of acute and chronic stressors and implicit in 
many of these stressors is the concept of perceived intrusiveness described earlier. The 
constraints that ESRD treatments impose can be extensive ranging from the dialysis 
procedural details through to the dietary and fluid intake restrictions and medication 
regime. The treatment is also thought to raise issues of independence especially in dialysis 
as individuals are totally dependent on artificial means of survival (such as the PD machine 
or PD exchange procedure), on medical professionals (Levy, 2000; 2003), and have little or 
no hope of recovery of adequate renal function.
There is consensus about which aspects of dialysis treatment are viewed as stressful; for 
example, activity limitations, fluid limitations and fatigue are frequently reported stressors 
in HD (Baldree et al., 1982; Gurklis & Menke, 1995; Lok, 1996; Welch & Austin, 1999; 
2001) although their ranking may vary from study to study. Welch & Austin (1999) found a 
consistent trend for HD stressors to become more intense over time. Stressors in HD may 
be different to those associated with PD. Bihl et al. (1988) found that stressors reported by 
CAPD patients were related to uncertainty of future, limits on vacation and frequent 
hospitalisation, while in HD patients perceived stressors were as described above, i.e. 
fatigue and boredom, limitation of fluid intake and length of treatment. Similar findings 
have been reported in other studies (Eichel, 1986; Fuchs & Schreiber, 1988).
Overall there is some suggestion that PD is less stressful than HD. Wolcott & Nissenson 
(1988) found that CAPD patients perceived less illness- and treatment-related stress 
compared to pair-matched HD patients, although Maiorca et al. (1995; 1996c) commented 
that after a number of years there may be bumout of either the PD patient or their caregiver.
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As patients age, there may come a point in time when he or she is no longer able to 
maintain PD.
This work has been useful in identifying the stressful aspects of dialysis however it is 
limited in several ways: Small samples sizes; recruitment of only hospital HD and CAPD 
patients such that we know nothing as to how other treatment options such as APD or 
transplantation are perceived. Most importantly, a number of key questions remained 
unanswered. The narrow focus of previous work on procedural treatment stress does not 
allow us to gauge and compare the overall appraisals of treatment impact across the 
different RRT groups and how these perceptions may be associated with both illness 
perceptions and broader outcomes such as HQoL.
The different natures of the treatments for ESRD provide an opportunity to investigate in a 
systematic manner treatment and illness perceptions in the same underlying condition. A 
better understanding of the interplay between illness and treatment beliefs might not only 
contribute further to the development of the Leventhal’s SRM but also explain better the 
impact of ESRD.
Beliefs regarding the treatment are likely to be of particular relevance/importance in ESRD 
since available treatments differ significantly not only technically but also in the intrusion 
and demands imposed upon patients. It is possible that even though all ESRD patients have 
the same underlying condition, the experience of different treatment might differentially 
affect beliefs, perceptions and adjustment. Some patients may conduct a disease vs. 
treatment effects comparison and this may occasionally influence treatment adherence. A 
study of 47 hospital HD patients showed significant associations between medication 
beliefs and medication adherence (Home, 1997). There have been no studies examining the 
relationship between treatment perceptions and HQoL in ESRD. The effect of treatment 
beliefs on outcome may be negative as well as positive. This is illustrated by a recent study 
in which breast cancer patients who, prior to treatment had strong concerns about the 
potential adverse effects of their treatment (chemotherapy or radiation), were subsequently 
more likely to experience adverse emotional and physical consequences (Buick, 1997). An 
awareness of patients’ perception of treatment offers the potential for a better understanding 
of patients’ response to illness and treatment with major implications for research and 
practice.
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Section 4: Symptoms in ESRD
Although the majority of ESRD research conducted in this area has been atheoretical 
‘symptom’ perceptions are in essence fundamental cognitive variables just like illness 
intrusiveness or the IPQ components discussed earlier. Symptoms are not just the mere 
manifestation of pathology but reflect individuals’ perception, interpretation and processing 
of physical signs. The quote below clearly illustrates this:
Symptoms belong to the lived experience o f the illness rather than being a precise map o f 
the underlying disease ’ (Benner & Wrubel, 1989).
It is important that studies have also failed to show a substantial impact of demographic, 
clinical and dialysis related variables on symptom reporting and symptom burden (Barrett 
et al., 1990; Merkus et al., 1999a). The SRM identity component is perceived to reflect 
symptom experience. According to the SRM, symptom experience is guiding self­
regulation. Symptoms are key factors in the cognitive representation of disease, they are 
targets for coping and treatment. Symptom amelioration is critical for the appraisal of 
progress in mitigating the health threat.
The previous literature indicates marked symptom burden in both dialysis and TX patients 
(Weisborg et al., 2003) Despite advances in the medical management of ESRD, many of 
the symptoms of renal failure continue to occur in a substantial number of ESRD patients 
(Killingworth & Van de Akker, 1996). Symptoms related to dialysis procedures or 
immunosuppressive medication complete the picture of renal symptomatology in ESRD.
A host of physical and psychological symptoms occur in patients on chronic dialysis 
(Merkus et al. 1999a), with considerable variation in their frequency and in the severity 
with which the symptoms affect the individuals concerned (Brunier, & Graydon, 1993; 
Curtin et al., 2002; Devins et al., 1993; McCann & Boore, 2000; Parfrey et al., 1988b; 
1989; Thomas-Hawkins, 2000).
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Fatigue and reduced energy are customarily ranked as the most important and prevalent 
symptoms for dialysis patients (Barrett et al., 1990; Cardenas & Kutner, 1982; Laupacis et 
al., 1992; Merkus et al., 1999a; Parfrey et al., 1988b; Srivastava, 1989).
Post-dialysis fatigue is a common and often incapacitating symptom in HD. Interestingly, 
no routinely measured parameter of clinical or dialytic function appears to predict post­
dialysis fatigue. In addition, painful nocturnal cramps (painful involuntary muscular 
contractions, typically in the lower extremities) interfering with normal life still remain a 
common complication of HD (Chou et al., 1985; De Vecchi et al., 1994; Lok, 1996; 
McGee, 1990; Riley & Antony, 1995; Romagnoli et al.,. 1998).
Treatment differences in symptom experience are not consistent with some studies 
reporting either more symptoms in HD compared to CAPD patients (Simmons et a l,  1984) 
or no group differences (De Vecchi et al., 2000; Merkus et al., 1999a; Waiser et al., 1998). 
Transplant patients also experience a range of symptoms, mainly resulting from the 
immunosuppressive medication although some of the renal specific symptoms may still 
persist (Barbosa et a l, 1995; De Geest & Philip, 2000; Forsberg et al., 1999; Franke et a l, 
1999; Winsett et al., 2001)
The potential impact of these symptoms, particularly occurring in this cumulative manner 
on other aspects of the individual’s life and HQoL is enormous. Symptom experience has 
been shown to be associated with sleep difficulties, and with mood problems, in particular 
depression and anxiety (Barrett et al., 1990; Killingworth & Van de Akker, 1996; Sklar et 
a l, 1996; 1999) and to adversely affect physical functioning and HQoL (Curtin et al., 
2002; DeGeest & Philip 2000; Hathaway et al., 2003; Kimmel et a l, 2003; Laupacis et a l, 
1992; McCann & Boore, 2000; Merkus et a l, 1999a). Determining the causal direction of 
these associations is problematic as mood difficulties may be driving symptom reporting or 
vice versa, the experience of symptoms affecting HQoL and physical functioning.
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Section 5: Study Aims and Hypotheses in relation to patients' beliefs
This selective literature overview emphasised the importance of patients’ beliefs and 
perceptions but also highlights the need for further research. Several key theoretical and 
empirical questions have not been addressed.
Little is known about the precise nature of the illness representations components in ESRD 
patients on different RRTs, their interrelations, their relationship to treatment beliefs and 
the role and relative importance of these beliefs in predicting various outcomes (i.e. HQoL) 
in ESRD patients. No studies have examined the dynamic nature of illness and treatment 
representation formation and changes in these cognitions over the course of ESRD.
It is reasonable to assume that illness representations develop and change over the course of 
ESRD and that the match or mismatch, at any point in time, between personal experience 
and personal beliefs could contribute to emotional distress or adversely affect HQoL. In 
some quarters, this type of distress has been referred to as dissonance (Festinger, 1964).
On the more theoretical angle, the role of treatment beliefs in the SRM model warrants 
further investigation.
The present study was thus designed to examine some of these issues
a. To assess whether individuals with ESRD develop systematic and coherent cognitive 
representations of their illness and treatment.
No specific hypotheses were formulated regarding the association between these two sets of 
beliefs.
b. To investigate whether the different forms of dialysis treatments (HD vs. PD) lead to 
differences in these illness and treatment beliefs.
c. To compare illness and treatment beliefs between dialysis and transplant patients.
d. To investigate the associations between these illness and treatment beliefs and HQoL.
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CHAPTER 4: NEUROPSYCHOLOGY A N D  ESRD
ESRD and the uraemic state that results from renal failure are known to have a variety 
of systemic effects including influences on the central nervous system (Fraser & Arieff, 
1988). Advanced uraemia and its clinical manifestations believed to be caused by the 
accumulation of neurotoxins, results in abnormalities in clinical and mental status and 
neuropsychological performance. The neurobehavioral syndrome in untreated uraemia 
or chronic renal failure (CRF) is characterised by confusion, inability to concentrate, 
decreased mental alertness, impaired memory and occasionally in some patients with 
severe untreated uraemia, hallucinations, tremors, myoclonous, and generalised non­
specific complaints progressing to frank encephalopathy with asterixis and seizures. 
There are characteristic electroencephalographic (EEG) findings, principally loss of 
alpha rhythm, shift of power spectrum to slow wave activity, and impairment of evoked 
potential responses. These are non specific findings typical of a toxic metabolic 
encephalopathy (Cooper et a l , 1978; Markland, 1984), but many of these complaints 
appear to be related to secondary anaemia as they improve with anaemia treatment 
(Eschbach, 1989).
With the improvements of RRT (dialysis and transplantation) the incidence and severity 
of these disturbances have declined such that the gross manifestations of advanced 
uraemia have largely disappeared (Pliskin et al., 2001). Consequently, studies of the 
dialysis-related epiphenomena such as dialysis encephalopathy and dialysis 
disequilibrium have drastically declined in recent years (Arieff, 1994; Brown & Brown, 
1995).
Current dialysis treatments, PD or HD do not however fully restore normal renal 
function. Dialysis of either modality rarely replaces more than 5-15% of normal 
Glomerular Filtration Rate. Consequently patients are restored from a lethal renal failure 
to one of severe renal insufficiency albeit without the grossly symptomatic uraemia. 
Even perfectly dialysed patients remain chronically ill as the level of renal function 
achieved is low compared to normal though adequate to avoid uraemia.
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Section 1. Neuropsychology and ESRD - Research findings
Our understanding of neuropsychological (NP) function in ESRD has evolved a great 
deal in the past 30 years. Early studies in the 1960’s and 1970’s documented the NP 
effects of uraemia and CRF, while investigations in the 1970’s and 1980’s focused on 
the NP outcomes following initiation of dialysis, the cognitive functioning of HD and 
PD patients, and correction of anaemia and aluminium toxicity. Recent investigations 
quantifying dialysis delivery have provided new insights into the NP effects of dialysis 
and several investigations into the effects of renal transplantation have also appeared.
In order to examine the literature on NP functioning in ESRD, a literature search was 
performed focusing on studies in which NP testing of ESRD patients was reported. 
Papers were identified for the present review through electronic databases (MedLine, 
PsychLit 1960-2000) using a combination of relevant keywords {'cognitive' ; 
'neuropsychological' ; ‘deficit' ; 'impairment' ; ‘fu n c tio n in g ‘dysfunction'processing ' ; 
'brain'\ 'norms' ; 'memory'', 'attention'', ‘concentration'psychomotor'', 'language'', 
'verbal'', 'visual'', 'speed'', 'response'', ‘in te llig en ce 'IQ '', 'abilities'', 'ESRD'', 
'dialysis'', 'renal'', 'failure'', 'transplantation’) and by manually searching the references 
of identified papers and other reviews. Single case studies and papers published in 
languages other than English were excluded.
Seventy-nine studies on the topic of NP functioning in ESRD were identified. Details of 
the characteristics of the studies are given in Table 4.1 .
Table 4.1: Authors, patient groups, number and list of neuropsychological tests
First Year Design N Sample No NP tests usedt
author Tests
Blatt 1966 Cross sectional 17 CRF 1 1
Schupak 1967 Cross sectional 25 HD 1 1
Trieschmann 1971 Cross sectional 83 CRF 1 1
Fishman 1972 Prospective 12 HHD 1 4
Gentry 1972 Cross sectional 21 HD 1 2
Greenberg 1973 Cross sectional 24 ESRD 1 1
Winokur 1973 Cross sectional 38 HD 1 1
Hagberg 1974 Prospective 23 HD 9 6, 7, 26, 59, 93, 94, 
95, 102
Teschan 1974a Prospective 44 CRF
HD
4 16, 55, 58, 98
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First Year Design N Sample No NP tests usedt
author Tests
Teschan 1974b Prospective n/s HD
CRF
16, 55, 98
English 1975 Cross sectional 29 HHD 3 1,28, 102
Ginn 1975a Cross sectional n/s CRF
HD
5 16, 55, 58, 65, 98
Ginn 1975b Cross sectional n/s CRF
HD
3 16,55,98
Heilman 1975 Cross sectional 24
12
CRF
CTL
10 14, 18, 20,31,32,
35, 39, 76, 77, 93, 97
Murawski 1975 Cross sectional 39
63
24
HD
CRF
CTL
1 65
Teschan 1975 Experimental 4 HD 2 58, 98
Teschan 1976 Prospective n/s CRF
HD
TX
3 29, 58, 65
Spehr 1977 Prospective 20 HD 3 30,74,89
Kaplan 1977- Cross sectional 47 CRF 1 3
deNour 78
Rabinowitz 1978 Cross sectional 17
11
HD
CRF
2 3, 92
Ginn 1978 Experimental 19 HD 2 29, 58
Teschan 1979 Prospective 72
70
18
45
CRF
HD
TX
CTL
5 16, 29, 55, 58, 65
Alexander 1980 Cross sectional 28
28
HD
CTL
2 65,66
Freeman 1980 Cross sectional 107
30
HD
CTL
1 1
Gilli 1980 Cross sectional 42
8
HD
CRF
2 1,5
Lewis 1980 Prospective 6 HD 5 20, 26, 62, 72, 73
Ryan 1980 Cross sectional 72 CRF 1
Ziesat 1980 cross sectional 28 HD 1 5
Kenny 1981 Prospective 50 HD 6 20, 55, 62, 85, 86
Ryan 1981 Cross sectional 16
16
16
HD
CRF
CTL
1 110
Teschan 1981 Experimental 10 HD 2 58, 65
McKee 1982 Prospective 34 mixed 
CRF HD
3 5, 20, 62
Souheaver 1982 Cross sectional 24
48
CRF 
CTL (x2)
2 1,110
Gilli 1983 Cross sectional 54 HD 2 1,5
Hart 1983 Cross sectional 24
18
20
HD
CRF
CTL
12 12, 14, 17, 18, 20 24, 
57, 62, 67, 84
Ratner 1983 Prospective 20 HD 15 2, 11,20,43,46,49, 
54, 55, 58, 62, 80,
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First
author
Year Design N Sample No
Tests
NP tests usedt
82, 85, 86, 90
Teschan 1983 Experimental n/s HD 1 58
Tennyson 1985 Prospective 10 HD 1 56
Conrad 1987 Prospective 16
10
HD
CTL
1 25
Gottlieb 1987 Prospective 9 HD 1 108
Jackson 1987 Cross sectional 57 HD 4 1,33,42, 92, 96
Rovelli 1988 Cross sectional 47 HD 4 19, 20, 22, 92
Spargue 1988 Cross sectional 10
6
HD
CAPD
5 23, 36, 37, 38, 108
Wolcott 1988a Cross sectional 17
17
HD
CAPD
5 21, 54, 55, 56, 61
Altmann 1989 Cross sectional 27 HD 7 33,112
Baker 1989 Cross sectional 25
9
10
HD
CAPD
CRF
2 1,3
Bolla Wilson 1989 Cross sectional 10
10
8
HD
CAPD
CRF
5 12, 48, 54, 55, 62
Grimm 1989 Pr-EPO 15 HD 1 54
Wolcott 1989 Pr-EPO 15 HD 8 21, 38, 54, 55, 56, 
60, 97,102
Grimm 1990 Pr-EPO 15
6
HD-EPO 
HD CTL
2 54, 108
Smith 1990 Prospective 29 HD 1 54
Ventura 1990 Cross sectional 62
33
HD
CTL
2 3, 11
Bolla 1991 Cross sectional 21 HD 5 54, 55, 59, 62, 108
Bosch 1991 Cross sectional 5 CRF 1 109
Brown 1991 Pr-EPO 14 HD 8 21, 38, 54, 55, 56, 
60, 97, 102
Churchill 1991 Prospective 47 HD >17 15,30,40,51,52, 
54, 55,69, 70,71, 
74, 78, 92, 101, 104, 
105, 106
Garcia-
Maldonado
1991 Cross sectional 28
11
n/s
HD
CAPD
CTL
1 54
Horina 1991 Pr-EPO 11 HD 3 20, 62, 108
Marsh 1991 Pr-EPO 24 HD 4 21,38, 55, 56
Bolla 1992 Cross sectional 35 HD 20 8, 12,21,31,40, 45, 
48, 50, 54, 55, 57, 
62, 79, 81, 82, 86, 
87,102, 107
Buoncristiani 1992 Cross sectional 22
15
HD
CAPD
2 20, 54, 108
Churchill 1992 Experimental 22 HD 18 1,8, 10, 11, 19, 20, 
38,41,53,54, 55, 
61,62, 65, 85, 92, 
93,102
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First Year Design N Sample No NP tests usedt
author Tests
Musolino 1992 Cross sectional 26 HD 8 5,21 ,47 ,61 ,65 ,68 , 
81,108
Rozeman 1992 Cross sectional 22
74
25
CRF
CAPD
HD
3 54, 55, 111
Temple 1992 Pr-EPO 9
9
HDEPO 
HD CTL
5 1, 21, 33,44, 63
Fox 1993 Cross sectional 30 mixed
HD
CAPD
2 1,5
Sagales 1993 Pr-EPO 43 HD 1 1
Fazekas 1995 Prospective 30 HD 2 108, 109
Temple 1995 Pr-EPO 9
8
CAPD
EPO
CAPD
CTL
6 21, 33, 54, 62, 63, 
100
Brickman 1996 Cross sectional 426 HD 8 5, 20, 27,31,53,55, 
65
Fazekas 1996 Cross sectional 20
20
HD
CTL
2 107, 108
Kramer 1996 Prospective 15
45
HD-TX
CTL
2 54, 108
Pliskin 1996 cross sectional 16
12
HD
CTL
13 1,5, 13,20,31,39, 
43,48, 53, 55, 62, 
82, 86, 91
Bremer 1997 Cross sectional 12
12
20
HD
CAPD
CTL
3 54, 55, 91
Sehgal 1997 Cross sectional 336 HD 1 108
Umans 1998 Cross sectional 10
10
HD
CTL
7 20, 53, 54, 55, 61, 
64, 65
Yount 1998 Cross sectional 554 mixed 
HD PD 
CRF
5 27, 53, 55, 62, 65, 69
Yavuz 2000 Cross sectional 112 HD 1 108
Kutlay 2001 Cross sectional 84 HD 1 108
Groothoff 2002 Cross sectional 98
16
12
TX
HD
PD
1 1
t  See appendix A for NP tests used in the studies
Note: CRF = chronic renal failure; HD = haemodialysis; CAPD = continuous ambulatory 
peritoneal dialysis; CTL = healthy controls; TX = transplant patients; Pr-EPO = prospective 
before and after erythropoietin treatment; ns = not stated
This chapter considers the NP impairments associated with ESRD treatments. It is 
organised into sections on (a) chronic renal failure, (b) haemodialysis, (c) peritoneal 
dialysis, (d) anaemia corrective treatment and (e) renal transplantation.
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Section 2: Chronic Renal Failure and NP functioning
CRF has been found to be associated with NP impairments (see reviews by Hart & 
Kreutzer, 1988; Osberg et al., 1982; Pliskin et al., 2001). Intellectual deterioration, 
impaired memory, and reduced mental efficiency, psychomotor speed and attention 
have been found on neuropsychological testing in CRF patients (Bosch & Schlebusch, 
1991; Ryan et al., 1980; 1981; Souheaver et al., 1982).
Results from early studies, conducted in the late 1970’s should be treated cautiously 
given their shortcomings related to insufficient methodological documentation of 
assessments, sample and methods, and the inclusion of patients with much more 
advanced uraemia than more recent studies (Blatt & Tsusima, 1966; Compty et al., 
1974; Fishman & Scheider, 1972, Greenberg et al., 1973; Kaplan De Nour et al., 1977; 
Malmquist et al., 1972; Rabinowitz, & van de Spuy, 1978; Sand et al., 1966, 
Trieschmann & Sand 1971). Those early studies are thoroughly reviewed by Hart & 
Kreutzer (1988) and Osberg et al. (1982) and to whom the reader is directed for more 
detail of this work.
Section 3: Dialysis and NP functioning
Studies of the NP performance of dialysis patients have involved comparisons with pre­
dialysis CRF patients, healthy controls and existing test norms.
Dialysis patients have generally been found to perform better that non-dialysed CRF 
patients (Baker et al., 1989; Hart et al., 1983; Ryan et a l, 1981) albeit not consistently 
so (Rozeman et a l,  1992; Yount et a l, 1999).
The level of severity of renal failure is a critical confounding factor in evaluating these 
studies. Teschan et a l, (1979) reported that haemodialysis patients performed 
significantly better than pre-dialysis patients with high creatinine levels on memory and 
attention tasks but their performance fell significantly short of that of pre-dialysis 
patients with low creatinine concentrations. Similarly, Gilli et al., (1980) found that pre-
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dialysis patients with residual renal function (5.9 ml/min creatinine clearance) had 
higher memory, full scale IQ and Performance IQ scores than dialysis patients with 
absolutely no residual renal function. One may speculate that unless creatinine clearance 
falls below a certain level indicating severe or near-terminal renal failure, the NP 
performance of pre-dialysis patients might not necessarily be inferior to that of dialysis 
patients. The lack of sufficient biochemical data in these studies prevents further 
examination of this hypothesis. In addition these studies should be viewed with caution 
due to their small sample sizes and multiple statistical comparisons with no apparent 
adjustments of significance levels.
3.1 HD and cognitive functioning
Prospective studies indicate that patients’ NP status improves with the initiation of HD 
(Gilli & DeBastiani, 1983; Hagberg, 1974; McKee et al., 1982; Teschan et al., 1974a). 
The improvement does not fully restore cognitive functioning to pre-morbid levels, and 
some reports indicate that cognitive dysfunction persists after the initiation of HD, in 
comparison to normative data or controls. In order to examine the impact of HD on 
different NP domains, the NP performance of individuals on HD is discussed according 
to NP domain examined.
Studies are summarised in terms of (a) measures of general intelligence (b) memory, (c) 
attentional processes and (d) other cognitive abilities and (e) generalised rating scales.
3.1.a Measures of General Intelligence
On intelligence tests, such as the Weschler’s Adult Intelligence Scale, HD patients show 
a deterioration of the total Intelligence Quotient although mean scores are still close to 
norms and fall in the range of low average IQ (Baker et al., 1989; Davis & Masey, 
1973; Fishman & Schneider, 1972; Gilli & De Bastianni, 1983; Greenberg. 1973; 
Hodna et al., 1991; Jackson et al., 1987; Maher et al., 1983; Pliskin et al., 1996; 
Schupak et al., 1967; Temple et a l, 1992; Ventura et al., 1990; Winokur et al., 1972). 
The decline in IQ scores is largely due to slowness in executing the performance tasks, 
which are timed. Verbal tests, requiring (well)-leamed knowledge do not tend to show 
any decline. Given this tendency it is not surprising that some studies have reported a 
large discrepancy between Verbal and Performance IQ (English et al., 1978; Temple et
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al., 1995; Ventura et a l, 1990), a pattern reflective of cortical dysfunction (Nissenson, 
1992b), and dementing illnesses.
Deterioration indices based on WAIS scores have also been used. English et al. (1978) 
reported the mean Weschler deterioration quotient of HD patients was outside the 
normal range. Baker et al. (1989) and Jackson et al. (1987) used a deterioration index 
based on reading scores as a marker of pre-morbid intellectual level and both concluded 
that there is a slightly higher incidence of deterioration in long-term HD and CAPD 
patients than would be expected in a random sample of the population.
Studies, which included control groups rather than norms, have produced mixed 
findings. No significant WAIS differences between HD patients and matched controls 
were reported by some investigators (Freeman et al., 1980; Pliskin et al., 1996) while 
others found that HD patients had significantly lower scores in WAIS tasks in particular 
with respect to performance tasks (Groothoff et al., 2002; Ventura et al., 1990).
3.1.b Memory
• Verbal memory
A large number of studies using a variety of tests assessed verbal memory function in 
HD patients. Test procedures have included standardised measures of verbal memory 
(e.g. Rey Auditory Verbal Learning Test) requiring immediate and delayed recall of 
words, digits, sentences or stories. On the whole, study findings suggest that verbal 
memory function is diminished particularly in registration, learning, and reproduction of 
recently acquired data, the ‘working’ memory being more vulnerable than information 
retrieval from long term memory.
Studies using control groups showed that HD patients perform less well than controls in 
verbal memory tasks (Altmann et a l, 1989; Buoncristiani et al., 1993; Fazekas et a l, 
1996; Musolino et a l, 1992; Rozeman et al., 1992; Teschan et a l, 1979; Wolcott et a l, 
1988a), although observed mean scores for HD patients do not always indicate deficits 
relative to norms (Brown et al., 1991; Churchill et al., 1992; Hagberg, 1974; Wolcott et 
a l, 1989).
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The literature is however by no means consistent. Contrary findings of uncompromised 
verbal memory function have also been reported (Hart et al., 1983; Marsh et al., 1991; 
Pliskin et ah, 1996; Ryan et ah, 1981).
• Non-verbal memory
A number of studies have evaluated non-verbal memory in HD patients (see Table 4.1). 
Various visual memory tests have been used typically involving the reproduction of 
designs and figures (e.g. Benton Visual Retention test) and/or recognition of designs 
and figures.
Performance in visual memory tasks appears to be compromised in HD patients, 
particularly with regard to reproduction tasks (Altmann et al., 1989; Bolla et al., 1992; 
Fazekas et al., 1996; Hart et a l, 1983; Musolino et al., 1992; Ratner et a l, 1983; 
Rozeman et al., 1992; Ventura 1990; Ziesat et al., 1980). No deficits have been found in 
visual recognition tasks (Hart et al., 1983) while others found equivalent visual memory 
abilities in HD and control participants (Pliskin et a l,  1996).
There are important methodological issues, which may in part account for 
inconsistencies in the findings. In the majority of the studies reporting memory deficits, 
NP assessments were taken at variable times mainly either prior to a dialysis run when 
uraemia is most severe, to immediately after when adverse physical states such as 
fatigue, nausea are frequently documented. This issue is particularly important as 
different results have been found depending on the timing of NP assessment relative to 
the dialysis cycle. Studies in which assessments were taken at 24-hours post-dialysis 
tend to show no memory deficits (Marsh et al., 1991; Pliskin et al., 1996; Wolcott et al., 
1989). For example, Pliskin et a l, (1996) found no significant difference between 
adequately dialysed HD patients (assessed at 24-hours post-dialysis) and matched 
controls in neither verbal nor visual memory tasks for immediate and delayed 
conditions, as well as percent of information retained. Exceptions are four studies 
(Fazekas et al., 1996; Hart et al., 1983; Ratner et al., 1983; Rozeman et a l, 1992) in 
which memory impairments, particularly pronounced in visual memory tasks were 
evident in HD patients at 24 hours post dialysis. Hart et al. (1983) found a significant 
impairment only in one of the five memory tests administered (visual memory task), 
with a tendency for impairment in a second.
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Other methodological differences in HD patients’ clinical characteristics, such as time 
on dialysis or adequacy of dialysis delivery are also likely to explain the different 
findings reported. For example, in the study by Hagberg (1974) HD patients were on 
treatment for less time (12 months) than participants in the previously referenced 
studies. Ventura et a l (1991) who compared memory functioning in HD patients who 
had been on treatment for either more or less than four years, reported significant better 
memory functioning for the group who had been on dialysis for less time. Pliskin et al. 
(1996) attributed the lack of significant NP differences between adequately dialysed HD 
patients and controls to adequate dialysis delivery. As however sample sizes of HD and 
control groups assessed in all these studies were very small (ranging from 10 to 16), it 
also plausible that studies were under-powered to detect significant differences.
Longitudinal studies do not indicate memory deterioration in HD patients although 
methodological qualifications such as the lack of comparison groups and small sample 
sizes make these findings difficult to interpret. Gilli & Bastianni (1983) reported a 
decline in memory quotient over periods of at least 1 year but McKee et a l (1982) and 
Hagberg (1974) found no evidence of deterioration in memory over period of 22 months 
and 6 months respectively. Patients on dialysis for 6 months versus 4.3 years performed 
similarly, although the latter group did tend to score lower on recall tasks (McKee et a l ,
1982).
3.1.c Attention - Concentration
A wide range of NP tests measuring attention, concentration, and psychomotor speed 
has been used. A basic distinction can be drawn between simple tests of attention (e.g. 
Trailmaking part A) and more difficult or complex tests of attention such as 
Trailmaking part B. Study findings differ according to the specific NP tests used, and 
the point of reference on which comparisons were made, i.e. normative data or healthy 
controls.
Attention impairments have been noted mainly in the performance of more complex 
attention tests rather than the more simple tasks. Earlier research (Alexander et a l , 
1980;Ginn, 1975; Ginn et a l , 1975; Murawski et a l, 1975; Teschan et a l, 1979) and 
several recent studies have shown that dialysis patients perform significantly worse than 
control groups on tasks of complex attention and mental tracking such as Trailmaking B
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or Stroop test (Altmann et al., 1989; Bremer et al., 1997; Brown et al., 1991; Churchill 
et al., 1992; Fazekas et a l , 1996; Grimm et a l, 1990; Krammer et a l, 1996; Marsh et 
a l, 1991; Musolino et a l, 1992; Pliskin et a l, 1996; Ryan et al, 1981; Rozeman et a l, 
1992; Wolcott et a l, 1988a, Yount et a l, 1999). However, some other measures of 
complex attention such as the Category test or the WAIS digit symbol test do not show 
deficits (Bremer et a l, 1997, Hart et a l, 1983, Pliskin et a l, 1996, Umans & Pliskin, 
1998). These inconsistencies may partly be attributed to small sample sizes assessed.
Findings on HD patients’ performance in relation to existing norms are mixed with 
some studies showing clear deficits (Ratner et a l, 1983; Rozeman et a l, 1992) and 
others not, with the observed mean scores falling in average or low average range 
(Brown et a l, 1991; Krammer et a l, 1996; Pliskin et a l, 1996; Umans & Pliskin, 1998; 
Wolcott et a l, 1989).
Evidence regarding less complex attention tasks is equivocal. Some studies recorded no 
deficits in simple attention or vigilance tasks such as Trail Making Part A for HD 
patients relative to healthy controls (Buoncristiani et a l, 1993; Hart et a l, 1983; Pliskin 
et a l, 1997; Ryan et a l, 1981; Umans & Pliskin, 1998; Wolcott et a l, 1989). Opposite 
findings have also been reported (Garcia-Maldonado et a l, 1991; Krammer et a l, 1996; 
Rozeman et a l, 1992).
Results of studies that employed normative comparisons to evaluate the performance of 
HD patients in simple tasks of attentional processes are conflicting. Deficits were 
documented only when patients were assessed prior to their dialysis session or at 
unspecified times (Churchill et a l, 1992; Garcia-Maldonado et a l, 1991; Smith et a l, 
1990; Wolcott et a l, 1988a). Mean scores were within normal range when assessments 
were taken at 24-hours post-dialysis and after anaemia corrective treatment (Brown et 
a l, 1991; Grimm et a l, 1990; Wolcott et al., 1989).
3.1.d Other cognitive abilities
Language and selective verbal functions, orientation, and constructional abilities (e.g. 
fluency, conceptual reasoning) appear to show no impairments as a result of HD 
(Altmann et a l,  1989; Bremer et a l, 1997; Brown et a l, 1991; Churchill et al., 1990;
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1992; Fazekas et al., 1996; Jackson et a l , 1987; Marsh et al., 1991; Wolcott et al. 1989; 
Ratner et al., 1983; Pliskin et al., 1996; Wolcott et al., 1989).
Findings regarding motor abilities appear to vary according to the specific tasks 
examined. Some studies reported bilateral impairments in tasks of gross motor strength 
such as grip strength (Pliskin et al., 1996; Ratner et al., 1983) and tasks of visual motor 
co-ordination requiring fine motor movement, i.e. grooved pegboard (Churchill et a l, 
1992; Ratner et al., 1983). In contrast, findings of intact performance or comparable to 
that of controls were found in manual dexterity tasks such the finger tapping and the 
purdue pegboard test (Churchill et al., 1991; Hart et al., 1983; Pliskin et al., 1997; Ryan 
e ta l,  1981).
3.1.e General rating scales and inventories
This section considers findings on generalised rating scales used to form gross 
diagnostic impressions. These are included even though such measures should not be 
regarded as NP tests. They provide crude estimation of general cognitive function and 
given their low sensitivity (Anthony et al., 1982) they are more suited as screening 
instruments (e.g. to exclude patients with dementia) rather than measures of cognitive 
abilities.
Contradictory findings have been reported for measures of general cognitive functioning 
such as Minimental State Examination (MMSE) with some studies reporting normal 
mean scores for HD patients and other studies documenting cognitive deficits (Gottlieb 
et a l, 1987; Krammer et al., 1996; Kutlay et al., 2001; Sehgal et a l, 1997).
The timing of test administration in relation to the dialysis cycle appears to be critical 
factor that differs between studies. Findings of ‘normal’ MMSE scores have been 
reported when HD patients when assessed either immediately after a dialysis session 
(Musolino et al., 1992) or at 120 minutes after a dialysis session (Buoncristiani et a l, 
1993), and at 24 hours post-dialysis (Grimm et a l, 1990) albeit not consistently so 
(Fazekas et al., 1995; 1996). In contrast, MMSE scores indicative of cognitive 
impairment were found when HD patients were assessed prior their dialysis session 
(Gottlieb et al., 1987; Sehgal et al., 1997). For example, Sehgal et al. (1997) assessed a 
large sample of 336 HD patients during dialysis and noted that the prevalence of
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cognitive impairment is markedly higher than that of the general population after 
controlling for age and education. They found that 30% of patients scored in the range 
of mild to moderate impairment.
Studies that used a control group reported significantly lower mean MMSE scores for 
HD patients assessed at 24-hours post-dialysis (Fazekas et al., 1995; 1996, Krammer et 
al., 1996).
3.2 Acute NP changes in HD patients
HD is an intermittent treatment with the result that renal clearance changes greatly from 
pre- to post-dialysis. This is reflected in significant physiological and biochemical 
changes occurring during haemodialysis (Lewis et a l, 1980; Ratner et al., 1983; Spehr 
et al., 1977). It is logical to assume that the patients’ ability to perceive, process, and 
organise information could fluctuate across the dialysis cycle.
The subsidiary question is whether any observed cognitive changes are correlated with 
specific components of the physiological changes such as the decrease of blood urea 
nitrogen, creatinine and potassium following this general line of reasoning. One would 
hence expect that in HD patients NP performance would be optimal on a midweek non­
dialysis day to avoid acute effects of dialysis or of its lack during the long weekend, and 
then worst on the first dialysis day of the week.
The data reviewed above tends to support this contention, with NP differences between 
HD and controls tending to occur prior to dialysis and no longer been apparent 24-hours 
after the completion of dialysis. Such fluctuations should not apply to (nearly 
continuously dialysed) PD patients for whom their nearly stable biochemical profile 
would predict no temporal changes in their cognitive functioning.
There is indeed some evidence that NP performance in HD patients parallels the 
treatment biochemical profile with systematic differences through the dialysis cycle 
(Osberg et al., 1982). Acute changes in cognition have been reported from immediately 
pre- to 24-hours post-dialysis (Buoncristiani et a l,  1993; Ginn et al., 1975a; Lewis et 
al., 1980; Spehr et al., 1977; Teschan et a l, 1974a). The evidence seems to suggest that 
24-hours post-dialysis is a time when cognitive function is optimal during the 
interdialytic interval. Little variation has been found over shorter time intervals through 
the dialysis cycle (Conrad et a l, 1987; Tennyson et al., 1985). NP improvements have
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been noted mainly in tasks of attention concentration and psychomotor abilities. In 
contrast, Ratner et al. (1983) found improvements in some but not all NP tests used (7 
out of 14) from before dialysis to 20-hours post-dialysis. As these changes in NP tests 
did not relate to changes in serum biochemistry levels the authors attributed the 
improvements to learning effects.
According to the early work of Teschan and co-workers, the adequacy of dialysis may 
be monitored by repeated NP measurements. NP scores have been found to vary directly 
with degree of uraemia with choice reaction time and continuous performance tests 
being sensitive indices in CRF patients not yet on dialysis (Teschan et al., 1979). 
Evidence on dialysed patients is unfortunately conflicting and inconsistent. Study 
findings are consistent in noting the lack of one-to-one correspondence between NP 
improvements and biochemical/physiological changes across dialysis (Ratner et al.
1983). Observed correlations were found to be generally small and non significant, 
perhaps due to the relatively small number of patients studied.
All above studies are limited by two main methodological flaws that constrain the 
generalisability and validity of their findings. Some relate to issues raised earlier, i.e. 
small sample sizes that undermine their power to detect significant effects, and 
insufficient control for salient clinical factors such as dialysis adequacy.
Most importantly though, their methodological limitations relate to study design, in that 
these investigations have failed to rule out factors other than treatment that might be 
driving the acute NP changes. It is also not possible to rule out the competing 
hypothesis that the observed acute NP improvements are due to learning or practice 
effects, by not having a concurrently assessed control group. The retest effect, defined 
as an improvement in performance after repeated presentation of a test, is a general 
problem for longitudinal NP studies (McCaffrey & Westervelt, 1995; Mitrushina & 
Satz, 1991). Effects of implicit or explicit learning, as well as of anxiety reduction are 
always an issue when the same task is repeated more than once. The sole use of parallel 
forms for the NP tests, employed by most of the previous research is not considered an 
adequate manipulation of test retest effects, as it cannot take account of strategy changes 
(McCaffrey & Westervelt, 1995).
Another competing hypothesis would be that factors other than biochemical changes 
might be driving the observed changes in cognitive functioning across the dialysis
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cycle. Mood may influence motivation to perform tasks, and stress, or fatigue may 
transiently influence NP performance. Subjective reports of the physical state appear to 
echo their biochemical profile with patients often reporting that they feel tired and 
lethargic the day of hemodialysis and best the day after haemodialysis. It would 
therefore be valuable to compare cognitive functioning in these two days (Smith & 
Winslow, 1990).
The need to control for intra-individual variability with regard to factors such as fatigue 
and mood becomes imperative if we are to understand NP functioning in dialysis. Such 
measures have not been included in the studies reviewed here and hence the extent to 
which they might have influenced the observed findings is unclear.
In view of these methodological shortcomings it is appropriate to conclude that 
evidence on acute NP changes is inconclusive and appears to raise more questions 
regarding the temporal course of cognitive abilities through the dialysis cycle.
3.3 PD and cognitive functioning
There have been few studies on the cognitive functioning of patients on PD. Most 
previous studies have recruited only CAPD patients, hence there is a complete paucity 
of data on the NP functioning of patients on APD.
Study findings for CAPD patients indicate that compared to norms, CAPD patients 
present with mild NP impairments in attention, concentration, and verbal memory 
(Baker et al., 1989; Kenny et al., 1981; Rozeman et al., 1992; Temple et al., 1995; 
Wolcott et al., 1988a). Mean performance in most of the NP tests used fell within or 
borderlined low average range.
Findings of studies using control groups are conflicting with one report of equivalent 
cognitive functioning (Buoncristiani et al., 1993) between groups and two reports of 
inferior NP performance in the CAPD group mainly in tests of attention and 
concentration (Bremer et al., 1997; Rozeman et al., 1992). There is only one 
longitudinal NP evaluation of PD patients. Kenny et al. (1981) repeatedly assessed 
patients while on intermittent PD and after 2, 12, 18 and 24 months on CAPD. 
Significant NP improvements in attention and concentration were found at 6 and 12
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months for the group as a whole, although NP impairments relative to norms were still 
evident for approximately 1/3 of patients. The validity of these findings is questionable 
as the study was conducted in the early days of CAPD and since then substantial 
technical improvements have been achieved and the findings could reflect learning the 
tests with repeat performance
Other inconsistencies in findings are likely to be largely due to studies’ methodological 
qualifications, the most important being the small sample sizes recruited. Data 
interpretation is further constrained by the inclusion of both HD and CAPD patients in 
some reports (Bremer et al., 1997) and the lack of documentation of relevant clinical 
parameters such as dialysis adequacy delivery and comorbidities, in the recruited 
samples. Lastly, research has overlooked certain areas of cognitive functioning such as 
non-verbal (visual) memory or psychomotor abilities. The assessment of these cognitive 
abilities in this population is hence a question for future research.
3.4 HD and PD comparisons
Comparing the NP impact of the alternative dialysis modalities is important as they 
have different physiological and biochemical processes. PD as described earlier is a 
continuous therapy in that it clears wastes to a variable degree whenever PD fluid is 
dwelling in the abdomen. By contrast, HD is an intermittent therapy, which provides no 
replacement for lost renal function between treatments but can provide above normal 
levels of clearance during dialysis; in other words biochemical indices vary greatly from 
immediately before to during and after dialysis. The two treatments also differ in their 
efficacy to remove specific molecules as discussed earlier (see Chapter 1; section 2.3). 
Thus if NP functioning depends differently on the peak concentration of toxins, on their 
rates of change over time or their time-averaged concentration, one might expect 
differences between HD and PD (Pliskin et a l, 2001).
There have been few comparative NP evaluations of HD and PD patients. In addition, in 
all previous investigations only hospital HD and CAPD patients were recruited so there 
is no data on how other treatment modalities such as home HD and APD fare in relation 
to the hospital HD and CAPD.
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Studies comparing cognitive functioning between patients on hospital HD and CAPD 
have produced inconsistent and contradictory findings. Some studies have shown more 
efficient cognitive functioning in CAPD patients compared to hospital HD 
(Buoncristiani et a l, 1993; Garcia-Maldonado et a l, 1991; Wolcott et a l, 1988a; Yount 
et a l, 1998) and others have reported no significant differences between groups 
(Rozeman et a l,  1992).
Procedural differences in the timing of the NP assessment relative to the cycle of 
dialysis appear to account for these contradictory findings. This point is particularly 
important because as described above systematic behavioural and electrophysiological 
differences accompany alterations in uraemic status over the period of days between HD 
sessions. Differences in NP performance favouring PD patients were found only when 
HD patients were assessed immediately prior to their dialysis. No systematic differences 
were evident when NP assessments were scheduled on a non-dialysis day (24-36 hours 
post-dialysis). The following studies illustrate this point.
The first comparative study was conducted by Wolcott et a l (1988a). Results indicated 
that there are detectable differences in performance on NP tests of verbal memory and 
attention/concentration between HD and matched CAPD patients. Even though the 
sample was small, CAPD patients had better NP scores than HD patients albeit their 
mean performance was still impaired compared to norms. The authors concluded that 
CAPD might be more efficient in reversing the cognitive deficits associated with 
uraemia. However HD patients were assessed thirty-to-sixty minutes before beginning a 
dialysis treatment. As discussed earlier this is probably a time when HD patients are at 
their worst.
Rozeman et a l  (1992) who assessed pre-dialysis, CAPD and HD patients 24-40 hours 
after their dialysis session by means of neurophysiological and NP measures, failed to 
demonstrate a better cognitive performance for CAPD. All groups differed significantly 
from controls but there were no significant differences between groups. A minor trend 
toward better cognitive performance of CAPD patients relative to HD patients on the 
Colour Vigilance test, an index of attention and response speed, was found but it did not 
reach statistical difference.
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In studies comparing NP performance of CAPD patients to that of HD patients assessed 
both prior and shortly after dialysis, reported significant differences in favour of the 
CAPD group only in relation to the pre-dialysis NP scores of HD patients (Buoncristiani 
et al., 1993). The authors of this study conclude that CAPD is better than HD since 
patients are able to steadily maintain normal or within normal limits cognitive function, 
whereas in hemodialysis, cognitive functioning is restored only transiently, in the post­
dialysis phase. Caution is however warranted in interpreting these findings, as practice 
effects have not been ruled out.
Yount et al. (1998), in the most recently published study, reported that CAPD patients 
performed significantly better on measures of focused attention than HD patients. 
Performance of memory tasks and tests of sustained attention was equivalent in both 
dialysis groups. Treatment modality was found to be a significant predictor of attention 
(favouring PD over HD) but as it accounted for only 1% increase in the explained 
variance, the authors concluded that this was not clinically significant. Although the 
study benefits from an exceptionally large sample of CRF, PD, and HD patients, the 
lack of specification of NP test administration for the HD group constrains data 
interpretation.
The possibility of pre-dialysis differences in cognitive function of patients chosen or 
opting for hospital HD and CAPD should be considered when evaluating treatment- 
modality differences. The modality selection process or assignment method may 
contribute to this potential source of bias. One might speculate that patients with higher 
cognitive function may opt for, or may be chosen for a home dialysis modality (such as 
CAPD), though there is presently no evidence to support this contention.
Moreover in general, studies comparing HD and PD are difficult to interpret because of 
the small sample sizes used, the absence or insufficient adjustment for casemix, and 
other confounding factors likely to impinge upon NP performance. Sociodemographic 
and clinical factors such as age, education, adequacy of dialysis, comorbidities, which 
have been shown to impact heavily on NP performance have not always been 
adequately examined (Hart & Kreutzer, 1988; Pliskin et al., 1996; 2001). Given the 
methodological shortcomings of previous research, it remains unclear whether there are 
general differences in cognitive functioning between well dialysed HD and PD patients. 
It is difficult to identify the NP processes which are likely to be implicated in the
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cognitive dysfunction seen in dialysis patients, and reliably ascertain the presence or not 
of modality induced cognitive deficits, as well as the merits of different dialysis 
treatments.
3.5 Anaemia and cognitive functioning
The possible cognitive deficits associated with ESRD may not be explained solely by 
uraemia but also by anaemia, that almost invariably accompanies ESRD (Nissenson,
1989). Anaemia is generally severe and can be detected in over 90% of patients with 
ESRD. It is caused by a relative deficiency of erythropoietin. Severe anaemia has been 
shown to be directly associated with cognitive dysfunction, mood disturbances and 
reduced energy. Anaemia corrective treatments, such as the use of androgens and blood 
transfusions, are problematic in many patients and rarely completely correct anaemia. 
Furthermore the risks associated with transfusions, including the development of 
cytotoxic antibodies and transmission of infection (hepatitis, human immunodeficiency 
syndrome) are substantial. The development of recombinant human erythropoietin 
(rHuEPO) has however provided an effective treatment to reverse anaemia in most 
ESRD patients (Eschbach et al., 1989) and thereby possibly improving attention, mental 
processing speed, learning, memory, energy and mood.
Studies that have used neurophysiological and NP tests in dialysis patients to measure 
the effect of increasing haematocrit through rHuEPO (thus improving cerebral oxygen 
delivery) on cognitive function are summarised in Appendix B.
In most of these studies cognitive function was assessed in patients after haematocrit 
was increased to 30 -  36%, indicating partial correction of anaemia as haematocrit 
levels are not completely normalised. Even though achieved haematocrit targets were 
similar, study follow-up times ranged from 2 to 12 months. This may be an important 
methodological consideration for the detection of NP improvements after haematocrit 
stabilisation.
Studies have shown that relative to normative data, dialysis patients’ NP scores are in 
the low average or below average range at baseline, i.e. before rHuEPO treatment but 
after anaemia correction normal NP functioning results (Brown et al., 1991; Wolcott et 
al., 1989). Significant NP improvements were found in general intelligence measures 
(Temple et al., 1992; 1995) and tests of attention, concentration and psychomotor speed
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such as the Symbol Digit Modality Test, Trail Making Test (Brown et al., 1991; Horina 
et al., 1991; Marsh et al., 1991; Temple et a l, 1992; Wolcott et a l,  1989) at 3 and 12 
months follow-up. Verbal learning, fluency and memory followed a similar pattern of 
improvement but changes have not always reached significance (Brown et a l, 1991; 
Horina et a l, 1991; Marsh et al., 1991; Temple et a l, 1992; Wolcott et a l, 1989).
Several explanations can be brought forward to account for these findings. First, it is 
plausible that the observed trends for language and learning may be due to improved 
attention capacity. Also, methodological issues related to small sample sizes also need 
to be considered, as studies might have been under-powered to detect significant 
changes. Moreover, the absence of control group in most of these studies further 
constrains data interpretation as observed improvements could be explained as learning 
or practice effects.
Section 4: Cognitive functioning in Transplantation
Most of the existing research on the NP aspects of kidney function has focused on the 
effects of dialysis treatment (Pliskin et al., 2001) or the cognitive functioning in 
paediatric transplant populations (Fennell et a l, 1984; Lawry et a l, 1994; Mendley & 
Zelko, 1999). There have been only a few studies that have examined NP aspects of 
kidney transplantation in adults (Farmer, 1994).
Teschan et al. (1976) studied 8 patients repeatedly during dialysis treatment and during 
4 -23 months following kidney transplantation. They found a significant improvement 
in EEG, choice reaction times and memory test scores following kidney transplantation. 
Teschan et al. (1979) compared CRF, dialysis and transplant patients to normal controls 
and found transplant patients to perform at levels comparable to those of normal 
controls on the attention and memory NP tasks. However the authors did not present 
comparisons between the dialysis and transplant groups.
Kramer et al. (1996) reported improved cognitive functioning as measured by the 
Trailmaking test and MMSE in a group of 16 HD patients before and after 
transplantation as compared to age-matched healthy subjects. Prior to transplantation,
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HD patients performed significantly worse than controls on both NP tests, but 
performance between groups did not significantly differ following transplantation.
There are methodological weaknesses in previous studies that limit interpretation and 
generalisability of findings. These relate to the small sample sizes, the NP tests used and 
insufficient adjustment for casemix and other confounding factors likely to impinge 
upon NP performance. Measures used did not assess cognitive domains found to be 
particularly impaired in ESRD patients (Pliskin et al., 2001) such as complex attention 
and mental processing or are not considered to be sensitive enough to subtle cognitive 
deficits, i.e. MMSE (Anthony et al., 1982).
Given these shortcomings a reinvestigation of this area with improved methodology is 
warranted to ascertain how the NP performance of TX patients compares to that of 
patients still on dialysis and to verify whether TX restores NP performance relative to 
normative data.
In addition, there are several empirical questions that have not been addressed in 
previous research. These included a comparison of the NP functioning between cadaver 
(CAD) transplant recipients and living related donor (LRD) transplant patients. It has 
been demonstrated that these two types of transplant show different clinical outcomes 
regarding patients and graft survival (see Chapter 1; section 2.4.b). One question 
addressed in this study was whether these differences are reflected in NP performance.
Another pertinent question in TX relates to the NP consequences of anti-rejection 
medication. The clinical benefits of transplantation are achieved at the cost of lifelong 
therapy with immunosuppressive drugs such as glucocorticoids and cyclosporin or 
Tacrolimus, resulting in CNS side-effects. These may range in severity and may include 
symptoms such as involuntary fine tremor, headache, insomnia, ataxia, parasthesias, 
impaired visual acuity and profound disturbances in mental status and focal neurologic 
deficits. Neurocognitive dysfunction such as delirium, dementia and deficits in memory 
and attention has been documented in organ transplant recipients receiving cyclosporin 
or tacrolimus (Christe, 1994; Craven, 1991; Trzepacz & Dimartini, 2000). While the 
neurological complications of these treatments are well-documented (Burke et al., 1994; 
Cohen & Raps, 1995; Craven, 1991) and there is evidence on neurotoxic effects and 
brain imaging changes with both Cyclosporin and Tacrolimus (Bartynski et al., 2001), 
no studies have examined their impact on NP functioning.
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Section 5: Limitations of previous research
The published literature in this field is beset with significant methodological and 
conceptual limitations.
1. Extremely low sample sizes.
2. Sociodemographic variables (such as patient age, education) have not been 
controlled for.
3. Disease factors (e.g. comorbidities; disease and treatment duration) have not been 
accounted for.
These issues have been highlighted by Pliskin et al. (1996; 2001). Pliskin attributed the 
NP deficits reported in previous research to lower and inadequate levels of dialysis 
delivery, uncorrected anaemia, unrecognised comorbidities and inadequate 
methodological control rather than ESRD per se.
The effects of anaemia on cognitive functioning have been discussed earlier. 
Furthermore many comorbid conditions, which are now common in ESRD patients (e.g. 
coronary artery disease, diabetes, uncontrolled hypertension), also contribute to NP 
dysfunction,
4. Dialysis adequacy delivery is another particularly important consideration 
overlooked in previous research.
Medical standards of dialysis adequacy for example have changed dramatically (Pliskin 
et al., 2001). Thus many patients studied earlier may have been relatively underdialysed 
at the time of assessment compared to current standards for dialysis prescription (Gotch 
& Sargent, 1985; Lowrie et al., 1981). Adequacy of dialysis remains an elusive term yet 
to be defined. Adequate dialysis refers to the "minimal effective dose" of dialysis that 
achieves stated clinical goals and standards regarding clearance of uraemic toxins. The 
vast majority of previous studies have failed to quantify or to report dialysis delivery, 
thus allowing for the possibility that patients might have been underdialysed at the time 
of assessment. The deficits reported in some studies may hence reflect an inadequate 
dialysis delivery. This is particularly the case for the older studies conducted before the 
establishment of minimal dialysis prescription suggested by the results of National Co­
operative Dialysis Study (NCDS; Gotch & Sargent, 1985). This issue is made more
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complex because dialysis standards have since crept upwards with more recent evidence 
in support for increased HD dose and PD dose prescriptions (CANADA-USA 
Peritoneal Dialysis Study Group, 1996; Port et al., 1998; Szczech et al., 2001). Indeed, 
no studies on PD patients recorded PD adequacy levels and only a few of the studies on 
HD patients reported dialysis prescription based on urea kinetic modelling (Churchill et 
a l , 1991; Churchill et a l, 1992; Kramer et a l, 1996; Pliskin et a l, 1996; Umans & 
Pliskin, 1998; Wolcott et a l, 1988a). Their findings seem to suggest well dialysed HD 
patients manifest little evidence of clinically significant NP impairments. Recent 
research found that ESRD patients receiving dialysis treatment at levels consistent with 
current NCDS standards and verified by urea kinetic modelling (KT/V = 1.1 or greater), 
did not have NP dysfunction when compared to well matched controls (Pliskin et a l, 
1996). Unfortunately the small sample sizes and other specific characteristics (e.g. 
lower educational status) of HD responders hinders drawing firm conclusions about the 
presence of NP deficits in well dialysed patients based on these otherwise 
methodologically sound studies.
5. The clinical management of renal patients today bears little resemblance to that of 
renal patients in the 70’s and 80’s when the vast majority of NP studies were 
conducted. The current ESRD population is now quite different than their 
counterparts 10 or 20 years ago. Current dialysis patients are older, often less 
educated, and of lower socio-economic status, more chronically ill, more apt to have 
had dialysis instituted earlier in the course of renal failure and more apt to receive 
adjunctive treatment to control secondary conditions such as hyperparathyroidism 
and anaemia.
6. The time of the NP assessments relative to the cycle of dialysis in the case of HD 
has not been controlled.
Section 6: The effect of NP functioning on other outcomes
Studies have reported significant associations between NP performance and HQoL 
outcomes (Bremer et al., 1997; Fox et al., 1993; McSweeny et al., 1985; Tarter & 
Switala, 2000; Yavuz et al., 2000). Bremer et al. (1997) found that NP impairments are 
not only predictive of emotional wellbeing and unemployment but play a mediating role 
between ESRD and vocational rehabilitation.
Despite these findings, evaluation of the NP implications of ESRD and associated 
treatments, once a popular research agenda, has been overlooked in recent literature and 
has rarely been integrated into renal treatment outcome research.
Section 8: Subjective Cognition
The study of NP outcomes in ESRD patients would not be complete without 
considering patients’ appraisal of their cognitive abilities. This area has been termed 
subjective cognition, and it is by definition more closely related to patients’ experience.
It is not uncommon for dialysis patients to report cognitive complaints particularly with 
memory and concentration (Brickman et al., 1996). These complaints are often 
anecdotally quoted in the renal literature (Pfettscher et a l, 1995; Smith & Winslow,
1990).
This is an important area of study as perceptions of cognitive functioning may have 
broader consequences on patients’ well-being. Subjective cognition being part of 
patients’ experience may be more strongly associated with outcomes such as emotional 
distress and HQoL. They could adversely affect their morale, discourage efforts to 
adhere to rigorous treatment regimen and impede their adjustment to ESRD.
A systematic evaluation of subjective cognition in patients on different dialysis 
treatment (HD and PD) and patients with a kidney transplant is still lacking.
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The extent to which these subjective cognitive complaints are related to objective 
indices of cognitive performance is not known. One study (Brickman et al. 1996) 
reported that NP scores in WAIS digit symbol were significant predictors of memory 
and attention complaints in dialysis patients, contributing a significant albeit very 
modest percentage (1.4%) of the total variance.
Research in different areas showed no association between subjective cognition and NP 
scores in patients following cardiac surgery (Khatri et al., 1999; Newman et al., 1989) 
or in elderly populations (Ponds et a l, 2000). As to whether these findings will be 
replicated in the renal population remains open to investigation.
The lack of significant association however does not necessarily suggest that either 
patients’ perceptions or reports are not valid or that NP tests are not sensitive enough to 
capture subjective experience. These findings highlight the conceptual distinction and 
independence between objective and subjective phenomena. Both have their place in 
evaluating the outcomes associated with ESRD and associated treatments.
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Section 9: Study aims and hypotheses regarding NP functioning
The present study was designed as a prospective investigation of a large cohort of 
patients on HD and PD as well as renal transplant patients to assess acute cognitive 
changes in the dialysis groups and to evaluate differences in cognitive functioning 
across the different renal replacement treatment modalities (i.e. HD, PD and TX).
The aims of the study were as follows:
(a) To examine NP changes in HD and PD patients, specifically any improvement 
within the cycle of dialysis, from immediately before HD and again at 24 hours post 
HD.
NP improvements were predicted for both groups but we anticipated that the magnitude 
of NP change would be greater for the HD group. Given the methodological limitations 
of previous research, formulating specific predictions regarding which of the specific 
cognitive abilities will change from pre- to post- dialysis was in our view unwarranted, 
so no a priori hypotheses were made. Greater NP improvements were predicted mainly 
for the HD group for which both learning and biochemical changes were expected 
across the two assessments.
(b) to compare NP performance of HD patients and PD patients over the same time 
period
Following this line of reasoning regarding the acute NP changes across the two dialysis 
groups, it was further hypothesised that group differences, if any, in NP functioning 
between HD and PD groups would be evident at the pre-dialysis (Tl) assessment when 
the HD group would be at their worst physiological state. These differences should be 
reduced or neutralised at the post-dialysis (T2) assessment when the HD group would 
have improved physiological functioning.
(c) To compare NP functioning between transplant and dialysis patients
It was hypothesised that TX patients should present with more efficient cognitive 
functioning compared to dialysis patients (irrespective of specific dialysis modality), as 
TX provides more efficient renal clearance/restores renal function. No a priori
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hypothesis was made regarding the association between transplant type, 
immunosuppressive medication and NP performance.
(d) To explore the relationship between NP functioning in ESRD patients (dialysis, 
transplantation) and biochemical measures.
This is a two-fold question:
• How do absolute levels of biochemistry relate to cognitive functioning in dialysis 
and TX patients?
No specific predictions regarding the relationship of specific biochemical assays and 
specific NP scores were made.
• Do any observed NP changes in the dialysis correspond with the biochemical and 
physiological changes that take place across the dialysis cycle?
We expected significant biochemistry changes from T1 to T2 assessment only for the 
HD patients and not for the PD group. We hypothesised that NP improvements in the 
HD group, if any, should parallel biochemical changes but no specific hypotheses, in 
terms of identifying particular biochemical predictors were formulated.
(e) To examine the relationship between objective and subjective cognitive functioning. 
This entailed:
• examining the associations between acute changes in objective NP functioning and 
perceived ratings of acute cognitive changes over time in HD and PD
• evaluating the association between objective NP scores and retrospective subjective 
evaluations of cognitive decline or amelioration since dialysis onset or receipt of a 
kidney transplant.
(0 to examine the association between objective NP functioning and HQoL
It was expected that absolute NP functioning will be associated with HQoL and it might 
possibly mediate the relationship between ESRD and HQoL. We were anticipating that 
these associations would be stronger for emotional well-being or aspects of HQoL. This 
expectation was based on the assumption that NP impairments could lead to frustration 
and feelings of emotional distress but should not impact on physiological function. Thus 
it was deemed unlikely that NP performance would be strongly associated with physical 
functioning and physical well-being.
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CHAPTER 5: M ETHODS
Section 1: Participants
The intention was to perform a robust study sufficiently powered to compare the three 
main treatment modalities for ESRD, namely HD, PD and transplantation. Initial a 
priori power calculations (Gpower version 2.1) using a power of .80 with a likelihood of 
type error set to .05 and the probability of type II error at .20 determined that a target 
sample of 159 patients would be necessary to detect a medium effect size (0.25) in three 
groups ANOVAs. No power calculations were made for the secondary comparative 
analyses between other sub-groups in the study.
The overall study population consisted of chronic dialysis and kidney transplant patients 
treated in two urban renal units. Patient recruitment began in October 1997 and was 
concluded in October 1999.
Patients were approached if they met the following inclusion criteria: (a) aged 18 years 
or more, (b) no history or clinical evidence of cerebrovascular disease as reflected by 
new, transient, or fixed neurological deficits, (c) no major visual or hearing 
impairments, or other sensory or motor impairments that prohibit them from completing 
the scheduled assessments, (d) absence of acute or chronic psychosis, evident 
depression, severe learning disabilities, and/or dementia, (e) currently stable, defined as 
not being acutely ill or hospitalised at the time of the assessments (patients hospitalised 
during the last 3 months for intercurrent problem or problems related to dialysis or TX 
were not eligible), (f) be fluent in written and spoken English, and (g) a minimum of 3 
months on their respective mode of treatment and dialysis techniques (e.g. the same 
dialysate or dialyser if on HD). This criterion was necessary since in several cases initial 
dialysis treatment modality is often provided on an urgent basis and is not always the 
treatment that the physician or the patient would select for long-term therapy.
Additionally patients with severe refractory anaemia (Hb < 8 g/dl) despite erythropoietin 
therapy, blood transfusions and supplemental iron, and patients with evidence of protein 
malnutrition as marked by serum albumin < 35 U/L or protein catabolic rates < .08 (in 
the last three consecutive assessments) were also excluded. Finally patients using 
medication with known NP effects during the previous 3 months were not eligible for 
participation. The different study samples are described below.
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1.1 Transplantation Sample: M iddlesex Hospital (M IDDX-TX)
Renal transplant recipients were recruited from the Middlesex Hospital, London, UK 
Transplant Unit. This sample completed the full study protocol and participants satisfied 
the inclusion criteria described above. Eligible TX patients were opportunistically 
recruited into the study based on their clinic attendance during the study window. One 
hundred and eighty one patients of the 288 registered MDDX-TX patients had scheduled 
appointments but 155 actually attended the transplant clinic. Thirty-three of them had to 
be excluded mainly due to their failure to speak the language of the tests and/or 
illiteracy. The remaining 123 eligible TX patients were sequentially approached to 
participate and 117 consented to the full protocol (response rate = 95.1%).
Table 5.1: Sociodemographic and clinical characteristics of the MIDDX-TX sample.
All T X C A D  T X L R D  T X
(n = 1 1 7 ) (n = 92) (n = 25)
M(Sd) %(n) M(Sd) %(n) M(Sd) %(n)
Age (years) 50.26 (12.33) 52.43 (12.11) 41.91 (9.41)
Gender
% male 59.8%  (70) 62%  (57) 52%  (13)
% female 40.2%  (47) 38%  (35) 48%  (12)
Ethnicity
% white 83.8%  (98) 85.9%  (79) 84%  (21)
% black-all 9.4%  (11) 8.7%  (8) 12% (3)
% indian/pakistani 1.71%  (2) 1.08%  (1) 4%  (1)
% asian-all 5.13%  (6) 6.53%  (6)
% other
Education (years) 11 .19 (3 .84 ) 10.7 (3.86) 13.04%  (3.20)
Educational level
% no formal qualification 23.1%  (27) 28.7%  (25) 8.3%  (2)
% vocational qualification 2.6%  (3) 3.4%  (3)
% GCSE/O-Level 28.2%  (33) 31%  (27) 25%  (6)
% A-Level/HND 23.1 (27) 22.8%  (21) 20.9%  (5)
% graduate/postgraduate 18.9%  (22) 12% (11) 45.9%  (11)
Relationship
% married 65%  (76) 65.9%  (60) 66.7%  (16)
% in cohab relationship 1.7% (2) 1.1% (1) 4 .2%  (1)
% divorced/separated 3.4%  (4) 4.4%  (4)
% widowed 5.1%  (6) 6.6%  (6)
% single 23.1%  (27) 22%  (20) 29.2%  (7)
Able to work
% able to work f/t p/t 71.1%  (81) 66.7%  (60) 87.5%  (21)
% not able 28.2%  (33) 33.3%  (30) 12.5%  (3)
114
Em ploym ent (post-TX)
% working f/t or p/t 49.1% (56) 42.2% (38) 75% (18)
% retired 21.9% (25) 26.7% (24) 4.2% (1)
% unemployed 8.5% (10) 10% (9) 4.2% (1)
% other 20.2% (23) 5.5% (5) 16.7% (4)
Employment (pre-TX)
% working f/t or p/t 68.4% (65) 65.6% (59) 79.2% (19)
% retired 6.1% (7) 6.7% (6 ) 4.2% (1)
% unemployed 6.1% (7) 5.6% (5) 8.3% (2)
% other 18.8% (2 2 ) 2 2 .2 % (2 0 ) 8.4% (2)
Income
% 0  - £ 1 0 ,0 0 0 23.4% (25) 28.2% (24) 4.5% (1)
% £ 1 0 ,0 0 1  - 2 0 ,0 0 0 21.5% (23) 24.7% (21) 9.1% (2)
% £20,001 -  30,000 19.6% (21) 18.8% (16) 22.7% (5)
% above £30,001 27.1% (29) 18.8% (16) 61.9% (13)
% do not wish to answer 8.4% (9) 9.4% (8 ) 4% (1)
Living arrangements
% rent 2 2 .6 % (26) 24.2% (22) 16.7% (4)
% own home 68.7% (79) 67% (61) 75% (18)
% live with parents 7.8% (9) 7.7% (7) 8.3% (2)
% other .9 (1 ) 1.1% ( 1)
Time TX (months) 70.70 (62.47) 59.08 (53.08) 113.46 (75.87)
Time RRT (months) 110.89 (77.37) 104.38 (70.66) 134.86 (96.11)
Time D L  (months) 31.67 (31.89) 36.67 (33.24) 12.75 (15.67)
ESRD-SI 7.94 (8.06) 9.21 (8.51) 3.29 (3.25)
Glumerofiltration rate 40.32(17.92) 38.96 (17.59) 45.16(18.62)
Comorbidity 3.20 (1.78) 3.34(1.77) 2.64(1.70)
% diabetes 5.1% (6 ) 6.5% (6 )
% hypertension 11.1% (13) 92.4% (85) 76% (19)
% heart disease 26.5% (31) 30.4% (28) 12% (3)
Primary Kidney Disease Diagnosis
% GN 17.1% (20) 31% (12) 32% (8 )
% APKD 12% (14) 15.2% (14)
% Reflux 12% (14) 14.1% (13) 4% (1)
% Diabetes 4.3% (5) 5.4% (5)
% Hypertension 8.5% (10) 10.9% (10)
% Other 54.71% (64) 34.3% (38) 64% (16)
Immunosuppression
% on Cyclosporin 59.8 (70) 57.6% (53) 6 8 % (17)
% Tacrolimus 36.4 (40) 38% (35) 20% (5)
% Prednisolone and other 6 % (7) 4.3% (4) 12% (3)
TX
% had previous TX 6.9% (8 ) 3.3% (3) 4% (1)
% past rejection (yes) 5 4 .4 % (64) 54.6% (50) 77.3% (19)
Haemoglobin 12.88 (1.70) 12.91 (1.76) 12.80(1.47)
Albumin 43.68 (5.27) 43.71 (5.74) 43.54 (2.93)
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Note. TX = transplant; CAD = cadaver; LRD = living related donor; RRT = renal replacement 
therapy; DL = dialysis; ESRD = ESRD = End Stage Renal Disease; GFR = glomerular filtration 
rate; GN = Glumeronephritis; APKD = Adult Polycystic Kidney Disease; 
i = values reported are Pearson’s chi-square with yate’s correction
All transplant recipients were on triple immunosuppressive therapy consisting of either 
cyclosporin or tacrolimus, steroids (prednisolone) and mycophenolic acid which was 
prescribed only for highly sensitised patients and/or in the event of delayed function for 
the first 6 months post-transplant operation.
1.2 Dialysis
The dialysis sample consisted of patients receiving different forms of dialysis at the 
renal units of the Middlesex and Royal Free Hospitals in London, UK. Of the total 
number of dialysis patients (n = 236) treated in the participating units, sixty-nine 
patients had to be excluded because they did not meet one or more of the inclusion 
criteria. The most common reason for excluding patients was their non-English speaking 
status (n = 42) and consequent inability to perform the NP tests and complete the 
research questionnaires.
Patients (eligible) on hospital HD and CAPD were systematically sampled with a 
random start from a list provided by the respective HD and PD nursing sister. An 
attempt was made to include patients of various age, ethnic groups and equivalent 
number of male and female patients as well as haemodialysis patients on different 
dialysis rota (i.e. morning, afternoon and evening) to achieve the widest possible 
distributions and to maximise representativeness of the sample. In contrast, all (eligible) 
patients established on APD (n = 31) and home HD (n = 29) were consecutively 
contacted to participate because of the substantially smaller number of patients 
established on these two dialysis treatments compared to the hospital HD and CAPD 
programme supported by the participating renal units.
Of the eligible 167 patients who were approached, a total of 145 agreed to the full 
research protocol (response rate = 88.4%). Among those who declined initial 
participation (n = 22) at baseline, reasons for non response included: time constraints (n
116
= 6), lack of interest and motivation = 5), poor health (n = 7), concerns about 
confidentiality (n = 1), reluctance to talk about self (n = 1) and reluctance to give 
requested blood samples {n = 2).
The resulting dialysis study sample included patients established on four different 
dialysis modalities: Hospital HD (n = 52), Home HD {n = 25), CAPD (<n = 45), and 
APD (n = 23). The details of these four dialysis groups are summarised in the Table 5.2.
Table 5.2: Sociodemographic and clinical characteristics of the four dialysis groups
Hospital HD Home HD CAPD APD
M(Sd) %(n) M(Sd) %(n) M (Sd) %(n) M(Sd) %(n)
Age (years) 46.85 (16.02) 5 1 .0 8 (1 2 .1 1 ) 53.84 (14.58) 49 .17  (9.74)
Gender
% male 57.5%  (30) 56%  (14) 26.7%  (12) 73.9%  (17)
% female 42.3%  (22) 44%  (11) 73.3%  (33) 26.1%  (6 )
Ethnicity
% white 63.5%  (33) 80%  (20 ) 57.8%  (26) 60.9%  (14)
% black-all 15.3% ( 8) 12% (3) 20%  (9) 21.7%  (5)
% indian/pakistani 5.8%  (3) 4%  (1) 13.3% (6 ) 8 .6 % (2 )
% asian-all 5.8%  (3) 4.4%  (2) 4 .3%  (1)
% other 9.6%  (5) 4%  (1) 4.4%  (20 4.3%  (1)
Education (years) 12.5 (6.34) 11.76 (4.13) 12.27 (5.32) 12.94 (4.76)
Educational level
% no formal qualification 17.3%  (9) 8% (2 ) 20%  (9) 13% (3)
% vocational qualification 3.8%  (2) 6.7%  (3) 8.7%  (2)
% GCSE/O-Level 25%  (13) 28%  (7) 28.9%  (13) 17.4%  (4)
% A-Level/HND 26.9%  (14) 32%  (9) 26.7% (12) 43 .5%  (10)
% graduate/postgraduate 25%  (13) 24%  (6 ) 11.1%  (5) 17.3%  (4)
Relationship
% married 44.2%  (23) 68% (17) 71.1%  (32) 65 .2%  (15)
% in a relationship 5.8%  (3) 4%  (1) 2 .2% ( 1)
% divorced/separated 5.8%  (3) 4%  (1) 8.9%  (4) 13% (3)
% widowed 9.6%  (5)
% single 34.6%  (18) 24%  (6 ) 17.8%  (8) 21.7%  (5)
Employment
% working f/t or p/t 32.7%  (17.7) 44%  (11) 20%  (9) 65.2%  (15)
% retired 34.6%  (18) 28%  (7) 42.2%  (19) 21.7%  (5)
% unemployed 21 .2% ( 11) 8% (2 ) 11.1%  (5) 8.7%  (2)
% other 20%  (5) 26.6%  ( 12) 4 .3%  (1)
Work change since DL
% no change 46.2%  (24) 56%  (14) 64.7%  (44) 72.7%  (16)
% increase 1.5% (1)
% decrease 23.1%  (12) 8% (2 ) 11.8% (8 13.6%  (3)
% had to leave work 30.8%  (16) 32%  (8) 22.1%  (15) 13.6%  (3)
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% change career 4% (1)
Able to work
% able to work f/t p/t 48.1% (15) 48% (12) 38.2% (26) 69.6% (16)
% not able 51.9% (27) 52% (13) 61.8% (42) 30.4% (7)
Income
% 0  -£10 ,000 67.3% (35) 40% (10) 71.1% (32) 34.8% (8)
% £10 ,001-20 ,000 17.3% (19) 48% (12) 22.2% (10) 21.7% (5)
% £20,001 -  30,000 7.7% (4) 8% (2) 4.4% (2) 26.1% (6)
% above £30,001 7.7% (4) 4% (1) 2.2% (1) 17.4% (4)
Income change since DL
% none 34.6% (18) 36% (9) 48.9% (22) 69.6% (16)
% increase 13.5% (7) 8% (1) 46.7% (21) 4.3% (1)
% decrease 51.9% (27) 56% (14) 4.4% (2) 26.1% (6)
Living arrangements
% rent 42.3% (22) 24% (6) 44.5 (20) 30.4% (7)
% own home 36.5% (19) 68% (17) 48.9% (22) 65.2% (15)
% live with parents 17.3% (9) 8% (2) 4.4% (2) 4.3% (1)
% other 3.8% (2) 2.2% (1)
Time DL (months) 38.94 (39.64) 88.44 (71.2) 21.56 (23.15) 12.94 (4.76)
Time RRT (months) 64 (60.45) 163.6 (84.26) 26.83 (36.59) 37 (48.34)
ESRD-SI 9.19(8.58) 13.48 (9.72) 12.47 (9.68) 10.52(10.33)
Kt/V 1.65 (.258) 1.75 (.195) 1.82 (.358)
URR .651 (.078) .659 (.058)
Comorbidity
% diabetes 11.5% (6) 100% (25) 31.3% (14) 21.7% (5)
% hypertension 11.5% (6) 44% (11) 86.7% (39) 91.3% (21)
% heart disease 36.5% (19) 44.4% (20) 34.8% (8)
Primary Kidney Disease Diagnosis
% G N 25% (13) 20% (5) 2 .2% (1) 4.3% (1)
% APKD 9.6% (5) 20% (5) 8.9% (4) 26.1% (6)
% Reflux 5.8% (3) 16% (4) 6.7% (3) 17.4% (4)
% Diabetes 9.6% (5) 17.8% (8) 13% (3)
% Hypertension 7.7% (4) 22.2% (10) 13% (3)
% Other
TX
% had previous TX 42.3% (23) 64% (16) 8.9% (4) 4.3% (1)
% on TX list 86.5% (45) 96% (24) 86.7% (39) 95.&% (22)
Haemoglobin 10.59(1.38) 11.42(1.66) 11.24(1.46) 11.21 (1.23)
Albumin 39.67 (3.49) 40.12(3.41) 34.68 (3.84) 37.48 (3.99)
Note : HD = haemodialysis; CAPD = continuous ambulatory peritoneal dialysis; APD =
automated peritoneal dialysis; DL = dialysis; f/t = full time; p/t = part time; RRT = renal 
replacement therapies; ESRD-SI = end-stage renal disease severity index; Kt/V = K is defined 
as the total urea clearance rate, t represents the number of minutes of dialysis and V is the urea 
distribution within the patient (dialysis adequacy); URR = urea reduction ratio; GN = 
glumeronephritis; APKD = Adult Polycystic Kidney Disease; TX = transplant.
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1.2.a Hospital HD
The hospital HD sample (n = 52; response rate = 92.85%) was predominantly male (n = 
30, 57.7%) and Caucasian (n = 34, 65.4%). Their average age was 46.85 years (SD = 
16.023, range = 19-77) and at the time of entry into the study all consenting hospital HD 
patients had been receiving high-flux haemodialysis for at least 3 months duration 
(mean = 38.942, SD = 39.46, range = 3-228 months).
They all had negligible residual renal function as determined by (endogenous) urea 
clearance and minimal (< 200ml) to no daily urine output. Haemodialysis was 
performed with cellulose acetate (Althin) or hemophane (gambro) membranes and 
volume controlled equipment. Dialysate was bicarbonate buffered and dialysis 
flow/dialysate flow rate was set at 500 to 600 ml/min. Blood flow rate was equal or 
greater than 200 ml/min (range = 200-300ml/min). Duration of individual dialysis 
sessions was equal or greater than 3 hours. The average treatment time per dialysis 
session was 3.96 hours typically three times a week. In both HD units, haemodialysis 
was offered at three shifts: morning, afternoon and evening to accommodate a large 
number of patients and individual needs. Out of the recruited HD participants, eighteen 
patients (34.6%) were dialysed in the morning (08:30 a.m.-12:00 a.m.), twenty patients 
(20.5%) in the afternoon (13:00 p.m.-17:00 p.m.), and fourteen (26.9%) in the evening 
(21:00pm-01:00 am hours).
1.2.b Home HD
Eligible home HD participants were recruited from only one renal unit (Royal Free 
Hospital) in which such a programme was in effect (Middlesex hospital did not run a 
Home HD programme). Of the 29 patients established on home HD, 25 patients 
consented to the study protocol (86.2% response rate).
Home HD participants, of whom n = 14 were male (68%) had a mean age of 51.08 
years (SD = .351, range = 30-69) and have been on the home HD programme for an 
average of 80.44 months (SD = 12.11, range = 9-312). Their home HD regime consisted 
of three four- to six-hour-long haemodialysis sessions a week (mean = 4.98 hours, SD = 
.51). Haemodialysis was performed using a bicarbonate dialyser with a dialysate flow 
rate of 250 to 500 ml/min and a blood flow rate equal or greater than 200 ml/min (range 
= 200-450ml/min).
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1.2.C CAPD
A total n = 45 CAPD patients (response rate = 88.23%) of whom 73.3% (n = 33) were 
male and predominantly of Caucasian race (n = 26, 57.8%) were recruited onto the 
study. They had a mean age of 53.84 years (SD = 14.59, range = 24-83) and had been on 
CAPD for an average of 21.56 months (SD = 23.15, range = 3-87).
All of the recruited participants had a double-cuffed silastic Tecknoff catheter 
positioned with the standard medical procedure approximately a week prior initiation of 
treatment. The daily exchange procedure was four- or five-times per day depending on 
clinical assessment. The daytime exchanges consisted of 2.27% glucose in all patients, 
with volumes of 1.5 L and/or 2 L. At the time of first assessment 35.6% of the 
participants (n = 16) were using 1 strong (2 L) and 3 weak bags (1.5 L) during a day, 
26.7% (n = 12) were performing 4 weak bags with a strong bag every other day and the 
remainder of the sample were on various other PD regimens. The prescribed bag 
strength regime and their recommended combination, however was varied depending on 
the patients clinical profile and needs (such as diabetic status or fluid overload) 
throughout the study period.
1.2.d APD
Of the total 31 of patients registered on the APD programme, twenty-three agreed to 
participate in this study (response rate = 71.87%). Patient selection for APD in the 
participating unit (MIDDX) was not elective but based on clinical criteria (such as 
peritoneal membrane function, residual renal function) and in some cases special social 
considerations (e.g. housing, work). Data from PET tests indicated that in our recruited 
APD sample five APD patients (21.7%) had low to average peritoneal transport, three 
(13%) patients had high peritoneal transport, whereas the majority of the APD 
participants (n = 15, 65.2%) were classified as high to average peritoneal transporters. 
Mean age was 49.17 years (SD = 9.745, range = 29 - 65).
APD was performed with the Homechoice cycler (Baxter) in all APD participants. The 
exchange procedure was once overnight using multiple hourly cycles in which spent 
dialysis solution was completely drained with each cycle. Night-time exchange volumes 
were 10L in eight patients (34.8%), 12L in thirteen patients (56.5%) and 15L in two
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patients (8.7%). APD participants received a total of 15 L of PD solution over a 8 - 9.5 
hours overnight (mean = 8.74, SD = .44) session with 5-10 exchanges using 1.5L to 
2.0L instilled volume and a dwell time of 45-75 minutes each time.
Appropriate PD regimens prescribed at study entry, were adjusted throughout the study 
period so as to ensure adequate dialysis delivery as indexed by a Kt/v of 2.0 or a total 
clearance of 70L week per 1.73 m2 as concluded in the CANUSA study (Canada USA 
Peritoneal Study Group, 1996) and the UK renal association guidelines (1997).
1.2.e Representativeness of dialysis sample
To evaluate whether the recruited dialysis sample was representative of the dialysis 
population treated in the participating renal units, demographic (age, gender, 
employment status) clinical and dialysis characteristics were collected for all dialysis 
patients that did not participate in our study protocol. The groups of non-participants (n 
= 132) included non-responders (n -  22) and non-eligible patients (n = 69) or patients 
who could not be contacted during the duration of the study {n = 41).
Comparisons between dialysis participants and non-participants (including non-eligible 
patients and patients who declined participation) were performed only for Hospital HD 
and CAPD patients as the number of non-responders on APD (n = 8) and home HD {n = 
4) was extremely small.
Independent samples r-tests, revealed only two statistically significant group differences. 
Hospital HD non-responders were significantly older {mean = 58.57, SD = 16.93; t(l 16) 
= -3.823, p  c.000) and had significantly higher albumin values {mean = 38.29, SD = 
3.63; t(105) = 3.508, p = .001) compared to hospital HD study participants. It should 
however be noted that mean albumin levels for both HD responders and non-responders 
were considered adequate as they met clinical benchmarks (<35g/dL). No significant 
differences were found between CAPD participants and non-participants. A tendency 
was noted for CAPD participants to have a lower Kt/V {mean = 1.81, SD = .402) 
relative to non-participants {mean = 2.00, SD = .46) but it did not reach significance (t 
(79) =-1.879, p = .064).
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Section 2. Beliefs and HQoL
2.1 Participants
Dialysis patients and transplant recipients took part in this study (see sections 1.1 -1.2)
2.2 Procedure
2.2.a Ethical Approval
Ethical approval for the study protocol was sought and successfully granted by the 
participating Hospital Ethics Committees.
2.2.b Recruitment
Recruitment procedures for both dialysis and transplant patients were identical. 
Opportunistic sequential recruitment of dialysis and transplant patients that met the pre­
stated inclusion criteria was undertaken. An invitation letter signed by a Nephrology 
consultant and an information sheet detailing the aims and procedures of the protocol 
were posted to all patients scheduled to attend the outpatient clinics or dialysis units for 
either one of their regular check ups or one of their dialysis sessions.
Approximately a week before patients’ pre-scheduled clinic appointments, the head 
researcher contacted the identified patients by telephone and individually invited them 
to take part in this research. Each of the potential participants was told that the research 
was being conducted to get a better understanding of their experience with their 
treatment (transplantation or dialysis) and that if they agreed to participate a researcher 
would administer a number of questionnaires and some tests of memory and 
concentration. Appointments were then made with consenting patients and further 
confirmed a few days prior to the respective interviews.
2.2.c Data collection
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After obtaining written consent from all patients, study questionnaires were presented 
and administered by the researcher.
All assessment sessions for transplant patients commenced with the collection of 
background information and proceeded with the administration of part 1 of the study 
questionnaire (see Appendix C) followed by the NP assessment (described in more 
detail in subsequent section 4.2). After an optional break, the assessment session was 
resumed and concluded with the administration of part 2 of the questionnaire (see 
Appendix C).
There was no theoretical reason that an order effect would be present in relation to the 
completion of questionnaires. The assessment was hence conducted to help the 
participants focus and think back about their perceptions and feelings about their 
treatment and illness experience. It was therefore decided to present the questionnaires 
in an order that began with most relevant to their ESRD experience (part 1) and finally 
ended with the more general ones (part 2).
Participants were asked to complete the questionnaire in the presence of the researcher, 
available at all times to clarify queries regarding the self-report measures used. Upon 
patients’ request however, the interviewer offered her assistance (e.g. reading out the 
questionnaire) to those patients.
In TX patients all measures were taken on one assessment session. In the dialysis 
patients study questionnaire was completed over two sessions scheduled to coincide 
with the repeated NP assessments. Part 1 was completed at the first assessment and part 
2 was administered the following day (second assessment) after repeated NP evaluation. 
Most assessments were conducted in a specially designated assessment room in Health 
Psychology Research Unit by the same researcher. The room was made available for the 
duration of the study to enable participants to complete the questionnaire and NP tests in 
privacy and without being disturbed by the dialysis ward and outpatients clinic activity. 
Given the complexity and time demands of this research protocol, patients’ comfort and 
convenience was a priority when arranging assessments. Upon patients expressed 
preference, therefore, home visits for the assessments were also arranged at times most 
convenient to research participants.
Each assessment required approximately 2 hours to complete. Assessment times varied 
depending on the patient.
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2.3 Measures
2.3.a Psychological measures
Questionnaires were selected to measure variables identified by the researchers as part 
of the model for this research. Important selection criteria were primarily the measures’ 
psychometric properties and its use and applicability with ESRD patients.
i. Sociodemographic Questionnaire
Demographic information including age, gender, ethnicity, education, marital and 
employment status, perceived work ability, housing/living arrangements and household 
income was collected by questionnaire (see Appendix C).
ii. Fatigue Rating Scale
The visual analogue scale (Brunier & Graydon, 1996) was used to measure fatigue.
The scale (100mm line) was anchored at either end by ‘no tiredness at all’ at the left end 
and ‘complete exhaustion’ at the other end. Participants were shown the scale and were 
asked to place a mark on the line that best described how tired they have been feeling 
right now, generally first thing in the_moming, in the middle of the day and before they 
go to bed. The intensity of fatigue was scored by measuring from the low end (left side) 
of the scale to the subjects’ mark in millimetres. A higher score indicated lower levels of 
fatigue.
The scale has been used with ESRD patients (Brunier & Graydon, 1996; McCann & 
Boore, 2000) and is significantly associated with more elaborate multi-item fatigue 
measures (Brunier & Graydon, 1996; McCann & Boore, 2000). The reliability and 
validity of VAS to measure subjective feelings has been demonstrated in various studies 
(e.g. Gift, 1989).
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iii. Illness Perception Questionnaire (IPQ)
The IPQ (Weinman et al., 1996) was used to assess causes, identity, timeline, 
consequences and control/cure dimensions that underline patients’ representation of 
illness (Leventhal et al., 1984; Lau et al., 1989).
The IPQ hence comprises 5 sub-scales and provides a quantitative assessment of the 
nature and strength of participants’ beliefs about each of the components of their illness 
representations. Designed specifically for use in the context of chronic illness, it has also 
been suggested that the IPQ should be used as a tool for assessing psychological needs 
of an individual ‘prior to renal transplantation’ (Wright, 1994). In this study a modified 
version of the questionnaire was used in that the IPQ has been adapted for use with 
dialysis and TX patients in accordance with the authors’ instructions.
The first part of the IPQ measures illness identity with a list of generic and condition- 
specific symptoms. To make this sub-scale more appropriate for ESRD patients, the 
core items of the IPQ (n = 12) were supplemented with items about ESRD and RRT 
specific symptoms. These were chosen for a number of reasons: (a) they had been 
reported by patients to be important (in the pilot stage of the study), (b) a review of these 
by a panel of renal clinicians involved in patient care approved their inclusion, and (c) 
finally because they had been incorporated by others in disease-specific questionnaires 
(Hays et al., 1994; 1996; Laupacis et al., 1992; Parfrey et al., 1989).
The modified dialysis version of the identity IPQ sub-scale therefore consisted of a total 
of 19 symptoms: the 12 core IPQ items and 7 renal-specific ones. The additional dialysis 
symptoms used for the assessment of dialysis patients were: hair loss, muscle spasms or 
stiffness (leg cramps), restless legs, itching, fatigue, and nausea.
The transplantation-specific version of the identify IPQ sub-scale contained all these 19 
items (core and renal items; n -  19) and an additional 22 items referring to potential 
side-effects associated with immunosuppressive medication. Examples of these 
additional items included weight gain, hair growth, gum problems, tremor, acne, 
impaired visual acuity, bruises, and weak muscles.
These transplant-specific adaptations were based on a comprehensive review of relevant 
research (De Geest et al., 1995), and recommendations made by transplant health care 
professionals.
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Patients were asked if they thought the symptom was part of their renal disease and to 
rate how often they experience the listed symptoms. The items measuring symptom 
occurrence are scored on a 4-point rating Likert scale ranging from 1 ( ‘never 
experienced’) to 4 ( ‘occurring all the time’). There are several ways to score the identity 
sub-scale. Authors suggest the illness identity scores can be classified as present and 
given a score of ‘1’ or absent and given a score of ‘O’. These individual item scores may 
then be aggregated to a total score with high higher scores indicating more symptoms. 
Alternatively, the scores (ranging from 0 to 3) can be summed to give a weighted illness 
identity, with higher scores indicating a higher level of symptom burden. For the 
purposes of this study the former scoring method (i.e. symptom count) was chosen as it 
the most widely used procedure in previous research.
The second part of the questionnaire consists of 28 statements using a 5-point Likert 
scale (‘strongly agree’- ‘agree'-‘uncertain'-‘disagree'-‘strongly disagree’) and provides 
separate scores for causes, consequences, timeline and control/cure.
The items of the causal sub-scale are scored individually as ‘each item represents a 
specific causal belief (Weinman et al., 1996). They are treated as stand-alone items and 
thus individual scores are obtained for the following: germ or virus, diet, pollution, 
heredity, chance, stress, own behaviour, other people, poor medical care in the past, and 
state of mind.
For the remaining three IPQ sub-scales (timeline; consequences; control/cure) item 
scores are summed and divided by the number of items in the sub-scale in question. The 
timeline sub-scale contains four items with scores ranging from 1 to 5 and higher scores 
representing a belief that the illness is going to last for a longer time. The consequences 
sub-scale contains seven items and scores ranged from 1 to 5 with higher scores 
representing a stronger belief that the illness has had serious consequences.
The cure/control sub-scale contains eight items. The original IPQ control item ‘what I 
do determines whether my illness gets better or worse’ was rephrased to form two 
separate ones (i.e. ‘what I do determines whether my illness gets better’ and ‘what I do 
determines whether my illness gets worse’) as patients in the pilot phase expressed 
distinct views regarding control expectancies with regard to clinical improvement or
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deterioration. Scores ranged from 1 to 5, with higher scores indicating a higher level of 
belief in control or potential for cure of the illness.
The IPQ has been used extensively in different illness populations including patients 
suffering from arthritis, diabetes, chronic fatigue or myocardial infarction, a thorough 
description of which is beyond the scope of this work (see review by Hagger & Orbell, 
2003).
Fairly extensive psychometric data have been published for all sub-scales. The 
psychometric properties of the IPQ have been evaluated in seven illness groups 
including individuals with asthma and diabetes, and renal dialysis patients. The internal 
reliability for each sub-scale is satisfactory, with Cronbach alpha coefficients .73 to .82. 
Similarly good test-retest data for each sub-scale have been obtained in patients with 
chronic illnesses and a range of concurrent, discriminant and predictive validity data 
have been published for different chronic illness groups (Weinman et al., 1996).
iv. Illness Effects Questionnaire (IEQ)
The IEQ (Greenberg & Peterson, 1997a; 1997b) has been used to measure illness 
intrusiveness. This 20-item scale assesses individuals’ perceptions about how illness 
interferes with or affects personal, social behaviours, and life in general. Questions 
range from perceived family and personal disruption to physical problems and fears 
about illness effects, e.g. “my illness creates problems between myself and my family”, 
“my illness disrupts my appetite”, “my illness prevents me from enjoying myself’.
The scale uses an eight-point ordinal response scale (each item is scored between 0 and 
7) where 0 represents no illness intrusiveness or the absence of a problem and values 
greater than 0 represent the severity of the problem of interference/disruptiveness. A 
total score is obtained by summing across individual ratings. Scores range from 0 to 140 
with scores between 56 and 88 indicating average distress/disruptiveness and scores 
above 89 indicating moderate to extreme distress (Greenberg & Peterson, 1997b). 
McGee et al. (1998) based on a HD sample, reported slightly different norms with 
scores between 47 and 74 indicating average distress/disruptiveness and those above 74 
indicating moderate to severe distress/disruptiveness.
The IEQ has been found to be a very reliable instrument with internal reliability of alpha 
= .93 and test retest reliability of .99 (Greenberg & Peterson, 1997a; 1997b). Its validity
127
has also been supported through correlations with measures including the illness 
behaviour questionnaire (IBQ; Pilowski & Spence, 1975) (Wise et al., 1994), measures 
of psychosocial impairment (Mancini et al., 1986; Wise et al., 1994), and depression in 
various medical populations (Rosenberg et al., 1988), including ESRD patients (Eitel et 
a l, 1995; Kimmel et a l, 1996; Sacks et a l, 1990).
IEQ scores have also been found to be associated with other outcomes in ESRD such as 
vocational, sexual and social adjustment, and life and marital satisfaction in dialysis 
patients (Kimmel et a l, 1995a; 1995b; 2000; 2003), and significant associations have 
also been shown with survival in HD (Kimmel et a l, 1998b; 2000). Finally, its 
sensitivity and responsiveness to treatment effects and interventions (e.g. pain 
management programme) has also been demonstrated (Stevens et al., 1988, Stratton, 
1989). Kimmel (2000b; 2001) has stated that the instrument’s reported associations with 
clinical and psychological outcomes as well as its intercorrelations and lack of 
correlations with severity of illness makes the IEQ ‘a potential prime psychosocial 
measure for use with ESRD patients treated with HD’.
v. Treatment Effects Questionnaire (TEQ)
The TEQ (Greenberg & Peterson 1997b) assesses patients’ perceptions of the physical 
and psychosocial impact associated with their treatment rather than their illness. It 
includes the evaluation of issues such as treatment impact, side-effects (e.g. 
appetite/sleep disturbance), treatment-associated distress (e.g. helplessness, 
preoccupation, anxiety), treatment effectiveness and dependency that are likely to 
impact heavily on adherence and quality of life
The TEQ contains 20 items and has the same administration and scoring format as the 
IEQ. Ratings are made along an 8-point ordinal scale ranging from 0 (strongly disagree) 
to 7 (strongly agree). A total score is obtained by summing across individual ratings 
with higher scores indicating greater disruption from the treatment. Authors attempted 
to have as much of the TEQ’s items content as similar to the IEQ’s as possible but since 
treatment yields its own issues, some dissimilar items were developed. The TEQ 
therefore shares 75% of the IEQ content (items: 1; 3; 4; 5; 7; 8; 10; 12; 13; 14; 15; 16; 
17; 18; 20 see appendix C).
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There is empirical support for TEQ’s psychometric properties. Its internal consistency is 
high (Greenberg & Petterson, 1997b). Significant associations (r = .66, p < .001) 
between TEQ total score and depressive symptoms from the Beck Depression Inventory 
have been reported in support of its construct validity and changes in TEQ scores at an 
intervention study demonstrate its clinical responsiveness and sensitivity to treatment 
changes (Heilbronner et al., 1989).
As suggested by the authors, TEQ may be particularly useful in treatment comparisons 
and it was in this respect that it was chosen for this study. Besides normative 
comparisons TEQ can be useful as a measure of effects of different treatments for the 
same disease as with different forms of dialysis (haemodialysis vs. peritoneal dialysis); 
for evaluating new or modified treatment to established treatments; or for obtaining a 
patients’ serial appraisal and adaptation to a treatment such as dialysis or moving from 
dialysis to having a kidney transplant (Greenberg & Peterson, 1997b). When different 
treatments, such dialysis modalities deliver essentially similar medical benefit, it may be 
that the patient’s appraisal of how acceptable a treatment is in terms of its general 
biopsychosocial consequences will influence the best individual treatment approach.
It was considered useful to use particularly in conjunction with the illness effects 
questionnaire (IEQ) as recommended by the authors (Greenberg & Peterson, 1997b). A 
comparison of the two relative scores may aid in understanding why adjustment or 
adherence problems exist for some patients in a way that would not be possible if the 
instruments were used separately/in isolation.
vi. Beliefs about your medicines Questionnaire (BMQ)
The BMQ (Home & Weinman, 1999) was used to assess patients’ representations of 
their prescribed medication. The questionnaire was administered only to transplant 
patients, as this was the group for whom medication (a regime of immunosuppressive 
agents) is the core treatment component. It was not used for the assessment of dialysis 
participants mainly to avoid burdening patients with too many questionnaires in addition 
to extra NP assessment session and because medication, albeit essential to dialysis 
patients management was seen as secondary to dialysis treatment itself.
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The BMQ consists of two sections: the BMQ specific which assesses representation for 
medications prescribed for personal use and BMQ -  general which assesses beliefs 
about medication in general. These two sections of the BMQ can be used in 
combination or separately.
For the purposes of this study the BMQ specific section was used. This comprises two 
5-item sub-scales assessing beliefs about the necessity of prescribed medication 
(specific necessity) and concerns about prescribed medication based on beliefs about the 
danger of dependence and long-term toxicity and the disruptive effects of medication 
(specific concerns). Examples of items from the necessity sub-scale include: "My health, 
at present, depends on my medicines" and "My medicines protect me from becoming 
worse." Examples of items from the ‘concerns’ sub-scale include: "I sometimes worry 
about the long term effects of my medicines" and "I sometimes worry about becoming 
too dependent on my medicines".
Respondents indicate their degree of agreement with each individual statement about 
medicines on a five-point Likert scale, ranging from l=strongly disagree to 5=strongly 
agree. Scores obtained for the individual items within each sub-scale are summed to 
give a sub-scale score. Thus, total scores for the necessity and concerns sub-scales range 
from 5 to 25. In order to facilitate comparisons between sub-scales, a mean item score 
was computed by dividing each scale score by the number of items, giving a range of 1 
to 5. Scores can be interpreted in two ways: as a continuous scale where higher scores 
indicate stronger beliefs in the concepts represented by the scale or by dichotomising at 
the scale midpoint. The continuous scale is used in statistical analyses as this provides 
richer information that is lost when the scale is dichotomised (Oppenheim, 1992).
The BMQ has satisfactory internal consistency and test-retest reliability. Concurrent and 
discriminant validity has also been established. Beliefs about medication have been 
found to be strongly associated with medication adherence (Home, 1997; 2003a; 2003b 
Home & Weinman, 1999; 2002; Byer & Myers, 2000).
vii. Spielberger State Anxiety Inventory (STAI)
Anxiety was measured using a short version of the STAI (Marteau & Bekker, 1997). 
The STAI (Spielberger et al., 1983) is designed to measure anxiety as a ‘state like’ or
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situationally determined condition; the scale has been used to measure the type of 
anxiety induced by stress associated with a medical condition or its treatment. The short 
version was preferred due its brevity. It contains 6 self-report items rated on a 4-point 
Likert scale ranging from ‘not at all’ to ‘very much so’. Higher scores signify greater 
anxiety. The scale has a satisfactory concurrent and construct validity and acceptable 
levels of internal consistency and is advocated as an alternative when the time demand 
and length of assessments is a consideration.
viii. Positive and Negative Affect Schedule, expanded-form (PANAS-X)
The expanded form of the positive and negative affect scale (Watson et al., 1988; 
Watson & Clark, 1994) was used as a measure of current affect. This scale was used to 
assess the independent dimensions of positive and negative affect which have reliable 
emerged as the dominant dimensions in the emotional experience (Almagoroth & Ben- 
Porathe, 1989; Meyer & Shack, 1989).
The PANAS-X comprises 60 adjectives describing positive and negative mood states. 
Items are grouped to form positive and negative affect summary scores and separate 
affective states. In addition to the general dimensions of positive and negative affect, the 
expanded form assesses 10 specific affects: fear, sadness, guilt, hostility, shyness, 
fatigue, joviality, self-assurance, attentiveness and serenity. The respondents rate the 
extent the have felt each of the affective states during their designated time frame, using 
a 5-point scale ranging from 'very slightly or not at all’ to ‘extremely \  The scale can be 
used with various time frame instructions. For the purposes of this study participants 
were asked to rate the adjectives according to the way they have felt at that particular 
moment in time, in other words ‘right now’.
The 10 PANAS items assessing positive mood (interested, excited, strong enthusiastic, 
proud, alert, inspired, determined, attentive, and active) and the 10 items assessing 
negative mood (distressed, upset, guilty, scared, hostile, irritable, ashamed, nervous, 
jittery, and afraid) were each summed to yield separate Positive Affect (PA) and 
Negative Affect (NA) scores for each participant.
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Internal consistency reliabilities have ranged from .86 to .90 for PA and from .84 to .87 
for NA and internal consistency is reported to be unaffected by the time frames used 
(Watson, 1988a; 1988b).
From the other specific affect sub-scales, scores were computed for guilt, fear, shyness, 
serenity sub-scales by adding relevant items. As with the general PA and NA 
dimensions, their psychometric properties have been thoroughly investigated and their 
merit in terms of normative, internal consistency, construct validity is clearly established 
(Bagozzi, 1993; Watson & Clark, 1991; 1992a)
In addition to the instrument’s extensive psychometric development and wide use in 
psychological research (Henson & Chang, 1998) there is also support for its 
responsiveness and sensitivity to change. Research also indicates that when used with 
short-term instructions (i.e. ‘moment’ or ‘today’), the PANAS-X sub-scales (including 
PA and NA) are sensitive to changing internal or external circumstances (Clark et al., 
1989; McIntyre et al., 1990; Watson, 1988a; Watson & Clark, 1992b), which made it 
the ideal instrument to assess mood variation over 24-hours as was the case with the 
dialysis participants in this study.
ix. Beck Depression Inventory (BDI)
The BDI (Beck et al., 1961) was used to assess the presence and severity of depression 
in dialysis and transplant patients. The BDI is composed of 21 items. Each category 
describes a specific behavioural manifestation of depression and consists of a graded 
series of four evaluative statements. Integer values of 0 to 3 are assigned to each 
statement to indicate the degree of severity where ‘0’ stands for the absence of a 
problem whereas ‘3’ represents an extreme problem. An advantage of the BDI is that it 
places the subject within a range of depression (none, mild, moderate, severe) rather 
than merely identifying whether a person meets the diagnostic criteria. Scores of 0 to 10 
indicate no depression, 11 to 18 signify mild depression, 19-25 moderate depression and 
26 or more indicate severe depression (Beck et al., 1961).
According to Gotlib & Cane (1987), the BDI is the preferred self-report questionnaire 
for measuring the intensity of depressive symptoms. Although the BDI does not provide 
a psychiatric diagnosis of depression nor does it provide information about periods of
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major depression that may have occurred in the past, it is a well-validated index of 
depression, correlating with diagnostic criteria for depression (Stehouer, 1987). Craven 
et al. (1988) assessed the validity of the BDI by determining the relationship between 
diagnosis of depression with the DSM-III and the BDI in a sample of renal dialysis 
patients. A threshold of 15 on the BDI produced optimal sensitivity (0.92), negative 
predictive value (0.99) and maximised Youden’s index of validity (0.72) for the use of 
BDI as a screening device for depressive symptoms in renal patients.
The BDI has been used extensively to assess depression in ESRD patients (Craven et 
al., 1988; Edgell et al., 1996, Kimmel et al., 1993; 1995; 1998a; 2000c; Peterson et al., 
1991; Shulman et a l, 1989). It has been found to be responsive over time in this context 
(Christensen et al., 2000; 2002).
For the analyses presented here, a subset of 15 cognitive depression items, comprising 
the Cognitive Depression Index (CDI) were selected to control for the confounding 
contribution of somatic symptoms of physical illness (Sacks et al., 1990).
The CDI focuses on thoughts and feelings related to the diagnosis of depression, such as 
guilt, disappointment, and failure, excluding its somatic items and hence can be used to 
reduce the possible confound between symptoms of medical illness and the somatic 
components of depression measured in the BDI (Beck et al 1988; Kimmel et al., 1993, 
Sacks et al., 1990). This subset was used because somatic effects of ESRD and 
associated treatment such as decreased sexual drive and loss of appetite are also 
symptoms of depression and thus their inclusion could result in misleading/falsely 
elevated scores of depression scores. The 15 CDI items as with all BDI items are 
answered on the same 4-point scale with a total score of 0 to 45. Examples of cognitive 
feelings surveyed include sadness, guilt, disappointment, failure and decision making.
The cognitive subset of items have been previously used in research on adjustment in 
ESRD (Brickman et a l, 1996; Eitel et a l, 1995; Kimmel et al., 1995a; 1995b; Peterson 
et a l, 1991; Sacks et al., 1990; Schneider et al., 1991). The CDI has been found to have 
a standardised internal consistency of .74 and has been shown to discriminate depressed 
from non depressed ESRD patients (Himichsen et al., 1989). The CDI has previously 
been highly correlated with the BDI in ESRD patients (Kimmel et a l, 1993; 1995a; 
1995b; 1996; Peterson et al., 1991), but unlike the BDI was not associated with
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measures of severity of illness, nutrition, renal function, and delivery of dialysis (Sacks 
et al., 1990).
x. The Medical Outcomes Study 36-item Short-Form Health Survey
HQoL was measured with the MOS SF-36 (Ware & Sherboume, 1992; Ware et al., 
1993; Ware & Koshinski, 1996)-UK version (Jenkinson et al., 1993; 1996). The SF-36 
UK version 2 (Jenkinson et al., 1999)* not yet published when dialysis patients’ 
recruitment and data collection commenced, was subsequently used with transplant 
participants (see Appendix C).
The SF-36 is a generic multidimensional measure of HQoL designed for use in clinical 
practice and research, health policy evaluation and general population surveys. It 
comprises eight multi-item sub-scales that represent physical and mental health status: 
physical functioning (PF; 10 items), social functioning (SF; 2 items), role limitations 
due to physical health problems (RPh; 4 items), role limitations due to emotional 
problems (REm; 3 items), mental health (MH; 5 items), vitality (VT; 4 items), bodily 
pain (BP; 2 items) and general health perceptions (GH; 5 items). There is a further 
unsealed item asking respondents about perceived health change over the last year.
The SF-36 was developed and extensively evaluated as part of the Medical Outcomes 
Study, and contains essential psychometric criteria that have been shown to be both 
reliable and valid and responsive in various clinical and demographic populations 
(Beaton et al., 1997; Hays et al., 1993a; Keller et al., 1998; Lowrie et al., 2000; 
McHomey et al., 1993; 1994; Ware et al., 1998). Normative data exist for the general 
English population (Brazier et al., 1992; Jenkinson et al., 1996; 1999).
It has been extensively used as an outcome measure in ESRD research (Cagney et al., 
2000) and is also incorporated into renal-specific HQoL questionnaires, namely the 
CHOICE (Wu et al., 2001) and KDQoL (Hays, et al., 1994). It has been proven to be 
both reliable and valid in both dialysis and transplant populations (Edgell et a l, 1996; 
Garratt et al., 1993; Khan et al., 1995; Rettig et al., 1997; Wight et al., 1998). Data in 
support of its responsiveness in ESRD have also been published (Meyer et a l, 1994).
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SF-36 has also been shown to be acceptable by renal patients (Kurtin et al., 1992) and 
its brevity and comprehensiveness provides a distinct advantage over other HQoL 
measures. It takes approximately 5-10 minutes to complete, a factor, which is important, 
when one considers the practicalities of the use of an instrument in a large-scale study of 
patients in a clinical environment. We therefore chose to use this tool because of an 
ample literature supporting its validity, and its ease of administration and interpretation
There are several scoring systems as described in the RAND 36-Item Health Survey or 
MOS SF-36™. These are reviewed by Hays et al., (1993b). For the purposes of this 
study the scoring instructions described in the UK SF-36 manual, which are based on 
the standard MOS system, were applied (Jenkinson et al., 1996). This is performed as 
follows: Sub-scale scores were transformed to 0-100 scales with higher scores indicating 
better HQoL (Ware & Sherboume, 1992). Scores represent the percentage of total 
possible score achieved. Subsequently the scales scores were standardised to the scale 
scores of a general UK population sample (N =8889, age range = 18-64 years, male =
43.4 %) by subtracting the general population mean from the individual mean and 
dividing by the corresponding scale SD from the general population. The resulting z- 
scores indicate how many SDs the observed SF-36 scores of dialysis or transplant 
patients fall below or above the scores of the reference population when the scores of 
the reference population are set to 0.
To facilitate interpretation and direct comparisons between scores from the original 
version of SF-36 and version 2 normative based scoring was used (NBS; Ware, 2000; 
Ware & Kosinski, 2001). NBS involves a linear t-transformation to ensure that in all SF 
36 sub-scales the general population mean is 50 with a SD of 10. NBS hence puts the 
sub-scales’ scores in both versions on the same metric making comparisons and their 
joint display meaningful. Without referring to tables of norms it is clear with the NBS 
method that scores above or below 50 can be interpreted as above or below the general 
population norm. And, because SDs for each scale are standardised at 10, it is easier to 
see exactly how far above (or below) the mean a score is in SD units.
The eight sub-scales were combined into a physical and a mental component score 
(PCS; MCS) (Ware et al., 1994; 1995). The PCS primarily reflects the dimensions of 
physical functioning, role limitation caused by physical health problems, pain, and
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general health perceptions. The MCS reflects primarily mental health, role limitations 
caused by emotional problems, social functioning and vitality. For the purpose of 
research, utilising the summary scores in contrast to using the eight individual SF-36 
measures, makes it possible to reduce the number of statistical comparisons and thereby 
the role of chance in testing hypotheses. Validation studies make it clear that little 
information is lost when aggregating the eight sub-scale scores into PCS and MCS 
(Ware etal., 1994; 1995).
2.3.b Medical measures
Patients’ medical notes were reviewed to extract relevant medical information (see 
Appendix D).
i. Dialysis adequacy measures
Dialysis adequacy was assessed by a calculated kinetic transfer/volume urea 
measurement (Kt/V) in both HD and PD patients. Only measurements of adequacy 
made within six months of the study assessment were used for analysis purposes. The 
average of the adequacy value was used for those patients who had more than one 
measure during the six-month period. Treatment was considered adequate when Kt/V 
met or exceeded the UK Renal Association Guidelines (1997) as follows: for CAPD, a 
Kt/V of 1.70; for APD (without a daytime dwell) a Kt/V of 2.0; for HD, a Kt/V of 1.20. 
Absolute scores for Kt/V on HD and PD are not directly comparable (Mallick et al., 
1998); consequently for analysis purposes these were converted to standard z-scores.
PD and HD adequacy measures are based on urea clearance but are routinely used as a 
proxy for measurement of the clearance of small solutes in general. They are described 
separately in the following sections, as the methods used for calculation are different 
between HD and PD patients.
(a) HD adequacy
Dialysis delivery in HD was assessed using two related methods: urea reduction ratio 
(URR) and a single pool of a variable volume urea kinetic determination of Kt/V 
(Gotch, 1995; Sargent & Gotch, 1975; 1989).
URR (Idem, 1991; Lowrie & Lew, 1991) reflects the fractional reduction in the blood 
urea nitrogen concentration during a haemodialysis session (Basile et al., 1990; 
Daugirdas, 1989; 1993; Gotch et a l , 2000). URR is calculated with the formula 100 x 
(l-[Ct/Co], in which Ct is the post-dialysis blood urea nitrogen (BUN) and Co is the 
predialysis BUN.
For the present study, when and where available Kt/V indices were documented in 
addition to URR as its use is recommended over that of URR on the premise that it 
offers enhanced accuracy for calculating total clearance scores (Li et al., 2000).
The Kt/V formula is a dimensionless urea kinetic parameter related to URR. The 
predialysis and postdialysis BUN concentrations, from which URR is calculated, and 
body weight are used in practice to estimate Kt/V. It is expressed as the ratio of total 
urea clearance (K in millimeters per minute) by the length of individual treatment (t: 
hours) product to the volume of urea distribution in a particular patient (V in 
millimeters). V stands as a proxy for body mass/size and therefore nutritional status.
Many formulae have been proposed to calculate Kt/V. In the present study the formula 
used in the participating renal units was applied. Kt/V was hence calculated by the 
second-generation Ln formula of Daugirdas (1993) as follows: Kt/V = -Ln(R - 0.008 x 
t)+(4 - 3.5 xR) xUF/W in which Ln is the natural logarithm; R is the postdialysis BUN 4 
predialysis BUN; t is the dialysis session length in hours; UF is the ultrafiltration 
volume in liters; and W is the patient’s postdialysis weight in kilograms.
Concerns and criticisms regarding limitations and inadequacies of both URR and Kt/V 
have been raised (Gotch, 2001; Lowrie et al., 1998) but a full discussion of these are 
beyond the scope of this study.
Both methods are widely accepted, compound measures of HD dose (National Kidney 
Foundation Dialysis Outcome Quality Initiative: NKF-DOQI 1997b), the routine use of 
which is recommended (NKF-DOQI 2000 website; w w w .kidney.org/ professionals/ 
kdoqi/guidelines) when formal urea modelling is not practised.
137
(b) Peritoneal dialysis adequacy.
Several methods of quantifying the PD dose have been described but no standard 
accepted method exists (Kopple et a l, 1995, Robertson et al., 1995). Total weekly 
Kt/Vurea and total creatinine clearance normalised to 1.73 m2 Body Surface Area 
(CLcr) are considered to be among the best options (Selgas et al., 1993) because they 
are most strongly associated with mortality and morbidity (Churchill, 1994; Churchill et 
al., 1996; Diaz-Buxo et al., 1999; Keshaviah et al. 2002; Rocco et a l, 2000; Szeto et 
a l, 2001; Teehan et al., 1994).
Both indices were recorded (if available) for the purposes of this study. The urea-based 
measure, Kt/Vurea, measures removal of the direct product of protein catabolism. The 
creatinine clearance (C L cr) measures removal of a product of muscle metabolism, 
which provides insight into lean (i.e., fat-free, oedema-free) body mass and possibly into 
adherence. The calculation of weekly Kt/V and CrCl was performed by standard 
methods, using data from 24-hour dialysate urea excretion and urine collections/and the 
serum urea concentration (NKF-DOQI 1997b). Peritoneal C L cr. urea Kt/V were 
calculated using the computer based kinetic modelling program PD Adequest™ version
1.4 (Vonesh, & Keshaviah, 1997; Vonesh etal., 1991).
ii. End-Stage Renal Disease Severity Index (ESRD-SI)
The ESRD-SI (Craven et al., 1991) was used as a measure of co-morbid illnesses and 
other ESRD complications. As implied by its name, it is a ESRD-specific comorbidity 
measure that assesses severity of illness (ESRD) as a function of 11 organic conditions: 
heart disease, cerebral vascular disease, peripheral vascular disease, peripheral 
neuropathy, bone disease, respiratory disease, visual impairment, access and dialysis 
events, autonomic neuropathy gastrointestinal disease and diabetes. For use with the 
transplant patients the item referring to ‘access or dialysis events’ was replaced with 
‘transplantation events’ (such as infection or rejection episodes) as the former was 
clearly inappropriate for patients with a functioning kidney transplant.
The index is designed for use by either an independent clinician investigator with full 
access to medical information, or the patients’ own physician. In this study a
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Nephrologist familiar with the patient completed the ESRD-SI on the basis of her 
knowledge of the patient’s condition and their medical record. The severity of each 
condition is scored on a Likert-type scale (‘absent’, ‘very mild’, ‘mild’, ‘moderate’, 
‘severe’, ‘very severe’). Each of these rating points corresponds to descriptions, which 
are provided for each ESRD-SI category. These examples are provided to guide the 
raters and to correspond to scores which are defined in the following ranges: 1-3 for 
biochemical or mild indication of disease; 4-6 for moderately severe physical signs, 
handicap or prognosis; 7-8 for severe physical handicap or prognosis; and 9-10 for an 
imminently lethal condition. The scoring system gives a different range of scores for 
each disease item and the additive sum of item scores provides the total severity index.
The inter-rater reliability of ESRD-SI has been reported at r = .92 with a test retest 
correlation of r = .92 over one-week period (Craven et a l, 1991). The ESRD-SI has 
been shown to be significantly related to age (Eitel et a l, 1995), functional ability 
(Griffin et a l, 1991) and physiological measures of severity of illness such as serum 
albumin and creatinine levels (Griffin et a l, 1995), i.e. blood serum levels that have 
been found to predict mortality risk in ESRD patients (Lowrie & Lew, 1990, Owen et 
a l, 1993).
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Section 3: NP outcomes in ESRD
3.1 Participants
Transplant and dialysis patients participated in this study (see sub-sections 1.1 - 1.2) 
Recruitment methods (for this sub-study) were therefore identical to those described in 
section 2.2.a.
3.2 NP Measures
NP tests were selected on the basis of previous reports of their sensitivity and their 
acceptance and extensive use in the general medical and renal literature (Lezak, 1995; 
Reitan, & Wolfson, 1993). As this study was designed as an exploratory investigation, a 
wide range of NP tests assessing various cognitive abilities (attention concentration, 
psychomotor speed, verbal memory, learning, visual memory, motor functioning) was 
used. Among those emphasis was given to tests of cognitive functions known to be 
impaired in renal patients, i.e. attention tasks (Hart & Kreutzer 1988; Pliskin et al., 
2001).
i. Trailmaking test - Forms A and B (TMT)
TMT (Reitan & Wolfson, 1993) is a two part measure of attention, visual scanning, 
motor speed and planning ability. Part A (TMT-A) requires participants to connect 25 
randomly arranged numbers in the right order. Part B (TMT-B) requires participants to
connect a series of numbers and letters in sequence (i.e., 1-A-2-B-3-C...... 13) as quickly
as possible. Both parts of the tests are timed (number of seconds) to completion with 
lower scores indicating better cognitive function. Slow scores on either part A or part B 
have been used as an indication of a likelihood of diffuse brain damage. A slow score on 
the part B in particular may indicate difficulties in conceptual motor tracking (Bremer et 
al., 1997). TMT is considered to be one of the best measures of generalised brain 
functioning (Reitan & Wolfson, 1993). Three parallel forms of Part B which have
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satisfactory comparability (Lezak, 1995) were used in order to keep practice effects at a 
minimum.
ii. Symbol Digit Modalities Test (SDMT)
SDMT (Smith, 1968; 1973) assesses a variety of cognitive functions, including 
immediate visual memory, learning, hand-eye co-ordination, and reading-writing ability. 
It is very sensitive for detection of an acquired acute or chronic cerebral deficit but is no 
specific for localisation of such a deficit (Smith, 1973).
It consists of rows containing 110 blank squares each paired with a randomly assigned 
abstract symbol. Above these rows there is a printed key that pairs each symbol with a 
number from one to nine. Following a practice run on the first ten, participants are 
requested to match the printed abstract symbols with the specific number identified in 
the key as quickly as possible within a specific time frame (90 seconds). The score is the 
number correct so that higher scores signify a better performance. The test lends itself to 
a written and oral administration form to allow comparisons between visuomotor and 
oral responses. The written administration was given first in accordance with the 
instructions (Lezak, 1995), followed by the oral administration.
iii. Rey Auditory Verbal Learning Test (RAVLT)
This is an auditory verbal memory task that assesses immediate memory as well as 
retrieval from short-term memory storage. RAVLT (Rey, 1964) also provides a learning 
curve, reveals learning strategies or their absence, elicits retroactive and proactive 
interference tendencies to confusion or confabulation of memory task and allows for a 
comparison between retrieval efficiency and learning.
It consists of five presentations with a recall of a list of 15 words, the one presentation 
of a second 15-word list and finally a sixth recall trial of the original word list. In the 
first 5 attempts, participants are asked to recall as many of the words as possible after 
each reading of the list by the examiner whereas for the last attempt word retrieval form 
short term memory is assessed as participants are requested to repeat as many words as
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they can but without the examiners reading them out. Alternative forms were used for 
the repeat assessments (Crawford et al., 1989; Lezak, 1995).
Two scores were obtained: total verbal recall from trials 1 to 5 (RAVLT-T) and drop in 
retention from trial 5 to 7 (RAVLT-D).
iv. Benton Visual Retention Test (BVRT)
BVRT (Benton, 1974) is a measure of visual perception, visual memory and 
visuoconstructive abilities.
Ten cards featuring 1 to 3 designs are sequentially presented to participants for 5 - 10 
seconds after which time participants are requested to reproduce or copy depending on 
the administration method employed. For this study, administration A was used which 
allows 10 seconds exposure to each of the 10 cards with immediate recall by drawing. 
Administration A was preferred primarily to ensure continuity and comparability with 
previous studies and also to minimise time costs and strain on the participants 
associated with the more lengthy administration forms (i.e. administration D). The 
BVRT has three equivalent forms which were used in this study in counterbalanced 
order.
The number of correct reproductions (BVRT-C) and number of errors (BVRT-E) were 
recorded. Six types of errors are recognised: omissions, distortions, preservations, 
misplacements and errors in size. Thus there can be, and not infrequently are, more than 
one error to a card. Tabulation of errors by type allows the examiner to determine the 
nature of patient’s problems on this test.
The BVRT is very stable and has a high reliability on repeated administrations (Lezak, 
1995). Since this test involves so many different capacities it is considered to be very 
sensitive to brain damage and it also appears to be sensitive to cognitive alterations that 
accompany normal ageing (Lezak, 1995). This test was not used in TX assessment due 
to some logistical constraints.
v. Grooved Pegboard (GP)
GP (Klove, 1963, Matthews & Klove 1964) is a test of fine motor co-ordination and 
manual dexterity. It is known to be sensitive to both focal and diffuse cerebral
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impairment and may aid in the detection of lateralised disability or motor dysfunction 
that can occur despite intact capacity for normal movement.
It involves placing 25 pegs as rapidly as possible into an equivalent number of similarly 
shaped holes, but whose orientation to the vertical varies to so that the test requires 
frequent turning and fitting of the pegs. The GP is a timed test so the score is timed to 
completion with higher scores demonstrating a slower and thus worse performance. 
Both dominant (GP-DOM) and non-dominant hands (GP-NDOM) were tested so that 
right to left hand score comparisons (indicative of right and left hemisphere disease) 
could be made. Hand dominance was determined as the hand used for signing the 
consent form.
vi. Subjective Cognition Scale (SCS)
A subjective cognition scale (Newman et al., 1989) was included in this study to 
determine if participants perceived any acute and long-term changes in their cognitive 
function as a result of their treatment (dialysis and transplantation).
The scale administered as a semi-structured interview includes nine questions. The 
questions look at nine areas of cognitive function and patients are asked to indicate 
whether each particular aspect had improved, deteriorated, or shown no change (a) since 
onset of treatment (dialysis or transplantation) and (b) compared to 24-hours previously.
The semi-structured interview on cognitive complaints was hence given twice to the 
dialysis groups, each time prior to each of the scheduled neuropsychological 
assessments. Appropriate amendments in the time frame of the scale (as mentioned 
above) were introduced so as to capture acute and long-term subjective cognitive 
complaints. At the time of the first NP assessment the long term perceived cognitive 
changes were assessed. Patients were asked to indicate cognitive amelioration or 
deterioration since their respective treatment was introduced (i.e. since dialysis onset or 
since transplantation).
During the second NP assessment (dialysis only), questions related to acute cognitive 
changes experienced over the 24-36 hour time interval were asked.
143
The nine cognitive domains addressed include: memory, problem solving, clarity of 
thinking, concentration, making mistakes, attention, clumsiness, decision making and 
speed of response. Five of these questions related to the objective NP tests used whereas 
the questions on problem solving activity, clarity of thinking and making mistakes are 
either too broad or were not specifically addressed in the neuropsychological tests 
described above.
These domains concern patients’ perspective on their cognitive functioning and can be 
compared to the formal objective neuropsychological evaluation using the NP tests 
described above. Previous studies using similar cognitive complaints self reported scale 
have highlighted the lack of one to one correspondence between self-report cognitive 
functioning and objective NP scores (Brickman et al., 1996).
3.3 Procedure
3.3.a NP Data Collection
TX patients completed only one assessment while both HD and PD patients completed 
two NP assessments over a 24 hours interval so as to evaluate acute NP changes over 
the dialysis cycle.
HD patients were assessed 2 hours prior to their regularly scheduled dialysis session 
(Tl) and at approximately 24 hours after the end of their last dialysis session (non 
dialysis day; T2). This interval, in accordance with previous research protocols (Lewis 
et al., 1980; Ratner et al., 1983) was chosen to allow time for the observed dialysis- 
related disequilibrium effects to wear off and to provide participants with a time of 
relative convenience for testing. It is to be noted that study participation for hospital HD 
patients necessitated an additional hospital visit to the three scheduled dialysis sessions. 
This posed problems for some patients and may explain some of the refusals to 
participate.
An identical protocol was followed for home HD with one unavoidable difference: T l 
assessment had to take place at the patients’ home rather than the hospital as travelling 
to hospital for the purposes for the study and then back home for dialysis would be 
severely disruptive. Home HD patients on their dialysis days are expected be at their
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home to set up HD machine and initiate dialysis session on time. The researcher 
therefore visited them at home to administer the NP tests.
Assessment time intervals for the PD group mirrored those of the HD group as these 
patients were in effect used as a control group. In order to reduce inconvenience, the 
first assessment was strategically planned to coincide with patients’ regular monthly 
check up at the PD Unit while the second assessment took place approximately 24 hours 
following their clinic visit. Each participant was tested at approximately the same time 
every day (± 3 hours) on the two assessments to control for variations in performance 
due to possible diurnal effects (Kraemer et al., 2000).
Every NP assessment session was structured as follows. After the completion of part 1 
of the study questionnaire and self-report cognition scale the researcher proceeded with 
the administration of neuropsychological tests. All participants were however given an 
option to have a break beforehand and resume in 10 minutes.
NP tests were administered in the order as listed above. This was determined primarily 
by their cognitive domain focus with all attention or memory tasks administered 
together, and secondarily by their degree of difficulty, with the relatively easier tasks 
within each cognitive domain preceding the more difficult ones so as to optimise 
patients co-operation, boost motivation and foster a sense of achievement, and thus 
optimise patients’ performance.
Parallel forms of the tests, where available, were used for the majority of the 
instruments in order to limit the effects of learning across the two assessments. The 
order of parallel form administration was counterbalanced. Practice trials were also 
administered, as per standard instructions for many of the tests (TMT-A; TMT-B, 
SDMT-W; SDMT-O; BVRT; GP-D; GP-ND) to ensure that the first testing did not 
reflect either the subjects’ lack of familiarity with the task or a less than stable threshold.
The neuropsychological testing situation was designed to elicit maximum performance 
from all participants with testing being discontinued if a patient became fatigued, 
nauseated or unable to perform at an optimal level. NP testing took approximately 30 - 
45 minutes. All assessments, with the exception of Home HD patients (Tl assessment) 
took place in the same specially designated room in the research unit.
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To reduce within individual variability due to external confounding variables the two 
NP assessments of dialysis patients were conducted under similar environmental 
conditions. This included keeping the same examiner for all assessments, using the 
same apparatus (e.g. pen) and conducting the tests as much as possible at the same time 
of the day, and in the same context (home visit or outpatient clinic) (Moffoot et al., 
1994; Porterfield et al., 1997).
Training of the examiner in NP assessment had also been undertaken prior to study 
recruitment. This included: NP test presentation (e.g. general principles, NP 
instructions, frequently encountered problems), attending sessions of NP assessment led 
by the NP instructor, and conducting supervised NP assessment of healthy volunteers, 
followed by 2 sessions of supervised assessment of clinical patients.
3.3.b Collection of blood samples
In order to relate NP functioning to biochemical variables, blood samples were taken 
after the completion of each NP testing session so as to avoid interference of possible 
venopuncture pain with participants’ NP performance. An experienced HD, PD or 
transplant sister was responsible for taking the blood samples. All blood samples were 
delivered to respective laboratories ideally within 2 hours of collection.
Laboratory analyses consisted of the measurements of blood concentration of urea 
(BUN), creatinine (Cr), sodium (NA+), potassium (K+), phosphate (PO4), calcium 
(Ca2+), alkaline phosphatase (Alk-P-Tase), haemoglobin (Hb) and albumin (Alb). The 
most recent aluminium values (if within 3 months) were also recorded.
In HD patients on their dialysis day assessment (first NP test administration), blood 
samples were drawn immediately after the study assessment while patients were being 
set up on the HD machine.
For the patients on home HD programme, however, blood sampling immediately prior 
to their dialysis session was not feasible because no medically trained staff was 
available to take the blood samples (Hospital regulations disallowed blood taking 
procedures by any person other than the ones appointed and officially (NHS) employed 
for patients’ health care and management).
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Section 4: The Development of the Transplant Effects Questionnaire
(TxEO)
In the absence of the availability of a psychometrically sound transplantation specific 
instrument, which examined the impact of transplantation, a questionnaire was 
developed to cover this aspect of the study. TxEQ was developed to assess additional 
domains not covered in traditional generic HQoL measures. The questionnaire was 
intended to elicit recipients’ emotional and cognitive responses to transplantation.
This section outlines the work on the development and psychometric evaluation of the 
Transplant Effects Questionnaire (TxEQ), which was subsequently used for the 
assessment of TX recipients.
Phase I describes the preliminary work conducted leading to the development of the 
initial TxEQ items.
Phase II consisted of two studies conducted to test the acceptability of the new 
instrument and to examine its psychometric properties:
■ Study la  was the piloting of the initial questionnaire and the evaluation of the 
internal structure of TxEQ leading to the development of the final TxEQ items
■ Study lb involved the confirmation of the internal structure of the new measure and 
validation analysis
4.1 Phase I: development of the initial TxEQ
To identify the issues facing transplant recipients, an extensive literature review, and 
field-testing based on focus group, in-depth interviews, pilot testing with transplant 
patients and expert panel review were used. The triangulation of such quantitative and 
qualitative methodologies was thought to be the best method to capture transplant 
patients’ perspective and experience.
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4. La Literature review
The published literature was examined by means of a computer-based search using the 
MedLine (1966-1999) and PsychLit databases (1966-1999). Combinations of the 
following key words were used: ‘transplantation'; ‘t r a n s p la n t ‘c a d a v e r ‘living 
related’; ‘donor'; ‘quality o f life'; ‘health status' ; ‘renal'; ‘stressors'; ‘adherence'; 
‘c o m p l i a n c e ‘immunosuppressive'; ‘m e d i c a t i o n 1 side-effects'; ‘donation';
‘emotional'; ‘adjustment'; ‘well-being'; \functioning’. Additional papers were identified 
by reviewing/manually searching reference lists of the obtained articles.
In each case note was made of the transplant group studied, the source of the transplant 
(cadaver or form a living donor), and the measures used (generic or transplant-specific).
Based on the review of literature a list of relevant open-ended questions was then 
constructed for use in a focus group and individual interviews with kidney transplant 
recipients. The questions covered the following issues and themes that had all emerged 
from the literature:
- impact of transplantation on patients and their families (e.g. What are the most 
important effects of having a transplant?)’)
- contrast between life prior and post-transplant (e.g. ‘Does life after transplantation 
meet your expectations?’)
- concerns related to and side effects of anti-rejection medication (e.g. ‘Were there 
any problems you have experienced in relation to your treatment or to your 
recovery?’)
- interpersonal attitudes towards donor or donor family (e.g. ‘What do you know 
about the donor?’; ‘Do you ever wonder about the characteristics of the donor?’)
- feelings of indebtedness gratitude and guilt towards the donor or donor family (e.g. 
‘How would you describe your feelings toward the donor/donor family?’; ‘Do you 
feel obliged to pay back the donor for the gift of donated organ?’)
4. Lb Field testing (Focus Group - Interviews)
A focus group and three semi-structured interviews with transplant recipients were 
conducted to explore issues of particular relevance and importance to transplant 
recipients.
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Patient input in the development process in particular might be critical to the success of 
an instrument in obtaining relevant data (Bergner et al., 1981; Hays et al., 1994). It was 
also thought that the first hand contact and discussion with the recipients themselves, in 
these early stages of the study would familiarise the researcher with the vocabulary and 
thinking pattern of patients with a kidney transplant and hence inform the phrasing and 
wording of the questionnaire items.
The focus group included one female and two male patients with a functioning cadaver 
kidney transplant (one female patient failed to attend due to some unexpected family 
illness). Three in depth interviews were subsequently undertaken with three male LRD 
TX recipients.
Both the focus group discussion and the interviews were run using a standardised 
protocol with open-ended questions as described above and discussion. Although the list 
of open-ended questions (see Appendix E) provided the basis of the discussion, when 
necessary researchers elaborated on issues raised by the participants and probed them to 
ensure that any subject of importance to the participants was adequately addressed.
The facilitators aimed not to take anything for granted and to be as ‘naive’ as possible.
A non-judgmental approach in relation to the content of the interviews and a
confirmative approach to the participants were the guidelines for the conversation. The 
interviews were conducted as informal conversation and allowed participants to put 
their reactions into words and test their opinions in a dialogue with the interviewer 
(Kvale, 1994). Discussions were audiotaped, transcribed (verbatim) and reviewed to
identify themes and group distinct thoughts into related categories (Bass et al., 1999).
Comments from focus group participants and interviewees indicated that many were 
concerned about the side-effects of immunosuppressive medication, but despite these 
concerns, self-reported adherence rates were very high.
Several participants raised concerns about the viability of their kidney and about 
resuming and engaging to physical and social activities that could potential threat their 
health or put their transplant at risk. Comments such as 'the freedom was replaced by a 
fear o f transplant failure’, 7  am still apprehensive about rejection 4 years after 
operation’ highlight these issues.
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All of the participants unanimously indicated that transplantation had met their pre­
transplant expectations about how they would feel. They had all anticipated that the 
receipt of a new kidney would release them from the constraints associated with dialysis 
and that it would facilitate and mark the return and resumption of normal living and 
activities. Quotes made by the participants include 7  hated dialysis'; 7  felt a lot better 
instantly after the o p e r a tio n ‘The kidney is freedom'', ‘it is worthwhile going for a 
transplant no matter what the circumstances are' .
It is also of interest that they no longer feel themselves to be patients despite fully 
acknowledging the vital importance of the treatment they continue to receive.
A common theme among participants, primarily living related transplant recipients that 
had not emerged in the literature review, related to issues ‘disclosure’ with regard to 
their transplant. The term ‘disclosure’ was used to describe:
(a) individuals' difficulty in talking about or expressing feelings about the donor 
or the act of donation
(b) recipients’ readiness or reluctance to communicate to others that they have a 
transplant
The issues to do with transplantation identified in this two-stage procedure were 
combined into items and refined by two raters. The resulting 315 items were 
subsequently assessed for comprehensibility and redundancy by two raters.
This process resulted in 51 items that represented nine key themes relating to receiving a 
transplanted organ: outcome of transplantation, fear of rejection, self-care principles, 
adherence, feelings of guilt, feelings of indebtedness, having a foreign body part, 
interpersonal relationships (i.e. with family and friends), and emotions.
The relevance, clarity and conciseness of the reduced pool of 51 were then subjected to 
expert panel review (transplant professionals including two renal consultants and two 
transplant nurses).
4.1.c Field testing - Pilot study
Lastly the resulting scale was successfully piloted with a small group (n = 7) of first 
time renal transplant recipients of whom four had received their transplant from a living 
related donor.
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The pilot sample consisting of 4 male and 3 female transplant recipients that had a mean 
age of 46.2 years (SD = 6.83) and who had their transplant an average of 7.66 years (SD 
= 4.95) prior to the pilot. Overall, patients reported the items to be clear. All participants 
in the pilot study reported no difficulties understanding the wording of the items and 
completing the new measure. The layout of the questionnaire was slightly modified as a 
result of patients’ feedback and specific recommendations.
4.2 Phase II: TxEQ application - Study la  and Study lb
In Phase 2, two studies were sequentially conducted to examine the psychometric 
properties and structure of this final pool of 51 items of the Transplant Effects 
Questionnaire (TxEQ).
Data collected in postal survey of a second transplant sample (study la) was used to 
explore the internal structure of the new measure (TxEQ). Data collected from the 
MIDDX transplant patients (see section 1.1) in a ‘face to face format’ (study lb) were 
then used to confirm the observed (in postal survey; study la) internal structure, and to 
examine test-retest reliability and criterion validity.
4.3 Postal Survey- Study la
4.3.a Procedure
For the development of TxEQ a second sample of renal transplant recipients was 
recruited from another transplant centre. Following ethics committee approval all (n = 
333) renal transplant patients registered at Royal Free Hospital (RFH) were sent a 
covering-invitation letter and a questionnaire pack consisting of the 51-item TxEQ, and 
questions about their medical history, and demographic details. To ensure and 
encourage frank responses the questionnaire had a code number but not the participants’ 
name. Four weeks were allowed to return the questionnaire. After that time a reminder 
letter and another copy of the questionnaire were sent to non responders and another 2 
weeks were allowed for completion after which time data collection was terminated.
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4.3.b Participants -  TX Sample 2: (RFH-TX)
For the postal survey all adult transplant recipients (n = 333) registered at the Royal Free 
Hospital, London UK (RFH-TX), Transplant outpatient clinic were invited to 
participate. No exclusion criteria other than age below 18 years of age were applied. Out 
of the 333 patients contacted, two hundred and thirty one (n = 231) patients completed 
and returned the questionnaire giving a response rate of 69.4%. This is higher than the 
anticipated response rate for this type of study (Grady & Wallston, 1988).
Participants were almost equally divided between male and female, had a mean age of 
45 years and had been living on a renal transplant for a mean of 9.93 (SD = 6.76) years 
(see Table 5.3)
Table 5.3: Sociodemographic and clinical characteristics of the RFH-TX sample
RHFTX
M(SD) %(N)
Age
Gender (% female) 
Source of TX (% LRD) 
Time since TX (in years) 
No of comorbidities
45.15 (14.51)
48.9(113)
22.1(51)
9.93 (6.76) 
.67(1.11)
Diabetes (%) 
Hypertension (%) 
Heart conditions (%)
9.1 (21) 
59.5 (138) 
6.9 (16)
Number of previous transplants 
On Dialysis prior Transplant (%)
Time on dialysis (months)
Education (age years left school) 
Relationship status (% in a relationship) 
Work status (% employed f/t, p/t, student) 
Able to work ( Ft, p/t)
Annual family income
34.52 (42.47) 
18.07 (4.47)
1.19 (.45)
57.6 (133) 
136 (58.6) 
68.8 (154)
91.7 (210)
0 -  £ 10,000 
£  10,001 - £  20,000 
£ 20,000 - £ 30,000 
>£30,000 
do not wish to answer 
Own home (%)_____________________
18.2(40)
18.2 (40) 
12.7 (28) 
18.6(41)
32.3 (71) 
60.5 (138)
Note: TX = transplantation; LRD = living related donor transplant; f/t = full time; p/t = part 
time
4.3.c Postal Survey-Measures
i. Sociodemographic and medical assessment
Sociodemographic questions included: age, gender, ethnic background, first language, 
marital status, time with current partner if any, educational qualification, years in 
schooling, working status pre and post transplantation and one question on perceived 
ability to work (Evans et al., 1985).
A list of items was also compiled to obtain basic medical information on patients’ 
dialysis and transplant history including ESRD diagnosis, previous transplant failures, 
time spent on dialysis, type of dialysis treatment and time elapsed since their current 
kidney transplant.
Patients were also asked to list any other disability, comorbidity or infirmity. 
Participants’ medical records were subsequently reviewed to confirm and verify 
presence or absence of the following comorbid conditions: diabetes, hypertension, 
ischaemic heart disease, coronary heart disease, atrial fibrillation and previous incidence 
of myocardial infarction. A comorbidity total score was computed by simply adding the 
number of diagnosed comorbid conditions.
ii. TxEQ
The 51-item Transplant Effects Questionnaire was used to assess transplant specific 
outcomes. The instructions of the TxEQ were as follows: 'We are interested in your own 
personal views of how you now see your experience with your kidney transplant. These 
are statements other people have made about their transplant experience. Please indicate 
the extent to which you agree or disagree with these statements by ticking the 
appropriate box.'
Questionnaire items were positively and negatively worded. A positive and negative 
item wording was used to avoid acquiescence, affirmation or agreement bias. They were 
presented in a mixed order and rated by the participants in a five point Likert scale 
ranging from strongly disagree to strongly agree (scored from 1 to 5).
See Appendix C for the TxEQ questionnaire sent to RFH TX participants
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4.3.d Analysis
Statistical analysis was performed using the SPSS for Windows (version 10.1). Item 
responses in the TxEQ from the study 1 sample were subjected to an exploratory 
principal components analysis (PCA) with varimax rotation (Kaiser normalisation). As a 
means of eliminating items to achieve a simple coherent structure extraneous items were 
omitted on the basis of: the Kaiser Meyer Olkin (KMO) statistic for each item, factor 
scree plot and final factor loading as described below (Norusis, 1992). The numbers of 
factors extracted was determined though observation of the altering gradient of a scree 
plot (a graph of Eigen values against factors) and an Eigen value of more than 1.
4.3.e Results -  Internal structure of TxEQ
Initial PCA resulted in a 15-factor structure. A factor scree plot suggested a six factor 
solution (46.7%). Subsequent omission of 27 items with low loadings (<.45) spread 
across these factors and less than 30% overlapping variance replicated the six factor 
solution, accounting for 64.2 % of the variance in the responses to the TxEQ. The KMO 
statistic for the remaining 24 items ranged from 0.69 to 0.86 (mean = 0.79). All six 
factors identified had acceptable internal reliabilities. Cronbach alphas ranging from .72 
to .86 (thus satisfying Nunnally’s criterion of 0.7; Nunnally, 1978) (Table 5.4 below).
Items were found to be largely grouped in conceptually coherent factors.
Factor 1 comprised six items relating to worries regarding the transplant (22.31%; a  = 
0.81). Items loading on factor 2 referred to feelings of guilt towards the donor (11.94%; 
a  = 0.76). Three items loaded respectively on the third factor tapping disclosure issues 
regarding the transplant (9.58%; a  = 0.86) and on the fourth factor reflecting medication 
adherence (8.73%), whereas factor 5 contained items relating to perceived responsibility 
towards others (6.63%; a  = 0.72). Factor 6 (5.04%), however, appeared to be 
thematically incoherent, with two items (C9 and D l) relating to adherence and a third 
(G2) to taking on qualities of the donor. However the two adherence items did load on 
the adherence factor (factor 4) (0.22 and 0.29, respectively) despite varimax rotation. It 
was therefore decided to group items C9 and D l into factor 4 and drop item G2 from 
further analysis. The resulting adherence factor showed high internal consistency (a = 
0.79).
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In summary the exploratory factor analysis (EFA) determined 6  factors which were 
reduced to 5 thematically coherent factors: worry about the transplant, guilt, adherence, 
disclosure and responsibility.
All five sub-scales had acceptable levels of internal consistency (Cronbach a  ranged 
from .72 to .8 6 ).
Table 5.4: PCA of theTxEQ*: factor loadings, variance explained, communalities,
Cronbach alpha
ITEMS Loading h2
Factor 1: 4worry about transplant'’
Eigenvalue = 3.14; Cronbach alpha = .81 Total R2: 13.1%;
B2 I am worried about damaging my transplant .82 .71
Bl With regard to my transplant I feel that I am carrying around 
something fragile
.76 .64
B5 I am hesitant to engage in certain activities because I am afraid of 
doing harm to my transplant
.75 .60
B3 I keep wondering how long my transplant will work .71 .59
Cl I monitor my body more closely .64 .46
D2 I worry each time my anti-rejection drug regime is altered by my 
doctor
.47 .53
Factor 2: ‘guilt regarding donor9
Eigenvalue = 2.94; Cronbach alpha = .76; AR2: 12.2%; Cumulative R2: 25.3%
E4 I feel guilty about having taken advantage of the donor .83 .77
El Sometimes I think that I have ‘robbed’ the donor of a vital part .76 .63
E3 The donor had to suffer to make me feel better .73 .58
F2 I have the feeling that the donor/the donors’ family has some 
control over me
.6 6 .61
E2 I do not have any feelings of guilt towards the donor -.56 .44
Factor 3: 4disclosure9
Eigenvalue = 2.47; Cronbach alpha = .8 6 ; AR2: 10.4%; Cumulative R2: 35.7%
12 I avoid telling other people that I have a transplant .90 .83
11 I am uncomfortable with other people knowing that I have a 
transplant
.8 6 .75
14 I have difficulty in talking about my transplant .85 .80
Factor 4: 4adherence9
Eigenvalue = 2.46; Cronbach alpha = .79; AR2: 10.3%; Cumulative R2: 45.9%
C6 Sometimes I do not take my anti-rejection medicines .85 .77
C2 Sometimes I forget to take my anti-rejection medicines .83 .77
C4 When I am too busy I may forget my anti-rejection medicines .80 .68
C9 Sometimes I  think I do not need my anti-rejection medicines .2 2 .76
Dl I fin d  it difficult to adjust taking my anti-rejection medicines .29 .62
the final questionnaire consists o f 23 items as 1 item was dropped for conceptual reasons
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Factor 5: ‘responsibility9
Eigenvalue = 2.22; Cronbach alpha = .72; AR2: 9.3%; Cumulative AR2: 55.1 %
F3 I think that I have a responsibility to the transplant team to do 
well
.77 .60
F6 I think that I have a responsibility to my friends and family to do 
well
.75 .60
F5 I feel that I owe the donor/the donor’s family something that I 
will never be able to repay
.73 .60
FI I feel that I have a responsibility to the donor/the donor’s family 
to do well
.65 .55
N ote : AR2 = additional variance explained
4.4 Studylb: TxEQ reproducibility and test-retest reliability - face to face assessment
4.4.a Procedure
The TxEQ was completed by consenting transplant patients (TX-MIDDX) who took 
part in the full study protocol (see section 1.1). Questionnaires were completed in the 
presence of a researcher in order to clarify any queries. The TxEQ was administered 
within the first 30 minutes of the assessment. To evaluate the test-retest reliability, 
another copy of the TxEQ was sent to all participants four weeks later together with an 
explanatory cover later. Recruitment, consenting and data collection procedures are 
described in more detail in section 2 .2 .
4.4.b Participants
Table 5.2 presented earlier depicts the sociodemographic and medical characteristics of 
the recruited sample (MEDDX-TX). Of 115 that completed the first administration of the 
TxEQ, eighty-two patients returned the same questionnaire at the second administration 
(postal survey) giving a response rate of 71.3% (attrition rate = 29.7%).
T-tests analyses between the two transplant samples (RFH-TX and MIDDX-TX) on 
sociodemographic and medical history variables revealed four significant differences. 
RFH TX participants were significantly older (t(251.13) = 3.25; p  = .001), had 
developed or been diagnosed with kidney disease at an older age (t(326) = 3.51, p  = 
.001), were significantly older when received their current kidney TX (t(259.27) = 5.62,
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p  = .0001), and had been living on their current transplant for less time compared to 
MIDDX TX participants (t(286.30) = -5.49; p  = .0001).
4.4.c Analysis
To confirm the internal structure observed in the TxEQ postal survey (RFH-TX; study 
la) TxEQ data from the MIDDX-TX sample were subjected to confirmatory factor 
analysis (CFA) using structural equation modelling. Statistical analysis was conducted 
using the windows version of AMOS 3.1.
There are a number of different fit indices that can be used in CFA, although no 
widespread agreement currently exists about which is the best (Maruyama, 1998). 
Closeness of fit based on the Root Mean Square Error of Approximation index 
(RMSEA) (Browne & Cudeck, 1993) was used to examine the extent of fit in the 
questionnaire factor structures from the two study samples.
The RMSEA is a measure of discrepancy of fit, as it illustrates how much error there is 
between the estimated parameters and the actual parameters taken from the data after 
taking into account number of degrees of freedom. The RMSEA measure was used in 
preference to the CFI (or any other measure of fit) because it provides a robust measure 
of closeness of fit for the model, which is considered by Browne and Cudeck (1993) to 
be "more reasonable than the requirement of exact fit". In addition, McCallum et al. 
(1996) recommend the use of RMSEA instead of point estimates of model fit in the 
population. Work by Rigdon (1996) has demonstrated the utility of the RMSEA as an 
index of the degree to which a confirmatory structure approximates the data being 
modelled. Hu & Bentler (1999) suggest optimal cut-off of close to 0.6 for RMSEA, with 
values of 0.08 being acceptable. Browne & Cudeck (1993) have suggested that values of 
0.05 and below indicate a close fit of the model and the values of the RMSEA between
0.05 and 0.08 approximate a reasonable error in approximating a given structure. They 
also provide a test of the hypothesis that the population RMSEA for the model is no 
greater than 0.05. Failure to reject this hypothesis at p < .05 signifies that the model is a 
close fit to the data.
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4.4.d Results
i. Internal structure
CFA was performed using the AMOS structural equation modelling application 
(Arbuckle, 1997). A measurement model was defined with 5 uncorrelated latent 
variables (as described in the exploratory factor analysis section above).
The resulting model was found to be a good fit for the data (RMSEA =0.08; pclose =
0.005) as defined by Browne & Cudeck (1993). Analysis of the second (MIDDX-TX) 
TxEQ data set confirmed the 5 factor structure: ‘worry about the transplant’, ‘guilt’, 
‘disclosure’, ‘adherence’ and ‘responsibility’.
ii. Test-retest reliability
One-month test retest reliability of the TxEQ was found to be acceptable for all sub­
scales (see Table 5.5). Test-retest correlation coefficients were r = .797 for factor 1 
(‘worry about the transplant’), r = .689 for factor 2 (‘guilt’), r = .60 for factor 3 
(‘disclosure’), r = .772 for factor 4 (‘adherence’) and r = .703 for factor 5 
(‘responsibility’)
4.4.e Discussion
The TxEQ was designed to allow a comprehensive, sensitive and easy to administer 
instrument of those aspects of transplantation that have been identified to be the most 
important. Although it was developed on individuals in receipt of a renal transplant it 
has been designed to be applicable to all forms of organ transplantation.
Principal components analysis of the TxEQ items produced a conceptually coherent 
factor structure, which was further confirmed on another data set using structural 
equation modelling. The resulting five TxEQ sub-scales were concerns and worry 
specific to the transplant, feelings of guilt regarding the donor, disclosure, perceived 
responsibility and medication adherence.
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The first two sub-scales appear to tap emotional responses that are likely to be triggered 
by transplantation (i.e. worrying over graft function and feelings of guilt towards the 
donor). These two dimensions tie in with earlier research findings (Castelnuovo- 
Tedesco, 1981; Chambers, 1982; Chaturvedi & Pant, 1985; Franke et al., 1999; 
Freyberger, 1983; Gubby, 1998; Kong & Molassiotis, 1999; Schlebusch, 1986; 
Schlebusch et al., 1989; Sutton & Murphy, 1989; Viederman, 1981).
Patients concerns regarding the viability of their transplanted organ are well-rooted in 
reality despite the major advances made in recent years. Although the figures for 
different transplanted organs do vary (Gruessner & Sutherland, 1989; Keck et al., 1999; 
US Renal Data System, 1999; 2001), in the case of renal transplantation in the UK, the 
rejection rate of kidneys is approximately 36% over 5 years (UK Renal Association 
Standards Subcommittee, 1997). Patients’ awareness of this possibility is likely to be 
further confirmed by the need to take anti-rejection medication, the experience of 
symptoms or possibly the occurrence of episodes of infection.
Feelings of guilt towards the donor have been reported in a range of other, mainly 
qualitative, studies (Basch, 1973a; 1973b; Chaturvedi & Pant, 1985; Cramond, 1971; 
Kemph, 1971; Mai, 1986). There is little research evidence on guilt however, in what 
may be considered the most pertinent area, where the organ may have been sourced 
from a living donor as is the case in renal transplantation, bone marrow transplantation 
and in some cases of lung and liver transplantation. Further research is required to 
establish the extent to which transplant recipients of other organs experience guilt and 
what underlies this dimension. The TxEQ specifically assesses guilt in relation to the 
donor and their family.
Whether to disclose the fact that one has a chronic illness is an option where the 
treatment or illness is not easily observed (Adams et al., 1997; Greene, 2000; Sheon & 
Crosby, 2003). In the case of kidney transplantation it appears that this is an important 
issue for some individuals. One may speculate that some are concerned about how they 
will be responded to, whilst others may be relatively unconcerned with others knowing 
that they have had a kidney transplant. Ndlovu & Louw (1998) noted the reluctance of 
African transplant recipients to talk about their transplant experience. The
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generalisability of this finding to transplant recipients from other ethnic groups has not 
been examined.
Disclosure may be perceived as a double-edged word; it may open up social support 
opportunities or conversely may lead to added stress due to stigmatisation, 
discrimination and disruption of personal relationships (Baker et al., 1999). The 
decision to disclose may be influenced by a range of factors, including 
sociodemographics of the individual, significant other, group or family dynamics or 
cultural or normative beliefs to name a few.
The fourth factor identified was that of adherence. Treatment adherence has been widely 
studied in transplant populations. Although existing research has been hampered 
because of various assessment methods each of which with its own strengths and 
weaknesses (Brickman & Yount, 1996), there is evidence to suggest that some 
transplant patients do not follow the advice and recommendations made regarding 
immunosuppressive medication (Wainwright & Gould, 1997), despite the associated 
health risks that this behaviour might precipitate.
The last TxEQ factor refers to ‘responsibility towards family, friends, or the medical 
team to do well’, an issue which has not received attention in transplantation research. 
The ‘responsibility’ dimension of the TxEQ appears to tap issues related to outcome 
responsibility likely to encompass both a cognitive (i.e. perceptions of responsibility) as 
well as an affective component (i.e. feelings of responsibility). Responsibility as 
measured by the TxEQ may hence be seen as qualitatively distinct from concepts such 
as locus of control or responsibility for graft survival studied in previous research 
(Bremer, 1995; Bremer et al., 1995; Frazier et al., 1994; Kiley et al., 1993; Kugler et a l , 
1994). Responsibility towards others may well be dependent on a range of other factors 
such as perceived social support and/or patients’ satisfaction with interpersonal 
relationships or with health care received. Further research is warranted to examine its 
relationship to these and other variables.
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4.5 Study lb: TxEQ Validation analysis
To demonstrate the convergent and discriminant validity of TxEQ sub-scales, their 
associations with conceptually similar measures were examined. These psychometric 
properties were assessed using the MIDDX-TX transplant data set (see section 1.1).
The TxEQ guilt sub-scale is thought to measure the same basic affect as the 
corresponding ‘guilt’ sub-scale from the PANAS-X (Watson & Clark, 1994).
Likewise, similarities were hypothesised between TxEQ worry and PANAS general 
negative affect, PANAS-X fear, PANAS-X sadness and the SF-36 mental health and 
mental composite score (Ware & Sherboume, 1992), and between the TxEQ adherence 
and the ‘reported adherence to medication scale’ (RAM; Home et al., 1999).
This latter measure was also used to investigate validity of the responsibility TxEQ sub­
scale, as it was hypothesised that TX patients with a strong sense of responsibility to do 
well will also demonstrate high treatment adherence rates.
Somewhat more tentative was the link assumed between PANAS-X shyness sub-scale 
and TxEQ disclosure but in the absence of other disclosure related measures in our 
assessments, this was explored.
Intercorrelations among these conceptually overlapping or linked scales are presented in 
Table 5.5.
Moderate-sized correlations were found between TxEQ adherence and BMQ adherence. 
TxEQ adherence scores were also found to be negatively associated with ‘concerns 
regarding medication’ and positively associated with ‘medication-necessity’ beliefs. 
Perceived responsibility was also associated with BMQ adherence scores, with stronger 
sense or feelings of responsibility to do well-being correlated with better, (i.e. more 
faithful) treatment adherence.
Correlations between mainly TxEQ worry, and other measures (PANAS sadness and 
fear sub-scales) although small in magnitude were in the predicted direction and 
statistically significant.
As anticipated TxEQ disclosure was not associated with PANAS shyness sub-scale 
suggesting that tendency to disclosure TX related information has little to do with being 
timid, shy or bashful and is more likely to reflect other factors.
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Table 5.5: Correlations between TxEQ sub-scales and other scales
TxEQ
worry
TxEQ
Guilt
TxEQ
disclosuret
TxEQ
adherencet
TxEQ
responsibt
PNS NA .143
PNS FearT .206*
PNS Sadnesst .206*
SF 36-MH _ 404****
SF 36-MCS -.314***
CDI+ .199* .006
PNS Guiltt -.075
PNS Shynesst -.043
BMQ-c -.343****
BMQ-nt .529****
RAM adht 629*** .208*
Note: PNS = positive and negative affect scale; PNS NA: negative affect from PANAS; MH =
mental health; MCS = mental component score; CDI = cognitive depression index; BMQ = 
Beliefs about your Medicines Questionnaire; BMQ-c = concerns about medication from the 
BMQ; BMQ-n = necessity sub-scale from BMQ; RAM adh = adherence from the Reported 
Adherence to Medication 
* p < .05. ** p < .01. *** p < .001. **** p < .0001
On the other hand disappointing and unexpected was the lack of significant associations 
between TxEQ guilt and PANAS guilt and cognitive depression, which is likely to 
reflect the difference between generalised feelings of guilt to feelings of guilt in relation 
to the act of donation. Guilt towards the donor might be confined to this experience and 
not manifest itself in more generic affective states. The implication of this interpretation 
is that the two measures truly reflect different aspects of the concept of guilt.
The evaluation of TxEQ validity is limited by the fact that due to the lack of availability 
of validated measures for some of the sub-scales (TxEQ disclosure; TxEQ 
responsibility), their criterion validity could not be established at this stage. Despite 
these limitations, the data described above provide preliminary evidence for the 
criterion-related validity, discriminant validity and the reliability for the TxEQ sub­
scales and support its use in this study.
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4.6 Comparisons between CAD and LRD TX recipients
A secondary analysis of the aggregated TxEQ dataset, i.e. including both RFH and 
MIDDX TX recipients (study la  and lb) was then performed to examine the TxEQ sub­
scales in relation to transplant source, namely cadaver and living related transplantation. 
These were conducted to assess differences between cadaver and living related donor 
TX recipients in TxEQ sub-scales. Such comparisons were also considered essential in 
elaborative validity phase (Foster & Cone, 1995), in which the meaning and utility of 
sub-scale scores are examined. There were no apriori hypotheses as to if or how 
transplant type might affect emotional and behavioural post-transplantation responses 
but such comparisons are valid ones to make in the context of validating a new 
instrument.
4.6.a Methods
Out of 453 patients contacted for study la  and lb, 347 patients consented to the 
protocols (response rate = 76.6 %).
The overall recruited transplant sample consisted of 54.4% males with a mean age of 
46.8 years (SD = 13.95) and a mean of 8.6 (SD = 6.55) years since their transplant. 
Approximately 25% (n = 75) had received their transplant from a living related donor.
Sociodemographic and medical characteristics of the CAD and LRD transplant patients 
are shown in Table 5.7 below.
Age, annual income and time spent on dialysis differed significantly between the two 
groups. LRD transplant recipients were younger (F(l, 340) = 21.37, p  = .0001), reported 
higher annual income (%2(334) = 11.04, p  = .014) and had spent significantly less time 
on dialysis prior to their transplant than CAD transplant patients (F(l, 296) = 16.04, p  = 
.0001). The difference in time on dialysis was anticipated given the elective nature of 
LRD transplantation that allows shorter delay between dialysis and transplantation. In 
subsequent comparisons between the two groups these differences were controlled for 
statistically.
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Table 5.7: Sociodemographic and clinical characteristics of the combined MIDDX and
RFH TX sample
LRD TX CAD TX
(n = 75) (n = 271)
M (SD) /  % (N) M (SD) /  % (N) r-value/ y 2 p  value
Age 40.37(11.93) 48.59 (14.03) 5.06 .001
Gender (% female) 40.8% (31) 47.3% (129) 1.00 .317
Time since TX (yrs) 9.28 (6.20) 8.37 (6.65) -1.10 .261
No of comorbidities 1.54(1.54) 1.95 (1.75) 1.96 .064
Diabetes (%) 6.6% (5) 8.8% (24) .381 .537
Hypertension (%) 56.6% (43) 72.5% (198) 7.076 .008
Heart conditions (%) 6.6% (5) 15% (41) 3.70 .054
No of previous transplants 1.11 (.31) 1.14 (.35) -.90 .368
Dialysis prior TX (%) 81.1% (60) 96.3% (260) 20.71 .001
Time on dialysis (months) 17.07 (24.94) 37.88 (40.78) 5.19 .001
Education (age yrs left school) 18.38 (3.46) 17.67 (4.68) -1.16 .273
Relationship status 65.3% (49) 60.1% (163) .66 .414
(% in a relationship)
Work status (% employed)) 75.3% (55) 50.5% (138) 13.07 .001
Able to work ( m, p/t) 82.2% (60) 66% (175) 7.049 .008
Annual family income 10.59 .014
0 - £10,000 15.8% (9) 29.5% (56)
£ 10,001 - £ 20,000 19.3% (11) 27.4% (52)
£ 20,000 - £ 30,000 21.1% (12) 19.5% (37)
> £ 30,000 43.9 % (25) 23.7% (45)
Own home (%) 60.5% (46) 63.8% (171) 1.54 .792
Note: LRD TX = living related donor transplant recipients; CAD TX = cadaver transplant
recipients; TX = transplantation; No = number; yrs = years; f/t = full time; p/t = part time
4.6.b Results
i. The effects o f transplant type
Analyses of covariance (covarying for age, income and dialysis duration) revealed a 
significant transplant type effect only on TxEQ guilt (see Table 5.8).
LRD transplant patients expressed significantly stronger feelings of guilt towards the 
donor {mean = 2.70, SD = .80) relative to CAD transplant recipients {mean = 2.05, SD. 
= .63; F(3, 200) = 26.27, p  c.000). There was a tendency for LRD patients to be more 
reluctant to disclose or talk about their transplant experience {mean = 4.03, SD. = .85)
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relative to CAD transplant counterparts {mean = 3.68, SD. =1.10; F{4, 207) = 3.58, p  = 
.06). There was no significant difference in reported levels of worry with regard to 
transplant, with both groups being equally concerned with the viability and functioning 
of their graft.
Table 5.8: TxEQ scores of CAD and LRD patients
LRD TX CAD TX _________
TxEQ Sub-scales M  (SD) M  (SD) F  p  value
Worry about transplant 3.29 (.80) 3.02 (.85) .384 .536
Guilt 2.70 (.80) 2.05 (.63) 26.269 .0001
Disclosure 3.68 (1.10) 4.03 (.85) 3.585 .06
Adherence 4.26 (.81) 4.34 (.68) .008 .930
Responsibility 3.76 (.81) 3.76 (.78) .829 .364
Note: LRD TX = living related donor transplant recipients; CAD TX = cadaver transplant 
recipients
ii. Associations between variables
Correlational analysis between sociodemographic, medical variables and TxEQ sub­
scales showed that increasing age was associated with less worry regarding the 
transplant (r = -.25, p  = .0001), less guilt (rs = -.14, p  = .012), more disclosure (rs = .24, 
p  = .0001), higher adherence to immunosuppressive medication (rs = .12, p -  .029) and 
more perceived responsibility to do well (rs = .28, p  = .0001).
In addition the number of comorbid conditions was positively correlated with more 
disclosure (rs = .17, p  = .005).
Significant, albeit weak associations were also found between the five TxEQ sub-scales 
suggesting links between emotional and behavioural aspects of post-transplantation 
adjustment.
Stronger feelings of guilt were significantly correlated with more worry about the 
transplant (rs = .25, p  = .0001), higher perceived responsibility (rs = .19, p  = .001), lower 
disclosure (rs = -.24, p  = .0001), and poorer medication adherence (rs = -.20, p  = .0001). 
Worry about the transplant also correlated with feelings of greater responsibility to do 
well (rs = .21, p  = .0001) and less disclosure about the transplant (rs = -.14, p  = .013).
165
4.6.C Discussion
This subsidiary analysis indicated that different forms of transplantation (LRD vs. CAD) 
may lead to different emotional responses albeit with no apparent QoL differences.
In particular feelings of guilt appear to be prominent in living related transplantation.
The significantly higher levels of guilt reported by LRD recipients are understandable 
given the different relationship between the transplant recipients and donor and their 
family (Aikawa, 1989) and the recognition of the sacrifice made by the donor. Most 
living related transplant recipients continue to have a relationship with the donor and in 
this study all donors were relatives of the recipients. The sacrifice made by the donor, 
the physical cost of donation and the perceived ongoing risk of having only one kidney 
may understandably lead to feelings of guilt (Pillay et a l , 1992). Although their 
incidence rates are very low, both early post-operative as well as later risks are attached 
to living donor transplantation (Johnson et a l, 1991a.', 1997b; Najarian et al., 1992). It is 
likely that transplant recipients will be very well aware of these risks (Jones et al., 
1993). Recipients of cadaver transplantation do not have any pre-existing relationship 
with the donor or his/her family and the prospect for future personal contact was limited, 
given the current practice in UK of discouraging or prohibiting direct contact between 
cadaver transplant recipients and donor families. Even in cases where some contact, 
typically in the form of correspondence, is established between cadaver recipients and 
donor families, this form of interaction tends to be more impersonal and exclusively 
regulated via the transplant co-ordinating centres. Although the recipient of a LRD 
kidney may well have increased levels of guilt and there have been some reports of 
depression and disrupted family relationships after donation to a family member 
(Russell & Jacob, 1993), most published reports have indicated an improved sense of 
well-being, quality of life and a boost in self-esteem for living kidney donors (Johnson 
et a l, 1999; Peters et a l, 2000; Switzer et a l, 2000).
These observed associations provide indirect support for the validity of the new 
instrument. The preliminary data reported here indicate that the psychometric properties 
of TxEQ are acceptable and support its use as a transplant specific research tool. TxEQ 
is self explanatory, simple to use and time cost-effective, features that make it an ideal 
instrument for use in a clinical environment. The TxEQ has potential to monitor on a
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regular basis the responses, psychological adjustment and treatment adherence in 
transplant recipients alongside the routine post-transplant medical assessments. From a 
research perspective, TxEQ may be used separately or in conjunction with more generic 
HQoL measures.
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CHAPTER 6: RESULTS NEUROPSYCHOLOGY
This chapter describes the results1 on the NP outcomes of ESRD patients. It is organised 
into three major sections: dialysis, TX and summary of results
Section 1: Dialysis Sample
1.1 Data analysis
All statistical analysis described in this thesis was performed using SPSS version 11 for 
Windows (Norusis, 1993).
First, the distributions of the NP tests and related psychological measures were 
examined by means of the Kolmorogov-Smimov goodness-of-fit test. Depression scores 
(BDI; CDI), negative affect, TMT-A, TMT-B, BVRT-C, BVRT-E, GP-DOM, GP- 
NDOM and RAVLT-D were found to be non-normally distributed. Logarithmic and 
square root transformations rendered most of these variables (BDI, CDI, TMT-A, TMT- 
B, GP-NDOM) to a normal distribution. It was not possible to render the BVRT scores 
(number correct and number of errors), RAVLT-D and GP-DOM, and negative affect 
scores to a normal distribution. These were nevertheless analysed as described below 
(using parametric tests when dialysis groups were compared across time) as the large 
study sample (> 20 df) provided some tolerance to violation of normality (Tabachnic & 
Fidell, 1989) but caution must be used in interpreting the findings in relation to these 
tests, because of the non-normal nature of the distribution.
To assess the need to incorporate control variables into the comparisons between 
dialysis groups several preliminary analyses were conducted. Independent t tests, 
analyses of variance (ANOVAs) and Chi square test or Fisher’s exact as appropriate 
(for categorical data) were performed to compare the dialysis groups on 
sociodemographic and clinical characteristics. Univariate statistics (Pearson’s or 
Spearman’s correlation coefficients as appropriate) were then used to examine
1 Exact p values are reported. If p was less than .000 then this was reported as = .0001
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relationships between casemix differences and other background variables and NP 
scores at Time 1 (Tl: pre-dialysis) and Time 2 (T2: 24-hours post-dialysis) as well as 
changes in the dependent variables (NP scores) over time. If any of these background 
variables differed significantly among dialysis groups (at p  < .05) and were significantly 
associated with the outcome in question, they were statistically controlled in subsequent 
comparative analyses.
The study had a prospective 2 (treatment as the between-subjects factor; HD vs. PD) by 
2 (time as the within subjects factor; T l and T2 assessment) design. A series of 2 x 2 
repeated measures analyses of (co)variance (ANCOVAs) were performed to examine 
acute neuropsychological, biochemical and mood changes in HD and PD patients over 
24 hours. Covariates used included anxiety and fatigue (for NP analyses only) and other 
variables were included according to the criteria described above. Significant main and 
treatment-by-time interaction effects were followed up with within-group repeated 
measures ANCOVAs run separately for the HD and PD group and between-groups 
ANCOVAs at T l and T2 assessments.
In the 2 x 2 repeated measures ANCOVAs to compare the two dialysis groups over 
time, p  values, uncorrected for multiple comparisons, were considered significant if p < 
.05. It is recognised that this would result in an increase in the Type I error rate. 
However, controlling for the Type I error rate by applying the Bonferroni adjustment 
would have resulted in a higher Type II error rate. This might have yielded an 
acceptable power for the main effects, but not for the interaction effect, which was of 
specific interest in this study. Subsequent post-hoc tests were controlled for overall 
Type I error by virtue of being conditional on the significance of the omnibus 
ANCOVA test, and therefore were not further controlled for multiple comparisons.
1.1.a Absolute NP scores
The independent contributions of mood, biochemical, clinical, and sociodemographic 
measures to cognitive function were assessed using a series of hierarchical multiple 
linear regressions. This was preferred over simple correlations to reduce the number of 
analyses conducted and in order to demonstrate that any contributions of mood and
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biochemical factors were independent of the effects of age and education on 
neuropsychological performance.
Predictors were entered in four blocks as follows: sociodemographic (age, education) 
and clinical (ESRD-SI, diabetic status, Kt/V), mood variables (CDI, STAI, PANAS) 
and biochemical measures. To determine entry into the models the stepwise method was 
used within blocks to avoid the problem of multicollinearity among variables 
(Tabachnick and Fidell, 1989). Only the variables bearing significant associations with 
the specific NP outcome at a criterion of p < .05 were included in the regressions. In 
addition to providing R2, adjusted R2, and standardised beta coefficients for significant 
associations, a variance-based measure of effect size was calculated as follows/2 = AR21 
(1- R2Totai)- Thus /  is defined as the ratio of additional variance explained by a predictor 
(or a regression model step) to the amount of variance that remains unexplained in the 
dependent variable (Cohen & Cohen, 1983). Small, medium and large effects 
correspond to /2 values of 0.06, 0.56 and 1.56 respectively.
Two competing hypotheses, i.e. whether mood or biochemistry are driving NP 
performance were examined by altering the order of entry for the last two blocks in the 
regression analyses. Specifically, to test the biochemistry hypothesis, biochemical 
variables were entered last in the regression equations after demographic, clinical and 
mood variables so as to examine the degree of improvement in prediction when 
biochemistry is added. The same approach was taken to assess the impact of mood 
variables after controlling for biochemistry. To test the mood hypothesis, mood 
variables were entered last preceded by biochemistry. In these last regressions to 
minimise the cases to number of variables ratio only the biochemical indices identified 
as significant predictors in the earlier set of regressions were included
1.1.b Change NP scores
Finally the relationship between changes in biochemistry, mood and NP performance 
was explored in HD and PD patients controlling for baseline levels. There are several 
methods to calculate change scores: simple delta-change scores (subtracting T l from 
T2) and residualised change scores. In this study we opted for residualised change
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scores for all neuropsychological (NP), biochemical, and mood measures in order to 
control more strictly for baseline covariation.
Residualised change scores were computed as follows: first, T2 scores were regressed 
onto corresponding baseline (Tl) scores to derive covariance (i.e. baseline) adjusted 
scores. Residualised change scores were then obtained by adding the individual 
unstandardised regression coefficients to respective T2 group means. This method is 
preferable to the use of simple change (delta) scores (Llabre et al., 1991).
Hierarchical multiple regressions, as described above, were then conducted in which 
mood and biochemistry change scores were regressed on NP change scores controlling 
for sociodemographic and clinical variables. As above, two sets of linear regressions 
were performed in which mood or biochemistry preceded each other in the last two 
steps of the analyses so as to evaluate their relative importance. This analysis was 
possible only for a subset of HD {n = 54) and PD patients (n = 54) for whom two 
suitable blood samples were obtained at the time of the assessments.
1.2 Sample characteristics
As there were no significant differences in any of the NP scores between the two forms 
of HD (hospital and home), nor between the two forms of PD (CAPD and APD) the 
sample was collapsed to form a single HD group (n = 75) and a single PD group (n = 
68) (see Appendix F).
Baseline characteristics of the resulting two groups including sociodemographic factors 
and clinical presentation of the patients are shown in Table 6.1.
The only sociodemographic factor differentiating between the two groups was gender 
with significantly more female participants on HD than PD (%2(145) = 4.25, p  = .05). 
There were also significant group differences in four medical variables. Significantly 
more PD patients had diabetes relative to HD patients (%2(145) = 10.27, p  = .001).
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Table 6.1: HD and PD participants’ sociodemographic and clinical characteristics
8 II PD {n = 68)
M SD % M SD % T J?
Age (years) 48.22 14.92 52.26 13.26 -1.7
Gender (% female) 42.9 26.5 4.25*
Ethnicity (% white) 68.8 58.8 3.29
% Married 57.1 70.1 2.81
% Employed 36.4 35.13 0.17
Income .002
£0-£ 10,000 58.4 58.8
£10,001-20,000 27.3 22.1
£20,001-30,001 7.8 11.8
£30,001- above 6.5 7.4
Education (years) 12.26 5.69 12.49 5.11 -.26
Time DL (months) 52.41 55.03 20.75 22.37 4 63****
Time RRT (months) 96.35 83.18 30.26 40.82 6.18****
ESRD severity 10.57 9.13 11.81 9.87 -.79
Kt/Va 1.69 .24 1.94 .42 .03
URR .65 .07 - -
% previous TX 94.1 50.6 33.1**
% on TX list 89.6 89.7 .00
% Diabetes 7.8 27.9 10.2**
% Hypertension 94.8 88.2 2.05
% Heart Disease 39 41.2 .073
Primary cause ESRD
% GN 23.4 2.9
% APKD 13 14.7 .09
% Reflux 9.1 10.3 .06
% Diabetes 6.5 16.2 3.44
% hypertension 5.2 16.2 3.58
* p <.05. ** p <.01. *** p <.001. **** p <.0001
Note. HD = haemodialysis; PD = peritoneal dialysis; DL = dialysis; RRT = renal replacement 
therapy; Kt/V = K is defined as the total urea clearance rate, t represents the number of minutes 
of dialysis and V is the urea distribution within the patient; URR = urea reduction ratio; GN = 
Glumeronephritis; APKD = Adult Polycystic Kidney Disease; ESRD = End Stage Renal 
Disease; URR = urea reduction ratio; TX = transplant
a = absolute values not directly comparable between HD and PD patients. b = Fisher exact test
PD patients were found to have been on current dialysis treatment (t(140) = 4.50, 
p  = .0001) and on renal replacement therapy in general (RRT) (t(143) = 6.08,/? = .0001) 
for less time compared to HD patients. HD patients were more likely to have 
glumeronephritis as their primary cause of ESRD relative to PD participants (Fisher’s 
exact Test p  = .0001). Some of these differences were anticipated as PD is often
172
regarded as the preferred initial modality for diabetic ESRD patients (Blake, 2001; 
Pasadakis & Oreopoulos, 2001).
Mean Kt/V levels indicated adequate dialysis levels for both dialysis groups and 
inspection of individual levels showed that the vast majority of the patients (86%, n = 
128) had Kt/V values equal or greater than the recommended standards. Seventeen 
patients (11.2%) did not have Kt/V measurements within the 6-month period (n = 7 HD 
and n = 10 PD patients). However an alternative measure for the HD patients (urea 
reduction ratio) indicated adequate dialysis and the Kt/V measure for the PD patients 
outside of the 6 months period also indicated adequate dialysis. The percentage of PD 
and HD patients for whom treatment was designated adequate was not associated with 
dialysis treatment (%2(135) = .338, p  = .56) although the numbers of non-adequately 
dialysed patients were extremely low.
Likewise, there were no significant differences in Kt/V levels achieved in the two 
groups (analysis performed on standardised z-scores), suggesting that HD and PD 
patients had comparably efficient dialysis delivery. Standardised z-scores were used as 
the absolute Kt/V scores in HD and PD are not directly comparable, because of the 
differences between continuous and intermittent removal in terms of the prevailing 
extracellular concentration of uraemic solutes (Mallick et al., 1998).
1.3 Absolute NP performance
The absolute NP scores of the HD and the PD patients in the two assessments are 
reported in Table 6.2.
A total NP score at T l and T2 assessment (NP-TO) was computed by adding the 
standard z-scores on the 10 NP indices. Scores in TMT-A, TMT-B, GP-DOM, GP- 
NDOM, BVRT-C and BVRT-E were reversed so higher scores in those individual tests 
and hence the derived summary index (NP-TO) signify better or more efficient 
cognitive functioning.
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Table 6.2: NP scores at T l and T2 in HD and PD
HD PD
Time 1 Time 2 Time 1 Time 2
TMT-Aa M 53.73 45.13 50.49 46.60
SD 37.32 32.34 25.98 26.35
TMT-Ba M 97.92 90.02 99.32 99.96
SD 51.72 51.72 44.74 46.74
SDMT-Wb M 40.92 47.10 41.31 44.73
SD 12.96 15.20 12.66 14.56
SDM T-Ob M 45.82 52.10 44.91 48.61
SD 14.22 16.58 13.24 15.87
RAVLT-T b (1-5) M 39.36 43.53 38.65 39.16
SD 11.94 11.78 9.20 8.77
RAVLT-1 trial M 5.14 5.79 4.85 5.11
SD 1.73 1.95 1.37 1.43
RAVLT-2 trial M 7.13 7.92 6.99 7.08
SD 2.39 2.45 1.86 1.78
RAVLT-3 trial M 8.14 8.99 8.07 8.34
SD 2.72 2.80 2.25 1.93
RAVLT-4 trial M 9.19 10.13 9.09 8.89
SD 3.11 2.84 2.55 2.37
RAVLT-5 trial M 9.75 10.70 9.65 9.73
SD 3.22 3.06 2.57 2.50
RAVLT-D (7-5) M 2.35 2.64 2.75 3.03
SD 1.70 2.09 2.20 1.61
BVRT-Cb M 5.08 5.97 4.75 4.97
SD 2.30 2.31 1.98 1.74
BVRT-EC M 8.64 6.61 8.47 7.82
SD 5.46 5.30 4.51 3.85
GP-DOMa M 88.66 85.12 93.65 91.95
SD 29.78 28.81 34.28 32.16
GP-NDOM a M 100.19 95.40 104.61 103.25
SD 34.59 34.31 43.64 39.71
NP-TO d M .291 1.09 -.333 -1.28
SD 7.94 7.89 6.58 6.31
Note. Tl = time 1 assessment; T2 = time 2 assessment; HD = haemodialysis; PD = peritoneal
dialysis; TMT-A = trail making test part A; TMT-B = trail making test part B; SDMT-W = 
symbol digit modality test written administration; SDMT-0 = symbol digit modality test oral 
administration; RAVLT-T = Rey Auditory Verbal Learning Test total word recall at trial 1 to 5; 
RAVLT-D = Rey Auditory Verbal Learning Test drop in retention from trial 5 to 7; BVRT-C = 
Benton Visual Retention Test number of correct reproductions; BVRT-E = Benton Visual 
Retention Test number of reproduction errors; GP-DOM = Grooved Pegboard dominant hand; 
GP-NDOM = Grooved Pegboard non dominant hand; NP-TO = total NP performance score 
a = Time to completion in seconds. b = number correct.c = number of errors. d = total of the 10 
NP indices (z-scores)
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1.4 NP performance of dialysis patients relative to normative data
To examine whether the NP performance of HD and PD groups was different to healthy 
controls, patients’ performance was compared to available age-related normative data 
and test norms (Lezak, 1995; Mitrushina et a l , 1999).
1.4.a Definition of NP impairment
Available norms that most closely matched the characteristics of the study sample as 
well as administration and scoring procedures were identified (Mitrushina et al., 1999).
The relative performance of dialysis participants compared to the normative group was 
evaluated. NP impairments were defined as follows (for detailed description see 
Appendix G). It should be stressed these criteria do not correspond to those set for 
clinical neuropsychological diagnoses/assessments and for the detection of clinically 
significant NP deficits.
■ Cut-off score of one or more Standard Deviations (SD) below the respective age 
norm (SDMT-W; SDMT-O; GP-DOM; GP-NDOM). In percentile ranking terms 
this would correspond to scores lower than the 16th percentile (low average 
performance). In normal distribution one would expect 15.86% scores being 1 SD or 
more below norms. The purpose of this criterion classification was to determine if 
the observed frequency of NP scores falling more than 1 SD below norms in dialysis 
patients exceeds 15.86%, i.e. that expected in normal distribution.
■ Score below the 25th percentile (TMT-A; TMT-B) indicative of borderline to low 
average performance.
■ Score, which is 3 points below the expected score in BVRT-C (suggestive of deficit) 
or in a more conservative fashion an obtained BVRT-C score 4 points lower than 
expected (strong indication of impairment).
■ In BVRT-E a score 4 points above the expected was considered as suggestive of 
impairment and in a similar fashion, more conservative classification was also 
made, with a BVRT-E score 5 points above expected considered a strong indication 
of impairment.
■ Total cognitive dysfunction was defined as the number of NP test scores (TMT-A; 
TMT-B; SDMT-W; SDMT-O; RAVLT-T; BVRT-C; BVRT-E; GP-DOM; GP-
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NDOM) in the impaired range of standard norms. This could range from 0 to 9, with 
higher scores signifying NP impairments in more areas of cognition.
1.4.b Prevalence of NP impairments
Having agreed on what constitutes impaired NP performance for each NP test used, 
normative comparisons were undertaken using two methods, i.e. group 
level/performance and individual level/performance:
i. Group based comparisons
These were performed by comparing patient group mean scores to test norms to 
determine whether dialysis patients as a group performed within or below normal 
population (see Appendix G). Consistent with previous research dialysis groups’ mean 
age was used to select the appropriate age brackets for these normative comparisons. 
These group comparisons showed that the mean scores of both dialysis groups at T1 and 
T2 were within normal range on the following NP tests (TMT-B, SDMT-W, SDMT-O, 
BVRT-C) whereas mean group scores in the remaining tests (TMT-A; GP-DOM; GP- 
NDOM; BVRT-E) across the two assessments indicated mild to moderately impaired 
NP performance.
Classification analysis of the type of errors in the visual memory task (BVRT) revealed 
that distortion errors were by far the commonest in both NP assessments (see Table 6.3).
Table 6.3: BVRT errors at T1 and T2 assessment in dialysis patients
Time 1 Time 2
BVRT -  errors % Mean (Sd) Range % Mean (Sd) Range
Distortion 93.8 3.91 (2.92) 0-15 8 6 .6 3.87 (2.83) 0-13
Rotation 81.9 1.52(1.18) 0-5 76.2 1.09(1.1) 0-5
Misplacement 64.1 1.10(1.08) 0-5 61.4 .85 (1.05) 0-4
Omission/addition 55.5 1.11 (1.69) 0-7 33.8 .63(1.11) 0-5
Preservation 36.6 .48 (.72) 0-3 38.7 .47 (.69) 0-4
Size 24.8 .39 (.93) 0 -8 17.6 .28 (.76) 0-5
Note: BVRT = Benton Visual Retention Test
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Normative comparisons with respect to RAVLT were complicated by the limitations of 
appropriate normative databases. On one hand, large normative databases (e.g. Query & 
Megran, 1983) were inappropriate for comparisons to our study sample, as there were 
based on mainly older male subjects. The most suitable normative data were stratified 
by gender and had relatively small sizes in resulting age/gender cells (Gefen e t al., 
1990). For study purposes this smaller size normative database was preferred as the 
sociodemographic characteristics of the normative sample resembled more closely those 
of the study sample and because the same scoring method was applied.
Comparisons to these norms indicated that dialysis patients’ mean total verbal recall 
scores were borderlining those of normal population.
Table 6.4: Frequencies of dialysis patients below NP tests norms
Time 1 Time 2
All DL HD PD All DL HD PD
%  (;n) % (n) %  (n ) % (n ) %  (n ) %  (n )
TMT-A 39.3% (57) 39% (30) 39.7% (27) 30.5% (43) 29.9% (23) 31.3% (20)
TMT-B 16.6% (24) 14.3% (11) 19.1% (13) 19.1% (27) 18.2% (14) 20.3% (13)
SDMT-W 42.1% (61) 42.9% (33) 41.2% (28) 29.8% (42) 22.1% (17) 39.1% (25)
SDMT-O 46.2% (67) 41.6% (32) 51.5% (35) 34% (48) 27.3% (21) 42.2% (27)
RAVLT-T 53.8% (78) 49.4% (38) 58.8% (40) 44.8% (65) 37.7% (29) 52.9% (36)
BVRT-C 80% (116) 75.3% (58) 85.3% (10) 64.8% (92) 51.9% (40) 80% (52)
BVRT-E 80.7% (117) 79.2% (61) 82.4% (56) 67.6% (96) 55.8% (44) 81.5% (56)
GP-DOM 43.1% (62) 42.1% (32) 44.1% (30) 39.6% (55) 30.3% (23) 50.8% (32)
GP-NDOM 50% (72) 52.6% (40) 47.1% (32) 44.6% (62) 39.5% (30) 50.8% (32)
Note. DL = dialysis; HD = haemodialysis; PD = peritoneal dialysis; TMT-A = trail making test 
part A; TMT-B = trail making test part B; SDMT-W = symbol digit modality test written 
administration; SDMT-O = symbol digit modality test oral administration; RAVLT-T = Rey 
Auditory Verbal Learning Test total word recall at trial 1 to 5; RAVLT-D = Rey Auditory 
Verbal Learning Test drop in retention from trial 5 to 7; BVRT-C = Benton Visual Retention 
Test number of correct reproductions; BVRT-E = Benton Visual Retention Test number of 
reproduction errors; GP-DOM  = Grooved Pegboard dominant hand; GP-NDOM  = Grooved 
Pegboard non dominant hand
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There was a great variability in individual performance irrespective of dialysis mode. 
The observed SDs in all NP scores are large, clearly indicating large individual 
differences in NP performance between patients on the same dialysis treatment. The 
heterogeneity of the dialysis sample (for example, they range in age from 20-81 years) 
may have contributed to the variability in the NP scores (see Table 6.2) and the 
‘inflated’ NP impairment rates (see Table 6.4).
Group-based comparisons overlook individual differences, thereby producing less 
sensitive and accurate normative comparisons. For instance, given the wide age range in 
the dialysis sample (20-81), group based comparisons might have created unfavourable 
comparisons for the more elderly participants. In the light of these shortcomings, 
evaluation of individual rather than group NP scores was deemed more appropriate.
ii. Individual based comparisons
This strategy involved evaluating individual rather than group performance against his 
or her respective age and gender (when available) norms to determine presence or not of 
impairment and then comparing the prevalence of NP impairments between groups and 
across the two assessments. This method enabled individuals performing at a level 
below norms, to be identified. The same criteria (described in section 1.4.a) to define 
NP impairments were used (see Appendix G).
Inspection of the individual scores relative to reference age norms showed that some 
patients had scores signifying pronounced NP impairments despite groups’ mean scores 
being within normal range (see Table 6.5).
In the combined dialysis sample, more than one third of patients (32.4% - 49.3%) 
performed at least 1 SD lower than norms described above at T1 assessment (SDMT-W; 
SDMT-O; TMT-A; GP-DOM; GP-NDOM; RAVLT-T). Individual T1 BVRT-C and 
BVRT-E scores for 21.4% and 37.9% of dialysis patients respectively ‘strongly’ 
indicated an impairment of visual memory. A lower but still considerable percentage 
(13.5% - 41%) of dialysis patients remained in the impaired NP score range at T2 
assessment (see Table 6.5).
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Table 6.5: Individual classification: Prevalence of NP impairments (% of patients 
performing below their respective norms)
ALL Dialysis
% Impairments (N)
HD PD
% Impairments (N) % Impairments (N )
TMT-A
Time 1 35.9% (52) 39% (30) 32.4% (22)
Time 2 23.4% (43) 23.4% (18) 23.4% (15)
TMT-B
Time 1 15.2% (22) 16.9% (13) 13.2% (9)
Time 2 13.5% (19) 13% (10) 13.2% (9)
SDMT-W
Time 1 32.4% (47) 32.5% (25) 32.4% (22)
Time 2 28.4% (40) 24.7% (19) 32.8% (21)
SDMT-O
Time 1 41.4% (60) 37.7% (29) 45.6% (31)
Time 2 30.5% (43) 26% (20) 35.9% (23)
RAVLT-T
Time 1 47.6% (69) 50.6% (39) 35.1% (27)
Time 2 34.8% (49) 44.1% (30) 34.4% (22)
BVRT-C
Time 1 36.6% (53)a/21.4%(31)b 31.2% (24)718.2%(14)b 42.6% (29)725% (17)b
Time 2 27.5% (39)713.8% (20)b 28.6% (22)722.1% (17)d 33.8% (22)715.4% (10)b
BVRT-E
Time 1 47.6% (69)737.9% (55)d 46.8% (36)c / 39% (30)d 48.5% (33)736.8% (25)d
Time 2 32.4% (46)724.6% (35)d 28.6% (22)722.1% (17)d 36.9% (24)727.7% (18)d
GP-DOM
Time 1 41.7% (60) 40.8% (31) 42.6% (29)
Time 2 37.4% (52) 32.9% (25) 42.9% (27)
GP-NDOM
Time 1 49.3% (71) 51.3% (39) 47.1% (32)
Time 2 41% (57) 35.5% (27) 47.6% (30)
Mean SD Mean SD Mean SD
Count of NP Impairments
Time 1 3.22 2.68 3.25 2.83 3.19 2.52
Time 2 2.40 2.53 2.25 2.65 2.57 2.03
a o __ ________ i ________ . b ,,a = 3 or more below expected score for number correct. b = 4 or more lower than expected
scores for number correct. c = 4 or more errors than expected no rm s.d = 5 or more errors than 
expected norms
Whereas the percentages of NP impairment in the region of 15% to 20% (e.g. TMT-B) 
do not raise concern as a similar percentage of general population would be expected to 
perform similarly (based on a normal distribution), this clearly does not apply to some 
NP tests, i.e. GP-DOM, GP-NDOM, SDMT-O and RAVLT-T. The prevalence of NP
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impairments in these tests at T1 and T2 far exceeded those expected in a normal 
population.
Me Nemar change tests (using the combined dialysis sample) showed significant 
changes in the presence of NP impairments from T1 to T2 in all NP tests except for 
TMT-B, SDMT-W, and GP DOM. Overall results indicated the observed frequency of 
NP impairments was significantly lower at T2 compared to T l: RAVLT-T (%2(143) =
11.115, p  = .001); GP-NDOM (bionomial distribution used exact p  = .008); SDMT-O 
(bionomial distribution used exact p = 000); TMT-A (bionomial distribution used, exact 
p = .000); BVRT-E (%2(143) = 8.028, p  = .005); and BVRT-C (bionomial distribution 
used exact p  = .035).
iii. Dialysis treatment (HD vs. PD) and prevalence ofNP impairments
Chi-square analysis indicated little association between the prevalence of NP 
impairments and dialysis modality. The percentage of patients falling into the impaired 
range of NP tests was roughly equivalent in the PD and HD groups at both assessments. 
Similar results were found with regard to number of NP impairments across NP tests. 
There were no significant group differences in the count of NP impairments at T l (U = 
2573, p  =.859) nor T2 (U = 2322, p  = .231) between HD and PD patients.
Repeated measures ANCOVAs (controlling for ESRD severity, diabetes, and dialysis 
duration) to examine changes in the count of NP impairments between HD and PD 
patients showed only a significant time effect (F(4, 141) = 48.831, p  = .0001). This 
indicated that the count of NP impairments decreased significantly for T l to T2 in the 
combined dialysis sample. The group effect was not significant hence suggesting that 
the count of NP impairments when averaged across time was equivalent in the two 
dialysis groups. The time by treatment interaction effect approached but did not reach 
significance (F(4, 141) = 3.250, p  =.074).
Me Nemar tests were performed to examine changes in the prevalence of NP 
impairments across the two assessments separately in the two groups. These analyses 
indicated marked changes in the HD but not the PD group.
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In HD patients, the observed frequency of NP impairments changed significantly across 
the two assessments (i.e. for immediately pre- to 24 hours post-dialysis): TMT-A (p = 
.0001); SDMT-O (p = .004); RAVLT-T (p = .002); BVRT-E (p = .002); and GP- 
NDOM (p = .0001). Changes in GP-DOM approached but did not reach significance (p 
= .070). In contrast, the frequency of NP deficits in the PD groups remained unchanged 
from T l to T2 with only SDMT-O being significant (p = .021).
1.5 Sociodemographic, medical variables and NP performance
1.5.a Absolute NP scores
The associations between sociodemographic, medical and absolute NP scores were 
examined with correlations, ANOVAs or their non-parametric equivalents as 
appropriate. These were performed on the combined dialysis sample, collapsing across 
PD and HD groups. This analysis was also used to identify which of the casemix 
differences might require statistical control in subsequent comparative analyses.
First the associations between casemix differences (diabetes, time on dialysis, gender) 
and NP scores were examined. Diabetes was strongly associated with all NP scores. 
ANOVA comparisons indicated that diabetic patients performed significantly worse 
than non-diabetic patients in all NP tests across the two assessments except for BVRT. 
These differences in all NP tests (except for RAVLT) remained significant even after 
the effects of age and education were partialled out using ANCOVAs (see Appendix H).
Gender, time spent on dialysis (either on current dialysis treatment or RRT in general) 
and primary kidney disease diagnosis had no significant relationship with any of the NP 
scores (data not shown).
The associations of various medical (Kt/V; ESRD severity) and demographic variables 
(e.g. age, employment status) with NP outcomes were also examined. Several 
significant correlations emerged (see Table 6.6).
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Table 6.6: Correlations between sociodemographic, medical variables and absolute NP
scores in the combined dialysis sample
Age Educationt Kt/V ESRD S it
TMT-A T1
T2
426****
524****
-.276*** 
- 309****
- 31****
-.279**
4 i i****
461****
TMT-B T1
T2
450****
513****
-.230** 
- 275***
-.267**
-.295***
332****
389****
SDMT-W T1
T2
- 499****
_ 494****
328****
343****
- 499**** 
_ 494****
- 411****
- 377****
SDMT-O T1
T2
-.525**** 
- 512****
345****
329****
- 525**** 
-.512****
-.458**** 
- 406****
RAVLT-T T1
T2
_ 448****
_ 407****
325****
.350****
.195* 
.148 ns
-.341**** 
- 308****
RAVLT-D T1
T2
.129 ns 
.104 ns
-.100 ns 
-.053 ns
-.005 ns 
.112 ns
.046 ns 
.067 ns
GP-DOMt T1
T2
589****
.562****
-.223**
-.211*
-.271** 
_ 34****
.453****
403****
GP-NDOM T1
T2
522****
.542****
-.285**
318****
-.224*
-.296***
.485****
.452****
BVRT-C+ T1
T2
- 367**** 
_ 449****
323****
.335****
.228**
214**
- 332****
- 283***
BVRT-E+ T1
T2
377****
473****
- 392****
- 379****
-.261**
-.245**
332****
.355****
+ Spearman’s correlations
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
Increasing age and ESRD severity were associated with more compromised cognitive 
functioning in all NP scores across the two assessments. The observed correlation 
coefficients ranged from r = .367 to r = .589 for age and from r = .224 to r = .499 for 
ESRD severity indicating moderate-sized correlations. Analysis of the associations 
between dialysis adequacy (z-scores) and NP performance at T l showed that higher 
Kt/V and values were associated with better NP performance (see Table 6.6).
ANCOVA comparisons between employed vs. non employed dialysis patients 
(covariates used: age, ESRD SI, and education) revealed that patients in employment 
performed significantly better in all NP tests (except RAVLT-T and RAVLT-D) than 
non-employed patients even after partialling out the effects of age, education and ESRD 
severity. Because the variables found to be significant correlates (age, education, 
ESRD-SI, dialysis duration, employment status, Kt/V) were not confounded with 
treatment status, these additional variables were not controlled for in subsequent 
comparative analyses.
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1.5.b Residualised change NP scores
In contrast to the observed associations with absolute NP scores, only a handful of the 
demographic and clinical variables were significantly correlated with acute change in 
NP scores.
Age and ESRD severity were inversely related to NP improvements whereas education 
was positively correlated with NP improvements. Age correlated with residualised 
change scores in TMT-A (r = .281, p  = .001); TMT-B (r = .254, p  = .002); BVRT-E (r = 
.286, p  = .001) and BVRT-C (r = -.305, p  = .0001). Education on the other hand 
correlated with RAVLT-T (rs = .178, p  = .035) and TMT-A (rs = -.246, p -  .003). 
Finally significant associations were found between ESRD severity and TMT-A (rs = 
.323, p  = .0001); TMT-B (rs = .306, p  = .0001) and BVRT-E (rs = .173, p  = .039).
1.6 Mood differences and relation to NP performance in Dialysis
Table 6.7 shows the correlations among the mood measures used in this study.
Table 6.7: Correlations between mood measures
BDI CDI STAI 1 NA I t PA 1 STAI 2 t NA 2t
BDI
CDI 92***
STAI 1 51***
NA I t .55*** 52*** 54***
PA 1 _ 5^*** - 53*** -.48*** _ 48***
STAI 2 1 52*** 52*** .65*** 51*** -.42***
NA 2 1 42*** 29*** 4g*** .66*** _ 27*** 22***
PA 2 _ 4 7 *** _ 45 *** - 38*** _ 27*** 54 *** _ 4 4 *** - 33 ***
+ = Spearman’s correlations
Note. BDI = beck depression inventory total score; CDI = cognitive depression index; ST A I1= 
Spielberger state anxiety at time 1; NA 1 = negative affect at time 1; PA 2 = positive affect at 
timel; STAI 2 = Spielberger State anxiety at Time 2; NA 2 = negative affect at time 2; PA 2 = 
positive affect at time 2.
*** p <.000
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Results indicated that all negative mood measures were significantly interrelated. 
Depression indices (BDI and CDI) were highly intercorrelated (r = .93, p  = .0001) and 
correlated significantly with all mood measures at both time points. All other 
correlations between mood measures (at each time point separately) were below .55 
indicating less than 30% shared variance and some degree of independence between the 
scores. Significant correlations were also noted between T l and T2 levels, with anxiety 
at T l for instance being correlated with T2 anxiety or positive affect at T l being 
correlated with T2 positive affect (see Table 6.7).
1.6.a State anxiety
i. Group differences
Table 6.8: State anxiety at T l and T2 in HD, PD and the combined dialysis
Time 1 Time 2
Mean SD Range Mean SD Range
HD 10.61 3.92 6 - 2 4 8.90 2.35 6 - 1 5
PD 11.46 4.06 6 - 2 4 10.76 3.45 6 -2 1
All dialysis 11.01 3.99 6 - 2 4 9.76 3.04 6 -2 1
Repeated measures ANCOVA on state anxiety (covarying for gender, time on dialysis 
and diabetic status) revealed a significant main effect for treatment (F(4, 138) = 4.71, p  
= .032), with HD patients reporting less anxiety than PD patients when averaged, and a 
significant main effect of time (F(4, 138) = 22.69, p  = .0001). Anxiety reports were 
reduced in both HD and PD patients from T l to T2.
ii. Relationship to NP functioning
State anxiety correlated with all the NP measures at T l (see Table 6.9). The correlation 
coefficients for the combined sample ranged from .22 to .27. Similar significant 
correlations were noted between T2 anxiety and T2 NP scores although the strength of 
correlations was somewhat lower than those of T l and no correlations were found for 
either RAVLT scores (see Table 6.9).
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Table 6.9: Correlations between state anxiety and NP scores at T l and T2 in the
combined dialysis sample
TIME 1 TIME 2
NP tests STAI 1 NP tests STAI 2+
TMT-A 1 .230** TMT-A2 .267***
TMT-B 1 .215** TMT-B 2 .167*
SDMT-W 1 -.260** SDMT-W2 -.182*
SDMT-O 1 -.286**** SDM T-02 -.226**
RAVLT-T 1 -.259* RAVLT-T2 -.114
RAVLT-D I t .1 2 2 RAVLT-D2+ -.008
GP-DOM 1+ .268*** GP-DOM2+ .232**
GP-NDOM 1 .243** GP-NDOM2 .2 1 1 *
BVRT-C 1+ -.223** BVRT-C2+ 2 7 3 ***
BVRT-E1+ .219** BVRT-E2+ _ 3 4 0 ****
NP-TOTAL1 287**** NP-TOTAL2 _ 264**
t  Spearman’s correlation coefficient 
* p <.05. ** p < 01. *** p <.001. **** p <.0001.
1.6.a Positive Affect (PNS-PA)
i. Group differences
Table 6.10: Positive affect at T l and T2 assessment in HD, PD, and combined dialysis
Time 1 Time 2
Mean______ SD______Range_____mean______ SD______Range
HD 24.48 8.13 1 0 -4 1 29.17 7.-2 1 1 -4 2
PD 22.97 6.44 1 1 -3 7 23.41 7.18 1 1 -4 0
All dialysis 23.77 7.40 1 0 -4 1 26.54 7.63 1 1 -4 2
Repeated measures ANCOVA (covarying for gender, time on dialysis, and diabetic 
status) was performed to examine changes in positive affect between HD and PD 
patients. This yielded a significant main effect for treatment group (7^(4, 137) = 6.224, p  
= .014), time (F(4, 137) = 29.978, p  =.001) and a significant treatment-by-time 
interaction effect (7X4, 137) = 9.329, p  = .003). Post-hoc tests (ANCOVAs) showed that 
positive affect levels increased significantly from pre- to 24-hours post-dialysis (7X3, 
73) = 43.8, p -  .0001) in HD patients. In contrast, positive affect reports remained 
unchanged in the PD group across the two assessments (7X3, 61) = .529, p  -  .47).
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B etw een groups post-hoc com parisons ind icated  that H D  patien ts reported  significantly  
h igher positive affect at T2 than PD patients (F (4, 137) = 13.28, p  = .001). No 
significant group d ifferences were ev ident at T l  positive affect reports (F(4, 140) = 
.927, p  = .337).
ii. R ela tionship  to N P  fu n c tio n in g
H igher levels o f positive affect correla ted  with m ore efficient cogn itive  function ing  at 
T l  in all N P tests (rs =.25 to r = .32) except for TM T-B  and R A V L T -D . M odera te-sized  
correla tions, in the pred icted  direction w ere also observed  fo r T2 N P scores with 
coefficien ts ranging from  r = .27 to r = .35 (see T able 6.11).
T able 6.11: C orrelations betw een positive affect and N P scores at T l  and T 2 in the
com bined  dialysis sam ple
TIME 1 TIME 2
NP tests PNS-PA 1 NP tests PNS-PA 2
TM T -A  1 307**** T M T -A 2 - 316****
TM T-B  1 -.145 T M T -B 2 273***
SD M T -W  1 .306**** SD M T -W 2 354****
SD M T -O  1 325**** S D M T -0 2 3 io****
R A V L T -T  1 279*** R A V L T -T 2 .350****
R A V L T -D  1+ -.125 R A V L T -D 2 t -.045
G P-D O M  I t -.267*** G P -D O M 2 t -.282***
G P-N D O M  1 -.230** G P-N D O M 2 - 274***
B V R T-C  I t .255** B V R T -C 2 t 273***
B V R T -E  I t -.276*** B V R T -E 2 t - 340****
N P -T O T A L 1 3 ^3**** N P -T O T A L 2 333****
fote: PNS-PA = PAN AS positive affect
t  Spearman’s correlation coefficient
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
1.6.c N egative A ffect (PN S-N A )
i. G roup differences  
N egative affect reports for the d ialysis groups are presented  in T ab le  6.12 below .
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Table 6.12: Negative Affect at T l and T2 in HD, PD and combined dialysis
T l T2
Mean SD Range Mean SD Range
HD 14.61 5.24 1 0 - 3 9 12.45 2.83 1 0 -2 3
PD 15.01 5.07 1 0 -3 7 14.08 4.55 1 0 -3 8
All dialysis 14.80 5.15 1 0 -3 9 13.20 3.79 1 0 -3 8
Repeated measures ANCOVA on negative affect (covarying for gender, time spent on 
dialysis and diabetic status) indicated only a significant effect for time (F(3, 137) = 
30.572,/? = .001) with dialysis participants reporting significantly lower negative affect 
at T2 relative to T l levels. The treatment effect was not significant suggesting that both 
PD and HD groups had equivalent levels of negative affect when averaged across the 
two assessments. No significant treatment-by-time interaction effect was found.
ii. Relationship to NP Performance
A similar but reversed pattern of correlations was found between PNS-NA and NP 
performance as found for PNS-PA (see Table 6.13). Correlations coefficients at T l 
indicated weak to moderate-sized correlations, ranging from rs = .21 to rs = .39 (ps < 
.01). Similar order correlations were also observed at T2 with coefficients in the range 
of rs =.19 to rs =.34 (ps <.01).
Table 6.13: Correlations between negative affect and NP scores at T l and T2 in the
combined dialysis sample
TIME 1 TIME 2
NP tests PNS-NA I t NP tests PNS-NA 2 t
TMT-A 1 330**** TMT-A2 2 5 9 **
TMT-B 1 ^26**** TMT-B 2 286***
SDMT-W 1 - 3 5 9 **** SDMT-W2 -.286***
SDMT-O 1 - 384**** SDM T-02 - 341****
RAVLT-T 1 -.215** RAVLT-T2 -.195*
RAVLT-D I t .119 RAVLT-D2t .024
GP-DOM 1+ 2 9 0 **** GP-DOM 2t .208*
GP-NDOM 1 .236** GP-NDOM2 .248**
BVRT-C I t -  27?*** BVRT-C2t -.246**
B V R T -E lt 339**** BVRT-E2t .254**
N P-T O TA L  1 - 398**** NP -TOTAL2 - 330****
t  Spearman’s correlation coefficient
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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1.6.C Depression (BDI; CDI)
i. Group differences
None of the depression scores (BDI nor CDI) were significantly different between HD 
(;mean BDI = 10.96, SD = 7.46; mean CDI = 6.66, SD = 5.38) and PD patients {mean 
BDI = 13.24, SD = 9.09; mean CDI = 8,SD  = 6.19).
The percentage of HD and PD patients scoring below or above the clinical cut-off for 
depression (i.e. a score of 15 on the BDI; Craven et a l, 1988) was also examined. 
Results showed that n = 24 (31.2%) of the HD patients and n = 28 (41.2%) of PD 
patients had BDI scores higher than 15 (total n = 52; 35.9% for combined dialysis 
sample). Chi square analysis showed that there were no significant differences between 
the two dialysis treatments in the prevalence of clinical depression (%2(145) = 1.572, p = 
.21).
In the absence of CDI specific cut-off scores, CDI scores were multiplied by 21/15 and 
a score of 15 was used as the benchmark score to define clinical depression. Chi-square 
analysis indicated no significant group differences/no association between dialysis 
treatment and clinical depression (CDI), with twenty-two (n = 22, 32.4%) of the PD 
patients and sixteen of the HD patients (n = 16, 20.8%) were defined as cases (%2(145) = 
2.501, p  = .114). It is of note however that compared to BDI scores, the CDI clinical 
cut-off evaluation resulted in a lower number of patients defined as cases {total n -  38; 
26.3%).
ii. Relationship to NP performance
(a) Linear relationships between BDI, CDI, and NP scores
The associations between depression scores and NP scores were in the predicted 
direction with higher levels of depressive symptoms being associated with poorer 
cognitive functioning at both assessments (see Table 6.14). Correlation coefficients 
varied from .19 to .29 at T l and from .19 to .34 at T2 for the BDI scores.
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Table 6.14: Correlations between depression scores and NP scores at T l and T2 
in the combined dialysis sample
TIME 1 TIME 2
BDI CDI BDI CDI
TMT Al 972*** .208* TMT A2 300**** .214*
TM TB1 .187* .1 1 2 TM TB2 .207* .131
SDMT W 1 _ 249** -.213** SDMT W2 -.255** -.240**
SD M T O l -.276*** -.235** SDMT 0 2 -.260** -.242 **
RAVLT-T 1 -.138 - .1 0 2 RAVLT-T2 -.186* - .121
RAVLT-D I t .014 -.058 RAVLT-D2t .049 .0 1 0
GP-DOM I t 2 7 4 *** .235** GP-DOM 2t 2 7 3 *** .257**
GP-NDOM 1 320**** .259** GP-NDOM2 3 4 3 **** 283***
B V R T -C lt -  9 7 0 *** -.233** BVRT-C2t -.226** -.223**
B V R T -Elt 2 9 3 **** 263*** BVRT-E2t 9 7 3 *** .269***
NP TOTAL1 - 279**** -.218** NP TOTAL2 - 309**** -.253**
t  Spearman’s correlation coefficient
* p < 05. ** p <.01. *** p <.001. **** p <.0001
Correlation coefficients for CDI were slightly lower than those observed for the 
total depression scores (BDI), ranging from .20 to 26 at T l and from .21 to .28 at T2. 
Partial correlations controlling for ESRD severity showed no significant associations 
between either measure of depression and NP scores (data not shown).
(b) Clinical levels o f  depression (total BDI and CDI score) and NP performance
To determine if patients with higher levels of depression (BDI) demonstrated 
greater NP impairments across the two assessments, the combined dialysis sample was 
split into two groups, below and above a cut-off score of 15. This benchmark score of 
15 has been proposed as the optimal cut-off point for a diagnosis of depression in 
dialysis patients (Craven et al., 1988).
T he non-depression group com prised  94 dialysis patien ts and had a m ean total BDI of 
6 .78 (SD = 3.34, range = 0 -  14). T he depression group (n = 51) had a m ean total BDI 
o f 21.40 (SD = 5.95, range = 14 -  38). T he clinical depression  group had h igher ESRD 
severity  scores (mean -  15.08, SD = 10.44) than the non-depressed  group (mean = 8.97, 
SD  = 8.15; t(8 3 .151) = -3.748, p  = .0001). The prevalence o f d iabetic  patients w as also 
h igher in the clinical depression group (%2(145) = 14.277,/? = .0001).
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Table 6.15: NP scores at T l and T2 between depressed vs. non depressed patients (BDI 
clinical cut-off = 15) in the combined dialysis sample
High BDI Low BDI
Time 1 Time 2 Time 1 Time 2
Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd)
TMT A 61.46 (33.58) 56.55 (33.47) 41.03 (25.85) 40.07 (25.85)
TMT B 109.32 (52.22) 106.17 (53.93) 92.56 (49.95) 88.33 (46.25)
SDMT-W 37.65 (11.13) 41.88 (13.99) 43.03 (12.17) 48.24(14.98
SDMT-O 41.02(13.28) 45.78 (15.82) 47.84(13.43) 53.04 (16.06)
RAVLT-T 37.07 (11.13) 38.75 (10.63) 40.12(10.37) 43.03 (10.50)
RAVLT-D 2.77 (1.59) 2.80 (1.57) 2.41 (2.13) 2.83 (2.05)
BVRT-C 4.56 (2.07) 5.12(1.94) 5.13(2.19) 5.73 (2.19)
BVRT-E 9.38 (4.69) 8.08 (4.70) 8.10(5.16) 6 .6 6  (4.67)
GP-DOM 103.29 (39.93) 100.26 (37.76) 84.08 (24.03) 81.86 (23.64)
GP-NDOM 118.30 (49.72) 114.91 (46.68) 93.22 (27.94) 90.54 (27.31)
NP TOTAL -2.60 (7.73) -2.52 (7.68) 1.39 (6.71) 1.41 (6.71)
Before partialling out the effect of these two casemix differences ANOVA comparisons 
showed that the patients in the clinical depression group performed significantly worse 
than non depressed patients in TMT-A, TMT-B, SDMT-W, SDMT-O, GP-DOM and 
GP-NDOM at both assessments. Adjustments for casemix differences however removed 
these group differences. ANCOVA comparisons (controlling for ESRD-SI and diabetes) 
indicated no significant group differences in any of the T l or T2 NP scores.
1.7 Physical Symptoms, Fatigue and NP performance
As physical symptoms and fatigue either as a result of illness, treatment or both are 
likely to affect NP performance, their temporal course over the 24-hours dialysis cycle 
and their association with concomitant NP changes were also examined.
1.7.a Fatigue
i. Group differences
Descriptive statistics indicated that both HD and PD patients on average, reported mild 
to moderate levels of fatigue immediately prior to each of their NP assessments (see 
Table 6.16).
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Table 6.16: Fatigue levels at T l and T2 in HD, PD, and the combined dialysis sample
Time 1 Time 2
Mean SD Range Mean SD Range
HD 62.27 2 1 .2 1 0 - 1 0 0 63.44 20.82 1 0 - 1 0 0
PD 59.19 22.60 25 -  100 56.85 21.53 7 - 1 0 0
All dialysis 60.83 21.85 0 - 1 0 0 60.40 21.05 7 -1 0 0
Note: Higher scores in fatigue rating scale signify lower fatigue
There were no differences in self-reported fatigue levels between the two dialysis 
groups or across the two assessments. Repeated measures ANCOVA controlling only 
for diabetic status (as gender and time spent on dialysis were not significantly 
associated with fatigue) showed no significant main (i.e. time/treatment) or interaction 
effects.
ii. R ela tionsh ip  to N P  perform ance
Spearman’s correlation analysis showed weak to moderate associations between 
concurrently measured levels of fatigue and cognitive functioning on some tests.
Table 6.17: Correlations between fatigue and NP scores at T l and T2 in the combined
dialysis sample
TIME 1 TIME 2
NP tests Fatigue 7+ NP tests Fatigue 2+
TMT-A 1 -.236** TMT-A2 - 295****
TMT-B 1 -.144 TMT-B2 -.225**
SDMT-W 1 .143 SDMT-W2 .183*
SDMT-O 1 .196* SDM T-02 .170*
RAVLT-T 1 .145 RAVLT-T2 .207*
RAVLT-D 1 -.167* RAVLT-D2+ .043
GP-DOM 1 - 287**** GP-DOM2+ -.262**
GP-NDOM 1 - 3 2 5 * * * * GP-NDOM2 -.313**
BVRT-C 1 h— 00 U\ * BVRT-C2+ - 287***
BVRT-E1 -.212 BVRT-E2+ -.262**
N P -T O T A L 1 2 7 7 *** NP -TOTAL2 2 9 2 * * * *
Note: Higher scores in fatigue rating scale signify lower fatigue 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
t  Spearman’s correlation coefficient
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Increased levels of fatigue (i.e. lower scores) correlated with more compromised 
cognitive functioning as indexed by longer time latencies in the time dependent tests 
(GP, TMT), and less number correct or more errors in other NP tests. The strongest 
correlations were noted between fatigue and NP scores in motor performance tasks such 
as GP.
1.7.b Concurrent symptoms
The effect of concurrent symptomatology on NP performance across the two 
assessments was investigated in two ways:
- in terms of symptoms occurrence, i.e. the number of symptoms patients reported 
immediately before each of the NP testing sessions.
- in a two-group analysis comparing NP scores in dialysis patients who report no 
symptoms/are completely asymptomatic vs. those who report one or more 
symptoms.
i. Group differences
Table 6.18: Concurrent symptoms at T l and T2 in HD, PD, and the combined dialysis
sample
____________Time 1 Time 2____________
Mean SD Range Mean SD Range
HD 2.65 2.62 0 - 1 1  2.25 2.83 0 - 1 7
PD 2.66 2.58 0 - 1 2  3.00 2.66 0 - 1 2
All dialysis 2.66 2.59 0 - 1 2  2.59 2.77 0 - 1 7
Dialysis patients reported on average less than 3 symptoms at the time of each of the 
two assessments (see Table 6.18). There was however wide inter-individual variation in 
number of symptoms reported in both dialysis groups. The range of reported symptoms 
was large, 0 to 12 for the PD group at both assessments and 0 to 11 and 0 to 17 in the 
HD group at T l and T2 respectively.
Repeated measures ANCOVA (covarying only for diabetes as neither gender, nor 
dialysis duration were significantly associated with symptoms) were performed to 
compare symptom reporting between PD and HD patients across the two assessments.
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This showed a significant treatment by time interaction effect suggesting that the course 
of symptom reporting differed between the two dialysis groups over the two 
assessments (F(2,142) = 5.497, p  = .02).
None of the post-hoc tests however yielded significant results after controlling for 
diabetic status. PD and HD reported an equal number of symptoms at the time of the 
two assessments. Symptom reporting also remained unchanged across the two 
assessments in both dialysis groups. Inspection of group means showed symptoms 
reporting across the two assessments followed a different course in PD and HD patients, 
that is likely to account for the significant interaction effect.
In HD patients, symptom occurrence was reduced from 2.65 (SD = 2.62) immediately 
before dialysis to 2.23 (SD = 2.85) at 24-hour post-dialysis although this was not 
significant. In PD patients, however the opposite trend was observed, with PD patients 
on average reporting more symptoms at T2 (mean = 3, SD = 2.67) than at Tl 
assessment (mean = 2.66, SD = 2.57) although this also failed to reach significance.
Inspection of the types of symptoms most frequently endorsed did not demonstrate a 
differential symptom profile between the two dialysis groups. Both HD and PD patients 
reported the same type of symptoms. The most frequently reported symptoms were 
fatigue, pain, loss of strength, lack of sex drive and stiff joints (see Table 6.19).
Several of the dialysis patients reported no symptoms at all at T l (26.5% of PD and 
23.4% of HD) and T2 assessments (21.2% of PD and 32.5% of HD). There were no 
significant differences in the number of asymptomatic patients between the two dialysis 
groups.
Even though treatment modality was unrelated, other clinical factors were associated 
with symptoms. Between groups comparisons revealed that patients who reported no 
symptoms at T l had significantly lower ESRD severity scores (mean = 4.88, SD = 5.97) 
than patients experiencing some symptoms at T l (mean = 13.23, SD = 9.51) (t (96.38) = 
- 6.17, p  = .0001). Similar findings occurred at T2 with higher ESRD severity scores for 
patients with symptoms (mean = 12.47, SD = 9.57) at T2 compared to the ones with no 
symptoms (M = 7.58, SD = 8.29), t(143) = -2.81, p = .005). No other sociodemographic 
or medical variables were associated with symptom reports.
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Table 6.19: Symptom reporting at T l and T2 by HD and PD patients
TIM E 1 TIM E 2
HD PD HD PDa
Symptoms %( N) %(7V) % (TV) %( N)
Fatigue 39% (30) 41.2% (28) 26% (2 0 ) 40% (26)
Stiff joints 29.9% (23) 14.7% (10) 29.9% (23) 24.6% (16)
Loss of strength 28.6% (2 2 ) 32.4% (22) 18.2% (14) 26.2% (17)
Pain 23.4% (18) 27.9% (19) 15.6% (12) 27.7(18)
Lack of sex drive 23.4% (18) 27.9% (19) 11.7% (9) 21.5% (14)
Breathlessness 15.6% (12) 19.1% (13) 7.8% (6 ) 24.6% (16)
Itching 15.6% (12) 19.1% (13) 11.7% (9) 30.8% (20)
Sleep difficulties 3.9% (3) 8 .8 % (6 ) 10.4% (8 ) 18.5% (12)
Dizziness 2 .6 % (2 ) 1.5% (1) 3.9% (3) 3.1% (2)
Headaches 11.7% (9) 5.9% (4) 11.7% (9) 9.2% (6 )
Hair loss 9.1% (7) 2.9% (2) 6.5% (5)
Loss of appetite 9.1% (7) 1 1 .8 % (8 ) 11.7% (9) 12.3% (8 )
Restless legs 6.5% (5) 13.2% (9) 9.1% (7) 7.7% (5)
Weight loss 5.2% (4) 4.4% (3) 3.9% (3) 3.1% (2)
Sore eyes 5.2% (4) 7.4% (5) 9.1% (7) 9.2% (6 )
Upset stomach 5.2% (4) 2.9% (2) 9.1% (7) 9.2% (6 )
Sleep difficulties 3.9% (3) 8 .8 % (6 ) 10.4% (8 ) 18.5% (12)
Dizziness 2 .6 % (2 ) 1.5% (1) 3.9% (3) 3.1% (2)
Nausea 2 .6 % (2 ) 2.9% (2) 6 (7.8) 6.2% (4)
Asymptomatic ptsb 23.4% (18) 26.5% (18) 32.5% (25) 21.2% (14)
Note: HD = haemodialysis; PD = peritoneal dialysis; pts = patients
a= 65 PD patients completed T2 assessment, valid percentages are reported 
b= number of patients reporting no symptoms associated with their condition
ii. Relationship to NP performance
Spearman’s correlational analysis revealed different patterns of correlations at T l and 
T2 assessments between NP functioning and number of symptoms.
At T l assessment the more symptoms dialysis patients reported the less efficient their 
cognitive performance in all NP tests except for RAVLT-D (Table 6.20). In contrast, 
symptom reporting appeared to be largely uncorrelated with cognitive functioning at T2. 
Only two significant albeit weak correlations were found between GP scores (T2) and 
concurrent symptoms.
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Table 6.20: Correlations between concurrent symptoms and NP scores at T l and T2 in
the combined dialysis group
TIME 1 TIME 2
NP tests Symptoms 7+ NP tests Symptoms 2 t
TMT-A 1 331 **** TMT-A2 .097
TMT-B 1 .227** TMT-B2 .0 1 2
SDMT-W 1 972*** SDMT-W2 .071
SDMT-O 1 - 3 1 5 **** SDM T-02 .0 1 2
RAVLT-T 1 -.230** RAVLT-T2 -.058
RAVLT-D 1 .117 RAVLT-D2t -.031
GP-DOM 1 360**** GP-DOM2+ .174*
GP-NDOM 1 3^2**** GP-NDOM2 .177*
BVRT-C 1 -.258** BVRT-C2+ -.077
BVRT-E1 .231** BVRT-E2+ .106
NP-TOTAL1 - 3 4 6 **** NP-TOTAL2 -.094
t  Spearman’s correlation coefficient
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
NP comparisons between asymptomatic dialysis patients and those experiencing or 
reporting symptoms at the time of the assessments were performed using ANCOVAs 
(controlling for ESRD severity). These analyses showed no significant main or 
interaction effects in cognitive functioning over T l and T2 assessments, indicating that 
symptoms were unrelated to changes in NP functioning (data not shown).
1.8 NP acute changes in dialysis patients
To examine whether the HD group showed improvements over 24 hours in contrast to 
the PD group, a series of repeated measures ANCOVAs (covariates: fatigue, anxiety, 
dialysis duration, and diabetic status) comparing the NP performance of the HD and PD 
groups over time were performed. This revealed a consistent pattern of results across all 
NP tests.
In none of the ANCOVAs was the main effect of dialysis treatment significant 
suggesting that both treatments result in equivalent cognitive functioning when T l and 
T2 assessments are averaged. The main effects of time was significant for all NP scores 
(ps <.002) except for RAVLT-D: TMT-A (F(6 , 133) = 67.708, p  = .0001), TMT-B (F(6 ,
133) =11.693, p  = .001), RAVLT-T (F(6 , 133) = 36.104, p  = .0001), BVRT-C (F(6 ,
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134) = 23.676, p  = .0001), BVRT-E (F(6, 134) = 28.023, p  = .0001), SDMT-O (F(6, 
133) = 114.204,/? = .0001), SDMT-W (F(6, 133) = 121.492, p  = .0001), GP-DOM (F(6, 
131) = 16.123, p  = .0001) and GP-NDOM (F(6, 131) = 11.724, p  = .002). These effects 
indicated improved NP performance at T2, anticipated through learning over such as a 
short interval (the relevant means are shown in Table 6.2 uncorrected for covariates)
The group by time interaction effect was significant for 9 of the 10 NP scores: TMT-A 
(F(6, 133) = 4.929, p  = .028); TMT-B (F(6, 133) = 7.822, p  = .006); SDMT-W (F(6, 
133) = 5.244, p = .024); SDMT-O (F(6, 133) = 4.701, p  = .032); RAVLT-T (F(6, 133) 
= 14.292, p = .0001); BVRT-C (F(6, 133) = 4.168, p  = .043); BVRT-E (F(6, 134) = 
7.38, p  = .007); GP-NDOM (F(6, 131) = 10.183, p = .002); and GP-DOM (F(6, 131) = 
6.686, p  = .0001). Follow-up simple effect tests (ANCOVAs) showed significant 
improvements in NP performance mainly for the HD group. HD patients’ performance 
in all NP measures improved significantly 24-hours post their dialysis relative to pre­
dialysis even after anxiety, fatigue, diabetes, and dialysis duration were controlled for 
(ps c.001). In contrast, PD patients’ performance remained largely unchanged across T l 
and T2 assessments with only TMT-A (F(6, 57) = 21.31, p  = .0001), SDMT-W (F(6, 
57) = 39.20, p  = .0001), SDMT-O scores (F(6, 57) = 31.05, p  = .0001) showing 
improvements. It is of note that these three NP tasks have no alternate forms, 
consequently greater learning was anticipated.
These data are depicted graphically in Figure 6.1.
Figure 6.1 a-i: Acute NP changes in HD and PD
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Post-hoc comparisons between the HD and PD groups on the T l and T2 NP scores 
showed no significant group differences. A trend was noted in T2 RAVLT-T (F(5, 139) 
= 3.352, p  = .062), with HD patients recalling more words than PD patients at the T2 
but this did not reach significance.
1.9 Blood biochemistry over time
It was hypothesised that improved biochemical status at 24-hours post-dialysis should 
underline any observed NP improvement in HD patients. Biochemical data were 
analysed to determine the temporal course of biochemistry profiles in the two dialysis 
groups and their associations with absolute NP performance and NP improvements.
197
1.9.a Group differences
A series of 2 x 2 repeated measures ANCOVAs (covarying for gender, diabetes, and 
dialysis duration) showed that biochemistry levels across the two assessments differed 
between the two treatment groups (Table 6.21).
Table 6.21: Biochemistry and Tl and T2 in HD and PD
HD PD
T l T2 T l T2 F
Urea (mmol/1) M 22.66 13.24 21.57 21.18 116.87
SD 4.82 4.12 6.12 6.25
Creatinine (mmol/1) M 798.5 534.1 808.60 806.00 87 13****
SD 183.9 192.5 231.30 226.3
Sodium (mmol/1) M 139.1 136.74 136.70 136.55 .044
SD 2.72 3.04 3.07 2.86
Albumin (g/dl) M 39.82 41.78 35.60 35.80 7.96**
SD 3.45 4.22 4.09 4.29
Calcium (mmol/1) M 2.46 2.60 2.35 2.33 4.44*
SD .22 .62 .21 .19
Haemoglobin (g/dl) M 10.86 10.58 11.23 11.08 .36
SD 1.52 1.48 1.37 1.37
Potassium (mmol/1) M 5.08 5.97 4.75 4.97 28.28**
SD 2.30 2.31 1.98 1.74
Phosphate (mmol/1) M 8.64 6.61 8.47 7.82 18.14****
SD 5.46 5.30 4.51 3.85
Alk-P-Tase (U/L) M 88.66 85.12 93.65 91.95 1.84
SD 29.78 28.81 34.28 32.16
Note. The F test denotes the group by time interaction effect for the 2 x 2 analysis of covariance.
Tl = time 1 assessment; T2 = time 2 assessment; HD = haemodialysis; PD = peritoneal dialysis; 
Alk-P-tase = Alkaline Phosphatase
a Normal serum albumin concentrations vary by laboratory methodology 
* p <.05. ** p <.01. *** p <.001. **** p <.0001
Time-by-treatment interaction effects were significant for BUN (F(3, 103) = 116.88, p= 
.0001), Cr (F(3, 103) = 87.13, p= .0001), K+ (F(3, 103) = 28.28, p= .0001), P 0 4 (F(3, 
97) = 18.14, p= .0001), Ca2+ (F(3, 98) = 4.44, p  = .038), and Alb (F(3, 92) = 7.59, p = 
.006). As anticipated, no significant differences were found in any of the biochemical 
assays for the PD group from T l to T2 while in the HD group biochemistry levels 
changed significantly for pre- to 24-hours post-dialysis with significant decreases in 
BUN (F(3, 50) = 212.06, p = .0001), Cr (F(3, 50) = 130.05, p < .0001), P 0 4 (F(3, 44) =
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19.78, p  = .0001), K+ (F(3, 50) = 61.84, p  = .0001) and increases in Alb (F(3, 42) = 
17.49, p = .0001), and Ca2+ levels (F(3,45) = 4.57, p  = .038).
PD and HD patients differed in their biochemistry across the two assessments. At T l 
HD patients had significantly higher Ca2+ (F(4, 144) = 8.942, p = .003), Alb (F(4, 139) 
= 44.979, p = .0001), P 0 4 (F(4, 140) = 8.449, p = .004), K+ (F(4, 140) = 37.905, p = 
.0001) and Sodium (F(4, 140) = 18.029, p  = .0001) compared to PD. Urea levels did not 
differ between groups at T l (F (4 ,140) = 3.109,/? = .08).
Consistent with the HD biochemistry profile, 24 hours post-dialysis Cr (F (4, 103) = 
37.048, p  = .0001) and BUN (F(4, 103) = 40.167, p  = .0001) were lower in HD whereas 
Ca2+ (F(4, 98) = 9.014, p  = .003), Sodium (F(4, 102) = 7.462, p  = .007) and Alb (F(4, 
93) = 44.032, p  = .0001) on the other hand remained significantly higher in HD patients 
relative to PD.
1.9.b Relationship to NP performance: T l absolute NP scores
To evaluate the relationship between biochemical measures and cognitive functioning, a 
series of hierarchical multiple regressions were performed on the combined sample (PD 
and HD) controlling for the effect of sociodemographic, medical, and mood variables 
(see Tables 6.22 - 6.27). Employment status was not included despite significant 
univariate associations as it was regarded an outcome/consequence of cognitive 
functioning rather than a predictor.
In the first instance, the biochemistry hypothesis was tested (i.e. entering biochemical 
values in the last step of the regression). From the mood indicators, only state anxiety 
and cognitive depression scores were included in these regression equations to reduce 
number of IVs in the models. They were selected over the remaining mood measures 
because they are the variables traditionally controlled for in NP evaluations (Lezak, 
1995) and because both (STAI and CDI) were strongly correlated with the other mood 
indicators, i.e. total BDI scores and positive and negative affect (see T^ble 6.7) with 
correlations ranging from r = .46 to r =.93.
Multiple regression analysis was not performed for RAVLT-D as none of the 
sociodemographic, medical, or mood measures was significantly associated with that 
NP score (in univariate analyses).
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Table 6.22: M ultiple regressions to predict TM T-A, TMT-B and SDM T-W  in dialysis:
standardised regression coefficient and cum ulative variance explained
TMT-A TMT-B SDMT-W
Cum Cum Cum Cum Cum Cum
P R2 AdjR2 P R2 AdjR2 (3 R2 AdjR2
Block 1
Age
Educ 
Block 2
.304
***
.21
/ 2=.336
.204
/ 2=315
.336
***
.208
/ 2=.318
.201 
f 2=. 295
-.326
***
.230 
f = .  362
.224 
f 2=. 363
ESRD SI .223 * .291 .279 .149 .247 .235 -.158 .284 .272
f = .  336 / 2=. 336 ns f = . .0 6 f 2=. 05 ns / 2=.083 f 2=. 073
Kt/V -.191* .329 .312 -.151* .273 .255 .168* .314 .297
/ 2=.129 / 2=.051 f = .  04 / 2=. 029 / 2=.047 f 2=.038
Diabetes 
Block 3
STAI .224 .374 .353 .220 .311 .288 -.237 .365 .344
** / 2=. 06 f = .  063 ** f = .  058 / 2=.048 ** / 2=.08 f 2=. 072
CDI
Block 4
BUN -.189
*
.346
/ 2=.054
.318
/ 2=.046
CA
P 04
K
Cr
Hb
Sod
Alb
AlkPho
N o te : / = variance-based measure of effect size calculatedI as /  = AR 2 / (1 - /?2Total); Cum =
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; STAI = state anxiety; CDI = cognitive depression index; NA = negative 
affect; BUN = blood urea nitrogen; CA = calcium; P04 = phosphate; K = potassium; Cr = 
creatinine; Hb = haemoglobin; Sod = sodium; Alb =albumin; AlkPho =alkaline phosphatase 
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
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Table 6.23: M ultiple regressions to predict SDM T-O, RAVLT-T and BVRT-C in
dialysis: standardised regression coefficient and cum ulative variance explained
SDMT-O RAVLT-T BVRT-C
Cum Cum Cum Cum Cum Cum
P R2 AdjR2 P R2 AdjR2 P R2 AdjR2
Block 1
Age -.370 .257 .251 -.392 .212 .205 -.131 .102 .095
*** / 2=.44 /= •  42 *** f= 3 2 2 / 2=.304 ns
''tli / 2=.128
Educ .145
ns
.135
/ 2=.045
.121
/ 2=.035
Block 2
ESRD SI .145 * .332 .321 .149 .273 .262 -.214* .172 .151
/ 2=.128 / 2=.126 ns f 2=. 094 / 2=.085 / 2=.052 oif
fS
Kt/V .205* .355 
f= . 039
.340
/ 2=.03
Diabetes 
Block 3
STAI -.254 .414 .395 -.263 .342 .326 -.120 .203 .177
** f= . 099 / 2=.091 *** N> M O f 2=. 095 ns / 2=.045 f 2=. 035
CDI
NA
Block 4
BUN
CA .232
**
.265
/ 2=.088
.234 
f 2=. 077
p o 4 .172* .293
/ 2=.040
.258 
f 2=. 032
K
Cr
Hb
Sod
Alb
AlkPho
Note: f  = variance-based measure of effect size calculated as f  = AR2 / (1- /?2Totai); Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; STAI = state anxiety; CDI = cognitive depression index; NA = negative 
affect; BUN = blood urea nitrogen; CA = calcium; P 0 4 = phosphate; K = potassium; Cr = 
creatinine; Hb = haemoglobin; Sod = sodium; Alb =albumin; AlkPho =alkaline phosphatase 
* p <.05. ** p < .01. *** p <.001. **** p <.0001. ns = non significant
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Table 6.24: M ultiple regressions to predict BVRT-E, GP-DOM  and GP-NDOM  in
dialysis: standardised regression coefficient and cum ulative variance explained
BVRT-E GP-DOM GP-NDOM
Cum Cum Cum Cum Cum Cum
P R2 AdjR2 P R2 AdjR2 P R2 AdjR2
Block 1
Educ -.219
**
.105 
f= .  139
.098
/ 2=.125
Age .122 .157 .143 .291 .167 .160 .394 .266 .26
ns / 2=. 069 f= .  057 ** / 2=.238 f 2=. 22 *** / 2=.444 / 2=.429
Block 2
ESRD SI .227* .186 .166 .125 .23 .217 .127 .230 .217
/ 2=. 038 f= .  029 ns / 2=. 088 f 2=. 079 ns f 2=. 088 / 2=. 079
Kt/V
Diabetes .148
ns
.257 
f 2=. 038
.239
/ 2=.030
.162* .362
/ 2=.044
.347 
/ 2=.051
Block 3
STAI
CDI .255 .298 .274 .223 .402 3827
** / 2=.058 / 2=.05 ** / 2=.057 / 2=.064
NA
Block 4
BUN
CA -.239
**
.242 
f 2=. 075
.217 
f= .  067
po4
K
Cr
Hb
Sod
Alb
AlkPho
Note: / =  variance-based measure of effect size calculated as f  = AR2 / (1- /?2Totai); Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; STAI = state anxiety; CDI = cognitive depression index; NA = negative 
affect; BUN = blood urea nitrogen; CA = calcium; P 0 4 = phosphate; K = potassium; Cr = 
creatinine; Hb = haemoglobin; Sod = sodium; Alb =albumin; AlkPho =alkaline phosphatase 
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
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The resulting regression models were moderately successful in predicting absolute NP 
scores in dialysis. Total adjusted R2 explained was 21.7% in BVRT-E, 27.6% in BVRT- 
C, 32.6% in RAVLT-T, 27.5% in GP-DOM, 38.2% in GP-NDOM, 35.3% in TMT-A, 
31.9% in TMT-B, 34.4% in SDMT-W and 39.5% in SDMT-O (see tables 6.22 - 6.24 
above).
Age significantly predicted all NP test scores. As indexed by beta weights (standardised 
regression coefficients), increasing age was associated with poorer performance in NP 
tasks. Greater ESRD severity and lower dialysis adequacy were also associated with 
more compromised cognitive functioning. Dialysis adequacy accounted for only a 
small, albeit significant percentage of the variance in TMT-A (AAdj.R2 = 3.3%, f  =  
.0608), TMT-B (AAdj.fi2 = 2 .1 % ,/  = .0402), SDMT-O (AAdj.fi2 = 1 .8 % ,/ = .0397), 
and SDMT-W (AAdj.fi2 = 2 .5 % ,/ = .0478).
State anxiety was consistently associated with verbal memory and all four attention NP 
scores explaining 4.1% <f = .0719863), 3.3% ( f  =  .058041), 4.7% ( f  =  .0798), 5.5% 
( f  =  .0998), 6.5% ( f  =  .1023) (Aadj.R2) of the variance in TMT-A, TMT-B, SDMT-W, 
SDMT-O and RAVLT-T respectively. Cognitive depression alone predicted 
psychomotor performance accounting for 3.6% (AAdj.R2) in both GP-DOM ( f  = 
.0561) and GP-NDOM < / = .0642) scores.
Among the biochemical measures, urea accounted for an additional AAdj .R2 = 3.1% ( f  
= .0536) of the explained variance in TMT-B but was not a significant predictor of any 
of the other NP tests. Interestingly regression coefficients (|3 = -.189, p =.012) indicated 
counterintuitive relationships in that lower urea levels were associated with longer time 
latencies in TMT-B task. Calcium contributed a small percentage in the explained 
variance in BVRT-E (AAdj.fi2 = 5 .1 % ,/ = .0746) and BVRT C (AAdj.fi2 = 5 .1 % ,/ = 
.0873) scores. Phosphate was similarly associated with BVRT-C (AAdj.R2 = 2 .3 % ,/ = 
.0397). None of the biochemical indices were significant predictors in the regression 
models for TMT-A, SDMT-W, SDMT-O, RAVLT-T, GP-DOM, GP-NDOM.
To further evaluate the role of biochemistry and mood another set of regressions were 
performed. NP scores at T1 were regressed to mood indicators (STAI, positive affect 
negative affect, CDI) controlling for demographic (age and education), clinical (ESRD
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severity , d iabetes, K t/V ) and biochem ical m easures (urea, calcium  and phosphate). O nly 
these three b iochem ical values w ere included, as in previous regressions (see Tables 
6 .22 - 6.24) show ed that they were the only  ones sign ificantly  associated  with cogn itive  
functioning . T he exclusion  o f the o ther b iochem ical values was also deem ed necessary  
so as to have a m ore favourable subjects-to-predictors ratio.
T hose analyses yielded a sim ilar pattern o f results as the ones reported  earlie r when 
m ood  and biochem istry  en tered  the regression in reverse o rder (see T ab les 6.25 - 6.27).
T able  6.25: M ultip le regressions to predict TM T-A , TM T-B  and SD M T -W  in dialysis 
w ith m ood at the last step: standard ised  regression coefficient, cum ulative variance
TMT-A TMT-B SDMT-W
p
Cum
R2
Cum
A d jR 2 P
Cum
R2
Cum
A d jR 2 P
Cum
R2
Cum
A d jR 2
Block 1
Age .284 .199 .204 .314 .198 .191 -.369 .236 .23
* * * / 2=.31 / 2=315 * * * / 2=.295 / 2=.274 * * * / 2=. 39 f= .  366
Educ 
Block 2
ESRD SI .24 .284 .272 .143 .235 .223 -.146 .289 .278
* * * / 2=.128 / 2=.113 ns
vOmoif(N / 2=.042 ns f 2=. 088 f= .  076
Kt/V -.191* .323 .306 -.155* .262 .244 .168* .319 .303
f= .  063 K
)
II o u> / 2=.04 f 2=. 029 f= .  05 / 2=.04
Diabetes 
Block 3
BUN
CA -.199 .346 .324 .130 .341 .320
ns f 2=. 037 f 2=. 028 ns f= .  036 f 2=. 027
p o 4 -.170* .299 
f= .  056
.276
/ 2=.046
Block 4
STAI .205
**
.382 
f 2=. 06
.357 
/ 2=.051
.184* .329
/ 2=.045
.302 
f= .  038
CDI
PNS-NA -.273
***
.395 
f= .  09 ooo
r- 
if
PNS-PA
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant 
Note:f=  variance-based measure of effect size calculated a s /  = AR2/ (1- R2Totai).
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Table 6.26: M ultiple regressions to predict SDM T-O, RAVLT-T and BVRT-C in
dialysis with mood at the last step: standardised regression coefficient, cum ulative
variance explained
SDMT-O RAVLT-T BVRT-C
Cum Cum Cum Cum Cum Cum
P R2 A d jR 2 P R2 A d jR 2 P R2 A d j R 2
Block 1
Age -.374 .26 .254 .-354 .22 .214 -.107 .104 .097
*** f= .468 f= .44 *** / 2=.342 f 2=. 322 ns / 2=.145 / 2=. 129
Educ .226
***
.285 
f= . 099
.273 
/ 2=. 089
Block 2
ESRD SI -.188* .334 .323 -.093 .307 .29 -.260 A l l .152
f= .  133 f= A 2 ns / 2=.034 f 2=. 026 ** f= .  051 / 2=.04
Kt/V .157*
n 
^ 
o 
^ .342 
/ 2=. 033
Diabetes 
Block 3
BUN
CA .136* .381
/ 2=.043
.361
/ 2=.042
.251
**
.248 
/ 2=. 106
.224
f=.096
p o 4 .187* .282 
f =.046
.252 
f 2=. 037
Block 4
STAI -.236
**
.357 
f= . 078
.336 
f 2=. 07
CDI
PNS-NA -.273
***
.445 
/ 2=.l 13
.422
/ 2=.106
PNS-PA
N o te : f =  variance-based measure of effect size calculated as /  = AR 2 / (1- R2Totai); Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; STAI = state anxiety; NA = negative affect; BUN = blood urea nitrogen; PA 
= positive affect; CA = calcium; P04 = phosphate 
* p <.05. ** p < 01. *** p <.001. **** p <.0001. ns = non significant
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Table 6.27: M ultiple regressions to predict BVRT-E, GP-DOM  and GP-NDOM  in
dialysis with mood at the last step: standardised regression coefficient, cum ulative
variance explained
BVRT-E GP-DOM GP-NDOM
Cum Cum Cum Cum Cum Cum
P R2 AdjR2 P R2 AdjR2 p R2 AdjR2
Block 1
Educ -.221
**
.109
/ 2=.146
.103
/ 2=.131
Age .123 .163 .149 .296 .170 .164 -.396 .266 .26
ns / 2=.07 f =059 *** f = .  243 f= .2 2 1 *** / 2=.469 / 2=.421
Block 2
ESRD SI .227* .191 .171 .128 .223 .221 .126 .330 .320
/ 2=.037 / 2=.028 ns f 2=. 09 / 2=.078 ns / 2=. 109 f = .  097
Kt/V
Diabetes .149
ns
.261 
f = .  029
.243 
f = .  03
.162 .362
/ 2=.053
.346
/ 2=.042
Block 3
BUN
CA -.238
**
.247
/ 2=.074
.223 
f 2=. 067
po 4
Block 4
STAI
CDI .223 .301 .278 .225 .403 .383
** f = .  057 II o 00 ** f 2=. 069 f 2=. 06
PNS-NA
PNS-PA
Note: f =  variance-based measure of effect size calculated as f  =  A R2 / ( 1 -  R 2Tota i); Cum =  
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; BUN = blood urea nitrogen; CA = calcium; P04 = phosphate STAI = state 
anxiety; PNS-NA = PANAS negative affect; PNS-PA = PANAS positive affect;
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
The resulting regression models explained 22.2% to 42.2%  (Adj.R2) of the variance in 
T1 absolute NP scores in the total dialysis sample: 22.2%  in BVRT-ER; 25.2%  in
206
BVRT-C; 33.6% in RAVLT-T; 35.7% in TMT A; 30.2% in TMT B; 37% in SDMT-W; 
42.2% in SDMT-O, 27.8% in GP-DOM; and 38.3% in GP-NDOM (see Tables 6.25 - 
6.27).
The same demographic, clinical and biochemical measures emerged as significant 
predictors. The observed multivariate associations indicated that increasing age, higher 
ESRD severity, lower dialysis adequacy, lower calcium and higher phosphate were 
associated with more compromised cognitive functioning.
Entering the biochemical measures before mood increased their predictive power as 
expected. For instance, results showed that calcium emerged as a significant predictor in 
SDMT-O, SDMT-W and TMT-A models explaining in order 1.9%, 1.7% and 1.8% 
(AAdj.R2) of the total variance. These associations however had failed to reach 
significance in the previous regressions in when biochemical measures were entered in 
the last step after mood (see Tables 6.22 - 6.24).
The addition of mood in the last step further improved the models. Mood measures 
predicted all NP scores with the exception of visual/non verbal memory (BVRT scores). 
They contributed an additional (AAdj.R2) 3.2% ( f  = .0592), 2.5% i f  = .0448), 6.1% ( f  
= .1138), 5% ( f  = .0886), 4.6% i f  = .0759), 3.5% ( f  = .0570), 3.7% ( f  = .0681) in the 
total variance of TMT A, TMT B, SDMT-O, SDMT-W, RAVLT-T, GP-DOM, and GP- 
NDOM respectively.
Specific mood predictors varied across NP scores. State anxiety was associated with 
RAVLT-T, TMT-A, TMT-B. Negative affect was associated with SDMT-O and 
SDMT-W whereas cognitive depression predicted psychomotor performance, namely 
GP-DOM and GP-NDOM scores.
1.9.c Relationship to NP performance: Residualised change NP scores
To examine whether the observed NP improvements at T2 were associated with 
biochemical changes, the multivariate associations among biochemical and NP 
residualised change scores were analysed with similar hierarchical multiple linear 
regressions. In the first set of regressions, biochemical variables were entered at the last 
step after sociodemographic (age, education), clinical (ESRD-SI, diabetes, Kt/V) and
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mood variables (CDI, STAI). The models had limited success in predicting NP change 
scores. Resultant models comprised single variables, i.e. either age or a biochemical 
/clinical parameter with little consistency across NP scores. Significant predictors varied 
depending on the NP outcome and the total percentage of variance explained was small, 
ranging from Adj./?2 = 5.3% to Adj./?2 = 15.2% (see Tables 6.29 -  6.30).
Significant predictors were calcium (SDMT-W: Adj./?2 = 10%, p = .335, p = .004, /  
=.1267, SDMT-O: Adj./?2 = 9.3% , 6 = .326, p = .005, /  =.1186), phosphate (GP- 
NDOM: Adj./?2 = 7.6% , P = .299, p  = . 0 1 1 , /  =.0985), and urea (RAVLT-T: adj./?2 = 
7.9% , p = -.304, p = . 0 0 5 , /  =.1094). The observed associations signify small effect 
sizes and indicated that improvements in NP performance were associated with 
concomitant increase in calcium and decrease in inorganic phosphate and in urea levels 
Age was the only variable to be significantly associated with acute changes in BVRT-C; 
BVRT-E; TMT-A and TMT- scores (see Tables 6.29 - 6 .3 0 ) .
Table 6.28: Multiple regressions to predict acute changes in SDMT-W; SDMT-O;
RAVLT- T: standardised regression coefficient, cumulative variance explained
SDMT-W______________ SDMT-O______________ RAVLT-T
Cum Cum Cum Cum Cum Cum
____________ (3 R2 Adj R2 p R2 Adj R2 p R2 Adj R2
Block 1
Age
Education
Block 2
ESRD SI
Kt/V
Diabetes
Block 3
State anxiety
Cognitive depression
Block 4
Urea -.304 .092 .080
** / = .  101 / = . .  87
Calcium .335 .112 .100 .326 .106 .093
** /= .1 2 6  f = .  I l l  ** / 2= .l 19 /= .1 0 3
Phosphate
Potassium
Creatinine
Haemoglobin
Sodium
Albumin
AlkPho__________________________________________________________________________________
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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Table 6.29: M ultiple regressions to predict acute changes in GP-DOM ; GP-NDOM ;
BVRT-E: standardised regression coefficient, cumulative variance explained
GP-DOM GP-NDOM BVRT-E
Cum Cum Cum Cum Cum Cum
3 R2 Adj R2 3 R2 Adj R2 P R2 Adj R2
Block 1
Age .281 .079 .066
** f 2=.086 f 2=. 071
Education
Block 2
ESRD SI
Kt/V .260 .73 .06
* / 2= 079 / 2=.064
Diabetes
Block 3
State anxiety
Cognitive depression
Block 4
Urea
Calcium
Phosphate .257 .090 .076
* f 2=.099 f= .  082
Potassium
Creatinine
Haemoglobin
Sodium
Albumin
Alkaline Phosphatase
Table 6.30: Multiple regressions to predict acute changes in TMT-A; TMT-B: BVRT-C:
standardised regression coefficient, cumulative variance explained
TMT-A TMT-B BVRT-C
Cum Cum Cum Cum Cum Cum
3 R2 Adj R2 3 R2 Adj R2 p R2 Adj R2
Block 1
Age .269 .073 .06 .257 .066 .053 -.405 .164 .152
* f =.079 / 2=.064 * / 2=.071 f= .  059 *** / 2=.196 / 2=.179
Education
Block 2
ESRD SI
Kt/V
Diabetes
Block 3
State anxiety
Cognitive depression
Block 4
Biochemistry'7
Note: f  = variance-based measure of effect size calculated as f  = A R2 / (1-■ /C -r o ta l);  Cum =
cumulative; ESRD SI = end-stage renal disease severity index; Kt/V = dialysis adequacy; 
a= biochemistry change scores entered: urea; creatinine; potassium, phosphate, sodium; albumin 
haemoglobin; albumin; alkaline phosphatase 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
209
In the second set of multiple regressions performed, the order of entry of biochemical 
and mood variables was reversed. Predictors entered the regression equations in the 
following order: sociodemographics, clinical variables, biochemistry (only urea, 
calcium, phosphate) and mood variables (CDI, STAI, positive affect and negative 
affect) (see Tables 6.31 - 6.33).
Three points in relation to the results need mentioning:
Firstly, the inclusion of more mood measures at the last step improved the overall 
predictability of the constructed models. The total amount of variance explained in the 
various NP outcomes increased somewhat albeit would still considered rather small 
(Adj./?2 ranging from 4.1% to 16.6%). Constructed models accounted for a small 
amount of variance in NP change scores. Total Adj./?2 are as follows: 12.56% in TMT 
B; 4.1% in TMT A; 12.24% in SDMT-W; 9.1% in SDMT-O; 14.4% in RALVT-T; 
12.8% in GP-NDOM; 11.7% in GP-DOM; 16.5% in BVRT-C; and 16.7% in BVRT-E 
residualised change scores.
Secondly, stronger associations were observed between changes in biochemistry and 
changes in cognitive functioning. It is of note that the effect of urea became significant 
on more NP outcomes when biochemistry was entered before mood. This was in the 
expected direction with decreases in urea being associated with improved functioning 
mainly in memory tasks, namely RAVLT-T (Adj./?2 = 10.3%; f  = .12), BVRT-E 
(AAdj.ft2 = 4 .3 % ;/ = .052), BVRT-CO (AAdj .ft2 = 4 .5 % ;/ = .054) and also in GP- 
DOM (Adj.ft2 = 4 .9 % ;/ = .055) change scores.
Thirdly, changes in positive and negative affect were similarly associated with changes 
in NP performance. Increased positive affect predicted improvement in NP performance 
on SDMT-W (AAdj.ft2 = 3 .5 % ;/ = .042), RAVLT-T (AAdj.ft2 = 4 .1 % ;/ = .048) and 
BVRT-E (AAdj./?2 = 5 .6 % ;/ = .067). On the other hand decreases in reported levels of 
negative affect was associated with better performance in TMT-B (AAdj./?2 = 5 .4 % ;/ = 
.062), GP-DOM (AAdj.ft2 = 6.8%; /  = .77) and GP-NDOM (AAdj.ft2 = 4.3%; /  = 
.049). Interestingly, depression or changes in levels of anxiety failed to emerge as 
significant predictors when entered together with positive and negative affect, despite 
being associated with absolute levels of NP performance at Tl.
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Table 6.31: M ultiple regressions to predict acute changes in TM T-A; TM T-B: SDM T-
W  in dialysis (mood at the last step): standardised regression coefficient, cum ulative
variance explained
TMT-A TMT-B SDMT-W
Cum Cum Cum Cum Cum  Cum
(3 R2 AdjR2 P R2 AdjR2 P R2 Adj R2
Block 1
Age .232 .054 .042 .293 .084 .072
* f = .  057 / 2=.044 ** f 2=. 098 f = .  075
Education 
Block 2
ESRD SI
Kt/V
Diabetes 
Block 3
BUN
CA .288
**
.096 .085 
f 2=.056 f = .  042
p o 4
Block 4
STAI
CDI
PNS-NA .252
*
.147
/ 2=.75
.126 
f 2=. 062
PNS-PA .220
*
.144 .122 
f 2=.056 / 2=.042
Note: f=  variance-based measure of effect size calculated as f  = AR2 /  (1- R2Totai ) ;  Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; BUN = blood urea nitrogen; CA = calcium; P04 = phosphate; STAI = state 
anxiety; CDI = cognitive depression index; PNS-NA = PANAS negative affect; PNS-PA = 
PANAS positive affect
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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Table 6.32: M ultiple regressions to predict acute changes in SDM T-O; RAVLT-T;
BVRT-C in dialysis (m ood at the last step): standardised regression coefficient,
cum ulative variance explained
SDMT-O RAVLT-T BVRT-C
Cum Cum Cum Cum Cum Cum
(3 R2 AdjR2 (3 R2 Adj R2 (3 R2 AdjR2
Block 1
Age -.333
**
.131
/ 2=.161
.120 
/ 2= .144
Educ
Block 2
ESRD SI
Kt/V
Diabetes 
Block 3
BUN -.286 .114 .103 -.234 .185 .165
** / 2= .136 / 2=.120 * f =.066 / 2=.054
CA .320
**
<N 
T  
O 
II
ZL 
<n 
■
 
'+-■>
.091
/ 2=.100
po4
Block 4
STAI
CDI
PNS-NA -.273
* * *
.445 
/ 2=. 113
.422
/ 2=.106
PNS-PA .232
*
.165
/ 2=.061
.144
/ 2=.048
Note: f = variance-based measure of effect size calculated as /  = AR2 / (1- ft2Totai); Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; BUN = blood urea nitrogen; CA = calcium; P04 = phosphate; STAI = state 
anxiety; CDI = cognitive depression index; PNS-NA = PANAS negative affect; PNS-PA = 
PANAS positive affect
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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Table 6.33: M ultiple regressions to predict acute changes in BVRT-E; GP-DOM ; GP-
N DOM  in dialysis (mood at the last step): standardised regression coefficient,
cum ulative variance explained
BVRT-E GP-DOM GP-NDOM
Cum Cum Cum Cum Cum  Cum
p R2 A d jR 2 (3 R2 A d jR 2 P R2 Adj R2
Block 1
Educ
Age .239
*
.079 
f = .  098
.068 
f 2=. 082
Block 2
ESRD SI
Kt/V
Diabetes
Block 3
BUN .176 .133 .111 .186 .061 .049
ns / 2=.067 / 2=.052 ns / 2=. 071 / 2=.055
CA
p o 4 .263 .096 .085 
* f 2=. 113 f 2=. 097
Block 4
STAI
CDI
PNS-NA .285
*
.139 
f 2=. 090
.117 
f 2=. 077
.236 .150 .128 
* / 2=.064 f = .  049
PNS-PA
Note: / =  variance-based measure of effect size calculated as f  =  AR2 /  (1- / ? 2Tota i) ;  Cum = 
cumulative; Educ = education; ESRD SI = end-stage renal disease severity index; Kt/V = 
dialysis adequacy; BUN = blood urea nitrogen; CA = calcium; P04 = phosphate; STAI = state 
anxiety; CDI = cognitive depression index; PNS-NA = PANAS negative affect; PNS-PA = 
PANAS positive affect
* p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
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1.10 Subjective Cognition Scale (SCS)
1.10.a Acute changes in subjective cognition
Dialysis patients’ responses to the nine-item questionnaire on perceived cognitive 
changes between T1 and T2 are shown in Table 6.34.
Whereas almost all PD patients reported no changes in their cognitive abilities over the 
two assessments, a considerable percentage of HD patients perceived positive cognitive 
changes from pre- to 24-hours post-dialysis. Although the percentages of HD patients 
reporting cognitive change varied depending on the specific cognitive domain, 31 HD 
patients (40.6%) in total reported more efficient cognitive abilities in one or more area 
of cognition. The most frequently self-reported areas of improvement post-dialysis with 
HD patients were concentration, followed by clarity of thinking and attention.
Table 6.34: Subjective cognition scale: acute changes at T l-  T2
Cognitive domain
HD PD
.......x2 ....+ve = -ve +ve = -ve
1. memoryi 6.5% 87% 6.5% 96.9% 3.1% 4.309 ns2
(5) (67) (5) (62) (2)
2. problem solving) 14.3% 83.1% 2.6% 1.6% 93.8% 4.7% 5.724*
( ID (64) (2) (1) (60) (3)
3. clarity of thinking) 33.8% 63.6% 2.6% 4.7% 87.5% 7.8% 16.353****
(26) (49) (2) (3) (56) (5)
4. concentration) 35.1% 59.7% 5.2% 87.5% 12.5% 25.538****
(27) (46) (4) (56) (8)
5. making mistakes) 2.6% 94.8% 2.6 100% ns = .501
(2) (73) (2) (64)
6. attention) 24.7% 74% 1.3% 98.4% 1.6% 16.197****
(19) (57) (1) (63) (1)
7. clumsiness) 2.6% 94.8% 2.6% 1.6% 98.4% .180 ns2
(2) (73) (2) (1) (63)
8. decision making) 2.6% 96.1% 1.3% 100% 1.868 ns2
(2) (73) (1) (64)
9. speed of response) 20.8% 76.6% 2.6% 98.4% 1.6% 13.006****
(16) (59) (2) (63) (1)
*p <.05. **** p <.0001. ns = non significant
Note\ +ve = positive change/improvement, = no change, -ve = negative change/deterioration
1 = Negative change and no change were combined as cells in negative change category had an 
expected frequency of less than 5 and values reported are Pearsons’s Chi-square with Yate’s 
correction
2 = Fisher exact test
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Chi-square analysis indicated that significantly more HD patients reported 
improvements in clarity of thinking, concentration, attention, and response speed 24- 
hours post-dialysis compared to PD (see Table 6.34 above).
l.lO .b Acute subjective cognition and acute NP change
The following analyses were restricted to the HD group as the PD group reported little 
change in their cognition.
In order to examine the relationship between subjective reports of cognitive change and 
changes in objectively assessed NP performance, HD patients were grouped into those 
reporting ‘improvement’ and those reporting either ‘no change’ or ‘deterioration’ post­
dialysis on the individual SCS items (clarity of thought, attention, concentration, speed 
of response). This two-group categorisation was necessary, as the small number of 
patients and their response distribution did not allow for a three-group analysis. 
Repeated measures ANOVAs were then performed to compare objective NP 
performance over time between those HD patients reporting ‘improvement’ and those 
reporting either ‘no change’ or ‘deterioration’ post dialysis on four SCS items.
In this analysis only the objective NP scores considered to reflect the particular 
cognitive dimension assessed by the grouping SCS items were used (see Table 6.35 - 
6.36).
Table 6.35: Absolute NP scores {Means and SDs) in acute cognitive improvement vs. 
no change or decline dialysis sub-groups: attention concentration
Attention Concentration
+ve -ve/= 
Mean (SD) Mean (SD)
+ve -ve/= 
Mean (SD) Mean (SD)
TMT-A T1 60.93 (45.91) 51.36 (34.17) 55.90 (28.33) 44.05 (35.29)
T2 53.12 (43.35) 42.52 (27.97) 47.13 (26.51) 94.95 (59.00)
TMT-B T1 112.09(71.01) 93.27 (46.12) 103.42(41.74) 94.94 (58.99)
T2 104.07(67.63) 85.41 (45.10) 95.09 (41.09) 87.27 (56.83)
SDMT-W T1 39.42(13.18) 41.41 (12.48) 37.41 (11.75) 42.82 (12.74)
T2 47.58 (16.47) 46.95 (14.91) 45.05 (13.86) 48.22 (15.89)
SDMT-O T1 44.58 (15.41) 46.22 (13.92) 42.19 (11.98) 47.78 (15.04)
T2 52.32 (18.40) 52.03 (16.11) 49.85 (14.39) 53.32 (17.67)
Note: +ve = positive change/improvement post dialysis; =/-ve = negative change/deterioration 
or no chnage post dialysis; TMT-A = trailmaking test part A; TMT-B = trailmaking test part B; 
SDMT-W = symbol digit modality test written; SDMT-O = symbol digit modality test oral
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Table 6.36: Absolute NP scores {Means and SDs) in acute cognitive improvement vs. 
no change or decline dialysis sub-groups: clarity of thinking; response speed
Clarity of thinking____________Speed of response
+ve -ve/= +ve -ve/=
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
TMT-A T1 51.05 (29.72) 55.09 (40.86) 46.38 (21.43) 55.65 (40.38)
T2 44.85 (27.38) 45.28 (34.85) 40.55 (22.10) 46.32 (34.57)
TMT-B T1 96.83 (44.82) 98.47 (57.76) 88.31 (27.67) 100.44(58.27)
T2 88.49 (44.32) 90.79 (55.51) 85.46 (38.30) 91.21 (54.90)
SDMT-W T1 39.73 (13.29) 41.53 (12.32) 42.06 (12.41) 40.62 (12.73)
T2 46.23 (15.21) 47.55 (15.32) 50.13 (15.29) 46.31 (15.20)
SDMT-O T1 44.69(13.38) 46.39 (14.72) 47.63 (12.58) 45.34 (14.76)
T2 51.92(16.12) 52.20(16.97) 56.50 (16.38) 50.95 (16.57)
RAVLT-T T1 40.50(11.28) 38.78 (12.33)
T2 43.69(11.09) 43.45 (12.22)
RAVLT-D T1 2.50(1.70) 2.27(1.72)
T2 3.00 (2.28) 2.45 (1.98)
BVRT-C T1 4.96 (2.34) 5.13(2.31)
T2 5.54 (2.39) 6.20 (2.25)
BVRT-E T1 9.42 (6.03) 8.23 (5.16)
T2 7.11 (5.11) 6.35 (5.42)
GP-DOM T1 93.69 (26.17) 86.04 (31.42) 90.63 (24.97) 88.13 (31.10)
T2 89.46 (27.29) 82.86 (29.58) 86.06 (25.82) 84.86 (29.75)
GP-NDOM T1 101.62 (29.3) 99.45 (37.29) 103.37(31.03) 99.35 (35.67)
T2 97.08 (30.19) 94.52 (36.53) 94.31 (28.61) 95.68 (35.89)
Note: +ve = positive change/improvement post dialysis; =/-ve = negative change/deterioration 
or no change post dialysis; TMT-A = trailmaking test part A; TMT-B = trailmaking test part B; 
SDMT-W = symbol digit modality test written; SDMT-O = symbol digit modality test oral; 
RAVLT-T = Rey auditory verbal learning test total recall (1-5) score; RAVLT-D = Rey 
auditory verbal learning test-drop in retention score; BVRT-C = Benton visual retention test- 
number correct; BVRT-E = Benton visual retention test-number of errors; GP-DOM = grooved 
pegboard dominant hand; GP-NDOM = grooved pegboard non dominant hand
The 26 (33.8%) patients reporting improved clarity of thinking were compared to the 51 
(66.2%) patients reporting either no change or deterioration on all NP scores (as clarity 
of thought was considered pertinent to all of them).
Nineteen HD patients reported attention improvement post dialysis. Their performance 
was compared to that of the remaining 58 patients on the tests considered to reflect 
attention (TMT-A; TMT-B; SDMT-W; SDMT-O).
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The 27 (35.1%) patients reporting improved concentration abilities were likewise 
compared to the 50 (64.9%) patients endorsing either no change or deterioration in 
concentration on the same tests as above (TMT-A; TMT-B; SDMT-W; SDMT-O). 
Finally NP scores in time-dependent tests (TMT-A; TMT-B; GP-DOM; GP-NDOM; 
SDMT-W; SDMT-O) were compared between patients reporting improved or not 
response speed post dialysis.
There were no significant group effects or group by time interaction effects in any of the 
comparisons performed (ps < 1), suggesting that perceived cognitive perceptions are 
unrelated to the objective indices of NP performance.
l.lO.c Acute Subjective cognition and mood
The associations between concurrent measures of mood (anxiety, positive affect, 
negative affect and depression) and subjective cognition ratings were examined by 
oneway ANOVAs using the T2 mood absolute scores. This analysis was performed 
only on HD patients, as the PD group perceived little to no variation in the subjective 
reports of cognition from T1 to T2.
As before, HD patients were grouped into those reporting cognitive improvement versus 
those reporting no change or deterioration in the cognitive domains. Results indicated 
little association between mood and perceptions of acute cognitive improvements.
There were no significant differences in BDI nor CDI scores between the resulting HD 
subgroups. HD patients who perceived enhanced clarity of thinking post dialysis tended 
to have higher total BDI scores (mean = 12.81, SD = 6.87) than patients reporting no 
change or deterioration (mean = 10.02, SD = 7.64) but this trend did not reach 
significance level (p = .06). State anxiety and negative mood were also unrelated to all 
but one of the SCS items, concentration albeit in a counterintuitive manner. 
Comparative analysis showed that HD patients reporting improvements in their ability 
to concentrate had significantly higher state anxiety at T2 (mean = 9.67, SD = 2.50) than 
those endorsing no change or deterioration (mean = 8.5, SD = 2.19; F (l, 75) = 4.514, p 
= .037).
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Negative affect also differed between these two subgroups with patients in the improved 
concentration group reporting higher levels of negative affect at T2 0mean = 13.37, SD 
= 3.59) relative to the other group (mean = 11.96, SD = 2.20; F (l, 75) = 4.571, p = 
.036). The opposite pattern was evident with respect to positive affect. Patients in the 
cognitive improvement group had higher level of positive affect (mean = 31.26, SD = 
5.07) than the no change or deterioration group (mean = 28.04, SD = 7.69) although this 
trend approached but did not reach significance (F(l, 74) = 3.82, p  = .054).
In addition to comparing T2 absolute mood scores, a similar analysis was performed on 
residualised change mood scores to determine whether reports of cognitive 
improvements were associated with concomitant mood changes rather than current 
mood.
There was only one significant finding. HD patients reporting improvement in their 
concentration abilities had significantly greater increase in their positive mood reports 
from pre- to 24-hours post-dialysis relative to those reporting no changes or 
deterioration (F(l,75) = 21.333, p  = .0001). Changes in negative mood measures 
(anxiety and negative affect) were unrelated to subjective reports of cognitive 
improvement.
l.lO.d Long term changes and subjective cognition
Patients’ reports of changes in their cognitive abilities experienced since the onset of 
dialysis treatment were also examined.
A substantial number of dialysis patients (66.2%, n = 96) reported deterioration in one 
or more aspects of cognition compared to their cognitive abilities/NP performance 
before dialysis onset. In contrast only 18.2 % (n = 25) of the dialysis respondents 
perceived improvement in their cognitive functioning since dialysis initiation.
The most frequently reported area of deterioration in the combined HD and PD sample 
was memory with 54.5% reporting that their memory abilities have deteriorated since 
dialysis initiation. Lack of concentration was the next most common cognitive 
complaint (44.8%) followed by clarity of thinking (29%), and problem solving (24.1%) 
(see Table 6.37).
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Table 6.37: Subjective Cognition: Long term changes in Dialysis
Cognitive domain
HD PD
x2+ve = -ve +ve = -ve
1. memory. 1.3% 44.2% 54.5% 4.4% 41.2% 54.4% .000 ns
(1) (34) (42) (3) (28) (37)
2. problem solving, 2.6% 72.7% 24.7% 1.6% 93.8% 4.7% .000 ns
(2) (56) (19) (1) (60) (3)
3. clarity of thinking 10.4% 59.7% 29.9% 2.9% 73.5% 23.5% 2.10 ns
(8) (46) (23) (2) (50) (16)
4. concentration. 1.3% 45.5% 53.2% 11.8% 52.9% 35.3% 4.008*
(1) (35) (41) (8) (36) (24)
5. making mistakes, 88.3% 11.7% 1.5% 94.1% 4.4% 1.651 ns
(68) (9) (1) (64) (3)
6. attention. 2.6% 77.9% 19.5% 7.4% 77.9% 14.7% .291 ns
(2) (60) (15) (5) (53) (10)
7. clumsiness. 87% 13% 85.3% 14.7% .003 ns
(67) (10) (58) (10)
8. decision making, 87% 13% 2.9% 80.9% 16.2% .095 ns
(67) (10) (2) (55) (11)
9. speed of response, 2.6% 81.8% 15.6% 88.2% 11.8% .180 ns
(2) (63) (12) (60) (8)
Note\ +ve = positive change/improvement, = no change, -ve = negative change/deterioration
i = Positive change and no change were combined as cells in positive change category had an 
expected frequency of less than 5 and values reported are chi-square with Yate’s correction
* p <.05. *** p <.001. ns = non significant
Significantly more HD patients felt that their concentration deteriorated since starting 
on dialysis compared to PD patients (%2(145) = 4.008, p  = .045). As however the two
dialysis groups differed significantly in age at dialysis onset, time on RRT, time on
current dialysis modality, and gender distribution the observed associations might 
reflect these differences rather than being solely due to dialysis modality effects.
In addition to examining the distribution of responses, three summary SCS scores were 
computed:
number of positive cognitive changes since dialysis (possible range from 0 to 9) 
with higher scores signifying improvement in more areas of cognitions
number/count of negative changes since dialysis (possible range from 0 to 9 with 
higher scores signifying deterioration in more areas of cognition)
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A summary score for subjective cognition was calculated by adding responses on all 
nine items. A score of 1 was given to reports of cognition improvement, a score of 2 
to reports of no change and a score of 3 was assigned to reports of cognitive 
deterioration. Scores could thereby range from 9 to 27, with higher scores signifying 
cognitive deterioration.
There no significant group differences in subjective cognition summary scores (see 
Table 6.38).
Table 6.38: Summary subjective cognition scores in dialysis
All DL HD PD
Mean SD Mean SD Mean SD
Total cognitive decline since DL 19.90 2.50 20.14 2.47 19.63 2.53
No + ve changes since DL .297 .746 .207 .592 .397 .883
No -  ve changes since DL 2.20 2.15 2.35 2.20 2.03 2.10
Note: DL = dialysis; HD = haemodialysis; PD = peritoneal dialysis; +ve = positive; -ve negative
l.lO.e Long term subjective Cognition scale and NP scores
To examine if perceived long-term cognitive deterioration is associated with actual NP 
performance, the data from the self-reported changes were collapsed into ‘improved’ 
and ‘no change’ versus ‘worse’. Between groups comparisons were then performed on 
the objective NP test scores, considered to reflect the particular cognitive dimension 
assessed by the grouping subjective cognition item (see Tables 6.35 -  6.36 and section
l.lO.b for NP tests related to subjective cognition items).
The reports of deterioration were as follows: Forty-two (29%) patients reported 
worsened clarity of thinking. Seventy-nine patients (54.5%) reported deterioration in 
memory. Sixty-five patients (44.8%) reported concentration decline since dialysis onset. 
Twenty-five (17.2%) patients reported decline in attention. Finally twenty dialysis 
patients reported deterioration in both response speed and motor abilities.
Results indicated some significant group differences, suggesting that perceptions of 
long-term changes in cognitive abilities bear some association with objective indices of 
NP performance but not consistently across all cognitive domains (Tables 6.39 -  6.41).
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Table 6.39: NP scores in cognitive decline vs. no change or improvement dialysis sub­
groups (clarity of thinking; response speed)
Clarity of thinking Response speed
-ve
Mean (SD)
+ve/=
Mean (SD)
-ve
Mean (SD)
+ve/=
Mean (SD)
TMT-A T1 56.5 (32.3) 50.4 (32.2) 66.1 (42.6) 49.9 (30.1)
T2 49.9 (27.7) 44.2 (30.3) 60.3 (33.9) 43.5 (42.6)
TMT-B T1 102.6 (42.7) 96.9 (51.9) 114.9 (54.7) 95.9 (48.2)
T2 102.1 (47.0) 91.6 (50.4) 111.9 (52.7) 91.8 (48.7)
SDMT-W T1 38.4(10.9) 42.2(13.1) 34.3 (12.4) 42.2(12.3)
T2 42.5 (12.7) 47.3 (15.5) 38.2(16.7) 47.2 (14.3)
SDMT-O T1 42.7 (12.5) 46.4(14.1) 39.1 (15) 46.4(13.3)
T2 46.8(14.1) 51.9(16.9) 43 (18.2) 51.7(15.7)
RAVLT-T T1 38.2(10.1) 39.3(11)
T2 40.6(11.1) 41.9(10.6)
RAVLT-D T1 2.5(1.86) 2.55 (1.9)
T2 2.84 (1.88) 2.8 (1.9)
BVRT-C T1 4.24(1.87) 5.2 (2.21)
T2 4.77 (1.85) 5.8 (4.77)
BVRT-E T1 9.69 (4.82) 8.09 (5.04)
T2 8.47 (4.12) 6.64 (4.85)
GP-DOM T1 96.2 (29) 88.8 (33) 104 (38.2) 88.9 (30.5)
T2 95.2 (29.7) 85.4 (30.4) 95.1 (30.4) 87.2 (30.4)
GP T1 104.7 (30.1) 101.2 (42.2) 119.9 (52.2) 99.42 (35.9)
NDOM T2 102.7 (30.7) 97.4 (39.1) 111.6 (38.3) 97 (36.5)
Note\ +ve = positive change/im provem ent or = no change, -ve = negative change/deterioration;
Perceptions of diminished clarity of thinking were associated with worse scores in 
BVRT-C at T1 (U = 1594, p  = .012) and at T2 (U = 1471, p  =.009), BVRT-E in T2 (U = 
1439, p  = .006) and finally longer time latencies in GP-DOM at T2 (U = 1529, p  =.048). 
Differences in T1 GP-DOM and BVRT-E approached but did not reach significance (U 
= 1715.5,/? = .06; U = 1722,/? = .054 respectively).
Likewise, patients who perceived that their response time has deteriorated since dialysis 
performed significantly worse than those who reported no such effects in some time- 
dependent NP tasks. These effects were significant for SDMT-W at T1 (t(143) = 2.637, 
p  = .009) and T2 (t(139) = 2.486, p  = .014), SDM T-O at T1 (t(143) = 2.238, p  = .027) 
and T2 (t( 139) = 2.191,/? = .03) and for TMT-A at T2 (t(139) = -2.34,/? = .021).
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Table 6.40: NP scores in cognitive decline vs. no change or improvement dialysis sub­
groups (attention; concentration)
Attention Concentration
-ve +ve/= -ve +ve/=
Mean (SD) Mean (SD Mean (SD Mean (SD
TMT-A T1 58.6 (37.7) 50.8 (31.2) 54.1 (30.7) 50.6 (33.8)
T2 50.8 (31.2) 44.7 (29.4) 47.8 (28.5) 44.2 (30.6)
TMT-B T1 106.2 (57.5) 96.9 (47.6) 102.6 (45.3) 95.3 (52.5)
T2 102.6 (54.3) 92.8 (48.6) 97.7 (46.5) 92.1 (51.9)
SDMT-W T1 38.5(12.1) 41.6(12.6) 39.1 (11.7) 42.7(13.1)
T2 44.4(15.1) 46.3 (14.9) 44.1 (14.1) 47.5 (15.4)
SDMT-O T1 43.9(14.4) 45.7 (13.6) 43.2(12.9) 47.1 (14.2)
T2 48.6(16.9) 50.9 (16.2) 48.4(15.1) 52.1 (17)
GP-DOM T1
T2
GP- T1
NDOM T2
Note: +ve = positive change/improvement, = no change, -ve = negative change/deterioration
Table 6.41: NP scores in cognitive decline vs. no change or improvement dialysis sub­
groups (memory; motor abilities)
________ Memory___________________ M otor abilities_____
-ve +ve/= -ve +ve/=
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
RAVLT-T T1 38.8(10.8) 39.2(10.6)
T2 40.9(11.6) 42.2 (9.57)
RAVLT-D T1 2.41 (1.88) 2.68 (2.04)
T2 2.68 (2.02) 2.97 (1.73)
BVRT-C T1 4.67 (2.17) 5.23 (2.12)
T2 5.17(2.11) 5.91 (2.07)
BVRT-E T1 9.2 (5.45) 7.79 (4.36)
T2 7.86 (4.90) 6.35 (4.90)
GP-DOM T1 116.6 (49.9) 86.9 (26.1)
T2 110.5 (45.6) 84.9 (26.2)
GP- T1 141.2 (61.8) 95.9 (29.9)
NDOM T2 135.8 (55.5) 93.4 (29.9)
Note: +ve = positive change/improvement, = no change, -ve = negative change/deterioration
Patients who felt that they have been having more minor accidents (e.g. dropping 
things) since dialysis onset took significantly longer time to complete the psychomotor 
task compared to patients who perceived either no change or improvement. This was
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evident at both assessments for GP-DOM (U = 722, p  = .003 for T l; U = 669, p  = .008 
for T2), and GP-NDOM (t(142) = -.3.689, p  = .001 for T l; t(137) = -4.627, p= .0001 for 
T2).
Similar trends were also noted for memory. Patients who felt that their memory had 
deteriorated since dialysis tended to perform worse in the visual memory task at T2; 
with less number correct (U = 2074.5, p  = .07) and more reproduction errors (U = 2068, 
p  = .07).
l.lO.f Factors associated with subjective cognition (long- term)
i. Sociodemographic and medical factors and subjective cognition
Complaints of cognitive deterioration were found to be significantly associated with 
clinical factors such as disease severity. Correlations using the three summary SCS 
scores indicated that ESRD severity was positively associated with overall perceptions 
of cognitive decline (rs = .32, p = .0001), count of perceived negative changes in 
cognition (rs = .30, p  = .0001) and inversely associated with count of positive changes in 
cognition (rs = -.20, p = .015).
Analysis of the individual SCS items showed that ESRD severity was significantly 
higher in the ‘cognitive decline’ group for clarity of thinking (U = 1514, p  = .005), 
memory (U = 2022, p  = .020), clumsiness (U = 844.5, p  = .020), and concentration (U = 
1945, p = .009).
Finally patients reporting deterioration in their attention had been on RRT for longer (U 
= 1069, p  = .024) and so did patients complaining of decline in their concentration (U = 
2004,/? = .018).
Among sociodemographics, age, gender, and work status had significant associations 
with long-term SCS perceptions.
Patients reporting deterioration in motor abilities (clumsiness) since dialysis onset were 
significantly older (t(143) = -2.008, p  = .043) and had started dialysis at an older age 
(t(143) = -2.553, p  = .012) compared to patients reporting either no change or 
improvement. Perceptions of worse response speed were similarly associated with 
advanced age (t(143) = -1.99, p  = .048).
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Gender (female) was associated with perceptions/complaints of worsened attention 
(X2(145) = 4.696, p  = .030), and concentration (%2(145) = 7.134, p  = .008). Female 
dialysis patients also had higher scores in overall perceptions of cognitive decline {mean 
= 20.55 SD = 2.52) than males {mean = 19.55 SD = 2.44; U = 1886.5, p  = .033) and 
reported more negative changes in their cognitive abilities {mean = 2.75 SD = 2.26) 
since the onset of dialysis compared to male patients {mean = 1.90 SD = 2.04; U = 
1873.5, p = .026).
Employment status was significantly associated with both summary SCS scores and 
individual SCS items. Overall perceptions of cognitive decline (U = 1681.5, p  = .002) 
and count of negative changes in cognitions (U = 1650, p  = .001) differed between 
employed and non-employed patients. The latter perceived greater cognitive 
deterioration {mean = 20.34 SD = 2.45) and reporting more negative changes {mean = 
2.60, SD = 2.11) in their cognitive abilities relative to employed patients {mean = 19.11 
SD = 2.43; mean = 1.48 SD = 2.05; respectively). These group differences were no 
longer significant after adjustment for ESRD severity and age {ps <. 06).
Chi-square analysis indicated significant associations between employment status and 
‘specific’ cognitive complaints although these may also reflect the effect of casemix 
differences in age and ESRD severity. Significantly more employed patients reported 
improvement in memory (%2(145) = 4.846, p  = .028); speed of response (%2(145) = 
4.390, p  = .036); decision making (%2(145) = 4.970, p  = .026) and concentration 
{% (145) = 10.509,/? = .001) since dialysis compared to non-employed patients.
ii. Mood and subjective cognition
A series of independent t-tests or Mann-Whitney tests were performed to investigate the 
association between mood measures and subjective complaints of cognitive decline 
since dialysis initiation. Patients in the cognitive decline groups as described above 
were compared to those reporting either no change or improvement on BDI, CDI, and 
concurrent levels of anxiety, positive and negative affect (see Table 6.42).
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Table 6.42: Long term subjective cognition scale and mood at T1 in dialysis
BDI CDI STAI PNS-NA! PNS-PA
t-value 
Mean/ SD
t-value
Mean/SD
t-value
Mean/SD
U-value 
Mean/SD
t-value
Mean/SD
Memory
- ve 
=/+ ve
-2.73**
13.73 (8.68) 
9.98 (7.4)
-2.75**
8.37 (5.83) 
5.98 (5.49)
-2.70**
11.81 (4.09) 
10.04 (3.66)
2070*
15.68 (5.79) 
13.74 (4.05)
ns
22.98 (7.66) 
24.71 (7.01)
Pr. Solving
- ve 
=/+ ve
-5.08***
17.77 (8.54) 
10.2 (7.38)
-4.49***
10.77 (5.83) 
6.18(5.34)
-2.98**
12.71 (4.47) 
10.46 (3.68)
1315.5**
16.54 (5.59) 
14.24 (4.9)
3.31***
20.28 (6.99) 
24.88 (7.2)
Thinking Cl.
- ve 
=/+ ve
-3.08**
15.26 (9.18) 
10.7 (7.59)
-2.53*
9.1 (6.20)
6.55 (5.47)
-2.45*
10.29 (3.45) 
9.54 (2.85)
1409.5*
16.54 (5.4) 
14.08 (4.89)
2.63**
21.28 (6.98) 
24.78 (7.35)
Concentration 
- ve 
=/+ ve
-3.75***
14.06 (8.56) 
9.93 (7.52)
-3.37***
8.76 (5.76) 
6.08 (5.56)
-2.01*
12.32 (4.16) 
9.93 (2.55)
1971.5*
15.93 (5.86) 
13.87 (4.31)
ns
22.61 (7.42) 
24.71 (7.28)
Mistakes
- ve 
=/+ ve
ns
16.16(9.25) 
11.65 (8.16)
-2.20*
10.75 (6.82) 
6.97 (5.61)
ns
12.16(3.27) 
10.9 (4.04)
ns
15.33 (4.22) 
14.75 (5.23)
ns
23.66 (6.38) 
23.78 (7.5)
Attention
- ve 
=/+ ve
-3.06**
16.56 (9.35) 
11.08 (7.79)
3.04**
10.4 (6.45) 
6.64 (5.45)
-2.74**
12.96 (3.94) 
10.6(3.89)
1051.5*
16.4 (4.89) 
14.46 (5.15)
2.17*
20.88 (7.6) 
24.37 (7.24)
Clumsiness
- ve 
=/+ ve
-2.578*
16(7.6)
11.39 (8.27)
-2.156*
9.35 (4.94) 
6.96 (5.86)
ns
11.6 (2.99) 
10.91 (4.13)
ns
14.8 (3.44)
14.8 (5.38)
ns
22.8 (6.05) 
23.92 (7.6)
Decision Mk 
- ve 
=/+ ve
-2.173*
15.66(10.1) 
11.41 (7.85)
ns
9.14(7.22) 
6.97 (5.48)
ns
12.04 (4.57) 
10.83 (3.87)
ns
15.33 (4.95) 
14.7 (5.19)
ns
22 (6.87) 
24.07 (7.46)
Resp Speed
- ve 
=/+ ve
ns
14.95 (5.30) 
11.56 (8.14)
ns
9.15(5.81) 
6.99 (5.75)
ns
12.85 (4.01) 
10.71 (3.92)
ns
15.6(4.1) 
14.67 (5.3)
-2.25*
21.95 (7.3) 
24.06 (7.39)
* p <.05. ** p <.01. *** p <.001. ns = non significant
Note. BDI = Beck depression inventory total score; CDI = cognitive depression index; STAI = 
Spielberger state anxiety; PNS-NA = PANAS negative affect; PNS-PA = PANAS positive 
affect; - ve = negative; =/+ ve = no change or positive; Pr. Solving = problem solving; Thinking 
Cl = clarity of thinking; Decision Mk = decision making
Even though observed differences varied depending on the particular aspect of 
cognition, a consistent pattern of results emerged. On the whole results indicated that 
patients who felt that their cognitive abilities have deteriorated since dialysis onset had 
significantly higher negative mood as indexed by higher mean group scores in BDI, 
CDI, STAI and PANAS-NA and reported significantly lower positive affect (see Table 
6.42).
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Among mood indicators, CDI depression scores consistently differentiated between the 
‘cognitive decline’ group and those who reporting no change or improvement with 
respect to all cognitive aspects except for ‘response speed’.
Likewise, correlational analysis showed that negative mood indicators (BDI, CDI, 
STAI, PANAS-NA) were positively associated with overall perceptions of cognitive 
decline (rs = .40, p  = .0001; rs = .36, p  = .0001; rs = .33, p -  .0001; rs = .23, p  = 006 
respectively) and number of perceived negative changes in cognition (rs = .39, p = 
.0001; rs = .34, p  = .0001; rs = .32, p  = .0001; rs = .23 , p  = .0001 respectively). They 
were also found to be negatively associated with number of perceived positive cognitive 
changes (rs = -.21, p  = .013; rs = .-21, p  = .011; rs = -.17, p -  .037 for BDI, CDI, and 
STAI respectively). In contrast, increased positive affect was significantly associated 
with less perceived long-term cognitive decline (rs = -.23, p -  .005).
iii. Prediction o f subjective cognitive complaints
To evaluate the contribution of demographic, medical, neuropsychological, and 
affective variables upon self-reported cognitive changes, hierarchical multiple 
regression using the stepwise method (at p  < .05) was performed. The stepwise method 
was preferred to avoid the problem of multicollinearity due to the significant 
intercorrelations among the predictor variables (particularly for mood indicators) 
(Tabachnick and Fidell, 1989).
The summary subjective cognition score was regressed to sociodemographic, medical, 
neuropsychological and mood variables. To produce a more favourable cases-to- 
variables ratio, data reduction procedures were applied. First, only the variables within 
each domain found to be significantly associated with the outcome were used. Second, 
T1 absolute NP scores were standardised and then added to produce a total NP score 
(NP-TO; see section 1.3). This composite score reflected overall NP functioning at T1 
with higher scores signifying more efficient cognitive functioning.
This composite NP score was used in subsequent regression analyses as a varimax 
rotated principal component analysis on T1 NP data (factor calculated using 
standardised z-scores) that was performed earlier in order to identify an underlying 
factor structure, failed to produce a clear-cut structure. In the PCA analysis (data not
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shown) two orthogonical factors were identified accounting for 77.5% of the variance. 
The first factor accounted for 66.94% of the variance and comprised tests measuring 
attention concentration and psychomotor speed TMT-A, TMT-B, SDMT-W, SDMT-0 
and GP-DOM, GP-NDOM. It was hence labelled ‘attention/ psychomotor’. The second 
factor, ‘memory recall’ explained 11.57% of variance. It comprised RAVLT total recall, 
BVRT correct and BVRT error, capturing the ability to recall information from recent 
memory. As however some measures (TMT-A and TMT-B) had almost equal loadings 
on both factors (loadings on factor 1 and factor 2 were only marginally different), it was 
considered inappropriate to use the resulting factor scores in the regression analysis. 
Thereby the composite NP score has been used in preference to factor scores.
Predictors entered the regression equation as follows: To control for any influence of 
participants’ age and educational level, these variables were entered in Block 1 and 
likewise dialysis modality and ESRD severity index were entered in Block 2 under 
forced entry criteria even though they did not correlate significantly with overall 
subjective cognitive decline/complaints. At step three the overall absolute NP score at 
T1 and number of NP impairments were entered followed by mood variables in the last 
step of the regression.
The final hierarchical regression model revealed that higher levels of cognitive 
depressive symptoms (CDI) were significantly associated with greater perceived 
cognitive decline since dialysis onset. The associations between ESRD severity and 
cognitive complaints were only significant at the first two steps, accounting for R = 
8.3% (Adj.R2 = 7.7%) but ceased to be significant when CDI entered next (p = .161, p  = 
.057). Likewise count of NP impairments explained AR2 = 2.7% (P = .110, p  = .188) but 
was not significant in the last step of regression (i.e. with CDI entry). The decrease in 
the standardised regression coefficients (beta weights) with CDI entry suggests that CDI 
symptoms may mediate the associations between disease severity and NP deficit and 
subjective evaluation of cognition.
CDI explained an additional 5.8% (AAdj.R2 = 5.3%; p = .266, p  = .002) of the cognitive 
complaints increasing the overall variance explained to 16.8% (AAdj.R = 15%). 
Neither objective NP test performance, nor any of the clinical or demographic variables 
were significantly associated with long-term subjective cognitive complaints.
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Section 2: Transplantation sample
2.1 Data analysis
Variables’ distributions were examined by Kolmorogov-Smimov goodness-of-fit test. 
With respect to NP variables, TMT-A, TMT-B, GP-DOM, GP-NDOM and RAVLT-D 
were found to be non-normally distributed in the transplant population. Logarithmic 
transformations rendered some of these tests (TMT-A, TMT-B, GP-DOM) to a normal 
distribution. It was not possible to render the RAVLT-D and GP-NDOM to a normal 
distribution. Among the mood variables measured in the transplant sample (PANAS 
PA, PANAS NA, BDI, CDI) only the cognitive depression index was found to be non- 
normally distributed. Logarithmic transformation successfully rendered CDI scores into 
normal distribution.
Chi-square, Pearson’s correlation coefficient, one way ANOVAs or their non parametric 
equivalent (as appropriate) were performed to examine univariate associations between 
sociodemographic, clinical, and mood variables with absolute NP scores. A series of 
hierarchical multiple regressions were also performed to identify the combination of 
variables that can best explain NP performance in transplant patients.
Univariate analyses of covariance (ANCOVAs) were performed to compare NP 
performance between (a) living related and cadaver transplant recipients and (b) 
transplant and dialysis patients. Covariates for these comparisons included the variables 
that were significantly different between groups on the condition that they were also 
significantly associated with the dependent variable in question (at p  < .05).
In comparisons involving more than two groups (as for instance in the comparisons of 
PD, HD and TX participants), post-hoc tests (Tukey’s Honest Difference Test; HSD) 
were conducted to isolate significant treatment group differences.
2.2 Sample characteristics
Sociodemographic and medical characteristics of the transplant sample and the LRD 
and CAD transplant patients separately are shown in Table 5.1 (see Chapter 5; section 
1. 1).
There were several statistically significant differences between the two transplant 
groups with respect to medical and sociodemographic variables.
LRD patients were significantly younger (t(l 14) = 3.95, p = .0001) and had higher 
educational level (t(107) = -2.68, p = .01) than cadaver transplant recipients.
Higher employment rates were also noted for the LRD group (%2(254) = 10.344, p  = 
.0001) although this is likely to be a reflection of age, and clinical group differences and 
not necessarily evidence of better work rehabilitation associated with that type of 
transplant. Significant associations were indeed found between employment and age 
(t(104.12) = -5.02, p  = .0001), education (t(106) = 3.12, p  = .002) and renal disease 
severity (t(95.12) = -3.41, p  = .001). LRD TX patients were also more likely to perceive 
themselves as able to work full or part time than CAD TX patients (%2(254) = 3.998, p  = 
.045). Annual income also differed between groups, as expected given the differences in 
employment status. There were significantly more CAD TX patients in the lowest 
income group (< £10,000) compared to LRD recipients (%2(254) = 6.054,/? = .0138). 
Clinical characteristics also differed between groups. ESRD severity scores were lower 
in the LRD group (t(102.67) = 5.38, p  = .0001). Living related transplant recipients had 
also spent significantly less time on dialysis prior to their transplant (t(73.18) = 4.47, p  
-  .0001) and had their current functioning graft longer than cadaver transplant patients 
(t(l 15) = - 3.37, p  = .01). The former was anticipated given the elective nature of LRD 
transplantation that allows shorter delay between dialysis and transplantation. In fact, 
there were significant more cases of pre-emptive transplantation in LRD patients 
compared to CAD patients (%2(254) = 4.846, p  = .028).
2.3 Absolute NP performance
Mean NP scores for the total transplant group and for CAD and LRD transplant 
recipients separately are presented in Table 6.36. A total NP score was computed by 
adding the standard z-score on the 8 NP indices used in the transplant population (TMT-
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A; TMT-B; SDMT-W; SDMT-O; RAVLT-T; RAVLT-D; GP-DOM; GP-NDOM). 
Where appropriate scores were reversed so as higher summary NP scores express more 
efficient cognitive functioning.
Table 6.43: Absolute NP scores {Means; SDs) in TX patients
CAD TX
(n = 92)
LRD TX
(n = 25)
All TX
(n = 117)
M SD M SD M SD
TM T-A fl 38.99 19.98 32.13 19.96 37.50 20.09
TMT-B fl 92.37 61.38 70.97 34.86 87.33 56.85
SDM T-W b 44.62 13.64 52.54 9.52 46.37 13.22
SDMT-O b 50.29 15.40 58.17 13.03 52.02 15.21
RAVLT -T  b (1-5) 45.65 10.12 52.83 9.68 47.20 10.41
R A V L T - trial 1 5.93 1.89 6.91 1.65 6.14 1.88
RAVLT -  trial 2 8.37 2.23 10.09 2.37 8.74 2.36
R A V L T -tria l 3 9.75 2.30 11.43 2.33 10.11 2.40
R A V L T -tria l 4 10.46 2.63 11.91 2.54 10.78 2.66
R A V L T -tria l 5 11.14 2.72 12.48 1.93 11.43 2.62
R A V L T -D  (7-5) 1.90 1.80 1.52 1.47 1.82 1.74
GP -  D O M a 78.99 26.98 68.11 19.93 76.55 25.89
G P - N D O M 3 90.22 31.35 75.37 21.37 86.87 29.96
N P-TO c .667 4.18 2.74 4.99 1.20 4.47
Note. TX = transplant; CAD = cadaver; LRD = living related donor; TMT-A = trail making test 
part A; TMT-B = trail making test part B; SDMT-W = symbol digit modality test written 
administration; SDMT-O = symbol digit modality test oral administration; RAVLT-T = Rey 
Auditory Verbal Learning Test total word recall at trial 1 to 5; RAVLT-D = Rey Auditory 
Verbal Learning Test drop in retention from trial 5 to 7; GP-DOM = Grooved Pegboard 
dominant hand; GP-NDOM = Grooved Pegboard non dominant hand; NP-TO = total NP 
performance score
3 = Time to completion in seconds. b = number correct.c = total of the 8 NP indices (z-scores)
* p <.05. ** p <.01. *** p <.001.
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2.4 NP scores and transplant type
2.4.a NP impairments: normative comparisons
The NP performance of TX patients was evaluated against normative data. Both average 
group and individual performance comparisons as described earlier were performed. 
The limitations of the former with regard to case sensitivity, which were highlighted 
earlier, need to be borne in mind (see section 1.4.a).
i. Group-based normative comparisons
Transplant patients’ mean age (50.2 years for combined TX sample) was used to select 
the appropriate age brackets for the group based normative comparisons. Inspection of 
observed mean scores indicated that transplant patients’ NP performance did not deviate 
significantly from respective norms. The mean NP scores of both the combined 
transplant sample as well as the CAD and LRD TX groups separately, were clearly 
within the normal range or better (upper average range) on all NP tests (TMT A; TMT- 
B, SDMT-W, SDMT-O, RAVLT-T; GP-DOM, GP-NDOM).
Unlike dialysis patients, no retention or retrieval problems were evident in the transplant 
sample as the average number of words forgotten after interference trial (from trial 5 
and 7) was 1.82. Only for a small proportion {n = 18, 16.8%) of the transplant patients 
did the drop-in-retention exceeded more than 3 words.
The percentages of CAD and LRD patients missing 3 or more words at the last recall 
trial was equally small (n = 17, 20.2%) for CAD and (n = 1, 4.3%) LRD patients 
(X2(116) = 2.222, p = . 136).
ii. Individual-based comparisons
The performance of each individual TX patient was evaluated against his or her age 
appropriate norms. Table 6.44 depicts the prevalence of NP impairments based on this 
individual based comparison, i.e. frequencies and percentages of TX patients that 
performed worse than their healthy counterparts.
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Table 6.44: Prevalence of NP impairments in TX  patients
All TX CAD LRD
% im pairm ent % im pairm ent % im pairm ent
TMT-A 11% (12) 11.6% (10) 8.7% (2)
TMT-B 7.7% (9) 9% (7) 8.3% (2)
SDMT-W 19.3% (21) 23.5% (20) 4.2% (1)
SDMT-O 27.6% (29) 31.7% (26) 13% (3)
RAVLT-T 21.5% (23) 25%(21) 8.7% (2)
GP-DOM 20.6% (22) 24.1% (20) 8.3% (2)
GP-NDOM 27.5% (28) 31.6% (25) 13% (3)
Mean SD Mean SD Mean SD
NP 1.23 1.71 1.49 1.74 .60 1.47
im pairm ent
Individual comparison of each TX participant with his/her respective age norm revealed 
that the percentage of TX patients whose NP performance fell short of their respective 
norms was in most cases relatively low. The prevalence of NP impairments ranged from 
7.7% to 27.6% of TX patients and must be considered in relation to a normal 
distribution.
The observed prevalence of NP impairments in TMT-A, TMT-B is relatively low 
(10.3% and 7.7% respectively). The finding that 27.6% of patients scored lower than 1 
SD below their norm in SDMT-O might be considered of more significance. Similarly, 
GP-NDOM appears to be affected in more TX patients than would be expected in a 
normal population.
Between group comparisons showed no difference between the two LRD and CAD in 
the prevalence of NP impairments (group or individual based classification) relative to 
norms (ps c .l) . The two groups differed significantly in total number of NP tests on 
which normative based impairments were noted, with CAD TX recipients performing 
below norms in more NP tests than LRD patients (U = 777.5, p = .008). However these 
differences disappeared when casemix differences were controlled for. ANCOVAs, 
controlling for ESRD-SI (there was no need to control for age and casemix differences 
as individual classification was based on age and education respective norms) showed 
no significant group differences between the two transplant groups (F(2, 114) = 1.883, p  
= .173).
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2.4.a Absolute NP test scores
Comparisons of absolute NP scores between the two transplant groups were performed 
using a series of ANCOVAs controlling for the following casemix differences: age, 
education, and ESRD severity. There was no need to control for RRT duration, dialysis 
duration, and time with TX as none of these variables were significantly associated with 
NP scores at p < .05.
Results replicated those reported earlier on the prevalence of NP impairments in that 
there were no significant differences between LRD and CAD transplant recipients in 
any of the observed absolute NP scores or the summary NP score. CAD and LRD 
transplant recipients were hence collapsed into one group for all subsequent NP 
analyses.
2.5 Factors associated with NP performance in TX patients
2.5.a Sociodemographic, medical variables and NP performance
Table 6.45: Correlations between sociodemographic, medical variables and NP scores in
TX patients
Age E ducationt GFR ESRD S it
TMT-A 461**** _ 443**** -.169 p<.08 .380****
TMT-B .408**** -.582**** -.009 .248*
SDMT-W - 564**** 4 9 * * * * .261** _ 434****
SDMT-O - 507**** 464**** .225* -.387****
RAVLT-T - 451**** 496**** .131 -.303**
RAVLT-Dt .028 -.083 -.117 .003
GP-DOM 392* * * * -.368**** -.157 312***
GP-NDOMt .346**** - 378**** -.281** 327***
Note: GFR = Glomerular Filtration Rate 
t  Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001
Univariate analysis indicated that higher educational level and younger age were 
significantly associated with better neuropsychological functioning. The observed
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correlation coefficients ranged from r = .36 to r = .56 for age and r = .34 to r = .58 for 
educational level, indicating moderate-sized correlations.
Employment status was also significantly associated with NP test performance, with 
employed TX patients demonstrating more efficient cognitive functioning relative to 
non employed TX patients (data not shown) even after the observed differences between 
employed vs. non employed patients in age, education and ESRD severity were taken 
into account. ANCOVA analyses (controlling for these casemix differences) revealed 
that employed patients performed better in SDMT-W (F(3, 98) = 6.309, p  =. 014), 
SDMT-O (F(3, 94) = 4.731, p  = .032), GP-DOM (F(3, 96) = 11.426, p  = .001), and GP- 
NDOM (F(3, 92) = 10.12, p  = .002). Observed group differences in the remaining tests, 
which were evident only in independent r-test or Mann-Whitney analyses, were muted 
when sociodemographic and clinical differences were controlled for.
Significant correlations were also noted between medical variables and cognitive 
functioning. Glomerular Filtration Rate (GFR), an indicator of graft function and 
clearance efficiency, was also found to be associated with NP performance. Higher GFR 
values indicating better clearance were associated with better scores in SDMT-W (r = 
.26, p  = .007); SDMT-O (r = .23, p  = .022); and GP-NDOM (rs = -.28, p = .005). Higher 
ESRD severity was significantly associated with more compromised cognitive 
functioning in all NP tests. The observed correlation coefficients ranged from rs = .25 to 
r^  = -.43. The NP performance of patients with ischaemic heart disease fell significantly 
short of that of patients with no heart problems in SDMT-W (F(l, 107) = 8.633, p  = 
.004), RAVLT-T (F(l,105) = 9.58, p  = .003). These differences however ceased to be 
significant when the age and education were controlled for in ANCOVAs (F(3, 99) = 
1.765, p = .187 for SDMT-W and F(3, 97) = 2.079, p  = .153 for RAVLT-T).
Neither time spent on dialysis prior to transplantation, number and duration of previous 
transplants (if any), time on RRT, nor time with their current transplant (duration of 
functioning graft) were associated with NP scores (data not show).
2.5.b Blood pressure and NP scores in TX patients
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) recordings were 
performed, with measurements made in both supine and sitting positions before the NP
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assessment. Pulse pressure ratings (PPR) expressed as the difference between diastolic 
and systolic pressure (taken when standing and lying) were also computed. Their 
correlations with indices of NP performance were examined and indicated several 
significant associations (see Table 6.46)
Table 6.46: Correlations between blood pressure and NP scores in TX patients
DBP-ly DBP-st SBP-ly SBP-st PPR-lyt PPR-st
TMT-A .018 -.003 .275** .247* .263** .278**
TMT-B -.042 -.021 .218* .247* .221* .287**
SDMT-W -.048 .026 -.254** i to H-* oo * -.273** -.261**
SDMT-O .024 .086 -.22* 1 1—* oo oo -.303** -.262**
RAVLT-T .045 -.018 -.204* -.196* -.144 -.204*
RAVLT-Dt .089 .179 .070 .049 .024 -.068
GP-DOM .055 -.018 .221* .123 .240* .20*
GP-NDOMt .042 -.058 .226* .198 .212* .214*
Note. DBP-Dly = diastolic blood pressure lying; DBP-st = diastolic blood pressure standing; 
SBP-Sly = systolic blood pressure lying; SBP-st = systolic blood pressure standing; PPR-ly = 
pulse pressure rating lying; PPR-st = pulse pressure rating standing;.
a = Time to completion in seconds. b = number correct. c = total of the 8 NP indices (z-scores)
+ Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001.
Concurrent levels of systolic blood pressure correlated significantly with measures of 
psychomotor speed (i.e. GP) and attention (SDMT-W, SDMT-O, TMT-A, TMT-B) 
with correlation coefficients ranging from .20 to .28. The direction of observed 
correlations indicated that higher levels of systolic blood pressure were associated with 
less efficient cognitive functioning.
Pulse pressure ratings were also significantly associated with 7 of the 8 NP scores (the 
exception being RAVLT-D). For instance, higher standing pulse pressure ratings 
correlated significantly with RAVLT-T (r = -.20, p -  .045), SDMT-O (r = -.26, p  = 
.009), SDMT-W (r = -.26, p = .008), GP-D (r = .20, p  = .045), GP-NDOM (rs = .21, p  = 
.036), TMT-A (r = .28, p  =.004) and TMT-B (r = .29, p -  .005). Similar sized 
correlations (rs) were found between lying pulse pressure ratings and NP scores. 
Interestingly, neither diastolic blood pressure measurement nor the presence of 
hypertension were associated with cognitive functioning (i.e. ANOVA comparisons 
showed no significant NP differences between patients with hypertension vs. those not 
diagnosed with hypertension).
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2.5.C Biochemistry and NP scores in TX patients
Only a few significant albeit weak correlations, in the expected direction were found 
between NP scores, mainly in NP tests of attention and concentration and biochemical 
measures. These however were not consistently replicated across all NP scores and 
therefore the findings should be treated with caution.
Increasing urea levels correlated with poorer performance in SDMT-W (rs = -.211, p  = 
.029), SDMT-O (rs = -.19, p  = .05) and TMT-A (rs = .205, p  = .033). The correlation 
between urea and GP-NDOM scores approached but did not reach significance (rs = 
.193, p  = .054). Higher albumin levels correlated with SDMT-W (rs = .295, p  = .036), 
SDMT-O (rs = .21, p  = .036), and TMT A (rs = -.218, p  = .024). Creatinine correlated 
significantly with GP-NDOM scores (rs = .197, p  = .049).
With respect to liver function, only Gamma Glutamyl Transferase was significantly 
associated with SDMT-W (rs = -21, p = .035), and SDMT-O scores (rs = -.21, p  = .038). 
Finally, no correlation was found between haemoglobin levels and NP scores probably 
due to the narrow range of haemoglobin levels observed. No other biochemical values 
were related to NP functioning.
2.5.d Immunosuppressive medication and NP performance
The influence of an immunosuppressive regime on NP performance was examined by 
comparing NP performance between TX patients on cyclosporin (n = 70) and TX 
patients treated with tacrolimus (n = 40). Seven patients who were on prednisolone and 
azathioprine only were not included in these analyses.
i. Sample characteristics
Significant casemix differences were found between the two groups requiring statistical 
control in subsequent analyses (see Appendix I) These indicated that patients on 
tacrolimus were significantly younger (t(107) = 2.164, p  = .033), and have been on RRT 
(U = 843, p  = .001) and with their transplant (U = 206.5, p -  .0001) for less time 
compared to patients on cyclosporin. Results also showed that significantly more 
diabetic patients were managed on tacrolimus (%2(110) = 4.094, p  = .043). There were 
no other clinical differences between groups.
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These differences appear to reflect the changes in the selection and management of TX 
patients or candidates. For instance, the differences in age and duration of RRT and of 
functioning graft (i.e. time with transplant) were anticipated, as tacrolimus only recently 
became available for the management of TX patients. The finding of more diabetic 
patients being treated with tacrolimus may also be attributed to changes that took place 
over time with regard to transplant selection criteria.
ii. NP comparisons: cyclosporin vs. tacrolimus
ANCOVAs (covarying for age and diabetes, as neither TX duration nor RRT duration 
were not significantly associated with any of the NP scores) were performed to compare 
cyclosporin-treated to tacrolimus-treated TX patients.
There were no significant differences in any of the NP scores, indicating different types 
of immunosuppressive medication have comparable effects on patients’ NP 
performance (see Table 6.47).
Table 6.47: NP performance in cyclosporin and tacrolimus treated TX patients
Cyclosporin___________ Tacrolim us
Mean SD Mean SD F P
TMT A a 37.82 18.22 35.94 20.35 .373 .543
TMT B a 90.90 63.24 80.52 44.91 1.172 .282
SDMT-W b 44.59 12.44 49.59 14.04 2.456 .120
SDMT-O b 50.56 14.83 54.65 15.34 .782 .379
RAVLT-T b 45.37 10.64 50.42 9.54 2.097 .091
RAVLT-D 1.746 1.703 1.974 1.881 .879 .351
GP-DOM8 76.94 27.44 75.64 21.61 .043 .835
GP-NDOM8 85.93 30.46 89.02 28.08 .651 .422
NP-TO 1.36 3.62 1.32 4.75 1.259 .746
NP-norm 1.17 1.45 1.35 1.98 .211 .647
Note. TMT-A = trail making test part A; TMT-B = trail making test part B; SDMT-W = symbol 
digit modality test written administration; SDMT-O = symbol digit modality test oral 
administration; RAVLT-T = Rey Auditory Verbal Learning Test total word recall at trial 1 to 5; 
RAVLT-D = Rey Auditory Verbal Learning Test drop in retention from trial 5 to 7; GP-DOM 
= Grooved Pegboard dominant hand; GP-NDOM = Grooved Pegboard non dominant hand; NP- 
TO = total NP performance score; NP-norm = count of NP impairment relative to norms
8 = Time to completion in seconds. b = number correct. c = total of the 8 NP indices (z-scores)
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Correlational analysis showed that increasing plasma/serum levels of cyclosporin 
correlated significantly with longer time latencies in GP-DOM (rs = .27, p  = .035), GP- 
NDOM (rs = .36, p  = .006), SDMT-O (rs = -.29, p  = .024), TMT-A (rs = .47, p  = .000) 
and TMT-B (rs = .33, p  = .011). In contrast, tacrolimus serum levels were unrelated to 
measures of NP functioning.
2.5.e Mood and NP performance
Correlations were used to examine the associations between NP outcomes and mood 
indicators in transplant patients. A non-parametric rank correlation (Spearman’s) was 
used for GP-NDOM and RAVLT-D, as they were not normally distributed in this 
sample. The strongest correlations were noted for total BDI scores, indicating poorer 
performance in RAVLT-T (r = -.27, p = .008), SDMT-W (r = -.31, p  = .002), SDMT-O 
(r = -.28, p  = .005) and in GP-DOM (r = .21, p  =.034) with higher depressive symptoms. 
Interestingly, no significant correlations were identified between negative affect and 
cognitive depression index and any of the NP scores. Positive affect was positively 
associated only with RAVLT-T (r = .24, p  = .027).
2.5.f Multivariate predictors of NP functioning in Transplantation
A series of hierarchical multiple regressions were performed to predict NP performance 
from a combination of sociodemographic and clinical variables. The results of the 
univariate analyses described above were used to select the predictor variables. Only the 
variables significantly associated with the specific NP scores at p  <. 05 were entered in 
the regressions. This was deemed necessary as the sample size (n = 117) prevented 
entry of all variables (especially biochemical assays).
The predictors and order of entry were: age, education (Block 1); ESRD-SI, ischaemic 
heart disease, GFR, pulse pressure ratings (Block 2), positive affect (Block 3), and urea, 
albumin, creatinine and gamma glutamyl transferase (Block 4). These variables were 
entered sequentially in blocks (as indicated) using the stepwise method to determine 
which variables within each block made the strongest contribution to the prediction of 
NP outcomes.
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Employment status was not included as a predictor as it was seen more as an outcome of 
cognitive functioning rather than a predictor. Total BDI scores were also not entered as 
they partly reflect symptoms of renal severity (see Chapter 5; section 2.3) and cognitive 
depression symptoms were not significantly associated with any of the NP scores (see 
previous section 2.5.e).
Multiple regression analysis was not performed for RAVLT-D as none of the 
sociodemographic, medical, or mood measures was significantly associated with that 
NP score.
Table 6.48: Multiple regressions to predict SDMT-W, SDMT-O and TMT-A in TX 
patients: standardised regression coefficient, cumulative variance explained
SDMT-W SDMT-O TMT-A
P
Cum
R2
Cum 
Adj R2 P
Cum
R2
Cum 
Adj R2 P
Cum
R2
Cum 
Adj R2
Block 1
Age -.466 .314 .306 -.357 .241 .232 .414 .230 .222
/ 2=.49 /= •  47 / 2=.36 f 2=. 33 /= •  32 f 2=. 30
Educ .203 * .292 .275 -.221* .276 .26
/ 2=.08 / 2=. 06 / 2=06 f = .  05
Block 2
ESRD SI -.233 * .360 .345 -.217 * .332 .308
II o f 2=. 06 /= •  06 N
>
II o
PPR 
GFR 
Block 3 
PNS-PA 
Block 4 
Urea 
Albumin 
Ggl
* p <.05. ** P < .01. *** p <.001. **** p < .0001.
Note: f  -  variance-based measure of effect size calculated as /  = AR2 / (1- /?2x0tai); ESRD = end- 
stare renal disease severity index; GFR = glomerular filtration rate; PPR = pulse pressure 
ratings; PNS-PA = PANAS positive affect; Ggl = gamma glutamyl transferase
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Table 6.49: M ultiple regressions to predict GP-DOM, GP-NDOM  and RAV LT-T in TX
patients: standardised regression coefficient, cum ulative variance explained
GP-DOM GP-NDOM RAVLT-T
Cum Cum Cum Cum Cum Cum
p R2 Adj R2 p R2 Adj R2 P R2 Adj R2
Block 1
Age .263 .129 .12 .266 .131 .121 -.389 .194 .183
* f = .  23 j 2- \ \  ** / = .  26 / 2=.15 f= .21 f 2=. 25
Education .241 * .276 
f 2=. 12
.235
/ 2=.07
Block 2
ESRD SI .256 * .186 
f = .  07
.168 .297
f = .  06 **
.21
f = .  10
.192 
/ 2=. 09
PPR
GFR
Block 3
PNS-PA .204* .296
/ 2=.03
.267
/ 2=.04
Block 4
Creatinine -
Urea -
Albumin -
Ggl -
* p <.05. ** p < .01. *** p <.001. **** p <.0001.
Note', f = variance-based measure of effect size calculated a s /  = AR2 / (1- R2j old\)', ESRD = end- 
stare renal disease severity index; GFR = glomerular filtration rate; PPR = pulse pressure 
ratings; PNS-PA = PANAS positive affect; Ggl = gamma glutamyl transferase
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Table 6.50: M ultiple regression to predict TM T-B in TX patients: standardised
regression coefficient, cum ulative variance explained
TMT-B
C u m  C u m
|3 R2 Adj R2
Block 1
Educarion -.364 .189 .18
f= .  26 / 2=.24
Age .292 .267 .25
** oif
n
f= .  09
Block 2
E S R D  SI 
PPR
GFR 
Block 3
P N S -P A  
Block 4
Urea
A lb um in
Ggl
* p <.05. ** p <  .01. *** p <.001. * ***  p <.0001.
Note: f =  variance-based  m easure o f  e ffec t  s iz e  ca lcu lated  a s / 2 =  A R2/ (1 - ft2Totai); E S R D  =  end- 
stare renal d isea se  sever ity  index; G FR  =  g lom erular filtration rate; PPR  =  p u lse  pressure  
ratings; P N S -P A  = P A N A S  p o sitiv e  affect; G gl =  gam m a glu tam yl transferase
R esults ind icated  that the total am ount o f variance explained  ranged  from  16.8%  to 
34.5%  across the d ifferen t N P scores and that am ong the host o f variables included  as 
predictors in these analyses, only three variables, nam ely  age, education, and E SR D  
severity  em erged  as significant predictors o f N P perform ance (see T ables 6.48 -  6.50). 
These three variables in conjunction exp lained  30.8%  (A dj.R 2) in the variance of 
SD M T -O ; A ge and ESR D  severity  accounted  for A d j.R 2 34.5%  in SD M T -W , 16.8%  in 
G P-N D O M  and 19.2%  in G P-D O M . F inally , age and educational level w ere sign ificant 
predictors o f T M T -A  (A dj.R 2 = 26% ) and TM T-B  (A dj.R 2 = 25% ) and in conjunction  
with positive affect explained  26.7%  o f the variance (A dj.R") in verbal recall (R A V L T  - 
T).
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2.6 NP comparisons: Dialysis vs. Transplantation
For the transplant group three sets of comparisons were performed: (1) with the 
combined dialysis sample in which HD and PD patients were collapsed to form one 
group, (2) with the PD group only, and (3) with the HD group only.
Before comparing the NP performance between dialysis and transplant patients, it was 
necessary to test for any significant casemix differences between the groups that would 
require statistical adjustments in subsequent comparative analysis.
2.6.a Combined Dialysis vs. Transplantation
i. Sample characteristics
To identify casemix differences to be controlled for, the sociodemographic and clinical 
profile of the combined dialysis sample was compared to that of transplant recipients. 
With respect to sociodemographics, results indicated significant differences in annual 
income (%2(243) = 38.602, p -  .0001), work status (%2(259) = 5.234, p = .022), and 
perceived work ability (%2(259) = 19.7, p -  .0001) in favour of transplantation. 
Transplant patients had also lower ESRD severity (F(l, 260) = 8.515, p  = .004), lower 
prevalence of diabetes (%2(262) = 9.107, p  = .003) and ischaemic heart disease (%2(262) 
= 5.265, p  = .022), and had been on RRT (F(l, 259) = 23.436, /?= .0001) and in their 
respective current form of treatment for longer relative to dialysis patients (U = 5332, 
p= .0001) (F(l, 260) = 24.559,/?= .0001).
The differences between the dialysis and transplant groups were anticipated. This was 
because dialysis patients with higher ESRD severity as indexed by the presence and 
development comorbidities or renal complications, and those of more advanced age are 
rarely considered as suitable transplant candidates. The worse clinical status of dialysis 
patients may also at least partially explain the different employment rates and the 
resulting annual income disparities between dialysis and transplant groups.
ii. Absolute NP scores
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C om parisons betw een the d ialysis and transplan t sam ples w ere perform ed on T1 NP 
scores fo r the d ialysis sam ple. O nly  the T1 N P perform ance o f the d ialysis sam ple was 
used in this analysis to avoid  learning effects.
A series o f A N O V A s (covarying for E SR D  severity, diabetes ischaem ic heart disease 
and tim e on R R T) was perform ed to com pare absolute N P perform ance betw een 
transp lan t and dialysis patients. T im e on current treatm ent m odality  was not used  as a 
covariate  as it was highly  correla ted  with tim e on R R T  and the latter had stronger 
corre la tions w ith N P scores (data not show n). A lso, no ad justm ents w ere m ade for 
em ploym ent and incom e d ifferences as these w ere regarded  as consequences ra ther than 
predictors o f N P functioning.
Results demonstrated that transplant patients performed significantly better in 4 NP 
tests: TMT-A (F(5, 249) = 6.147, p  = .014); SDMT-O (F(5, 244) = 4.385, p  = .037); 
RAVLT-T (F(5, 246) = 21.024, p  = .0001); RAVLT-D (F(5, 246) = 8.77, p  = .003). 
Trends in the same direction were also noted in SDMT-W (F(5, 248) = 3.137, p  = .078); 
GP-DOM (F(5, 245) = 3.548, p  = .061) but did not reach significance.
iii. Prevalence o f NP impairments
Table 6.51: Prevalence of NP impairments in TX and dialysis patients
All TX 
% impairment
DL (T1)
% impairment
TX vs. DL
______ __x2
TMT-A 11% (12) 35.9% 20 391****
TMT-B 7.7% (9) 15.2% 2.199
SDMT-W 19.3% (21) 32.4% 5.487*
SDMT-O 27.6% (29) 41.4% 5.030*
RAVLT-T 21.5% (23) 47.6% 18.081****
GP-DOM 20.6% (22) 41.7% 12 432****
GP-NDOM 27.5% (28) 
Mean SD
49.3% 
Mean SD
11 859****
NP
impairment
1.231 1.714 2.627 2.182
* p <.05. ** p <.01. *** p < 001 **** p <.0001.
Chi-square analysis indicated that significantly less TX patients fell in the impaired NP 
range of standard norms relative to dialysis patients: GP-DOM (%2(251) = 12.432, p  = 
.0001); GP-NDOM (x2(246) = 11.859, p  = .0001); SDMT-W (x2(254) = 5.487, p
243
.019), SDMT-O (x2(250)= 5.03, p = .025), and TMT-A (%2(254) = 20.39, p  = .0001) 
(see Table 6.43).
The percentage of TX patients for which a considerable drop in retention (RAVLT-D) 
was noted after interference was substantially lower (n = 18, 16.8%) than that observed 
in the combined dialysis sample (n = 41, 28%; %2(252) = 4.50, p = .034).
ANCOVAs (controlling for ESRD-SI, diabetes and ischaemic heart disease) also 
showed that the count of NP impairments was also significantly lower in the transplant 
group compared to dialysis (F(5, 256) = 16.375,/? = .0001).
2.6.c PD patients vs. TX patients
i. Sample characteristics (PD; HD; TX)
Three group comparisons (HD, PD and TX patients) indicated significant group 
differences in sociodemographic and medical variables: income, perceived work ability, 
time on current treatment, time on RRT in general, ESRD severity index and diabetic 
status.
Significantly more TX patients rated themselves as able to work full or part-time 
(% (259) = 21.11, p  = .0001) and reported an annual income in the higher brackets 
(%2(243) = 25.88, p  = .0001) than HD and PD patients. They also had been on RRT 
(F(2, 259) = 28.39, p  = .0010) for longer compared to the two dialysis groups and were 
less likely to have diabetes (%2(262) = 23.16, p  = .0001). Comorbidity and clinical 
severity differences as indexed by the ESRD-SI however were only evident between PD 
and TX patients. Post-hoc (HSD) tests also showed that PD patients had higher ESRD 
severity than TX patients (F(2, 159) = 4.598, p = .011)
ii. Absolute NP scores
Transplant patients’ NP performance was compared to NP scores of PD patients (at both 
T1 and T2).
It was decided to include the T2 scores for the PD group in these comparisons even 
though 7 of 10 NP test scores did not change significantly across the two assessments 
and despite the fact that T2 scores in PD patients would reflect a learning effect, not 
anticipated in the scores of TX patients who were only tested once. The reason for this
244
was that such an ‘unfavourable’ comparison would constitute a much stronger test of 
the NP benefits of transplantation over and above learning effects.
Comparisons were performed using ANCOVAs including ESRD severity, diabetes, 
ischaemic heart disease and RRT duration as covariates. Time on current dialysis 
treatment was not included as it highly correlated with RRT duration and was less 
consistently associated with NP scores.
These analyses showed a significant group effect in two T1 NP scores: RAVLT-T (F(5, 
169) = 13.334, p = .0001) and RAVLT-D (F(5, 169) = 5.694, p  = .018). Relative to TX 
recipients, PD patients had significantly lower memory scores, both in terms of 
immediate recall from short-term memory (RAVLT-T) as well as in retention ability 
after interference (RAVLT-D). Attention, concentration and psychomotor abilities were 
comparable in the two groups.
The second set of comparisons using the T2 NP scores for the PD patients replicated the 
above findings. Transplant patients’ memory scores were superior to those of PD 
patients even though PD patients were administered the test twice (F(5, 165) = 11.104, p 
= .001 for RAVLT-T and F(5,165) = 14.114, p  = .000 for RAVLT-D).
iii. Prevalence ofNP impairments
Chi-square analysis revealed that significantly more TX patients performed comparable 
to their age reference norms compared to PD patients at T l: RAVLT-T (%2(175) = 
10.078, p  = .002); RAVLT-D (x2(175) = 8.921, p  = .003); GP-DOM (x2(170) = 9.822, p  
= .002); GP-NDOM (%2(170) = 9.869, p  = .009); SDMT-O (x2(173)= 5.883, p =  .015); 
SDMT-W (x2(177) = 3.389, p  = .048); and TMT-A (x2(177) = 12.292, p  = .0001). NP 
impairments in TMT-B did not differ between the two groups.
Most of these differences persisted even when T2 NP scores were used for the PD 
patients: RAVLT-D (%2(175) = 16.867, p  = .0001); GP-DOM (x2(170) = 9.609, p  = 
.002); GP-NDOM (%2(165) = 6.949, p  = .008); SDMT-W (%2(173) = 4.025, p  = .045); 
and TMT-A (x2(173) = 4.729, p = .030). The only exceptions were RAVLT-T and 
SDMT-O.
ANCOVAs (controlling for ESRD SI) indicated that TX patients presented with overall 
less NP impairments (i.e. in less areas of cognition) (mean = 1.23, SD = 1.71) compared
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to PD patients at T1 {mean = 2.57, SD = 2.03; F(2, 182) = 15.539, p  = .0001) and T2 
0mean = 2.67, SD = 2.32; F(2, 182) = 13.532, p  = .0001).
2.6.c HD patients vs. TX patients
i. Absolute scores
NP scores of HD patients at both assessments were used, as significant acute NP 
changes were documented for pre- to 24-hours post-dialysis. It should however be 
recognised that comparisons using post-dialysis (T2) scores favoured the HD group as 
they have been earlier exposed to the NP tests whereas TX patients were only 
administered the tests once. This is especially the case for TMT-A, SDMT-W and 
SDMT-O in which practice effects were clearly demonstrated for PD patients (see 
section 1.8).
A series of ANCOVAs (controlling for ESRD severity and time on current treatment) 
was similarly performed to compare NP scores of HD and TX patients. Results 
indicated more compromised cognitive functioning for the HD patients when assessed 
immediately before their dialysis session (T1 assessment). NP scores of HD patients at 
T1 fell significantly short of those of TX patients in RAVLT-T (F(3, 180) = 17.589, p  = 
.0001); TMT-A (F(3, 183) = 10.337, p  = .002), SDMT-O (F(3, 178) = 4.351, p  = .038), 
SDMT-W (F(3, 183) = 4.781, p  = .030), and GP-DOM (F(3, 179) = 4.743, p  = .031). 
The difference in RAVLT-D was nearly significant (F (3 ,180) = 3.853),/? = .051).
In contrast to T1 comparisons, NP performance of HD patients at 24-hours post-dialysis 
(T2) did not differ to that of transplant patients. Only RAVLT-D scores differed 
significantly between groups, with HD patients still demonstrating at 24-hours post­
dialysis, less efficient retention after interference (F(3, 180) = 6.948, p  = .009) 
compared to TX patients. In none of the other nine ANCOVA comparisons was the 
main effect of treatment (HD vs. TX) significant (ps c .l).
ii. Prevalence ofNP impairments
Comparisons of the frequency of NP impairments between HD and TX patients yielded 
a similar pattern of results in that the prevalence of NP impairments at T1 was greater in
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HD patients compared to those with a transplant: TMT-A (%2(186) = 20.167, p  = .0001); 
RAVLT-T 0c2(184) = 17.035, p  = .0001); SDMT-W (x2(186) = 4.225, p =. 040); GP- 
DOM (X2(183) = 8.838, p =.003); GP-NDOM (x2(178) = 10.567, p = .001).
The observed associations between treatment and NP impairments (SDMT-W; GP- 
DOM; GP-NDOM) disappeared when comparing incidence of NP impairment in HD 
patients based on the 24-hours post-dialysis performance (T2) vs. to that of transplant 
recipients. The group differences however in RAVLT-T and TMT-A impairment 
classification favouring transplantation persisted. Chi square analysis indicated that 
even at the T2 ‘24 hours post-dialysis’ assessment significantly more HD patients 
performed worse than age referenced norms in TMT-A (%2(186) = 5.102, p  = .024) and
RAVLT-T (%2(184) = 4.166,/? = .041) compared to TX patients.
In terms of overall neurocognitive dysfunction (as indexed by number of tests in which 
NP impairments were noted), ANCOVAs (covarying for ESRD severity) showed that 
TX patients had lower count of NP impairments (T1 {mean = 1.23, SD = 1.71) 
compared to HD patients at T1 {mean = 2.67, SD =1.23; F{2, 191) = 20.951, p  = .0001)
and T2 {mean = 1.89, SD = 2.19; F{2, 191) = 20.951, p = .048).
2.7 Subjective Cognition Scale -  Transplantation
2.7.a Post Transplantation Changes in subjective cognition
The responses of transplant patients on the SCS scale measuring perceptions of change 
in their cognitive abilities since transplantation are shown in Table 6.52.
The distribution of responses in the nine cognitive domains assessed indicated a greater 
variability in TX patients’ reports compared to dialysis. Although the majority of 
patients (45.9% -  76.1%) perceived no cognitive changes since transplantation, there 
was also a substantial number of patients who reported either cognitive improvement or 
decline from pre- to post- transplantation.
Overall, TX patients (59.8%, n = 70) in total, reported more efficient cognitive abilities 
in one or more area of cognition. The most frequently reported area of cognitive
247
improvement with transplant patients was clarity of thinking (36%, n = 40), followed by 
attention (27%, n = 30) and speed of response (24.3%, n = 27).
An equally high percentage (52.1%, n = 61) of patients however, perceived that one or 
more of their cognitive abilities had deteriorated since receiving their transplant. 
Memory was the most frequently reported area of difficulty with these patients, with 
32.4% reporting that they were worse/more forgetful since transplantation. 
Concentration was the next most common cognitive complaint (19.8%), followed by 
problem solving (18.9%).
Table 6.52: Long term changes in subjective cognition in TX patients
Cognitive domain + ve change = no change - ve change
2. Memory 12.6% (12) 55% (61) 32.4% (36)
3. Problem solving 15.3% (17) 62.4% (73) 18.9% (21)
4. Clarity of thinking 36% (40) 45.9% (51) 18% (20)
5. Concentration 21.6% (24) 58.6% (65) 19.8% (22)
6. Making mistakes 12.6% (14) 77.5% (86) 9.9% (11)
7. Attention 27% (30) 59.5% (66) 13.5% (15)
8. Clumsiness 7.2% (8) 80.2% (89) 12.6% (14)
9. Decision making 15.3% (17) 72.1% (80) 12.6% (14)
10. Speed of response 24.3% (27) 61.3% (68) 14.4% (16)
Improvement (1 or >)a 59.8% (70)
Deterioration (1 or >)b 51.1% (61)
a improvement in just one or more of the nine cognitive domains/ subjective cognition items 
b deterioration in just one or more of the nine cognitive domains/ subjective cognition items
2.7.b Transplant type and subjective cognition
Pearson’s chi square comparisons with Yate’s correction showed no association 
between transplant type and reports of cognitive decline or improvement since 
transplantation in any of the domains examined (as indexed by the SCS items) (data not 
shown).
In addition to examining the distribution of responses in the nine SCS items, the 
associations of TX type to the three summary SCS scores were examined (see Table 
6.53). These were calculated as described in section l.lO.e.
248
Table 6.53: Subjective cognition summary scores in TX patients
All TX pts CAD LRD
Mean SD Mean SD Mean SD
Total cognitive decline since TX 17.80 3.23 17.77 3.17 17.92 3.50
No + ve changes since TX 1.72 2.17 1.79 2.15 1.46 2.26
No -  ve changes since TX 1.52 1.99 1.56 1.97 1.37 2.10
Note: TX pts = transplantation patients; CAD = cadaver transplant recipients; LRD = living 
related donor transplant recipients; TX = transplantation; +ve = positive change/improvement; - 
ve = negative change/deterioration
ANCOVAs (controlling for casemix differences, i.e. time with TX) showed no 
significant differences between LRD and CAD TX groups in any if the three summary 
scores (see Table 6.53 above for group means): total of cognitive decline (F(2, 108) = 
.759, p  = .389); number of positive changes (F (2, 108) = .160, p  = .690); and number of 
negative changes (F(2, 108) = .912, p = .342).
2.7.C Absolute NP scores and Subjective cognition
The associations between objective NP scores and subjective reports of cognition were 
investigated using a series of Mann-Whitney or Independent group t-tests (as 
appropriate). Comparisons between TX patients reporting improvement vs. those 
reporting cognitive decline since transplantation were performed on the objective NP 
scores, considered to reflect the particular cognitive function assessed by the grouping 
subjective cognition item. Patients reporting no change were excluded from this 
analysis.
The 20 (18%) TX patients reporting worsened clarity of thinking were compared to the 
40 (36%) TX patients reporting improvement on all NP test scores. Only the findings on 
RAVLT-T (total recall at trials 1 to 5) reached significance with patients reporting more 
clarity in thinking since transplantation recalling significantly more words than the 
‘cognitive decline’ group (t(29.48) = 2.21, p  = .035).
There were no significant differences in RAVLT scores between patients complaining 
of memory difficulties (n = 36, 32.4%) and those reporting better memory abilities 
(12.6%, n = 14).
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TX patients reporting concentration (18%, n = 22) and attention (13.5%, n = 15) decline 
since transplantation were compared to the ‘cognitive improvement’ group on the tests 
considered to measure attention (TMT-A; TMT-B; SDMT-W; SDMT-O). Results 
showed that the latter group (‘attention improved’) performed significantly better in the 
SDMT-W than those patients registering deterioration their attention abilities (t(43) = 
2.09, p = .043). A similar trend/tendency was noted in the SDMT- O but did not reach 
significance (t(42) = 1.91, p  = .06).
The subjective complaints related to response speed were compared to performance on 
the speed/time dependent NP tasks (TMT-A; TMT-B; SDMT-W; SDMT-O; GP-DOM; 
GP-NDOM). Patients reporting deterioration (14.4%, n = 16) in their response speed 
were not found to perform differently/worse than those (24.3%, n = 27) reporting 
improvement in any of the above NP tests.
On the whole these group comparisons revealed some significant differences between 
objective and subjective cognition but with little consistency across NP measures and 
across the different SCS domains.
Correlational analysis between summary subjective cognition measures and the 
total/summary score of objective NP scores and number of NP deficits showed no 
significant correlations (ps < .1) (data not shown).
2.7.d Factors associated with subjective cognition in TX
i. Sociodemographic and medical factors
Correlations (Spearman's rs) and ANOVAs (or ANCOVAs as appropriate) were 
conducted to examine the associations between sociodemographic and medical 
variables and subjective cognitions (i.e. the three summary scores).
Employment status was the only sociodemographic variable significantly associated 
with SCS summary scores and distribution of responses in the individual SCS items. 
ANCOVA showed that employed TX recipients reported significantly fewer negative
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changes in their cognitive abilities {mean = 1.15, SD = 1.74) than non-employed 
participants {mean = 1.98, SD = 2.179) {F{2, 105) = 6.304, p  = .014). chi square 
analysis showed that a gretaer percenatge of non employed patients reported 
deterioration in the attention abilities compared to employed participants (%2(108) = 
7.286,/? = .026).
With respect to medical variables, the only significant correlations observed were 
between SCS summary scores and time spent on dialysis prior to TX, time since 
transplantation and GFR. The longer patients had their transplant, the more cognitive 
decline they reported (rs = .26, p  = .009) and less positive cognitive changes they 
perceived (rs = -.259, p  = .006).
Conversely, time spent on dialysis prior to transplantation was associated with more 
positive evaluation of cognition. The longer time on dialysis the more positive cognitive 
changes TX patients reported (rs =.195, p  = .045) and the lower their overall subjective 
cognitive decline score (rs = -.211,/? = .030)
Lower GFR levels were similarly associated with overall perceived cognitive decline(rs 
= -.22, p  = .021) and count of negative changes in cognition (rs = -.21, p  = .028), 
suggesting that deteriorating TX function is associated with more negative evaluations 
of cognition.
No other significant associations were identified between the three SCS summary scores 
and sociodemographic and medical variables (i.e. age, gender, ESRD severity index, 
comorbidity).
ii. Immunosuppressive medication
The association between immunosuppressive medication and reports of cognitive 
change since transplantation was also examined. In contrast to findings on absolute NP 
scores chi-square analysis showed only one significant association between type of 
immunosuppressive medication and cognitive complaints.
Results indicated that significantly more TX patients treated with cyclosporin reported a 
deterioration in their memory abilities compared to patients on tacrolimus (%2(48) = 
3.862,/? = .022).
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Between group comparisons on the summary subjective cognition scores (without 
casemix adjustments) also showed that patients on cyclosporin reported significantly 
fewer positive changes in their cognitive abilities {mean = 1.35, SD = 2.00) relative to 
patients on tacrolimus {mean = 2.44, SD = 2.44; t (108) = -2.590, p  = .011).
This difference was removed when time with TX was controlled for {F{2, 102) = 1.252, 
p = .266). Likewise, the count of negative changes and total cognitive decline scores did 
not differ between groups (F(2, 102) = 1.520, p = .220 and F{2, 102) = .0001, p = .990 
respectively).
iii. Mood measures
Independent f-tests were performed to investigate the association between mood 
measures and subjective complaints of cognitive decline in TX patients. Patients in the 
‘cognitive decline’ groups as described above were compared to those reporting 
improvement on BDI, CDI, positive affect, and negative affect.
Results indicated that levels of mood differed significantly between TX patients 
reporting improvement vs. those reporting deterioration since their transplant.
TX patients who felt that their cognitive abilities have deteriorated since transplantation 
reported more depression, more negative affect and less positive affect (see Table 6.47). 
Likewise, Spearman’s correlational analysis showed that the more cognitive decline 
(summary SCS score) the lower the positive affect (rs = -.277, p  = .009) and the higher 
the depression scores (rs = .322, p = .001 for BDI and rs = .26, p  = .009 for CDI). The 
correlation coefficient for negative affect approached but did note reach significance (rs 
= .199, p = .058).
The number of negative changes was also correlated with mood, i.e. lower positive 
affect (rs = - .30, p  = .003), more negative affect (rs = .31, p  = .001) and more depression 
(rs = .41, p= .0001; rs = .39, p  = .001 for total BDI and CDI scores respectively). No 
significant correlations were found between any mood measure and the number of 
perceived positive changes in cognition.
252
Table 6.54: M ood and perceptions of long-term cognitive changes since TX
BDI CDI PNS-NA PNS-PA
t-value
mean/SD
t-value
mean/SD
t-value
mean/SD
t-value
mean/SD
Memory
-ve
-i-ve
ns
9.40 (6.96)
9.38 (8.8)
ns
6.15 (4.87)
6.31 (6.01)
ns
18.75 (5.66) 
16.55 (4.45)
ns
28.23 (6.97) 
32.45 (8.49)
Pr. Solving
-ve
+ve
-2.36* 
12.42 (6.85)
6.5 (8.02)
ns
8.11 (4.91)
4.62 (5.52)
-2.28* 
20.56 (5.95) 
16.5 (3.2)
ns
26.31 (7.42) 
30.23 (5.93)
Clarity thinking 
-ve 
+ve
-2.26* 
11.47 (6.46) 
6.91 (6.92)
ns
6.82 (4.17)
4.70 (4.92)
ns
19.86 (7.27) 
17.26 (3.91)
3.63*** 
23.07 (7.9) 
31.23 (6.49)
Concentration
-ve
-hve
ns
11.05 (7)
8.08 (8.13)
ns
7.4 (4.76)
5.37 (5.65)
ns
20.78 (7.48) 
16.28 (3.27)
ns
25.73 (7.55) 
29.44 (7.78)
Mistakes
-ve
+ve
ns
10.8(5.13) 
11.07 (8.72)
ns
7.3 (4.59)
7.64 (5.91)
ns
18.25 (5.44) 
17.69 (2.81)
ns
29.2 (4.63) 
28.82 (8.94)
Attention
-ve
+ve
-3.43** 
14.26 (7.07) 
6.62 (6.96)
-3.43** 
9.33 (4.88)
4.2 (4.6)
ns
19.08 (5.82) 
16.53 (3.05)
2.20* 
24.36 (6.15) 
29.81 (7.13)
Clumsiness
-ve
+ve
ns
11.42 (8.92) 
8.25 (9.88)
ns
7.07 (5.7)
5.75 (6.58)
ns
18.38 (3.79) 
16(5)
ns
26.16 (8.73)
38 (3.67)
Decision
making
-ve
+ve
ns
11.75 (7.56) 
9.23 (9.49)
ns
8.33 (4.94)
6.82 (7.07)
ns
20.09 (6.86) 
17.06 (4.09)
ns
28.63 (7.2) 
29.31 (7.76)
Response speed 
-ve 
+ve
ns
12 (7.75)
9.22 (8.33)
ns
8(6.15)
5.96 (5.94)
ns
17.83 (5.63) 
17.76 (6.31)
ns
27.36 (7.83) 
31.13 (8.49)
Improvement1
No +ve 
1 or < +ve
ns
7.71 (5.46) 
8.19(7.35)
ns
5.31 (5.22)
4.71 (4.36)
ns
17.57 (5.08) 
17.35 (6.97)
ns
30.78 (7.53) 
28.41 (6.66)
Decline5
1 or < -ve 
no -ve
-3 99*** 
10.23 (7.24) 
5.43 (4.93)
-3.63*** 
6.58 (5.36)
3.35 (3.67)
-2.88** 
19.14(6.21) 
15.80 (4.87)
2.41* 
28.13(7.13) 
31.71 (7.05)
Note: BDI = tota Beck depression scores; CDI = cognitive depression index; PNS-NA =
PANAS = PANAS negative affect; PNS-PA = PANAS positive affect; +ve = positive
change/improvement; -ve =negative change/deterioration
a = Comparisons between patients reporting no improvement at all in any of the 9 cognitive 
domains since TX vs. patients reporting improvement in at least one or more areas of cognition 
b = Comparisons between patients reporting no decline at all in any of the 9 cognitive domains 
since TX vs. patients reporting decline/deterioration in at least one or more areas of cognition 
* p <.05. ** p <.01. *** p <.001. ns = non significant
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iv. Prediction o f subjective cognitive complaints
The independent contribution of sociodemographic, medical and psychological 
variables to the prediction of cognitive complaints (total SCS score) in TX patients was 
estimated using hierarchical multiple regression (stepwise method).
Only the variables found to be univariately associated with subjective cognition were 
included in this analysis, namely employment status, time on TX, and time on dialysis 
and mood measures. Identified predictors entered the regression equation in separate 
blocks: sociodemographic variables as block 1, medical and clinical variables as block 
2, followed by mood indicators at the last step of the regression. To control for any 
influence of participants’ age and educational level, these variables were entered in 
Block 1 and likewise ESRD severity index (ESRD-SI) was entered in Block 2 under 
forced entry criteria even though they did not correlate significantly with overall 
subjective cognitive decline.
The resultant regression model explained R2 = 11.2% (Adj.R2 = 9.6%) of the variance in 
subjective cognitive decline. Significant predictors were time elapsed since TX (P = 
.239, p  = .008) that accounted for R2 = 5.5% (Adj.R2 = 4.6%) of the variance and 
positive affect (p = -.239, p  = .008) that added AR2 = 5.7% (AAdj.R2 = 5%). Regression 
coefficients indicated that the longer the time elapsed since TX, and the lower the 
positive affect, the greater the cognitive complaints.
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Section 3: Summary of Results
• A substantial number of dialysis patients performed worse than age reference norms 
in attention, memory and psychomotor speed tasks
• There were no significant differences in NP scores between dialysis groups
• Acute changes in NP performance were evident only for HD in contrast to PD. This 
parallels the changes observed in biochemistry over the period of dialysis in the HD 
group although the relation to any particular biochemical change was not 
established.
• Concomitant changes were also noted in state mood indicators but these were also 
not consistently associated with acute NP changes
• Dialysis patients perceived that their cognitive abilities have declined since dialysis 
onset, particularly memory and concentration function. Significantly more HD 
patients reported day to day NP improvement relative to PD.
• Objective NP scores were mainly unrelated to indices of subjective cognition. Mood 
on the other hand was significantly associated with complaints of cognitive 
deterioration since dialysis (in most areas) and reports of post dialysis concentration 
improvement.
• The NP performance of TX patients was within normal range and was mainly 
predicted by age, education and ESRD severity. TX type (CAD vs. LRD) and 
immunosuppression (tacrolimus vs. cyclosporin) was unrelated to cognitive 
functioning.
• TX patients outperformed PD on memory tasks. They also performed better than 
HD patients on almost all NP tests but only when compared to pre- dialysis NP 
scores and not when assessed at 24 hours post- dialysis.
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There was great variability/diversity in TX patients’ subjective reports of their 
cognitive abilities since transplantation, with some patients reporting more efficient 
cognitive functioning and other a decline in cognitive abilities.
Time elapsed since transplantation and positive affect predicted subjective cognition 
in TX recipients whereas the contribution of objective NP functioning was not 
significant.
CHAPTER 7:
DISC USSIO N OF THE NEUROPSYCHOLOGICAL FIN D IN G S
One of the main focuses of this study was to evaluate NP functioning in patients with 
ESRD. This study revisits an area that was first addressed in the 1970’s and 1980’s 
however this earlier research was limited by methodological flaws that cast doubt on the 
validity and generalisability of its findings in the modem ESRD population. Many of 
these studies used very small samples, failed to address sociodemographic (i.e. age, 
education) and clinical factors (e.g. co-morbidity) and the timing of NP testing in 
relation to the dialysis cycle was not reported. The NP outcome of ESRD was therefore 
re-investigated with improved methodology to overcome previous limitations and with a 
wider focus to address issues not explored in the early research.
Study findings on absolute NP performance will be selectively discussed first in two 
sections mirroring the order that the results were presented.
Section 1: Dialysis
1.1 The prevalence of NP impairments in dialysis
To evaluate the performance of dialysis patients relative to norms, the observed 
prevalence of NP impairments relative to that expected in a normal distribution was 
calculated. For the purposes of the study NP impairments were defined as scores lower 
than 1 Sd below norms, which if expressed in ‘percentile rank terms’ correspond to 16th 
percentile and signify low average to borderline performance (Mitrushina et al. 1999). 
Such a definition of NP impairment should not be confused or be regarded as evidence 
of NP deficits. Caution in warranted in assigning clinical weight or significance in these 
findings as for example a score that occurs in less than 1% of normal sample would 
carry greater clinical weight than a score that occurs in 15% of normal sample.
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Normative comparisons using group means indicated that dialysis patients performed 
comparably to their healthy counterparts in the majority of NP tests with some mild 
impairments mainly in motor function and selective memory functions (i.e. BVRT 
errors) consistent with previous studies (Churchill et al., 1992).
Individual-based comparisons in which NP scores of each individual patient were 
evaluated against his or her respective age reference norms indicated the prevalence of 
NP ‘impairment’ might be higher than would be expected based on group comparisons. 
One third or more of dialysis patients performed 1 Sd below their respective norms, 
particularly in memory and motor tasks, which is double that expected in normal 
distribution (15.86%). Previous studies have also shown mild memory deficits in 
dialysis patients (Brown et al., 1991; Teschan et al., 1979; Wolcott et al., 1988a).
Study findings suggested memory impairments were manifested in both immediate 
verbal recall-retrieval and in retention after interference. There was substantial 
reduction in the number of words recalled after interference by both dialysis groups and 
at both assessments. On trial VII both dialysis groups recalled an average of 2.35/2.75 
(HD/PD) words less than on trials V at first assessment and 2.64/3.03 (HD/PD) less at 
second assessment. These findings indicate that even though the appearance of a 
learning curve over the previous five trials demonstrates some ability to learn, for some 
of the patients this gain is not maintained on the delayed recall (trial VII). It is of note 
that for a significant proportion of HD (20.8% at T1 and 29.9% at T2) and PD (36.8% at 
T1 and 44.1% at T2) patients recall dropped more than 3 words from trial V to trial VI. 
This is regarded an abnormal drop and probably reflects a retention or retrieval problem 
(Lezak, 1995). It should also be noted that this percentage increased from T1 to T2 
despite the overall word retention at trials 1 to 5 increased.
Findings of impaired motor function in dialysis patients have been reported previously 
(Pliskin et al., 1996). The observed rates of motor impairment in our sample were fairly 
similar for dominant and non-dominant hands. Although they reflect a central problem 
an alternative explanation is that they may have resulted from undiagnosed joint 
dysfunction, muscle weakness due to electrolyte abnormalities, subtle nutritional 
deficits, or de-conditioning. It is also possible that hand dysfunction due to dialysis 
related amyloidosis which is prevalent in HD patients (Carroll et al., 1993; Limaye et 
al., 2001) may have had complicated patients’ GP performance further. The role of a 
fistula interfering with the psychomotor tasks was given consideration but there was no
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evidence that an uncomplicated fistula interfered with motor functioning when not in 
use. In our sample 79.2% {n = 61) of the HD patients were dialysed using a fistula on 
their non-dominant hand, 11.7% (n = 9) had a fistula on their dominant hand and 9.1% 
(n = 8) were dialysing using a catheter line. It is important that no overall group 
differences were found, suggesting the presence of a fistula was not important.
Impairments in attention abilities were evident in three of the four tasks (TMT-A; 
SDMT-W; SDMT-O) and only in individual-based comparisons. The differential 
performance of patient across the TMT-A and TMT-B is noteworthy. TMT mean scores 
indicated that patients had more difficulty completing TMT-A than TMT-B test, a 
finding at odds with previous research (Bremer et al., 1997). While only 15.2% (n = 22) 
of the dialysis patients fell below the 25th percentile for TMT-B, more than twice as 
many patients {n = 52, 35.9%) fell below the 25th percentile for TMT-A (individual 
level classification). The finding of higher incidence of impairment in TMT-A rather 
than TMT-B is intriguing. Previous research showed that performance of dialysis 
patients is more compromised in complex attention tasks (such as TMT-B) rather than 
more simple attention tasks (Brown et al., 1991; Churchill et al., 1992; Fazekas et a l , 
1996; Rozeman et a l , 1992). It would also be intuitive to expect that due to its added 
complexity, the TMT-B is likely to pose more difficulty for patients than TMT-A.
Some authors have interpreted discrepancies in performance in the two TMT parts as an 
indication of a laterality of brain damage (Golden et a l, 1981) but this has largely been 
discredited in the literature (Horn & Reitan, 1990; Salthouse & Fristoe, 1996). Perhaps, 
a possible explanation might relate to the order of administration. TMT-A was 
administered first, before the TMT-B, and as such the completion of TMT-A before 
TMT-B might have familiarised patients to test procedures or relevant cognitive 
strategies and hence positively affect subsequent performance.
Although NP research involving normative comparisons is valuable, the significance of 
the findings is dependent on the appropriateness and quality of the normative databases 
against which comparisons were made and NP impairments were defined. No normative 
study ordinarily allows a perfect fit to the population under study and the limitations of 
any dataset used for inferential purposes should be borne in mind. Although existing 
normative databases were scrutinised to identify the one that most closely matched the 
characteristics of our sample, method of administration and scoring procedures, the
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resulting choices on which the definition of NP deficits were based, were far from 
optimal. Caution is therefore warranted in interpreting and generalising these findings.
The assessment of closely matched healthy volunteers would be one advance for future 
investigations on the incidence or prevalence on NP impairments in ESRD. Test norms 
as they involve historical, non-concurrently assessed healthy controls, often in low 
numbers may not necessarily represent the most appropriate reference point. A study by 
Pliskin et al. (1996) clearly illustrates this point. Although there were no significant 
differences in NP performance between HD patients and matched healthy controls, both 
groups (including the healthy volunteers) demonstrated mildly impaired NP function 
relative to test norms.
Nevertheless it is important to emphasise that the majority of dialysis participants in this 
study performed within the average or low average range of the various cognitive tasks). 
Patients’ performance in the various NP tests was also found to be comparable and in 
some cases superior, to that reported in previous studies of dialysis patients 
(Buoncristianni et al., 1992; Pliskin et al., 1996; Smith et al., 1990; Umans et al., 1998; 
Wolcott et al., 1988a). This may reflect relative improvements in treatments or selection 
differences for dialysis.
1.2 Dialysis modality and NP performance
One of the key aims of this study was to compare the NP outcomes associated with 
different dialysis treatments. The differential biochemical profiles and patterns of renal 
clearance achieved by HD and PD beg the question as to how intermittent vs. 
continuous treatment might affect patients’ cognition.
Such comparisons albeit valid, posit difficulties as they are subject to a range of 
potential confounding factors (Pliskin et al., 2001). For instance, modality selection bias 
may operate. Patients’ treatment mode is not purely elective. Medical and non-medical 
considerations (financial reimbursement, facilities, physician bias, and patients’ 
preferences) are well recognised to impact on modality selection. (Nissenson et al., 
1993). Modality selection bias and case-mix differences can be thought to place bias on 
the results and make a true, valid treatment evaluation and between treatment 
comparisons difficult. In the absence of a possibility of a randomised design coupled
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with the multiplicity of potential confounding factors, careful consideration was given 
in designing and conducting a methodological tight and adequately-powered 
experimental study to overcome many of the methodological shortcomings of previous 
research and to take into account the majority of the aforementioned considerations.
These included the relatively large sample of medically stable and adequately dialysed 
HD and PD patients that met stringent inclusion criteria, assessments of several 
cognitive abilities at two time points, careful timing of NP assessment relative to the 
cycle of dialysis, and inclusion of both psychosocial and biomedical variables. All 
confounding factors, likely to increase variability and introduce biases when 
comparisons were made between the two-dialysis modalities, were either eliminated by 
appropriate patient selection procedures or if systematically different between groups, 
adjusted for in all analyses. Intra-individual variability is also an issue with repeated NP 
assessments. Mood may influence motivation to perform the tasks, and stress, fatigue, 
or other physical symptoms may transiently alter performance on NP tasks across 
administration trials (Rasmussen et al., 2001). Concurrently measured levels of mood 
and fatigue were hence included in the analysis even when there were no differences 
between groups, to ensure statistical control of such ‘intra-individual’ confounders. 
Methodological control was seen as a priority for two reasons. First, it minimises 
unnecessary inflation of the number and extent of differences between HD and PD 
participants, and hence the probability of Type 1 error. Second, it maximises the 
identification of differences in cognitive performance that would go undetected in a 
non-controlled study and may hence increase the probability of Type 2 error.
This study demonstrated that careful matching for confounding variables has a marked 
effect on the results obtained when comparing cognitive function in patients on different 
dialysis modalities.
Treatment comparisons in this study indicate that HD and PD patients present 
equivalent cognitive functioning. Although NP performance varied greatly between 
patients, there were no systematic significant differences between dialysis modalities. 
The prevalence of NP impairments was not different in PD and HD. These findings are 
similar to some studies (Rozeman et al., 1992) but are at odds with some other reports 
of more compromised cognitive functioning in HD patients compared to PD patients 
(Garcia-Maldonado et al., 1991; Yount et a l, 1998; Wolcott et al., 1988a).
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One potential reason for this inconsistency may relate to variations in the timing of the 
assessment over the dialysis cycle in many studies. In contrast, in this study NP 
performance was assessed at two time points, immediately before dialysis and 24 hours 
later. For the HD patients this is likely to reflect the worst and the best physiological 
state. Other differences include the size and composition of the patient groups and the 
heterogeneity of the population.
In addition, the inconsistency may be due to the continued improvements in the delivery 
and techniques of HD, such as dialysis adequacy standards and increased 
biocompatibility, as the bulk of conflicting studies were performed some time ago. 
Study findings demonstrate the importance of methodological control in studies of NP 
outcomes of ESRD (Pliskin et a l, 2001) and emphasise the need for caution in 
interpreting results from poorly controlled studies.
The clinical implications of these results are that adequate HD treatment leads to stable 
cognitive functioning and is not an inferior treatment option to PD. Other investigators 
have similarly failed to find significant difference in the NP performance between 
healthy controls and adequately dialysed HD patients (Pliskin et al., 1996). Thus 
concerns over cognitive impairment should not enter the decision-making process when 
selecting renal replacement modality. However consideration regarding the see-saw 
effect of biochemistry and potentially of NP functioning may influence clinical 
judgement.
1.3 Acute neuropsychological changes
To determine whether NP performance changes over the dialysis cycle, HD patients 
were assessed immediately before and again 24-hours post-dialysis. These times were 
chosen on the grounds that HD patients’ biochemical profiles would differ on these two 
occasions and that more normal physiology would be evident at the time post-dialysis 
compared to pre dialysis values (Ratner et al., 1983). The main hypothesis was that 
normal biochemistry at 24-hours post-dialysis would produce improved NP functioning 
post-dialysis compared to immediately prior to dialysis. The competing hypothesis was 
that any discernible NP improvements in HD patients would be attributed only to 
learning effect.
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Changes over time do suggest a greater variability in NP performance in HD during the 
dialysis cycle. While the PD group’s NP performance showed little change over time, 
the HD group showed improvement in most of the tests, in line with their changing 
physiological state. Previous studies have demonstrated similar short-term changes but 
were unable to rule out learning effects (Ginn et al., 1975a; Lewis et al., 1980; Ratner et 
al., 1983) as no control group was used.
The test-retest or learning effect defined as an improvement in performance after 
repeated presentation of a test, is a general problem for longitudinal NP studies 
(McCaffrey & Westervelt, 1995; Mitrushina et al., 1991). Effects of implicit or explicit 
learning, as well as of anxiety reduction are always an issue when the same task is 
performed twice. To tease out the effects of biochemical changes and thus avoid such 
problems of interpretation of learning effects PD patients were assessed at the same 
time intervals. With their more stable physiological functioning it was assumed that any 
changes in NP functioning would be attributable to learning whereas improvements in 
HD patients should reflect both learning as well as improved physiological state. The 
assessment of a PD group enabled an assessment to be made for learning effects on the 
NP tests in an ESRD population (McCaffrey & Westervelt, 1995). It was hypothesised 
that the practice effects for HD and PD patients would be comparable and hence any 
additional NP improvement in HD patients 24-hours post-dialysis would be attributed to 
fluctuation in their physiological status.
There are other differences in the methodology of the present study, which add strength 
to these findings. These include a sufficiently large sample size to detect changes, and 
consideration and adjustment of possible confounding variables to allow for more 
robust analysis.
Results were in accord with our hypothesis and indicated that HD patients demonstrated 
significantly greater NP improvements (absolute NP scores and in the prevalence of NP 
impairments) in all the cognitive domains examined, across the two assessments relative 
to PD patients. Such improvements were evident in all NP tests employed, i.e. attention, 
concentration, motor abilities, and verbal learning and memory tasks after controlling 
for concurrently measured levels of fatigue and anxiety.
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Although such improvements with repetition of NP tests over such a short time interval 
were anticipated, the finding of significant interaction effects signifies that the observed 
improvements in the NP performance of the HD group are not simply the result of a 
learning effect. Post-hoc analyses demonstrated significant changes (reflecting both 
learning coupled with actual improvements) across the two assessments for the HD 
group but virtually no significant changes for the PD group. The PD patients produced a 
relatively consistent NP performance across the two assessments except the three tests, 
for which no parallel administration forms were used, which showed significant 
improvements from T1 to T2. These improvements suggest that these tests are more 
susceptible to learning with repetition over a short time period.
Previous studies have reported findings in the same direction but due to small sample 
sizes statistical differences have not always been detected (Ratner et al., 1983) or when 
they have, generalisation of findings was limited (Lewis et al., 1980). Such uniform 
significant short-term changes in range of cognitive domains (attention, concentration, 
verbal learning and memory, and psychomotor speed) have not been reported previously 
in HD.
An important question attendant on the issue of dialysis modality and 
neuropsychological performance is the clinical significance of the acute changes 
exhibited by HD patients. The fact that this group’s performance did show acute 
changes over the dialysis cycle relative to the PD group has clinical significance at least 
with regard to the cognitive performance reflecting the impact of the two dialysis 
techniques. Although the exact links to biological measures were not established in the 
study, it does suggest that the issue of biological fluctuations in HD is important. 
Perhaps the issue of whether cognitive improvements are behaviourally important 
becomes secondary when judging their clinical relevance as long as they are reliable 
markers of brain functioning and can be used to improve dialysis delivery and 
procedures. This fact appears to have been recognised by the shift to a more frequent 
(daily) HD regimen (Pieiratos, 2004). It remains to be established whether the cognitive 
fluctuations with this regimen are reduced.
There are two further issues with regard to the importance of these acute fluctuations in 
cognition. One is whether these changes are evidenced in real life problems for the 
patients. This was not specifically addressed in the study reported only in as much as it 
was examined through quality of life. Further research could potentially examine 
patients performance in real life tasks at the two occasions studied here.
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Daily performance-type measures would be essential for examining how acute/daily 
fluctuations in the cognitive abilities of HD patients might relate to functioning of 
patients on the real world. It is possible that acute NP changes might have implications 
on patients’ everyday functioning like daily activities, work performance or social 
interactions but these have not been measured in this study. Compensation-coping 
mechanisms are also likely to operate in that patients who are aware of such daily 
cognitive fluctuations might strategically structure the type or the load of daily activities 
and routines in a different manner at dialysis and non-dialysis days or might be forced 
to make particular lifestyle or career choices to accommodate daily variations in 
cognitive functioning. The magnitude of these effects or adjustments is also likely to be 
highly dependent on the personal circumstances or characteristics of the person and 
environment. These are speculations, which need to be addressed by empirical research. 
The second question revolves around the awareness of patients of these cognitive 
fluctuations. This was examined in the study by asking patients about changes in their 
cognitive performance over the 24-hour cycle. This is reported later (see Section 3: 
Subjective Cognition).
The aetiology of such transient effects remains elusive. The hypothesised links between 
biochemistry and NP performance received only limited support in this study. On one 
hand the observed significant changes in urea, creatinine, albumin, calcium, potassium 
and phosphate in the HD group were consistent with the impact of dialysis. As predicted 
no such changes were found in the PD group reflecting their continuous dialysis and 
resultant relatively stable physiological state.
The findings however failed to support a link between the accumulation of uraemic 
toxins and absolute cognitive performance. Biochemical measures were not reliably and 
consistently associated with NP performance (Ratner et al., 1983).
The amount of variance explained by biochemical predictors was small and variance 
based measures of effect sizes indicated small effects ( f  values < 0.06). Multiple 
regressions indicated that levels of calcium, phosphate and urea predicted more efficient 
cognitive functioning in 3 out of 10 absolute NP scores (Wolcott et al., 1988a). 
Regression coefficients however indicated counter intuitive associations in that high 
urea and calcium concentrations were associated with better NP absolute scores. 
Although associations may be considered spurious, they also prompt questions 
regarding the influence of urea toxicity. Other investigators have similarly concluded
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that evidence on the toxicity of widely researched solutes such as urea is far from being 
conclusive (Dhondt et al., 2001).
Changes in calcium and urea were also associated with changes in NP performance over 
24 hours. It is of note that the associations between urea changes and NP improvement 
were in the expected direction (unlike those reported for absolute scores). A decrease in 
urea was associated with greater memory improvements while increases in calcium over 
the two assessments predicted improvement in attention (SDMT-W; SMDT-O).
In conclusion, NP improvements paralleled changes observed in biochemistry over the 
period of dialysis in the HD group although the relation to any particular biochemical 
change was not established.
Alternative physiological explanations not explored in this study are discussed overleaf.
The absence of significant associations between NP performance and other biochemical 
assays was to an extent expected. In untreated pre-dialysis patients, in whom 
biochemical levels can very over a wide range, NP impairments clearly occur in 
conjunction with high biochemical values reflecting the severity of the illness (Ginn, 
1975a; 1975b; Hart et a l , 1983; Teschan et al., 1974a; 1974b; Teschan, 1979). In 
dialysis patients, biochemical values are allowed to fluctuate only within narrow limits 
and in this sample, all biochemical measures were within the normal physiological 
range for adequately-dialysed patients. Consequently the lack of significant correlations 
between parameters such as haemoglobin and NP performance may reflect the lack of 
sufficient value range (Bergstrom, 1997; Vanholder et al., 1994).
Significant associations may only become evident when biochemical levels fall below a 
certain threshold and these minimal levels were exceeded in this study. Several studies 
have consistently demonstrated that uncorrected anaemia is associated with cognitive 
deficits and that erythropoeitin treatment leads to NP improvements (Grimm et a l, 
1990; Pickett et al., 1999; Stivelmann, 2000; Temple et a l, 1995). Mean haemoglobin 
levels in the study were adequate (> 10 g/dl) and those patients who were previously 
anaemic were on erythropoeitin in order to obtain a haemoglobin concentration of no 
less than 10-11 g/dl. It is likely therefore that this explains the absence of significant 
associations between NP and haemoglobin.
The accumulation of different compounds, other than the group of small solutes 
measured in this study, namely middle or large molecules and protein-bound solutes
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(Dhondt et al., 2001; Vanholder et a l, 1995; 2001) might be responsible for changes in 
cognitive functioning. Their association with NP functioning has yet to be investigated.
It also remains possible that other alternative physiological pathways or molecules, not 
examined in this study may also account for the observed NP changes.
For example, the marked fluid shifts with their potential for inducing haemodynamic 
instability in haemodialysis may have NP implications for HD patients. Brain density 
changes have been observed across the dialysis cycle in HD with severe dehydration in 
the pre-dialysis phase (Detori et al., 1982; La Greca et a l, 1980; 1982). More recent 
investigations using MRI have similarly noted such alterations in brain hydration during 
the cycle of haemodialysis although the pathological NP consequences of which remain 
speculative (Silver et al., 1996; Walters et a l, 2001). Experimental research conducted 
in healthy volunteers has shown links between dehydration and NP performance (Cian 
e ta l,  2001; Gopinathan et a l, 1988).
Finally, acute NP changes may also be related to other haemodynamic changes such as 
blood pressure or the production and release of cytokines during the cycle of 
haemodialysis. Studies have observed large variation in blood pressure during a HD 
session and the fluctuation of blood pressure levels from pre- to post-dialysis and during 
the interdialytic period (Elisaf et al., 1996; Kooman et al., 1992; Santos et al., 2003). 
Chronic hypertension has profound effects on cognition (Elias, 1998; Swan et al., 
1998). However little is known about the NP implications of the observed acute blood 
pressure changes during the cycle of HD (Metry et al., 2002).
To conclude, although study findings provided partial support for the hypothesised 
biochemical basis of the observed NP changes, further research pursuing this question is 
warranted. Taken together the overall pattern of results suggest that particular 
physiological changes either solely or in combination during the haemodialysis cycle 
should be implicated in the these transient NP effects. A simple biological explanation 
may not be sufficient enough to account for NP effects.
Study findings also indicated that factors other than biochemistry may be equally or 
perhaps more important in explaining absolute NP scores as well as changes in NP 
scores.
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Multifactorial models for cognitive functioning including sociodemographic, medical, 
biochemical and mood variables were tested. Hierarchical multiple regressions assessed 
the contribution of mood and biochemistry over and above the effect of 
sociodemographic and medical variables. In these analyses the order of entry for 
biochemistry and mood was reversed to add to methodological rigour and not because 
the two were considered as strictly competing hypotheses.
Results indicated that when mood was entered after biochemistry in the equations, it 
contributed significantly to the prediction of both absolute NP scores and NP 
improvements over and above variance explained by biochemical values. There is 
overwhelming evidence supporting the close association between mood and cognitive 
functioning (Dijkstra et al., 2002; Murata et al., 2000; Norman et al., 2002), but to our 
knowledge this is the first report of concomitant acute changes in mood and cognition. 
The observed acute changes in mood are probably the result of a combination of factors, 
in particular familiarisation of subjects with the testing procedures and the researcher 
and preference for a non dialysis day (HD) or a non PD clinic attendance day (PD). 
Acute changes in NP functioning were associated with changes in positive and negative 
affect. Increased positive affect predicted improvement in NP performance on SDMT- 
W, RAVLT-T and BVRT-E. On the other hand decreases in reported levels of negative 
affect was associated with better scores in TMT B, GP-DOM and GP-NDOM.
Interestingly, depression traditionally associated with NP performance (Coker & 
Shumaker, 2003; Suhr, 2003), was unrelated to acute NP improvements. Depression and 
anxiety failed to emerge as significant predictors of NP change when entered together 
with positive and negative affect, despite being associated with absolute levels of NP 
performance (Tl). Although the difference in timeframe of depression and PANAS 
measures might at least partly account for this finding, the same explanation does not 
apply for anxiety as this also reflected momentary affect.
The associations between positive mood and NP functioning are of note. Positive 
emotions have received considerably less attention, perhaps related to the prevailing 
view of physical and mental health as the absence of a disease and negative emotions 
(Ryff & Singer, 1998), as well as the fact that positive emotions are less differentiated 
than negative emotions (Erlsworth & Smith, 1998). Positive emotions have been 
associated with better health outcomes (Affleck et al., 1987; Bower et al., 1998;
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Kiecolt-Glaser et al., 2002) but their associations to NP outcomes have been 
overlooked. Indeed although a substantial empirical literature exists on depression and 
NP status (and health in general), almost none exists for ‘positive affect’ and cognitive 
functioning (La Rue et al. 1995). Altogether these findings point to the importance of 
measuring positive and not only negative affect in line with previous research on self­
assessed health (Benyamini et al., 2003).
Finally our results indicated that sociodemographic and clinical factors, namely age, 
education and ESRD severity were associated with NP functioning in both univariate 
and multivariate analysis. The effects of age, education, disease severity and 
comorbidities are well known and such associations have consistently been documented 
in the literature (e.g. Kutlay et al., 2001; Mitrushina et al., 1999).
The finding that dialysis adequacy predicted NP functioning is unique. Previous 
investigators have stressed the need to consider delivery of dialysis in NP investigations 
of dialysis patients (Pliskin et a l, 1996; Umans et al., 1998). This study is the first 
report of a significant association between the two. Even though all patients met the 
minimum criterion for adequate dialysis, study results show that increases in urea 
clearance (dialysis dose) above national standards produced further improvement in NP 
functioning. This finding is at odds with studies investigating the association between 
Kt/V and survival (Held et al., 1996; Owen et al., 1993) in which no dose-effect 
relationships were found. It suggests that assessment of brain functioning and survival is 
different. This is perhaps not surprising given that patients do not tend to die of 
neurological problems.
Section 2: Transplantation
On all measures of cognitive function TX recipients fared no worse than respective age- 
reference populations. These formal observations accord with previous data from earlier 
studies (Kramer et a l, 1996; Teschan et al., 1979). It is possible that other tests might 
have detected deficits not appreciated in our study, but the NP tests performed are 
widely used, well-standardised and covered a range of cognitive areas (Lezak, 1995). 
That normal or near normal NP functioning can be expected following renal 
transplantation will be reassuring to patients. Many are aware of the possibility of
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cognitive difficulties in the wake of ESRD and some might have experienced problems 
while on dialysis. It also highlights the potential of renal TX to reverse some of the NP 
deficits associated with dialysis and to restore NP functioning back to normal or pre- 
morbid levels.
The hypothesis that TX patients would demonstrate more efficient cognitive functioning 
than dialysis patients, received modest support. TX patients outperformed dialysis 
patients only in certain NP tests and not across all the cognitive domains assessed. The 
NP advantage of TX was evident for memory function (immediate recall and retention) 
and for two of the four attention measures (TMT-A; SDMT-O). By contrast there were 
no differences on other measures of attention (TMT-B; SDMT-W) and on measures of 
motor abilities (GP-DOM; GP-NDOM).
Methodological factors might account for these findings. Significance levels were not 
adjusted for multiple comparisons, which would have negated the significance of 
SDMT-O and TMT-A differences (as p  would have been dropped to .0071). Other 
investigators have similarly resorted to reporting uncorrected p  values (Pliskin et al., 
1996) to ensure that no potential findings would be overlooked. It is important that the 
differences in RAVLT-T scores would still be significant even when adjusted for 
multiple comparisons. The effect on memory may therefore reflect true differences 
between dialysis and transplant patients, suggesting that this is an area of functioning 
particularly sensitive or vulnerable to the effects of dialysis. Alternatively it may relate 
to differences in the relative sensitivity of NP tests of attention and memory.
It is also possible that other aspects of the TX group’s performance may have reduced 
the likelihood of finding NP differences in comparison to the dialysis group. Most of 
NP tests with the exception of non-verbal memory task are timed and involve motor 
activity. Slowness in execution might be related to other factors such as tremor, 
common in some TX patients. This is however unlikely as none of the TX recipients 
presented with visible evidence of tremor and no differences were found in the SDMT- 
O in which no manual activity is involved. In addition when comparisons (ANCOVAs 
not reported) were repeated controlling for concurrently reported symptoms no 
differences between dialysis and TX patients in other tests involving motor ability (GP- 
DOM; GP-NDOM; TMT-B; SDMT-W) were found.
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Comparisons to TX were repeated separately for HD and PD patients. PD and TX 
patients performed comparably in all NP tests except for the memory tasks (RAVLT-T). 
More consistent differences in favour of transplantation were noted in relation to HD 
patients but only when compared to HD’s pre-dialysis NP scores (Tl), a time when NP 
functioning is at its worst across the dialysis cycle. This adds weight to study findings 
on the acute NP improvement for the HD group and highlights the importance of the 
timing of NP assessment when treatment comparisons are performed. Comparing HD 
patients on pre-dialysis NP scores would have led to a clear overestimation of the NP 
benefits of transplantation. A word of caution is however warranted. The HD group’s 
second assessment (24-hours post-dialysis) would have included the effects of learning 
whereas the TX patients were assessed on only one occasion.
The data showed that when casemix differences are controlled for, dialysis and 
transplant patients have roughly equivalent cognitive functioning in tests of attention 
and psychomotor abilities except for memory, which contrasts with commonly held 
views that TX by improving the organ-system functioning and restoring kidney function 
should result in amelioration of NP functioning. These findings might be related to 
technological improvements of dialysis over recent years with resulting improved renal 
clearance. They may also be related to the characteristics of our dialysis sample, which 
consisted of clinically stable and adequately-dialysed patients. It is possible that more 
marked group NP differences would have emerged had study inclusion criteria been less 
strict. A prospective design assessing NP function before and after TX would overcome 
limitations related to sample selectivity and would provide a stronger test of the NP 
changes brought about by kidney TX.
The links between biochemical markers of renal function and NP performance in TX 
did not receive strong support in this dataset. Correlations, albeit in the predicted 
direction, were weak and inconsistent and were not replicated in the multiple regression 
analyses. The findings of the univariate analysis did suggest that immunosuppressive 
medication may adversely impact upon NP outcomes within the TX group (Tarter & 
Switala, 2000). Correlational analysis indicated that plasma levels of cyclosporin were 
inversely associated with NP scores although NP performance was equivalent between 
patients treated with cyclosporin and those on tacrolimus. One may speculate that the 
vasoconstricion properties of cyclosporin may be related to this finding but further
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research is needed to examine the NP effects of these and the newer immunosuppressive 
agents such as sirolimus.
In addition systolic blood pressure correlated significantly with measures of 
psychomotor speed and attention in the univariate analysis but not in the multivariate 
analysis. Research on the relationship of blood pressure and cognitive functioning has 
not presented a clear picture with some studies finding a relationship and other not 
(Waldstein & Elias, 2001). The direction of the observed correlations in this study 
indicated that higher levels of systolic blood pressure were associated with less efficient 
cognitive functioning.
Regression models indicated that only age, education and ESRD severity predicted 
cognitive functioning post-transplantation. The first two variables have been commonly 
found to be associated with NP performance in non-patient samples (Lezak, 1995; 
Mitrushina et al., 1999). Positive affect contributed significantly to the prediction of 
memory abilities in TX patients, which suggests that the induction and maintenance of 
positive mood somehow positively influences or enhances cognitive abilities and 
resources. The pathways through which positive emotions might impact upon NP 
outcomes are not known, but they are likely to occur though physiological mechanisms, 
as well as indirectly through motivational or psychological processes. The total variance 
explained was however small to moderate, suggesting that other factors other than the 
ones assessed in this study might have a stronger effect on NP outcomes post­
transplantation and might be more important/powerful determinants of NP performance 
in TX patients.
The strong associations found between employment and NP performance in TX (and in 
dialysis) suggested that NP outcomes might impact upon other areas of functioning and 
wellbeing (Bremer et al., 1997; Wolcott et a l, 1988a). Work rehabilitation is a major 
goal of most renal programmes and the extent to which patients return, or maintain 
employment while on dialysis or after a kidney transplant may be dependent on several 
factors: educational level, the specific work the individual engaged in prior to onset of 
dialysis, personality factors, public policy regarding eligibility for medical and state 
benefit schemes and perhaps treatment modality (Julius et al., 1989a; Waiser et al., 
1998) The extent to which work rehabilitation or vocational function in ESRD might be
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facilitated or prohibited by cognitive functioning as study findings suggest merits more 
investigation.
The directionality of these relationships in this study cannot be established. It is possible 
that employment is an outcome of efficient cognition or conversely that it acts as potent 
resilient factor for NP deterioration. Although there is some evidence for the adverse 
health implications of unemployment (Dooley et a l , 1996; Kasl & Jones, 2000; Ross. & 
Mirowsky, 1995), little is known as to whether employment opportunities and work 
performance are potentiated by efficient cognitive functioning or vice versa. In other 
words, whether cognitive abilities are preserved within the working environment as 
opposed to atrophying due to illness-related early and forced retirement from the 
working arena.
Section 3: Subjective Cognition
The study of NP outcomes in ESRD patients would not have been complete without 
considering patients’ own appraisal of their cognitive abilities. This was termed 
subjective cognition.
Subjective cognition is linked to the notion of metacognition from the field of cognitive 
neurospychology. Metacognition refers to evaluation and control of one’s cognition. It 
is also described as the knowledge or the cognitive processes that monitor or control 
cognition or the feeling/knowing states of human conscious cognition. Subjective 
cognition in the context of this work was broadly defined as self-reported cognitive 
functioning and evaluations and perceptions of cognitive abilities. It refers to ‘thinking 
about thinking’.
Subjective cognition implies self-evaluation, self-monitoring and self-awareness and as 
such may also be related to other illness beliefs such as those in self-regulation theory. 
In that light subjective cognition may inform and complement patients’ cognitive 
representation of their illness or treatment as it reflects beliefs about the cognitive 
impact of ESRD. It is also possible that subjective cognitive judgements may include 
‘separate’ beliefs or perceptions of the nature of cognitive change: timeline (e.g. short­
lived vs. long-standing), severity (e.g. perception of mild cognitive deterioration), 
consequences or control/cure perceptions. The measure used for the purposes of this
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study did not allow us to tease out these issues and moreover used the treatment 
modality as a trigger point for patients to reflect upon changes.
It is not clear what people consider when judging their cognitive abilities. These 
evaluations might relate to the presence or absence of symptoms of cognitive 
performance (concrete manifestations of e.g. memory or attentional failures), their 
ability to do what they need to do (functioning on an intellectual level) or their general 
well-being and health. Contextual and situational cues as well as social prevalent 
schemas/norms may also exert some influence in the formation of these judgements 
(e.g. anticipated age-related cognitive decline; other patients with similar complaints), 
and in individuals’ responses to them (e.g. seeking help).
Even though its relationship to psychological variables such as mood has been 
examined in this thesis, further work is needed to ascertain how these subjective 
cognitive evaluations feed into patients understanding of their condition, their 
subsequent coping behaviours and how they fit into and interact with patients’ other self 
-  perceptions as well as illness and treatment representations.
Another manner of examining the importance of subjective evaluation of cognitive 
abilities would be to examine these in relation to other generic assessments patients 
make of their illness and their HQoL. Subjective cognition evaluation may add to 
perceptions of illness burden and adversely affect outcomes such as adjustment and 
HQoL. Subjective cognitive functioning has also been considered as an additional 
dimension of QoL and relevant sub-scales are included in generic and disease-specific 
measures such as the SIP (Bergner et a l , 1981) and KDQoL (Hays et al., 1994). This 
thesis examined the way in which these judgements related to HQoL (see Chapter 9).
For the purposes of this thesis, long-term and short-term appraisals were investigated. 
Patients were asked to consider how their cognitive abilities might have changed since 
treatment initiation (either dialysis or transplantation) and acutely from day-to-day (T1 
to T2 assessment; dialysis patients only). This method on comparative judgements 
employed in this study is somewhat different to measures of cognitive 
complaints/difficulties used in other research. It was nevertheless considered more 
appropriate to use a comparative judgement, as the main focus of this work was acute 
intraindividual cognitive change.
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3.1 Reports of subjective cognition in dialysis and TX
Taken together our findings indicate that patients could evaluate their cognitive abilities 
and had clear views on the long-term course of these abilities and their day-to-day 
variation.
This study indicated that compared to PD patients, who perceive little or no changes in 
their day-to-day cognitive functioning, a substantially larger number of HD patients 
report changes, namely improvement in their cognitive abilities from pre-to post­
dialysis.
Long-term changes in cognitive abilities were also reported. A considerable number of 
dialysis patients perceived cognitive deterioration particularly with respect to memory 
and concentration since initiation of dialysis, in line with previous research (Brickman 
et a l, 1996). Memory complaints are common not just in the dialysis population but 
also in other patient groups (Klepstad et a l, 2002; Matotek et a l,  2001; Metzger & 
Denney, 2002; Newman et a l, 1989; Sullivan et a l, 2002) and in the general population 
(Comijs et a l, 2002) so the disease specificity of these findings is questionable. Dialysis 
modality was largely unrelated to reports of cognitive deterioration since treatment 
initiation. The only exception was concentration. A greater number of HD patients 
complained of deterioration in their concentration abilities compared to PD. This sole 
difference (significant only at p < .05) is more likely to be a chance finding rather than a 
true treatment effect.
An alternative and perhaps more plausible explanation would be that that casemix 
differences in time on RRT and on current dialysis modality are to account for this 
difference.
Firstly, the observed group difference in time on RRT, by definition implies that ‘more’ 
ageing has occurred for the HD group as more time has elapsed since treatment onset 
and the time of the assessment, hence more age-related cognitive decline should be 
anticipated for this group. This means that the reference point to base subjective 
cognition evaluations differs between HD and PD. This is a key issue as the subjective 
cognition measure used in this study in essence involved comparative judgements of 
cognitive abilities pre- and post- treatment onset. It stands to reason that for HD patients 
who have been in the RRT programme longer, their ‘pre dialysis’ functioning refers
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back to a much younger age than that of PD patients who albeit of the same age, have 
been in the programme for significantly less time.
Finally, patients who have been on RRT for longer (i.e. HD group) have been exposed 
for longer on the non-specific accumulative adverse effects associated with chronic 
illness and associated treatment. These non-specific effects as well as some of the 
unavoidable complications of ESRD and associated treatment (such as hypertension) 
may only become manifest after some time, and these may in turn influence cognition 
and subjective reports of cognition.
There was great variability in perceptions of cognitive change (deterioration or 
improvement) among TX respondents. Although the majority of patients endorsed no 
change in their cognitive abilities since their transplant, the remainder of the sample had 
different views as to whether deterioration or improvement had occurred. Other than 
memory, which was the most frequently endorsed domain of deterioration, and clarity 
of thinking, which was the most frequently endorsed domain of improvement, a clear 
pattern of which cognitive domains were more likely to be perceived as worse or better 
after transplantation did not emerge.
Sociodemographic and medical factors may at least partly explain the diversity in TX 
patients’ subjective cognitive evaluations. For instance, time since transplantation and 
time on dialysis prior to receiving the transplant (that varied greatly in the TX sample), 
were found to be associated with subjective cognition summary scores.
The associations between cognitive complaints and time elapsed since TX may be due 
to ageing, prolonged exposure to immunosuppressive medication with its resultant side- 
effects, or the response shifts in TX patients expectations with time. For instance, it may 
be that newly transplanted patients have different, i.e. lower expectations regarding 
restoration of cognitive abilities with TX. They may also be less likely or less inclined 
to notice/register or complain of cognitive difficulties early after a life-saving TX 
operation that brings about drastic improvement in their general health and physical 
functioning. Increased emotional well-being typically documented in recently 
transplanted patients might also explain these findings as mood has been shown to 
affect subjective cognition (Newman et al., 1989).
Such psychological factors might also be driving the inverse associations between time 
on dialysis and reports of cognitive deterioration although mood indicators examined in
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this study were not linearly associated with these two variables (time on TX and time on 
Dialysis). Notwithstanding, the diversity in patients’ subjective reports demonstrates the 
extent to which post-transplantation experience (a dimension of which is subjective 
cognition) might differ from patient to patient and highlights the need to prospectively 
examine the development and course of cognitive reports post-transplantation.
3.2 NP performance and subjective cognition
It is important that there was little relation between objective NP testing and subjective 
cognition. Only a few significant associations were noted between absolute NP scores 
and complaints of long-term deterioration (most significant only at p < .05) but these 
were not consistent across cognitive domains nor in all tests of the same cognitive 
function and they also failed to emerge in the multiple regression analyses. Given these 
inconsistencies and the increased risk of type I error due to multiple testing, it is likely 
that the observed relationships are spurious.
Previous ESRD studies using similar self-report scales have also highlighted the lack of 
correspondence between self reports of cognitive functioning and objective NP scores 
(Brickman et al., 1996). Similar findings have also been reported in different fields for 
other patient groups (Khatri et al., 1999; Klepstad et al., 2002; Kremer et al., 2002; 
Mayou, 1986; Newman et al., 1989). The lack of significant associations should not be 
interpreted as evident for the poor validity of patients’ reports. Cognitive complaints 
may reflect a general state of feelings of diminished well-being and as such are critical 
in evaluating the impact of ESRD and treatments. They may also have implications for 
future cognitive functioning as one study on elderly general population has 
demonstrated that memory complaints predicted future memory performance (Jorm et 
al., 2001).
It is also possible that other variables not measured in this study may mediate or 
moderate the relationship between objective and subjective cognition. For instance, 
individual exposure to cognitive demands in daily life may moderate the NP 
performance-complaint relationship in such a way that cognitive complaints are more 
likely to be reported by patients in 'high demand' than in 'low demand' situations 
(Gleissner et al., 1998). Future studies should address this question.
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3.3 Mood and subjective cognition
Our findings in conjunction with previous reports directly address the origin of reports 
of cognitive functioning, and suggest that they are not generally the result of brain 
dysfunction. The presumption of an organic aetiology is likely to lead to an 
inappropriate evaluation and treatment. Indeed, as measured by our extensive 
neuropsychological battery, objectively measured changes in cognitive functioning were 
not the cause of cognitive complaints in these patients. Thus the aetiology of cognitive 
complaints appears to be largely psychological.
Clinical experience further suggests that subjective cognitive complaint reports may 
have an alternative significance to that of objectively assessed cognitive functioning that 
warrants further investigation. For example subjective cognitive complaints are 
common symptoms of major depression (Diagnostic and Statistical Manual of Mental 
Disorders; DSM-IV 1994). Some empirical evidence exists on the relationship between 
perceptions of cognitive status and affect. Brickman et al. (1996) for instance found that 
affect and personality were more predictive of subjective cognitive complaints in 
haemodialysis patients than medical or neuropsychological factors. Similar findings 
have been reported in other medical populations (Comijs et a l , 2002; Khatri et al., 
1999; Moore et al., 1997; Newman et al., 1989; Ponds et al., 2000; Tun et al., 1987).
Study findings have provided equivocal support for the association between mood and 
subjective cognition. This hypothesis remained largely unsubstantiated in this study. 
Significant associations occurred with little consistency across measures (mood 
variables and cognitive domains as indexed by the SCS items) and across samples 
(dialysis and transplantation). For instance, analysis of the TX data failed to fully 
replicate the significant associations found in the dialysis sample between depression 
and reports of cognitive decline. Even within the dialysis sample mood measures were 
similarly unrelated to reports of acute cognitive improvement across the cycle of 
dialysis despite being associated with long-term subjective cognition.
Analyses indicated that affect was associated only with subjective ratings of 
concentration (in dialysis). Mood and anxiety however were unrelated to reports of 
cognitive improvement in other areas of subjective cognitions. Furthermore the 
observed associations appear to be at odds with previous findings. Study results 
indicated that perceptions of cognitive improvement in concentration abilities were
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related to higher scores in both negative and positive mood indicators including anxiety, 
negative affect and positive affect at 24-hours post-dialysis. Higher affect whether 
positive or negative was associated with perceptions of improvement in concentration. 
The significant associations between concurrent negative mood and reports of cognitive 
improvements appear at first sight to be counterintuitive to study predictions and 
previous research findings. These warrant further discussion.
One explanation for these findings could be that patients with an anxious or negative 
mood might tend to focus more on monitoring, internal states and everyday functioning 
including cognitive abilities. They would hence, by being more introspective and more 
alert and vigilant to their internal state, become more likely to perceive acute changes 
such as improvements or less likely to dismiss a cognitive failure than others who do 
not have high levels of depressed and anxious mood. Numerous studies have indeed 
noted significant associations between affect and symptom reporting (Griffin et al., 
1999; Watson & Pennebaker, 1989) that provide indirect support for this explanation.
An alternative explanation might be that perceptions of transient NP improvement 
might be causing more intense emotional responses both in terms of negative and 
positive affect. That is, perceiving fluctuating cognitive abilities, even in the form of 
day-to-day improvements might be more likely to lead to the development and 
maintenance of anxious and negative mood, than perceptions of stable cognitive 
abilities. As only a handful of HD patients (n < 5) felt a deterioration in a particular 
aspect of cognitive ability, group comparisons were in essence performed between 
patients who reported improvements and those who felt that their cognition was 
unaltered. Perceptions of undifferentiated or unchanged cognitive abilities across the 
dialysis cycle may be seen as desirable and reassuring to patients, whereas perceptions 
of acute improvement may provoke negative affect associated with the unreliability and 
inconsistency of cognitive functioning/abilities.
Methodological differences between the present and previous studies might also explain 
the inconsistent results. Most of these other studies have examined the objective scores 
of those reporting a deficit in an area of cognition. In the study of acute changes in 
subjective cognition, the analysis was based on a reported improvement. Subjective 
reports of cognitive deterioration may be more strongly associated with anxiety and 
depressed mood than their absence with an improvement. This may explain the lack of
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significant association with the perception of cognitive performance in 8 of the 9 
domains assessed.
In line with that argument, other study findings have consistently demonstrated 
significant associations between affect and reports of cognitive deterioration (Sawrie et 
al., 1999). Dialysis patients who perceived that their cognitive abilities had deteriorated 
since dialysis onset had higher negative mood, e.g. depression and reported lower 
positive affect relative to patients who perceived either no change or improvement in 
their cognition. Regression analysis showed that depression was the only significant 
predictor of cognitive complaints in line with previous research (Sullivan et al., 2002).
From a conceptual point of view, one could speculate that cognitive complaints and 
cognitive improvement may not necessarily be the opposite ends of the same dimension 
but rather independent aspects of subjective cognition similar to that between positive 
and negative affect which appear to represent distinct qualities of mood. Thus the 
previously reported findings of a significant association between depression and 
cognitive complaints or ratings of cognitive deterioration may not be generalisable to 
perceptions of improvements.
Section 3: Study limitations
There are a number of limitations of the present study of NP functioning and subjective 
cognition.
First, the dialysis sample in this study consisted of relatively healthy, clinically stable 
and well-dialysed patients. Consequently the results may not be generalisable to other 
dialysis samples. It is plausible that neuropsychological performance would be more 
compromised in patients whose delivered dialysis dose do not meet the minimum 
national standards.
A word of caution is warranted when using the term ‘well or adequately dialysed’ as 
used in this study. As is common practice we used urea kinetics to establish dialysis 
dose. It should be noted though that urea is only a marker solute and measures of 
haemodialysis adequacy such as Kt/V and URR are only surrogates for the clearance of 
other solutes. For example, even when appropriate minimum Kt/V or URR is routinely 
delivered, a patient may still be inadequately dialysed in terms of potassium removal, 
correction of acidosis, or failure to render the patients a sufficient protein/calorie intake 
to prevent malnutrition. Similarly an appropriate minimum Kt/V or URR may be 
routinely delivered but the duration of haemodialysis may be too short to remove an 
adequate volume of fluid to re-establish euvoleamia. The flux of other larger molecular 
solutes and membrane biocompatibility may be equally important issues but are beyond 
the scope of this work. The recruited dialysis patients were described as well dialysed 
based only on their Kt/V values.
Secondly, the study sample size limited comparative analyses to two or three way 
ANOVAs. Even though post-hoc power calculation indicated that the overall recruited 
sample size (i.e. 262) yielded a power of .88, this is qualified by the unequal sample 
sizes and relatively small samples for 3 subgroups: home HD; APD and LRD TX.
In the case of the last group, the particular sampling strategy employed for the 
recruitment of TX patients (TX patients were recruited opportunistically; i.e. based on 
clinic attendance during the study window) led to the over-representation of the CAD 
TX group as these are overrepresented in the clinic. An alternative strategy would have 
been to match the LRD TX patients to a comparative group of CAD patients. As the
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primary hypothesis was to compare TX to the two dialysis groups it was decided to 
maximise the numbers in the TX group regardless of the source of their kidney.
Small sample sizes for the home HD and APD groups were unavoidable though as the 
overall number of patients established on these modalities in the participating units did 
not exceed 31. The small dialysis study sample did not allow a four group analysis to 
compare acute neuropsychological changes between all four dialysis modalities, namely 
hospital HD, home HD, CAPD and APD (post-hoc power calculation indicated that the 
sample of 145 patients yielded a power of .70 for medium effect size). Given that the 
procedures involved in these treatment are to varying degrees different, this is an issue 
warranting further investigation by future research. It is recommended that a sample of a 
minimum 180 patients (45 patients in each sub-group) would be necessary for a robust 
investigation of the effect of dialysis treatment on cognitive functioning (medium effect 
size = .25; power = .80)
Few other investigations have enlisted a larger number of dialysis and transplant 
patients when the focus was on NP performance. This study sample size is notably 
larger than most previous studies with the exception of an investigation by Yount et al. 
(1998). That study however presents methodological shortcomings (e.g. inadequate 
description of sample and assessment procedures, unspecified timing of the assessment, 
and the absence of an illness severity measure) that limit generalisability of its findings.
Finally, this study design did not allow us to determine long-term cognitive changes 
experienced by dialysis patients relative to controls. Although time spent on dialysis 
was unrelated with neuropsychological performance, it is plausible that cognitive 
function may deteriorate as a function of increasing time on dialysis (Baker et al., 1989; 
Ventura et al., 1990) and this may either be dependent or independent of dialysis 
modality. A well-designed prospective longitudinal trial of both PD and HD patients 
with adequate case-mix adjustment will help us to understand this complex issue better.
Given the associations of ESRD disease severity and diabetes with neuropsychological 
test scores in this study, it will be important to examine the effect of comorbid factors 
superimposed on chronic renal failure on cognitive functioning. In addition as 
depression is the most commonly encountered psychological problem in patients with 
ESRD (Finkelstein & Finkelstein, 1999; Sacks et al., 1990; Wuerth et al., 2001) its 
impact on NP outcomes deserves more attention in future research.
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CHAPTER 8: PATIENTS’ BELIEFS RESULTS
Section 1: Dialysis sample
1.1 Data analysis
The distribution of study variables was examined using Kolmorogov-Smimov tests to 
ascertain whether the dataset was suitable for parametric analyses.
To assess the need to incorporate control variables in the comparisons between 
treatment groups, several preliminary analyses were conducted. Firstly, independent t 
tests, analyses of variance (for continuous data), chi square test or Fisher’s exact as 
appropriate (for categorical data) were performed to compare the groups on 
sociodemographic and clinical characteristics. Secondly, univariate analysis (Pearson’s 
correlation coefficients, ANOVAs or their non-parametric equivalents) was used to 
examine relationships between these variables and study outcomes (i.e. beliefs, HQoL). 
If any of these background variables differed significantly among dialysis groups (at p < 
.05) and were significantly associated with the outcome in question, they were 
statistically controlled for in subsequent comparative analyses.
Group differences in beliefs and SF-36 scores between the treatment groups were 
examined using ANCOVAs (covarying for casemix differences as described above), 
with p  values uncorrected for multiple comparisons considered significant if p < .05. 
When appropriate Tukey’s honestly significant difference (HSD) post-hoc tests were 
performed to explore significant effects in the omnibus ANCOVAs.
In contrast to the strong arguments stressing the importance of removing the effect of 
sociodemographic and other medical differences when comparing HQoL outcomes 
between different RRT groups, the need to control for group differences in biochemistry 
is questionable. The reason being that although biochemical parameters such as albumin 
and haemoglobin have been found to be associated with HQoL measures such as SF-36 
scores (Lowrie et a l , 2000), their values may be directly related to aspects of the 
particular treatments (Xue et al., 2002). Therefore, one may or may not wish to make
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adjustments for them when contemplating possible HQoL differences between 
treatments. For the purposes of this study, the comparative analyses for HQoL data were 
run twice, with and without the inclusion of biochemical data.
The relationship between independent variables (sociodemographic, clinical, 
psychological, neuropsychological) and study outcomes (beliefs; HQoL) was explored 
by univariate and multivariate analysis. Univariate relationships were assessed using 
independent r-tests, ANOVAs, Pearson’s correlations or where appropriate their non- 
parametric equivalents. Any obvious non-linear relationships were then sought by 
examining scatterplots of the individual dimension scores, summary scores and the 
independent variables. No non-linear relationships were detected so simple hierarchical 
multiple regression models were then constructed. All significant correlates identified 
from univariate analysis were included as independent variables in the regression 
models. These entered the regression equations in a specified order: (a) 
sociodemographics (b) clinical and (c) psychological variables. The ‘additivity’ effects 
were checked by evaluating the appropriate interaction terms in the last step of the 
regression. Missing values were replaced by means and the entry of variables into the 
model was determined using the ‘stepwise’ method with a p value for entry of .05 and 
for removal of 0.1. The stepwise method was preferred to avoid/address the problem of 
multicollinearity among variables (Tabachnick & Fidell, 1989).
To search for violations of necessary assumptions in multiple regression, normal plots 
of the residuals of the regression models were produced. Residuals were examined for 
normality and the absence of any trend in value (the prime assumption of multiple 
regression). In every model reported below the assumptions were met.
1.2 Sample characteristics
Sociodemographic and clinical characteristics of the four dialysis groups were described 
earlier (see Chapter 5; section 1.2).
Significant differences were noted between the four dialysis groups in the following 
variables: work status (^2(145) = 14.486, p  = .002), income (y2(145) =13.474,/? = .004), 
time on RRT (F(3, 141) = 32.809, p  = .0001), time on dialysis (F(3, 141) = 13.099, p  =
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.0001), prevalence of diabetes (^2(145) = 8.797, p  = .003) and albumin (F(3, 140) = 
18.455, p  = .0001). Subsequent Tukey’s ’ post-hoc tests showed that home HD patients 
had been on RRT and on dialysis for longer than the other three groups. Albumin levels 
were lower in the CAPD group relative to patients on hospital HD (p = .0001), home 
HD (p = .0001) and APD (p = .019). Inspection of observed and expected frequencies 
indicated that there were more diabetic patients on CAPD compared to the other three 
treatments. A greater percentage of CAPD and hospital HD patients were not employed 
and in the lowest income bracket compared to APD and home HD patients.
1.3 Descriptives -  beliefs in dialysis
Internal consistency, means and Standard deviations (SD) of the IPQ sub-scales, and the 
Illness and Treatment Effects Questionnaires (IEQ; TEQ) are presented in Table 8.1.
Table 8.1: Illness and Treatment Beliefs in Dialysis
HD PD
All DL Hospital Home All HD CAPD APD All PD
Identity a .860 .861 .861
M 12.43 12.35 12.12 12.27 13.22 11.43 12.62
SD 4.15 4.45 3.29 4.09 4.01 4.91 4.23
Timeline a .664 .654 .670
M 4.344 4.34 4.54 4.40 4.21 4.42 4.28
SD .622 .575 .741 .636 .662 .455 .605
Control a .651 .603 .713
M 3.10 3.13 3.07 3.11 2.98 3.29 3.09
SD .587 .537 .678 .582 .616 .510 .596
Conseq a .708 .711 .706
M 3.52 3.51 3.51 3.51 3.61 3.38 3.53
SD .658 .642 .707 .659 .680 .609 .661
IEQ a .887 .861 .906
M 74.19 73.15 70.96 72.44 82.64 63.52 76.18
SD 27.46 26.69 25.35 26.12 28.28 26.72 28.98
TEQ a .881 .848 .912
M 58.68 57.73 62.72 59.35 64.55 44.96 57.92
SD 25.61 22.93 25.88 23.87 26.13 26.24 27.60
Note: DL = dialysis; HD = haemodialysis; PD = peritoneal dialysis; CAPD = continuous
peritoneal dialysis; APD = automated peritoneal dialysis; Conseq = IPQ consequences; IEQ = 
illness intrusiveness; TEQ = treatment intrusiveness
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Different IEQ and TEQ scores correspond to different levels of disruption/distress. 
Table 8.2 presents the occurrence of mild (24-55), average (56-88), moderate (89-120) 
or extreme (above 120) disruption across dialysis groups.
Dialysis’ mean scores in the IEQ and TEQ measures signify moderate level of distress 
and disruption (scores 56-88) associated with illness and treatment (Greenberg & 
Peterson, 1997b).
APD treatment appeared to be the least intrusive or negatively perceived form of 
treatment. Group mean scores indicate that APD patients perceived the least disruption 
associated with their illness and treatment (lowest IEQ and TEQ scores) followed by 
hospital HD, home HD with CAPD last having the highest intrusiveness scores.
Table 8.2: Level of illness and treatment disruption in Dialysis
IE Q Minimal Mild Average Moderate Extreme
%(n) %(n) % (n) %(n) % (n)
HD 3.9% (3) 15.6% (12) 58.4% (45) 19.5% (15) 2.6% (2)
Hospital 3.8% (2) 15.4% (8) 55.8% (29) 21.2% (11) 3.8% (2)
Home 4% (1) 16% (4) 64% (16) 16% (4)
PD 1.5% (1) 26.5% (18) 35.3% (24) 29.4% (20) 7.4% (5)
CAPD 2.2% (1) 17.8% (8) 33.3% (15) 37.8% (17) 8.9% (4)
APD 43.5% (10) 39.1% (9) 13% (3) 4.3% (1)
All DL 2.8% (4) 20.7% (30) 47.6% (69) 24.1% (35) 4.8% (7)
T E Q Minimal Mild Average Moderate Extreme
%(n) %(n) % (n) % (n) % (n)
HD 6.5% (5) 36.4% (28) 44.2% (34) 11.7% (9) 1.3% (1)
Hospital 5.8% (3) 38.5% (20) 46.2% (24) 7.7% (4) 1.9% (1)
Home 8% (2) 32% (8) 40% (10) 20% (5)
PD 8.8% (6) 44.1% (30) 32.4% (22) 14.7% (10)
CAPD 2.2% (1) 40% (18) 40% (18) 17.8% (8)
APD 21.7% (5) 52.2% (12) 17.4% (4) 8.7% (2)
All DL 7.6% (11) 40% (58) 38.6 (56) 13.1% (19) 0.7% (1)
Note\ IEQ = illness intrusiveness; TEQ = treatment intrusiveness; HD = haemodialysis; PD =
peritoneal dialysis; CAPD = continuous ambulatory peritoneal dialysis; APD = automated 
peritoneal dialysis; DL = dialysis
The IPQ scores do not reflect an evaluative component to the same extent as IEQ and 
TEQ items and have no discriminative score range.
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The percentage of patients scoring above the midpoint for the IPQ and BMQ sub-scales 
were hence computed (Table 8.3). This provides an indication of patients holding 
particularly strong beliefs about the construct being measured by each particular scale.
Table 8.3: Percentages of above midpoint IPQ scores in Dialysis
All DL
HD PD
Hospital Home All HD CAPD APD All PD
Timeline 95.2% 96.2 96% 96.1% 91.1% 100% 94.1%
(138) (50) (24) (74) (41) (23) (62)
Control 51% 48.1% 44% 46.8% 46.7% 73.9% 55.9%
(74) (25) (11) (36) (21) (17) (38)
Conseque 73.1% 75% 68% 72.7% 73.3% 73.9% 83.5%
nces (106) (39) (17) (56) (12) (17) (50)
These figures reveal that dialysis patients view their condition as long term (chronic 
timeline beliefs) and as having significant consequences in their lives (n = 106, 73.1% 
having greater than midpoint scores).
There was a greater diversity in patients’ scores in the control IPQ sub-scale, with only 
51% (n = 74) of the patients scoring above midpoint (indicative of stronger beliefs that 
the condition is controllable).
The obtained mean IPQ scores point to the same conclusions in that timeline beliefs 
were stronger whereas the mean scores in the consequences and control beliefs being in 
the range of 3 out of 5 (i.e. uncertain), would rather reflect patients’ uncertainty 
regarding the controllability of their condition and the extent of illness-related 
consequences in their life.
To evaluate symptom reports two symptom scores were obtained:
(a) the number of symptoms patients associated with their illness (consistent with 
previous work using the IPQ)
(b) the frequency of reports of each symptom by patients. The mean scores for each 
symptom and the number of patients endorsing that symptom as part of their kidney 
condition are shown in Table 8.4.
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Table 8.4: Symptom scores in Dialysis: Means, SDs and Percentages
All dialysis HD PD
M SD % M SD % M SD %
Fatigue 2.79 .914 92.4 2.70 .919 92.2 2.88 .907 92.6
Muscle cramps 2.38 .810 88.9 2.17 .719 85.5 2.60 .849 92.6
Loss of strength 2.48 1.028 81.4 2.42 .978 84.4 2.56 1.098 77.9
Pain 2.19 .876 78.6 2.08 .839 75.3 2.32 .905 82.4
Itching 2.14 .940 72.4 2.04 .924 67.5 2.25 .952 77.9
Lack of sex drive 2.44 1.178 71.7 2.35 1.189 67.5 2.54 1.165 76.5
Stiff joints 2.19 1.014 70.3 2.36 1.05 76.6 1.99 .938 63.2
Poor alertness and 1.94 .818 69.7 1.92 .807 70.1 1.96 .836 69.1
concentration
Breathlessness 1.99 .837 69.7 1.86 .756 64.9 2.15 .902 75
Nausea 1.83 .670 67.6 1.79 .656 66.2 1.87 .689 69.1
Restless legs 2.05 .956 66.7 1.87 .885 60.5 2.25 .998 73.5
Sleep difficulties 2.11 1.028 65.5 1.94 1.004 57.1 2.31 1.026 75
Upset stomach 1.81 .754 62.8 1.78 .788 58.4 1.85 .718 67.6
Dizziness 1.69 .640 59.3 1.66 .620 58.4 1.72 .666 60.3
Headaches 1.73 .729 58.6 1.82 .773 63.6 1.63 .667 52.9
Loss of appetite 1.86 .918 57.2 1.68 .850 49.5 2.07 .951 66.2
Weight loss 1.57 .779 43.4 1.62 .779 48.1 1.51 .782 38.2
Sore eyes 1.48 .698 37.9 1.56 .734 44.2 1.40 .650 30.9
Hair loss 1.45 .865 26.9 1.49 .881 31.2 1.40 .849 22.1
The scores for the causal sub-scales were treated separately. Participants that either 
‘strongly agreed' or ‘agreed' that the factor was a causal contributor to their kidney 
condition were placed in one group labelled ‘factor was a cause’ and those who either 
‘strongly disagreed' or ‘disagreed' formed the second group labelled ‘factor was not a 
cause’.
Results showed that patients endorsed few causal beliefs {mean = 1.68, SD = 1.07). 
External factors such as ‘chance’ and ‘poor medical care’ were the most frequently cited 
causes of the kidney condition, endorsed by 85.2% (n = 109) and 26.2% (n = 38) of the 
dialysis patients respectively. A slightly smaller percentage of patients (24.1%, n = 35) 
believed that their condition was hereditary.
Only a fraction of dialysis patients attributed their illness to their own behaviour (n = 
15, 10.4%) or to other people (n = 16, 11.1%). There was little spread in patients’ 
responses in the remaining six causal items. They were therefore excluded from 
subsequent analyses
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1.4 Intercorrelations between illness and treatment beliefs
Significant moderate-to-strong sized positive correlations were found between beliefs 
regarding the effect of illness and treatment, namely IPQ consequences, illness 
intrusiveness and treatment intrusiveness. Correlation coefficients ranged from r = .52 
to r = .73 (see Table 8.5). Strong control beliefs were negatively correlated with illness 
and treatment intrusiveness (r = -.45, p  = .0001; r = -.37, p  = .0001 respectively), 
consequences (r = -.36, p  = .0001), and identity (rs = -.29, p  = .0001).
Correlations between identity and IEQ, TEQ, and other IPQ scores were in the opposite 
direction, with more symptoms being associated with lower control beliefs (rs = -.29, p 
= .0001), more consequences (rs = .42, p  = .0001) and higher illness and treatment 
intrusiveness (rs = .66, p  = .0001 and rs = .47,/? = .0001 respectively).
Table 8.5: Intercorrelations between dialysis patients’ beliefs
TEQ IEQ Identityt Timelinet Control Conseq
TEQ
IEQ 734****
Identityt .662****
Timelinet .031 .179* .114
Control - 374**** - 455**** - 294**** -.105
Conseq 522**** .555**** 421***** .115 - 364****
Note\ TEQ = treatment intrusiveness; IEQ = illness intrusiveness; Conseq = IPQ consequences 
+ = Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p = .0001
Independent sample /-tests showed several significant associations between causal 
beliefs and other cognitions. Patients attributing their disease to poor medical care 
reported significantly more illness consequences (t(143) = -2.366, p  = .019) and more 
illness related disruption (t(143) = -2.315, p  =.022) than patients not endorsing such 
causal beliefs. Similar differences were noted between patients blaming their illness on 
‘their own behaviour’ compared to those who did not. The ‘self-blame’ group had 
stronger identity beliefs (U = 659, p  = .04), and perceived more consequences (t(143) = 
-2.12, p  = .036) and illness intrusiveness (t(143), p = -2.382, p = .019). Finally patients 
regarding their illness as hereditary reported more symptoms as part of their disease (U 
= 1473.5, p  =.036).
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1.5 Group comparisons: Dialysis treatments
To examine whether illness and treatment beliefs differ between dialysis groups a series 
of ANCOVAs were performed comparing (a) HD to PD patients and (b) all four dialysis 
groups (Hospital HD, Home HD, CAPD and APD). Only the casemix differences that 
were significantly associated with the outcome in question were used as covariates in 
these analyses (see Table 8.6).
Table 8.6: The relationship of casemix differences and beliefs in dialysis
IEQ TEQ IPQ
Identity
IPQ
Timeline
IPQ
Control
IPQ
Conseq
IPQ
Causal
Gender - - - - - - -
Work + + + + + + -
Income - - - - + - -
Diabetes + - - - + - +
DL duration - - - - - -
RRT duration - - + + - -
Primary kidney 
disease diagnosis
- - - “ “ - +
+ = significant association / used as a covariate 
- = non significant association / not used as a covariate
1.5.a HD vs. PD
ANCOVAs HD vs. PD comparisons revealed no significant differences in patients’ 
beliefs. Both patient groups held similar beliefs and representations regarding their 
illness and their treatment.
Chi-square analysis revealed that PD patients were more likely than HD patients to 
attribute their illness to ‘poor medical care’ (%2(145) = 7.381, p = .007) and ‘their own 
behaviour’ (%2(145) = 4.695, p  = .03). These differences might reflect casemix 
differences in prevalence of diabetes, which could not be controlled for in Chi-square 
analyses. Perhaps one would expect attributions of self-blame and poor medical care in 
the PD group as more PD patients had diabetes and had developed ESRD as a 
complication of poor diabetic glucose control. Significant associations were indeed 
found between prevalence of diabetes (and IDDM as primary kidney disease diagnosis) 
and attributions of self-blame (%2(145) = 7.983, p  = .005) but not with ‘poor medical 
care’ causal beliefs.
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1.5.b Four dialysis group comparisons
Next, differences in beliefs between all four dialysis groups (hospital HD; home HD; 
CAPD; APD) were examined. A series of one way ANCOVAs were performed 
followed by Tukey’s post-hoc tests if the main treatment effect was significant.
An inherent limitation of SPSS is that it does not allow the inclusion of covariates when 
using the function of one-way ANOVAs with post-hoc tests. This presented a problem 
as some of the casemix differences were also significantly associated with some of the 
DVs (see Table 8.6 above), thereby indicating that their effect should be controlled for 
in all planned group comparisons including post-hoc tests.
To partial out the effect of these casemix differences in post-hoc comparisons, 
residualised scores were obtained for IEQ, TEQ, IPQ control, IPQ timeline and IPQ 
symptoms. These were calculated by regressing each of the beliefs to casemix 
differences (see Table 8.6 above). The resulting residualised scores represented the 
actual value of the DV minus the value predicted by the regression equation.
These reflected IEQ scores minus the effect of diabetes and work status, TEQ scores 
minus the effect of work, IPQ control scores minus the effect of diabetes, work and 
income, and finally timeline and identity scores minus the effect of RRT duration and 
work status. These scores were then used in the post-hoc group comparisons (if omnibus 
ANCOVA was significant).
Analyses showed only a significant group difference, namely on treatment intrusiveness 
(F(3, 141) = 3.382, p  = .020). The group effect on IPQ identity and IEQ approached but 
did not reach significance (F (4 ,140) = 2.571, p  = .057 and F{4, 140) = 2.345, p  = .076).
Post-hoc comparisons indicated significant TEQ differences only between the two PD 
groups, with APD patients perceiving significantly less disruption associated with their 
treatment (mean difference I-J/t = 19.599, p  = .014) relative to patients on CAPD. There 
were no other significant differences among the four dialysis groups.
The mean difference between APD and Home HD patients’ TEQ scores approached but 
did not reach significance (mean difference I-J/t = 17.76, p  = .071). There was a 
tendency for home HD patients to perceive more treatment disruption compared to APD 
patients. The relatively low numbers of APD and home HD patients assessed might
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have undermined the power to detect significant differences between the two home- 
based treatments.
Chi-square analysis showed only one significant difference in causal beliefs among the 
four dialysis groups. Significantly more CAPD patients believed that their illness was 
caused by poor medical care compared to the other three groups (x2(145) = 7.908, p  = 
.048). The extent to which this reflects casemix differences cannot be determined, as 
statistical adjustments are not possible in chi-square analysis.
1.6 Factors associated with beliefs in dialysis
1.6.a Sociodemographic and medical variables
Age was negatively correlated with control beliefs (r = -.26, p  = .002). Education 
correlated with both control (rs = .22, p  = .008) and timeline beliefs (rs = .25, p  = .003), 
with more years of education being associated with stronger beliefs that the kidney 
condition is chronic, yet controllable (see Table 8.7).
ANOVAs indicated that perceptions of illness (F(l, 143) = 5.09, p  = .026) and 
treatment disruption (F(l, 143) = 8.94, p  = .003), identity (F(l, 143) = 4.76, p  = .031), 
control (F(l, 143) = 18.21, p  = .0001), and timeline beliefs (F(l, 143) = 4.85, p  = .029) 
differed significantly between employed and non-employed patients. The differences in 
treatment perceptions (F(3, 141) = 4.86, p  = .029), control (F(3, 141) = 5.33, p  = .022), 
and timeline beliefs (F(3, 141) = 4.65, p  = .032) remained significant after adjustments 
for age and ESRD-SI.
Control beliefs also differed among patients on different income brackets with patients 
in the higher income brackets (> £30,000) reporting stronger beliefs in the 
controllability of their condition compared to patients in the lowest income group (< 
£10,000) (F(l, 143) = 7.36, p  = .007; F(3, 141) = 9.59, p = .02 after age , ESRD-SI 
adjustments).
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Table 8.7: Correlations between beliefs and sociodemographic and clinical variables in
Dialysis
TEQ IEQ Identityt Timelinet Control Conseq
Age -.041 .157 .013 -.078 -.256** -.054
Educationt -.075 -.054 -.048 .248** .22** -.102
ESRD SI+ .242** 332* * * * .223** -.042 _ 424**** .132
DL timet .046 .020 .166* .116 .007 .103
RRT timet .068 .068 .204* .216** .020 .129
Kt/V -.130 -.201* -.045 .035 281*** -.264**
Note: TEQ = treatment intrusiveness; IEQ = illness intrusiveness; Conseq = consequences; 
ESRD = end-stage renal disease severity index; DL time = time on dialysis; RRT time = time on 
renal replacement therapies 
t  = Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001
Medical variables were also associated with patients’ beliefs. Higher ESRD severity 
was associated with more ‘negative’ perceptions, such as higher illness intrusiveness (rs 
= 33, p  < .000), higher treatment intrusiveness (rs = 24, p  = .003), more symptoms (rs = 
.22, p  -  .007), and lower perceptions of control (rs = -.41, p  = .0001). ESRD severity 
was also higher in patients reporting particular causal attributions vs. those who did not. 
This was significant with regard to all causal attributions (i.e. the four beliefs with 
adequate response spread to allow for comparative analyses), i.e. ‘poor medical care’ (U 
= 1545, p  = .028), ‘chance’ (U = 1406, p  = .011), ‘own behaviour’ (U = 589, p  = .012) 
and ‘other people’ (U = 640, p  =.013) except ‘hereditary’ causal beliefs.
Diabetic status was also significantly associated with illness perceptions. Patients with 
diabetes, in particular, reported significantly more illness-related disruption (F(l, 143) = 
4.302, p  = .04) and believed less strongly that their condition is amenable to control 
(F(l, 143) = 7.164, p  = .008). Diabetic status was associated with causal attributions of 
self-blame (%2(145) = 7.983, p  = .005). There was also a tendency for patients with 
diabetes to report more symptoms but this did not reach significance levels (F(l, 143) = 
3.741, p  = .055).
Significant, albeit weak correlations were also noted between perceived symptoms and 
RRT duration (rs = .20, p  = .014), and current dialysis duration (rs = .17, p = .046). 
Longer time on RRT correlated significantly with stronger chronic timeline beliefs (rs =
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.18, p = .029). Higher dialysis adequacy was significantly associated with stronger 
control (r = .281, p  = .001), lower consequences beliefs (r = -.264, p  = .003), and higher 
IEQ scores (r = -.201, p  = .023).
Causal beliefs were associated with primary kidney disease diagnosis. Patients who 
developed ESRD due to diabetes were more likely to report attributions of self-blame 
(%2(145) = 5.552, p -  .018) and those who developed ESRD due to Adult Polycystic 
Kidney disease were more likely to report hereditary causal beliefs (%2(145) = 20.553, p 
= .0001).
1.6.b Mood measures
Mood measures were associated with patients’ illness and treatment beliefs (see Table 
8.8). The general pattern of results indicated that higher levels of depression, anxiety, 
and negative affect are associated with more ‘negative’ illness and treatment 
perceptions such as lower control beliefs, more symptoms and higher reports of illness 
and treatment intrusiveness.
In contrast positive affect appears to be associated with more ‘positive’ illness and 
treatment beliefs.
Table 8.8: Correlations between mood measures and beliefs in Dialysis
TEQ IEQ Identityt Timelinet Control Conseq
BDI .558**** 603**** 48i**** .076 -.458**** 503****
CDI .528**** 54**** 402**** .139 _ 424**** .482****
STAI 388**** 455**** .315**** .003 - 329**** .341****
PNS-PA -.240** - 329**** -.205* .139 .465**** -.249**
PNS-NAt 445**** 420**** 338**** -.044 - 370****
Note: CDI = cognitive depression index; STAI = Spielberger state trait anxiety inventory; PNS- 
PA = PANAS positive affect; PNS-NA = PANAS negative affect; TEQ = treatment effects 
questionnaire; IEQ = illness effects questionnaire; Conseq = illness consequences 
+ = Spearman’s correlations 
p <.05. ** p <.01. *** p <.001. **** p <.0001
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1.6.C Cognitive functioning
The next analysis addressed the question of whether the differences in illness and 
treatment beliefs might be associated with differences in other illness-related variables 
that have been hypothesised to contribute to the burden of ESRD. NP functioning was 
hence investigated.
First linear relationships were explored by means of correlations. Three summary NP 
scores were used:
(1) the mean of overall NP functioning at T1 and T2 (NP-TO).
(2) the mean of number NP impairments at T1 and T2 (number of NP tests in which 
patients’ scores fell more than 1 SD below their age respective norms) (NP-Norm)
(3) A summary score reflecting acute change in NP functioning. The latter was 
expressed as the difference in overall NP functioning between T1 and T2 (NP 
change). The higher change scores reflect the greater the improvement in NP 
functioning across the two assessments
Findings indicated that the less efficient the cognitive functioning the more negative 
patients’ illness and treatment beliefs and perceptions.
Results for instance showed significant correlations between average NP performance 
(NP-TO) and timeline and control beliefs. The more efficient the cognitive functioning 
the stronger patients believed that their condition is amenable to control (r = .344, p = 
.0001) and is of a more chronic nature (rs = .183, p  = .035). Likewise the more NP 
impairments observed across the assessed areas of cognition (NP-Norm), the lower the 
control (rs = -.326, p  = .0001) and timeline beliefs (rs = -.202, p  = .015), and the higher 
patients’ perceptions regarding treatment disruptiveness/burden (rs = .177, p  = .034). 
Some significant associations were found between causal beliefs and cognitive 
functioning. Patients reporting ‘ poor medical care’ causal beliefs had less efficient 
cognitive functioning (NP-TO; t(137) = 2.593, p  = .011) and more NP impairments 
(NP-Norm; U = 1423, p  =.006) compared to patients not expressing such causal 
attributions. Number of NP impairments was also higher in patients blaming other 
people for their illness (U = 644.5, p  = .014) compared to those who did not hold such 
causal beliefs.
The composite score of acute changes in NP performance was unrelated to illness and 
treatment perceptions.
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Section 2: Transplantation sample
2.1 Descriptives -  beliefs
Internal consistency, means and Standard deviations (SDs) of the IPQ sub-scales, the 
Illness and Treatment Effects Questionnaires (IEQ; TEQ) and the Beliefs about 
Medicines Questionnaire (BMQ) are presented in Table 8.9.
Table 8.9: Illness and Treatment beliefs in Transplantation
All TX CAD LRD
Identity*1 a .879
M 9.11 9.52 7.48
Sd 4.41 4.31 4.51
Identity-mb a .781
M 8.83 9.22 8.83
Sd 4.51 4.19 4.63
Identity-txc a .906
M 18.25 18.74 16.30
Sd 8.04 7.88 8.51
Timeline a .743
M 4.05 4.05 4.02
Sd .737 .744 .725
Control a .720
M 3.37 3.35 3.47
Sd .600 .625 .481
Consequences a .731
M .330 3.29 3.31
Sd .655 .672 .595
IEQ a .917
M 36.70 39.19 28
Sd 27.19 28.38 21.58
TEQ a .892
M 29.29 29.48 28.67
Sd 22.35 22.69 21.58
BMQ necessity a .788
M 4.35 4.32 2.40
Sd .719 .571 .775
BMQ concerns a .677
M 2.41 4.51 2.44
Sd .719 .561 .569
a = Identity score based on 19 items used for dialysis (IPQ core items and renal-specific)
1 = score based on the 22 symptoms related to side effects of immunosuppressive medication 
c = identity score based on the 41 items used for TX patients (IPQ core items, renal specific and 
TX immunosuppression side effects)
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Mean scores in the IEQ (mean = 36.7; SD  = 27.19) and the TEQ (mean = 29.3; SD = 
22.36) indicate mild distress associated with perceived disruption caused by illness or 
treatment compared to other medical patients (Greenberg & Peterson, 1997b). 
Transplant patients, as a group perceived few areas in their life as being affected by 
their condition and their treatment. Distribution of scores according to severity of 
perceived disruption also showed that a large percentage of TX patients had scores 
lower than 24, signifying minimal disruption/distress due to illness or treatment (see 
Table 8.10).
Table 8.10: Level of illness and treatment disruption in Transplantation
IEQ Minimal 
(below 24)
Mild
(24-55)
Average
(56-88)
Moderate
(89-120)
Extreme 
(above 120)
%(n) %(n) % (n) %(n) % (n)
CAD 32.1% (27) 47.6% (40) 11.9% (10) 8.3% (7)
LRD 54.2% (13) 37.5% (9) 8.3% (2)
Total TX 37% (40) 45.4 (49) 11.1% (12) 6.5 (7)
TEQ Minimal Mild Average Moderate Extreme
%(n) %(n) %(71) % (n) % (n)
CAD 42.9% (36) 42.9% (36) 13.1% (11) 1.1(1)
LRD 54.2% (13) 33.3% (8) 12.5% (3)
Total TX 45.4% (49) 40.7(44) 13% (14) .09% (1)
Note: IEQ = illness intrusiveness; TEQ = treatment intrusiveness; CAD = cadaver transplant 
patients; LRD = living related donor transplant patients; TX = transplant patients
Inspection of mean IPQ scores (see Table 8.9) indicate that on average TX patients 
believed strongly that their condition is likely to be chronic as opposed to acute (n = 91; 
88.3% had greater than midpoint scores) and that it is likely to be amenable to control or 
cure (n = 73; 70.9 % had greater than midpoint scores). Mean scores on the 
‘consequences’ IPQ component also suggest that patients as a whole tended to agree 
that their condition has had significant consequences in their life (n = 61; 59.2% had 
greater than midpoint scores).
The most frequently cited causes of their condition were ‘chance’ endorsed by 62.5% (n 
= 64) of TX recipients, ‘heredity’ by 23.1% (n = 24), and ‘poor medical care’ reported 
by 22.1% (n = 23) of the participants. A lower percentage attributed their condition to 
‘stress’ (16.3%, n = 17) and ‘germ/virus’ (15.4%, n = 16). The remaining causal items
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were dropped from subsequent analyses due to insufficient numbers endorsing the 
causes.
Transplantation is also accompanied by a variable symptomatology. For the assessment 
of symptoms in TX patients, an extended questionnaire including generic, renal-specific 
and transplantation-specific symptoms was used.
Three symptom scores were hence calculated:
• one score based on the 19-items also used for dialysis (identity: including IPQ 
identity core items and some renal-specific symptoms). This was used for 
comparisons with dialysis patients
• a score referring to immunosuppressive medication side effects (identitv-m: 22 
items)
• a total symptom score including all 41 items (identitv-tx). This was used in all 
subsequent analyses involving only TX patients only, unless stated otherwise or 
comparisons with dialysis patients were performed.
Inspection of total symptom scores (identity-tx) indicates that TX recipients reported a 
wide range of generic, and ‘transplantation or renal specific’ symptoms (range 1-38 out 
a possible score of 41).
With regard to generic symptoms, the majority of them reported fatigue {n = 90, 
79.6%), breathlessness (n = 77, 68.1%), and stiff joints (n = 68, 60.7%).
With regard to ‘transplantation-specific’ symptoms (i.e. symptoms manifested as the 
result of immunosuppressive medication), weight gain, increased appetite were the most 
frequently reported side-effects endorsed by 64.3% (n = 72) and 60.7% in = 68) of the 
TX recipients respectively, followed by tremor (n = 65; 58.6%) and excessive hair 
growth (n = 51; 45.1%). Finally, infections were also frequently experienced by TX 
recipients (n = 69; 61.1%).
Mean BMQ scores suggest that transplant patients expressed very strong beliefs in the 
necessity of immunosuppressive medication (n = 105; 98.1% of the TX participants had 
greater than midpoint scores) and that they were unconcerned about the harmful 
potential of their immunosuppressive drug regime (n =93; 85.3% had equal or lower 
than midpoint scores).
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2.2 Comparisons - CAD vs. LRD TX patients
ANCOVAs were conducted to investigate the effect of transplant type on the patients’ 
beliefs. Casemix differences significantly associated with the outcome in question were 
used as covariates (see Table 8.11).
Table 8.11: The relationship between casemix differences and beliefs in Transplantation
BMQ
n
BMQ
c
IEQ TEQ IPQ
Identity-tx
IPQ
Timeline
IPQ
Control
IPQ
Conseq
Age - - - - - - + -
Education - - - - + - - -
Work - - + + + - + -
Income - - - - - + - -
ESRD-SI - - + + + - + -
RRT duration - - - - - - + -
DL duration - - - - - - - -
+ = significant association / used as a covariate 
- = non significant association / not used as a covariate
Note: BMQ-n = beliefs about necessity of medication; BMQ-c = concerns about medication; 
IEQ = illness intrusiveness; TEQ = treatment intrusiveness; ESRD-SI = end stage renal disease 
severity index; RRT = renal replacement therapy; DL = dialysis
Group comparisons (ANCOVAs) indicated no significant differences between the two 
transplant groups in any of the illness or treatment beliefs. Likewise chi-square analysis 
showed no significant associations between type of transplant and causal beliefs. LRD 
and CAD transplant recipients were hence collapsed to form one group (i.e. combined 
transplant) in subsequent analyses.
2.3 Intercorrelations between illness and treatment beliefs
Significant associations were noted between illness and treatment beliefs (see Table 
8.12). The strongest correlation was between patients’ perceptions of illness and 
treatment intrusiveness (rs = .815, p  = .0001).
Illness disruption was also significantly associated with all IPQ components: identity-tx 
(total symptom score; r = .52, p  = .0001), identity-m (i.e. medication side-effects; r = 
.46, p  = .0001), consequences (r = .63, p  = .0001), control (r = -.32, p  = .001), timeline 
(r = .28, p  = .005), and concerns regarding medication (r = .41, p  = .0001). Perceptions
299
of treatment disruption were similarly associated with all these beliefs albeit correlation 
coefficients were lower than those observed for illness disruption.
Table 8.12: Correlations between illness and treatment beliefs in Transplantation
Ident-tx Ident-m Timel Conseq Control IEQ TEQ+ BMQ-c
Ident-m .925
****
Time! .050 .028
Conseq .329
****
.271
***
.393
****
Control .05 .028 -.35
****
-.224*
IEQ .522
****
.457
****
.277
***
.635
****
-.318
***
TEQ+ .406
****
.405
****
.234* .538
****
-.219* .815
****
BMQ-c .383
****
.429
****
-.033 .288*** -.167 .407
****
.413
****
BMQ-n
t
-.016 -.019 .308*** 273*** -.002 .110 -.033 -.249**
Mote: Ident-tx = extended 42 item version of identity sub-scale (generic, renal and transplant 
specific symptoms; Ident-m = immunosuppressive medication side effects (23 items); timel = 
timeline IPQ sub-scale; conseq = consequences IPQ sub-scale; IEQ = illness effects
questionnaire; TEQ = treatment effects questionnaire; BMQ-c = medication concerns sub-scale 
of the beliefs about your medicines questionnaire; BMQ-n = medication necessity sub-scale of 
the beliefs about your medicines questionnaire 
+ Spearman’s correlations 
* p < .05. ** p < .01. *** p <.001. **** p <.0001
Correlational analysis on the IPQ data revealed that timeline and perceived
consequences correlated significantly with all other IPQ sub-scales as well as illness and
treatment disruption and beliefs regarding medication. Control beliefs were negatively 
correlated with timeline, consequences and perceptions of illness and treatment 
intrusiveness.
Finally, beliefs regarding medication were found to be associated with illness beliefs. 
Concerns regarding medication side-effects was associated with symptom experience 
(total 41-item symptom score and TX medication-specific 22-item symptom score). 
Correlation coefficients were higher for the TX specific symptoms as expected with
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greater concerns regarding immunosupression side-effects being associated with reports 
of more TX medication-specific symptoms.
Perceptions of the impact of illness and treatment as expressed by IPQ consequences, 
IEQ and TEQ scores also correlated with ‘concerns’ about the effects/harmful potential 
of immunosuppressive medication. Negative correlations were found between 
‘necessity’ beliefs and ‘side-effect concerns’ beliefs (rs = -.25, p  = .01).
The associations between causal attributions and other beliefs were examined in a series 
of independent group f-tests or Mann-Whitney tests (as appropriate) comparing patients 
endorsing or not ‘chance’, ‘hereditary’, ‘poor medical care’, ‘germ/virus’ and ‘stress’. 
Between groups comparisons indicated only one significant difference. Patients 
attributing their conditions to ‘chance’ had stronger medication necessity beliefs (mean 
= 22.19, SD = 2.64) than patients not endorsing chance as a cause for their condition 
{mean = 20.08, SD = 3; U = 903.5; p  = .019).
2.4 Factors associated with beliefs
2.4.a Sociodemographic and medical variables
Significant associations were found between patients’ illness and treatment beliefs and 
several sociodemographic and medical factors (see Table 8.13).
With respect to sociodemographic variables, only a few significant associations were 
found, with little consistency across the variables.
Age was negatively associated only with control perceptions and gender with 
medication concerns. Female transplant recipients believed more strongly in the harmful 
potential effect of immunosuppressive medication {mean = 12.98, SD = 3.32) relative to 
male TX patients {mean = 11.38, SD = 3.66; t(107) = -2.314, p  = .023).
Education was negatively associated with symptom experience both in terms of overall 
generic and renal symptomatology as well as symptoms experienced as medication side 
effects.
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Table 8.13: Correlations between sociodemographic, clinical variables and beliefs in
Transplantation
Iden-tx Iden-m Timel Conseq Control IEQ TEQ+ Bmq-c Bmq-n
+
Age .158 .025 .058 -.063 -.296
**
.065 .108 -.007 .000
Educatt -.346
****
-.256
**
.118 .028 .194 -.168 -.102 -.156 .110
Esrd-SI+ .217* . 1 1 1 .134 .165 -.286
**
.326
***
.269
***
.014 -.017
GFR -.374
****
-.320
***
.034 -.149 .247* -.438
St!***
-.267
***
-.098 -.048
RRTdrt .023 -.049 .079 .028 -.227
**
.058 .015 -.091 .065
TXdrt .121 .086 .212* .108 -.294
**
.036 .086 -.039 .107
DLdrt .158 .024 .085 .006 .032 .045 -.005 -.074 -.002
Note: Ident-tx = extended 42 item version of identity sub-scale (generic, renal and transplant 
specific symptoms; Ident-m = immunosuppressive medication side-effects (23 items); timel = 
timeline IPQ sub-scale; conseq = consequences IPQ sub-scale; IEQ = illness effects 
questionnaire; TEQ = treatment effects questionnaire; BMQ-c = medication concerns sub-scale 
of the beliefs about your medicines questionnaire; BMQ-n = medication necessity sub-scale of 
the beliefs about your medicines questionnaire ; Educat = educational level; Esrd-SI = end stage 
renal disease severity index; GFR = glomerular filtration rate; RRT dr = renal replacement 
therapy duration; TX dr = transplant duration; DL dr = dialysis duration;
+ = Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001
Illness and treatment beliefs differed between employed vs. non employed TX 
recipients. Between groups comparisons revealed that employed patients reported less 
symptoms (total 41 item score; F(1, 110) = 6.005, p  = .016), illness disruption (F(l, 
106) = 6.954, p  = .01) and treatment effects (F(l, 106) = 7.318, p  = .008) and had 
stronger control beliefs (F(l, 101) = 5.869, p  = .017) compared to non-employed 
patients. These differences bar IPQ identity-tx (41 item TX extended symptom 
checklist) remained significant even after the effects of age and ESRD severity were 
taken into account by means of ANCOVAs.
Clinical risk indicators and medical factors were associated with more negative 
treatment and illness perceptions (see Table 8.13).
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Higher ESRD severity correlated significantly with lower control beliefs (rs = -.29, p  = 
.003), more symptoms (identity-tx; rs = .22, p = .021), higher perceptions of illness 
intrusiveness (rs = .33,p  = .001), and higher perceptions of treatment intrusiveness (rs = 
.27, p  = .005). With respect to particular comorbid conditions, ANOVA comparisons 
showed that TX patients suffering from ischaemic heart disease reported lower 
perceptions of control than patients with no such diagnosis (F(l, 101) = 5.416, p  = 
.022).
Higher Glomerular Filtration Rate, a measure of clearance achieved by the transplanted 
kidney (with higher scores signifying more efficient functioning) was associated with 
higher control beliefs (r = .25, p  = .013), less symptoms (r = -.37, p  = .0001) and less 
perceived illness (r = -.44, p = .0001) and treatment disruption (r = -.27, p  = .006). 
Finally, a significant association was noted between duration of current functioning 
graft and timeline beliefs, indicating that the longer TX patients lived with their 
transplant the more strongly they believed that in the chronic nature of their condition 
(rs = .21,p = .032).
There were no significant associations between causal beliefs and sociodemographic or 
medical variables (data not shown).
2.4.b Immunosuppressive medication
The next analysis compared illness and treatment beliefs between TX patients treated 
with different immunosuppressive agents, namely cyclosporin (n = 70) and tacrolimus 
(n = 40). Two sets of comparisons were performed: (a) without casemix adjustments 
and (b) with casemix adjustments (age, duration of functioning graft, RRT duration, 
diabetes). Only casemix differences that were significantly associated with the 
outcomes in question were included as covariates.
Oneway ANOVAs (without adjustments for casemix differences) revealed that patients 
on cyclosporin had lower control beliefs (F(l, 99) = 5.385, p  =.022) and held stronger 
chronic timeline beliefs than patients on Tacrolimus (F(l, 94) = 11.979, p  = .001). 
These differences however were no longer significant after duration of functioning graft 
and age were controlled for, hence suggesting that it was these two variables rather than
303
immunosuppressive regime driving these perceptions. It should be noted that the 
treatment effect on timeline beliefs approached but did not reach significance (F(3, 92) 
= 3.614,/? = .06).
There were no group differences in necessity and concerns medication beliefs. The two 
groups also did not differ in the reported symptoms. A trend was noted for cyclosporin- 
treated patients to express stronger ‘medication necessity’ beliefs than tacrolimus- 
treated patients (F(l, 99) = 3.618, p  = .06) but this did not reach significance (no 
covariates were included as neither age nor duration of TX functioning were associated 
with medication beliefs).
2.4.c Mood measures
Negative mood as signified by high CDI symptoms and PNS-NA correlated with more 
negative illness and treatment perceptions such as more illness and treatment disruption 
and more perceived illness consequences. The opposite pattern (inverse correlations) 
was observed for positive affect.
Table 8.14: Correlations between mood and beliefs in TX
Iden-tx Iden-m Timel Conseq Control IEQ TEQt Bmq-c Bmq-n
+
BDI .440 .382 .178 .587 -.402 .628 .508 .321
***
.188 
p <.058
CDIt .305
**
.246
*
.173 .616 -.321
***
.469 .419 -.245
*
.248
*
PNS NA .246
*
.211
*
.135 .295
**
-.09 .294
**
.302
**
.130 -.038
PNS PA -.243 -.120 -.237
*
-.392 .152 -.566
Si****
-.319
**
-.202 
p <.055
-.049
Note: BD ! = total depression score; CDI = cognitive depression index; PMS PA = PANAS
positive affect; PNS NA = PANAS negative affect; Ident-tx = extended 42 item version of 
identity sub-scale (generic, renal and transplant specific symptoms; Ident-m = 
immunosuppressive medication side effects (23 items); timel = timeline IPQ sub-scale; conseq 
= consequences IPQ sub-scale; IEQ = illness effects questionnaire; TEQ = treatment effects 
questionnaire; BMQ-c = concerns about medication; BMQ-n = beliefs about the necessity of 
medication
+ = Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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2.4.d Cognitive functioning
Two NP scores were used: the mean of overall NP performance (NP-TO) and the mean 
number of NP tests in which TX patients scored more than 1 SD below their respective 
age norm (NP-Norm). Results showed no significant associations between any of these 
NP indices and illness and treatment beliefs (data not shown).
Section 3: Dialysis vs. Transplantation
TX patients were not compared separately to HD and PD as previous analysis showed 
no significant differences in illness nor treatment beliefs between the two dialysis 
groups. Five group comparisons involving TX vs. hospital HD vs. home HD vs. CAPD 
vs. APD were performed only in perceptions of treatment intrusiveness (TEQ) as this 
was the only variable in which the dialysis subgroups differed significantly.
3.1 Sample characteristics: combined dialysis and transplant
As reported earlier, there were significant differences between dialysis and transplant 
groups in sociodemographic and medical variables: time on RRT; time on current 
treatment; ESRD severity; diabetes; ischaemic heart disease; income and work status 
(see Chapter 5; section 2.6.a). Significant associations were found between casemix 
variables and patients’ cognitions, indicating the need to include covariates in 
subsequent comparative analyses (see Table 8.15 below).
The casemix differences were associated with causal attributions albeit not consistently 
across the different causal items.
Patients with the lowest yearly income (< £10,000) were more likely to report ‘chance’ 
causal attributions (%2(240) = 5.438, p = .020) compared to those with higher income. A 
greater percentage of non-employed patients attributed their illness to other people 
(%2(249) = 6.359, p  = .012) relative to employed patients.
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ESRD severity was higher among patients expressing attributions of ‘own behaviour’, 
‘other people’ (U = 1234.5, p  = .01), and ‘poor medical care’ (U = 4637.5, p  = .024) vs. 
those who did not endorse these beliefs. Diabetes was associated with ‘self-blame’ and 
‘poor medical care’ attributions in that patients with diabetes were more likely to 
attribute their illness to their ‘own behaviour’ (%2(249) = 13.318, p  = .0001) and ‘poor 
medical care’ (%2(249) = 9.593, p  = .002) compared to non-diabetic participants. 
Ischaemic heart disease was similarly associated with ‘own behaviour’ (%2(249) = 
6.413, p  = .011) and ‘other people’ causal beliefs (%2(249) = 4.01, p = .046).
Table 8.15: The associations between casemix differences and beliefs in DL and TX
Covariates used in DL vs. TX comparisons
IEQ TEQ IPQ IPQ IPQ IPQ IPQ
________ Identity3 Timeline Control Conseq Causesb
Work + + + - + + +
Income + + + - + - +
ESRD-SI + + + - + + +
Heart disease + + + - + + +
Diabetes + + + - + + +
RRT duration + + - - - - -
Current treatment - - + - - - -
duration
+ = significant association / used as a covariate 
- = non significant association / not used as a covariate
3 = identity scores used were based on the 19 items also used with dialysis participants 
b = significant association but no covariate could be used in causal beliefs comparisons
3.2 Comparison results
Two sets of comparisons between dialysis and transplant patients were performed: (1) 
using simple effects ANOVAs without casemix adjustments, (2) using ANCOVAs with 
casemix adjustments.
Results of ANOVA comparisons (without casemix covariates) showed significantly 
more symptoms (i.e. stronger identity beliefs) (F(l, 256) = 38.728, p  = .0001), stronger 
chronic timeline beliefs (F(l, 247) = 11.871, p  = .001), increased treatment disruption 
(F(l, 251) = 90.701, p  < .000), illness disruption (F(l, 251) = 116.309, p < .000) and
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illness consequences (F(l, 246) = 6.797, p  = .01) and decreased control beliefs (F(l, 
246) = 12.641, p  = .0001) voiced by the dialysis group.
These differences persisted even after casemix differences were partialled out. The 
treatment effect was still significant in IEQ (F(7, 233) = 71.346, p  = .0001); TEQ (F(7, 
233) = 64.367, p  = .0001); IPQ identity (F(7, 233) = 27.065, p  = .0001); IPQ timeline 
(F(l, 246) = 11.871, p  = .001); and IPQ control (F(6, 229) = 4.169, p  = .042). A 
tendency was noted for transplant patients to perceive less consequences associated with 
their condition relative to dialysis patients but this difference did not reach significance 
levels (F(5, 242) = 3.123, p  = .078).
Five group ANCOVAs to compare treatment perceptions between TX and dialysis 
subgroups (hospital HD; home HD; CAPD; APD) similarly indicated a significant 
treatment main effect (F(10, 230) = 18.209, p  = .0001). Tukey’s post-hoc tests indicated 
that all four dialysis groups reported significantly higher treatment intrusiveness than 
transplant recipients.
Group differences in causal beliefs were investigated with chi-square analysis, thereby 
not allowing for casemix differences adjustments. Results indicated that a greater 
percentage of dialysis patients endorsed ‘chance’ (%2(249) = 5.309, p  = .021) and ‘own 
behaviour’ causal attributions (%2(249) = 6.753, p  = .009) compared to TX patients. The 
association between treatment and ‘germ-virus’ causal beliefs approached but did not 
reach significance. This trend indicated that more TX patients attributed their condition 
to ‘germ or virus’ (%2(249) = 3.810, p  = .051) relative to dialysis participants. 
Significant differences in causal beliefs are likely to reflect casemix differences, as 
these cannot be controlled for in chi-square analysis.
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Section 4: Summary of Results
• Dialysis and transplant patients hold coherent models of their ESRD consistent with 
SRM and expressed views regarding their treatment regime.
• Illness and treatment beliefs differed between patients on dialysis and transplant 
recipients. TX patients held lower chronic timeline beliefs, believed more strongly 
in the controllability of ESRD, reported less illness and treatment intrusiveness, 
perceived less consequences and less symptoms associated with their condition 
relative to dialysis patients
• There were no significant differences in illness and treatment beliefs between 
patients on different dialysis treatments, with the exception of treatment 
intrusiveness. CAPD patients perceived their treatment to be significantly more 
burdensome compared to patients on APD.
• Significant interrelations were noted between the different IPQ components and 
between illness and treatment beliefs in both dialysis and transplantation
• Significant correlations were found between patients’ beliefs and age, ESRD SI, 
mood and cognitive functioning. The overall pattern of correlations indicated that 
more negative illness and treatment perceptions were associated with increasing age 
and ESRD severity, negative-valenced mood and less efficient cognitive 
functioning.
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C H A PTER  9: HQOL RESULTS
Section 1: Dialysis sample
1.1 H Q oL  D escrip tives
T able 9.1: H Q oL  {Means, SDs, Cronbach alpha ) in D ialysis
All DL
HD PD
Hs-HD Hm-HD All HD CAPD APD All PD
GHa a .727 .721 .736
M 30.38 30.06 33.16 31.07 29.01 30.73 29.59
SD 8.82 8.35 10.45 9.13 8.68 8.07 8.45
PF" a .923 .919 .926
M 27.20 27.15 31.2 28.46 23.02 31.18 25.78
SD 16.45 16.64 15.14 16.19 16.02 17.16 16.75
BP" a .873 .866 .874
M 4.90 42.28 43.78 42.77 35.20 45.84 38.8
SD 12.03 11.64 11.2 11.45 11.99 10.11 12.4
VT" a .882 .877 .871
M 40.85 42.68 44.85 43.38 35.81 42.24 37.99
SD 10.82 10.88 10.98 10.89 10.54 7.65 10.08
RPh" a .811 .788 .839
M 35.32 35.46 39.03 36.62 29.86 41.66 33.86
SD 13.06 12.33 13.49 12.74 11.33 13.75 13.34
REm" a .805 .810 .798
M 45.46 45.89 48.66 46.79 44.18 43.51 43.95
SD 12.42 12.69 10.39 12.01 12.93 12.78 12.79
SF" a .711 .741 .677
M 35.74 37.58 38.65 37.93 30.52 38.61 33.26
SD 13.73 12.42 14.08 12.90 14.7 12.09 14.31
MH" a .827 .823 .827
M 45.37 45.49 48.60 46.50 42.68 46.85 44.09
SD 10.70 10.33 10.39 10.39 11.30 9.97 10.97
MCS
M 47.24 48.17 50.22 48.84 45.08 46.10 45.42
SD 10.37 9.75 9.90 9.79 11.01 10.51 10.77
PCS
M 28.87 29.3 32.32 30.28 23.49 34.64 27.27
SD 13.19 12.23 13.13 12.52 12.59 13.4 13.84
N ote: Hs-HD = hospital haemodialysis; Hm-HD = home haemodialysis; GH = general health;
PF = physical functioning; BP = bodily pain; VT = vitality; RPh = role limitations due to 
physical problems; REm = role limitations due to emotional problems; SF = social functioning; 
MH = mental health; MCS = mental component score; PCS = physical component score 
“ = normative based scoring (population mean = 50 and SD  = 10)
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In keeping with previous research, observed  m ean scores in PC S, PF, G H , RPh and SF 
w ere m ore than 1 SDs  below  general population norm s (N orm ative B ased  Scoring 
population  m ean = 50, Sd =  10) w hile m ean scores reflecting em otional w ell-being  (e.g. 
M C S, M H , R E m ) tended  to be closer (i.e. w ithin 1 SD) to population  m ean (see Table 
9.1).
T here w ere also obvious differences in the SF-36 profile  o f the fou r d ialysis groups. For 
instance, C A PD  patients had m arkedly  low er SF-36 scores than the o ther d ialysis 
groups, w ith average scores in 8 out o f  the 10 SF-36 sub-scales falling  m ore than 1 SD  
below  those o f general population norm s.
T he num ber o f ind iv iduals w ho could  be considered  to have severely  im paired  H Q oL, 
defined  as a score on PCS or M CS o f 2 or m ore SDs below  the general population m ean 
(corresponding  to the low est 2.5%  scoring  o f the general population), w as calculated .
T able 9.2: Prevalence o f M CS and PCS im pairm ent in D ialysis
HD PD
All DLHs-HD Hm-HD All HD CAPD APD All PD
% (n) % (n) % (n) % (n) % (n) % (n) % (n)
P C S 51.9% 48% 50.6% 64.4% 39.1% 55.9% 53.1%
< 2 SD (27) (12) (39) (29) (9) (38) (77)
M C S 1.9% 4% 2.6% 11.1% 13% 11.8% 6.9%
< 2 SD (1) (1) (2) (5) (3) (8) (10)
Note: Hs-HD = hospital haemodialysis; Hm-HD = home haemodialysis
U sing this criterion , 53.1%  (n = 77) o f the total d ialysis sam ple w ere found to be 
severely  im paired  on the PCS and 6 .9% , o f d ialysis respondents (n = 10), had M CS 
scores that w ere sim ilarly  im paired.
1.2 H Q oL  com parisons am ong d ialysis treatm ents
T o  investigate the effect o f treatm ent m odality  after accounting fo r casem ix  d ifferences 
tw o sets o f com parisons (A N O V A s or A N C O V A s as appropriate) w ere perform ed:
■ H D  vs. PD patients
■ H ospital H D  vs. H om e H D  vs. C A PD  vs. A PD  patients
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1.2.a Two group comparisons: HD vs. PD
i. Sample characteristics
T o identify  w hich o f the casem ix d ifferences betw een PD and H D  (gender, d iabetes, 
d ialysis duration, R R T duration, A lbum in and Hb) m ight require statistical control in 
subsequent com parative analyses, their univariate associations w ith SF-36 scores were 
exam ined  (see Table 9.3 fo r sum m ary o f  results).
T able 9.3: T he associations betw een casem ix differences and H Q oL  in d ialysis (HD;
PD )
Covariates used in HD vs. PD comparisons
PF GH BP RPh REm MH SF VT PCS MCS
Gender - - - + - - +
Diabetes + - + + - + + + + -
RRT time - - - - - - -
Time on dialysis - - - - - - -
Albumin + + + + + + + -
+ = significant association /  used as a covariate 
- =  non significant association /  not used as a covariate
ii. Absolute HQoL scores
In the first set o f analyses A N C O V A s (controlling  for casem ix d ifferences) w ere 
perform ed on H Q oL  betw een patien ts on H D  (hospital and hom e) and patien ts on PD 
treatm ents (C A PD  and APD ).
R esults indicated  that at T l ,  H D  patien ts had significantly  h igher scores in v itality  (F(2 , 
142) = 4.911, p = .028) and M CS (F (2 , 142) = 6 .146, p = .014) com pared  to PD 
patients. T he treatm ent effect on vitality  was no longer significant after album in levels 
w ere included  as covariates in the analysis (F (3, 140) = .114,/? = .736).
iii. Prevalence o f HQoL impairments
The association betw een dialysis m odality  and the prevalence o f severe PCS and M CS 
im pairm ents was exam ined  with ch i-square analysis. None w ere detected  for PCS
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(%2(145) = .397, p  = .53). The prevalence o f severe M CS im pairm ent was significantly  
g rea ter in the PD  group com pared  to H D  (F isher’s exact test p  = .046).
1.2.b F our groups com parisons: H ospital HD  vs. hom e HD vs. C A PD  vs. APD
i. Sample characteristics
Significant group d ifferences betw een the four d ialysis groups w ere noted  in w ork 
status, incom e, d iabetes, R R T duration and tim e on current treatm ent requiring  
statistical control in subsequent group com parisons. Table 9.4  lists the casem ix 
d ifferences that w ere used as covariates w hen com paring  SF-36 scores betw een the four 
d ialysis groups, on the condition that they were also significantly  associated  with the 
particu lar SF-36 score.
T able 9.4: The associations betw een casem ix differences and H Q oL  in d ialysis (hospital
H D; hom e HD; C A PD ; A PD )
Covariates used in Hosp HD vs. Home HD vs. CAPD vs. APD
_________________________________________ comparisons_________________________
__________________PF GH BP RPh REm MH SF VT PCS MCS
Work status + + + + - + + + +
Income + - + + - +
Diabetes + - + + - + + + +
RRT duration - - _ . . .
Duration of - - - - - - - - - -
current treatment
A lb um in  +  +  +  +  - - +  +  +
+ = significant association / used as a covariate 
- = non significant association / not used as a covariate
As evident from this table income and work status were strongly associated with the 
physical dimensions of SF-36. Although there is no clear consensus as to whether work 
and income ought to be controlled for in HQoL comparisons, these were nevertheless 
included as covariates as it was thought that this would provide a much stronger test of 
any treatment effects on HQoL over and above socio-economic considerations.
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It is also arguable whether to control for biochemical differences (i.e. albumin) given 
that these reflect treatment differences. Comparative analyses were hence conducted 
with and without the inclusion of albumin.
ii. Absolute HQoL scores
HQoL differences between all four groups were examined using a series of ANCOVAs 
controlling for casemix differences if appropriate (see Table 9.1 for SF-36 mean scores). 
Significant main effects were followed with Tukey’s HSD post-hoc tests.
To account for casemix differences in post-hoc comparisons, residualised scores were 
obtained for the SF-36 sub-scales and summary scores. These were obtained by 
regressing each of the SF-36 sub-scales on casemix differences in order to obtain the 
unstandardised regression coefficient, a value that reflects the observed SF-36 scores 
minus the effect of diabetes, work status and/or income (as appropriate; see Table 9.4). 
This procedure was not necessary when comparing the four groups on GH, REm and 
MCS as no significant associations were found between casemix differences and these 
SF-36 scores.
ANCOVAs controlling for all casemix differences except albumin indicated a 
significant treatment effect on BP (F(6, 138) = 2.769, p  = .044) and VT (F(5, 139) = 
2.748,/? = .045).
Post-hoc tests using residualised scores showed no significant differences between the 
four dialysis groups. A trend was noted for CAPD to report more bodily pain relative to 
hospital HD patients but this did not reach significance (p = .081). Post-hoc tests on 
absolute scores however indicated that CAPD patients reported significantly more 
bodily pain than the other three dialysis groups.
With regard to VT scores, significant differences were noted only between CAPD and 
hospital HD and Home HD patients. After controlling for albumin (in addition to 
diabetic status) however, the treatment effect in vitality and bodily pain ceased to be 
significant.
It is also of note that by excluding income, and work status from the list of covariates 
significant differences were found in all physical dimensions of SF-36 (PCS; BP; RPh; 
VT), with CAPD patients faring significantly worse than APD patients in these sub­
scales.
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iii. Prevalence of HQoL impairments
Chi-square analyses showed no significant differences in the prevalence of severe PCS 
(%2(145) = .4.418, p  = .22) and MCS impairments (%2(145) = 4.928, p = .152) among the 
four groups.
1.3 Factors associated with HQoL in dialysis
The associations between the sociodemographic, clinical, psychological variables and 
HQoL were examined using univariate and multivariate analyses.
1.3.a Sociodemographic and medical variables
Univariate analyses showed several significant relationships between HQoL and 
sociodemographic, medical and psychological variables (see Table 9.5) in addition to 
those described earlier (see sub-sections 1.2.a and 1.2.b)
The physical dimensions of SF-36 were strongly associated with age of dialysis 
patients, with scores deteriorating as a function of age (correlation coefficients ranging 
from r = -.24 to r = -.41) but no significant correlations were observed between age and 
the emotional SF-36 sub-scales.
Gender (Female) was associated with lower scores in MCS (F(l, 144) = 5.2387, p  = 
.0236) and MH (F(l, 144) = 7.2487, p  = .0079).
ANOVAs (with Tukey’s HSD post-hoc tests) indicated that dialysis patients on the 
lower income brackets (i.e. earning less than £10,000 per year) had significantly lower 
physical well-being (PCS F(3, 141) = 7.654, p  = .0001; PF F(3, 141) = 4.724, p = .004; 
BP F(3, 141) = 7.805, p  = .0001; RPh F(3, 141) = 7.603, p  = .0001) than patients with 
higher income.
ANOVAs (without casemix adjustments) indicated that employed patients had higher 
scores in most SF-36 sub-scales, exceptions being MCS and REm. Adjustments for age 
and ESRD severity did not alter the observed group differences in physical SF-36 
dimensions: PCS (F(3, 141) = 4.272, p = .041); PF (F(3, 141) = 17.319,/? = .0001); RPh
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(F(3, 141) = 12.061, p = .001). Differences in VT approached but did not reach 
significance (F(3, 141) = 3.538, p  = .062), whereas the effect on MH was no longer 
significant after casemix adjustments.
Table 9.5: Correlations between HQoL and sociodemographic and medical variables in
Dialysis
PFt GH BP RPh
+
Rem
t
MH SFt VT PCS MCS
Age -.415 -.121 -.268
***
-.239
**
.090 .004 -.150 -.314 -.405 .109
Education
+
.210
*
.206
*
.233
*
.141 .020 .074 .146 .233
*
.258
**
.034
DL time 
durationt
-.040 -.048 .038 .026 .097 -.006 .056 .078 -.007 .082
RRT time -.040 -.099 .025 .027 .056 -.030 .080 .080 .003 .055
No combt -.519 -.384 -.313
***
-.371 -.009 -.144 -.253
**
-.381 -.535 -.019
ESRD Sit -.635 -.382 -.424 -.370 -.131 -.293 -.313 -.470 -.594 -.131
Kt/V .312 .212
*
.254
**
.217
*
-.050 -.048 .220
*
-.157 -.078 -.099
Albumin .222
**
.170
*
.259
**
.191
*
.044 .096 .223
**
.314 .241
**
.078
Hb -.027 -.030 -.222
**
-.031 -.110 -.048 -.067 -.157 -.078 -.099
Note: DL = dialysis; RRT = renal replacement therapy; ESRD-SI = end-stage renal disease 
severity index; Kt/V = dialysis adequacy measure; Hb = haemoglobin GH = general health; PF 
= physical functioning; BP = bodily pain; VT = vitality; RPh = role limitations due to physical 
problems; REm = role limitations due to emotional problems; SF = social functioning; MH = 
mental health; MCS = mental component score; PCS = physical component score 
+ Spearman’s correlation coefficient 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
With respect to clinical characteristics, an increasing number of comorbid conditions 
(ESRD severity) correlated with decreasing HQoL scores in 8 of 10 SF-36 sub-scales. 
Correlation coefficients ranged from r = -.31 to r = -.63, signifying moderate-sized 
correlations.
In addition to diabetes, ischaemic heart disease was similarly associated with lower SF- 
36 scores (i.e. poorer HQoL) in PCS (F(l, 144) = 26.347, p  = .0001), PF (F(l, 144) =
315
25.540, p  = .0001), RPh (F(1, 144) = 10.706, p  = .001), BP (F(l, 144) = 11.531, p  = 
.0009), SF (F(l, 144) = 8.981, p  = .003), VT (F(l, 144) = 15.925, p  = .0001), and GH 
(F(l, 144) = 17.493, p  = .0001). Of particular note are the observed significant 
correlations with mental health, suggesting that increased disease burden as indexed by 
comorbidities may adversely affect both physical and emotional well-being.
Significant associations were noted between dialysis adequacy and HQoL 
predominantly with respect to physical parameters: PCS (r =.37, p = .0001), GH (r = 
.21, p  = .017), VT (r = .25, p  = .004), PF (rs = .31, p  = .0001), RPh (rs = .22, p  = .017), 
BP (rs = .25, p  = .004) and SF (rs = .22, p  = .013). Correlation coefficients indicated 
concomitant changes in HQoL with increases in dialysis adequacy levels. These 
analyses were performed on standardised z-scores as the absolute Kt/V values of 
peritoneal and haemodialysis dialysis adequacy measures are not equivalent.
It was intended to examine the associations between critical levels of dialysis delivery 
and HQoL, but as there were insufficient numbers in the ‘poor/inadequate dialysis’ 
groups (n = 6 in CAPD, n =1 in APD group n -  2 in Home HD and n = 10 in Hospital 
HD group), these comparisons were not feasible and were therefore abandoned.
1.3 .b Beliefs
Correlational analysis on the total dialysis sample also showed that illness and treatment 
beliefs were consistently associated with all SF-36 scores (see Table 9.6).
Correlation coefficients indicated moderate-sized associations in the expected direction. 
Better HQoL was associated with higher IPQ control beliefs, lower illness and treatment 
effect perceptions, lower perceived IPQ consequences, and less perceived symptoms.
Timeline beliefs were found to be inversely correlated with general health perceptions. 
The stronger the beliefs on the chronicity of the illness the more negative patients’ 
evaluations of general health.
316
Table 9.6: Correlations between beliefs and HQoL in Dialysis
PFt GH BP RPh
t
Rem
t
MH SFt VT PCS MCS
IPQ timet .025 -.162
p<.051
.097 .014 .020 -.036 -.083 .127 .028 -.028
IPQ
Control
.491 .502 .386 .317 .210
*
.393 .399 .514 .486 .308
IPQ
Conseq
-.271
***
-.504 -.334 -.234
**
-.228
**
-.43
***
-.342 -.430 -.336 -.359
IPQ
identityt
-.381 -.403 -.431 -.296 -.223
**
-.406 -.439 -.469 -.408 -.364
IEQ -.524 -.535 -.480 -.405 -.273
***
-.515 -.51 -.555 -.537 -.395
TEQ -.400 -.421 -.410 -.336 -.336 -.550 -.401 -.429 -.407 -.436
Note: Conseq = consequences; IEQ; illness intrusiveness; TEQ = treatment intrusiveness; GH = 
general health; PF = physical functioning; BP = bodily pain; VT = vitality; RPh = role 
limitations due to physical problems; REm = role limitations due to emotional problems; SF = 
social functioning; MH = mental health; MCS = mental component score; PCS = physical 
component score
t  Spearman’s correlation coefficient 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
As treatment perceptions were strongly associated with illness perceptions, particularly 
beliefs about illness intrusiveness (r = .73, p  = .0001), it is possible that the observed 
significant correlations between treatment beliefs and HQoL would be due to effects of 
illness perceptions rather than an indication of a direct association between the two of 
them.
Partial correlations were therefore conducted to re-examine the associations between 
treatment beliefs and HQoL after taking into account the effect of illness intrusiveness. 
Results demonstrated that beliefs about treatment intrusiveness were still significantly 
correlated with psychological dimensions of SF-36, namely MH (r = -.30, p  = .0001), 
REm (r = -.28, p  = .005), and MCS (r = -.23, p  = .005) but not with remaining sub­
scales and PCS (ps <.l).
Independent group r-tests and Mann-Whitney tests (as appropriate) comparing SF-36 
scores between patients endorsing or not particular causal beliefs (i.e. ‘chance’; ‘poor 
medical care’; ‘hereditary; ‘own behaviour’; ‘other people’) showed no significant 
group differences.
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1.3.c Mood variables
Significant correlations were noted between mood and HQoL. Negative mood 
indicators were associated with compromised emotional and physical well-being with 
correlation coefficients ranging from r = .26 to r = .67. As anticipated the strongest 
correlations were found between mood measures and emotional well-being on the SF- 
36, with correlations between mood and physical indicators of HQoL being somewhat 
lower, i.e. in the range of low to moderate associations.
Table 9.7: Correlations between mood and HQoL in Dialysis
PF+ GH BP RPh
+
REm
+
MH SFt VT PCS MCS
BDI -.619
****
-590
****
-.517
****
-.444
****
-.512
****
-.669
****
-.570
****
-.624
****
-.599 -.547
****
CDI -.570
****
-.578
****
-.466
****
-.452
****
-.419
****
-.666
****
-.556
****
-.557
****
-.535 -.543
****
STAI -.403
****
-.349
****
-.411
****
-.257
**
-.383
****
-.564
****
-.388
****
-.447
****
-.355 -.466
****
PNS NA+ -.425
****
-.333
****
-.417
♦ St!**
-.260
**
-.405
****
-.570
****
-.386
****
-.493
****
-.361 -.482
****
PNS PA .478
****
.377
****
.421
****
.287
****
.314
****
.470
****
.506
****
.476
****
.339 .420
****
Note: BDI = total beck depression scores; CDI = cognitive depression index; STAI = state 
anxiety; PNS NA = PANAS negative affect; PNS PA = PANAS positive affect; GH = general 
health; PF = physical functioning; BP = bodily pain; VT = vitality; RPh = role limitations due to 
physical problems; REm = role limitations due to emotional problems; SF = social functioning; 
MH = mental health; MCS = mental component score; PCS = physical component score 
+ Spearman’s correlation coefficient 
p <.05. ** p <.01. *** p <.001. **** p <.0001
1.3.d Cognitive functioning
To examine the association between cognitive functioning and HQoL, correlations were 
performed between SF-36 scores and indices of NP performance. For these analyses, 
three summary scores reflecting patients’ overall cognitive functioning (see earlier 
section 1.6.c) were used in preference to the individual NP scores to reduce the number 
of correlations and thereby the chance of type I error.
318
These included the number of NP impairments relative to age respective norms (NP- 
Norm), the mean of the two derived NP summary scores across the two assessments 
(NP-TO) and the change score in overall NP performance from T1 to T2 (acute NP- 
change).
Table 9.8: Correlations between cognitive functioning and HQoL in Dialysis
NP-TO NP-change NP-Norm
Full Partial Full Partial Full Partial
PCS .146 .019 -.022 -.429**** -.235**
MCS .085 .137 .163* .202* -.131 -.081
GH .129 -.0001 .225** .259** -.173* -.013
PF+ 558**** .238** -.002 -.096 - 458**** -.284***
BP 292* * * * .131 .045 .028 - 338**** -.223**
RPht 360**** .151 .078 .024 - 314**** -.200*
REmt .176* .232** .093 .078 -.193* -.187*
MH .194* .181* .121 .155 p<.064 -.230** -. 161p<.054
SF+ .257** .066 .112 .112 -.208* -.063
VT 317*** * .109 .157 p<.06 .153 p<.068 - 339**** -.119
Note: GH = general health; PF = physical functioning; BP = bodily pain; VT = vitality; RPh = 
role limitations due to physical problems; REm = role limitations due to emotional problems; 
SF = social functioning; MH = mental health; MCS = mental component score; PCS = physical 
component score 
+ Spearman’s correlations 
* p <.05. ** p <.01. p <.001 0001.
Results showed several significant associations, primarily in relation to physical 
dimensions of SF-36. Cognitive functioning correlated significantly with PCS, PF, RPh, 
BP, VT, BP and MH. Correlations ranged from .17 to .41 (see Table 9.8).
Correlational analyses were repeated using a series of partial correlations taking into 
account two variables: age and ESRD-SI, a weighed index of comorbidity and renal 
complications (see Table 9.8). Partialling out the effect of these two variables rendered 
some of the previous (significant) correlations between overall cognitive functioning or 
acute NP change and SF-36 scores (PCS, BP, SF, VT) non-significant, with only the 
associations between physical functioning, role limitations-emotional and mental health 
and NP summary scores remaining significant.
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With respect to NP Impairments (NP-Norm), partial correlations produced a similar 
pattern of results. It should be noted that only ESRD-SI was partialled out in the case of 
NP impairments as classification of individual NP performance as impaired or not (i.e. 
within or lower than norms) was based on age respective normative data. ESRD-SI 
adjustments reduced the strength of observed correlations but did not completely 
remove their significance.
A separate correlational analysis was performed on the HD sample alone to examine 
whether acute changes in overall cognitive functioning for pre- to 24-hours post-dialysis 
(NP-change) were associated with HQoL levels. Results indicated that changes in 
overall NP performance from T1 to T2 (HD group only) was unrelated to SF-36 scores 
(ps <.1; data not shown).
1.3.e Subjective cognition
The associations between subjective cognition and HQoL were examined using two 
subjective cognition indices: Overall cognitive decline since initiation of dialysis (SCS- 
TO) and overall acute subjective cognitive change from T1 and T2 (acute SCS-TO). 
Higher scores in both summary scores signified perceptions of greater cognitive decline.
Table 9.9: Correlations between indices of subjective cognition and HQoL in dialysis
SCS-TO Acute SCS-TO
Full Partial Full Partial
PCS -.346 **** -.209 * .040 .046
M CS - 350 **** - 307 **** -.027 -.130
G H - 323 **** - 944 ** -.011 -.019
PF+ 358 **** - 331 **** .082 .089
RPh+ -.438 **** .009 .082 .008
R E m t - 267 **** - 231 ** -.013 -.082
M H - 423 **** - 352 **** -.026 -.093
SF+ - 376 **** - 298 **** -.027 -.096
VT _ 440 * * * * .026 -.008
Note: GH = general health; PF = physical functioning; BP = bodily pain; VT = vitality; RPh 
= role limitations due to physical problems; REm = role limitations due to emotional 
problems; SF = social functioning; M H = mental health; MCS = mental component score; 
PCS = physical component score 
t  Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001 **** p <.0001.
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Results indicated that perceptions of greater cognitive decline since dialysis onset were 
associated with poorer HQoL. Significant correlations ranging from r = -.13 to r = -.44. 
were evident in both physical and emotional SF-36 dimensions (see table 9.9). These 
associations remained significant even after the effect of age and ESRD was controlled 
for with partial correlations.
In contrast, acute subjective cognition was unrelated to SF-36 scores.
1.3.f Multivariate analysis
Subsequently, all variables univariately associated either with physical (PCS) and 
mental (MCS) component scores were presented stepwise to hierarchical multiple 
regressions to assess their independent prognostic value for HQoL in dialysis patients.
Predictors were entered in a specified order. On the first step sociodemographic 
variables (age; education; gender; income; work status) were entered to control for their 
relationship with HQoL. Medical variables (dialysis modality; ESRD SI; dialysis 
adequacy; dialysis duration; albumin; diabetic status) were entered on the second step. 
Indices of cognitive functioning and cognitive complaints followed at step 3. Patients’ 
illness and treatment beliefs entered at step 4. As there was no specific hypothesis 
regarding their primacy, illness and treatment beliefs were entered together rather than 
as separate blocks. In the last block, cognitive depression scores were entered.
To evaluate the contributions of patients’ beliefs over and above attributed to mood, 
regression analyses were repeated entering mood indicators before patients’ beliefs .
In each of the blocks described only the variables significantly associated with PCS or 
MCS were included. Variables that were significantly associated with the individual 
sub-scales but not the summary scores were also included on the grounds that PCS and 
MCS reflect a weighted summary of the eight SF-36 sub-scales. The only exceptions 
were education, gender (Block 1) and time on dialysis (Block 2) that were entered under 
forced entry despite the lack of significant correlations with either summary component 
or individual SF-36 scores, so as to control for their potential influence.
Finally in order to create a more favourable case to variables ratio, certain variables 
were excluded from regression analyses. Neither diabetes nor ischaemic heart disease
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status entered the regression equation as separate variables as these were included in the 
total disease severity and comorbidity weighted index score (ESRD-SI).
Mood measures assessing daily affective state (PANAS, STAI) were also left out given 
their acute time frame ( ‘at the moment’) that made them inappropriate predictors of 
HQoL over the previous 4 weeks preceding measurement. Cognitive depression (rated 
over a longer time frame) was retained. The significant intercorrelations noted between 
CDI and other mood measures (see chapter 6; sub-section 1.6) suggests that little will be 
lost by this strategy.
It should be noted that regressions included variables with non-normal distribution (e.g. 
education, ESRD-SI). This was deemed essential, as there was no alternative way of 
conducting analyses of similar type.
Multivariate analyses results indicated that a large proportion of the variance in PCS (R2 
= 58.7%; adj.R = 56.3%) was explained by a combination of sociodemographic, 
medical and psychological variables.
Significant predictors (as in the last step of regression) were: work status, age, ESRD 
severity, dialysis adequacy (Kt/V), illness intrusiveness and cognitive depression. As 
presented in Table 9.10, sociodemographic and medical variables accounted for R2 = 
45.8% (Adj. R2 = 43.9%) of the total variance indicating a medium effect size i f  -  
.845). Perceptions of illness intrusiveness independently contributed an additional AR2 
= 8.5% (AAdj.R2 = 7.6%) in the explained variance (Fchange (1, 137) = 26.542, p  = 
.0001) and depression added AR2 = 2.8% (AAdj.R2 = 2.6) in the total variance explained 
(Fchange (1, 136) = 8.861,/? = .003).
Subjective cognitive complaints, a significant PCS predictor at steps 6 and 7 of the 
regression model, was no longer significant with the entry of depression in the equation, 
suggesting a mediating effect for depression.
The entry of mood measures before patients’ cognitions did not alter the results. The 
overall variance explained was still R2 = 58.7% (Adj. R2 = 56.3%) and significant PCS 
predictors as in the last step were again: work status (R2 = 20.6%), age (AR2 = 8.4%), 
ESRD severity (AR2 = 11.2%), dialysis adequacy (AR2 = 3%), cognitive depression 
(AR2 = 7.4%) and illness intrusiveness (AR2 = 4.1%). The only, minor difference was 
that illness intrusiveness had a smaller independent yet significant contribution to the 
overall variance explained (Fchange (1, 137) = 13.539,/? = .0001) (see Appendix J).
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Table 9.10: M ultiple regressions to predict PCS and MCS in dialysis: standardised
regression coefficients, cum ulative variance explained
PCS MCS
p Cum R2 Cum
Adj.R2
P Cum R2 Cum
AdjJ*2
Block 1
Work Status .140* .212 
/ = .  513
.206 
/ = .  471
Age -.165* .295 
/  =.201
.285
/= .1 8 1
Gender .105 ns .035
/ = .  055
.029 
/  =.044
Education
Income
Block 2
Dialysis group .162* .075
=.063
.062 
/  = 051
ESRD severity -.248*** .408 
/ = .  274
.395 
/ = .  252
Kt/V .125* .438
/= .0 7 3
.422
f  =.062
Albumin .076 ns .458
/= .0 4 8
.439 
/ = .  039
Haemoglobin
Block 3
NP functioning 
NP impairments 
SCS TO -.010 ns .475 
/ = .  041
.452 
/  =.030
-,141ns .194
/ = .  189
A l l
f = M 6
Block 4
IEQ _ 2 4 5 *** .560 
/ = .  206
.538 
/ = .  197
TEQ -.181* .287
/ = .  148
.266
/= .1 3 6
IPQ conseq 
IPQ control 
IPQ identity
Block 5
CDI -.218** .587 
f  = 065
.563 
/  =.057
-.356 .370 
**** j z _ J22
.347 
/ = •  124
Note: / =  variance-based measure of effect size calculated as f  = AR2 / (1- R2T0tai); cum =
cumulative variance; Kt/V = dialysis adequacy; NP= neurospychological; IEQ = illness 
intrusiveness; TEQ = treatment intrusiveness; conseq =consequences; CDI = cognitive 
depression index
p <.05. ** p <.01. *** p <.001. **** p <.0001. ns = non significant
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Hierarchical regression analysis to predict MCS were performed with and without the 
inclusion of CDI in the last step. The reason being that there is a significant overlap 
between CDI and MCS as both are essentially measuring or reflecting the same 
underlying concept, i.e. emotional well-being.
The resulting regression model explained R2 = 28.7% (Adj.R2 = 26.6%) of the MCS 
variance with treatment group, treatment perceptions and illness consequences being 
significant multivariate correlates at the last step of the regression (see Table 9.10). 
Gender and treatment group explained R2 = 6.2% of the total variance, with male gender 
and HD status being associated with higher MCS scores. Perceptions of cognitive 
decline adversely impacted upon emotional well-being (AR2 = 11.9%; Fchange (1, 141) 
= 20.766, p  = .0001). Among the psychological variables, beliefs about treatment 
intrusiveness made the strongest independent contribution explaining AR2 = 9.3% of the 
variance explained (Fchange (1,141) = 3..408, p  = .0001).
Inclusion of mood measures in the last block of the regression (see Table 9.10) changed 
final results, by rendering the contribution of gender, and cognitive complaints no 
longer significant. The resulting model explained a total of R = 37% (Adj.R = 34.7%), 
significant predictors as in the last step being dialysis modality, perceptions of treatment 
intrusiveness, and depressive mood. Gender and subjective cognitive complaints ceased 
to be significant predictors in the last stage of entry (CDI). The changes in beta weights 
suggest a mediation effect for cognitive depression.
Reversing the order of entry for mood and cognitions produced similar results with 
treatment group, CDI and treatment intrusiveness explaining R2 = 37% (Adj.R2 = 
34.7%) of the MCS variance (see Appendix J).
Section 2: Transplantation sample
The bulk of the findings reported below are based on the sample from the Middlesex 
Hospital used in the main (full protocol) study. Where equivalent data was available on 
the large sample recruited from Royal Free Hospital, then additional analyses were 
performed.
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2.1 Sample Characteristics
Sociodemographic and clinical characteristics of the TX sample recruited from MIDDX 
have been reported earlier (Chapter 5; section 1.1). Observed casemix between CAD 
and LRD TX participants are also detailed in previous sections (see Chapter 6; section 
2.4).
2.2 Descriptives - HQoL in Transplantation
HQoL levels as measured by the eight SF-36 sub-scales were found to be similar in both 
LRD and CAD transplant recipients. Group mean scores in all SF-36 sub-scales were all 
within 1 Sd of those reported for general population and so were the physical and 
mental component scores (PCS and MCS).
Table 9.11: HQoL in TX patients
All TX CAD TX LRD TX
GHa a .828 .836 .823
M (SD) 45.22(11.48) 44.23 (11.77) 49.05 (9.51)
PF* a .935 .937 .856
M  (SD) 41.97 (14.80) 39.99(15.36) 49.81 (8.61)
BP* a .903 .913 .77
M  (SD) 48.88 (12.56) 47.58 (13.14) 53.96 (8.35)
VT* a .665 .614 .856
M  (SD) 52.09(16.24) 52.18 (17.75) 51.72 (8.08)
RPh* a .948 .952 .869
M  (SD) 43.67 (14.23) 41.69(14.83) 50.39 (8.85)
REm* a .927 .931 .846
M  (SD) 47.17 (12.42) 46.01 (13.19) 51.77 (7.23)
SF* a .70 .683 .776
M  (SD) 47.69 (10.34) 47.01 (10.72) 50.40 (8.34)
MH* a .759 .775 .644
M  (SD) 49.91 (9.42) 49.67 (9.96) 50.86 (6.92)
MCS
M  (SD) 51.40 (9.04) 51.50 (9.39) 51.02 (7.67)
PCS
M  (SD) 42.96 (14.96) 40.96(15.39) 50.81 (10.04)
Note: CAD TX = cadaver transplant recipients; LRD TX = living related donor transplant recipients PF =
physical functioning; BP = bodily pain; VT = vitality; RPh = role limitations due to physical problems; 
REm = role limitations due to emotional problems; SF = social functioning; MH = mental health; MCS = 
mental component score; PCS = physical component score 
* = normative based scoring (population mean = 50 and SD  = 10)
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2.3 HQoL comparisons -  LRD vs. CAD Transplantation
2.3.a Prevalence of HQoL impairments
The number of individuals who could be considered to have severely impaired HQoL, 
defined as a component HQoL score (PCS or MCS) of 2 or more SDs below the general 
population mean (mean = 50, SD = 10) corresponding to the lowest 2.5% scoring of the 
general population, was calculated. Using this criterion, 19.8% (n = 22) of the total 
transplant sample (n = 20, 21.7% of CAD and 8.7% of LRD, n = 2) were found to be 
severely impaired on the PCS. In contrast only 2.7% (n =3) of TX respondents (4.3% of 
LRD, n = 1 and 2.3% of CAD, n = 2) had MCS scores that were similarly impaired. No 
association was found between type of transplant and prevalence of severe impairments 
in PCS (Fisher’s exact test significance = .156) and in MCS (Fisher’s Exact test 
significance = 1.00).
When however scores were classified as falling within 1 SD of the population mean (a 
less stringent criterion of impairment) or not, transplant-type differences were detected. 
Chi square analysis showed that significantly more CAD patients (n = 35, 30.1%) had 
PCS scores lower (> 1 SD) than norms, relative to LRD patients in = 3, 7.9%) (%2(111) 
= 5.786, p < .  017).
As however the sample size of LRD TX patients recruited in the main study from the 
Middlesex hospital was fairly small (n = 25), it was decided to repeat this analysis in the 
combined TX population including both participants from Middlesex Hospital and from 
the Royal Free Hospital totalling n = 347 (of whom n = 75 had received a LRD 
transplant) (see Chapter 5; Table 5.7).
A similar pattern of results emerged. Of the combined Middlesex and Royal Free 
Hospital transplant sample recruited, 22.6% (n = 79) patients (24.5% of CAD, n = 67 
and 15.8% of LRD, n = 12) were found to be severely impaired on the PCS. In contrast, 
only 10% of TX respondents (11.8% of LRD, n = 9 and 9.5% of CAD, n = 26) had 
MCS scores that were similarly impaired. Chi-square analysis showed that the 
prevalence of physical HQoL impairment (PCS) was greater in CAD than LRD patients 
(X (337) = 7.627, p = .022). MCS impairment prevalence was similar between the two 
transplant groups.
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2.3.b Absolute HQoL scores
Group comparisons were performed without the casemix adjustments by using 
independent f-tests or Mann-Whitney tests (as appropriate). These showed significant 
group differences only in the physical dimensions of SF-36. LRD TX patients had 
higher scores, i.e. better HQoL than CAD TX patients in PCS (U = 599, p  =.002); PF (U 
= 599, p = .001); BP (U = 732.5, p  = .02); and RPh (U = 647.5, p  = .005).
Analyses of covariance, ANCOVAs (see Table 9.12 for covariates used) were then used 
to investigate the effect of transplant type on the HQoL domains after casemix 
differences were taken into account (with p values, uncorrected for multiple 
comparisons, considered significant if p  < .05).
Table 9.12: The associations between casemix differences and HQoL in TX
Covariates used in CAD vs. LRD TX comparisons
PF GH BP RPh Rem MH SF VT PCS MCS
Age + - + + - - - - + +
Education + - + + - - - - + -
Work status + + + + + - + - + -
Income + + + + + - - - + -
ESRD-SI + + + + + - + + + -
RRT duration - - - - - - - - - -
DL duration - - - - - - - - -
Note: ESRD-SI = end -stage renal severity index; RRT = renal replacement therapy; DL = 
dialysis; GH = general health; PF = physical functioning; BP = bodily pain; VT = vitality; RPh 
= role limitations due to physical problems; REm = role limitations due to emotional problems; 
SF = social functioning; MH = mental health; MCS = mental component score; PCS = physical 
component score
+ = significant association / used as a covariate 
- = non significant association / not used as a covariate
There were no significant group differences in any of the SF-36 sub-scale scores or the 
two component scores. LRD and CAD TX patients reported equivalent levels of HQoL 
after casemix adjustments.
An identical analysis of the HQoL data in the combined TX sample recruited from both 
the Middlesex and Royal Free Hospital similarly failed to find significant HQoL
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differences between LRD (n = 75) and CAD (n = 271) patients after adjustments for 
age, income and dialysis duration differences (see Appendix K).
2.3. Factors associated with HQoL in Transplantation
2.3.a Sociodemographic and medical variables
Univariate analyses showed several significant relationships between HQoL and 
sociodemographic and medical variables in the TX sample (see Table 9.13).
Table 9.13: Correlations between HQoL and sociodemographic and medical variables in
Transplantation
PFt GH BPt RPht REmt MH SFt VTt PCSt MCS
Age -.482 -.179 -.316
***
-.236
*
-.045 .148 -.015 .008 -.479 .277
**
Educationt .372 .131 .307
***
.226
*
.171 -.022 .133 .035 .342 -.106
TX timet .004 .054 -.055 .131 -.008 .045 .110 -.042 .034 .061
DL time t -.045 .009 .013 -.090 -.145 -.015 -.134 .059 -.052 -.016
RRT time 
t
.029 .026 -.010 .052 -.096 -.025 .024 .048 -.043 -.30
No comrbt -.324 -.184 -.348 -.204* -.053 .019 -.095 -.123 -.366 .082
ESRD Sit -.518 -.397 -.499 -.421 -.260
**
-.062 -.203
*
-.299
***
-.571 -.047
GFR .375 .38
***
.416 .317
***
.292
**
.192
*
.316
***
.269
**
.393 .175
Hb .309
***
.412
***
.25
**
.327
***
.231
*
.205
*
.224
*
.20* .321
***
.143
Albumin .248
**
.162 .21* .143 .165 -.004 .175 .155 .272
**
.119
Note\ TX-time = time elapsed since transplantation; RRT = renal replacement therapy; DL = 
dialysis; ESRD-SI = end-stage renal severity index; No comrb = number of comorbidities; GFR 
= glomerular filtration rate; GH = general health; PF = physical functioning; BP = bodily pain; 
VT = vitality; RPh = role limitations due to physical problems; REm = role limitations due to 
emotional problems; SF = social functioning; MH = mental health; MCS = mental component 
score; PCS = physical component score 
t  Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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The physical dimensions of SF-36 were strongly associated with age, with scores in BP, 
GH, PF, RPh, PCS deteriorating as a function of age (correlations ranging from rs = -.24 
to rs = -.48). Interestingly age was positively associated with emotional well-being, i.e. 
higher MCS scores (r = .276, p  = .003).
The only significant HQoL difference between male and female transplant patients was 
found in physical functioning in favour of male patients (F(l, 112) = 3.985, p  = .048). 
This difference was however not significant when adjustments were made for casemix 
differences (age and ESRD-SI) (F (3 ,110) = 2.666,/? = .105).
Higher education correlated significantly with better physical HQoL as indexed by 
higher scores in BP, RPh, PF and PCS but these significant associations were again due 
to age. Partial correlations controlling for age showed no significant associations 
between education and HQoL (r = .157, p  = .062 for PCS; r = .181, p  = .062 for PF; r = 
.138,/? = .138 for RPh; r = .143,/? = .144 for BP).
Annual income was also associated with the HQoL, particularly physical well-being. 
ANOVA comparisons between patients on the four different income groups indicated 
that transplant patients on the lower income brackets (i.e. earning less than £10,000 per 
year) had significantly poorer HQoL, as indexed by lower scores in PCS (F(3, 96) = 
7.378, p  = .0002), PF (F(3, 97) = 7.988, p  = .0001), BP (F(3, 97) = 5.714, p  = .0012), 
RPh (F(3, 96) = 5.518, p  = .0016), and REm (F(3, 97) = 3.386, p  = .0213) than patients 
with higher incomes. No systematic differences were found between the other three 
income groups.
ANOVA comparisons between employed and non-employed TX patients indicated 
significant group differences, favouring employed patients, primarily in physical SF-36 
dimensions. These remained significant even after adjustments for age and ESRD 
severity differences using ANCOVAs: PCS (F(3, 108) = 9.446, p  = .003); GH (F(3, 
108) = 10.673, p  = .001); BP (F(3, 109) = 5.005, p  = .027); PF (F(3, 109) = 8.623, p  = 
.004); RPh (F(3, 108) = 9.889, p  =.002); REm (F(3, 109) = 18.999, p  = .0001); and SF 
(F (3 ,109) = 8.445,/? = .004).
With respect to clinical characteristics, increased ESRD severity correlated significantly 
with decreasing HQoL scores in 8 of 10 SF-36 sub-scales. Spearman’s correlation
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coefficients ranged from rs = -.20 to rs = -.57, signifying moderate- to strong-sized 
correlations (see Table 9.12). Ischaemic heart disease, in particular was associated with 
lower scores (i.e. poorer HQoL) in PCS (U = 672, p  = .0001), PF (U = 731.5, p  = .001), 
RPh (U = 848.5, p  = .008), GH (F(l, 111) = 9.678, p = .002), BP (U = 832, p  = .004) 
and SF (U = 954, p  = .042).
Higher GFR values, signifying better kidney function were associated with better HQoL 
as indexed by higher SF-36 scores. Correlation coefficients ranged from r = .191 to rs = 
.416, with the strongest correlations being observed for the physical sub-scales of SF-36 
(e.g. PCS, BP). The association GFR and MCS approached but did not reach 
significance (r = .175, p  = .067).
Neither time spent on dialysis and RRT prior to transplantation, number and duration of 
previous transplants (if any), nor time with their current transplant (duration of 
functioning graft) were associated with SF-36 scores.
2.4.b Immunosuppressive medication
The impact of immunosuppressive treatment on HQoL for TX patients was also 
examined.
Firstly HQoL comparisons were performed between TX patients on tacrolimus (n = 40) 
vs. those on cyclosporin (n = 70; see Appendix I) using Mann-Whitney or Independent 
/-tests (as appropriate). There was no need to control for TX duration (the only 
significant casemix difference between the two groups), as it had no association with 
SF-36 scores.
No significant group differences were found, hence suggesting that immunosuppressive 
regimen appears to be unrelated to HQoL or that the two treatments are comparable in 
their HQoL effects.
Secondly, correlations between serum levels of cyclosporin and tacrolimus and SF-36 
scores were performed and again no significant associations were found (ps < .1).
1.3.c Beliefs
Correlations were performed to examine the relationship between patients’ beliefs (IPQ; 
TEQ; IEQ; BMQ) and HQoL (see Table 9.14).
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Table 9.14: Correlations between beliefs and HQoL in TX
PFt GH BP+ RPht REmt MH SF+ VT+ PCSt MCS
IPQ time .029 -.204
*
-.033 .072 .037 -.103 .004 -.197
*
.005 -.034
IPQ
control
.271
**
.319 .202
*
.207* .252* .199
*
.088 .242
*
.224* .049
IPQ
Consequences
-.255
**
-.506 -.231
*
-.329
***
-.402 -.374 -.451 -.458 -.223* -.363
IPQ identity -.563 -.432 -.495 -.517 -402 -.286 -.351 -410 -.534 -.131
IPQ ident-tx -.494 -.414 -.472 -.456 -.409 -.29
**
-.34 -.406 -.469 -.161
IPQ ident-m -.348 -.336 -.37 -.326 -.334 -.252
**
-.28
**
-.324
***
-.335 -.169
IEQ -.489 -.675 -.458 -.492 -.422 -.467 -.524 -.524 -.463 -.292
***
TEQ+ -.442 -.501 -.389 -.395 -.374 -.369 -.473 -.42 -.394 -.32
***
BMQ-n -.112 -.093 -.112 -.084 -.034 -.094 -.074 -.159 -.059 -.072
BMQ-c -.274
**
-.321
***
-.164 -.138 -.284
**
-.306
***
-.312
***
-.255
**
-.154 -.305
***
Note: ident-tx = extended 42 item version of identity sub-scale (generic, renal and transplant 
specific symptoms; ident-m = immunosuppressive medication side-effects (23 items); IEQ = 
illness effects questionnaire; TEQ = treatment effects questionnaire; BMQ-n = beliefs about the 
necessity of medication; BMQ-c = concerns about medication; GH = general health; PF = 
physical functioning; BP = bodily pain; VT = vitality; RPh = role limitations due to physical 
problems; REm = role limitations due to emotional problems; SF = social functioning; MH = 
mental health; MCS = mental component score; PCS = physical component score 
+ = Spearman’s correlations 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
Results showed significant associations between cognitions and both the physical and 
psychological SF-36 dimensions, with more negative beliefs being associated with 
poorer HQoL. Correlation coefficients ranged from rs = .29 to rs = .49 for identity-tx 
(expanded 41-item symptom checklist) and from rs = .23 to rs = .46 for IPQ 
consequences. Stronger control beliefs were associated with higher SF-36 scores, i.e. 
better HQoL (rs = .20 to r =.32).
Consistent with previous work, strong correlations were also observed between illness 
intrusiveness, treatment intrusiveness and SF-36 scores, indicating that higher scores in
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illness and treatment intrusiveness were associated with poorer HQoL. Correlation 
coefficients ranged from r = -.29 to r = -.67 for illness intrusiveness and from r = -.32 to 
r = -.50 for treatment intrusiveness. The latter associations (i.e. TEQ) however ceased to 
be significant when the effect of illness intrusiveness was partialled out, clearly 
suggesting a minimal effect of treatment perceptions on HQoL in TX patients. When 
partial correlation analysis was reversed (i.e. partialling out treatment intrusiveness in 
correlations between IEQ and SF-36), illness intrusiveness remained a significant 
correlate of HQoL, albeit the strength of observed associations was lower.
Medication beliefs were also significantly correlated with HQoL. Concerns regarding 
the effects of immunosuppressive medication had a negative effect on physical and 
psychosocial dimensions of HQoL (MCS, GH, MH, PF, REm, SF, VT) (r = -.26 to r = - 
.32). ‘Timeline’ and ‘medication necessity’ beliefs appeared to be largely unrelated to 
HQoL in transplant patients although this is likely to be due to insufficient range of 
values in these two variables. The vast majority of patients believed strongly in the 
chronic nature of their condition and expressed strong beliefs regarding the necessity of 
their prescribed immunosuppressive medication.
1.3.d TxEQ Sub-scales
Higher levels of worry regarding TX viability from the TxEQ were associated with 
more compromised HQoL, particularly with respect to emotional well-being sub-scales. 
As seen in Table 9.14 below TX worry was inversely correlated with MCS (r = -.314, p 
= .001); MH (r = -.404, p  = .0001); GH (r = -.231, p  = .017); SF (rs = -29, p  = .003); and 
VT (rs = -.356, p  = .0001). Perceived responsibility correlated significantly only with 
physical functioning (rs = -.198,/? = .04).
1.3.e Mood variables
Significant associations were also found between mood measures (CDI; PANAS-PA; 
PANAS-NA) and HQoL. As anticipated higher cognitive depression and negative affect 
correlated with poorer HQoL whereas the opposite was true for positive affect. It is also 
of note that cognitive depression and positive affect were associated with the physical 
dimensions of SF-36 (PCS; PF; BP; RPh; GH) as well as the psychological SF-36 sub­
scales (as anticipated).
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Table 9.15: Correlations between mood and HQoL in Transplantation
PF+ GH BP+ RPht REmt MH SFt VT+ PCS+ MCS
BDI -.425
* * * *
-.473
* * * *
-.364
* * * *
-.468
* * * *
-.516
* * * *
-.492
* * * *
-.465
* * * *
-.515
* * *
-.326
* * * *
-.349
* * * *
CDI -.309
* * * *
-.381
****
-.281
* *
-.376
* * * *
-.508
****
-.503
****
-.396
* * * *
-.449
****
-.212
*
-.453
****
PNS-NA -.152 -.252
*
-.092 -.208* -.281
*
-.391
****
-.343
***
-.208
*
-.077 -.219
*
PNS-PA .314
**
-.391
****
.319
**
.445
* * * *
.327
* * * *
.491
H e***
.505
* * * *
.435
* * * *
.278
* *
.385
* * * *
+ Spearman’s correlation coefficient 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
1.3.f Cognitive functioning
Correlations were used to test the associations between cognitive functioning and HQoL 
in transplantation. As before two NP indices were used: a composite score of NP 
performance (summary of standardised individual NP test scores; NP-TO) and count of 
NP impairments (NP-Norm: number of NP tests in which TX patients performed worse 
than age-respective norms). Significant associations were found between NP 
functioning and HQoL, primarily with respect to physical dimensions of SF-36 (see 
Table 9.16). The more NP impairments experienced and the less efficient the cognitive 
functioning the more compromised the HQoL.
Table 9.16: Correlations between indices of cognitive functioning and HQoL in TX
SF-36 sub-scales
NP-TO NP-Norm
Full Partial
.102
Full
- 339****
Partial
PCSt .346*** -.202*
MCS -.209 .001 -.046 .116
General Health .185 .134 -.233* -.194*
Bodily Paint .183 -.127 -.285** -.140
Physical Functioningt 334**** .122 - 311*** -.210*
Role Physicalt .24* .174 _315*** -.262**
Role Emotionalt .054 .034 -.197* -.179 p<.058
Mental Health -.168 -.043 -.124 -.219*
Social Functioningt -.084 .127 -.202* -.105
Vitalityt -.010 .009 -.112 -.029
Note: NP-TO = composite score of NP performance; NP-Norm = count of NP impairments
t  Spearman’s correlations coefficient 
* p <.05. ** p <.01. *** p <.001. **** p <.0001.
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Partial correlations however (partialling out the effect of age and ESRD-SI) altered the 
findings.
Overall NP performance (NP-TO) for instance was no longer significantly associated 
with SF-36 scores. In contrast most of the associations between the number of NP 
impairments and HQoL remained significant even after the effect of ESRD-SI was 
partialled out (there was no need to include age as NP impairments were defined 
relative to age norms). However observed correlation coefficients were lower. It is also 
of note that partialling out ESRD-SI, the correlations between mental health and NP 
impairments became significant (r = -.219 , p  = .0 2 ).
1.3.g Subjective Cognition
Correlational analysis showed significant associations between SF-36 and indices of 
subjective cognition in TX. Perceptions of greater cognitive decline since 
transplantation (SCS-TO) correlated with lower SF-36 scores except for mental health 
and MCS (correlational coefficients ranged between ry = -.20 to rs = -.23).
Partial correlations adjusting for the effect of age and renal severity and comorbidity 
removed some of the significant associations with PF, BP, VT, RPh and SF. Only the 
associations with GH and RPh retained their significance (see Table 9.17).
Table 9.17: Correlations between indices of subjective cognition and HQoL in TX
SCS-TO
SF-36 Sub-scale Full Partial
PC St -.232 * -.205 *
MCS -.064 - .1 1 2
General health -.229 * -.208*
Bodily paint -.208 * -.160
Physical functioningt -.217 * -.146
Role physicalt -.256 ** -.272**
Role emotionalt -.193 * -.150
Mental Health -.125 -.158
Social Functioningt -.196 * -.146
Vitalityt - .2 2 0  * -.039
t  S p earm an ’s correlations c o e ffic ie n t  
* p < .05; ** p < .01
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1.3.h Multivariate analysis
To examine which variables accounted for the variance in HQoL, hierarchical multiple 
regression analyses using the stepwise method were subsequently conducted. Physical 
and mental component scores (PCS; MCS) were regressed on the sociodemographic, 
clinical, neuropsychological and psychological variables. The variables selected for 
these analyses were those significantly associated with the outcome in question in the 
univariate analyses. Regressions were performed on the combined TX sample as the 
small number of LRD patients made running the regressions separately for CAD and 
LRD patients inappropriate.
Predictors used in the PCS regression included: age, education, work status, income 
(Block 1); ESRD severity, GFR, albumin and haemoglobin (Block 2); Overall cognitive 
functioning, number of NP impairments, subjective cognitive complaints (Block 3); 
IEQ, TEQ, IPQ consequences, IPQ control, IPQ identity-tx (extended 41-item symptom 
list) (Block 4); and cognitive depression (Block 5).
The results (as in the last step of regression) indicated that age, income, ESRD severity, 
haemoglobin, perceptions of illness disruption and identity beliefs were significant 
multivariate predictors of PCS in transplant patients, accounting for 65.8% (Adj.R2 = 
63.6%) of the variance (see Table 9.18). Sociodemographic and clinical variables jointly 
explained the largest amount of PCS variance (R2 = 53.5%; AR2 = 51.4%) with 
measures of variance-based effect sizes indicating a large effect size i f 2 = 1.56 jointly).
Among the patients’ beliefs only perceptions of illness intrusiveness and perceived 
symptoms appeared to impact on physical HQoL explaining AR2 = 12.3% of the total 
variance i f  = .36 indicative of small effect size). Mood, added in the last step did not 
contribute significantly in the PCS prediction.
Multiple regressions in which the order of beliefs and mood was reversed (i.e. mood 
was entered before patients cognitions) revealed a similar pattern of results (see 
Appendix L). A total of 65.8% (Adj.R2 = 63.6%) of the variance was explained by work 
status, age, income, ESRD severity, haemoglobin, cognitive depression, illness 
intrusiveness and identity beliefs.
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Table 9.18: Hierarchical multiple regressions to predict PCS and MCS in TX:
standardised regression coefficients and cum ulative variance explained
________ PCS  MCS ________
_  Cum R2 Cum p Cum R2 Cum
Block 1
n i i j  . x v
Work Status .040 ns ,204
/ = .  596
.197
Age -.2 0 0 ** .270
/ =  193
.257 289*** 
/ = •  1 0 2
.073 .065
Income .182** .302 
f  =.094
.283
Education
Block 2
ESRD severity _ 3 4 2 **** .462
/ = .4 7 1
.443
GFR .144 ns
/= -0 7 1
.124 .109
Haemoglobin .151* .535 
/ = .  2 1 1
.514
Albumin
Block 3
NP functioning
NP impairments 
Block 4 f -  .360 / = .1 8 4
IEQ - 254**** .630 
f  =.278
.610
TEQ
IPQ conseq -.144 
/ = .  121
.2 1 2 191
IPQ control
IPQ identity-tx _ 1 9 9 ** .658
/ =  .0819
.636
BMQ-concems -.196* 
f  =.063
.257 .230
TxEQ worry 
Block 5
CDI -.2 0 0 * 
/ = .  038
.284 252
Note: f =  variance-based  m easure o f  e ffe c t  s iz e  ca lcu lated  as /  =  AR2 /  (1 - / ? 2T o t a i ) ;  cu m  =
cu m u lative; G FR  =  glom erular filtration index; N P  =  n eu rop sych o log ica l; IEQ =  illn ess  
in trusiven ess; T E Q  =  treatm ent in trusiven ess; co n seq  = co n seq u en ces; id en tity-tx  =  identity  
score based  on the 41 item s used  for T X  patients (IPQ  core item s, renal sp e c ific  and T X  
im m u n osu p p ression  sid e effec ts);  T xE Q  =  worry about transplant from  the T ransplant E ffec ts  
Q uestionnaire; C D I =  co g n itiv e  d ep ression  index  
* p < .0 5 . ** p < .0 1 . ***  p < .0 0 1 . * ***  p < .0 0 0 1 . ns = non sign ifican t
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In the multiple regression to explain MCS, age (Block 1); ESRD severity, GFR levels, 
Haemoglobin (Block 2); NP deficits (Block 3); IEQ, TEQ, IPQ consequences, BMQ 
concerns (Block 4); worry about TX viability (Block 5); CDI (Block 6) were used.
It should be noted that even though Block 2 variables were not directly related with 
MCS scores, they were still entered in the regression as they correlated significantly 
with more than half of the SF sub-scale scores that contribute to the calculation of MCS 
scores. It was also thought that their inclusion would provide a more stringent test for 
the effect of patients’ beliefs on emotional well-being over and above the effect of 
medical indicators.
To reduce the cases-to-variables ratio, only cognitive depression, the stronger univariate 
MCS correlate, was included in preference to PANAS sub-scales for these regression 
analyses. Three sets of regressions were performed: without the inclusion of mood, with 
mood entering last after patients cognitions, and finally with mood entering before 
patients’ beliefs.
When mood was not included in the analysis, the final regression indicated that age (P = 
.289; R2 = 7.3%), glomerular filtration rate (P = .171; AR2 = 5.1%) illness consequences 
(P = -.244; AR2 = 8.7%) and concerns about medication (P = -.220; AR2 = 4.5%) 
explained R2 = 25.7% (Adj.R2 = 23%) of the MCS variance.
Inclusion of mood improved model prediction but also rendered the effect of GFR and 
consequences beliefs non significant. The resulting regression model to predict MCS in 
the combined TX sample explained R2 = 28.4% (Adj.R2 = 25.2%) of the variance with 
only age, concerns about medication side-effects and cognitive depression being 
significant predictors at the last stage of entry (Table 4). The effect of perceived 
consequences (IPQ), which was significant at step 3 and 4, was not found to be 
significant at the last stage of entry (CDI), suggesting a mediating effect for cognitive 
depression. F2 values indicated small effect sizes for all significant predictors.
Reversing the order of entry so that mood entered before patients’ cognitions did not 
considerably alter the results. The resulting regression model explained R2 = 26.9% 
(adj.R2 = 24.3%) of the variance in MCS scores. Significant predictors (last step) were 
age, cognitive depression, and BMQ concerns. Perceived illness consequences did not 
emerge as a significant predictor (see Appendix L).
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Section 3: HQoL comparisons -  Dialysis vs. Transplantation
HQoL levels reported by transplant recipients were compared to those reported by 
dialysis patients. These analyses were performed using (a) the combined dialysis sample 
(hence collapsing across all four dialysis groups) in order to evaluate how dialysis 
treatment in general compared to transplantation and (b) the HD and PD groups 
separately. In all comparisons, casemix differences between transplant and dialysis 
patients were statistically controlled for using ANCOVAs, providing that they were also 
significantly associated with HQoL.
3.1 Two group comparisons: combined dialysis vs. TX
3.l.a  Sample characteristics
Casemix differences between TX and dialysis patients were found (see chapter 6; 
section 2.6.a). There were also significant group differences between transplant and 
dialysis patients in biochemistry. Of them, only the differences in serum albumin and 
haemoglobin levels will be discussed as being more relevant, i.e. empirically linked to 
HQoL (Lowrie et  a l . ,  2000). As expected, transplant patients had significantly higher 
albumin (U = 2268, p  = .0001) and Hb (t(220,55) = -9.22, p  = .0001) than dialysis 
patients. Variables were used as covariates in subsequent comparisons providing that 
they were significantly associated with the outcome in question (Table 9.19).
Table 9.19: The associations between casemix differences and HQoL in the combined
dialysis and TX sample
Covariates used in dialysis vs. TX comparisons
PF GH BP RPh Rem MH SF VT PCS MCS
Work status + + + + + + + + + -
Income + + + + + + + + + -
ESRD SI + + + + + + + + + -
Diabetes + + + + - + + + + -
Heart disease + + + + + + + + + -
RRT time + + + + - - + + + -
Time on treatment - + - + - - + + - +
Haemoglobin + + + + + + + + + -
Albumin + + + + + + + + + +
+  =  sign ifican t a ssoc ia tion  /  used as a covariate  
- =  non sign ifican t assoc ia tion  /  not used as a covariate
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3.1.b HQoL absolute scores
ANCOVAs between transplant and the combined dialysis sample (covarying for work 
status, income, ESRD severity, time on RRT, time on current treatment modality, 
diabetes and ischaemic heart disease as appropriate) showed that HQoL was superior in 
transplant patients.
In the first set of comparisons, no adjustments were made for biochemistry casemix 
differences. Transplant patients scored significantly higher in 8 of the 10 SF-36 sub­
scales: PCS (F(7, 234) = 36.359, p  = .0001), PF (F(7, 235) = 28.431, p  = .0001), RPh 
(F(8, 233) = 6.057, p  = .015), BP (F(7, 235) = 6.734, p  = .01), GH (F(8, 233) = 92.635, 
p  = .0001), VT (F(6, 236) = 16.887, p  = .0001), SF (F(8, 234) = 24.286, p  = .0001), and 
MCS (F(2, 255) = 7.561, p  = .006). A tendency for higher MH scores in TX patients 
was noted but did not reach significance (F(6, 236) = 3.599, p  = .059).
In the second set of comparisons haemoglobin and albumin were also included as 
covariates. These ANCOVAs indicated that transplant patients’ scores were still 
significantly higher in PCS (F(9, 227) = 12.261, p  = .001), PF (F(9, 228) = 11.047, p  = 
.001), GH (F(10, 226) = 34.534, p  < .000), VT (F(10, 227) = 12.129, p  = .002) and SF 
(F(10, 227) = 7.372, p  = .007).
3.1.c Prevalence of severe HQoL impairments
Chi-square analysis of the observed prevalence of HQoL impairment in dialysis and 
transplant patients confirmed the ANCOVAs results in that HQoL impairments were 
more prevalent in dialysis patients particularly with respect to physical well-being.
When HQoL impairment were defined as more than 1 SD below norms (indicative of 
mild-moderate impairment), chi-square analysis indicated that a significant treatment 
effect in both MCS and PCS classification. Significantly more dialysis patients (n = 
113, 77.9%) had lower than average PCS scores (1 Sd or more lower than norms) than 
did transplant patients (n = 22, 19.8%; %2(256) = 49.621, p  = .0001). A larger proportion 
for the dialysis patients (n = 39, 26.9%) had MCS scores lower than 1 or more SDs than
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those of general population compared to transplant patients (;n =10, 9%; X (256) = 
12.998, p = .0001).
Chi square analysis was also used to compare the prevalence of severe (i.e. more than 2 
SDs below norms) HQoL impairments. Differences in the prevalence rates of PCS 
severe impairments persisted when using this criterion, with significantly more dialysis 
patients (n = 77, 53.1%) scoring in the range of severe PCS impairments relative to 
transplant patients {n = 22, 19.8%; X  (256) = 29.367, p = .0001).
No differences were noted in the prevalence rates of severe MCS impairment between 
dialysis (n = 10, 6.9%) and TX patients (n = 3, 2.6%; %2(256) = 2.294, p  = .13).
3.2 Three groups comparisons: HD vs. PD vs. TX
3.2.a Sample characteristics
Three group comparisons (HD; PD; TX) indicated significant group differences in 
sociodemographic and medical variables: income, perceived work ability, time on 
current treatment, time on RRT in general, ESRD severity index and diabetic status. 
These casemix differences were controlled for in subsequent comparisons, providing 
that they were significantly associated with the particular SF-36 score.
Table 9.20: The associations between casemix differences and HQoL in HD vs. PD TX
comparisons
_______ Covariates used in PD vs. HD vs. TX comparisons______
_________________ PF GH BP RPh REm MH SF VT PCS MCS
Income (2 groups) + + + + + + + + +
ESRD SI + + + + + + + + +
Diabetes + + + + - + + + +
RRT time + + + + - - + +  +
Current treatment - + - +  - - + + - +
Haemoglobin + + + + + + + + +
Albumin + + + + + + + + +  +
+ = significant association / used as a covariate
- = non significant association / not used as a covariate
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3.2.b Absolute HQoL scores
As significant HQoL differences were noted between HD and PD patients (see sub­
section 1.2.a) three group comparisons (HD vs. PD vs. TX) were undertaken using 
ANCOVAs covarying for group casemix differences (see Table 9.19).
These were followed by Tukey’s HSD post-hoc tests if the main effect of the omnibus 
ANOVA3 was significant at p < .05. Residualised SF-36 scores, in which the effect of 
casemix differences (diabetes, ESRD severity, time on RRT, time on current treatment 
and income) has been partialled out (as appropriate, i.e. only if significant with the SF- 
36 score in question), were used as dependent variables in post-hoc analyses.
In the first set of comparisons no adjustments were made for biochemical differences as 
these were seen as a reflection of treatment differences. Covariates used were thereby 
chosen among the remaining sociodemographic and clinical variables.
Results indicated a significant treatment effect on: PCS (F(6, 235) = 17.835, p  = .0001); 
PF (F(6, 236) = 12.834, p  = .0001); BP (F(6, 236) = 5.375, p  = .005); GH (F(7, 234) = 
45.917, p  = .0001); SF (F(7, 235) = 13.775, p  = .0001); VT (F(7, 235) = 9.312, p  = 
.0001), RPh (F(7, 234) = 3.315, p  =.038); and MCS (F(3, 254) = 5.321, p  = .005). 
Despite the significant effect on MCS, no differences were found in REm, MH 
suggesting that when casemix differences are accounted for, HD, PD and TX patients 
report equivalent levels of emotional well-being.
Post-hoc tests revealed that TX patients had higher scores than both HD and PD patients 
in PCS (ps = .0001); PF (ps = .001); GH (ps = .0001); SF (ps <.001); and VT (ps <.01). 
Differences in BP and MCS were only significant between TX and PD patients and not 
between TX and HD patients, with transplant patients reporting higher emotional well­
being (MCS) and less pain (BP) compared to PD patients.
After adjustment for laboratory values (albumin and haemoglobin), group differences 
were still evident in PCS (F(8, 228) = 6.253, p  = .002), PF (F(8, 229) = 4.491, p = 
.012); GH (F(9, 227) = 17.849, p = .0001); SF (F(9, 228) = 4.267, p  = .015); and VT 
(F(9, 228) = 5.636, p  = .004). The previously observed differences in BP and MCS 
failed to reach significance in these comparisons.
Subsequent post-hoc tests were performed on the residualised scores, i.e. absolute 
scores regressed to casemix differences as described above including albumin and Hb 
levels. These revealed only two significant differences. One in GH with PD and HD
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patients having significantly lower GH scores than TX patients and another in PCS. The 
latter was only significantly different between PD and TX patients (p = .046). When 
casemix differences were accounted for, no other post-hoc tests revealed significant 
differences
It should be noted that post-hoc tests with no casemix adjustments (i.e. using absolute 
SF-36 scores rather than the residualised SF-36 scores) showed more significant group 
differences always in favour of transplantation over both PD and HD groups: PCS; PF; 
BP; GH; RPh; SF; VT.
3.2.c Prevalence of HQoL impairments
Chi-square analysis showed that HQoL impairments were more prevalent in HD and PD 
patients compared to TX patients. Results indicated that relative to HD and PD patients, 
significantly less TX patients had PCS scores lower than 1 SD (%2(254) = 50.082, p  = 
.0001) or 2 SDs (%2(254) = 29.784,/? = .0001) below population mean.
The HQoL advantage of transplantation was also evident in MCS score classification 
(%2(254) = 14.312, p  = .001 for MCS more than 1 SD below norm; %2(254) = 8.59, p  = 
.014 for MCS more than 2 SDs below norm)
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Section 4: Summary of results
• Physical HQoL is substantially impaired in dialysis patients relative to the general 
population. Emotional well-being (HQoL) on the other hand remains within normal 
limits.
• Comparisons between different dialysis treatments indicated that PD patients have 
lower scores in MCS and vitality compared to HD. Four group comparisons have 
similarly shown that CAPD patients scored significantly worse on vitality than the 
two HD groups. Vitality differences in both cases ceased to be significant after 
adjustments for albumin levels.
• Regression analysis indicated that age, employment status, dialysis adequacy, 
perceptions of illness intrusiveness and cognitive depression explained 58.7% of the 
variance in PCS scores in dialysis.
• The regression model to predict MCS scores explained 35.8% of the variance with 
dialysis treatment, treatment intrusiveness and cognitive depression being 
significant at the last step of the regression.
• HQoL in TX patients is comparable to that of the general population and superior to 
that of dialysis patients, particularly with respect to physical well-being.
• A range of factors was associated with HQoL in TX patients. Age, income, 
haemoglobin, illness intrusiveness and identity accounted for 65.8% of variance in 
PCS whereas age, medication concerns and cognitive depression explained 28.4% in 
MCS.
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CHAPTER 10:
D ISC USSIO N OF PATIEN TS’ BELIEFS A N D  HQOL FIND ING S
This chapter presents a discussion of the study and related findings on HQoL and illness 
and treatment beliefs in ESRD. It is organised in three sections: section one focuses on 
patients’ beliefs, section 2 discusses HQoL, and section 3 discusses determinants of 
HQoL in dialysis and TX.
Section 1: Illness and treatment beliefs
One of the aims of the present study was to examine the content and nature of illness 
and treatment cognitions in ESRD patients and to examine their interrelationships and 
their explanatory role in outcomes such as HQoL. The present study used Leventhal’s 
SRM as an explanatory and predictive tool. The model’s scope was expanded to include 
perceptions of illness intrusiveness and perceptions of treatment (Home, 1997; 2003b). 
Treatment cognitions assessed comprised perceptions of treatment intrusiveness 
(Greenberg & Peterson, 1997b), and medication beliefs (Home et al., 1999).
1.1 Dialysis
Dialysis patients have a dominant view of their illness, comprised of a strong illness 
identity, mainly external attributions for their condition and pessimistic beliefs about 
controllability, consequences and timeline of their illness. Consistently high scores on 
the identity, consequences and timeline beliefs (and the high percentage of above 
midpoint scores) suggest that dialysis patients believe their illness has a wide range of 
symptoms, a profound impact on their lives and is likely to last a long time. Illness and 
treatment intrusiveness scores indicated moderate levels of distress compared to other 
medical patients (Greenberg & Peterson, 1997b) and are comparable to those reported 
in other dialysis samples (Eitel et a/., 1995; Kimmel et al., 1998b; 2000; Patel et al., 
2002; Sacks et al., 1991). These negative illness beliefs do not appear to be just a
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consequence of having a chronic physical illness. When compared to patients with 
rheumatoid arthritis, diabetes and chronic back pain on the IPQ (Weinman et a l , 1996), 
dialysis patients in this study had lower control beliefs; consequences beliefs were 
however similar across groups. The lack of variance on beliefs about the timeline of 
their illness reflects these patients’ accurate understanding of their illness.
Investigation of patients’ causal beliefs regarding their illness revealed that the vast 
majority of dialysis patients held a causal model which featured prominently 
attributions to chance, poor medical care and heredity. Genetically inherited disorders 
such Adult Polycystic Kidney disease that may be diagnosed quite early on before renal 
implications manifest, are some of the commonest causes of ESRD. Heredity beliefs 
reflecting patients’ knowledge were anticipated at least for a subgroup of patients. The 
results indeed showed that heredity beliefs are more likely to be reported by dialysis 
patients with family predisposition to kidney disorders, such as polycystic kidney 
disease.
The largest percentage of patients attributed ESRD to chance. This finding may reflect 
cases of medical uncertainty in establishing primary kidney disease diagnosis, and /or 
patients’ uncertainty or poor understanding or lack of knowledge about their medical 
history. In cases of non-established aetiology for ESRD, chance attributions may be 
regarded as realistic as well as self-protective.
Perhaps even more intriguing is the finding that a substantial number of dialysis patients 
attributed ESRD to poor medical care in the past. Attributions related to medical 
mismanagement were also found in qualitative investigations of dialysis patients 
(Krespi et al., 2003). In our study, such attributions were more frequent in PD and 
diabetic patients. Whether this implied ‘poor medical care’ as in poor self-management 
by the patients themselves (e.g. poorly controlled diabetes leading to ESRD; 
uncontrolled hypertension) or poor medical care within the context of the health 
services and health care delivery as in misdiagnosis, late diagnosis or lack of timely or 
effective treatment, could not be determined in this study. Both interpretations are 
equally plausible. Nevertheless in both cases such causal attributions appear to echo 
patients’ relative dissatisfaction with medical care either before or after entering the 
system as ESRD patients.
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1.2 Transplantation
TX patients’ illness model consisted of chronic timeline beliefs, causal attributions of 
chance, hereditary and poor medical care, and reports of few symptoms associated with 
their condition. TX patients also expressed more positive views regarding the impact of 
illness and treatment on their lives and the controllability of their condition in 
comparison to patients on dialysis. Illness and treatment intrusiveness were in the mild 
range and IPQ consequences scores indicated ambivalence regarding the severity of 
illness consequences on their lives.
TX patients were relatively unconcerned about the side effects of immunosuppression 
and expressed strong beliefs in the necessity of their prescribed medication. ‘Necessity’ 
scores are comparable with those reported by other patient groups (e.g. asthma and 
diabetes) whereas ‘concern’ scores were somewhat lower especially in comparison with 
cardiac, asthma and psychiatric patients (Home et al., 1999). These low concern scores 
may reflect uncertainty about the impact of medication rather than an unconcerned 
attitude. Alternatively low worry scores may be due to the fact that patients tend to 
receive detailed information regarding potential side effects of anti-rejection medication 
early post-TX or even before the operation.
Lower control and more chronic timeline beliefs were found for patients on Cyclosporin 
compared to those on Tacrolimus but these effects disappeared when time since TX and 
age were controlled for. The decline in graft function with the resultant increase in 
physical symptoms, and the manifestation of more immunosuppressive side-effects over 
time might explain why patients who have had their TX for a long time expressed 
stronger views that ESRD is chronic and less amenable to control.
1.3 Intercorrelations between beliefs
Illness and treatment cognitions showed logical interrelations in both dialysis and TX. 
For example, TX patients were more likely to regard their immunosuppressive 
medication to be necessary if they viewed their illness as chronic, with negative 
consequences. This replicates findings in other patient groups (Home & Weinman, 
2002). Strong concerns regarding immunosuppressive medication were related to
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patients’ symptoms, more negative evaluation of treatment burden and more negative 
perceptions regarding the intrusiveness and consequences associated with illness.
Perceptions of treatment intrusiveness, a construct that refers to the impact of treatment 
on patients’ lives was significantly associated with all SRM components except 
timeline. Of note are also the high correlations between illness and treatment 
intrusiveness as measured by the Dlness Effects Questionnaire and the Treatment 
Effects Questionnaire. These are more likely than not to reflect the conceptual 
similarities and substantial item overlap across the two measures, and may also indicate 
how patients attempt to mirror their responses to the two questionnaires.
There are however other likely interpretations. For instance, the observed significant 
associations may also imply that the distinction between the illness and treatment may 
become more blurred in ESRD than perhaps in other illness groups. In ESRD medical 
treatment is very prescriptive (dialysis is chronic and ongoing procedure), the impact of 
treatment and that of illness may become less easily differentiated that may explain 
patients’ responses. This distinction may be particularly difficult to make in TX 
reflecting in addition patients’ ambivalence as to whether transplantation constitutes a 
treatment for an underlying condition or a new state of health, a new condition or a new 
illness (Johnson, 1990).
Although specific instructions were written detailing the intended meaning of the terms 
‘illness’ and ‘treatment’, namely directing patients to think of their ESRD as their 
illness and their RRT (including associated medication and diet and fluid intake as 
applicable) as their treatment, it is possible that questionnaire items may be perceived 
and interpreted very differently by respondents (Mallinson, 2002).
The study findings also showed that illness cognitions (and the SRM components) were 
also related in a logically consistent way. The pattern of interrelations exhibited is 
consistent with those observed by studies on various other illnesses (e.g. Moss-Morris et 
al., 1996; Petrie et al., 1996; Weinman et al., 1996), a recent metanalytical review 
(Hagger & Orbell, 2003), and with Leventhal’s model (1980). Correlations were strong 
and significant but did not exhibit associations of a magnitude that was indicative of 
conceptual overlap. Identity beliefs were negatively associated with control but 
positively related to serious consequence beliefs and illness intrusiveness. Control 
beliefs were inversely related to illness intrusiveness, illness consequences and
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symptom (identity) beliefs and the more negative beliefs of illness intrusiveness and 
illness consequences were also inter-correlated. Causal attributions were also associated 
with other illness cognitions (Shiloh et al., 2002). Attributing illness to own behaviour 
or medical care was associated with heightened perceptions of illness symptoms, 
consequences and illness intrusiveness, although these associations could be explained 
by differences in diabetic status between patients endorsing or not these causal beliefs.
1.4 Treatment modality and beliefs
It has been suggested that illness representations are based on factual information, 
personal experience and a variety of cultural beliefs. It is reasonable to assume that 
illness and treatment beliefs develop and change over the course of an illness and hence 
the experience of different treatments is likely to influence them. As described earlier, 
treatment exigencies vary greatly in different dialysis treatments and between dialysis 
and transplantation. The differential treatment demands placed upon patients should 
affect beliefs about illness and treatment intrusiveness, perceptions of control, 
consequences and timeline beliefs. The data reported here provide modest support that 
illness representations and cognitions appear to be formed at least in part as a function 
of personal treatment experience.
Comparisons involving transplant vs. dialysis patients revealed significant group 
differences consistently across the various beliefs assessed. Transplant patients believed 
less strongly that their condition is chronic, reported less symptoms and perceived more 
control and less disruption associated with either their illness or their treatment relative 
to their dialysis counterparts. These findings are consistent with previous studies 
(Devins et a l , 1990a) and with the prediction that the less intrusive and demanding 
nature of transplantation should lead to more positive illness and treatment 
representations. Constraints can be extensive, for example when renal replacement 
involves maintenance dialysis that must be administered repeatedly. CAPD for example 
typically involved four daily 30- to 60-minute dialysate fluid exchanges; HD requires 
thrice 3-5 hour long sessions for which the vast majority of patients have to attend a 
hospital or satellite centre. Successful transplantation in contrast, involves little more 
than daily ingestion of immunosuppressive medications. As all casemix differences 
were statistically controlled, the observed differences in illness and treatment beliefs
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should reflect the effect of differential treatments experienced by the two groups rather 
than other sociodemographic and medical variables.
A word of caution is however warranted regarding the interpretation of illness and 
treatment perceptions in TX and the meaning attributed in the terms illness and 
treatment by transplant patients although specific instructions were used to clarify the 
intended meaning of the terms. It is unclear for instance whether transplantation, 
immunosuppression or both were construed as the treatment by TX patients.
Illness beliefs appeared to be largely unrelated to dialysis modality, although inspection 
of group mean scores revealed a consistent pattern across all illness cognitions: APD 
patients held more positive illness beliefs. For example, they had the strongest 
perceptions of control and the lowest perceived consequences, followed by hospital HD, 
home HD with the CAPD patients last. Comparative analysis (with casemix 
adjustments) however failed to reveal systematic significant differences in illness 
cognitions between any of the dialysis modalities. In keeping with previous research 
(Devins et a l, 1983; 1990; 1994; Sacks et a l, 1990), our findings indicate that ESRD 
patients on dialysis hold similar beliefs regarding their illness despite the experience of 
different treatments. The only exceptions to this were the observed significant 
associations between PD treatment and causal attributions of ‘self-blame’ and ‘poor 
medical care’. These are however more likely to reflect the differential proportion of 
patients with diabetes between dialysis treatments. Significant associations were found 
between prevalence of diabetes (and IDDM as primary kidney disease diagnosis) and 
attributions of ‘self-blame’ but not with poor medical care causal beliefs. As chi-square 
analysis does not permit casemix adjustments it was not possible to determine whether 
dialysis modality or alternatively diabetes might be driving/affecting patients’ causal 
attributions.
The latter explanation is however favoured on several grounds. Firstly, comparative 
analysis on the other illness beliefs demonstrated that the effect of casemix variables 
(including diabetes) outweighed that of dialysis modality. For instance casemix 
adjustments (including diabetes) muted the effect of dialysis treatment on control 
beliefs, which was significant in uncontrolled comparisons. It is also a more plausible 
explanation; as ESRD is a common diabetic complication, perhaps one should also 
expect that living with diabetes might fuel stronger attributions of poor medical care or
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internal attributions (i.e. ‘own behaviour’) as diabetic control is so dependent on 
personal behaviour (Norris et al., 2002).
The only significant difference between patients on different dialysis modalities was in 
perceptions of treatment burden. Patients on CAPD perceived significantly more 
treatment-related disruption compared to APD patients, a finding that substantiates the 
differential objective demands and procedural differences of CAPD vs. APD. In 
contrast to APD that is automatically performed overnight, CAPD involves repeated 
daily administrations (three or four exchanges a day). It hence requires more patient’ 
input, takes up more of patients’ waking time and is more likely to interfere more with 
everyday activities and patients’ lifestyle. Bro et al. (1999) reported that significantly 
more time for work, family, and social activities was available to patients on APD 
compared those on CAPD. This is the first report to document significant differences in 
treatment perceptions between the two PD groups. Maiorca et a l (1995a; 1996c) for 
instance commented that after a number of years there may be burnout of either the 
CAPD patient and their caregiver but no comparisons with other dialysis treatment 
groups were undertaken. From a methodological point of view, this treatment effect 
provides some support the discriminant validity of the TEQ.
The mean difference between APD and Home HD patients’ TEQ scores approached but 
did not reach significance. There was a tendency for home HD patients to perceive more 
treatment disruption compared to APD patients. The relatively low numbers of APD 
and home HD patients assessed, might have undermined the power to detect significant 
differences between the two home based treatments.
Contrary to previous studies (Wolcott & Nissenson, 1988a) patients on HD treatments 
did not perceive more treatment burden relative to PD patients. The lack of significant 
differences in treatment perceptions between patients on HD and those on PD is 
noteworthy. PD has been advocated as the treatment that potentially allows more 
control and increased independence in patients’ lives (Ronco & La Greca, 1997), in that 
it avoids repeated visits to dialysis units, is pain free, quick to perform, thereby 
minimising disruption to patients’ lives. HD, on the other hand, albeit more common 
treatment, is often described as time-consuming, invasive, and painful (Binik et al., 
1989; Levy, 2000; 2003). Patients’ perceptions of treatment intrusiveness did not echo 
these notions as both dialysis groups (HD and PD) perceived their respective treatments
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as imposing the same level of disruption on physical, social and personal life and 
behaviours.
Four group comparisons also did not indicate a more favourable evaluation of the home 
treatments (APD; CAPD; home HD). They were on the whole perceived equally 
burdensome or disruptive as hospital-based HD. Although this may at first glance seem 
counterintuitive, especially if one considers the logistics of hospital vs. home care, there 
are some, perhaps less obvious, advantages associated with hospital HD, such as closer 
medical supervision and more opportunities for social support among patients. Regular 
contact with hospital staff and other patients enables the creation and maintenance of 
strong social networks and resources as well as the reassurance of repeated, often 3 
times per week, health care professional involvement in care. The reassuring nature of 
this may mitigate against the impact of the time disruption of hospital- based HD. It is 
possible that these factors, not measured in this study, might affect at least indirectly 
patients’ treatment evaluation, and hence explain the lack of significant differences in 
TEQ perceptions.
In conclusion study findings suggest that ESRD patients on different dialysis modalities 
expressed different beliefs regarding the burden of treatment albeit not always 
significantly so. As however study assessments focused solely on perceptions of 
treatment intrusiveness, this might have lead to a rather perfunctory measure or 
assessment of treatment perceptions. Therefore, it remains unclear whether other 
treatment cognitions (e.g. treatment effectiveness) might also differ between groups. 
Recent research in cardiac disease (Hirani et al. 2003) showed that treatment 
representations comprise beliefs about ‘treatment value’, ‘emotional impact of 
treatment’, ‘decision dissatisfaction’, and ‘treatment pessimism’.
Section 2: HQoL
One of the principle outcomes assessed in this study was HQoL. The objectives were to 
examine HQoL levels in ESRD patients, to compare HQoL across all form of RRTs and 
to identify the sociodemographic, clinical, cognitive and psychological variables that 
determine HQoL in ESRD. Although HQoL has been extensively studied in ESRD, this 
study was the first to include patients on four dialysis modalities and two groups of 
kidney TX patients.
2.1 Dialysis
In accordance with previous research (Lamping et a l, 2000; Merkus et al., 1999b; 
Mingardi et a l, 1999) results showed that dialysis has a significant impact on patients’ 
physical aspects of HQoL whereas mental health and emotional well-being is generally 
similar to normative data.
Lower scores in the dialysis patients were found in all SF-36 domains that reflect 
discomfort by physical impairment such as physical functioning, pain, role performance 
and general health. The severely reduced physical HQoL of dialysis patients in 
comparison to the general population has been reported in many other studies (reviewed 
in Merkus, & Krediet, 2000). A substantially high number of dialysis patients (53%) 
were found to have a physical component score on the SF-36 (PCS) which was severely 
impaired (more than 2 SDs below general population mean). Such a score corresponds 
to the 2.5th percentile of the distribution of HQoL scores in the general population. This 
finding indicates that over half of those assessed reported significant limitations in all 
physical activities, such as walking or climbing stairs, were severely bothered by pain 
and rated their health as poor. This finding may have clinical implications as poor 
HQoL (poor physical performance assessed by PCS) has been found to be 
independently associated with poorer outcomes such as increased mortality and 
hospitalisation rate (De Oreo, 1997; Lopes et a l 2003; Mapes et a l,  1999; 2003).
In contrast, mean scores of dialysis patients on the SF-36 sub-scales that reflected 
emotional HQoL were close to those expected in the general population. The prevalence
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of impaired emotional well-being was what would be expected from a normal 
distribution, with 6.9% (w = 10) of dialysis patients scoring 2 SDs below norms. This 
finding is in agreement with previous reports (De Oreo, 1997; Devins et al., 1990a; 
Groothoff et al., 2003; Mittal et al., 2001a; 2001b).
A greater effect on self-assessed physical, compared to mental, health has also been 
found in other chronic diseases (Hays et al., 1995). It may be that with chronic disease 
the impact on aspects of mental or emotional well-being becomes blunted over time as 
psychological adaptation takes place (Andrykowski et al., 1993), consistent with 
Taylor’s theory of cognitive adaptation to life-threatening events (Taylor, 1983).
The finding of uncompromised emotional well-being is remarkable when the number of 
physical, psychological and even economic hardships these dialysis patients face, is 
considered.
A possible explanation is the fact that any type of dialysis is lifesaving. Without 
treatment all patients would be dead and this simple fact causes dialysis patients to rank 
their HQoL as high or higher than observers (Seedat et al., 1987). Patients are also 
likely to change their internal standards, values, or conceptualisation of quality of life 
and therefore assess it differently as they adapt to their situation. This phenomenon of 
internal adaptation that results from recalibration of internal standards and 
reconceptualisation of the frame of references used to produce HQoL judgements is 
often referred to in the psychological literature as "response shift" and may explain 
these apparently paradoxical HQoL.
A reverse response shift is demonstrated by the finding that patients awaiting a kidney 
transplant had a mean HQoL of 5.23 on a 10 point scale; this rose to 7 after 
transplantation. However, when at 5 months, 12 months, and 18 months after 
transplantation these patients were asked to rate what their HQoL had been before 
surgery the mean retrospective scores were 3.27, 3.14, and 3.05, respectively (Adang et 
al., 1998). Before transplantation these patients had relatively successfully adapted to 
their condition, and thus had rated their HQoL more highly than when they later re­
evaluated it from the advantage point of improved health after TX. The process of 
denial may also play a role in mediating these perceptions (i.e. HQoL evaluation) 
(Devins et al., 1986-87), a reaction that may ultimately be adaptive as suggested by 
Binik et al. (1989).
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2.2 HQoL comparisons between different dialysis treatments
The issue of HQoL advantages or outcomes associated with different treatment 
modalities is important to both the decision making process for patients and in 
evaluating available treatments. From a healthcare policy point of view, considering 
HQoL levels afforded by ESRD patients on different treatment could potentially inform 
policy makers and influence the allocation of the existing constrained resources.
To evaluate the effect of treatment modality on HQoL comparisons between all 
available treatment options for ESRD, hospital HD, home HD, CAPD, APD, CAD TX 
and LRD TX recipients were performed. This enabled two, three and four group 
comparisons to be undertaken, such as between dialysis and transplant patients and 
between patients on different dialysis modalities either in terms of PD vs. HD regimens 
or in the four dialysis groups. Furthermore all comparative analyses were undertaken 
with methodological rigour as suggested by Cameron et al. (2000) and Greenfield et al. 
(1994). Since many variables differ significantly between RRT groups and may hence 
introduce biases and confounders in group comparisons, this research has addressed the 
problem of casemix by undertaking a careful identification, and measurement of 
relevant case-mix variables and followed this by appropriate statistical adjustments. 
Furthermore, residualised scores were computed and used in post-hoc comparisons in 
preference to absolute scores to allow for statistical adjustments.
The findings showed dialysis patients on different modalities had equivalent scores in 
most SF-36 sub-scales after casemix adjustments. The equivalence of HQoL in patients 
on different dialysis treatments found in the present study is in accordance with 
previous research (De Wit et al., 2002; Gudex, 1995; Moreno et al., 1996a; 1996b), but 
could also be related to the inadequate power to detect differences between groups. The 
number of patients on home HD and APD in particular, was relatively small (n < 30) 
and this might account for the lack of significant differences between the four dialysis 
groups despite a significant main effect on pain and vitality in the omnibus ANCOVAs. 
This suggests that the hypothesised effect of dialysis treatment on HQoL may be subtle 
and it will hence be important to replicate these findings with larger samples.
From a methodological point of view it is of note that the results of post-hoc 
comparisons differed between residualised and absolute scores. For instance, post-hoc
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tests on pain absolute scores indicated that CAPD patients reported significantly more 
pain than all other dialysis groups but no two groups were different when residualised 
pain scores were used. This highlights the importance of adequate statistical adjustment 
for casemix differences in all omnibus and post-hoc comparisons.
Comparisons between patients on HD and PD regimes showed that energy levels and 
emotional well-being might be better preserved in HD than in PD. HD patients had 
higher MCS scores and a lower prevalence of severe MCS impairments. Treatment 
status was also found to be a significant multivariate predictor of MCS in multiple 
regression analyses.
Vitality scores were likewise higher in HD compared to PD although adjustments for 
albumin negated this effect. Controlling for albumin had also removed the significant 
main effect on pain and vitality when the four dialysis groups were compared. Other 
studies have also found that PD patients, particularly those on CAPD had lower physical 
HQoL relative to HD (Julius et al., 1989a; Merkus et a l, 1999; Mittal et al., 2001b) but 
as in this study, lower albumin in the PD group explained to some extent the observed 
differences (Mittal et a l, 2001b). This highlights the importance of albumin to patients’ 
physical functioning and well-being (Lowrie et a l, 2000), in addition to clinical 
outcomes such as survival (Maiorca et a l, 1995b; Pifer et a l,  2002). One might 
speculate whether the lower serum albumin levels observed for the PD patients in this 
study was an indication that these were ‘sicker’ patients and thus had lower vitality 
scores. It is interesting to note that the PD patients were not different from HD patients 
on comorbid disease and renal severity. The dialysis groups also were not different in 
haemoglobin levels, which would be expected to affect energy levels.
The finding of higher emotional well-being in HD patients contrasts previous claims of 
more opportunities for psychological adjustments afforded by PD treatments (Cameron 
et a l, 2000; Diaz-Buxo et a l, 2000; Merkus et a l,  1997; Simmons & Abress, 1990; 
Wolcott & Nissenson, 1988a). The difference in findings may be attributable to 
methodological issues, including use of different instruments and other variations in the 
metrics and tools (Deniston et a l, 1989), random sample variability and differences in 
relative statistical power, which are common problems in naturalistic research 
(McClelland & Judd, 1993; Tunnell, 1977).
355
The findings also contradict the commonly held view in the medical community that 
CAPD, by allowing more flexibility and control over treatment, might be 
psychologically beneficial. There is however only limited support for these clinical 
impressions. Research has found little or no difference in psychosocial outcomes based 
on differences in control over treatments (Devins et al., 1981; Levenson & Glocheski 
1991; Sacks et al., 1990). Devins et a l , (1981) for instance examined depression in 
three group patients: low control (hospital HD), medium control (hospital self­
administered HD) and high control (CAPD). No relationship was found between the 
amount of behavioural control and depression.
A study by Eitel et al., (1995) showed that this relationship might be moderated by 
clinical variables. Their findings indicate that with increases in disease severity a 
relationship between behavioural control over treatment and depression becomes 
evident. In particular, as severity of illness increases and possibly less amenable to 
control, high-control (CAPD) patients have significantly higher depression than do low 
control (HD) patients. Their findings imply that as illness becomes more severe, control 
over treatment might become an added burden to the patient resulting in poorer 
adjustment. The psychological costs of control have been noted previously in the 
literature (Brownell, 1991).
Findings of better emotional outcomes in HD compared to PD are by no means 
unprecedented. For instance, Maiorca et a l (1998) showed that although CAPD and 
APD patients had a greater degree of independence and more positive attitudes than 
Hospital hemodialysis, they were also found to be more anxious and insecure. Griffin et 
a l , (1994) also found better psychological adjustment in HD patients relative to PD 
although group differences in time on treatment limit the validity of these effects. HD 
patients in that study had been treated for longer and consequently there might have had 
more time to adjust. However a longer time on RRT is unlikely to lead to more 
favourable HQoL as there is evidence to suggest that HQoL decreases over time in 
dialysis patients (Merkus et a l , 1999a).
Study findings showed no relationship between HQoL and treatment duration (total 
interval since dialysis onset irrespective of dialysis modality and time on current 
dialysis treatment) in keeping with previous findings (Evans et a l , 1985; Wolcott et a l, 
1988a). In this study HD and PD groups also differed with regard to time on RRT and 
on their current dialysis modality but these variables as well as other sociodemographic
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and clinical casemix differences that could introduce biases were controlled for in all 
the comparisons.
Several potential explanations can be suggested to account for the observed MCS and 
vitality differences in PD and HD.
First the continuous burden of PD compared with the intermittent nature of HD and 
peritonitis may place patients at risk for emotional distress. PD may be stressful on a 
more sustained basis due to the responsibility that a patient must take for their health 
and well-being (Mittal et al., 2001b). Emotional well-being might also be expected to be 
lower for PD patients whose continuous nature of their treatment might make the 
boundaries between treatment and non treatment less distinct than for HD patients 
(especially in relation to hospital HD). It might be more difficult for PD patients to 
suppress or inhibit distressing aspects of their illness given the daily treatment routine 
whereas HD being an intermittent treatment taking place within distinct blocks every 
week might be intruding less in daily activities and thoughts. Hospital HD in particular 
has the added advantages of being completely separated from patients’ home 
environment and might discourage the spill-over of treatment related stress in other 
aspects of patients’ lives.
MCS differences may also result from differences in the demands associated with PD 
and HD. HD whether performed at hospital or at home, typically entails 3 sessions a 
week, hence allowing perhaps more dialysis free days to pursue valued social, leisure 
and other daily activities without treatment interruption. Time requirements have been 
found to be greater in CAPD patients compared to HD but this was not been measured 
in the current study (Devins et al., 1990a; De Vecchi et al., 1994). Another study 
comparing home HD patients to CAPD has indeed found that home HD reported less 
adverse effect of kidney disease on lifestyle, better cognitive functioning, sleep and 
treatment satisfaction than did PD patients (Carmichael et al., 2000).
Yet another potential reason for this finding may be that PD patients experience greater 
distress, and isolation due to a lack of social support from similar others (i.e. fellow 
patients) and medical staff in comparison to HD patients. HD, especially when delivered 
at hospital offers more opportunities for regular social interaction amongst patients and 
with medical staff. Home HD necessitates a trained assistant, typically the patients’
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partner or other family member that might also create a more favourable environment 
for supportive social interactions between patients and the designated assistant. There is 
a vast literature attesting to the psychological benefits of social support on physical and 
emotional well-being (Christensen et al., 1989; 1992; 1994; Cohen & Wills, 1983; 
Wallston et a l , 1983). The more regular contact of HD patients with health care staff 
might also mean that patients medical needs or emergencies are more promptly taken 
care of or addressed, and it might also serve to alleviate treatment- or illness-related 
worries and concerns and hence contribute to patients’ well-being. It is possible that 
fewer opportunities for such social interactions and for the establishment of supportive 
networks are present in PD patients. The sense of isolation, (which was not measured in 
the current study) might be greater among some PD (CAPD) patients, especially the 
elderly or those living alone (Eitel et a l , 1995). A study by McLaughlin et a l (2003) 
showed that hospital HD patients were reluctant to change to self-care PD regimes 
because of fear of social isolation (McLaughlin et a l , 2003) but no PD patients were 
assessed.
An alternative explanation for the differences in MCS between HD and PD patients is 
that these differences are due to variations in interpersonal expectancies placed upon 
and experienced by the patients (Ditto & Hilton, 1990).
Previous literature suggest that medical staff assume that CAPD patients are healthier 
and better adjusted than HD patients (Levy, 1988; Witenberg et a l, 1983). PD 
advocates have also promoted PD as the treatment that allows more control over 
patients’ lives (Ronco & La Greca, 1997). These assumptions on the part of medical 
staff, significant others or patients may lead to increased expectations of self-sufficiency 
and expectations to maintain or resume normal life style. However if inappropriate, 
these may come to be perceived as burdensome, undermine patients’ sense of control 
and prevent them from getting the support they need. Patients’ perceived inability to 
meet others’ expectations has been shown to lead to poorer psychological adjustment 
(Hatchett et a l, 1997). Placing such expectations of control or empowerment on 
patients who do not feel they can successfully accept the responsibility associated with 
them is another example of the negative costs of control (Thompson et a l, 1988). Such 
expectations may not be placed on HD patients or maybe not to the same extent. Lower 
interpersonal expectations on the other hand may be associated with less burden and 
more support for these patients, resulting in better emotional adjustment and well-being.
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Differences in patients’ personal expectations rather than interpersonal expectation 
might also account for the HQoL differences. Unmet expectations (discrepancy between 
health expectations and health experiences) are thought to adversely impact HQoL (Carr 
et al., 2001). HD patients may have lower expectations than PD. Consequently their 
lives would probably be more likely to meet their expectations despite their physical 
disabilities. Further research is needed to examine personal and interpersonal 
expectations across the different ESRD treatments and to explore their role in 
determining HQoL in ESRD.
Finally, it is also possible that treatment selection might have played a role. Patients 
with poorer emotional well-being may not have chosen or been chosen for HD. Because 
this study is based on cross-sectional data it is difficult to differentiate a treatment effect 
from treatment selection. A longitudinal study assessing patients prior to and post 
dialysis onset, and controlling for MCS levels pre- dialysis onset, would be required to 
determine the influence of treatment modality on HQoL outcomes.
Although the question of which dialysis treatment confers the best HQoL outcomes is 
an important one it is also likely that each form of therapy (i.e. HD, PD) may have a 
role to play during the lifetime of patients with renal failure. Perhaps a move to identify 
ways in which the differing modalities complement each other is required. In this 
respect it is interesting to note the recent report by Van Biesen et al. (1998) suggesting 
that patients starting on PD and then switched to HD had better survival than those 
remaining on their initial treatment of either type.
This study confirmed previous studies regarding the HQoL advantage of TX relative to 
dialysis (Evans et al., 1985; Jofre et al., 1998; Wight et al., 1998). Casemix adjusted 
comparisons indicated that TX patients scored significantly higher than their dialysis 
counterparts in almost all SF-36 sub-scales except for MH and REm. Physical HQoL 
differences persisted even after adjustments for casemix differences and biochemistry. 
A literature review has similarly concluded that the TX HQoL advantages over 
comparison groups such as dialysis are less apparent in mental health and emotional 
well-being (Dew 2000a; Dew et al., 1997). The uncertainty related to graft viability is 
thought to account for the lack of superiority of kidney TX in terms of psychosocial 
adjustment and emotional well-being (Kalman et a l, 1983). Study findings showed that
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TX worry was prominent in TX recipients and that it correlated with emotional well­
being.
Alternatively lack of significant differences in emotional well-being might be related to 
the use of a generic HQoL measure, namely the SF-36 which by definition is less 
sensitive to specific emotional concerns of the ESRD patients than disease specific QoL 
measures. The SF-36 emotional sub-scales in other words may have failed to capture 
ESRD-specific aspects of emotional well-being. The combined use of disease specific 
and generic HQoL measures would be recommended for future research. Nevertheless it 
is important to recognise that as study findings indicate, global emotional well-being 
indicators are not related to dialysis vs. transplantation status.
It is also important to note that the observed SF-36 scores in TX showed comparable 
HQoL relative to general population norms (Dew et al.,. 2000b). These mean values 
however mask the fact that a substantially high number of TX patients (n = 79, 22.6%) 
have very low PCS scores (being more than 2 SDs below population mean) which 
indicate severe impairments in physical function. Such a score corresponds to the 2.5th 
percentile of the distribution of HQoL scores in the general population. Patients were on 
average 70.7 months from TX suggesting that these findings are not simply a residual of 
pre-transplantation physical dysfunction associated with uraemia and dialysis (Dew et 
al., 2000b; Julius et a l, 1989b).
Only a fraction of TX had severe MCS impairments despite PCS impairments. These 
findings suggest that for a proportion of individuals emotional well-being remains 
uncompromised despite the severely affected physical HQoL. The magnitude of 
physical well-being impairments highlights the significant functional limitations post- 
TX for some patients (Hathaway et al., 2003) and reinforces the importance of efforts to 
affect HQoL favourably and complete advance directives in this group of patients.
The findings on HQoL in CAD and LRD TX were consistent with those reported by 
Evans et al. (1984) and Julius et al. (1989b) in that HQoL appears to be unaffected by 
transplant type. Both living-related and cadaver transplant recipients reported equivalent 
HQoL levels in all SF-36 sub-scales with mean scores for both groups being within one 
standard deviation of the mean of a normal population. This finding is reassuring and
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further documents the attraction of renal transplantation as a mode of treatment that 
largely restores individuals’ HQoL.
The inability to detect significant HQoL differences between the two transplant groups 
in the SF-36 sub-scales may have several possible explanations. The primary reason 
may be that the transplant procedure itself accounts for such large HQoL improvements 
that the detection of additional incremental differences in HQoL between LRD and 
CAD treatments is very difficult to detect. If this explanation is correct then the clinical 
benefits observed with LRD continue to be the most important factors in distinguishing 
between these two transplant options.
Section 3: HQoL determinants in ESRD
One of the aims of this study was to identify the combination of illness and patient 
variables that best predicts HQoL in dialysis and transplantation. Although this has been 
the subject of intense investigation, this study adds to previous research by examining 
multifactorial models of HQoL that included sociodemographic, medical, 
neuropsychological, mood variables, and patients’ cognitions. Previous studies have 
predominantly focused on the first two sets of variables overlooking the role of illness 
and treatment cognitions and mood (Mingardi et a l , 1999; Mittal et a l, 2001a; Moreno 
et a l, 1996a; Wolcott et a l, 1988b).
Although a few studies (see review by Hagger & Orbell, 2003) have evaluated the 
separate roles of illness and treatment beliefs, and mood in HQoL, no published studies 
have evaluated their relative contribution as well as their synergistic effect on HQoL. 
Moreover assessing treatment beliefs alongside illness perceptions has allowed us to 
evaluate the relative contribution of these two sets of beliefs to HQoL.
Results indicated that several different factors including sociodemographic, medical and 
psychological variables were associated with HQoL, although specific predictors and 
the strength of the observed associations differed in physical and emotional well-being 
as indexed by PCS and MCS (SF-36). The contributions of each set of variables will be 
separately discussed in the following four sections.
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3.1. Sociodemographics
The overall pattern of results indicates that sociodemographic and medical variables 
were mainly associated with the physical HQoL and less consistently so with the 
emotional HQoL.
Age was the key demographic factor that was independently associated with both 
physical and emotional dimensions of HQoL. Observed associations indicated that 
physical function deteriorated as a linear function of age (in both dialysis and TX) 
whereas the opposite pattern of results was evident for emotional well-being. Increasing 
age in TX patients was associated with higher MCS. These findings confirm previous 
research in which older age is consistently related to worse physical HQoL (Merkus et 
al., 1997; Mittal et al., 2001a; 2001b; Moreno et al., 1996a), and also findings of others 
(Horina et al., 1992; Kimmel et al., 1998b; Lowrie et al., 1997; 2000) who report that 
elderly patients frequently show greater satisfaction with some aspects of their life than 
younger patients. The relationship of age with mental health/emotional well-being has 
often been described as ‘non-linear’ (with "middle age" respondents often having 
relatively low mental health scores and “older age” having higher or better emotional 
well-being), in that the emotional impact of illness is attenuated with advanced age (De 
Oreo, 1997; Kutner, 1994; Kutner & Jassal, 2002). Older persons appear to use different 
reference points to evaluate their HQoL than do younger persons. Older respondents 
tend to downplay the negative aspects of situations giving them neutral meaning 
compared to younger adults (Diehl et al., 1996). Also, changes in expectations about 
health and well-being across the life span may explain the association between age and 
emotional well-being in TX (Kutner, 1994).
Significant associations were also found in this study between gender and MCS (only in 
the dialysis sample), in line with other studies using the SF-36 (Mingardi et al., 1999; 
Moreno et a l, 1996a). The gender effect on emotional well-being is consistent with 
previous research (see reviews Bebbington, 1996; Harris, 2003) and may reflect the 
tendency for women to be more willing to report negative emotional states (Sack et a l, 
1990; Newman, 1984). It is interesting that this relationship was not found in the TX 
sample that had generally high scores in emotional well-being sub-scales.
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Lack of paid-employment (including retirement) and lower income were both associated 
poorer HQoL, mainly physical well-being confirming previous findings (Blake et al., 
2000; Curtin et al., 1996; Harris et al., 1993; Hathaway et al., 1998). Multiple 
regressions indicated that both employment and income were independent predictors of 
physical function, with variance explained being over and above the effect of various 
other sociodemographic, clinical psychological variables. It is also noteworthy that 
dialysis modality did not affect likelihood of working and that the effect of work and 
income outweighed that of dialysis modality on HQoL. Controlling for work and 
income negated all the significant differences between dialysis groups on physical 
dimensions of HQoL.
The direction of these relationships needs further investigation as these findings beg the 
question as to whether better physical well-being may lead to work rehabilitation or 
facilitate maintaining work activity while on dialysis, thus ensuring better income 
despite illness and treatment constraints or vice versa in that employment and income 
confer better physical HQoL.
Each of these non-illness variables has been found to be related to HQoL among the 
general population in exactly the same way as observed in the current study and so the 
fact that they are involved similarly in ESRD is not surprising. These findings serve as 
an important reminder, however that the HQoL in ESRD is very much dependent on 
several contextual variables (such as socio-economic status) that are to a great extent 
independent of ESRD and RRTs (Greenfield et al., 1994; Valderrabano et al., 2001).
3.2 Clinical/medical variables
Among clinical variables, ESRD severity, albumin, haemoglobin and GFR were 
associated with HQoL although observed associations were not consistently found 
across dialysis and TX. Importantly, in multivariate analyses their contribution was 
small and not always significant, especially with regard to MCS scores.
ESRD severity, a weighted index of comorbidity and renal complications, was found to 
be consistently associated with physical HQoL scores in univariate analyses and was the 
strongest clinical predictor of PCS in both dialysis and TX patients (in multivariate 
analyses). The observed association point to the detrimental effect of comorbid factors 
superimposed on ESRD in reducing patients’ HQoL. The role of comorbidity in ESRD
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has repeatedly been demonstrated in previous research (Jofre et al., 1998; Valderrabano 
et al., 2001; Merkus et al., 1999b; Mittal et a l , 2001a).
The associations of other clinical markers and biochemical values with HQoL were 
found less consistently across dialysis and transplantation. For instance, albumin 
predicted HQoL in dialysis but not in TX. The serum albumin remains a powerful yet 
enigmatic predictor of poor outcomes in ESRD (Leavey et al., 1998; Mapes et al., 
2003). In recent years a body of evidence has accumulated suggesting that a low serum 
albumin concentration reflects the presence of inflammation and malnutrition (Bistrian,
1998). The observed associations between SF-36 scores and albumin (in dialysis) 
particularly with respect to physical dimensions of SF-36 is consistent with previous 
research (Mittal et a l, 2001a; 2001b) and the general perception that low serum 
albumin levels may reflect poor overall general health.
Haemoglobin on the other hand predicted HQoL in TX but not in dialysis. Although, the 
lack of significant associations between haemoglobin and HQoL in dialysis is in 
contrast with studies carried out over a decade ago, it is in keeping with more recent 
studies (Bakewell et al., 2002; Merkus et al., 1999b; Mingardi et al., 1999). Treatment 
and prevention of anaemia in renal dialysis patients using erythropoietin is now standard 
practice in many renal clinics and was routinely used in the participating units. The low 
haemoglobin levels typically associated with poor physical function were not present in 
this study and therefore it is not surprising that no association was found between 
haemoglobin and HQoL.
The findings also indicated that as glomerular filtration rate decreased the physical 
HQoL deteriorated in TX. Similar associations have been reported in patients with renal 
insufficiency or on dialysis (Merkus et al., 2000; Shidler et al., 1998) but this is the first 
report in TX patients. The symptomatology that accompanies diminishing kidney 
function (e.g. fatigue, loss of energy, weakness) may mediate the association between 
GFR and well-being (Rocco et al., 1997).
The observed significant associations between dialysis adequacy and physical well­
being are consistent with some reports (Chen et al., 2000; Manns et a l, 2002; Merkus et 
al., 2000) but are in contrast with other studies (De Oreo 1997; Merkus et al., 1999b; 
Mittal et al., 2001; Morton et al., 1996).
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3.3 Beliefs and mood
On a multivariate level, sociodemographic and clinical factors did not explain a large 
amount of the variation in HQoL. Although study findings support their explanatory 
value for PCS scores, they only explained a small percentage of variance in the MCS 
scores. The indications are that factors other than sociodemographic and medical 
variables are also important in explaining HQoL. Within this study, illness and 
treatment beliefs were postulated to have significant effects on HQoL and were hence 
included in the models built to predict HQoL in ESRD.
Both univariate and multivariate analyses showed that illness and treatment beliefs were 
significantly associated with HQoL in both dialysis and transplantation.
Correlations showed that more negative illness and treatment beliefs, i.e. perceptions of 
illness and treatment disruptiveness, perceptions of high illness consequences and low 
control, and strong identity beliefs were associated with poorer HQoL in both dialysis 
and TX patients. Similar findings have been reported for various other illness groups 
(Moss-Morris et al., 1996; Murphy et al., 1999; Scharloo et al., 1998; Steed et al.,
1999) and for ESRD (Eitel et a l, 1995; Patel et al., 2002). Some of these univariate 
associations remained significant even after statistical adjustments for 
sociodemographic (age, income), illness (e.g. albumin, ESRD severity) and treatment 
variables (e.g. mode of renal replacement), demonstrating that the impact of patients’ 
cognitions cannot be accounted for by these factors.
Regression analyses showed that patients’ cognitions are predictive of both physical and 
emotional HQoL and that individual differences in illness and treatment beliefs account 
for more variance than individual differences in sociodemographic and clinical variables 
in predicting HQoL, particularly emotional well-being (MCS). The size of the effects 
for illness and treatment beliefs were not large but were obtained using a conservative 
strategy in which the effects of several demographic and medical history variables were 
controlled. Regression analyses also indicated that the specific beliefs that predicted 
HQoL outcomes differed between the two groups (dialysis and TX) and between the 
physical and emotional HQoL dimensions. The overall pattern of results indicated that
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illness beliefs were primarily associated with physical HQoL and treatment perceptions 
with emotional HQoL.
Multiple regression analysis on PCS revealed that illness intrusiveness was the only 
cognitive variable that was multivariately associated with physical well-being in 
dialysis. Illness intrusiveness and identity also predicted physical HQoL in TX.
Illness intrusiveness has previously been found to contribute to psychosocial impact of 
ESRD on outcomes such as depression rather than physical well-being (Devins 1994; 
Devins et al., 1990a; 1990c; 1997; Sacks et al., 1990; Eitel et al., 1995).
The contribution of timeline, consequences, control, and identity components of SRM, 
despite being significantly correlated with SF-36 scores in univariate analyses, failed to 
reach significance in PCS regressions.
Although lack of sufficient range in some of these variables (i.e. timeline) and 
multicollinearity (as indexed by the moderated interrelations among predictors, 
especially between IPQ consequences with illness intrusiveness) could explain the 
absence of significant multivariate associations, methodological considerations 
regarding the ratio of cases to number of variables in the regression analysis also need 
to be kept in mind when interpreting results.
Nevertheless, the observed multivariate associations between illness intrusiveness and 
PCS provide indirect support for the role of perceived consequences in HQoL due to 
their conceptual overlap (as both illness intrusiveness and perceived consequences 
reflect the same underlying concept, patients perceptions of the effect of their illness on 
their lives). The IEQ measures a patient’s perception of the extent to which illness 
interferes with or modifies personal and social behaviour, i.e. is intrusive in patient’s 
life. It therefore reflects a concept similar to that assessed by the 'IPQ-consequences' 
sub-scale (observed intercorrelations were high r -  .635 and r = .555 for TX and 
dialysis respectively). When regressions were performed without IEQ, IPQ 
consequences emerged as a significant predictor (data not shown).
There are however measurement differences in the length of scales and the response 
categories that could explain why IEQ rather than IPQ consequences predicted PCS. 
The 20-item IEQ allows a greater specificity in the measurement of illness impact than 
the substantially shorter IPQ sub-scale, by detailing a range of life domains and
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behaviours likely to be affected by ESRD. These are implied but not directly assessed 
by the IPQ consequences items. One would expect therefore that if an association 
between perceptions of illness impact and HQoL exists, IEQ would be a more powerful 
determinant of HQoL because of its greater specificity. IEQ items are also scored on an 
8-point Likert scale ensuring a wider range of responses as opposed to IPQ consequence 
items, which rated on a 5-point Likert scale. An alternative way to evaluate beliefs 
regarding the impact of illness would have been to construct a combined score for the 
two measures or use only one of the two. Further work is warranted to examine the 
degree of similarity between these IEQ and IPQ consequences and the value of IEQ as a 
HQoL measure as advocated by some investigators (Kimmel, 2000a; 2000b).
Finally some of the IPQ consequences items (e.g. ‘my illness has had major 
consequences in my life’, ‘my illness has strongly affected the way other people see me’ 
or ‘my illness has affected the way I see myself as a person’) may have both positive 
and negative connotations and therefore be interpreted in both a positive and a negative 
fashion. For instance, the phrasing of ‘my illness has had major consequences on my 
life’ item creates the potential for both a positive and negative change as illness may 
bring a family closer together or add stress to family life. Their ambiguous meaning 
might have led to different interpretations, which further might explain why IPQ 
consequences were not a significant predictor in the multivariate analyses performed. 
The recent move towards ‘positive’ psychology demonstrates that as paradoxical as it 
may seem even within the context of chronic illness, positive consequences/outcomes 
may occur (Affleck & Tennen, 1996; Andrykowski et al., 1993; Antoni et al., 2001). 
Many different terms have been used including ‘benefit finding’, ‘growth’, ‘meaning 
making’ and more to describe a range of positive outcomes in this growing area of 
research.
Greater symptom burden, a score reflecting the occurrence of generic, renal and 
medication-related symptoms explained an additional amount of HQoL (PCS) variance 
in TX. These associations are consistent with previous findings on the adverse effects of 
symptomatology and immunosuppression side-effects on HQoL (Hathaway et al., 2003; 
Merkus et al., 1999a; De Geest & Philip, 2000; Keown, 2001).
Study findings showed no direct influence of perceived symptoms on HQoL in dialysis 
when background variables were adjusted for. The lack of multivariate associations 
contrasts with previous findings (Curtin et al., 2002; Weisbord et al., 2003). There
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might however be an indirect effect on HQoL in that symptom beliefs affect perceptions 
of illness intrusiveness compromising HQoL as a result (Devins et al., 1990c). 
Observed correlations indicate that as symptom frequency increases there is an increase 
in the impact the illness has on patients’ lives (increased illness intrusiveness) and that 
in turn affects HQoL.
Methodological issues related to scoring may have also compromised power to detect 
significant associations between identity and HQoL. In this study, identity scores were 
estimated as the number/count of symptoms associated with ESRD, which is in 
agreement with the authors’ recommendations and previous research (Weinman et al., 
1996). An advantage of combining individual items is that random error that occurs 
with respect to individual symptoms is averaged out. A disadvantage of summation is 
that one is not able to distinguish the number of symptoms from the extent of their 
occurrence. For example, a patient who reports 4 symptoms as occurring very often 
obtains the same total score of 4 as a patient who reports four symptoms occurring 
rarely. The various ways that the same symptom score can be arrived at may be partly 
attributed to the lack of multivariate associations between identity and PCS in dialysis.
Specific symptoms might also have a greater impact on HQoL rather than aggregate 
scores. Employing individual/separate scores would additionally examine if each 
symptom differentially affected HQoL. For instance, itchiness or dry skin albeit 
frequently reported by dialysis patients, might have less grave HQoL implications 
compared to fatigue, breathlessness or pain. There is some evidence that this must be 
the case in ESRD. Devins et al. (1990c) for instance, found that muscle pain was 
associated with QoL but not headaches. Pain in particular, a pervasive medical problem, 
has been found to account for substantial levels of disability and to contribute greatly to 
the overall burden of illness (Kimmel et al., 2003; Turk & Melzack, 2001). Inextricably 
linked to depression and other negative moods, pain can increase disease severity and 
mortality (Staats, 1998). Additionally, pain may disrupt many aspects of physical, 
mental, and social functioning (Leventhal et al., 1998). Identifying those symptoms 
more likely to impinge upon HQoL and assessing their relative contribution of different 
symptoms in patients’ HQoL has not been addressed in the present study.
In addition to specific symptoms, symptom variability may also be pertinent in HQoL 
especially for dialysis patients. It is possible that the fluctuating nature of symptoms 
may also have obscured meaningful associations in dialysis. Analyses comparing HD
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and PD groups on symptoms reporting across the two assessments (pre- to 24-hours 
post-dialysis) indicated a significant dialysis treatment by time interaction effect, a 
finding consistent with the finding of low intra-observed reliability for symptoms 
assessed within 1-week interval (Parfrey et al., 1989). This may have implications when 
retrospective evaluations of symptoms associated with ESRD are made. Therefore 
future studies should consider symptom variability, the number of symptoms endorsed, 
and the degree of burden of each individual symptom as well as frequency and duration 
of symptom occurrence.
Finally although there is some work on symptom appraisal and related processes 
(Pennebaker, 1982; Petrie & Weinman, 2003), little is also known about how patients 
judge the relative contribution of underlying illness and treatment on their symptoms. 
This is an important area of research as mistaken attributions may effect outcomes such 
as distress, HQoL or may trigger non-adherence (Nerenz et al., 1984; Thune-Boyle et 
a l , 2003).
Regression analyses on MCS indicated that the effect of treatment beliefs outweighed 
that of illness beliefs. Treatment intrusiveness was the most powerful predictor of MCS 
in dialysis accounting for 9.3% (AR2 = 8.9%) of the total variance explained. Although 
this signifies a small effect size, it is noteworthy that treatment perceptions added to the 
variance explained by dialysis modality as it highlights the independent contributions of 
objective treatment and subjective treatment appraisals in predicting emotional well­
being.
In contrast to the significant univariate associations, the resulting regression model did 
not demonstrate a substantial impact of illness beliefs on emotional well-being in 
dialysis patients. Again the effect of multicollinearity between the IVs may cause some 
of these variables to lose statistical significance when entered simultaneously as one 
regression block. The decision to enter illness and treatment beliefs in one block was 
justified, as there appeared to be no a priori hypothesis regarding their primacy.
In TX, perceived consequences and medication beliefs reflecting concerns about 
medication side-effects accounted for almost half of the total MCS variance explained 
(AR2 = 13.3%). These findings suggest that the power of Leventhal’s SRM (Leventhal 
et al., 1996; 1998) to explain variation in emotional well-being in TX was enhanced by
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taking into account beliefs about medication. Only medication beliefs however were 
found to have a direct effect on HQoL adding a small albeit significant (4.5%) 
percentage in variance explained. Perceived consequences were no longer significant 
when CDI scores entered the regression equation, suggesting a mediating effect for the 
latter. Patients’ beliefs about the consequences of their illness influence their mood (i.e. 
depressive affect), which in turn adversely impact upon emotional HQoL. The 
observation that treatment beliefs were substantially and independently related to MCS 
is consistent with previous findings about treatment effectiveness (Hampson et al.,
2000) and substantiate the role of treatment beliefs in adherence (Home & Weinman, 
2002).
Treatment intrusiveness was not a significant predictor of MCS in TX. This could be 
attributed to insufficient variance on TEQ scores, which were uniformly very low 
among TX recipients.
Previous research has demonstrated the importance of illness beliefs in ESRD but 
evidence on the role of treatment perceptions in this patient population was lacking. The 
independent contribution of treatment beliefs in the prediction of HQoL provide some 
evidence for the theoretical predictions that treatment beliefs add to the explanatory 
power of SRM (Home & Weinman, 2002), although these relations need to be re­
investigated with path analysis or structural equation modelling procedures. This type of 
analysis would advance knowledge of the structure and interactions between illness and 
treatment beliefs/representations within the self-regulatory framework and would also 
reveal the direct or indirect links between these variables and HQoL by testing 
mediational hypotheses. For instance, regression analysis showed no direct associations 
between control beliefs and HQoL unlike previous research (Jopson & Moss Morris, 
2003). Although this might mean that control beliefs are less relevant in ESRD 
outcomes, it is more plausible that these beliefs may be indirectly linked to outcomes, in 
that their influence on MCS might be mediated by illness intrusiveness or treatment 
perceptions. In particular, patients who view their illness as uncontrollable are more 
likely to perceive more illness or treatment related disruption, which may in turn 
adversely affect HQoL. Mediating effects have indeed been demonstrated for IPQ 
consequences and beliefs regarding treatment necessity in studies of other patient 
groups (Home & Weinman, 2002). Control beliefs may also be implicit in illness and 
treatment intrusiveness ratings as exemplified by respective IEQ and TEQ items ‘my 
illness is difficult to control’ and ‘treatment side effects are difficult to control’.
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Path analyses would also have the added advantage of providing further supportive 
evidence of the predictive ability of illness and treatment cognitions as the correlational 
and regression analyses in this study do not provide evidence to support a causal 
relationship.
The specificity of beliefs and behaviour links and the fact than they can be easily 
identified early on in ERSD is important. Unlike other factors, such as personality or 
sociodemographic variables, these links provide considerable potential for developing 
cognitively based interventions. Thus if negative thinking can be identified and an 
intervention instituted to foster more adaptive models and expectations, then improved 
levels of functioning and well-being could be expected. Recent work by Petrie et al., 
(2002) have demonstrated an earlier return to work for MI patients in an illness 
perception changing intervention. An important implication of this study is that attempts 
to improve HQoL in dialysis and TX patients should not focus only on illness beliefs 
but also address treatment perceptions. The latter may also produce changes in HQoL. 
On the whole study findings provide moderate support for the extended self-regulatory 
theory that includes illness and treatment perceptions.
Mood variables (patients’ depression scores) showed a significant inverse association 
with physical and emotional indicators of HQoL. Previous research has shown similar 
associations (Franke et a l, 2003; Iliescu et al., 2003; Kimmel et al., 1993; 1996; Maor 
et al., 2001; Steele et a l, 1996; Walters et al., 2002; Watnick et al., 2003).
In accordance with previous findings depression was found to be a much stronger 
determinant of HQoL than clinical measures such as dialysis adequacy (Martin et al., 
2000; Steele et al., 1996). As proposed by Benito-Leon et al (2002) there are three 
possible explanations for these results. Firstly depression could, affect patients HQoL 
through an influence on psychological variables, such as perceived support and self­
esteem. Secondly, depression may impact directly upon HQoL by causing fatigue, sleep 
difficulties, and memory and concentration disturbances. Thirdly, patients with previous 
poor HQoL may be at greater risk for depression.
The amount of variance explained by depression was smaller than that of patients’ 
cognitions although this may be related to the specificity of measurement. General 
feelings of depression may be more distal and hence less powerful determinants of
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ESRD outcomes than the most proximal social cognitions assessed by SRM 
components and treatment perceptions. Prediction may be enhanced when more specific 
emotions or mood predictors having direct relevance to illness are used. The revised 
version of IPQ (Moss-Morris et al., 2002) allows the assessment of emotional responses 
generated by illness rather than general mood so its use is strongly recommended in 
future research. A greater understanding of the emotional representation of illness and 
the emotional processing component of self-regulation is needed and future studies 
ought to reflect this perspective using more appropriate methodology.
A final word of caution is warranted in interpreting the observed associations between 
depression and MCS scores, as there is some conceptual overlap between the two 
measures. MCS and MH scores correlate with validated measures of depression 
(Beusterien et a l, 1996b) and have even been used as a first stage screening for 
depression in previous studies (Lopes et al. 2002; Mittal et al., 2001a; 2001b; Ware et 
a l, 1994).
3.4 Neuropsychological functioning
The hypothesis that NP functioning would be associated with HQoL, particularly 
emotional well-being, received very modest support. Although significant correlations 
were noted in the predicted direction when univariate analyses were performed, NP 
functioning failed to predict HQoL in the regression analyses even when entered into 
the regression model before patients’ cognitions and mood.
Several factors may have limited the predictive validity of NP indices in the 
multivariate analyses. In previous studies where significant associations were 
documented, simple regression models including only age, education and NP scores 
were tested (Bremer et al., 1997; McSweeny et a l, 1985).
In this study the constructed regression models incorporated several background 
variables to ensure that observed associations are not confounded by the influence of 
factors such as age, education employment, clinical severity, or dialysis delivery. It may 
be that the independent contribution of NP functioning on HQoL becomes less apparent 
when a range of sociodemographic and clinical variables (including treatment modality) 
are controlled for in the first steps of the model. Secondly, the use of a summary NP 
score rather than individual NP scores, albeit in accordance with previous studies
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(Shifren et al., 1999) might have obscured significant associations between specific 
cognitive abilities (e.g. memory) and HQoL. There is indeed evidence that specific NP 
tests served as better predictors of specific life functions. McSweeny et al. (1985) for 
instance found that the Aphasia Screening Test (Reitan & Wolfson, 1993) was the best 
predictor of communication skills. The associations of different cognitive functions to 
HQoL have not been explored in this study.
It is also possible that cognitive functioning might be more closely associated with 
mental health outcomes such as depression (Honn & Bomstein, 2002; LaRue et al., 
1995; Shifren et al., 1999) or with performance-type of outcomes such as daily 
activities or employment rather than more global outcomes such as HQoL (Bremer et 
al., 1997; Putzke et a l, 2000). The correlations between physical functioning and NP 
performance indices were higher than those observed for the summary component 
scores in keeping with previous research (Harder et al., 2002) and significant 
associations were also found between depression and NP scores. It is however unclear 
whether NP abilities/functioning amplify emotional distress or whether emotional 
distress influences NP performance. In the analysis, only linear associations between 
NP performance and HQoL were tested but it is possible that associations may only 
become evident when NP performance is severely impaired.
Cognitive functions may indirectly impact upon HQoL. For instance compromised 
memory or speed of information processing may directly influence most of daily 
activities and indirectly affect well-being. On the whole study findings suggest that NP 
functioning is relevant to HQoL outcomes, but further research is needed to test the 
pathways involved.
The present results also demonstrated that subjective cognitive complaints were more 
strongly associated with HQoL than objective indices of NP performance. Observed 
correlations were higher and more consistent across the SF-36 sub-scale scores. 
Cognitive complaints predicted a small albeit significant proportion of the explained 
variance in PCS and MCS scores in dialysis.
It is likely that these associations were mediated by depression. In other samples 
significant associations have also been found between depressive symptoms and reports 
of subjective cognitive complaints (Brickman et al., 1996; Khatri et a l, 1999; Newman 
et al., 1989). Although the observed association with HQoL may be related to method
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variance across measures, subjective cognition scores reflect patients’ appraisals of their 
cognitive capacity or disability triggered by their illness or treatment and hence have 
particular relevance to HQoL evaluations. The inclusion of cognitive sub-scales in some 
generic and kidney specific QoL measures exemplifies this point (Begner et al., 1981; 
Hays etal., 1994).
Section 4: Conclusion
The present study expands our understanding of the role of treatment modality on 
HQoL and also provides a first step toward unravelling the complex associations 
between HQoL and cognitive and psychological variables in ESRD patients. Although 
only a controlled randomised study can be definite about treatment effects, the 
convergence of study findings with previous research and the careful adjustment of 
casemix differences together suggest real differences between PD and HD patients, and 
between TX and dialysis. The findings of this study emphasise the need to examine 
multifactorial models of HQoL in ESRD, and to consider both medical and 
psychological factors if we are to understand physical and emotional well-being in 
dialysis and transplant populations.
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CHAPTER 11:
CLINICAL IMPLICATIONS STUDY LIMITATIONS AND 
AVENUES FOR FUTURE RESEARCH
Section 1: Clinical implications of study findings
The study has several clinical implications:
■ Dialysis patients present with HQoL impairments. This suggests that there is still 
room for improvement in treatment delivery and in the clinical management. 
Physicians/nephrologists need to be aware that even well-dialysed ambulatory may 
feel pronounced physical functioning limitations and severe pain that disrupt role 
performance and adjustment.
■ Findings also suggest that particular attention should be given on the emotional 
well-being of PD patients as this group is faring worse than their HD counterparts. 
PD patients’ worries and concerns as well as emotional needs should be given 
consideration in the health care practice. Given that they spend much time away 
from the hospital the ability to be in contact and be contacted by the health care 
professionals should be considered.
■ Health care professionals need to become aware that patients have their own ideas 
about their condition and their treatment and that these sets of beliefs and 
perceptions affect broader outcomes such as emotional and physical HQoL/well- 
being. More importantly, beliefs and cognitions are potentially amenable to change 
and could hence be targeted by appropriate interventions. Addressing illness and 
treatment misconceptions has the potential to produce changes in patients’ HQoL.
■ The finding that patients hold beliefs about treatment, which may conflict with the 
medical views yet, influence emotional wellbeing has implications for clinical 
practice. Eliciting and alleviating concerns regarding the impact of treatment may 
enhance the therapeutic partnership between clinician and patients and facilitate 
patients’ emotional adjustment and potentially adherence to treatment.
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■ Findings can also be used to develop paradigms for doctor patient interaction that 
will generate ‘adaptive’ shared perceptions of disease and treatment congruent with 
respect to symptom formation, timelines and consequences for both illness and 
treatment that may contribute to overall sense of patients’ well-being.
■ It is also important to recognise that the gross and pronounced NP impairments 
reported in early studies on dialysis population were not found in this study. 
Although there is some evidence for mild NP impairments relative to norms, a 
substantial number of dialysis patients present with uncompromised cognitive 
abilities. This attests to the medical advances in the delivery and techniques of 
dialysis, as well as the continuing efforts to improve renal replacement therapies and 
patient outcomes. The findings also highlight the importance of adequate dialysis 
delivery so achieving these clinical goals should be the aim for all patients on 
dialysis.
Section 2: Limitations of the study
Several limitations require qualifications of the conclusions drawn.
2.1 Shortcomings in applying the theoretical framework
Even though the theoretical model/framework proved useful, a number of problems 
exist in translating theoretical premises into study designs and subsequent execution.
The self-regulatory framework describes a circular feedback system engaging and 
linking complex cognitive and emotional processes, coping and outcomes through a 
series of constant appraisal processes. The cognitive and emotional representations of 
illness are constantly changing in light of changing coping efforts, changing 
environmental factors such as (perceived) changes in disease and treatment 
characteristics. It should be clear that fully testing this self-regulatory system is virtually 
impossible. Not only is the complexity of this framework hard to research but also it is 
only possible to capture the dynamics of the changes that influence outcomes and
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feedback loops using frequent measurements. Due to the lack of resources in this project 
this has not been done.
In this thesis only one basic principle derived from the self regulatory theory is used, 
namely the relationship between illness representations and HQoL; the study in other 
words was not intended to fully test the SRM theory although designing the model of 
HQoL determinants and explaining results relied on the self-regulatory theory.
2.2 Study design
The first and foremost methodological limitation relates to the cross sectional design of 
this study, which negates the ability to make any judgements regarding causality from 
these data. Drawing conclusions regarding causality can be problematic with cross 
sectional designs and correlational and regression analyses. The cross-sectional nature 
of the data provides a snapshot of the interrelations between key variables but precludes 
making firm causal conclusions as to whether beliefs and mood drive or determine 
HQoL.
2.3 Sample
The second methodological issue relates to the sample size and representativeness. The 
recruited ESRD sample, albeit one of the largest in studies involving NP assessments, 
was still relatively small for particular types of analyses such as comparing all four 
dialysis groups, and inadequate for testing structural equation models (Loehlen, 1998; 
Ullman, 2001). The small sample sizes of certain subgroups such as APD and home HD 
patients or patients with LRD transplants may also have prevented detecting significant 
differences when for instance, the four dialysis groups were compared, or when LRD 
patients were compared to CAD TX patients.
Moreover, study eligibility criteria and the resulting study sample characteristics limits 
the generalisability of observed findings on the broader ESRD population in the UK. 
The strict inclusion criteria for the dialysis sample on one hand and the rigorous 
research protocol on the other hand meant that conclusions are based on a highly
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selective sample of ESRD patients, that may not therefore be representative of the 
general ESRD population. The study selection criteria, which are unavoidable 
requirements for studies involving NP assessments were deliberately chosen to exclude 
patients in very poor medical and psychological health and thus it is not known whether 
the observed results would be generalisable to other dialysis populations, particularly 
patients that are not adequately dialysed, or those with certain co-morbid conditions and 
medical complications. Similarly study findings may not be generalisable to non- 
English speaking populations, or more ethnically diverse groups. This highlights an 
important area of concern in psychological assessments and the need for cross-cultural 
versions of the measures to meet the needs, linguistically and culturally, of different 
ethnic groups.
Conducting further studies on the broader ESRD population, not represented in this 
study would hence be a fruitful endeavour and recruiting even larger samples to enable 
effective multigroup analysis should be pursued in future research.
2.4 Materials
Study findings are also highly dependent upon the measures used for assessing the 
variables in question.
Study measures for illness cognitions, mood, and HQoL have been subject to validation 
and standardisation and as they are widely used in the international research community 
it was possible to compare study results with many other studies. The only shortcomings 
regarding study assessment is the lack of disease-specific measures and reliance on 
exclusively self-report measures. The generic instruments used for study assessment 
may not have been sufficiently sensitive to detect differences among the subgroups. SF- 
36 for instance, is a generic measure that assesses broad concepts and may not be 
sensitive to disease or treatment specific issues as would a disease-specific instrument 
(Hays et al. 1994). The observed differences among the two TX groups in the TxEQ 
sub-scales (i.e. ‘guilt’) in absence of HQoL differences illustrate this point.
Specific problems/issues with certain sub-scales and measures are discussed below.
The Illness Perception Questionnaire and the Illness Effects Questionnaire have been 
used to assess illness cognitions. As discussed earlier (see Chapter 10; section 1.3) it is
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not clear how questionnaire items were perceived and interpreted by transplant 
recipients. Clearly more work is needed in this area to unravel the complexities of 
illness and treatment cognitions particularly in TX and to determine the meaning that 
these carry within the TX population and the best or most appropriate methods to 
measure these cognitions in the TX population.
The assessment of illness and treatment cognitions is complicated in ESRD patients due 
to comorbidity. ESRD is often the consequence of diabetes or hypertension or may 
result in the development of other comorbid conditions typically referred to as renal 
complications (e.g. bone disease; hypertension; anaemia). Renal patients present a 
spectrum of coincident diseases, which have their time courses, secondary 
complications and other disturbances. It could be maintained that these conditions 
would obscure the effect of ESRD and associated treatments on cognition and HQoL. It 
is important to consider the effect of comorbidities and other conditions when 
interpreting the results of any study. To minimise the impact of comorbid conditions 
respondents were instructed to respond to the questionnaires keeping their ESRD or 
specific treatment modality in mind (as appropriate) and adjustments for ESRD severity 
and comorbidities were made in statistical analyses. One issue to keep in mind when 
adjusting for “comorbid” conditions is that one investigator’s “comorbid” condition 
may be another investigator’s definition of a more severe level of a primary condition, 
e.g., bone disease among those with ESRD. In that case, for instance it must be kept in 
mind that the “adjustment” for bone disease takes away from the estimate of the burden 
of ESRD.
Finally there were several variables that were not assessed in the current protocol, yet 
may have been related to the ESRD outcomes examined in this work. Assessments that 
would have been interesting include personality, social support, interpersonal and 
personal expectations, coping and treatment adherence.
2.5 Questionnaire administration method
Participants’ responses to questionnaire items may be subject to experimental demand 
and social desirability, especially in interview-based assessment. Although only in a 
handful of cases the study questionnaire was read out to the participants, it is possible
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that the mere presence of the researcher during questionnaire completion/while patients 
filled in the measures might have biased their responses. On the other hand the 
inclusion/use of interviewer-administered questionnaires ensured that study 
participation would not be restricted only on patients who can complete measures on 
their own and hence the risk of selection bias against patients with older age, minority 
status and higher level of comorbidity would be lower (Unruh et al., 2003)
Section 3: Additional recommendations for future research
A summary of research recommendations presented previously and a number of yet 
unaddressed issues are presented below. The following issues could inform the future 
research agenda and greatly advance the field of psychonephrology.
3.1 Study design issues
An avenue for future research is to adopt longitudinal designs with long-term follow up 
data and repeated assessments to test the direction of causality in the relationships, and 
dynamic interactions between illness and treatment cognitions and HQoL, and to 
delineate how these variables change over time in the course of ESRD, or when patient 
switch from one treatment modality to another, such as pre- and post- transplantation or 
after a transplant failure.
From a statistical point of view a useful addition to the present analyses would have 
been to subject (correlational) data/matrices to path analyses to test mediational 
hypotheses and to determine the role of treatment cognitions within the self regulatory 
framework and the interrelations between the illness representation components and 
between illness and treatment beliefs (see Chapter 10; section 3.3).
Future research will therefore need to focus not only on longitudinal designs but also on 
elaborate statistical procedures to unravel the complex, dynamic interactions and model 
predictions. A longitudinal design coupled with such ‘advanced’ statistical techniques 
and procedures may provide a more powerful way of assessing the true relationships 
between cognitions and HQoL outcomes.
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3.2 Measures
Future studies would benefit by the use of both generic and disease-specific measures 
for the assessment of HQoL. Future studies are also encouraged to pursue assessments 
of individualised QoL to unravel the life domains or aspects that each individual 
regarded as crucial in determining his or her overall QoL, rather than baseing 
assessment solely on generic HQoL measures. HQoL instruments may also well require 
modification and refinements to address the key longer-term HQoL issues (Jamieson & 
Jamieson, 2003). In addition, qualitative approaches also have their place in ESRD 
research as they may offer more insight and a greater understanding in the issues that 
are likely to be of particular relevance and importance in ESRD patients, and in the 
different treatment groups.
Finally more work needs to be done in the area of treatment perceptions among the RRT 
groups. A study of how treatment is perceived and evaluated by patients and the 
implications of such appraisals deserves more attention, and the use of both quantitative 
and qualitative methodologies is strongly recommended.
3.3 Medication
In evaluating how the impact of treatment modality on ESRD outcomes, more attention 
should be given to other aspects of treatment regime such as prescribed medication and 
their HQoL and neuropsychological implications.
Dialysis and TX patients are typically taking numerous medications. Little is known 
about the effects of these medications on NP outcomes and HQoL and there appears to 
be great variation among hospital units in physicians’ prescription practices and in 
patients’ prescribed medication regime as well as in patients’ adherence. 
Antihypertensive medication for instance may seriously affect cognitive outcomes and 
physical well-being indicators (i.e. sexual function). While it may not be possible to 
directly control for medication effects, strategies for evaluating and minimising their 
confounding effect should be adopted in future research.
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3.4 Response Shift
Response shift is a change in the meaning of one’s self evaluation of a target construct 
as a result of (a) a change in one’s internal standards of measurements; (b) a change in 
one’s values (i.e. the importance of component domains constituting the target 
construct); or (c) reconceptualisation of the target construct (Spamgers & Schwartz 
1999). As a consequence of response shift, HQoL may remain within acceptable levels 
or improve even in the light of deteriorating physical conditions. Response shift is 
therefore a HQoL predictor and may be explained in terms of the self-regulatory theory. 
Measuring response shift would have been a valuable addition to this study. Information 
on changes in internal standards, values and conceptualisation could provide 
information on the dynamic changes in the illness and treatment beliefs/representations 
and HQoL.
3.5 Research priorities
In addition to the above generic recommendations for future research, several key 
themes emerge from the data with respect to priorities for future research.
■ Biochemical -  physiological mechanisms underlying the acute NP changes in HD. 
This study failed to explain why NP performance improved pre to 24 post-dialysis. 
Future work is needed to test alternative physiological pathways and the role of 
different molecules in predicting NP outcomes in ESRD
■ More work is also needed to explore the links between dialysis adequacy and 
cognitive functioning. Whether there is a continuous dose-response relationship 
demonstrating progressive resolution of NP deficits as a function of increased 
dialysis delivery at values of Kt/V in excess of clinical minimum standards or 
whether most NP deficits resolve at some threshold value of dialysis adequacy and 
there is little improvement with further increases, short of restoring renal function 
with transplantation remains to be determined.
■ The clinical significance of acute NP changes and NP impairments should be the 
focus of future investigations. Studies are needed to examine how, if and the extent
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to which the observed NP changes and the mild NP deficits observed in this study 
impact upon patients’ functioning and performance in the ‘real world’.
■ Subjective cognition is an intriguing area for future research. Work is needed in a 
number of research fronts.
1. There is need for laboratory work on how people appraise and respond to 
(experimentally induced) cognitive failures or successes.
2. There is also the need to work with illness populations especially patients with 
condition such as ESRD that can potentially affect cognitive functioning to understand 
how illness and treatment shape patients perceptions of cognitive abilities and if or how 
these subjective judgements change over time and in response to disease progression or 
treatment changes.
An understanding of the key processes involved in perceiving, interpreting cognitive 
changes or rating cognitive abilities and their related behavioural, emotional or other 
consequences has the potential to inform and improve understanding of patients’ 
personal model of their illness and also provide a greater insight in their experience.
■ The longitudinal effects of end-stage renal disease and associated treatments 
(dialysis; transplantation) on illness and treatment representations, cognitive 
functioning and quality of life. The important question that needs to get addressed is 
the progression of cognitive functioning and HQoL over time in both dialysis and 
transplantation and as patients switch from one form of treatment to another, for 
instance pre to post-kidney transplantation or following rejection of transplant and 
return on to dialysis treatment.
■ Studies ideally should examine neuropsychological functioning in the broader 
context of psychological health and sense of well-being. Further interdisciplinary 
research that crosses the boundaries of neuropsychology and health psychology is 
strongly recommended to unravel the complex interactions between cognitive, 
emotional, neurospychological and behavioural processes and outcomes.
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■ Potential interventions to assist patients in dealing with the complexities of 
treatment and the course of ESRD and with a view to favourably influencing HQoL 
and adjustment. These studies could potentially guided by the illness and treatment 
beliefs identified as important in this study or alternatively be more tied to a 
particular model. Although this work has identified potential targets for intervention, 
this research could explore methods for producing adaptive changes in patient 
undergoing renal replacement therapy.
■ As illness and treatment models evolve within the belief systems, social networks 
and are subject of culture influences exploring socio-cultural or ethnic differences in 
illness and treatment representations should lead to a greater understanding of their 
impact on ESRD outcomes. Future investigation would benefit form diversifying the 
research ESRD population to include different ethnic and cultural groups.
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APPENDICES
Appendix A:
Index of NP tests used in previous ESRD studies
DOMAINS NEUROPSYCHOLOGICAL TESTS
Intelligence 1. WAIS
2. Quick Test
3. Weschler Bellevue Intelligence test
4. Shipley-Hartford IQ scale
Non-verbal/visual 
memory
5. Weschler Memory Scale (WMS)
6. Memory for designs test
7. Visual Retention test
8. Rey Osterich complex figure test
9. Taylor’s complex figure test
10. Recurring Figures test
11. Benton visual retention test
12. WMS:Visual reproduction
13. Tactual performance test
14. Facial recognition memory task
15. Unspecified visual memory tasks
Verbal memory 16. Auditory short term memory task
17. WMS: Mental control
18. WMS: Logical
19. Story recall / short story recall
20. Digit span / digit retention
21. Rey Auditory Verbal Learning Test
22. Word span
23. Serial digit learning test
24. Free verbal learning task
25. Buschke selective reminder recall test
26. WMS: Paired associates
27. Enhanced cued recall
28. Whalton-Black modified word learning test
29. Contitnuous memory test
30. Unspecified verbal memory tasks
Verbal functions and 
language skills 
(e.g. reading verbal 
expression fluency)
31. WAIS Vocabulary WAIS Information
32. Alexia test
33. National Adult Reading Test (NART)
34. Schonell graded word reading test
35. Agraphia (writing verbal academic skills)
36. Visual naming test
37. Token test
38. Conttolled Oral Word Association (COWA)
39. Aphasia test/aphasia screening test
40. Repetition tasks (aphasia syllable words phrases)
41. Animal naming
42. Graded difficulty naming test
43. Color naming
44. Borkowski verbal fluency test
45. FAS
46. Word fluency (by Thurstone 1938)
47. Set test of verbal fluency (by Newcombe 1969)
48. Boston Naming test
49. Speech-Sound perception test
50. Reading comprehension task
51. Unreferenced naming tasks (by Churchill 1991 )
52. Unreferenced writing tasks (by Churchill 1991)
Attention
concentration
53. Stroop word/color test
54. TMT A
55. TMT B
56. SDMT
57. Symbol digit paired associate learning task
58. Choice reaction time
59. Visual reaction time measure
60. Number cancellation protocol
61. Corsi block tapping test
62. Digit symbol
63. PAS AT
64. Gordon diagnostic system vigilance test
65. Continuous performance test
66. Vigilance continous performance test 
computerised
67. Digit vigilance test
68. Barrage test (by Diller 1974)
69. Digits forward
70. Digits backward
71. Letter cancellation test counting As
72. Critical reaction time
73. Critical flicker fusion
74. Unspecified attention tasks
Orientation 75. Spatial relations (spatial orientation)
76. Finger agnosia (body orientation)
77. R-L confusion (body orientation)
78. time place age
Perceptual function 79. Hopper visual organisation test
80. Rhythm test
Motor function/ 
Performance
81. Luria motor sequences
82. Grip strength
83. Gibson’s spiral maze
84. Purdue Pegboard
85. Grooved Pegbgoard
86. Finger tapping
87. Apraxia
88. Mirror test
89. Unspecified motor tasks
Concept formation 
and reasoning
90. Proverbs test (by Gorham 1956)
91. Category test/computerised category test
92. Raven’s advanced progressive matrices
93. WAIS: Similarities
94. WAIS: Opposites
95. WAIS: Synonymes
96. Graded difficulty arithmetic test
97. WAIS: Arithmetic/mathematics
98. Answer recognition test
99. WAIS: Comprehension
100. Picture completion
101. Unspecified conceptual ability tests
Construction (-al 102. WAIS: Digit block
function) combines 103. WAIS: Object assemply
perceptual ability 104. Clock drawing
with motor response 105. Necker cube
106. Unspecified construction tasks
Dementia evaluation 107. Matis dementia rating scale
108. Mini mental state examination
Neuropsychological 109. Luria nebraska neuropsychological battery
batteries for 110. Halstead-reitan battery
assessm ent of brain 111. Neurobehavioral Evaluation System
function 112. Bexley Maudsley automated psychological
tests
Appendix B :
Review of studies examing the effects of erythropoietin 
anaemia corrective tretament on neuropsychological
outcomes
Study N Hct Hct Method Measures
 pre-EPO Post-EPO____________________
Wolcott 1989 HD=15 22.8 36.1
Grimm 1990 HD=15 22.7 30.6
Ctl=6
Brown 1991 HD=14 24.6 36
Marsh 1991 HD=24 23.7 36.5
Horina 1991 HD=13 18-35 20-39
Temple 1992 HD=9 Hb5.8 Hb = 9.3
Ctl=9
Sagales 1993 HD=43 N/s >30
Cttl=8
Temple 1995 CAPD= N/s Hb>10
Pickett 1999 HD=20 31.6 42.9
NP tests TMT-A, TMT-B,
SDMT,-NCP,
RAVLT, COWAT,
WAIS
BAEP Auditory Oddball
P3 TMTA, MMSE
NP tests
N1 Auditory oddball;
P2 TMT-B; SDMT;
P300 COWAT; RAVLT
NP tests
N1 Auditory oddball
P2 TMT-B; SDMT;
P300 COWAT; RAVLT
NP tests
NP tests WAIS Digit Symbol
WAIS Digit Span
NP tests NART; WAIS;
PASAT; RAVLT;
COWAT
QEEG Visual oddball
P3 WAIS subscales
NP tests
NP tests TMT-A; PASAT;
WAIS; RAVLT;
NART
QEEG Auditory oddball
ERP/BA CPT
EP
Abbreviations: HD = hemodialysis; Ctl = controls; CAPD = continuous ambulatory peritoneal 
dialysis; Hct = hematocrit; Hb = haemoglobin; n/s = not stated QEEG = qualitative 
electroencaphalogram; ERP = event related potentials; CPT = continuous performance test; 
TMT-A = Trail Making test part A; TMT-B = Trail Making test part B; COW AT = Controlled 
Oral Word Association Test; RAVLT = Rey Auditory Verbal Learning test
Appendix C: 
Study questionnaires
fJCL
M E D IC A L
S C H O O L
ST. PETER’S HOSPITAL
THE MIDDLESEX HOSPITAL
The Impact of Kidney Transplantation and Dialysis on 
People’s Lives
Questionnaires Part I
In this part of our survey we would like to obtain some information about 
you and your experience with your kidney transplant and finally we would 
like you to ask you for your views about your health and how you feel.
Your responses are confidential and the completed questionnaires will 
not be seen by any of the staff involved in your care.
Date:_____________ Code:
OCX
M E D IC A L
S C H O O L
The Impact of Kidney Transplantation and Dialysis on 
People’s Lives
C O N SEN T F O R M
(please delete as necessary)
1. I have read the information sheet about this study Yes / No
2. I have had a chance to ask questions and discuss this study Yes / No
3. I have received satisfactory answers to my questions Yes / No
4. I understand that I am free to withdraw from this study:
- at any time
- without giving a reason Yes / No
5. Do you agree to take part in this study? Yes / No
SIGNED:.__________________________________  DATE:_______________
NAME (in block letters):
RESEARCHER:
I confirm that I have explained the nature and purpose of the study to the participant:
SIGNED:
Some Details About You
Your response to the following questions about yourself (e.g. age, employment 
status) would be very helpful. Please circle one number fo r  each question or write in
the answer on the lines provided.
[1] W hat is your date of birth? (please write in) __________________________
[2] W hat is your first language? (please write in )__________________________
[3] How would you describe your ethnic background? (please circle one number)
1 B lack-C aribbean 2 B lack-A frican
3 B lack-o ther 4 Indian
5 Pakistani 6 B angladeshi
7 C hinese 8 A sian O ther
9 A rabic 10 W hite
11 O ther 12 D o not w ish to answ er
[4] How would you describe your relationship status? (please circle one number)
1 m arried  4  single
2 w idow ed 5 living w ith partner
3 d ivorced
[5] How old were you when you left full-time education? years old
[6] W hat is your highest educational qualification? (please write in)
[7] Are you now able to work for pay full-time, part-tim e not at all?
(please circle one number)
1 I am able to work for pay full-time
2 I am able to work for pay part-time
3 I am unable  to work for pay
[8a] Which of the following responses best characterises your current work 
activity or employment status? (please circle one number)
1 employed full-time 5 retired
2 employed part-time 6 looking after home and family
3 self-employed 7 student
4 unemployed 8 other
[8b] Which of the following responses best characterises your work activity or 
employment status before you received your transplant/or started dialysis?
(please circle one number)
1 employed full-time 5 retired
2 employed part-time 6 looking after home and family
3 self-employed 7 student
4 unemployed 8 other
[9] What approximately is the current estimated annual income of your overall 
family? (please circle one number)
1 £ 0  - £ 10,000 2 £ 10,001 - £ 20,000 
3 £ 20,001-£ 30,000 4 £ 30,001 - above
5 don’t wish to answer
[10] Which of the following best describes your living arrangements:
(please circle one number)
1 rent from local authority 2 rent from private landlord
3 own home 4 live with parents
5 other
[11] Do you have any long standing illness, disability or infirmity? (If yes please 
give details)
[12a] How old were you when you have been diagnosed with kidney failure?
(please write in) _________________  years old
[12b] Have you been on dialysis before you received your transplant?
(please circle one number/write in)
1 I have never been on dialysis
2 I have been on CAPD How long have you been on CAPD?_________
3 I have been on hemodialysis . How long have you been on HD?____________
[12c] When have you received your transplant? (please write in the date)________
[12d] Where have you received your transplant? (please circle one number/write in)
1 at the Middlesex Hospital
2 other hospital (please give details) ___________________________
[12e] Where does your transplant come from? (please circle one number/write in)
1 from a non-Yw'mg donor
2 from a living donor
If your transplant is from a livine donor, please give details about your relationship to 
your donor (eg. sister, father, friend) and tell us if this person is still alive:
[12f] Did you have any previous transplants? (please circle one number/write in)
1 no, this is my first transplant
2 I have had a transplant before
If you had more than one transplant please give details:
- Which organ was transplanted?
- Was the transplant from a living donor or from a non-living donor?
- When was the transplantation?
SYMPTOM QUESTIONNAIRE
Please indicate how often you experience the following symptoms as part o f  your 
condition. I f  you experience any o f these symptoms at this point in time, please tick
the last grey column on your right
1) Pain All of the 
time
Frequently Occasionally Never R IG H T
N O W
2) Nausea All of the 
time
Frequently Occasionally Never R IG H T
N O W
3) Breathlessness All of the 
time
Frequently Occasionally Never R IG H T
N O W
4) Weight loss All of the 
time
Frequently Occasionally Never R IG H T
N O W
5) Fatigue All of the 
time
Frequently Occasionally Never R IG H T
N O W
6) Stiff joints All of the 
time
Frequently Occasionally Never R IG H T
N O W
7) Sore eyes All of the 
time
Frequently Occasionally Never R IG H T
N O W
8) Headaches All of the 
time
Frequently Occasionally Never R IG H T
N O W
9) Upset stomach All of the 
time
Frequently Occasionally Never R IG H T
N O W
10) Sleep difficulties All of the 
time
Frequently Occasionally Never R IG H T
N O W
11) Dizziness All of the 
time
Frequently Occasionally Never R IG H T
N O W
12) Loss of strength All of the 
time
Frequently Occasionally Never R IG H T
N O W
13) Hair loss All of the 
time
Frequently Occasionally Never R IG H T
N O W
14) Itching All of the 
time
Frequently Occasionally Never R IG H T
N O W
15) Loss of appetite All of the 
time
Frequently Occasionally Never R IG H T
N O W
16) Poor concentration or 
mental alertness
All of the 
time
Frequently Occasionally Never R IG H T
N O W
17) Impotence or lack of sex 
drive
All of the 
time
Frequently Occasionally Never R IG H T
N O W
18) Muscle spasm or 
stiffness (including leg cramp)
All of the 
time
Frequently Occasionally Never R IG H T
N O W
19) Restless legs All of the 
time
Frequently Occasionally Never R IG H T
N O W
Symptom questionnaire continued (Transplantation supplement)
20) Weight gain All of the 
time
Frequently Occasionally Never R IG H T
N O W
21) Increased appetite All of the 
time
Frequently Occasionally Never R IG H T
N O W
22) Fever/Chills All of the 
time
Frequently Occasionally Never R IG H T
N O W
23) Flu-like symptoms All of the 
time
Frequently Occasionally Never R IG H T
N O W
24) Infections All of the 
time
Frequently Occasionally Never R IG H T
N O W
25) Diarrhoea All of the 
time
Frequently Occasionally Never R IG H T
N O W
26) llusions/Hallucinations All of the 
time
Frequently Occasionally Never R IG H T
N O W
27) Disorientation All of the 
time
Frequently Occasionally Never R IG H T
N O W
28) Excessive hair growth All of the 
time
Frequently Occasionally Never R IG H T
N O W
29) Tremor All of the 
time
Frequently Occasionally Never R IG H T
N O W
30) Extreme excitement All of the 
time
Frequently Occasionally Never R IG H T
N O W
31) Restlessness All of the 
time
Frequently Occasionally Never R IG H T
N O W
32) Clumsiness of 
movements
All of the 
time
Frequently Occasionally Never R IG H T
N O W
33) Swollen face All of the 
time
Frequently Occasionally Never R IG H T
N O W
34) Acne All of the 
time
Frequently Occasionally Never R IG H T
N O W
35) Impaired visual acuity
(eg: cataracts; glaucoma)
All of the 
time
Frequently Occasionally Never R IG H T
N O W
36) Striation or bruises All of the 
time
Frequently Occasionally Never R IG H T
N O W
37) Problems with the back All of the 
time
Frequently Occasionally Never R IG H T
N O W
38) Problems with the gums All of the 
time
Frequently Occasionally Never R IG H T
N O W
39) Numbness in the limbs All of the 
time
Frequently Occasionally Never R IG H T
N O W
40) Weak muscles All of the 
time
Frequently Occasionally Never R IG H T
N O W
41) Muscle wasting All of the 
time
Frequently Occasionally Never R IG H T
N O W
42) Other (p lease  specify ) All of the 
time
Frequently Occasionally Never R IG H T
N O W
The Short Form 36 Health Survey Q uestionnaire  (SF-36 V2)
The following questions ask for your views about your health and how you feel 
about life in general. If you are unsure about how to answer any question, try 
and think about your overall health and give the best answer you can. Do not 
spend too much time answering as your immediate response is likely to be the
most accurate.
1. In general, would you say your health is:
(Circle One Number)
Excellent................................................................................... 1
Very good ................................................................................  2
Good.........................................................................................  3
F a ir...........................................................................................  4
Poor..........................................................................................  5
2. Compared to one year ago, how would you rate your health in general 
now?
(Circle One Number)
Much better now than one year a g o .................................  1
Somewhat better now than one year ag o ........................ 2
About the same as one year ago......................................... 3
Somewhat worse now than one year ago........................ 4
Much worse now than one year ago.................................  5
2. The following items are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much?
(Circle One Number on Each Line)
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or 
playing golf
c. Lifting or carrying shopping bags
d. Climbing several flights of stairs
e. Climbing one flight of stairs
f. Bending, kneeling, or stooping
Yes, 
Limited 
a Lot
Yes, 
Limited 
a Little
2
2
2
2
No, Not 
Limited 
at All
3
3
3
3
g. Walking m ore than a mile
h. Walking half a mile
i. Walking 100 yards
j. Bathing or dressing yourself
During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities a s  a resu lt of your physical 
health?
(Circle One Number on Each Line)
a. Cut down the am ount of 
tim e you spent at work and 
other activities ?
b. Accom plished less than 
you would like ?
c. Were limited in the kind of 
work and other activities ?
d. Had difficulty performing 
the work and other 
activities?
All of Most of Some A little None
the the of the of the of the
time time time time time
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
5. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities a s  a resu lt of any emotional 
problem s (such as feeling depressed or anxious)?
(Circle One Number on Each Line)
All of Most of Some A little None
the the of the of the of the
time time time time time
Cut down the am ount of
time you spent at work and 
other activities ?
1 2 3 4 5
Accom plished less than 
you would like ?
Didn’t do work or other
1 2 3 4 5
activities a s  carefully a s  
usual ? 1 2 3 4 5
6. During the p ast 4 weeks, to what extent have your physical health or 
em otional problem s interfered with your normal social activities with 
family, friends, neighbours, or clubs?
(Circle One Number)
Not at a l l ..............................................................................  1
Slightly.................................................................................  2
Moderately...........................................................................  3
Quite a b it............................................................................  4
Extremely.............................................................................  5
7. How much bodily pain have you had during the p ast 4 w eeks?
(Circle One Number)
None..................................................................................... 1
Very mild..............................................................................  2
M ild.......................................................................................  3
Moderate.............................................................................  4
Severe.................................................................................  5
Very severe......................................................................... 6
8. During the p ast 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)?
(Circle One Number)
Not at a l l ..............................................................................  1
A little b it..............................................................................  2
Moderately...........................................................................  3
Quite a b it............................................................................  4
Extremely.............................................................................  5
9. These questions are about how you feel and how things have been with you 
during the past 4 w eeks. For each question, please give the one answer that 
comes closest to the way you have been feeling.
How much of the time during the past
All 
of the 
Time
a. Did you feel full of life?
b. Have you been a very 
nervous person?
c. Have you felt so down in 
the dumps that nothing 
could cheer you up ?
d. Have you felt calm and 
peaceful ?
e. Did you have a lot of 
energy?
f. Have you felt 
downhearted and low ?
g. Did you feel worn out?
h. Have you been a happy 
person?......
i. Did you feel tired
i. How much of your time 
has your health or 
emotional problems 
limited your social 
activities
4 w eeks
(Circle One Number on Each Line)
Most A Good Some A None
of the Bit of of the Little of the
Time the Time of the Time
Time Time
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
11 . Please choose the answer that best describes how TRUE 
of the following statements is for you.
or FALSE each
(Circle One Number on Each Line)
Definitely Mostly 
True True
Don’t
Know
Mostly
False
Definitely
False
a. I seem to get ill more easily 
than other people 1 2 3 4 5
b. I am as healthy as anybody I 
know
1 2 3 4 5
c. I expect my health to get 
worse
1 2 3 4 5
d. My health is excellent 1 2 3 4 5
IEQ
Your responses to this questionnaire help us understand how your illness (your transplant and 
any kidney related symptoms) disrupts your life. Answer each statement by circling one 
number under the description that matches your recent experience. The higher number you 
circle, the more you believe the illness disrupts your life.
I Disagree
S tro n g ly  M o d e ra te ly  S o m e w h a t A  l i t t le
I Agree
A  l i t t le  S o m e w h a t M o d e ra te ly  S tro n g ly
1. My illness makes sleeping 
difficult
0 1 2 3 4 5 6 7
2. My illness creates problems 
between myself and my family 
(or friends)
0 1 2 3 4 5 6 7
3. My sex life is suffering 0 1 2 3 4 5 6 7
4 . 1 am in pain or feel 
discomfort
0 1 2 3 4 5 6 7
5 . 1 worry about my illness 0 1 2 3 4 5 6 7
6. Some people do not take my 
illness seriously enough
0 1 2 3 4 5 6 7
7 . 1 experience many different 
symptoms
0 1 2 3 4 5 6 7
8. My appetite is poor 0 1 2 3 4 5 6 7
9. My illness is the main 
difficulty in my life
0 1 2 3 4 5 6 7
1 0 .1 don’t work as well at my 
job, in school or at my hobbies
0 1 2 3 4 5 6 7
I Disagree
S tro n g ly  M o d e ra te ly  S o m e w h a t A  l i t t le
I Agree
A  l i t t le  S o m e w h a t M o d e ra te ly  S t ro n g ly
11. My illness threatens my 
life
0 1 2 3 4 5 6 7
12. My illness requires me to 
go for frequent treatment
0 1 2 3 4 5 6 7
13. My memory or mind is not 
as good now
0 1 2 3 4 5 6 7
1 4 .1 don’t enjoy life as much 0 1 2 3 4 5 6 7
15. My illness is difficult to 
control
0 1 2 3 4 5 6 7
1 6 .1 depend on others to do 
things I used to do myself
0 1 2 3 4 5 6 7
1 7 .1 am less active now 0 1 2 3 4 5 6 7
1 8 .1 can be a burden on others 
to care for
0 1 2 3 4 5 6 7
19. At times, I wonder if I will 
ever be the person I was before 
I became ill.
0 1 2 3 4 5 6 7
20. All things considered, my 
illness disrupts my life
0 1 2 3 4 5 6 7
TEQ
Your responses to this questionnaire help us understand how your treatment disrupts your life. 
Answer each statement by circling one number under the description that matches your recent 
experience. The higher number you circle, the more you believe treatment disrupts your life.
I Disagree
S tro n g ly  M o d e ra te ly  S o m e w h a t A  l i t t le
I Agree
A  l i t t le  S o m e w h a t M o d e ra te ly  S tro n g ly
1. Treatment side-effects make 
sleeping difficult
0 1 2  3 4 5 6 7
2. This treatment is worse than 
my illness
0 1 2  3 4 5 6 7
3. Treatment side-effects 
disrupt my sex life
0 1 2  3 4 5 6 7
4. There is pain / discomfort 
from treatment
0 1 2  3 4 5 6 7
5 . 1 worry about treatment 
side-effects
0 1 2  3 4 5 6 7
6 . My life revolves around this 
treatment
0 1 2  3 4 5 6 7
7. There are many bad side 
effects
0 1 2  3 4 5 6 7
8. Treatment side-effects ruin 
my appetite
0 1 2  3 4 5 6 7
9. As a result of treatment my 
appearance has worsened
0 1 2  3 4 5 6 7
10. As a result of treatment I 
don’t work as well at my job, 
in school or at my hobbies
0 1 2  3 4 5 6 7
I Disagree
S tro n g ly  M o d e ra te ly  S o m e w h a t A  l i t t le
I Agree
A  l i t t le  S o m e w h a t M o d e ra te ly  S t ro n g ly
11. Treatment is ineffective 0 1 2  3 4 5 6 7
12.1 frequently have to visit 
the doctor or clinic for 
treatment
0 1 2  3 4 5 6 7
13. Treatment side-effects 
disrupt my memory or mind
0 1 2  3 4 5 6 7
14. Treatment prevents me 
enjoying myself
0 1 2  3 4 5 6 7
15. Treatment side-effects are 
difficult to control
0 1 2  3 4 5 6 7
16. As a result of treatment, I 
depend on others for help with 
everyday activities
0 1 2  3 4 5 6 7
17. As a result of treatment I 
am less active
0 1 2  3 4 5 6 7
18. Going for treatment can 
burden on my family or friends
0 1 2  3 4 5 6 7
19. My illness is getting worse 0 1 2  3 4 5 6 7
20. All things considered, 
treatment disrupts my life
0 1 2  3 4 5 6 7
PANAS-X
This sc a le  c o n s is ts  of a number of w ords and p h rases that d< 
different fee lin gs and em otions. Read each  item and then me 
appropriate answ er in the sp a c e  next to that word. Indicate t< 
extent vou feel th is w av riaht now, at this verv m om enl
ascribe 
irk the 
3 what
1 cheerful very slightly 
or not at all
a little moderately quite a bit extremely
2 disgusted very slightly 
or not at all
a little moderately quite a bit extremely
3 attentive very slightly 
or not at all
a little moderately quite a bit extremely
4 bashful very slightly 
or not at all
a little moderately quite a bit extremely
5 sluggish very slightly 
or not at all
a little moderately quite a bit extremely
6 daring very slightly 
or not at all
a little moderately quite a bit extremely
7 surprised very slightly 
or not at all
a little moderately quite a bit extremely
8 strong very slightly 
or not at all
a little moderately quite a bit extremely
9 scornful very slightly 
or not at all
a little moderately quite a bit extremely
10 relaxed very slightly 
or not at all
a little moderately quite a bit extremely
11 irritable very slightly 
or not at all
a little moderately quite a bit extremely
12 delighted very slightly 
or not at all
a little moderately quite a bit extremely
13 inspired very slightly 
or not at all
a little moderately quite a bit extremely
14 fearless very slightly 
or not at all
a little moderately quite a bit extremely
15 disgusted with self very slightly 
or not at all
a little moderately quite a bit extremely
16 sad very slightly 
or not at all
a little moderately quite a bit extremely
17 calm very slightly 
or not at all
a little moderately quite a bit extremely
18 afraid very slightly 
or not at all
a little moderately quite a bit extremely
19 tired very slightly 
or not at all
a little moderately quite a bit extremely
20 amazed very slightly 
or not at all
a little moderately quite a bit extremely
21 shaky very slightly 
or not at all
a little moderately quite a bit extremely
22 happy very slightly 
or not at all
a little moderately quite a bit extremely
23 timid very slightly 
or not at all
a little moderately quite a bit extremely
24 alone very slightly 
or not at all
a little moderately quite a bit extremely
25 alert very slightly 
or not at all
a little moderately quite a bit extremely
26 upset very slightly 
or not at all
a little moderately quite a bit extremely
27 angry very slightly 
or not at all
a little moderately quite a bit extremely
28 bold very slightly 
or not at all
a little moderately quite a bit extremely
29 blue very slightly 
or not at all
a little moderately quite a bit extremely
30 shy very slightly 
or not at all
a little moderately quite a bit extremely
31 active very slightly 
or not at all
a little moderately quite a bit extremely
32 guilty very slightly 
or not at all
a little moderately quite a bit extremely
33 joyful very slightly 
or not at all
a little moderately quite a bit extremely
34 nervous very slightly 
or not at all
a little moderately quite a bit extremely
35 lonely very slightly 
or not at all
a little moderately quite a bit extremely
36 sleepy very slightly 
or not at all
a little moderately quite a bit extremely
37 excited very slightly 
or not at all
a little moderately quite a bit extremely
38 hostile very slightly 
or not at all
a little moderately quite a bit extremely
39 proud very slightly 
or not at all
a little moderately quite a bit extremely
40 jittery very slightly 
or not at all
a little moderately quite a bit extremely
41 lively very slightly 
or not at all
a little moderately quite a bit extremely
42 ashamed very slightly 
or not at all
a little moderately quite a bit extremely
43 at ease very slightly 
or not at all
a little moderately quite a bit extremely
44 scared very slightly 
or not at all
a little moderately quite a bit extremely
45 drowsy very slightly 
or not at all
a little moderately quite a bit extremely
46 angry at self very slightly 
or not at all
a little moderately quite a bit extremely
47 enthusiastic very slightly 
or not at all
a little moderately quite a bit extremely
48 downhearted very slightly 
or not at all
a little moderately quite a bit extremely
49 sheepish very slightly 
or not at all
a little moderately quite a bit extremely
50 distressed very slightly 
or not at all
a little moderately quite a bit extremely
51 blameworthy very slightly 
or not at all
a little moderately quite a bit extremely
52 determined very slightly 
or not at all
a little moderately quite a bit extremely
53 frightened very slightly 
or not at all
a little moderately quite a bit extremely
54 astonished very slightly 
or not at all
a little moderately quite a bit extremely
55 interested very slightly 
or not at all
a little moderately quite a bit extremely
56 loathing very slightly 
or not at all
a little moderately quite a bit extremely
57 confident very slightly 
or not at all
a little moderately quite a bit extremely
58 energetic very slightly 
or not at all
a little moderately quite a bit extremely
59 concentrating very slightly 
or not at all
a little moderately quite a bit extremely
60 dissatisfied with self very slightly 
or not at all
a little moderately quite a bit extremely
Fatigue rating scale
Using a scale  ranging from 0 to 100 w here 0 m eans total exhaustion and 
100 m eans no fatigue at all, p lease  indicate how fatigued you are feeling 
right now by circling the  appropriate num ber:
0 25 50 75 100
I__________ I_______ i_______ i__________ I
Total Very fatigued Mediocre Good No fatigue at
exhaustion all
STAI QUESTIONNAIRE
Please read each  sta tem ent and then tick the appropriate box for each  
question  to indicate how you feel right now, a t th is very m o m en t.
Not at all Som ew hat M oderately Very m uch
a. I feel calm 2 3 4
b. I am tense 2 3 4
c. I feel upset 2 3 4
d. I am relaxed 2 3 4
e. I feel content 2 3 4
f. I am worried 2 3 4
Thank you for completing this questionnaire
OCX
M E D IC A L
S C H O O L
ST. PETER’S HOSPITAL
THE MIDDLESEX HOSPITAL
The Impact of Kidney Transplantation and Dialysis on 
People’s Lives
Questionnaires Part II
In this part of our survey we would like to obtain some information about 
how you now see your illness and your treatment. Finally we would like 
you to ask you for your views about your health and how you feel.
Filling in these questionnaires should take approximately 15-20 minutes 
and we would like to ask you to return the completed questionnaires within
the next seven days.
Your responses are confidential and the completed questionnaires will 
not be seen by any of the staff involved in your care.
Please return the completed questionnaires in the stamped and addressed
envelope provided.
Date:_____________ Code: ________
I f  you have any questions or comments please feel free to contact 
Konstadina Griva on 
T ransplant Effects Q uestionnaire
We are interested in your own personal views o f  how you now see your experience 
with your kidney transplant. These are statements other people have made about 
their transplant experience. Please indicate the extent to which you agree or 
disagree with these statements by ticking the appropriate
A
1 Sometimes I think it would have been 
better for me not to go for a transplant
strongly
agree
agree Uncertain disagree strongly
disagree
A
2 Life after transplantation meets with my 
expectations
strongly
agree
agree Uncertain disagree strongly
disagree
A
3 My quality of life is now like it was 
before my illness
strongly
agree
agree Uncertain disagree strongly
disagree
A
4 It is difficult for me to adjust to my life 
after transplantation
strongly
agree
agree Uncertain disagree strongly
disagree
A
5 After transplantation I have difficulties 
in resuming an independent role
strongly
agree
agree Uncertain disagree strongly
disagree
A
6 Transplantation is an alternative 
treatment rather than a cure for my 
illness
strongly
agree
agree Uncertain disagree strongly
disagree
A
7 Now I have more freedom than I had 
before the transplantation
strongly
agree
agree Uncertain disagree strongly
disagree
B
1 With regard to my transplant I feel that 
I am carrying around something fragile
strongly
agree
agree Uncertain disagree strongly
disagree
B
2 I am worried about damaging my 
transplant
strongly
agree
agree Uncertain disagree strongly
disagree
13
3 I keep wondering how long my 
transplant will work
strongly
agree
agree Uncertain disagree strongly
disagree
B
4
I am worried about my routine 
transplant check-ups
strongly
agree
agree Uncertain disagree strongly
disagree
B
5 I am hesitant to engage in certain 
activities because I am afraid of doing 
harm to my transplant
strongly
agree
agree Uncertain disagree strongly
disagree
C
1 I monitor my body more closely than 
before I had the transplant
strongly
agree
agree Uncertain disagree strongly
disagree
c
2 Sometimes I forget to take my anti- 
rejection medicines
strongly
agree
agree Uncertain disagree strongly
disagree
C
3 I never miss my regular transplant clinic 
check-ups
strongly
agree
agree Uncertain disagree strongly
disagree
C
4 When I am too busy I may forget my 
anti-rejection medicines
strongly
agree
agree Uncertain disagree strongly
disagree
C
5 I report all my symptoms to my 
doctor/to the transplant clinic
strongly
agree
agree Uncertain disagree strongly
disagree
C
6 Sometimes I do not take my anti­
rejection medicines
strongly
agree
agree Uncertain disagree strongly
disagree
C
7 It doesn’t matter at what time of day I 
take my anti-rejection medicines
strongly
agree
agree Uncertain disagree strongly
disagree
C
s I try to lead a healthier life than I did 
before the transplantation
strongly
agree
agree Uncertain disagree strongly
disagree
C
') Sometimes I think I do not need my stronglyagree
agree Uncertain disagree Strongly
disagree
anti-rejection medicines
I )
]
I find it difficult to adjust to taking my 
prescribed anti-rejection drug regime
strongly
agree
agree Uncertain disagree strongly
disagree
D I worry each time my anti-rejection 
drug regime is altered by my doctor
strongly
agree
agree Uncertain disagree strongly
disagree
I )
3
Dealing with the side-effects of my 
anti-rejection medicines is difficult for 
me
strongly
agree
agree Uncertain disagree strongly
disagree
D
4
I have experienced unpleasant side- 
effects with my anti-rejection medicines
strongly
agree
agree Uncertain disagree strongly
disagree
F.
1
Sometimes I think that I have ‘robbed’ 
the donor of a vital part
strongly
agree
agree Uncertain disagree strongly
disagree
E
L,
I don’t have any feelings of guilt toward 
the donor
strongly
agree
agree Uncertain disagree strongly
disagree
E
J)
The donor had to suffer to make me feel 
better
strongly
agree
agree Uncertain disagree strongly
disagree
E
4
I feel guilty about having taken 
advantage of the donor
strongly
agree
agree Uncertain disagree strongly
disagree
F
1
I think that I have a responsibility to the 
donor/the donors’ family to do well
strongly
agree
agree Uncertain disagree strongly
disagree
F I have the feeling that the donor/the 
donors’ family has some control over 
me.
strongly
agree
agree Uncertain disagree strongly
disagree
F
3
I think that I have a responsibility to the 
transplant team to do well
strongly
agree
agree Uncertain disagree strongly
disagree
F
4
Accepting an organ from another person 
has added stress to my life
strongly
agree
agree Uncertain disagree strongly
disagree
F
5
I feel that I owe the donor/the donors’ 
family something that I will never be 
able to repay
strongly
agree
agree Uncertain disagree strongly
disagree
F
6
I think that I have a responsibility to my 
friends and my family to do well
strongly
agree
agree Uncertain disagree strongly
disagree
G
I Sometimes I wonder about the 
characteristics and the life style of the 
donor
strongly
agree
Agree Uncertain disagree strongly
disagree
G
2
I am concerned that I could take on 
various qualities of the donor (e.g. 
personality/ habits/ behaviour change)
strongly
agree
Agree Uncertain disagree strongly
disagree
G
3
My transplant is a threat to my personal 
identity
strongly
agree
Agree Uncertain disagree strongly
disagree
G
4
My transplant is part of my body just 
like any other organ in my body
strongly
agree
Agree Uncertain disagree strongly
disagree
G
5
I have got the feeling that the transplant 
still belongs to the donor
strongly
agree
Agree Uncertain disagree strongly
disagree
G
6
Where the transplant comes from does 
not come into my mind at all
strongly
agree
Agree Uncertain disagree strongly
disagree
I I
1
My relationship with my family has 
deteriorated since transplantation
strongly
agree
Agree Uncertain disagree strongly
disagree
H
-> I feel resentful towards people who will 
not consider organ donation
strongly
agree
Agree Uncertain disagree strongly
disagree
H The fact of needing a transplant added 
tension to my life
strongly
agree
Agree Uncertain disagree strongly
disagree
11
4
There are bad feelings now in my 
family because of the search for a donor
strongly
agree
Agree Uncertain disagree strongly
disagree
H
5
My relationship with my family has 
become closer since transplantation
Strongly
agree
Agree Uncertain disagree strongly
disagree
H
6
The fact that I was looking for a 
transplant affected my relationship with 
friends and family
Strongly
agree
Agree Uncertain disagree strongly
disagree
1
1
I am uncomfortable with other people 
knowing that I have a transplant
Strongly
agree
Agree Uncertain disagree strongly
disagree
1
2
I avoid telling other people that I have a 
transplant
Strongly
agree
Agree Uncertain disagree strongly
disagree
1
3
When I think about the donor I get 
emotional
Strongly
agree
Agree Uncertain disagree strongly
disagree
1
4
I have difficulty in talking about my 
transplant
Strongly
agree
Agree Uncertain disagree strongly
disagree
Living Related Donor Transplantation TxEQ supplement
These are statements other people who received a transplant from  a living donor 
have made about their transplant experience. Please indicate the extent to which you 
agree or disagree with these statements by ticking the appropriate box.
L
1
I am worried more about the donor than 
I am about myself
Strongly
agree
Agree uncertain disagree strongly
disagree
L
2 I would feel guilty if anything happened 
to the donor
Strongly
agree
Agree uncertain disagree strongly
disagree
L
3
My relationship with the donor has 
deteriorated since transplantation
Strongly
agree
Agree uncertain disagree strongly
disagree
L
4
My relationship with the donor has 
become closer since transplantation
Strongly
agree
Agree uncertain disagree strongly
disagree
Cadaver Transplantation TxEQ suppplement
These are statements other people who received a transplant from  a non-living 
donor have made about their transplant experience. Please indicate the extent to 
which you agree or disagree with these statements by ticking the appropriate box.
N
1
I feel guilty because the donor is dead 
while I am still alive
strongly
agree
Agree uncertain disagree strongly
disagree
N
~) I don’t feel responsible at all for the 
donors death
strongly
agree
Agree uncertain disagree strongly
disagree
N
3
I want to have contact with the donor’s 
family
strongly
agree
Agree uncertain disagree strongly
disagree
N
4
I don’t want to know too much about 
the donor
strongly
agree
agree uncertain disagree strongly
disagree
Thank you fo r  completing this questionnaire Please turn the page
YOUR VIEWS ABOUT IMMUNOSUPPRESSIVE MEDICINES
PRESCRIBED FOR YOU
We would like to ask you about your personal views about immunosuppressive medicines 
prescribed for you. These are statements other people have made about their medicines. Please 
indicate the extent to which you agree or disagree with them by ticking the appropriate box. 
There are no right or wrong answers. We are interested in your personal views.
Views about the immunosuppressive medicines prescribed for you
8S 1 My health, at present, depends on my 
medicines
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 2 Having to take medicines worries me Strongly
agree
Agree Uncertain Disagree Strongly
disagree
A S 2 I sometimes alter the doses of my medicine to 
suit my own needs
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 3 My life would be impossible without my 
medicines
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 4 Without my medicines I would be very ill Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 5 I sometimes worry about long-term effects of 
my medicines
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 6 My medicines are a mystery for me Strongly
agree
Agree Uncertain Disagree Strongly
disagree
AS1 I sometimes forget to take my medicines Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 7 My health in the future will depend on my 
medicines
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 8 My medicines disrupt my life Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 9 I sometimes worry about becoming too 
dependent on my medicines
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
B S 1 0 My medicines protect me from becoming 
worse
Strongly
agree
Agree Uncertain Disagree Strongly
disagree
CS 11 I can cope without my medicines Strongly
agree
Agree Uncertain Disagree Strongly
disagree
Questions about taking your medicines:
A S 3 Some people forget to take their medicines. 
Overall, how often does this happen to you?
V e ry  o fte n O fte n S o m e tim e s R a re ly N e v e r
A S 4 Some sav that they miss out a dose of their 
medication, or adiust it to suit themselves. 
Overall, how often do you do this?
V e ry  o fte n O fte n S o m e tim e s R a re ly N e v e r
A S 5 Others say that they alter the dose of their 
medicines for one reason or another.
How often do you do this with your 
medicines?
V e ry  o fte n O fte n S o m e tim e s R a re ly N e v e r
IMMUNOSUPPRESSIVE MEDICINES PRESCRIBED FOR YOU
1) Azathioprine (Azathioprine; Imuran)
a) How often should you take this drug?
b) Do you think this drug causes side-effects? (If yes, please give details):
c) During the past four weeks how often have you not taken this drug?
2) Mycophenolate Mofetil (CellCept)
a) How often should you take this drug?
b) Do you think this drug causes side-effects? (If yes, please give details):
c) During the past four weeks how often have you not taken this drug?
3) Prednisolone (Prednisolone, Precortisyl Forte, Prednesol)
a) How often should you take this drug?
b) Do you think this drug causes side-effects? (If yes, please give details):
c) During the past four weeks how often have you not taken this drug?
4) Cyclosporine (Neoral; Sandimmun)
a) How often should you take this drug?
b) Do you think this drug causes side-effects? (If yes, please give details):
c) During the past four weeks how often have you not taken this drug?
5) Tacrolimus (Prograf)
a) How often should you take this drug?
b) Do you think this drug causes side-effects? (If yes, please give details):
c) During the past four weeks how often have you not taken this drug?
ILLNESS BELIEFS
We are  in te rested  in your own personal view s of how you now se e  you 
illness (condition). P lease  indicate how m uch you ag ree  or d isag ree  with 
the  following s ta tem en ts  abou t your illness by ticking the  appropria te
box.
1) The symptoms of my illness change a 
great deal from day to day
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
2) The symptoms of my illness are 
distressing to me
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
3) The symptoms of my illness are 
puzzling to me
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
4) I am aware of my symptoms all the 
time
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
5) The symptoms of my illness are 
constant
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
6) A germ or virus caused my illness Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
7) Diet played a major role in causing 
my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
8) Pollution of the environment caused 
my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
9) My illness is hereditary - it runs in my 
family
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
10) It was just by chance that I developed 
my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
11) My illness is largely due to my own 
behaviour
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
12) Other people played a large role in 
causing my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
13) My illness was caused by poor 
medical care in the past
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
14) My state of mind played a major part 
in causing my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
15) My illness will last a short time Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
16) My illness is likely to be temporary 
rather than permanent
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
17) My illness will last for a long time Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
18) My illness comes and goes in cycles Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
19) My illness is a serious condition Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
20) My illness has had major 
consequences for my life
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
21) My illness has become easier to live 
with
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
22) My illness has not had much effect Strongly Agree Neither agree Disagree Strongly
on my life agree or disagree disagree
23) My illness has strongly affected the 
way I see myself as a person
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
24) My illness has affected the way other 
people see me
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
25) My illness has serious economic and 
financial consequences
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
26) My illness will improve Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
27) There is a lot I can do to control my 
symptoms
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
28) There is very little that can be done 
to improve my symptoms
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
29) There is very little that can be done 
to improve my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
30) Recovery from my illness is largely 
dependent on chance or fate
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
31) What I do determines whether my 
illness gets better
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
32) What I do determines whether my 
illness gets worse
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
33) My treatment will be effective in 
curing/controlling my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
34) Stress was a major factor in causing 
my illness
Strongly
agree
Agree Neither agree 
or disagree
Disagree Strongly
disagree
Thank you  fo r  com pleting  th is questionnaire
Fatigue rating scale
Using a scale  ranging from 0 to 100 w here 0 m eans total exhaustion  and 
100 m eans no fatigue at all, p lease  indicate how fatigued you are  feeling 
right now by circling the  appropriate num ber:
0 25 50 75 100
|  ! |  | ________________________
Total Very fatigued Mediocre Good N ofa tgueat
exhaustion all
STAI QUESTIONNAIRE
Please read each  sta tem ent and then tick the  appropriate box for each  
question  to indicate how you feel right now, at th is very m o m e n t.
Not a t all Som ew hat M oderately Very m uch
a. I feel calm 1 2 3 4
b. I am tense 1 2 3 4
c. I feel upset 1 2 3 4
d. I am relaxed 1 2 3 4
e. I feel content 1 2 3 4
f. I am worried 1 2 3 4
PANAS-X
This sca le  c o n s is ts  < 
different feelings an 
appropria te  answ er 
ex ten t vou have
Df a num ber of w ords and p h ra se s  tha t d esc rib e  
id em otions. Read each  item and  then  m ark the  
in the  sp a c e  next to  that w ord. Indicate to w hat 
feel th is  wav riqht now. at th is  verv m om ent.
1 cheerful very slightly 
or not at all
A little moderately quite a bit extremely
2 disgusted very slightly 
or not at all
A little moderately quite a bit extremely
3 attentive very slightly 
or not at all
A little moderately quite a bit extremely
4 bashful very slightly 
or not at all
A little moderately quite a bit extremely
5 sluggish very slightly 
or not at all
A little moderately quite a bit extremely
6 daring very slightly 
or not at all
A little moderately quite a bit extremely
7 surprised very slightly 
or not at all
A little moderately quite a bit extremely
8 strong very slightly 
or not at all
A little moderately quite a bit extremely
9 scornful very slightly 
or not at all
A little moderately quite a bit extremely
10 relaxed very slightly 
or not at all
A little moderately quite a bit extremely
11 irritable very slightly 
or not at all
A little moderately quite a bit extremely
12 delighted very slightly 
or not at all
A little moderately quite a bit extremely
13 inspired very slightly 
or not at all
A little moderately quite a bit extremely
14 fearless very slightly 
or not at all
A little moderately quite a bit extremely
15 disgusted with self very slightly 
or not at all
A little moderately quite a bit extremely
16 sad very slightly 
or not at all
A little moderately quite a bit extremely
17 calm very slightly 
or not at all
A little moderately quite a bit extremely
18 afraid very slightly 
or not at all
A little moderately quite a bit extremely
19 tired very slightly 
or not at all
A little moderately quite a bit extremely
20 amazed very slightly 
or not at all
A little moderately quite a bit extremely
21 shaky very slightly 
or not at all
A little moderately quite a bit extremely
22 happy very slightly 
or not at all
A little moderately quite a bit extremely
23 timid very slightly 
or not at all
A little moderately quite a bit extremely
24 alone very slightly 
or not at all
A little moderately quite a bit extremely
25 alert very slightly 
or not at all
A little moderately quite a bit extremely
26 upset very slightly 
or not at all
A little moderately quite a bit extremely
27 angry very slightly 
or not at all
A little moderately quite a bit extremely
28 bold very slightly 
or not at all
A little moderately quite a bit extremely
29 blue very slightly 
or not at all
A little moderately quite a bit extremely
30 shy very slightly 
or not at all
A little moderately quite a bit extremely
31 active very slightly 
or not at all
A little moderately quite a bit extremely
32 guilty very slightly 
or not at all
A little moderately quite a bit extremely
33 joyful very slightly 
or not at all
A little moderately quite a bit extremely
34 nervous very slightly 
or not at all
A little moderately quite a bit extremely
35 lonely very slightly 
or not at all
A little moderately quite a bit extremely
36 sleepy very slightly 
or not at all
A little moderately quite a bit extremely
37 excited very slightly 
or not at all
A little moderately quite a bit extremely
38 hostile very slightly 
or not at all
A little moderately quite a bit extremely
39 proud very slightly 
or not at all
A little moderately quite a bit extremely
40 jittery very slightly 
or not at all
A little moderately quite a bit extremely
41 lively very slightly 
or not at all
A little moderately quite a bit extremely
42 ashamed very slightly 
or not at all
A little moderately quite a bit extremely
43 at ease very slightly 
or not at all
A little moderately quite a bit extremely
44 scared very slightly 
or not at all
A little moderately quite a bit extremely
45 drowsy very slightly 
or not at all
A little moderately quite a bit extremely
46 angry at self very slightly 
or not at all
A little moderately quite a bit extremely
47 enthusiastic very slightly 
or not at all
A little moderately quite a bit extremely
48 downhearted very slightly 
or not at all
A little moderately quite a bit extremely
49 sheepish very slightly 
or not at all
A little moderately quite a bit extremely
50 distressed very slightly 
or not at all
A little moderately quite a bit extremely
51 blameworthy very slightly 
or not at all
A little moderately quite a bit extremely
52 determined very slightly 
or not at all
A little moderately quite a bit extremely
53 frightened very slightly 
or not at all
A little moderately quite a bit extremely
54 astonished very slightly 
or not at all
A little moderately quite a bit extremely
55 interested very slightly 
or not at all
A little moderately quite a bit extremely
56 loathing very slightly 
or not at all
A little moderately quite a bit extremely
57 confident very slightly 
or not at all
A little moderately quite a bit extremely
58 energetic very slightly 
or not at all
A little moderately quite a bit extremely
59 concentrating very slightly 
or not at all
A little moderately quite a bit extremely
60 dissatisfied with self very slightly 
or not at all
A little moderately quite a bit extremely
BECK INVENTORY
On this questionnaire are groups of statements. Please read each group of 
statements carefully. Then pick out the one statement in each group which best 
describes the way you have been feeling the PAST W EEK. INCLUDING 
TODAY! Circle the number beside the statement you picked. If several 
statements in the group seem to apply equally well, circle each one. Be sure to 
read all the statements in each group before making your choice.
1. 0 I do not feel sad
1 I feel sad
2 I am sad all the time and cannot snap out of it
3 I am so sad and unhappy that I cannot stand it
2. 0 I am not particularly discouraged about the future
1 I feel discouraged about the future
2 I fell I have nothing to look forward to
3 I feel that the future is hopeless and that things cannot improve
3. 0 I do not feel like a failure
1 I feel I have failed more than the average person
2 As I look back on life, all I can see is a lot of failure
3 I feel I am a complete failure as a person
4. 0
1 I get as much satisfaction form things as I used to
2 I don’t enjoy things the way I used to
3 I don’t get real satisfaction out f anything anymore
5. 0 I don’t feel particularly guilty
1 I feel guilty a good part of the time
2 I feel guilty most of the time
3 I feel guilty most of the time
6. 0 I don’t feel I am being punished
1 I feel I may be punished
2 I expect to be punished
3 I feel I am being punished
7. 0 I don’t feel disappointed in myself
1 I am disappointed in myself
2 I am disgusted with myself
3 I hate myself
8. 0 I don’t feel I am any worse than anybody else
1 I am critical of myself for my weaknesses or mistakes
2 I blame myself all the time for my faults
3 I blame myself for everything bad that happens
9 0 I don’t have any thoughts of killing myself
1 I have thought of killing myself but I would not carry them out
2 I would like to kill myself
3 I would kill myself if I had the chance
10. 0 I don’t cry anymore than usual
1 I cry more than I used to
2 I cry all the time now
3 I used to be able to cry, but now I can’t try even though I want to
11. 0 I am more irritated now than I ever am
1 I get annoyed or irritated more easily than I used to
2 I feel irritated all the time
3 I don’t get irritated at all by the things that used to irritate me
12. 0 I have not lost interest in other people
1 I am less interested in other people than I used to be
2 I have lost most of my interest in other people
3 I have lost all my interest in other people
13. 0 I make decisions about as well as I used to
1 I put off making decisions more than I used to
2 I have greater difficulty making decisions than before
3 I can’t make decisions at all anymore
14. 0 I don’t fell I look any worse than I used to
1 I am worried that I look old and unattractive
2 I feel there are permanent changes in my appearance that make me look 
unattractive
3 I believe I look ugly
15. 0 I can work as well as before
1 It takes an extra effort to get started in the morning
2 I have to push myself very had to do anything
3 I can’t do any work at all
16. 0 I can sleep as well as usual.
1 I don’t sleep as well as I used to.
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
3 I wake several hours earlier than I used to and cannot go back to sleep.
17 0 I don’t get more tired than usual
1 I get tired more easily than I used to
2 I get tired form doing almost nothing
3 I am too tired to do anything
18. 0 My appetite is no worse than usual
1 My appetite is not as good as it used to be
2 My appetite is much worse now
3 I have no appetite at all anymore
19. 0 I have not lost much weight, if any lately
1 I have lost more than 5 pounds I am purposely trying to lose weight
2 I have lost more than 10 pounds bv eating less. YES NO
3 I have lost more than 15 pounds
20. 0 I am no more worried about my health than usual
1 I am worried about physical problems such as aches and pains; or upset 
stomach; or constipation
2 I am very worried about physical problems that is hard to think of much else
3 I am so worries about physical problems that I cannot think about anything else
21. 0 I have not noticed any recent change in my interest in sex
1 I am less interested in sex than I used to be
2 I am much less interested in sex now
3 I have lost interest in sex completely
Neuropsychological Assessment -  Transplantation T1
Date: ______________  C o d e :______________
SUBJECTIVE COGNITION SCALE
I would like to ask you some questions about how your abilities may have changed fo r  
you since your transplantation. It is very important for our understanding o f  the effects 
o f transplantation that you answer as honestly as possible.
Since the onset of Transplantation are you...
1) more or less alert and thinking more or less 
clearly
More No change Less
2) forgetting things (eg. things that have happened 
recently; where you put things; keeping 
appointments)
More No change Less
3) having more or less minor accidents (eg. 
Dropping things; tripping)
More No change Less
4) reacting more or less quickly to things that are 
said or done
More No change Less
5) having more or less difficulty in solving 
problems and learning new things
More No change Less
6) having more or less difficulty in making 
decisions
More No change Less
7) able to keep your attention to a task for more or 
less time
More No change Less
8) making more or less mistakes More No change Less
9) having more or less difficulty in doing things 
which include thought and concentration
More No change Less
1) Trailmaking A & B
Trail A: time to finish: |_|___ | :_|___ |___ | : |___ |__ |
Trail B: time to finish: j_ |__ j :_j__ |__ | : |__ |__ |
2) Symbol Digit Modalities Test
Written assessment:_____ |_|____ |____ |
Oral assessment::
3) Rey Auditory Verbal Learning Test
Triall\___| Trial2\___| Trial 3 \_ Trial4\___| Trial5\___| Trial6\___|
Trial7\___|
4) G rooved Pegboard
dom inant hand? (dominant hand trail is administered first)
Dominant hand: 1 1 l : l 1 h i  1 1 drops: |
Non-dominant hand: 1 . 1 h  1 1 -h i 1 1 drops: \......|
6) F istu la right arm |__| left arm |__|
Neuropsychological Assessment -  DIALYSIS T1
Date:__________________  Code: _______
SUBJECTIVE COGNITION SCALE
I would like to ask you some questions about how your abilities may have changed fo r  
you since you started on dialysis. It is very important for our understanding o f the 
effects o f  dialysis that you answer as honestly as possible.
Since the onset of dialysis are you...
1) more or less alert and thinking more or less 
clearly
More No change Less
2) forgetting things (eg. things that have happened 
recently; where you put things; keeping 
appointments)
More No change Less
3) having more or less minor accidents (eg. 
Dropping things; tripping)
More No change Less
4) reacting more or less quickly to things that are 
said or done
More No change Less
5) having more or less difficulty in solving 
problems and learning new things
More No change Less
6) having more or less difficulty in making 
decisions
More No change Less
7) able to keep your attention to a task for more or 
less time
More No change Less
8) making more or less mistakes More No change Less
9) having more or less difficulty in doing things 
which include thought and concentration
More No change Less
1) Trailm aking A & B
Trail A: time to finish:___|__| | : |___ | | : |___|___ |
Trail B: time to finish: |__| | : |___ | | : |___|___ |
2) Sym bol Digit M odalities T est
Written assessment:_____ |_|_____|___ j
Oral assessment:: |_|_____|___ |
3) Rey Auditory Verbal Learning Test
Trial! \___ | Trial2\ | Trial 3 \___| Trial4\___ | Trial5\___ | Trial6\___ |
Trial7\ j
4) Benton Visual Retention test
No correct: ___________ No o f  errors: ___________ Type o f  errors:,
5) Grooved Pegboard
dom inant hand? (dominant hand trail is administered first)
Dominant hand: 1 1 h i  1 h i  1 drops: |
Non-dominant hand: 1 1 h i  1 h i  1 1 drops: | |
6) Fistula right arm |__| left arm |__|
Neuropsychological Assessment -  DIALYSIS T2
Date:_____________  Code: _________
SUBJECTIVE COGNITION SCALE
I  w ou ld  like to ask you  som e questions about how  yo u r  ab ilities m ay have changed  fo r  
you since your last dialysis session. It is very im portant fo r  o u r  understanding  o f  the  
e ffec ts  o f  d ia lysis tha t you  answ er as honestly  as possible.
Since your last dialysis session are you...
1) more or less alert and thinking more or less 
clearly
More No change Less
2) forgetting things (eg. things that have happened 
recently; where you put things; keeping 
appointments)
More No change Less
3) having more or less minor accidents (eg. 
Dropping things; tripping)
More No change Less
4) reacting more or less quickly to things that are 
said or done
More No change Less
5) having more or less difficulty in solving 
problems and learning new things
More No change Less
6) having more or less difficulty in making 
decisions
More No change Less
7) able to keep your attention to a task for more or 
less time
More No change Less
8) making more or less mistakes More No change Less
9) having more or less difficulty in doing things 
which include thought and concentration
More No change Less
1) Trailm aking A & B
Trail A: time to finish: 1 I 1:1 1 1:11 1 1 ( ■ ■ ■ ■
Trail B: time to finish: | | | : | 1 h i 1 1 1
2) Symbol Digit Modalities Test
W ritten assessm en t: | |
O ral a ssessm en t:: I I
3) Rey Auditory Verbal Learning Test
T ria l] \___| Tria l2 \___| Tria l3 \___| Tria l4 \___| T ria l5 \___| T ria l6 \___|
T ria l7 \___j
4) Benton Visual retention te s t
N o correct:   N o o f  errors:
Type o f  errors: ________________________
5) G rooved Pegboard
dom inant hand? (d o m in a n t h a n d  tra il is adm in is tered  f i r s t )
D o m in a n t hand: 1- 1 h i  1 l : l 1 1 drops: |
N o n -d o m in a n t hand: 1 1 h i  1 I ' l  1 1 d ro p s: | |
Appendix D:
Medical measures recorded for the study
RENAL STUDY MEDICAL DOCUMENTATION 
Date of assessment: Code:
please refer to clinical notes/values that are closest to the date of assessment
Primary kidney disease diagnosis (please circle all that apply) 
date:____ (day)_____(month)_____(year)
hypertension 1
diabetes 2
polycystic kidney disease 3
chronic glumeronephritis 4
chronic pyelonephritis 5
reflux nephropathy 6
other (please specify) 7 _________
Renal Replacement treatment onset
date : ____ (day)_____(month)_____(year)
Comorbidity:
•  diabetes ( y / n ) .......................................... (IDDM/NIDDM )
•  hypertension ( y / n )
• Ischemic Heart disease ( y / n )  (please specify if necessary)
•  OTHER COMORBID CONDITIONS (PLEASE LIST IF ANY)
Medication (dosages): EPO  units per week
______ m gs________ m gs_______ m gs_________mgs
_______m gs________ m gs_______ m gs_________mgs
_______m gs________ m gs_______ m gs_________mgs
Hospitalisation episodes in the preceding 6-8 months: (y I n)
• Access site problems (HD patients o n ly ) (y /n )
•  hospitalisation due to access problems (y / n)
•  procedures performed due to access problems (y /n )  ... ... (please specify)
• catheter site problems (PD pts only) ( y / n )
•  hospitalisation due to access problems (y /n )
•  procedures performed due to access problems (y / n) (please specify)
Current dialysis of TX treatment
CAPD 1 exchanges per day
litres per exchange 
types of bags
APD 2 hours per day
total volume 
fill volume 
no of cycles
Hemodialysis 3 times a week
hours per run 
dialysate used 
blood flow rate 
ACCESS
Dialysis History (if details available):
dialysis
period
type of dialysis 
treatment
date of onset of dialysis 
period
Date of discontinuation of 
dialysis period
number 1
number 2
number 3
ACTIVE TRANSPLANTATION LIST (y I n)
If no why (please write in_____________________
Residual Urine Function (y/n) ____
ID W G _________________________________
RENAL STUDY 
RENAL STUDY MEDICAL DOCUMENTATION 
Date of assessment: Code:
please refer to clinical notes/values that are closest to the date ot assessment
OUTPATIENTS APPOINTMENT:
URINE: please tick out of range values
Creatinine nmol/L | |
Total Protein 2Ih  (0-0.1)
Total Protein mg/mmol creat(0-13)
SERUM:
Urea mmol/L (2.8-7.6) | |
Bicarbonate mmol/L (20-30)
Sodium mmol/L (136-145)
Potassium mmol/L (3.3-4.8)
Bilirubin Total umol/L (3-17)
Creatinine umol/L (62-133)
Calcium mmol/1 (2.20-2.60)
Inorganic Phosphate mmol/L (0.7-1.5)
Alkaline Phosphatase U/L (45-122)
Alanine Transaminase U/L (7-63)
Gamma Glutamyl Transferase U/L(11-50M 7-32F)
Albumin g/L (35-50) | |
DRUG BLOOD LEVELS: 
Cyclosporin: ug/L | |
Tacrolimus - ug/L
HAEMATOLOGY:
WBC
RBC
HB
HCT
MCV
MCH
MCHC
PLT
NEU xlOA9 
LYM xlOA9 
MON xlOA9 
EOS xlOA9 
BAS xlOA9 
NEUTS % 
LYMPHS % 
MONOS % 
EOSINOS % 
BASOS %
Appendix E:
Open ended questions used in focus groups discussion for the 
development of Transplant Effects Questionnaire (TxEQ)
IMPACT OF TRANSPLANTATION
•  W hat are the m ost im portant effects on you o f having a transplant
•  A re you happy about your decision to have a transplant
•  D id /D oes life after transplantation m eet w ith your expectations
W ould  you decide to do it again
W ould  you recom m end it to others
•  D o you have any m ajor concerns regard ing  you transplant
•  W hat aspect o f you transplant w ere you m ost afraid  o f before  the transplnat
•  A fter the operation, w hat w ere m ost anxious about
•  W ere there o ther problem s that you have experienced  in relation to your treatm ent/
in relation to your recovery
• D o you w orry  about the effect o f im m unosuppressants
•  D o you th ink o f kidney transplantation as an alternative treatm ent or a cure ESR D
D ependence on dialysis treatm ent dependency on im m unosuppressive drugs
• T o  w hat degree does the fear o f losing the k idney rem ain significant
•  D id /have you experienced  any ad justm ent challenges fo llow ing  discharge form
hospital
•  H as your transplant affected you view  o f your body (your body im age)
•  D id  you take up lots o f activities after your transplant
TYPE OF RENAL REPLACEMENT TREATMENT
•  D o you th ink that transplantation is a m ore satisfactory treatm ent for E SR D  than 
dialysis
•  D o you see the transplant as a release from  the constrain ts o f d ialysis and as a 
return to a life o f freedom
• Is there anyth ing  you lost when you left d ialysis/anyth ing  you m iss about dialysis
INTERPERSONAL ATTITUDES-DEPENDENCY INDEBTNESS GUILT AND 
BODY IMAGE
•  D o you feel indebted to the donor in any w ay
• Is there a dependency  betw een recip ien t and donor (e.g. issues o f  unrepayable 
obligation and proprietorial investm ent)
•  D o you th ink you have responsib ility  for doing well (e.g. not rejecting  the kidney, 
going back to w ork)
•  D o you th ink  the transplan ted  kidney  is your kidney, or does it belong  to the donor, 
o r both
•  Are you concerned  that you could  take on various qualities o f  the donor 
(personality /habits/behaviour change)
•  H ave you ever referred  to the k idney  as the dono r’s (if so w hen)
TYPE OF TRANSPLANT
• W as the type o f transplant im portan t (LR D ;LU R D ;C A D ). In w hat and w ould  you 
have preferred  another type o f transplan t
•  W ere there characteristics about the donor (e.g. age gender) w hich w ere im portant 
to you
INTERPERSONAL ATTITUDES: CADAVER TX
•  W hat do you know  about the donor
•  D oes it w orry  you that you do not know  m ore about the donor
•  D o you feel uncom fortable about being alive w hile the donor fam ilies’loved one is 
dead
•  H ow  m uch contact d id  you have w ith the donor fam ily
•  D id /do  you feel ob ligated / do you have the desire to m eet the do n o r’s fam ily
•  H ow  m uch contact d id  you have w ith the dono r’s fam ily
•  D o you fear that the donor fam ily m ight w ant som e invo lvem ent in your life
•  D o you feel indebted tow ards the donor and his/or her fam ily
•  D id  w aiting for the death o f an unknow n person caused  strong feelings
•  D o you ever think about the origin o f  the cadeveric k idney/ the donor and his or her
fam ily
• D id  you ever w onder about the characteristics o f the donor, and if  so, which 
characteristics do you th ink about
INTEPERSONAL ATTITUDES: LRD TX: RELATIONSHIP RECIPIENT- 
DONOR
•  H ow  w ould  you describe your rela tionship  with the donor o f your k idney
• H ave there been any changes in your relationship  with the donor since transplant
•  H ow  has the act o f donation affected  your relationship  w ith the donor and your 
fam ily
•  H as the do n o r’s in terest in your life changed
•  D o you som etim es w ish you had received  a cadaveric k idney instead o f a kidney 
form  a living related  donor
•  D o you th ink that the donor has given up som ething which is part o f h im /her for 
no th ing  in return
•  A re there any conflicts w ithin you fam ily  because o f donation (or because o f refusal 
to donate)
•  W as it painful for you to d iscover w hich fam ily  m em bers w ere w illing  to donate and 
w hich w ere not w illing  to donate
•  H ave the fam ily  relationships changes after donation
•  W as it d ifficu lt for you to ask your fam ily  to donate a k idney
•  D o you th ink  your fam ily  has been b rought together by the transplan t experience or 
not
•  H ow  w ould  you describe your feelings tow ards the donor
INTEPERSONAL ATTITUDES: LRD TX: PERCEIVED HEALTH OF DONOR
•  D o you have guilt feelings tow ard the donor for the pain and suffering inflicted
•  D o you have w orries about the long-term  im pact o f donation on the dono r’s Q oL 
and acute (or long term ) changes as a result o f surgery
•  D o you have a feat that donating a kidney will m ake the donor m ore vulnerable to 
possib le developm ent o f k idney d isease
INTEPERSONAL ATTITUDES: LRD TX: RELATIONSHIP RECIPIENT- 
DONOR
H ow  w ould  you describe your feelings tow ards the nondonors 
D o you feel anger tow ards the non donors
D o you th ink that the decision not to donate is understandable and excusable
Appendix F:
NP scores at Time 1 and Time 2 assessment in the four 
dialysis groups: hospital HD -  Home HD -  CAPD - APD
Hospital HD Home HD CAPD APD
T1 T2 T1 T2 T1 T2 T1 T2
TMT A M 58.76 48.56 43.27 38 52.03 48.06 47.48 44
Sd 42.28 36.21 21.01 34.07 22.61 45.52 31.92 30.43
TMTB M 102.76 94.13 87.84 81.463 102.83 107.1 92.43 87.23
Sd 60.46 58.19 33.49 4.07 42.25 45.52 49.51 47.15
SDMT-W M 41.02 47.67 40.72 45.92 39.33 42.39 45.17 48.91
Sd 13.05 16.01 10.72 13.58 12 14.68 13.29 13.66
SDMTO M 46.08 52.81 50.64 40.72 42.91 45.98 48.83 53.3
Sd 14.65 17.24 15.35 10.72 12.86 16.43 13.37 13.93
RAVLT-T M 39.86 43.71 43.16 45.28 37.84 38.31 40.22 40.65
Sd 12.51 12.51 10.3 13.55 9.19 8.13 9.19 9.82
RAVLT 1 M 5.17 6.02 5.08 5.32 4.73 4.8 5.09 5.65
Sd 1.84 2.07 1.49 1.6 1.34 1.31 1.44 1.49
RAVLT 2 M 7.27 7.88 5.32 6.84 6.93 6.83 7.09 7.52
Sd 2.43 2.59 1.6 2.3 1.76 1.73 2.06 1.81
RAVLT 3 M 8.23 8.96 7.96 9.04 8 8.27 8.22 8.48
Sd 2.91 3.01 2.33 2.35 2.35 1.66 2.09 2.37
RAVLT 4 M 9.29 10.21 9 9.96 8.84 8.9 9.57 8.87
Sd 3.19 3.02 3 2.47 2.52 2.29 2.59 2.56
RAVLT 5 M 9.88 10.63 9.48 10.84 9.33 9.51 10.26 10.13
Sd 3.27 3.17 3.17 2.88 2.63 2.5 2.38 2.51
RAVLT-D M 2.22 2.46 2.64 3 2.67 3.07 2.91 2.95
Sd 1.71 2.2 1.68 1.82 2.20 1.51 2.23 1.82
GP DOM M 93.5 89.18 78.78 76.82 95.66 96.73 89.73 83.04
Sd 34.5 33.41 11.82 12.68 31.97 33.36 38.88 28.38
GP NDOM M 104.68 98.56 91.03 88.93 105.65 109.67 102.56 91.29
Sd 39.44 39.35 19.18 19.72 40.68 42.82 49.82 30.53
BVRT-C M 5 5.79 5.24 6.36 4.15 4.73 5.91 5.39
Sd 2.51 2.47 1.83 1.91 1.62 1.45 2.13 2.14
BVRT-E M 9.17 6.71 7.52 6.4 9.46 8.28 6.52 6.95
Sd 5.96 5.50 4.11 4.96 3.94 3.29 4.99 4.67
NP-TO M -.334 .712 1.36 1.79 -1.35 -2.52 1.65 1.02
Sd 8.97 8.98 5.38 5.34 5.97 6.07 7.37 6.23
Note. T1 = time 1 assessment; T2 = time 2 assessment; TMT-A = trail making test part A; 
TMT-B = trail making test part B; SDMT-W = symbol digit modality test written 
administration; SDMT-0 = symbol digit modality test oral administration; RAVLT-T = Rey 
Auditory Verbal Learning Test total word recall at trial 1 to 5; RAVLT-D = Rey Auditory 
Verbal Learning Test drop in retention from trial 5 to 7; BVRT-C = Benton Visual Retention 
Test number of correct reproductions; BVRT-E = Benton Visual Retention Test number of 
reproduction errors; GP-DOM = Grooved Pegboard dominant hand; GP-NDOM = Grooved 
Pegboard non dominant hand; NP-TO = total NP performance score
a = Time to completion in seconds. b = number correct.c = number of errors. d = total of the 10 
NP indices (z-scores)
Appendix G
Norms and definition of neuropsychological impairments 
used in comparing group and individual neuropsychological 
scores to test norms/normative data
Group mean based 
classification
Individual mean based 
classification
Age Norm NP Age Norm NP 
deficit deficit
>49 20s+30s >42
secs 40s >45
50s 
60s 
70s
>135 20s+30s
TMT-A
Norms by: 
Davies 1968
TMT-B
Norms by 
Davies 1968
SDMT-W
Norms by: 
Centofant & Smith 
1979
SDMT -  O
Norms by 
Centofant & Smith 
1979
GP-DOM
Norms by 
Bornstein 1985
GP-NDOM
No
rms by
Bornstein 1985
RAVLT-T male
Norms by 
Gefen et al. 1990
50s
45 - 54 46.8±8.4 
yr
45 - 54 54.5±9.1 
yr
40 - 59 68.1±10.6 
yr
40 - 59 74.2±15.6 
yr
50 - 59 47.6 ±8.5 
yr
secs 40s
50s 
60s 
70s
< 38 .4  18-24 yr
25-34 yr 
35-44 yr 
45-54 yr 
55-64 yr 
65-74 yr
<45.4 18-24 yr
25-34 yr 
35-44 yr 
45-54 yr 
55-64 yr 
65-74 yr
>83.6 20-39 yr
40-59 yr 
60-69 yr
>89.9 20-39 yr
40-59 yr 
60-69 yr
16-19 yr
20-29 yr
30-39 yr
40-49 yr
50-59 yr
60-69 yr
^ 70 yr
>49
>67
>105
>94
>100
>135
>173
>292
55.2 ±7.5 <47.7
53.6 ±6.6 <47
51.1 ±8.1 <43
46.8 ±8.4 <38.4
41.5 ±8.6 <32.9
37.4 <26
±11.4
62.7 ±9.1 <53.6
61.2 ±7.8 <53.4
59.7 ±9.7 <50
54.5 ±9.1 <45.4
48.4 ±9.1 <39.3
46.2 <33.4
±12.8
60.9 >77.1
±16.2 >83.6
68.6 >90.1
±15.0
75.5
±14.6
66.2 >83.3
±17.1 >89.9
74.2 >98.6
±15.7
83.1
±15.5
53.4 ±5.4 <48
54.9 ±7 <47.9
46 ±10.9 <35.1
47.5 ±8.3 <39.2
47.6 ±8.5 <39.1
36.7 ±8.4 <28.3
32.6 ±8.3 <24.3
RAVLT-T 5 0  - 59 4 7 .6  ± 7 .7  < 3 9 .8  16-19  yr 5 6 .5  ± 6 < 5 0 .5
Female yr 2 0 -2 9  yr 5 5 .3  ± 6 .6 < 4 8 .7
3 0 -3 9  yr 5 5 .9  ± 6 .3 < 4 9 .6
Norms by 4 0 -4 9  yr 52 .1  ±7 .1 < 45
Gefen et al. 1990 5 0 -5 9  yr 4 7 .6  ± 7 .7 < 3 9 .8
6 0 -6 9  yr 4 9  ±7 .1 < 4 1 .9
£ 7 0  yr 4 1 .6  ± 6 .6 < 35
BVRT-C 45  -  5 4 7 < 7  15-44  yr 8 < 8
Norms by yr 4 5 -5 4  yr 7 < 7
Benton 1974 5 5 -6 4  yr 6 < 6
BVRT-E 4 0  -  54 4  > 4  15-39  yr 3 > 3
Norms by yr 4 0 -5 4  yr 4 > 4
Benton 1974 5 5 -5 9  yr 5 >5
6 0 -6 4  yr 6 > 6
Note. T M T -A  = trail m aking test part A; T M T -B  =  trail m aking test part B; S D M T -W  =  sym b ol 
d ig it m odality  test written adm inistration; S D M T -0  = sym b ol d ig it m od a lity  test oral 
adm inistration; R A V L T -T  =  R ey A ud itory  V erbal L earning T est total w ord recall at trial 1 to 5; 
R A V L T -D  =  R ey  A uditory V erbal L earning T est drop in retention  from  trial 5 to  7; B V R T -C  =  
B enton  V isu al R etention  T est num ber o f  correct reproductions; B V R T -E  = B en ton  V isu al 
R eten tion  T est num ber o f  reproduction errors; G P -D O M  =  G rooved  Pegboard dom inant hand; 
G P -N D O M  = G rooved  Pegboard  non dom inant hand; yr =  years
Appendix H:
ANCOVA comparisons: diabetes, employment and absolute 
neurospychological scores at Time 1 and Time 2 
assessments (combined dialysis sample)
Variable Direction NP test Df F p  value
Diabetes Poorer GP-DOM T1
T2
3, 140 
3, 135
15.408
13.543
.0001
.0001
Poorer GP-
NDOM
T1
T2
3, 140 
3,135
14.295
12.091
.0001
.001
Poorer SDMT-W T1
T2
3, 141 
3, 137
7.789
6.897
.006
.010
Poorer SDMT-O T1
T2
3, 141 
3, 137
8.236
7.649
.005
.006
Poorer RAVLT-T T1
T2
3, 141 
3, 137
13,319
4.099
.0001
.045
Poorer TMT A T1
T2
3, 141 
3, 137
9.095
9.102
.003
.003
Poorer TMTB T1
T2
3, 141 
3, 137
4.732
7.467
.031
.007
Employment Better GP-DOM T1
T2
4, 140 
4, 134
4.937
4.724
.028
.031
Better GP-
NDOM
T1
T2
4, 140 
4, 134
11.005
10.574
.001
.001
Better BVRT-CO T1
T2
4, 140 
4, 137
10.180
5.571
.002
.02
Better BVRT-ER T1
T2
4, 140 
4, 137
10.566
5.573
.001
.02
Better SDMTW T1
T2
4, 140 
4, 136
18.792
16.730
.0001
.0001
Better SDMT O T1
T2
4, 140 
4, 136
16.558
13.734
.0001
.0001
Better TMT A T1
T2
4, 140 
4, 136
14.165
10.882
.0001
.001
Better TMTB T1
T2
4, 140 
4, 136
7.730
10.810
.006
.001
Note. T1 = time 1 assessment; T2 = time 2 assessment;; TMT-A = trail making test part A; 
TMT-B = trail making test part B; SDMT-W = symbol digit modality test written 
administration; SDMT-O = symbol digit modality test oral administration; RAVLT-T = Rey 
Auditory Verbal Learning Test total word recall at trial 1 to 5; RAVLT-D = Rey Auditory 
Verbal Learning Test drop in retention from trial 5 to 7; BVRT-C = Benton Visual Retention 
Test number of correct reproductions; BVRT-E = Benton Visual Retention Test number of 
reproduction errors; GP-DOM = Grooved Pegboard dominant hand; GP-NDOM = Grooved 
Pegboard non dominant hand; NP-TO = total NP performance score
a = Time to completion in seconds. b = number correct.c = number of errors. d = total of the 10 
NP indices (z-scores)
* p < .05. ** p < .01. *** p < .001.
Appendix I:
Sociodemographic and medical characteristics in 
cyclosporin and tacrolimus-treated transplant patients
Cyclosporin TX 
(N =  70)
Tacrolimus TX 
(N = 40)
M(SD) % (N) M(SD) % (N)
A g e 5 2 . 5 2 ( 1 2 . 6 7 ) 4 7 . 2 0 ( 1 1 . 8 4 )
G e n d e r  (%  fe m a le ) 3 2 .9 %  ( 2 3 ) 5 0 %  ( 2 0 )
E th n ic ity  (%  w h ite ) 8 2 .9 %  ( 5 8 ) 8 2 .5 %  ( 3 3 )
% M a rr ied 7 1 .4 %  ( 5 0 ) 57=5%  (5 7 .5 % )
% E m p lo y e d  ( f /t , p /t  p o s t - T X ) 4 9 .3 %  (3 3 ) 4 7 .5 %  ( 1 9 )
% E m p lo y e d  ( f /t , p /t  p r io r -T X ) 7 7 .6 %  ( 5 2 ) 4 7 .5 %  ( 1 9 )
% A b le  to  w o r k  ( f /t ,  p /t) 7 2 .1 %  ( 4 9 ) 6 6 .7 %  ( 2 6 )
I n c o m e
% 0  - £ 1 0 , 0 0 0 1 7 .1 %  ( 1 2 ) 3 3 .3 %  ( 1 2 )
% £  1 0 ,0 0 1  - £ 2 0 , 0 0 0 1 5 .7 %  ( 1 1 ) 3 0 .6 %  ( 1 1 )
% £  2 0 ,0 0 1  - £  3 0 ,0 0 0 1 8 .6 %  ( 1 3 ) 1 6 .7 %  (6 )
% £ 3 0 ,0 0 1  a n d  a b o v e 3 0 %  ( 2 1 ) 1 9 .4 %  (7 )
% n o t  w is h  to  a n sw e r 18 .6 %  ( 1 3 )
E d u c a t io n  (y e a r s ) 1 0 .8 8  ( 3 .6 6 ) 1 1 .5 8  ( 3 .8 0 )
T im e  w ith  T X  (m o n th s ) 8 3 .0 3  ( 4 4 .7 9 ) 2 4 .0 7  ( 3 9 .7 4 )
T im e  R R T  (m o n th s ) 1 1 7 .2 7  ( 7 1 .5 3 ) 7 7 .4 7  ( 6 0 .0 9 )
T im e  D L  (m o n th s ) 2 5 .2 3  ( 2 7 .7 0 ) 4 2 .6 1  ( 3 6 .8 9 )
E S R D  se v e r ity 7 .9 3  ( 7 .5 6 ) 2 .9 5  ( 1 .8 8 )
N u m b e r  o f  c o m o r b id it ie s 3 .2 8  ( 1 .6 5 ) 8 .5 8  ( 8 .8 8 )
G lo m e r u la r  F iltra tio n  R a te 3 7 .9 8  ( 1 1 .5 8 ) 4 0 . 6 2 ( 1 6 . 3 6 )
% d ia b e te s 1 .4%  ( 1 ) 12 .5 %  (5 )
% H y p e r te n s io n 9 1 .4 %  ( 6 4 ) 85%  ( 3 4 )
% H ea rt D is e a s e 3 0 %  ( 2 1 ) 2 2 .5 %  (9 )
% P a st  R e je c t io n  (%  y e s ) 50 %  (3 5 ) 2 5 %  ( 1 0 )
P r im a r y  k id n e y  d is e a s e
% G N 2 1 .4 %  (1 5 ) 10%  (4 )
% A K P D 14 .3 %  ( 1 0 ) 10%  (4 )
% R e f lu x  n e p h r o p a th y 8 .6 %  (6 ) 15%  (6 )
% I g A  n e p h r o p a th y 5 .7 %  (4 ) 7 .5 %  (3 )
% O b str u c t iv e  u ro p a th y 5 .7 %  (4 ) 2 .5 %  (1 )
% D ia b e te s 1 .4%  (1 ) 10%  (4 )
% h y p e r te n s io n 7 .1 %  ( 5 ) 1 2 .5 %  (5 )
Note-. TX = transplantation; f/t = full time; p/t = part time; RRT = renal replacement therapies; 
DL = dialysis; ESRD = end stage renal disease; GN = glumeronephritis; APKD = adult 
polycystic kidney disease
Appendix 3 :
Multiple regressions to predict HQoL in dialysis with mood 
entering before beliefs: standardised regression coefficients 
(3)/ cumulative explained variance (R2) and cumulative 
adjusted variance (Adj. R2)
PCS MCS
P R Adj.R2 p R2 Adj.R2
Block 1
Work Status .140* .212 .206
Age -.165* .295 .285
Education
Gender .105 ns .035 .029
Income
Block 2
Dialysis group .162* .075 .062
ESRD severity -.248*** .408 .395
Kt/V .125* .438 .422
Albumin .076 ns .458 .439
Haemoglobin
Block 3
NP functioning
NP impairments
SCS TO -.010 ns .475 .452 -.141 ns .194 .177
Block 4
CDI -.218** .549 .526 -.356**** .348 .329
Block 5
IEQ -.245*** .587 .563
TEQ -.181* .370 .347
IPQ consequences
IPQ control
IPQ identity
Note: PCS = physical component score (SF-36); MCS = mental component score (SF-36); 
ESRD = end-stage renal disease; Kt/V = dialysis adequacy; NP = neuropsychological; SCS-TO 
= subjective cognition summary score (cognitive complaints); CDI = cognitive depression 
index; IEQ = illness intrusiveness; TEQ = treatment intrusiveness 
* p < .05. ** p < .01. *** p < .001. ns = non significant
Appendix K:
HQoL in LRD and CAD TX recipients in the combined TX 
sample recruited from MIDDX and RFH hospital transplant
units
LRD CAD
SF-36 subscale Mean (SD) Mean (SD) F p value
General Health 43.42(11.84) 42.41 (12.55) .654 .420
Physical functioning 45.51 (12.83) 38.75 (15.80) 2.035 .155
Social functioning 44.71 (8.92) 43.03 (9.60) 1.149 .285
Role physical 45.56 (12.32) 40.99(15.13) 1.304 .255
Role emotional 47.55 (11.4) 46.06(13.31) .699 .404
Bodily Pain 49.49(11.53) 46.87 (15.75) .721 .397
Vitality 51.20(8.16) 51.50(12.53) .957 .329
Mental Health 48.74 (9.41) 50.12(10.06) .227 .635
Physical Component Score 45.12(12.83) 40.11 (15.30) .351 .554
Mental Component Score 48.94 (7.56) 50.78 (9.37) .233 .630
Note\ LRD = living related donor transplant recipients; CAD = cadaver transplant 
recipients
Appendix L:
Multiple regressions to predict PCS and MCS in TX with 
mood entering before beliefs
PCS MCS
3 R* Adj.R2 3 R2 Adj.R2
Block 1
Work Status .040 ns .204 .197
Education
Age -.2 0 0 ** .270 .257 .299*** .073 .065
Income .182** .302 .283
Block 2
ESRD severity - 3 4 2 **** .462 .443
GFR .149 ns .124 .109
Albumin
Haemoglobin .151* .535 .514
Block 3
NP functioning
NP deficits
SCS-TO
Block 4
CDI -.273** .227 206
PNS PA
Block 5
IEQ - 254**** .630 .610
TEQ
IPQ
consequences
IPQ control
IPQ identity-x -.199** .658 .636
BMQ-concems -.214* .269 .243
TX worry
Note: PCS = physical component score (SF-36); MCS = mental component score (SF-3<
ESRD = end-stage renal disease; GFR = glomerular filtration rate; NP = neuropsychologic
SCS-TO = subjective cognition summary score (cognitive complaints); CDI = cognitive 
depression index; PNS PA = PANAS positive affect; IEQ = illness intrusiveness; TEQ = 
treatment intrusiveness; TX worry = TxEQ worry about the transplant subscale 
* p < .05. ** p < .01. *** p < .001. ns = non significant
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The Transplant Effects Questionnaire (TxEQ): 
The development of a questionnaire for assessing 
the multidimensional outcome of organ 
transplantation -  example of end stage 
renal disease (ESRD)
J. P. Ziegelmann1, K. Griva1, M. Hankins4, M. Harrison1, 
A. Davenport3, D. Thompson and S. P. Newman *
'Unit o f Health Psychology, Department of Psychiatry and Behavioural Sciences, 
University College London, UK
in stitu te  of Urology and Nephrology, The Middlesex Hospital, London, UK 
3Renal Unit, Royal Free Hospital, London, UK
4Division of Psychiatry and Psychology, Guy’s, Kings & Thom as’s School of Medicine, 
London, UK
O b je c t iv e s .  To develop a questionnaire to  assess th e  responses o f transp lan t 
recipients to  th e  receip t o f an organ, including th e ir  self-care behaviour.
D e s ig n . Following a lite ratu re review, open-ended  interview s and a focus group, 
a transp lan t questionnaire  was developed. Two studies (Study I: N =  231, Study 2:
N  = 105) w ere  conducted  to  evaluate its psychom etric p roperties .
M e th o d s . A pool o f 5 1 items was derived from  them es identified in published studies 
and from  interview s and a focus group discussion with renal transp lan t recipients.
T hese  w ere  co n stru c ted  into a questionnaire  and w ere  th en  adm inistered to  tw o  renal 
transp lan t ou t-patien ts  populations. Item responses of study sam ple I w ere  subjected 
to  principal com ponents analysis (PCA) using varimax ro ta tion  to  exam ine th e  
s tru c tu re  o f responses. In o rd e r  to  investigate th e  stability o f th e  fac to r s tru c tu re  
found in Study I, item  responses o f th e  second sample w ere subjected  to  confirm atory 
fac to r analysis (CFA) using structura l equation modelling.
R e su lts . PCA indicated six factors th a t accounted  fo r 64.2% o f th e  variance. W ith  
ex tran eo u s items om itted , th e  final questionnaire  derived from  Study I has 24 items 
c lustered  around five conceptual co h e ren t factors: w o rry  ab o u t tran sp lan t (22.1%),
* Requests for reprints should be addressed to Prof Stanton P. Newman, Unit o f  Health Psychology, Department 
o f  Psychiatry and Behavioural Sciences, University College London, Wolfson Building, 48  Riding House Street, London 
W IN  8AA, UK.
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guilt regarding d o n o r (I 1.9%), disclosure (9.58%), medication adherence (8.73%), and 
responsibility (6.63%). CFA on  th e  final 24-item  version o f th e  TxEQ  revealed th a t 
th e  resulting model was a good fit fo r th e  Study 2 data (RMSEA= 0.08, p c lo se=  .005).
C o n c lu s io n s . T he  TxEQ  has potential application as a m easure in th e  area o f 
transp lan ta tion  research. CFA dem onstra ted  th a t th e  fac to r s tru c tu re  o f th e  TxEQ  is 
co n sis ten t across different renal transp lan t ou t-patien ts populations. F u rth er research 
is cu rren tly  in progress to  assess o th e r  groups of transp lan t recipients and to  examine 
its relationship to  o th e r  m easures.
There is increasing demand for outcome analysis including health-related quality of 
life after medical and surgical interventions. Because of the high cost, interest in 
transplantation outcomes is particularly intense (Wright-Pinson et a l,  2000). Advances 
in medical and surgical technology and the advent of new immunosuppressive medica­
tion, immunological conditioning, sophisticated tissue typing and histocompatibility 
techniques have revolutionized organ transplantation and improved survival rates 
considerably (Hunt, 1998; Schweitzer 8c H)bbs, 1995). Organ transplantation has 
now become a viable treatment alternative for many medical disorders and is principally 
limited in the developed world by a shortage of organs (Cecka, 2000). Despite the 
improved efficacy, however, there remains a significant failure rate in the acceptance 
of the donated organ and the risk of mortality of a return to intensive treatment. 
For example, in heart transplants, 1-year survival in the USA in 1999 was 83.2%and 
the survival rate for lung transplantation was 70.6% (Keck et a l ,  1999). In pancreas 
transplantation, reported ly e a r  patient and graft survival rates were 91% and 69% 
(Sutherland, Moudry-Munns, 8c Gillingham, 1998). In the case of kidney transplant­
ation, the 5 -7  year failure rate is 50% for cadaver transplants. So for many recipients 
of donated organs there are considerable risks of failure, which often results in death. 
In kidney transplantation, there is also a real prospect of a return to dialysis (US Renal 
Data System, 1992).
In general, the relative success of transplantation has led to a shift in research 
agendas beyond the success of the procedure and graft survival to include an examin­
ation of recipients’ psychological response to organ transplantation and their functioning 
and quality of life (I^naeur, 1994). G ven that potential recipients of an organ have 
generally poor functioning, it is not surprising that transplantation has been found to 
lead to quality of life improvements (Bravata, Olkin, Barnato, Keefe, 8c Owens, 1999; 
Dew et a l ,  1997; Wright-Pinson et a l ,  2000). What is more important is that the levels 
of quality of life in studies of transplant patients have typically been reported as 
equivalent or to nearly equivalent to that of the general population (Dressier, 1991; 
Evans et a l ,  1985; Insense, Vilardell, Aranzabal, 8c Lago, 1999; Painter et a l ,  1997). 
However, health care providers and transplant recipients themselves have become 
increasingly aware that organ transplantation may give rise to a new set of stressors, 
psychosocial challenges and adaptive demands (Grady, Jalowiec, 8c White-Williams, 
1996; PBnson, 1987; Fhthaway 8c Strong, 1988; McQuellon et a l ,  1998; Robertson, 
1999; Wainwright, Fallon, 8c Gould, 1999). It may be expected that recipients of 
different transplanted organs will have many similar types of concerns but that these 
may vary in the degree of importance that is attached. Commonly reported stressors 
identified across a range of transplant populations include the cost and side-effects 
of immunosuppressive medication, worries about the viability of transplanted organ, 
fear of rejection, and the need to adhere to a rigorous post-transplant care regime 
(Fallon, Gould, & Wainwright, 1997; Frey, 1990; Gubby, 1998; Phthaway, Strong, & 
Ganza, 1990; Phuser, Williams, Strong, Ganza, & Hathaway, 1991; Phyward et a l ,  1989;
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Kong 8c Molassiotis, 1999; Sutton & Murphy, 1989; White, Ketefian, Starr, & Voepel- 
Lewis, 1990). It has been argued that a viable organ transplantation, albeit a life-saving 
procedure for several end-stage medical conditions, does not cure disease but rather 
extends life by trading one chronic disease for another, i.e. chronically compromised 
immune system leading to significant pressures to adhere to a complex regimen 
(Johnson, 1990). Immunosuppressive therapy continues indefinitely after organ trans­
plantation and is often accompanied by some dietary restrictions. Transplant recipients 
are also required to regularly attend out-patient transplant clinic and laboratory 
appointments and checkups, although their frequency decreases with time. They are 
also expected to engage in several preventative or health protective behaviours (e.g. 
using sun-block agents) or monitoring behaviours (e.g. monitoring themselves for 
early signs of rejection and taking appropriate action if symptoms are detected). 
Accumulating evidence suggests that a considerable number of transplant recipients 
fail to adhere completely to the above treatment recommendations (Bunzel & Laeder- 
ach-Hbfmann, 2000; Colon, Popkin, Matas, & Callies, 1991; Rovelli et al., 1989; 
Schweizer et al., 1990). This is of particular concern in the light of evidence indicating 
that poor adherence is a major determinant of graft failure (Dunn et al., 1990; Hong 
e ta l ,  1992; Kalil, Efeim-Duthoy, &Kasiske, 1992; Schweizer et al., 1990) and mortality 
(Rondriguez, Diaz, Colon, & Santiago-Delphin, 1991). A recent review on studies in 
organ transplantation concluded that there are few studies addressing this important 
dimension (Rodrigue, Greene, & Boggs, 1994).
Besides the more direct issues related to post-transplantation treatment regime, 
studies have identified a num ber of other areas of concern and potential stress for 
organ recipient. These include impact on family relationships, physical and psycho­
social post-transplant adjustment (e.g. resuming an independent role, changes in 
physical and social activity), integration of the transplant to body image, and emotional 
responses, most notably feelings of gratitude and guilt towards the donor or donor’s 
family as well as feelings of personal inadequacy and/or responsibility for ultimate 
graft survival (Bosnak, 1996; Bunzel, Schmidl-Mohl, Grundbock, & Wollenek, 1992; 
Bunzel&Wollenek, 1992; Bunzel, Wollenek, &:Grundbock, 1992; Hathawayef^/., 1990; 
Kuhn et al., 1988; Lewino, Stocks, & Cole, 1996; Mai, 1986; Rauch & Kneen, 1989; 
Robertson, 1999; Schlebusch, 1986; Schlebusch, Pillay & Louw, 1989, 1992; Witzke et 
al., 1997).
The issue confronting transplant recipients, although clearly of high relevance, 
remain largely unexplored by generic Health-related Quality of life (HQoL) instruments 
widely used in transplantation research. Although these have provided useful data 
and offer ready comparisons across studies and patient groups, because such instru­
ments must address a wide range of issues, they fail to capture the specific and often 
subtle emotional and behavioural concerns of transplant recipients. Measurement 
specificity is the alternative approach, and the value of condition-specific instruments 
has been widely recognized (Bradley, 1994; Welch, 1994). Specific instruments are 
expected to provide a more sensitive measurement of processes and responses unique 
to transplantation, but existing transplantation-specific measures have been proven to 
be unproductive, as they present limitations both in terms of their content and cover­
age as well as their psychometric properties. Transplantation-specific quality of life 
instruments (Quality of life Inventory, QOU: Carrington, Tarter, Switala, & Van Thiel, 
1996; Bone Marrow Transplantation Symptoms Checklist: Kfe et al., 2000; End Stage 
Renal Disease Symptom Checklist-Transplantation Module, ESRD-SCL Eranke et al., 
1999; Heart Transplant Symptom checklist: Grady&Jalowiec 1995; General Efealth/QoL
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rating scale: Lanuza, Lefaiver, Cabe, Farcas, &: Garrity, 2000; Kidney Transplant Ques­
tionnaire, KTQ laupacis et al., 1993) assess mainly physical functioning, usually 
incorporating psychological and/or social functioning, thus having little consideration 
of transplant-specific emotional responses or treatment-related issues.
There appear to be no widely used psychometric ally sound instruments to assess 
the specific responses to receiving an organ transplant. Afew studies feature transplant- 
specific measures but those that do, tend to employ idiosyncratic instruments, the 
psychometric properties and development of which are not always described in 
sufficient detail for research or clinical use (fife et al., 2000; Kerr, Johnson, Pandian, 
Gillingham, & Matas, 1997; lanuza et al., 2000; Siegal, Fhnson, Viswanathan, Margolis, & 
Butt, 1989; Teichman, Burker, Weiner, & Egan, 2000; Witzke et al., 1997; Wolcott, 
Wellisch, Fawzy, & Landsverk, 1986). For example, Wolcott et al. (1986) developed a 
recipient questionnaire for bone marrow transplant patients but do not report on its 
psychometric properties nor item content. Other investigators (Bortman et al., 1999; 
Greenstein, Siegal, &: the Compliance Study Group, 1997; Qstrowski, Wesolowski, 
Makar, & Bohatyrewicz, 2000; Schlitt et al., 1999) employed transplantation-specific 
questionnaires but analysed each item separately, reporting the percentages of patients 
endorsing or not a particular item rather than identifying subscales and establishing 
or examining the psychometric properties of their measure.
One central problem in the existing questionnaires is their limited scope. Typically 
the measures are tailored to study particular samples, such as kidney, bone marrow 
or heart transplant patients (Franke et a l ,  1999; Grant et al., 1992; Jacobs et a l ,  1998; 
Ketefian &Starr, 1990; Laupacis et a l,  1993; McQuellon eta l., 1997; Molassiotis, 1999; 
Parfrey et a l ,  1989; Park eta l., 1992; Sutton &: Murphy, 1989; Wirth & Barton, 1985) or 
designed to assess newly transplanted patients (Hayward et a l ,  1989). This restricts 
their use with other transplant populations. Furthermore, the existing transplant- 
specific questionnaires appear to cover some, but not all, of the important aspects 
of post-transplant experience identified in the literature.
Other transplantation-specific measures have been designed especially to measure 
a very specific single concept such as body image (Fife et a l,  2000; Body Image 
Questionnaire, BIQ Schlebusch et a l,  1992), symptom experience (Heart Transplant 
Symptom Checklist: Grady &: Jalowiec, 1995; Transplant Symptom Frequency and 
Distress Scale: Lough, Lindsey, Shinn, &: Stotts, 1987), treatment (Heart Transplant 
Regimen: Grady & Jalowiec, 1995), knowledge about transplant regimen (De Geest 
et a l ,  1995) or understanding of self-care principles (Wirth & Barton, 1985) and, thus, 
albeit of great value, their narrow focus implies limitations. Transplant stressor instru­
ments, on the other hand, are somewhat more comprehensive in their content but 
have been designed to measure and document the stressors of organ transplantation 
rather than measuring the effects of these stressors (Heart Transplant Stressor Scale: 
Grady &c Jalowiec, 1995; Recipient Stressor Scale: Gubby, 1998; Kidney Transplant 
Recipient Scale, KTRSS: Fhyward et a l ,  1989; Kidney Transplant Questionnaire, KTQ 
Ketefian & Starr, 1987). Overall, none of the existing measures elucidates the emotional 
and behavioural issues associated with transplantation and this limits our understand­
ing of the psychological processes of organ transplantation.
With these issues in mind, the aim of this study was to develop a transplant- 
specific instrument to provide a thorough coverage of an individual’s emotional and 
behavioural response to receiving a transplanted organ and the pressures and stresses 
that this may cause. The Transplant Effects Questionnaire (TxEQ) reported in this paper 
is an instrument designed to allow a comprehensive, sensitive, and easy to administer
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instrum ent of those aspects of transplantation that have been identified as being 
the most important. Although it was developed on individuals in receipt of a renal 
transplant, it has been designed to be applicable to all forms of organ transplantation.
Method
Developm ent o f  the Transplant Effects Questionnaire (TxEQ)
To identify the issues facing transplant recipients, the published literature was exam­
ined by means of a computer-based search using the MedLine and Psychlit databases. 
Combinations of the following key words were used: transplantation, transplant, 
cadaver, living related, donor, quality of life, stressors, adherence, compliance, immuno­
suppressive medication, side effects. Additional papers were obtained by manually 
searching references lists of the obtained papers.
Based on the review, a list of relevant open-ended questions was then constructed 
for use in a focus group and individual interviews with kidney transplant recipients. 
The questions covered the following issues:
• impact of transplantation on patients and their families (e.g. What are the most 
important effects of having a transplant?)
• contrast between life prior to and post-transplant (e.g. Does life after transplant­
ation meet your expectations?)
• concerns related to anti-rejection medication and side-effects of anti-rejection 
medication (e.g. Were there any problems you have experienced in relation to your 
treatment or to your recovery?)
• interpersonal attitudes towards donor or family (e.g. What do you know about the 
donor?; Do you ever wonder about the characteristics of the donor?)
• feelings of indebtedness, gratitude and guilt towards the donor or donor family 
(e.g. Ffow would you describe your feelings toward the donor/donor family?; Do 
you feel obliged to pay back the donor for the gift of the donated organ?)
Issues identified in this two-stage procedure were combined into items and refined 
by two raters. The resulting 315 items were subsequently assessed for comprehensi­
bility and redundancy by two raters. This process resulted in 51 items that represented 
nine key themes relating to receiving a transplanted organ: outcome of transplantation, 
fear of rejection, self-care principles, adherence, feelings of guilt, feelings of indebted­
ness, having a foreign body part, relationships with family and friends, and emotions. 
The relevance, clarity and conciseness of the reduced pool of 51 was then subjected 
to expert panel review (transplant professionals including consultants and nurses). 
Lastly, the resulting scale was successfully piloted with a small group (N  = 7) of renal 
transplant recipients. Two studies were then conducted to examine and test the 
psychometric properties and structure of this final pool of 51 items.
STUDY I 
Exploratory factor analysis 
Participants
Following ethics committee approval all (N  = 333) patients registered at a London 
teaching hospital were sent a covering letter and a questionnaire pack consisting of
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the 51-item Transplant Effects Questionnaire (TxEQ), questions about their medical 
history, and demographic questions. Other self-report questionnaires were completed 
but are not considered in this report. To ensure and encourage frank responses, the 
questionnaire had a code number but not the participant’s name. A period of 4 weeks 
was allowed in which to return the questionnaire. After that time a reminder letter and 
another copy of the questionnaire were sent to non responders and another 2 weeks 
were allowed for completion, after which time data collection was terminated.
Atotal of 231 patients completed the questionnaire, giving a response rate of 69.4% 
Participants were almost equally divided between male and female, had a mean age of 
45 years and had been living with a renal transplant for a mean of 9.93 (SD 6.76) years 
(see Table 1).
T a b le  I . Participants in Study I and Study 2
Study 1 Study 2
N 231 105
Sex (% female) 48.9 39.0
Source o f transp lan t (% living related) 22.1 22.9
C u rren t em ploym ent status (% employed) 58.4 47.6
Relationship status (% living w ith p artner) 57.6 69.5
Age (years) 45.15 (SD 14.51) 50.85 (SD 12.18)
Mean num ber o f  com orbid  illnesses 0.67 (SD l.l  1) 0.73 (SD 1.09)
Dialysis experience (% previous dialysis patients) 90.5 93.3
Mean to tal tim e sp en t on  dialysis (in m onths) 34.52 (SD 42.47) 28.61 (SD 29.26)
Mean num ber o f  transp lan ts 1.19 (SD 0.45) 1.13 (SD 0.39)
Mean tim e since transplan ta tion  (in years) 9.93 (SD 6.76) 6.49 (SD 5.16)
Aleasures
Transplant Effects Questionnaire (TxEQ)
The instructions of the TxEQ were as follows: ‘We are interested in your own personal 
views of how you now see your experience with your kidney transplant. These are 
statements other people have made about their transplant experience. Please indicate 
the extent to which you agree or disagree with these statements by ticking the 
appropriate box’.
The measure contained 51 positively and negatively worded items. A positive and 
negative wording of most of the items was used to avoid acquiescence, affirmation or 
agreement bias. They were presented in a mixed order and rated by the participants 
using a 5-point likert scale ranging from ‘strongly disagree’ to ‘strongly agree’ (scored 
from 1 to 5).
Analysis
Statistical analysis was performed using the Windows versions of SPSS(6.1) and AMOS. 
Item responses from the Study 1 sample were subjected to an exploratory principal 
components analysis (PCA) with varimax rotation (Kaiser normalization). As a means 
of eliminating items to achieve a simple coherent structure, extraneous items were 
omitted on the basis of the Kaiser-Meyer-Olkin (KMO) statistic for each item, factor scree 
plot, and final factor loading as described below (Norusis, 1992).
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Results
Initial PCA resulted in a 15-factor structure. A factor scree plot suggested a six factor 
solution (46.7°/). Subsequent omission of 27 items with low loadings (< .45) spread 
across these factors and less than 30% overlapping variance replicated the six-factor 
solution, accounting for 64.2%of the variance in the responses to the Transplant Effects 
Questionnaire. The KMO statistic for the 24 items ranged from .69 to .86 (mean= .79) 
(Table 2). All six factors identified had acceptable internal reliabilities. Cronbach as 
ranged from .72 to .86.
Items were grouped in conceptually coherent factors. Factor 1 comprised six 
items relating to worries regarding the transplant (22.3%). Items loading on factor 2 
referred to feelings of guilt towards the donor (11.9%). Three items loaded respect- 
ivelyon the third factor, tapping disclosure issues regarding the transplant (9.6%), and on 
the fourth factor, reflecting medication adherence (8.7%), whereas factor 5 contained 
items relating to perceived responsibility towards others (6.6%). Fbwever, factor 6 
(5.0%) appeared to be thematically incoherent, with two items (C9 and D l) relating 
to adherence and a third (G2) to taking on qualities of the donor. However, the two 
adherence items did load on the adherence factor (factor 4) (.22 and .29, respect­
ively) despite varimax rotation. It was therefore decided to group items C9 and Dl 
into factor 4 and drop item G2 from further analysis. The resulting adherence factor 
showed high internal consistency (a = .79). In summary, the exploratory factor 
analysis (ERA) determined six factors which were reduced to five thematically 
coherent factors: w orry about the transplant, guilt, adherence, disclosure, and 
responsibility.
STUDY 2
Confirmatory factor analysis 
Participants
Study 2 protocol involved both extensive questionnaire evaluation and comprehensive 
neuropsychological assessment. For this study, 111 sequential patients were 
approached to participate and 105 consented to the full protocol (response rate 
= 94.6%). The resulting sample had a mean age of 50.85 years and consisted of 39.9% 
females. Mean time since transplantation was 6.5 years (see Table 1).
t-Test analyses of the two samples on sociodemographic and medical history 
variables revealed only two significant differences: Study 2 participants were signifi­
cantly older (t(232) = 3.71;p < .001), and had been living with their current transplant 
for less time than Study 1 participants (r(258) = 5.1 t , p  < .001).
Analysis
To test whether the internal structure reported in Study 1 held also in patients from a 
different sample, confirmatory factor analysis was performed on the data from Study 2. 
Item responses from the Study 2 sample were subjected to confirmatory factor analysis 
using structural equation modelling. Goseness of fit based on the root mean square 
error of approximation index (RMSEA) (Browne &Cudeck, 1993) was used to examine 
the extent of fit in the questionnaire factor structures from the two study samples. The 
RMSEAmeasure was used in preference to the CFI (or any other measure of fit) because
400 J. P. Ziegelmann et al.
it provides a robust measure of closeness of fit for the model, which is considered 
by Browne and Cudeck (1993) to be “more reasonable than the requirement of exact 
fit”. In addition, McCallum, Browne, and Sugawara (1996) recommend the use of 
RMSEA instead of point estimates of model fit in the population. Work by Rigdon 
(1996) has demonstrated the utility of the RMSEA. as an index of the degree to which 
a confirmatory structure approximates the data being modelled. Browne and Cudeck 
(1993) have suggested that values of .05 and below indicate a close fit of the model 
and the values of the RMSEA between .05 and .08 approximate a reasonable error in 
approximating a given structure. They also provide a test of the hypothesis that 
the population RMSEA for the model is no greater than .05. failure to reject this 
hypothesis at/? < .05 signifies that the model is a close fit to the data.
T a b le  2 . F acto r loadings, com m unalities, percentage o f variance explained fo r principal com ponen ts 
analysis using varimax ro tation  w ith Kaiser norm alization on th e  24 identified item s o f th e  Transplant 
Effects Q u estio n n aire  (TxEQ)
Items Loading
F a c to r  I: ‘w o rry  a b o u t tra n sp la n t1 Eigenvalue = 3.14; C ronbach  a. =  .81
Percentage o f to ta l variance explained: 13.1%; percentage o f cumulative variance 
explained: 13.1%
B2 I am w orried  ab o u t damaging my transp lan t .82
Bl W ith  regard to  my transp lan t I feel th a t I am carrying around som ething
fragile .76
B5 I am hesitan t to  engage in certain activities because I am afraid o f doing
harm  to  my transp lan t .75
B3 I keep w ondering how  long my transplan t will w ork  .71
C l I m o n ito r my body m ore  closely than before I had th e  transp lan t .64
D2 I w o rry  each tim e my anti-rejection drug regime is altered by my d o c to r  .47
F a c to r  2: *guilt regarding donor* Eigenvalue = 2.94; C ronbach a  = .76
Percentage o f to ta l variance explained: 12.2%; percentage o f cumulative variance 
explained: 25.3%
E4 I feel guilty abou t having taken advantage of th e  d o n o r .83
EI Som etim es I think th a t  I have ‘robbed’ th e  d o n o r o f a vital p art .76
E3 T he d o n o r had to  suffer to  make m e feel b e tte r  .73
F2 I have th e  feeling th a t th e  d o n o r/th e  d o n o r’s family has som e contro l
o v er m e .66
E2 I do n o t have any feelings o f guilt tow ard  th e  d o n o r -  .56
F a c to r  3: ‘disclosure* Eigenvalue = 2.47; C ronbach a  = .86
Percentage o f to ta l variance explained: 10.4%; percentage o f cumulative variance 
explained: 35.7%
12 I avoid telling o th e r  people th a t I have a transp lan t
II I am uncom fortab le w ith o th e r  people knowing th a t I have a transp lan t
14 I have difficulty in talking ab o u t my transp lan t
.90
.86
.85
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Table 2. contd.
Item s Loading
F a c to r  4 : ‘a d h eren ce ’ Eigenvalue = 2.46; C ronbach a  =  .79
Percentage o f to ta l variance explained: 10.3%; percentage o f cum ulative variance
explained: 45.9%
C 6 Som etim es 1 do n o t take my anti-rejection medicines .85
C 2 Som etim es 1 forget to  take my anti-rejection medicines .83
C 4 W hen  1 am to o  busy 1 may forget my anti-rejection medicines .80
C 9 Sometimes 1 think 1 do not need my anti-rejection medicines .23
D 1 1 find it difficult to adjust to taking my prescribed anti-rejection drug regime .29
F a c to r  5: ‘resp o n sib ility* Eigenvalue = 2.22; C ronbach a  = .72
Percentage o f to tal variance explained: 9.3%; percentage o f cumulative variance
explained: 55.1%
F3 1 th ink  th a t 1 have a responsibility to  th e  transplan t team  to  do well .77
F6 1 th ink th a t  1 have a responsibility to  my friends and my family to  do well .75
F5 1 feel th a t  1 ow e th e  d o n o r/th e  d o n o r’s family som ething th a t 1 will never
be able to  repay .73
FI 1 th ink th a t  1 have a responsibility to  th e  d o n o r/th e  d o n o r’s family to  do
well .65
Results
Internal structure
Confirmatory factor analysis (CFA) was performed using the AMOS structural equation
modelling application (Arbuckle, 1997). A measurement model was defined with five
uncorrelated latent variables (as described in the exploratory factor analysis section
above). The resulting model was found to be a good fit for the data (RMSEA = .08;
/>close = .005) as defined by Browne and Cudeck (1993).
Test-retest reliability
One-month test-retest reliability of the TxEQ was found to be acceptable for all subscales
except for the responsibility subscale (see Table 3).
T a b le  3 . O n e  m onth  te s t- re te s t  reliability
W o rry  Guilt D isclosure A dherence Responsibility
T est-re test reliability rt |t2 = .797 rt | t 2 = .689 rt it2 =  -600 rt .t 2 = .772 rt i t2 = -70
N =  81 N =  73 N =  82 N =  82 N =  80
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DISCUSSION
In this paper we have described the development and initial evaluation on renal 
transplant recipients of the psychometric properties and structure of the Transplant 
Effects Questionnaire (TxEQ) constructed to assess the multidimensional effects of 
organ transplantation. The evidence of the range of areas and concerns of transplant­
ation coupled with the absence of a comprehensive transplantation instrument 
provided the rationale for the development of this measure. The items were elicited 
based on an extensive review of the transplantation literature, a transplant focus group 
and in-depth interviews with transplant recipients. The combined approach of such 
quantitative and qualitative methodologies was thought to be the best approach to 
capturing transplant recipients’ perspectives on their post-transplant experience.
Data from 336 renal transplant recipients were used to examine the internal con­
sistency and internal structure of the resulting TxEQ. Principal components analysis of 
the TxEQ items produced a conceptually coherent factor structure, which was further 
confirmed on another dataset using structural equation modelling. The resulting five 
TxEQ subscales were concerns and worries specific to the transplant, feelings of guilt 
regarding the donor, disclosure, perceived responsibility and medication adherence.
The first two subscales appear to tap emotional responses that are likely to be 
triggered by transplantation (i.e. worrying over graft function and feelings of guilt towards 
the donor). These two dimensions tie in with earlier research findings (Franke etal., 1999; 
Ereyberger, 1983; Gubby, 1998; Kong & Molassiotis, 1999; Schlebusch, 1986; Schlebusch 
et a l , 1989; Viederman, 1981). Patients’ concerns regarding the viability of their 
transplanted organ are well rooted in reality despite the major advances made in recent 
years. Although the figures for different transplanted organs do vary (Keck et a l, 1999; 
Sutherland etaL, 1989; US Renal Data System, 1992), in the case of renal transplantation in 
the UK, the participants in this study, the rejection rate of kidneys is approximately 36% 
over 5 years (Renal Association, 1997). Patients’ awareness of this possibility is likely to be 
further confirmed by the need to take anti-rejection medication, the experience of 
symptoms, or possibly the occurrence of episodes of infection.
Peelings of guilt towards the donor have been reported in a range of other, mainly 
qualitative, studies (Chambers, 1982; Chaturvedi & Pant, 1985; Mai, 1986). There is 
little research evidence on guilt, however, in what may be considered the most perti­
nent area, where the organ may have been sourced from a living donor, as is the case 
in renal transplantation, bone marrow transplantation and in some cases of lung and 
liver transplantation. Further research is required to establish the extent to which 
transplant recipients of other organs experience guilt and what underlies this dimen­
sion. The TxEQ specifically assesses guilt in relation to the donor and the donor’s family.
W hether to disclose the fact that one has a chronic illness is an option where 
the treatment or illness is not easily observed (Greene, 2000). in the case of kidney 
transplantation, it appears that this is an important issue for some individuals. One 
may speculate that some are concerned about how they will be responded to, whilst 
others maybe relatively unconcerned about others knowing that theyhave had a kidney 
transplant (Ndlovu Louw, 1998). Issues of stigmatization associated with cancer 
survivorship in bone marrow transplantation, for instance, might be related to dis­
closure tendency in those patients (Baker, Zabora, Polland, & Wingard, 1999).
The fourth factor identified was that of adherence. Treatment adherence has 
been widely studied in transplant populations. Although existing research has been 
hampered because of various assessment methods, each having its own strengths
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and weaknesses (Brickman & Yount, 1996), there is evidence to suggest that some 
transplant patients do not follow the advice and recommendations made regarding 
immunosuppressive medication (Wainwright & Gould, 1997) despite the associated 
health risks that this behaviour might precipitate.
The last TxEQ factor refers to responsibility towards family friends or the medical team 
to do well, an issue which has not received attention in transplantation research. The 
‘responsibility* dimension of the TxEQ appears to tap issues related to outcome respon­
sibility likely to encompass both a cognitive (i.e. perceptions of responsibility) as well as an 
affective component (i.e. feelings of responsibility). Responsibility as measured by the 
TxEQ may hence be seen as qualitatively distinct from concepts such as locus of control or 
responsibility for graft survival studied in previous research (Bremer, 1995; Bremer, EEffly, 
Boxx, &;Weaver 1995; Erazier, DavisAli, &Dahl, 1994; Kiley, Lam, &; Pollack, 1993; Kugler 
et al., 1994). Responsibility towards others may well be dependent on a range of other 
factors such as perceived social support and/or patient’s satisfaction with interpersonal 
relationships or with health care received. The modest test-retest reliability coefficients 
observed may thus reflect changes in those relationships over the inter-test interval. Further 
research is warranted in order to examine its reproducibility and stability.
The preliminary data reported here indicate that the psychometric properties of 
TxEQ are acceptable and support its use as a transplant specific research tool. TxEQ 
is self explanatory, simple to use and time and cost-effective, features that make it an 
ideal instrument for use in a clinical environment. The TxEQ has potential to monitor 
on a regular basis the responses, psychological adjustment and treatment adherence 
in transplant recipients alongside the routine post-transplant medical assessments. From 
a research perspective, TxEQ may be used separately or in conjunction with more 
generic HQ oL measures. The questionnaire might also contribute to research on the 
effects of different transplantation modalities, such as cadaver to living-related grafts, 
and it can also be used to assess the impact of the more recent and rather ‘controversial* 
animal-derived transplants. Further research is currently in progress to assess other 
groups of transplant recipients and examine the instrument’s relationship to other 
measures and to the clinical status of transplant patients.
A cknow ledgem ents
This research was supported by a grant from Alexandros Chassis Foundation and the Reta Lila 
Weston Institute o f Neurological Studies, UCL, to Konstadina Griva and a scholarship from the 
German Academic Exchange Service (DAAD) to Jochen R Ziegelmann, w hich are both gratefully 
acknowledged. The research constitutes part of K. Griva*s PhD thesis.
References
Arbuckle, J. L (1 9 97). Amos user’s guide. Chicago: Smallwaters.
Baker, E, Zabora, J., Polland, A , & Wingard, J. (1999). Reintegration after bone marrow 
transplantation. Cancer Practice, 7, 190 -1 9 7 .
Bortman, G , Delgado, D., Cohen Arazi, H , Martin, J., Valente, E, Vazquez, E Santini, M , & 
Nojek, G  (1999). Analysis of quality of life before and after heart transplantation. Trans­
plantation Proceedings, 3 / ,  2555.
Bosnak, R  (1996). Integration and ambivalence in transplants. In D. Barret (Ed.), Trauma and 
dreams (pp. 2 1 7 -2 3 0 ). Cambridge, MA EErvard University Press.
Bradley, G  (1994). Handbook of psychology and diabetes: A guide to psychological measure­
ments in diabetes research and management. Amsterdam: EErwood Academic.
404 J. P. Ziegelmann et al.
Brava ta, D. M , Olkin, L, Barnato, A  E , Keeffe, E  B., & Owens, D. K  (1999). Pfealth-related quality 
o f  life after liver transplantation: Ameta-analysis. Liver Transplantation Surgery; 5, 3 1 8 -3 3 1 .
Bremer, B. A  (1995). Absence of control over health and the psychological adjustment to 
end-stage renal disease. Annals of Behavioral Medicine, 7 , 2 2 7 -2 3 3 .
Bremer, B. A , Hrffly, D., Boxx, R  M , & Weaver, A  (1995). Patients* perceived control over 
their health care: An outcome assessment of their psychological adjustment to renal failure. 
American Journal of Medical Quality, 10, 149-154 .
Brickman, A  L , & Yount, S. E  (1996). Noncompliance in end-stage renal disease: A  threat 
to  quality of care and cost containment .Journal of Clinical Psychology in Medical Settings, 3, 
3 9 9 -4 1 2 .
Browne, M  W., & Cudeck, R  (1993). Alternative ways of assessing model fit. In K. A  Bollen & 
J. S. Long (Eds.), Testing structural equation models (pp. 2 0 5 -2 3 4 ). Newbury Park, CA Sage 
Publications.
Bunzel, B., & Laederach-Pbfmann, K. (2000). Solid organ transplantation: Are there predictors 
for posttransplant noncompliance? A  literature overview. Transplantation, 70, 711 -716 .
Bunzel, B., Schmidl-Mohl, B., Grundbock, A , & Wollenek, G  (1992). Does changing the heart 
m ean changing personality? A  retrospective inquiry on 47 heart transplant patients. Quality 
o f life Research, 1, 2 5 1 -2 5 6 .
Bunzel, B., & Wollenek, G  (1992). living with a donor heart: Peelings and attitudes of patients 
toward the donor and the donor organ .Journal of Heart and Lung Transplantation, 11, 
1 1 5 1 -1 1 5 5 .
Bunzel, B., Wollenek, G., & Grundbock, A  (1992). Psychosocial problems of donor heart 
recipients adversely affecting quality of life. Quality of Life Research, 1, 3 0 7 -3 1 3 .
Carrington, P, Tarter, R  E , Switala, J., & Van Thiel, D. (1996). Comparisons of quality of life 
betw een  alcoholic and non-alcoholic patients after liver transplantation. American Journal of 
Addictions, 1 8 -2 2 .
Gecka, J. M  (2000). Kidney transplantation from living unrelated donors. Annual Review of 
Medicine, 51, 3 9 3 -4 0 6 .
Chambers, M  (1982). Psychological aspects of renal transplantation. Lnternational Journal 
o f Psychiatry and Medicine, 12, 2 2 9 -2 3 6 .
Chaturvedi, S. K., &Pant, V L (1985). Emotional reactions and long term emotional adjustment 
in renal transplant recipients. Lndian Journal of Psychological Medicine, 8, 3 -9 .
Colon, E  A , Pop kin, M  K., Matas, A  J., & Callies, A  (1991). Overview of noncompliance in 
renal transplantation. Transplantation Reviews, 5, 175-180 .
De Geest, S., Borgermans, L , Gemoets, H , Abraham, L, Vlaminck, H , Evers, G , & 
Vanrenterghem, Y  (1995). Incidence, determinants, and consequences of subclinical non- 
com pliance w ith immunosuppressive therapy in renal transplant recipients. Transplantation, 
59, 3 4 0 -3 4 7 .
Dew, M  A , Switzer; G. E , Goycoolea, J. M , Allen, A  S., DiMartini, A , Kormos, R  L , & Griffith, B. P 
(1997). Does transplantation produce quality of life benefits? A  quantitative analysis of the 
literature. Transplantation, 64, 1261-1273 .
Dressier; D. K. (1991). Psychosocial effects of cardiac rehabilitation. Journal o f Intensive Care 
Medicine, 6, 1 2 6 -1 3 4 .
Dunn, J., Golden, D., Van Buren, C  T., Lewis, R  M., Lawen, J., & Kahan, B. D. (1990). Causes 
of graft loss beyond tw o years in the cyclosporine era. Transplantation, 49, 3 4 9 -3 5 3 .
Evans, R  W , Manninen, D. L , Garrison, L P, Jr., Phrt, L G., Blagg, C  R , Gutman, R  A , H ill, A  R , 
& Lowrie, E  G  (1985). The quality of life of patients with end-stage renal disease. New 
England Journal of Medicine, 312, 553 -5 5 9 .
Ballon, M., Gould, D., & Wainwright, S. P (1997). Stress and quality of life in the renal transplant 
patient: A  preliminary investigation. Journal of Advanced Nursing, 25, 5 6 2 -5 7 0 .
fife , B. L , Huster, G  A , Cornetta, K. G , Kennedy, V N ,  Akard, L P, & Broun, E R  (2000). 
Longitudinal study of adaptation to the stress of bone marrow transplantation. Journal of 
Clinical Oncology, 18, 1539-1549 .
Development o f the Transplant Effects Questionnaire 405
Franke, G  H , Reimer, J., Kohnle, M , Luetkes, P, Maehner, N ,  & H eem ann, U. (1999). Quality of 
life in end-stage renal disease patients after successful kidney transplantation: Development 
o f the ESRD symptom checklist -  transplantation module. N ephron, 83, 3 1 -3 9 .
Frazier; E A , DavisAli, S. H , & Dahl, K. E  (1994). Correlates of noncom pliance among renal 
transplant patients. Clinical Transplantation, 8, 5 5 0 -5 5 7 .
Frey, G  M  (1990). Stressors in renal transplant recipients at six weeks after transplant. A m erican  
N ephrology Nurses Association Journal, 77, 4 4 3 -4 4 6 , 450; discussion 447.
Freyberger, H  (1983). The renal transplant patient: Three-stage m odel and psychotherapeutic 
strategies. In N  B. Levy (Ed.), Psychonephrology II Psychological p rob lem s in k idney fa ilure  
a n d  their trea tm en t (pp. 2 6 5 -2 7 7 ). N ew  York: Plenum Press.
Grady K. L , & Jalowiec, A  (1995). Predictors of compliance with diet 6 months after heart 
transplantation, 24 , 3 5 9 -3 6 8 .
Grady K. L , Jalowiec, A , & White-Williams, G  (1996). Improvement in quality of life in patients 
w ith  heart failure w ho undergo transplantation. Journal o f  H eart a n d  Lung Transplantation, 
7 5 , 7 4 9 -7 5 7 .
Grant, M , Ferrell, B., Schmidt, G  M , Fonbuena, P, Niland, J. G , & Forman, S. J. (1992). 
Measurement of quality of life in bone marrow transplantation survivors. Q uality o f  life  
Research j 7, 3 7 5 -3 8 4 .
Greene, K. (2000). Disclosure of chronic illness varies by topic and target: The role of stigma and 
boundaries in willingness to disclose. In S. Petronio (Ed.), Balancing the secrets o f  p r iva te  
disclosures (pp. 1 2 3 -1 3 5 ). Mahmwah, Nf: Lawrence Erlbaum Associates.
Greenstein, S. M , Siegal, B., & the Compliance Study Group (1997). Post renal health beliefs and 
ethnicity. Transplantation Proceedings, 29 , 3 7 4 1 -3 7 4 2 .
Gubby, L (1998). Assessment of quality of life and related stressors following liver transplantation. 
Jou rn a l o f  Transplant C oordination , 8, 113 -118 .
Fhnaeur, S. B. (1994). What transplantation can teach us about health care reform. N ew England 
Jou rn a l o f  M edicine, 3 3 0 , 8 5 8 -8 5 9 .
fdanson, P (1987). Current concepts in renal transplantation. A m erican N ephrology Nurses 
A ssociation  Journal, 15, 3 6 7 -3 6 8 , 415.
Hathaway D., & Strong, M  (1988). Theory, practice, and researchin transplant nursing. Am erican  
N ephrology Nurses Association Journal, 15, 9 -1 2 .
Hathaway, D., Strong, M , & Ganza, M  (1990). Posttransplant quality of life expectations. 
A m erican  N ephrology Nurses Association Journal, 17, 4 3 3 -4 3 9 , 450; discussion 4 4 0 -4 4 1 .
Hiuser, M  L, Williams, J., Strong, M , Ganza, M , & Fhthaway D. (1991). Predicted and actual 
quality of life changes following renal transplantation. A m erican N ephrology Nurses Associa­
tion  Journal, 18 , 2 9 5 -2 9 6 , 299 -304 ; discussion 3 0 4 -3 0 5 .
Hayward, M  B., Kish, J. P, Jr., Frey, G  M , Kirchner, J. M , Carr, L S., & Wolfe, C  M  (1989). An 
instrument to identify stressors in renal transplant recipients. A m erican N ephrology Nurses 
A ssociation Journal, 16, 8 1 -8 5 .
Fbng, J. H , Sumrani, H , Delaney, V, Davis, R , Dibenedetto, A , & Butt, K. M  (1992). Causes of 
late renal allograft failure in the cyclosporin era. Nephron, 62, 2 7 2 -2 7 9 .
Flint, S. A  (1998). Current status of cardiac transplantation. Journal o f  Am erican M edical 
Association , 280 , 1692 -1698 .
Insense, B., Vilardell,J., Aranzabal, J., &Lago, A  M  (1999). Quality of life in renal hepatic and heart 
transplant patients. Transplantation Proceedings, 31 , 2 6 4 7 -2 6 4 8 .
Jacobs, R  J., Pescovitz, M  D., Brook, B., Birnbaum, J., Dean, J., & Pus, N  (1998). A  self­
administered quality of life questionnaire for renal transplant recipients (letter). Nephron, 
79 , 123 -124 .
Johnson, K. A  (1990). Medical technology and public meaning: The case ofviable organ transplanta­
tion. InJ. Shanteau & R  J. Fhrris (Eds.), Organ donation  a n d  transplantation: Psychological an d  
beh aviou ra l factors  (pp. 168-178). Washington: American Psychological Association.
Kalil, R  S., Ffeim-Duthoy, K  L , &Kasiske, B. L (1992). Patients with a low  income have reduced 
renal allograft survival. Am erican Journal o f  K idney Diseases, 20 , 6 3 -6 9 .
406 J. P. Ziegelmann et al.
Keck, B. M , Bennett, L E , Rosendale, J., Daily O. P, Novick, R  J., & Fbsenpud, J. D. (1999). 
Worldwide thoracic organ transplantation: A  report from the UNOS/ISHIT International 
Registry for Thoracic Organ transplantation. Clinical Transplants, 1998, 3 5 -4 9 .
Kerr, S., Johnson, E , Pandian, K., Gillingham, K , & Matas, A  (1997). Psychological impact of 
a failed kidney transplant. Transplantation Proceedings, 29 , 1573.
Ketefian, S., & Starr, A  J. (1990). Kidney transplant questionnaires: Manual Ann Arbor, MI: The 
University of Michigan School of Nursing.
Kiley, D. J., Lam, G  S., & Poliak, R  (1993). A  study of treatment compliance following kidney 
transplantation. Transplantation, 33 , 5 1 -5 6 .
Kong, I. L , & Molassiotis, A  (1999). Quality of life, coping and concerns in Chinese patients after 
renal transplantation. International Journal of Nursing Studies, 36, 3 1 3 -3 2 2 .
Rugler, J., Tenderich, G , Stahlhut, P, Posival, H , Korner, M  M , Korfei; R , & Kruskemper, G. M  
(1994). Emotional adjustment and perceived locus of control in heart transplant patients. 
Journal o f Psychosomatic Research, 38, 4 0 3 -4 0 8 .
Kuhn, W. E, Myers, B., Brennan, A  E, Davis, M  H , Lippman, S. B., Gray, L A , & Pool, G  E  (1988). 
Psychopathology in heart transplant candidates. Journal of Heart Transplantation, 7, 
2 2 3 -2 2 6 .
Lanuza, D. M , Lefaiver, G , Cabe, M  Me., Farcas, G  A , & Garrity E  Jr. (2000). Prospective study 
of functional status and quality of life before and after lung transplantation. Chest, 118, 
115 -122 .
Laupacis, A , Pus, N ,  Muirhead, N ,  Wong, G , Ferguson, B., & K eow n, E (1993). Disease-specific 
questionnaire for patients w ith a renal transplant. Nephron, 64, 2 2 6 -2 3 1 .
Lewino, D., Stocks, L , & Cole, G  (1996). Interaction or organ donor families and recipients. 
Journal of Transplant Coordination, 6, 191 -195 .
Lough, M  E , lindsey, A  M , Shinn, J. A , & Stotts, N  A  (1987). Impact of symptom frequency and 
symptom distress on self-reported quality of life in heart transplant recipients. Heart and 
Lung, 16, 1 9 3 -2 0 0 .
Mai, E M  (1986). Graft and donor denial in heart transplant recipients. American Journal of 
Psychiatry, 143, 1159 -1161 .
McGallum, R  G , Browne, M  W , & Sugawara, H  M  (1996). Power analysis and determination 
of sample size for covariance structure modelling. Psychological Methods, 1, 130-149 .
McQuellon, R  P, Russell, G  B., Celia, D. E, G aven, B. L, Brady, M , Bonomi, A , & Hard, D. D. 
(1997). Quality of life measurement in bone marrow transplantation: Developm ent of the 
Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMr) scale. Bone 
Marrow Transplant Journal, 19, 3 5 7 -3 6 8 .
McQuellon, R  P, Russell, G. B., Rambo, T. D., G aven, B. L , Radford, J., Perry, J. J., G uz, J., & 
Hard, D. D. (1998). Quality of life and psychological distress of bone marrow transplant 
recipients: The ‘time trajectory to recovery over the first year. Bone Marrow Transplant 
Journal, 21, 4 7 7 -4 8 6 .
Molassiotis, A  (1999). Further evaluation of a scale to screen for risk of emotional difficulties 
in bone marrow transplant recipients. Journal of Advanced Nursing, 29, 922-927.
Ndlovu, P, & Louw, J. (1998). Making sense of kidney transplantation: A  view  from African 
recipients. Clinical Transplantation, 12, 2 5 0 -2 5 5 .
Norusis, M  J. (1992). SPSS for Windows: Professional statistics (Release 5). Chicago: SPSS.
Qstrowski, M , W esolowski, T., Makar, D., & Bohatyrewicz (2000). Changes in quality of life after 
renal transplantation. Transplantation Proceedings, 32, 1371 -1374 .
Painter, P L, Luetkemaeier, M  J., Moore, G  E , Dibble, S. L, G ee n , G  A , Myll, J. Q , & Q rlson , L L 
(1997). Hbalth-related fitness and quality of life in organ transplant recipients. Transplanta­
tion, 64, 1 795 -1 8 0 0 .
Parfrey, P S., Vavasour, H , Bullock, M , Ffenry, S., Fhrnett, J. D., & Gault, M  H  (1989). 
Developm ent of a health questionnaire specific for end-stage renal disease. Nephron, 52, 
2 0 -2 8 .
Park, H , Bang, W  R , Kim, S. J., Kim, S. T., Lee, J. S., Kim, S., & L^n, J. S. (1992). Quality of life
Development o f the Transplant Effects Questionnaire 407
of ESRD patients: Developm ent of a tool and comparison betw een transplant and dialysis 
patients. Transplantation Proceedings, 24, 1435-1437 .
Rauch, J. B., & Kneen, K. K. (1989). Accepting the gift of life: Heart transplant recipients’ post­
operative adaptive tasks. Social Work in Health Care, 14, 4 7 -5 9 .
Rigdon, E  E  (1996). CFT versus RMSEA: A  comparison of tw o fit indexes for structural equation 
modelling. Structural Equation Modelling, 3, 3 6 9 -3 7 9 .
Robertson, G. (1999). Individuals’ perception of their quality of life following a liver transplant: 
An exploratory study. Journal of Advanced Nursing, 30, 4 9 7 -5 0 5 .
Rodrigue, J. R , Greene, A  E, & Boggs, S. R  (1994). Current status of psychological research in 
organ transplantation. Journal of Clinical Psychology in Medical Settings, 1, 4 1 -7 0 .
Rodriguez, A , Diaz, M , Colon, A , & Santiago-Delpin, E  A  (1991). Psychosocial profile of 
noncom pliant transplant patients. Transplantation Proceedings, 23, 1807 -1809 .
Rovelli, M , Palmeri, D., Vossler, E , Bartus, S., H ill, D., & Schweizer; R  (1989). Noncompliance 
in organ transplant recipients. Transplantation Proceedings, 21, 8 3 3 -8 3 4 .
Schlebusch, L (1986). Medical psychology and psychonephrology: Contributions of clinical 
psychology. South African Journal of Psychology, 16, 4 7 -5 6 .
Schlebusch, L , Pillay B. J., & Louw, J. (1992). Body-image differences in live related and cadaver 
renal transplant recipients. South jtfrican Journal of Psychology, 22, 7 0 -7 5 .
Schlebusch, L , Pillay B. J., & L d u w , J. (1989). Depression and self-report disclosure after live 
related donor and cadaver renal transplants. South African Medical Journal, 75, 4 9 0 -4 9 3 .
Schlitt, H  J., Brunkhorst, R , Schmidt, H  H  J., Nashan, B., Haverich, A , & Raab, R  (1999). 
Attitudes of patients before and after transplantation towards various allografts. Transplanta­
tion, 68, 5 1 0 -5 1 4 .
Schweitzei; J. B., & H>bbs, S. A  (1995). Renal and liver disease: End-stage and transplantation 
issues. In M  G  Roberts (Ed.), Handbook of pediatric psychology, (pp. 4 2 5 -4 4 5 ). N ew  York: 
Guilford Press.
Schweitzei; R  T., Rovelli, M , Palmeri, D., Vossler, E , Hull, D., &Bartus, S. (1 9 9 0 ).Non-compliance 
in organ transplant recipients. Transplantation, 49, 374-377.
Siegal, B. R , Hanson, P, Viswanathan, R , Margolis, R , & Butt, K. M  (1989). Renal transplant 
patients’ health beliefs. Transplantation Proceedings, 21, 3 9 7 7 -3 9 7 8 .
Sutherland, D. E , Moudry-Munns, K. G , & Gillingham, K. (1998). Pancreas transplantation: 
Report from the International Registry and a preliminary analysis of United States results 
from the N ew  United Network for Organ Sharing (UNOS) Registry Clinical Transplantation, 
1 9 -4 3 .
Sutton, T. D., & Murphy, S. P (1989). Stressors and patterns of coping in renal transplant patients. 
Nursing Research, 38, 4 6 -4 9 .
Teichman, B. J., Burker, E  J., Weiner, M , &Egan, T. M  (2000). Factors associated with adherence 
to treatment regimens after lung transplantation. Progress in Transplantation, 10, 113 -121 .
Renal Association (1997). Treatment of adult patients with renal failure: Recommended 
standards and audit measures. (2nd ed.). London: Royal College of Physicians and the 
Renal Association.
US Renal Data System (1992). Annual data report. Bethesda, M D National Institutes of Health, 
National Institute of Diabetes and Digestive Kidney Diseases.
Viederman, M  (1981). The trajectory of patients with long term kidney transplants: A  pilot 
study. In N  B. Levy (Ed.), Psychonephrology / (p p . 195 -217 ). N ew  York: Plenum Press.
Wainwright, S. P, & Gould, D. (1997). Non-adherence with medications in organ transplant 
patients: Aliterature review. Journal of Advanced Nursing, 26, 9 6 8 -9 7 7 .
Wainwright, S. P, Fallon, M , & Gould, D. (1999). Psychosocial recovery from adult kidney 
transplantation: Aliterature review .Journal of Clinical Nursing, 8, 2 3 3 -2 4 5 .
Welch, G  (1994). Assessment of quality of life following renal failure. In H  McGee & G Bradley 
(Eds.), Quality of life following renal failure: Psychosocial challenges accompanying high 
technology medicine (pp. 5 5 -9 7 0 . Reading: H rw o o d  Academic.
White, M  J., Ketefian, S., Start; A  J., & Voepel-Lewis, T. (1990). Stress, coping, and quality of life
408 J. P. Ziegelmann et al.
in adult kidney transplant recipients. American Nephrology Nurses Association Journal, 17, 
4 2 1 -4 2 4 , 431; discussion 425.
Wirth, E H , & Barton, C  E (1985). An instrument to measure self-care principles of renal 
transplant recipients. American Nephrology Nurses Association Journal, 12, 3 5 3 -3 5 6 .
Witzke, O., Becker, G , Eranke, G , Binek, M , Philipp, T., & Efeemann, U. (1997). Kidney 
transplantation improves quality of life. Transplantation Proceedings, 29 , 1569-1570 .
Wolcott, D. L , Wellisch, D. K , Eawzy E L, & Landsverk, J. (1986). Adaptation of adult bone 
marrow transplant recipient long-term survivors. Transplantation, 41, 4 7 8 -4 8 4 .
Wright-Pinson, G , Feurer, I. D., Payne, J. L , Wise, P E , Shockley, S., &Speroff, T (2000). Efealth 
related quality of life after different types of solid organ transplantation. Annals of Surgery; 
2 32 , 5 9 7 -6 0 7 .
Received 31 July 2000; revised version received 4 June 2001 
APPENDIX
Scoring algorithm s for the TxEQ
Step 1:
Strongly agree = 1; agree = 2; uncertain = 3; disagree = 4; strongly disagree = 5 
Step 2: 
Recode all items except c2, c4, c6, c9, d l , e2, i l ,  i2, i4: (1 = 5) (2 = 4) (3 = 3) (4 = 2) 
(5 =  1)
Step 3:
Compute factor 1 : Worry about transplant
With higher scores indicating more worry 
w orry= b l + b2 + b3 + b5 + c l + d2
Compute factor 2 : Guilt regarding donor
With higher scores indicating more feelings o f  guilt 
guilt= e l + e2 + e3 + e4 + f2
Compute factor 3: Disclosure
With higher scores indicating more disclosure
disclosure = il + i2 + i4 
Compute factor 4 :Adherence:
With higher scores indicating better adherence related behaviour 
adherence = c2 + c4 + c6 + c9 + dl
Compute factor 5 : Responsibility
With higher scores indicating more responsibility 
responsibility = fl + f3 + f5 + f6
